ID   ABC3B_HUMAN             Reviewed;         382 AA.
AC   Q9UH17; B0QYD2; O95618; Q20WL1; Q5IFJ4; Q7Z2N3; Q7Z6D6; Q9UE74;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   22-APR-2020, entry version 164.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3B;
DE            Short=A3B;
DE            EC=3.5.4.38;
DE   AltName: Full=Phorbolin-1-related protein;
DE   AltName: Full=Phorbolin-2/3;
GN   Name=APOBEC3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT LYS-146, AND INDUCTION.
RC   TISSUE=Keratinocyte;
RX   PubMed=10469298; DOI=10.1046/j.1523-1747.1999.00682.x;
RA   Madsen P.P., Anant S., Rasmussen H.H., Gromov P., Vorum H., Dumanski J.P.,
RA   Tommerup N., Collins J.E., Wright C.L., Dunham I., Macginnitie A.J.,
RA   Davidson N.O., Celis J.E.;
RT   "Psoriasis upregulated phorbolin-1 shares structural but not functional
RT   similarity to the mRNA-editing protein apobec-1.";
RL   J. Invest. Dermatol. 113:162-169(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=16060832; DOI=10.1089/aid.2005.21.611;
RA   Rose K.M., Marin M., Kozak S.L., Kabat D.;
RT   "Regulated production and anti-HIV type 1 activities of cytidine deaminases
RT   APOBEC3B, 3F, and 3G.";
RL   AIDS Res. Hum. Retroviruses 21:611-619(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANTS GLU-62 AND
RP   LYS-146.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT LYS-146.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   GENE FAMILY ORGANIZATION, TISSUE SPECIFICITY, RNA-BINDING, ZINC-BINDING,
RP   AND INTERACTION WITH APOBEC3G.
RX   PubMed=11863358; DOI=10.1006/geno.2002.6718;
RA   Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J.,
RA   Navaratnam N.;
RT   "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on
RT   chromosome 22.";
RL   Genomics 79:285-296(2002).
RN   [7]
RP   REVIEW ON APOBEC FAMILIES.
RX   PubMed=12683974; DOI=10.1016/s0168-9525(03)00054-4;
RA   Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.;
RT   "Messenger RNA editing in mammals: new members of the APOBEC family seeking
RT   roles in the family business.";
RL   Trends Genet. 19:207-216(2003).
RN   [8]
RP   FUNCTION IN HIV-1 INFECTIVITY.
RX   PubMed=12859895; DOI=10.1016/s0092-8674(03)00515-4;
RA   Mariani R., Chen D., Schroefelbauer B., Navarro F., Koenig R., Bollman B.,
RA   Muenk C., Nymark-McMahon H., Landau N.R.;
RT   "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.";
RL   Cell 114:21-31(2003).
RN   [9]
RP   FUNCTION IN SIV RESTRICTION.
RX   PubMed=15466872; DOI=10.1074/jbc.m408802200;
RA   Yu Q., Chen D., Koenig R., Mariani R., Unutmaz D., Landau N.R.;
RT   "APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency
RT   virus replication.";
RL   J. Biol. Chem. 279:53379-53386(2004).
RN   [10]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=16527742; DOI=10.1016/j.cub.2006.01.031;
RA   Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R.,
RA   Weitzman M.D.;
RT   "APOBEC3A is a potent inhibitor of adeno-associated virus and
RT   retrotransposons.";
RL   Curr. Biol. 16:480-485(2006).
RN   [11]
RP   DOMAIN CMP/DCMP DEAMINASE.
RX   PubMed=17020885; DOI=10.1074/jbc.m604980200;
RA   Hakata Y., Landau N.R.;
RT   "Reversed functional organization of mouse and human APOBEC3 cytidine
RT   deaminase domains.";
RL   J. Biol. Chem. 281:36624-36631(2006).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16699599; DOI=10.1371/journal.ppat.0020041;
RA   Wichroski M.J., Robb G.B., Rana T.M.;
RT   "Human retroviral host restriction factors APOBEC3G and APOBEC3F localize
RT   to mRNA processing bodies.";
RL   PLoS Pathog. 2:E41-E41(2006).
RN   [13]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [14]
RP   REVIEW ON FUNCTION IN HBV RESTRICTION.
RX   PubMed=18448976; DOI=10.1097/qco.0b013e3282fe1bb2;
RA   Bonvin M., Greeve J.;
RT   "Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases
RT   as effectors in innate immunity against the hepatitis B virus.";
RL   Curr. Opin. Infect. Dis. 21:298-303(2008).
RN   [15]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18667511; DOI=10.1128/jvi.02471-07;
RA   Stenglein M.D., Matsuo H., Harris R.S.;
RT   "Two regions within the amino-terminal half of APOBEC3G cooperate to
RT   determine cytoplasmic localization.";
RL   J. Virol. 82:9591-9599(2008).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes
RT   and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [17]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=20062055; DOI=10.1038/nsmb.1744;
RA   Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.;
RT   "APOBEC3 proteins mediate the clearance of foreign DNA from human cells.";
RL   Nat. Struct. Mol. Biol. 17:222-229(2010).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21835787; DOI=10.1128/jvi.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a
RT   conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [19]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [20]
RP   FUNCTION IN HTLV-1 RESTRICTION.
RX   PubMed=22457529; DOI=10.1128/jvi.06570-11;
RA   Ooms M., Krikoni A., Kress A.K., Simon V., Muenk C.;
RT   "APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic
RT   virus type 1.";
RL   J. Virol. 86:6097-6108(2012).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22915799; DOI=10.1128/jvi.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by P
RT   bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [22]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) which acts as an inhibitor
CC       of retrovirus replication and retrotransposon mobility via deaminase-
CC       dependent and -independent mechanisms. After the penetration of
CC       retroviral nucleocapsids into target cells of infection and the
CC       initiation of reverse transcription, it can induce the conversion of
CC       cytosine to uracil in the minus-sense single-strand viral DNA, leading
CC       to G-to-A hypermutations in the subsequent plus-strand viral DNA. The
CC       resultant detrimental levels of mutations in the proviral genome, along
CC       with a deamination-independent mechanism that works prior to the
CC       proviral integration, together exert efficient antiretroviral effects
CC       in infected target cells. Selectively targets single-stranded DNA and
CC       does not deaminate double-stranded DNA or single- or double-stranded
CC       RNA. Exhibits antiviral activity against simian immunodeficiency virus
CC       (SIV), hepatitis B virus (HBV) and human T-cell leukemia virus type 1
CC       (HTLV-1) and may inhibit the mobility of LTR and non-LTR
CC       retrotransposons. {ECO:0000269|PubMed:12859895,
CC       ECO:0000269|PubMed:15466872, ECO:0000269|PubMed:16060832,
CC       ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:20062055,
CC       ECO:0000269|PubMed:22457529}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxycytidine in a single-stranded DNA + H(+) + H2O = a
CC         2'-deoxyuridine in a single-stranded DNA + NH4(+);
CC         Xref=Rhea:RHEA:50948, Rhea:RHEA-COMP:12846, Rhea:RHEA-COMP:12847,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:85452, ChEBI:CHEBI:133902; EC=3.5.4.38;
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC   -!- SUBUNIT: Homodimer. Interacts with APOBEC3G. Does not interact with
CC       APOBEC1. {ECO:0000269|PubMed:11863358}.
CC   -!- INTERACTION:
CC       Q9UH17-2; O95994: AGR2; NbExp=3; IntAct=EBI-17624977, EBI-712648;
CC       Q9UH17-2; Q12982: BNIP2; NbExp=3; IntAct=EBI-17624977, EBI-752094;
CC       Q9UH17; P11802: CDK4; NbExp=9; IntAct=EBI-2967317, EBI-295644;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16699599,
CC       ECO:0000269|PubMed:18667511, ECO:0000269|PubMed:21835787,
CC       ECO:0000269|PubMed:22915799}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UH17-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UH17-2; Sequence=VSP_009802;
CC       Name=3;
CC         IsoId=Q9UH17-3; Sequence=VSP_044900;
CC   -!- TISSUE SPECIFICITY: Expressed at high and moderate levels in peripheral
CC       blood leukocytes, spleen, testes, heart, thymus, prostate and ovary.
CC       Also expressed at low levels in several other tissues.
CC       {ECO:0000269|PubMed:11863358, ECO:0000269|PubMed:20308164}.
CC   -!- INDUCTION: Phorbol 12-myristate 13-acetate (PMA) induces overexpression
CC       in keratinocytes. Up-regulated by IFN-alpha.
CC       {ECO:0000269|PubMed:10469298}.
CC   -!- DOMAIN: The CMP/dCMP deaminase domain 1 mediates RNA binding, RNA-
CC       dependent oligomerization and virion incorporation whereas the CMP/dCMP
CC       deaminase domain 2 confers deoxycytidine deaminase activity and
CC       substrate sequence specificity. {ECO:0000269|PubMed:17020885}.
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes found in
CC       a cluster, thought to result from gene duplication, on chromosome 22.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be due to a competing donor splice
CC       site. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD00089.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAD00090.1; Type=Frameshift; Note=Frameshifts result in two separate ORFs termed phorbolins 2 and 3.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U61083; AAD00089.1; ALT_INIT; mRNA.
DR   EMBL; U61084; AAD00090.1; ALT_FRAME; mRNA.
DR   EMBL; AY743217; AAW31743.1; -; mRNA.
DR   EMBL; CT841510; CAJ86440.1; -; mRNA.
DR   EMBL; AL022318; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC053859; AAH53859.1; -; mRNA.
DR   CCDS; CCDS13982.1; -. [Q9UH17-1]
DR   CCDS; CCDS58807.1; -. [Q9UH17-3]
DR   RefSeq; NP_001257340.1; NM_001270411.1. [Q9UH17-3]
DR   RefSeq; NP_004891.4; NM_004900.4. [Q9UH17-1]
DR   PDB; 2NBQ; NMR; -; A=187-382.
DR   PDB; 5CQD; X-ray; 2.08 A; A/C=187-378.
DR   PDB; 5CQH; X-ray; 1.73 A; A=187-378.
DR   PDB; 5CQI; X-ray; 1.68 A; A=187-378.
DR   PDB; 5CQK; X-ray; 1.88 A; A=187-378.
DR   PDB; 5SXG; X-ray; 1.93 A; A/B=191-378.
DR   PDB; 5SXH; X-ray; 1.78 A; A/B=191-378.
DR   PDB; 5TD5; X-ray; 1.72 A; A=187-378.
DR   PDB; 5TKM; X-ray; 1.90 A; A/B=1-191.
DR   PDB; 6NFK; X-ray; 1.86 A; A=187-378.
DR   PDB; 6NFL; X-ray; 1.73 A; A=187-378.
DR   PDB; 6NFM; X-ray; 2.53 A; A=187-378.
DR   PDBsum; 2NBQ; -.
DR   PDBsum; 5CQD; -.
DR   PDBsum; 5CQH; -.
DR   PDBsum; 5CQI; -.
DR   PDBsum; 5CQK; -.
DR   PDBsum; 5SXG; -.
DR   PDBsum; 5SXH; -.
DR   PDBsum; 5TD5; -.
DR   PDBsum; 5TKM; -.
DR   PDBsum; 6NFK; -.
DR   PDBsum; 6NFL; -.
DR   PDBsum; 6NFM; -.
DR   SMR; Q9UH17; -.
DR   BioGrid; 114950; 79.
DR   IntAct; Q9UH17; 22.
DR   MINT; Q9UH17; -.
DR   STRING; 9606.ENSP00000327459; -.
DR   iPTMnet; Q9UH17; -.
DR   PhosphoSitePlus; Q9UH17; -.
DR   BioMuta; APOBEC3B; -.
DR   DMDM; 12643884; -.
DR   EPD; Q9UH17; -.
DR   jPOST; Q9UH17; -.
DR   MassIVE; Q9UH17; -.
DR   PaxDb; Q9UH17; -.
DR   PeptideAtlas; Q9UH17; -.
DR   PRIDE; Q9UH17; -.
DR   ProteomicsDB; 2630; -.
DR   ProteomicsDB; 84274; -. [Q9UH17-1]
DR   ProteomicsDB; 84275; -. [Q9UH17-2]
DR   Antibodypedia; 35027; 163 antibodies.
DR   DNASU; 9582; -.
DR   Ensembl; ENST00000333467; ENSP00000327459; ENSG00000179750. [Q9UH17-1]
DR   Ensembl; ENST00000335760; ENSP00000338897; ENSG00000179750. [Q9UH17-2]
DR   Ensembl; ENST00000407298; ENSP00000385068; ENSG00000179750. [Q9UH17-3]
DR   GeneID; 9582; -.
DR   KEGG; hsa:9582; -.
DR   UCSC; uc003awo.3; human. [Q9UH17-1]
DR   CTD; 9582; -.
DR   DisGeNET; 9582; -.
DR   GeneCards; APOBEC3B; -.
DR   HGNC; HGNC:17352; APOBEC3B.
DR   HPA; ENSG00000179750; Tissue enhanced (bone).
DR   MIM; 607110; gene.
DR   neXtProt; NX_Q9UH17; -.
DR   OpenTargets; ENSG00000179750; -.
DR   PharmGKB; PA24892; -.
DR   eggNOG; ENOG410JBA1; Eukaryota.
DR   eggNOG; ENOG41119MS; LUCA.
DR   GeneTree; ENSGT00940000164701; -.
DR   HOGENOM; CLU_047918_0_0_1; -.
DR   KO; K18750; -.
DR   OrthoDB; 586309at2759; -.
DR   PhylomeDB; Q9UH17; -.
DR   TreeFam; TF331356; -.
DR   Reactome; R-HSA-72200; mRNA Editing: C to U Conversion.
DR   Reactome; R-HSA-75094; Formation of the Editosome.
DR   ChiTaRS; APOBEC3B; human.
DR   GeneWiki; APOBEC3B; -.
DR   GenomeRNAi; 9582; -.
DR   Pharos; Q9UH17; Tbio.
DR   PRO; PR:Q9UH17; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; Q9UH17; protein.
DR   Bgee; ENSG00000179750; Expressed in mucosa of transverse colon and 80 other tissues.
DR   ExpressionAtlas; Q9UH17; baseline and differential.
DR   Genevisible; Q9UH17; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000932; C:P-body; IBA:GO_Central.
DR   GO; GO:0004126; F:cytidine deaminase activity; IBA:GO_Central.
DR   GO; GO:0047844; F:deoxycytidine deaminase activity; IMP:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0016554; P:cytidine to uridine editing; IBA:GO_Central.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0070383; P:DNA cytosine deamination; IBA:GO_Central.
DR   GO; GO:0080111; P:DNA demethylation; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0045869; P:negative regulation of single stranded viral RNA replication via double stranded DNA intermediate; IBA:GO_Central.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR002125; CMP_dCMP_dom.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   SUPFAM; SSF53927; SSF53927; 2.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES_1; 2.
DR   PROSITE; PS51747; CYT_DCMP_DEAMINASES_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Antiviral defense; Hydrolase; Immunity;
KW   Innate immunity; Metal-binding; Nucleus; Polymorphism; Reference proteome;
KW   Repeat; RNA-binding; Zinc.
FT   CHAIN           1..382
FT                   /note="DNA dC->dU-editing enzyme APOBEC-3B"
FT                   /id="PRO_0000171753"
FT   DOMAIN          29..138
FT                   /note="CMP/dCMP-type deaminase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01083"
FT   DOMAIN          210..326
FT                   /note="CMP/dCMP-type deaminase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01083"
FT   ACT_SITE        255
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255"
FT   METAL           66
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           97
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           100
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           253
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           284
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           289
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         191..382
FT                   /note="YLMDPDTFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVLMDQHMGFLCNEA
FT                   KNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENT
FT                   HVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPWD
FT                   GLEEHSQALSGRLRAILQNQGN -> LRIFSVAFTAAMRSCASWTWFLLCSWTRPRSTG
FT                   SLGSSPGAPASPGAVPGKCVRSFRRTHT (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_009802"
FT   VAR_SEQ         242..266
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15461802"
FT                   /id="VSP_044900"
FT   VARIANT         62
FT                   /note="K -> E (in dbSNP:rs2076109)"
FT                   /evidence="ECO:0000269|PubMed:15461802"
FT                   /id="VAR_018142"
FT   VARIANT         98
FT                   /note="P -> L (in dbSNP:rs2076110)"
FT                   /id="VAR_018143"
FT   VARIANT         109
FT                   /note="S -> A (in dbSNP:rs17000697)"
FT                   /id="VAR_033455"
FT   VARIANT         146
FT                   /note="T -> K (in dbSNP:rs5995649)"
FT                   /evidence="ECO:0000269|PubMed:10469298,
FT                   ECO:0000269|PubMed:15461802, ECO:0000269|PubMed:15489334"
FT                   /id="VAR_018144"
FT   VARIANT         351
FT                   /note="R -> H (in dbSNP:rs1053813)"
FT                   /id="VAR_048722"
FT   CONFLICT        103..104
FT                   /note="KL -> NV (in Ref. 1; AAD00090)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227..228
FT                   /note="TW -> WM (in Ref. 1; AAD00089)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        255..256
FT                   /note="EL -> DW (in Ref. 1; AAD00089)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        306
FT                   /note="R -> P (in Ref. 1; AAD00089)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        356
FT                   /note="F -> S (in Ref. 2; AAW31743)"
FT                   /evidence="ECO:0000305"
FT   HELIX           14..21
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   STRAND          32..43
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   STRAND          46..61
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   HELIX           63..65
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   HELIX           67..78
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   STRAND          86..94
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   HELIX           98..110
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   STRAND          114..122
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   HELIX           128..131
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   HELIX           134..140
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   STRAND          144..147
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   HELIX           150..160
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   HELIX           174..188
FT                   /evidence="ECO:0000244|PDB:5TKM"
FT   HELIX           195..202
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   STRAND          215..224
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   STRAND          227..230
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   HELIX           232..234
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   STRAND          236..239
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   HELIX           245..247
FT                   /evidence="ECO:0000244|PDB:2NBQ"
FT   HELIX           254..261
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   HELIX           262..265
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   STRAND          269..271
FT                   /evidence="ECO:0000244|PDB:2NBQ"
FT   STRAND          273..281
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   HELIX           289..299
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   TURN            300..302
FT                   /evidence="ECO:0000244|PDB:2NBQ"
FT   STRAND          303..311
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   HELIX           319..328
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   STRAND          332..335
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   HELIX           338..348
FT                   /evidence="ECO:0000244|PDB:5CQI"
FT   HELIX           362..377
FT                   /evidence="ECO:0000244|PDB:5CQI"
SQ   SEQUENCE   382 AA;  45924 MW;  DA6EDD23E8856240 CRC64;
     MNPQIRNPME RMYRDTFYDN FENEPILYGR SYTWLCYEVK IKRGRSNLLW DTGVFRGQVY
     FKPQYHAEMC FLSWFCGNQL PAYKCFQITW FVSWTPCPDC VAKLAEFLSE HPNVTLTISA
     ARLYYYWERD YRRALCRLSQ AGARVTIMDY EEFAYCWENF VYNEGQQFMP WYKFDENYAF
     LHRTLKEILR YLMDPDTFTF NFNNDPLVLR RRQTYLCYEV ERLDNGTWVL MDQHMGFLCN
     EAKNLLCGFY GRHAELRFLD LVPSLQLDPA QIYRVTWFIS WSPCFSWGCA GEVRAFLQEN
     THVRLRIFAA RIYDYDPLYK EALQMLRDAG AQVSIMTYDE FEYCWDTFVY RQGCPFQPWD
     GLEEHSQALS GRLRAILQNQ GN
//
ID   AT1A1_HUMAN             Reviewed;        1023 AA.
AC   P05023; B2RBR6; B7Z2T5; B7Z3U6; F5H3A1; Q16689; Q6LDM4; Q9UCN1; Q9UJ20;
AC   Q9UJ21;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   22-APR-2020, entry version 236.
DE   RecName: Full=Sodium/potassium-transporting ATPase subunit alpha-1;
DE            Short=Na(+)/K(+) ATPase alpha-1 subunit;
DE            EC=7.2.2.13;
DE   AltName: Full=Sodium pump subunit alpha-1;
DE   Flags: Precursor;
GN   Name=ATP1A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2430951; DOI=10.1093/oxfordjournals.jbchem.a121726;
RA   Kawakami K., Ohta T., Nojima H., Nagano K.;
RT   "Primary structure of the alpha-subunit of human Na,K-ATPase deduced from
RT   cDNA sequence.";
RL   J. Biochem. 100:389-397(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Retinal pigment epithelium;
RX   PubMed=7536695; DOI=10.1016/0378-1119(94)00812-7;
RA   Ruiz A., Bhat S.P., Bok D.;
RT   "Characterization and quantification of full-length and truncated Na,K-
RT   ATPase alpha 1 and beta 1 RNA transcripts expressed in human retinal
RT   pigment epithelium.";
RL   Gene 155:179-184(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Cervix, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-61.
RX   PubMed=1970326; DOI=10.1016/0888-7543(90)90475-a;
RA   Shull M.M., Pugh D.G., Lingrel J.B.;
RT   "The human Na, K-ATPase alpha 1 gene: characterization of the 5'-flanking
RT   region and identification of a restriction fragment length polymorphism.";
RL   Genomics 6:451-460(1990).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 85-148.
RC   TISSUE=Placenta;
RA   Zhang J.-S., Yang J.X., Fang M.W., Lu S.D.;
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 168-189 AND 213-244.
RX   PubMed=3035563; DOI=10.1073/pnas.84.12.4039;
RA   Shull M.M., Lingrel J.B.;
RT   "Multiple genes encode the human Na+,K+-ATPase catalytic subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4039-4043(1987).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 198-943 (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2891135; DOI=10.1073/pnas.84.22.7901;
RA   Chehab F.F., Kan Y.W., Law M.L., Hartz J., Kao F.T., Blostein R.;
RT   "Human placental Na+,K+-ATPase alpha subunit: cDNA cloning, tissue
RT   expression, DNA polymorphism, and chromosomal localization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7901-7905(1987).
RN   [11]
RP   PROTEIN SEQUENCE OF 199-216, AND INTERACTION WITH HLA-DR1.
RX   PubMed=1380674; DOI=10.1038/358764a0;
RA   Chicz R.M., Urban R.G., Lane W.S., Gorga J.C., Stern L.J., Vignali D.A.A.,
RA   Strominger J.L.;
RT   "Predominant naturally processed peptides bound to HLA-DR1 are derived from
RT   MHC-related molecules and are heterogeneous in size.";
RL   Nature 358:764-768(1992).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 253-341 AND 420-444.
RX   PubMed=3036582; DOI=10.1016/0014-5793(87)80677-4;
RA   Sverdlov E.D., Monastyrskaya G.S., Broude N.E., Ushkaryov Y.A.,
RA   Allikmets R.L., Melkov A.M., Smirnov Y.V., Malyshev I.V., Dulubova I.E.,
RA   Petrukhin K.E., Gryshin A.V., Kiyatkin N.I., Kostina M.B., Sverdlov V.E.,
RA   Modyanov N.N., Ovchinnikov Y.A.;
RT   "The family of human Na+,K+-ATPase genes. No less than five genes and/or
RT   pseudogenes related to the alpha-subunit.";
RL   FEBS Lett. 217:275-278(1987).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 471-619.
RA   Ovchinnikov Y.A., Monastyrskaya G.S., Arsenyan S.G., Broude N.E.,
RA   Petrukhin K.E., Grishin A.V., Arzamazova N.M., Severtsova I.V.,
RA   Modyanov N.N.;
RT   "Amino acid sequence of the 17-kilodalton fragment of the cytoplasmic
RT   region of the alpha-subunit of NA+,K+-ATPase.";
RL   Dokl. Biochem. 288:270-272(1986).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=7711835; DOI=10.3109/09687689409160435;
RA   Hundal H.S., Maxwell D.L., Ahmed A., Darakhshan F., Mitsumoto Y., Klip A.;
RT   "Subcellular distribution and immunocytochemical localization of Na,K-
RT   ATPase subunit isoforms in human skeletal muscle.";
RL   Mol. Membr. Biol. 11:255-262(1994).
RN   [15]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [16]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J.,
RA   Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S.,
RA   Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [17]
RP   INTERACTION WITH CLN3.
RX   PubMed=18621045; DOI=10.1016/j.yexcr.2008.06.016;
RA   Uusi-Rauva K., Luiro K., Tanhuanpaeae K., Kopra O., Martin-Vasallo P.,
RA   Kyttaelae A., Jalanko A.;
RT   "Novel interactions of CLN3 protein link Batten disease to dysregulation of
RT   fodrin-Na+, K+ ATPase complex.";
RL   Exp. Cell Res. 314:2895-2905(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-542, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   INTERACTION WITH FXYD3.
RX   PubMed=21454534; DOI=10.1074/jbc.m110.184101;
RA   Bibert S., Liu C.C., Figtree G.A., Garcia A., Hamilton E.J., Marassi F.M.,
RA   Sweadner K.J., Cornelius F., Geering K., Rasmussen H.H.;
RT   "FXYD proteins reverse inhibition of the Na+-K+ pump mediated by
RT   glutathionylation of its beta1 subunit.";
RL   J. Biol. Chem. 286:18562-18572(2011).
RN   [22]
RP   INTERACTION WITH SLC35G1 AND STIM1.
RX   PubMed=22084111; DOI=10.1073/pnas.1117231108;
RA   Krapivinsky G., Krapivinsky L., Stotz S.C., Manasian Y., Clapham D.E.;
RT   "POST, partner of stromal interaction molecule 1 (STIM1), targets STIM1 to
RT   multiple transporters.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:19234-19239(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-16, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [26]
RP   INVOLVEMENT IN CMT2DD, VARIANTS CMT2DD ARG-48; THR-592; THR-597; ALA-600;
RP   THR-600; PHE-601 AND ALA-811, CHARACTERIZATION OF VARIANTS CMT2DD ARG-48;
RP   ALA-600 AND ALA-811, AND FUNCTION.
RX   PubMed=29499166; DOI=10.1016/j.ajhg.2018.01.023;
RA   Lassuthova P., Rebelo A.P., Ravenscroft G., Lamont P.J., Davis M.R.,
RA   Manganelli F., Feely S.M., Bacon C., Brozkova D.S., Haberlova J.,
RA   Mazanec R., Tao F., Saghira C., Abreu L., Courel S., Powell E., Buglo E.,
RA   Bis D.M., Baxter M.F., Ong R.W., Marns L., Lee Y.C., Bai Y., Isom D.G.,
RA   Barro-Soria R., Chung K.W., Scherer S.S., Larsson H.P., Laing N.G.,
RA   Choi B.O., Seeman P., Shy M.E., Santoro L., Zuchner S.;
RT   "Mutations in ATP1A1 Cause Dominant Charcot-Marie-Tooth Type 2.";
RL   Am. J. Hum. Genet. 102:505-514(2018).
RN   [27]
RP   INVOLVEMENT IN HOMGSMR2, VARIANTS HOMGSMR2 ARG-302; ARG-303 AND ARG-859,
RP   CHARACTERIZATION OF VARIANTS HOMGSMR2 ARG-302; ARG-303 AND ARG-859, AND
RP   FUNCTION.
RX   PubMed=30388404; DOI=10.1016/j.ajhg.2018.10.004;
RA   Schlingmann K.P., Bandulik S., Mammen C., Tarailo-Graovac M., Holm R.,
RA   Baumann M., Koenig J., Lee J.J.Y., Droegemoeller B., Imminger K.,
RA   Beck B.B., Altmueller J., Thiele H., Waldegger S., Van't Hoff W., Kleta R.,
RA   Warth R., van Karnebeek C.D.M., Vilsen B., Bockenhauer D., Konrad M.;
RT   "Germline de novo mutations in ATP1A1 cause renal hypomagnesemia,
RT   refractory seizures, and intellectual disability.";
RL   Am. J. Hum. Genet. 103:808-816(2018).
CC   -!- FUNCTION: This is the catalytic component of the active enzyme, which
CC       catalyzes the hydrolysis of ATP coupled with the exchange of sodium and
CC       potassium ions across the plasma membrane. This action creates the
CC       electrochemical gradient of sodium and potassium ions, providing the
CC       energy for active transport of various nutrients.
CC       {ECO:0000269|PubMed:29499166, ECO:0000269|PubMed:30388404}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O + K(+)(out) + Na(+)(in) = ADP + H(+) + K(+)(in) +
CC         Na(+)(out) + phosphate; Xref=Rhea:RHEA:18353, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29101, ChEBI:CHEBI:29103,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         EC=7.2.2.13;
CC   -!- SUBUNIT: The sodium/potassium-transporting ATPase is composed of a
CC       catalytic alpha subunit, an auxiliary non-catalytic beta subunit and an
CC       additional regulatory subunit. Interacts with regulatory subunit FXYD1
CC       (By similarity). Interacts with regulatory subunit FXYD3
CC       (PubMed:21454534). Interacts with SIK1 (By similarity). Binds the HLA
CC       class II histocompatibility antigen DR1 (PubMed:1380674). Interacts
CC       with SLC35G1 and STIM1 (PubMed:22084111). Interacts with CLN3; this
CC       interaction regulates the sodium/potassium-transporting ATPase complex
CC       localization at the plasma membrane (Probable).
CC       {ECO:0000250|UniProtKB:P06685, ECO:0000269|PubMed:1380674,
CC       ECO:0000269|PubMed:21454534, ECO:0000269|PubMed:22084111,
CC       ECO:0000305|PubMed:18621045}.
CC   -!- INTERACTION:
CC       P05023; P05026: ATP1B1; NbExp=2; IntAct=EBI-358778, EBI-714630;
CC       P05023; P13693: TPT1; NbExp=5; IntAct=EBI-358778, EBI-1783169;
CC   -!- SUBCELLULAR LOCATION: Cell membrane, sarcolemma
CC       {ECO:0000269|PubMed:7711835}; Multi-pass membrane protein
CC       {ECO:0000255}. Melanosome {ECO:0000269|PubMed:17081065}.
CC       Note=Identified by mass spectrometry in melanosome fractions from stage
CC       I to stage IV. {ECO:0000269|PubMed:17081065}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long;
CC         IsoId=P05023-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P05023-2; Sequence=VSP_000415, VSP_000416;
CC       Name=3;
CC         IsoId=P05023-3; Sequence=VSP_044242;
CC       Name=4;
CC         IsoId=P05023-4; Sequence=VSP_047309;
CC   -!- PTM: Phosphorylation on Tyr-10 modulates pumping activity.
CC       Phosphorylation of Ser-943 by PKA modulates the response of ATP1A1 to
CC       PKC. Dephosphorylation by protein phosphatase 2A (PP2A) following
CC       increases in intracellular sodium, leading to increase catalytic
CC       activity (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease 2DD (CMT2DD) [MIM:618036]: A
CC       dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the
CC       peripheral nervous system, characterized by progressive weakness and
CC       atrophy, initially of the peroneal muscles and later of the distal
CC       muscles of the arms. Charcot-Marie-Tooth disease is classified in two
CC       main groups on the basis of electrophysiologic properties and
CC       histopathology: primary peripheral demyelinating neuropathies
CC       (designated CMT1 when they are dominantly inherited) and primary
CC       peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group
CC       are characterized by signs of axonal degeneration in the absence of
CC       obvious myelin alterations, normal or slightly reduced nerve conduction
CC       velocities, and progressive distal muscle weakness and atrophy.
CC       {ECO:0000269|PubMed:29499166}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hypomagnesemia, seizures, and mental retardation 2 (HOMGSMR2)
CC       [MIM:618314]: An autosomal dominant disease characterized by
CC       generalized seizures in infancy, severe hypomagnesemia, and renal
CC       magnesium wasting. Seizures persist despite magnesium supplementation
CC       and are associated with significant intellectual disability.
CC       {ECO:0000269|PubMed:30388404}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type) (TC 3.A.3)
CC       family. Type IIC subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D00099; BAA00061.1; -; mRNA.
DR   EMBL; X04297; CAA27840.1; -; mRNA.
DR   EMBL; U16798; AAC50131.1; -; mRNA.
DR   EMBL; AK295095; BAH11971.1; -; mRNA.
DR   EMBL; AK296362; BAH12332.1; -; mRNA.
DR   EMBL; AK314777; BAG37313.1; -; mRNA.
DR   EMBL; AL136376; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471122; EAW56644.1; -; Genomic_DNA.
DR   EMBL; BC003077; AAH03077.1; -; mRNA.
DR   EMBL; BC001330; AAH01330.1; -; mRNA.
DR   EMBL; BC050359; AAH50359.1; -; mRNA.
DR   EMBL; M30310; AAA51801.1; -; Genomic_DNA.
DR   EMBL; M30309; AAA51801.1; JOINED; Genomic_DNA.
DR   EMBL; L76938; AAA92713.1; -; Genomic_DNA.
DR   EMBL; M16793; AAD56251.1; -; mRNA.
DR   EMBL; M16794; AAD56252.1; -; mRNA.
DR   EMBL; J03007; AAA51803.1; -; mRNA.
DR   EMBL; M27572; AAA35573.1; -; Genomic_DNA.
DR   EMBL; M27579; AAA35574.2; -; Genomic_DNA.
DR   EMBL; X03757; CAA27390.1; -; mRNA.
DR   CCDS; CCDS53351.1; -. [P05023-4]
DR   CCDS; CCDS53352.1; -. [P05023-3]
DR   CCDS; CCDS887.1; -. [P05023-1]
DR   PIR; A24414; A24414.
DR   RefSeq; NP_000692.2; NM_000701.7. [P05023-1]
DR   RefSeq; NP_001153705.1; NM_001160233.1. [P05023-4]
DR   RefSeq; NP_001153706.1; NM_001160234.1. [P05023-3]
DR   RefSeq; XP_016856849.1; XM_017001360.1. [P05023-3]
DR   RefSeq; XP_016856850.1; XM_017001361.1. [P05023-3]
DR   SMR; P05023; -.
DR   BioGrid; 106966; 192.
DR   ComplexPortal; CPX-125; Sodium:potassium-exchanging ATPase complex.
DR   DIP; DIP-38196N; -.
DR   IntAct; P05023; 99.
DR   MINT; P05023; -.
DR   STRING; 9606.ENSP00000445306; -.
DR   BindingDB; P05023; -.
DR   ChEMBL; CHEMBL1807; -.
DR   DrugBank; DB00511; Acetyldigitoxin.
DR   DrugBank; DB01430; Almitrine.
DR   DrugBank; DB01370; Aluminium.
DR   DrugBank; DB14517; Aluminium phosphate.
DR   DrugBank; DB14518; Aluminum acetate.
DR   DrugBank; DB01244; Bepridil.
DR   DrugBank; DB01158; Bretylium.
DR   DrugBank; DB01188; Ciclopirox.
DR   DrugBank; DB01078; Deslanoside.
DR   DrugBank; DB01119; Diazoxide.
DR   DrugBank; DB01396; Digitoxin.
DR   DrugBank; DB00390; Digoxin.
DR   DrugBank; DB00903; Etacrynic acid.
DR   DrugBank; DB00774; Hydroflumethiazide.
DR   DrugBank; DB06157; Istaroxime.
DR   DrugBank; DB13996; Magnesium acetate.
DR   DrugBank; DB01378; Magnesium cation.
DR   DrugBank; DB13749; Magnesium gluconate.
DR   DrugBank; DB14515; Magnesium lactate.
DR   DrugBank; DB14514; Magnesium levulinate.
DR   DrugBank; DB01092; Ouabain.
DR   DrugBank; DB14500; Potassium.
DR   DrugBank; DB14498; Potassium acetate.
DR   DrugBank; DB01345; Potassium cation.
DR   DrugBank; DB13620; Potassium gluconate.
DR   DrugBank; DB14499; Potassium sulfate.
DR   DrugBank; DB09479; Rubidium Rb-82.
DR   DrugBank; DB01021; Trichlormethiazide.
DR   DrugCentral; P05023; -.
DR   TCDB; 3.A.3.1.1; the p-type atpase (p-atpase) superfamily.
DR   CarbonylDB; P05023; -.
DR   iPTMnet; P05023; -.
DR   MetOSite; P05023; -.
DR   PhosphoSitePlus; P05023; -.
DR   SwissPalm; P05023; -.
DR   BioMuta; ATP1A1; -.
DR   DMDM; 114374; -.
DR   EPD; P05023; -.
DR   jPOST; P05023; -.
DR   MassIVE; P05023; -.
DR   MaxQB; P05023; -.
DR   PaxDb; P05023; -.
DR   PeptideAtlas; P05023; -.
DR   PRIDE; P05023; -.
DR   ProteomicsDB; 26208; -.
DR   ProteomicsDB; 51768; -. [P05023-1]
DR   ProteomicsDB; 51769; -. [P05023-2]
DR   ProteomicsDB; 6547; -.
DR   Antibodypedia; 4542; 680 antibodies.
DR   DNASU; 476; -.
DR   Ensembl; ENST00000295598; ENSP00000295598; ENSG00000163399. [P05023-1]
DR   Ensembl; ENST00000369496; ENSP00000358508; ENSG00000163399. [P05023-3]
DR   Ensembl; ENST00000537345; ENSP00000445306; ENSG00000163399. [P05023-4]
DR   GeneID; 476; -.
DR   KEGG; hsa:476; -.
DR   UCSC; uc001ege.5; human. [P05023-1]
DR   CTD; 476; -.
DR   DisGeNET; 476; -.
DR   GeneCards; ATP1A1; -.
DR   HGNC; HGNC:799; ATP1A1.
DR   HPA; ENSG00000163399; Tissue enhanced (intestine, parathyroid gland).
DR   MalaCards; ATP1A1; -.
DR   MIM; 182310; gene.
DR   MIM; 618036; phenotype.
DR   MIM; 618314; phenotype.
DR   neXtProt; NX_P05023; -.
DR   OpenTargets; ENSG00000163399; -.
DR   Orphanet; 521414; Autosomal dominant Charcot-Marie-Tooth disease type 2DD.
DR   Orphanet; 85142; NON RARE IN EUROPE: Aldosterone-producing adenoma.
DR   PharmGKB; PA62; -.
DR   eggNOG; KOG0203; Eukaryota.
DR   eggNOG; COG0474; LUCA.
DR   GeneTree; ENSGT00940000154840; -.
DR   HOGENOM; CLU_002360_4_3_1; -.
DR   InParanoid; P05023; -.
DR   KO; K01539; -.
DR   OMA; FARIMPE; -.
DR   OrthoDB; 100699at2759; -.
DR   PhylomeDB; P05023; -.
DR   TreeFam; TF312838; -.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   Reactome; R-HSA-936837; Ion transport by P-type ATPases.
DR   ChiTaRS; ATP1A1; human.
DR   GeneWiki; ATPase,_Na%2B/K%2B_transporting,_alpha_1; -.
DR   GenomeRNAi; 476; -.
DR   Pharos; P05023; Tclin.
DR   PRO; PR:P05023; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P05023; protein.
DR   Bgee; ENSG00000163399; Expressed in cortex of kidney and 236 other tissues.
DR   ExpressionAtlas; P05023; baseline and differential.
DR   Genevisible; P05023; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0005623; C:cell; IEA:GOC.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:BHF-UCL.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; ISS:UniProtKB.
DR   GO; GO:0014704; C:intercalated disc; IEA:Ensembl.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0045121; C:membrane raft; ISS:ARUK-UCL.
DR   GO; GO:0031090; C:organelle membrane; IGI:ARUK-UCL.
DR   GO; GO:0060342; C:photoreceptor inner segment membrane; ISS:ARUK-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0042383; C:sarcolemma; ISS:BHF-UCL.
DR   GO; GO:0005890; C:sodium:potassium-exchanging ATPase complex; IDA:BHF-UCL.
DR   GO; GO:0036126; C:sperm flagellum; IDA:ARUK-UCL.
DR   GO; GO:0030315; C:T-tubule; IGI:ARUK-UCL.
DR   GO; GO:0043531; F:ADP binding; IEA:Ensembl.
DR   GO; GO:0030506; F:ankyrin binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; ISS:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0016791; F:phosphatase activity; IEA:Ensembl.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IEA:Ensembl.
DR   GO; GO:0030955; F:potassium ion binding; ISS:BHF-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:ARUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0031402; F:sodium ion binding; ISS:BHF-UCL.
DR   GO; GO:0005391; F:sodium:potassium-exchanging ATPase activity; IDA:BHF-UCL.
DR   GO; GO:1990239; F:steroid hormone binding; IDA:BHF-UCL.
DR   GO; GO:0086002; P:cardiac muscle cell action potential involved in contraction; TAS:BHF-UCL.
DR   GO; GO:0086064; P:cell communication by electrical coupling involved in cardiac conduction; TAS:BHF-UCL.
DR   GO; GO:0030007; P:cellular potassium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0071383; P:cellular response to steroid hormone stimulus; IDA:BHF-UCL.
DR   GO; GO:0006883; P:cellular sodium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0060081; P:membrane hyperpolarization; IEA:Ensembl.
DR   GO; GO:0086009; P:membrane repolarization; IDA:BHF-UCL.
DR   GO; GO:0086013; P:membrane repolarization during cardiac muscle cell action potential; IC:BHF-UCL.
DR   GO; GO:0031947; P:negative regulation of glucocorticoid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045822; P:negative regulation of heart contraction; IEA:Ensembl.
DR   GO; GO:0045823; P:positive regulation of heart contraction; IEA:Ensembl.
DR   GO; GO:0045989; P:positive regulation of striated muscle contraction; IEA:Ensembl.
DR   GO; GO:1990573; P:potassium ion import across plasma membrane; IDA:BHF-UCL.
DR   GO; GO:1902600; P:proton transmembrane transport; IBA:GO_Central.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:1903779; P:regulation of cardiac conduction; TAS:Reactome.
DR   GO; GO:0086004; P:regulation of cardiac muscle cell contraction; IEA:Ensembl.
DR   GO; GO:0002028; P:regulation of sodium ion transport; ISS:UniProtKB.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; IEA:Ensembl.
DR   GO; GO:0055119; P:relaxation of cardiac muscle; TAS:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:1903416; P:response to glycoside; IDA:BHF-UCL.
DR   GO; GO:0036376; P:sodium ion export across plasma membrane; IDA:BHF-UCL.
DR   CDD; cd02608; P-type_ATPase_Na-K_like; 1.
DR   Gene3D; 3.40.1110.10; -; 1.
DR   Gene3D; 3.40.50.1000; -; 1.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR023299; ATPase_P-typ_cyto_dom_N.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR023298; ATPase_P-typ_TM_dom_sf.
DR   InterPro; IPR008250; ATPase_P-typ_transduc_dom_A_sf.
DR   InterPro; IPR036412; HAD-like_sf.
DR   InterPro; IPR023214; HAD_sf.
DR   InterPro; IPR005775; P-type_ATPase_IIC.
DR   InterPro; IPR001757; P_typ_ATPase.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   SUPFAM; SSF56784; SSF56784; 1.
DR   SUPFAM; SSF81653; SSF81653; 1.
DR   SUPFAM; SSF81660; SSF81660; 1.
DR   SUPFAM; SSF81665; SSF81665; 1.
DR   TIGRFAMs; TIGR01106; ATPase-IIC_X-K; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 2.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Cell membrane;
KW   Charcot-Marie-Tooth disease; Direct protein sequencing; Epilepsy;
KW   Ion transport; Magnesium; Membrane; Mental retardation; Metal-binding;
KW   Neurodegeneration; Neuropathy; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Potassium; Potassium transport; Primary hypomagnesemia;
KW   Reference proteome; Sodium; Sodium transport; Sodium/potassium transport;
KW   Translocase; Transmembrane; Transmembrane helix; Transport.
FT   PROPEP          1..5
FT                   /id="PRO_0000002483"
FT   CHAIN           6..1023
FT                   /note="Sodium/potassium-transporting ATPase subunit alpha-
FT                   1"
FT                   /id="PRO_0000002484"
FT   TOPO_DOM        6..87
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        88..108
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        109..131
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        132..152
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        153..288
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        289..308
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        309..320
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        321..338
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        339..772
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        773..792
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        793..802
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        803..823
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        824..843
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        844..866
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        867..918
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        919..938
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        939..951
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        952..970
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        971..985
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        986..1006
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1007..1023
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          82..84
FT                   /note="Phosphoinositide-3 kinase binding"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        376
FT                   /note="4-aspartylphosphate intermediate"
FT                   /evidence="ECO:0000250"
FT   METAL           717
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000250"
FT   METAL           721
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000250"
FT   BINDING         487
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         9
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDN2"
FT   MOD_RES         10
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P06685"
FT   MOD_RES         16
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         21
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDN2"
FT   MOD_RES         40
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06685"
FT   MOD_RES         47
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06685"
FT   MOD_RES         228
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDN2"
FT   MOD_RES         260
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDN2"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06685"
FT   MOD_RES         484
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06685"
FT   MOD_RES         542
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         661
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDN2"
FT   MOD_RES         668
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDN2"
FT   MOD_RES         675
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VDN2"
FT   MOD_RES         943
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000250|UniProtKB:P06685"
FT   VAR_SEQ         1..31
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044242"
FT   VAR_SEQ         2..4
FT                   /note="GKG -> AFK (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047309"
FT   VAR_SEQ         638..681
FT                   /note="NETVEDIAARLNIPVSQVNPRDAKACVVHGSDLKDMTSEQLDDI -> SGPM
FT                   SRGKSWSSPATQPSSSVSWWCSGPTWSSVRPGGIRSSSRG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7536695"
FT                   /id="VSP_000415"
FT   VAR_SEQ         682..1023
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7536695"
FT                   /id="VSP_000416"
FT   VARIANT         47
FT                   /note="S -> I (in dbSNP:rs12564026)"
FT                   /id="VAR_048374"
FT   VARIANT         48
FT                   /note="L -> R (in CMT2DD; no effect on Na(+)-dependent
FT                   currents; dbSNP:rs1553190285)"
FT                   /evidence="ECO:0000269|PubMed:29499166"
FT                   /id="VAR_081039"
FT   VARIANT         302
FT                   /note="L -> R (in HOMGSMR2; results in altered sodium and
FT                   potassium transport as shown by in vitro functional
FT                   expression of the homologous rat variant)"
FT                   /evidence="ECO:0000269|PubMed:30388404"
FT                   /id="VAR_081937"
FT   VARIANT         303
FT                   /note="G -> R (in HOMGSMR2; results in altered sodium and
FT                   potassium transport as shown by in vitro functional
FT                   expression of the homologous rat variant)"
FT                   /evidence="ECO:0000269|PubMed:30388404"
FT                   /id="VAR_081938"
FT   VARIANT         592
FT                   /note="I -> T (in CMT2DD; unknown pathological
FT                   significance; dbSNP:rs1553192086)"
FT                   /evidence="ECO:0000269|PubMed:29499166"
FT                   /id="VAR_081040"
FT   VARIANT         597
FT                   /note="A -> T (in CMT2DD; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:29499166"
FT                   /id="VAR_081041"
FT   VARIANT         600
FT                   /note="P -> A (in CMT2DD; shows fewer Na(+)-dependent
FT                   currents than wild-type protein; dbSNP:rs1553192091)"
FT                   /evidence="ECO:0000269|PubMed:29499166"
FT                   /id="VAR_081042"
FT   VARIANT         600
FT                   /note="P -> T (in CMT2DD; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:29499166"
FT                   /id="VAR_081043"
FT   VARIANT         601
FT                   /note="D -> F (in CMT2DD; unknown pathological
FT                   significance; requires 2 nucleotide substitutions)"
FT                   /evidence="ECO:0000269|PubMed:29499166"
FT                   /id="VAR_081044"
FT   VARIANT         811
FT                   /note="D -> A (in CMT2DD; shows fewer Na(+)-dependent
FT                   currents than wild-type protein; dbSNP:rs1553192783)"
FT                   /evidence="ECO:0000269|PubMed:29499166"
FT                   /id="VAR_081045"
FT   VARIANT         859
FT                   /note="M -> R (in HOMGSMR2; results in altered sodium and
FT                   potassium transport as shown by in vitro functional
FT                   expression of the homologous rat variant)"
FT                   /evidence="ECO:0000269|PubMed:30388404"
FT                   /id="VAR_081939"
FT   CONFLICT        248
FT                   /note="N -> S (in Ref. 3; BAG37313)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        323
FT                   /note="F -> L (in Ref. 3; BAH11971)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        475
FT                   /note="A -> T (in Ref. 13; CAA27390)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        499
FT                   /note="S -> A (in Ref. 13; CAA27390)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        502
FT                   /note="Q -> R (in Ref. 13; CAA27390)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        523
FT                   /note="L -> I (in Ref. 13; CAA27390)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        892
FT                   /note="D -> G (in Ref. 3; BAH11971)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1023 AA;  112896 MW;  F3C6FDE04FB3F667 CRC64;
     MGKGVGRDKY EPAAVSEQGD KKGKKGKKDR DMDELKKEVS MDDHKLSLDE LHRKYGTDLS
     RGLTSARAAE ILARDGPNAL TPPPTTPEWI KFCRQLFGGF SMLLWIGAIL CFLAYSIQAA
     TEEEPQNDNL YLGVVLSAVV IITGCFSYYQ EAKSSKIMES FKNMVPQQAL VIRNGEKMSI
     NAEEVVVGDL VEVKGGDRIP ADLRIISANG CKVDNSSLTG ESEPQTRSPD FTNENPLETR
     NIAFFSTNCV EGTARGIVVY TGDRTVMGRI ATLASGLEGG QTPIAAEIEH FIHIITGVAV
     FLGVSFFILS LILEYTWLEA VIFLIGIIVA NVPEGLLATV TVCLTLTAKR MARKNCLVKN
     LEAVETLGST STICSDKTGT LTQNRMTVAH MWFDNQIHEA DTTENQSGVS FDKTSATWLA
     LSRIAGLCNR AVFQANQENL PILKRAVAGD ASESALLKCI ELCCGSVKEM RERYAKIVEI
     PFNSTNKYQL SIHKNPNTSE PQHLLVMKGA PERILDRCSS ILLHGKEQPL DEELKDAFQN
     AYLELGGLGE RVLGFCHLFL PDEQFPEGFQ FDTDDVNFPI DNLCFVGLIS MIDPPRAAVP
     DAVGKCRSAG IKVIMVTGDH PITAKAIAKG VGIISEGNET VEDIAARLNI PVSQVNPRDA
     KACVVHGSDL KDMTSEQLDD ILKYHTEIVF ARTSPQQKLI IVEGCQRQGA IVAVTGDGVN
     DSPALKKADI GVAMGIAGSD VSKQAADMIL LDDNFASIVT GVEEGRLIFD NLKKSIAYTL
     TSNIPEITPF LIFIIANIPL PLGTVTILCI DLGTDMVPAI SLAYEQAESD IMKRQPRNPK
     TDKLVNERLI SMAYGQIGMI QALGGFFTYF VILAENGFLP IHLLGLRVDW DDRWINDVED
     SYGQQWTYEQ RKIVEFTCHT AFFVSIVVVQ WADLVICKTR RNSVFQQGMK NKILIFGLFE
     ETALAAFLSY CPGMGVALRM YPLKPTWWFC AFPYSLLIFV YDEVRKLIIR RRPGGWVEKE
     TYY
//
ID   A0A087WZX0_HUMAN        Unreviewed;      1462 AA.
AC   A0A087WZX0;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   22-APR-2020, entry version 43.
DE   SubName: Full=B-cell CLL/lymphoma 9-like protein {ECO:0000313|Ensembl:ENSP00000482938};
GN   Name=BCL9L {ECO:0000313|Ensembl:ENSP00000482938};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000482938, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [2] {ECO:0000213|PubMed:16964243}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [3] {ECO:0000313|Ensembl:ENSP00000482938, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4] {ECO:0000213|PubMed:18220336}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.D., Yates J.R.;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [5] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [6] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [7] {ECO:0000213|PubMed:19608861}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [8] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [9] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [11] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13] {ECO:0000313|Ensembl:ENSP00000482938}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
RN   [14] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AP004609; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; XP_005271569.1; XM_005271512.2.
DR   RefSeq; XP_005271570.1; XM_005271513.2.
DR   SMR; A0A087WZX0; -.
DR   jPOST; A0A087WZX0; -.
DR   PeptideAtlas; A0A087WZX0; -.
DR   PRIDE; A0A087WZX0; -.
DR   Antibodypedia; 32548; 125 antibodies.
DR   Ensembl; ENST00000526143; ENSP00000482938; ENSG00000186174.
DR   GeneID; 283149; -.
DR   UCSC; uc058ibp.1; human.
DR   CTD; 283149; -.
DR   EuPathDB; HostDB:ENSG00000186174.12; -.
DR   HGNC; HGNC:23688; BCL9L.
DR   OpenTargets; ENSG00000186174; -.
DR   eggNOG; ENOG410IEDB; Eukaryota.
DR   eggNOG; ENOG410XRMX; LUCA.
DR   GeneTree; ENSGT00730000110915; -.
DR   OrthoDB; 156519at2759; -.
DR   ChiTaRS; BCL9L; human.
DR   GenomeRNAi; 283149; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000186174; Expressed in cerebellum and 189 other tissues.
DR   ExpressionAtlas; A0A087WZX0; baseline and differential.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:InterPro.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:InterPro.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR015668; Bcl-9/Bcl-9l.
DR   InterPro; IPR024670; BCL9_beta-catenin-bd_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR15185; PTHR15185; 1.
DR   Pfam; PF11502; BCL9; 1.
PE   1: Evidence at protein level;
KW   Proteomics identification {ECO:0000213|EPD:A0A087WZX0,
KW   ECO:0000213|MaxQB:A0A087WZX0, ECO:0000213|PeptideAtlas:A0A087WZX0,
KW   ECO:0000213|ProteomicsDB:A0A087WZX0};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN          361..393
FT                   /note="BCL9"
FT                   /evidence="ECO:0000259|Pfam:PF11502"
FT   REGION          1..201
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          234..463
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          851..1047
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1079..1164
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        8..33
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        46..63
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        100..116
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        242..289
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        294..330
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        363..388
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        404..421
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        879..924
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        938..961
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        978..1012
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1013..1027
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1083..1098
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1099..1124
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1128..1146
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1147..1162
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   1462 AA;  153087 MW;  AC6BB84FE844E728 CRC64;
     MHPENKLTNH GKTGNGGAQS QHQNVNQGPT CNVGSKGVGA GNHGAKANQI SPSNSSLKNP
     QAGVPPFSSL KGKVKRDRSV SVDSGEQREA GTPSLDSEAK EVAPRSKRRC VLERKQPYSG
     DEWCSGPDSE EDDKPIGATH NCNVADPAMA APQLGPGQTT QLPLSESSVP GAPHGPPPGL
     RPDAPGGGGG GGGVPGKPPS QFVYVFTTHL ANTAAEAVLQ GRADSILAYH QQNVPRAKLD
     QAPKVPPTPE PLPLSTPSAG TPQSQPPPLP PPPPPAPGSA PPALPPEGPP EDSSQDLAPN
     SVGAASTGGG TGGTHPNTPT ATTANNPLPP GGDPSSAPGP ALLGEAAAPG NGQRSLVGSE
     GLSKEQLEHR ERSLQTLRDI ERLLLRSGET EPFLKGPPGG AGEGGPPAQA PPPPQQPPTA
     PPSGLKKYEE PLQSMISQTQ SLGGPPLEHE VPGHPPGGDM GQQMNMMIQR LGQDSLTPEQ
     VAWRKLQEEY YEEKRRKEEQ IGLHGSRPLQ DMMGMGGMMV RGPPPPYHSK PGDQWPPGMG
     AQLRGPMDVQ DPMQLRGGPP FPGPRFPGNQ IQRVPGFGGM QSMPMEVPMN AMQRPVRPGM
     GWTEDLPPMG GPSNFAQNTM PYPGGQGEAE RFMTPRVREE LLRHQLLEKR SMGMQRPLGM
     AGSGMGQSME MERMMQAHRQ MDPAMFPGQM AGGEGLAGTP MGMEFGGGRG LLSPPMGQSG
     LREVDPPMGP GNLNMNMNVN MNMNMNLNVQ MTPQQQMLMS QKMRGPGDLM GPQGLSPEEM
     ARVRAQNSSG VMGGPQKMLM PSQFPNQGQQ GFSGGQGPYQ AMSQDMGNTQ DMFSPDQSSM
     PMSNVGTTRL SHMPLPPASN PPGTVHSAPN RGLGRRPSDL TISINQMGSP GMGHLKSPTL
     SQVHSPLVTS PSANLKSPQT PSQMVPLPSA NPPGPLKSPQ VLGSSLSVRS PTGSPSRLKS
     PSMAVPSPGW VASPKTAMPS PGVSQNKQPP LNMNSSTTLS NMEQGTLPPS GPRSSSSAPP
     ANPPSGLMNP SLPFTSSPDP TPSQNPLSLM MTQMSKYAMP SSTPLYHNAI KTIATSDDEL
     LPDRPLLPPP PPPQGSGPGI SNSQPSQMHL NSAAAQSPMG MNLPGQQPLS HEPPPAMLPS
     PTPLGSNIPL HPNAQGTGGP PQNSMMMAPG GPDSLNAPCG PVPSSSQMMP FPPRLQQPHG
     AMAPTGGGGG GPGLQQHYPS GMALPPEDLP NQPPGPMPPQ QHLMGKAMAG RMGDAYPPGV
     LPGVASVLND PELSEVIRPT PTGIPEFDLS RIIPSEKPSS TLQYFPKSEN QPPKAQPPNL
     HLMNLQNMMA EQTPSRPPNL PGQQGVQRGL NMSMCHPGQM SLLGRTGVPP QQGMVPHGLH
     QGVMSPPQGL MTQQNFMLMK QRGVGGEVYS QPPHMLSPQG SLMGPPPQQN LMVSHPLRQR
     SVSLDSQMGY LPAPGGMANL PF
//
ID   BCL9L_HUMAN             Reviewed;        1499 AA.
AC   Q86UU0; A1A4C1; Q67FY1; Q6ZWJ0; Q6ZWK2;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   22-APR-2020, entry version 139.
DE   RecName: Full=B-cell CLL/lymphoma 9-like protein;
DE            Short=B-cell lymphoma 9-like protein;
DE            Short=BCL9-like protein;
DE   AltName: Full=Protein BCL9-2;
GN   Name=BCL9L; Synonyms=DLNB11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=15371335; DOI=10.1101/gad.317604;
RA   Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S., Hammerschmidt M.,
RA   Birchmeier W.;
RT   "Essential role of BCL9-2 in the switch between beta-catenin's adhesive and
RT   transcriptional functions.";
RL   Genes Dev. 18:2225-2230(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Kubo T., Arai Y., Ohira M., Gamou T., Maeno G., Sakiyama T., Toyoda A.,
RA   Hattori M., Sakaki Y., Nakagawara A., Ohki M.;
RT   "Identification of a 500-kb region of common allelic loss in chromosome
RT   11q23 in non-MYCN amplified type of neuroblastoma.";
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 707-1499 (ISOFORM 4).
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 865-1499 (ISOFORMS 1/2), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 466-1499 (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=12964048;
RA   Katoh M., Katoh M.;
RT   "Identification and characterization of human BCL9L gene and mouse Bcl9l
RT   gene in silico.";
RL   Int. J. Mol. Med. 12:643-649(2003).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-915, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   INTERACTION WITH CTNNB1.
RX   PubMed=17052462; DOI=10.1016/j.molcel.2006.09.001;
RA   Sampietro J., Dahlberg C.L., Cho U.S., Hinds T.R., Kimelman D., Xu W.;
RT   "Crystal structure of a beta-catenin/BCL9/Tcf4 complex.";
RL   Mol. Cell 24:293-300(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [10]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17129358; DOI=10.1111/j.1349-7006.2006.00363.x;
RA   Sakamoto I., Ohwada S., Toya H., Togo N., Kashiwabara K., Oyama T.,
RA   Nakajima T., Ito H., Adachi S., Jigami T., Akiyama T.;
RT   "Up-regulation of a BCL9-related beta-catenin-binding protein, B9L, in
RT   different stages of sporadic colorectal adenoma.";
RL   Cancer Sci. 98:83-87(2007).
RN   [11]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17309600; DOI=10.1111/j.1349-7006.2007.00430.x;
RA   Toya H., Oyama T., Ohwada S., Togo N., Sakamoto I., Horiguchi J.,
RA   Koibuchi Y., Adachi S., Jigami T., Nakajima T., Akiyama T.;
RT   "Immunohistochemical expression of the beta-catenin-interacting protein B9L
RT   is associated with histological high nuclear grade and immunohistochemical
RT   ErbB2/HER-2 expression in breast cancers.";
RL   Cancer Sci. 98:484-490(2007).
RN   [12]
RP   IDENTIFICATION IN A COMPLEX WITH CDC73; CTNNB1 AND PYGO1, AND INTERACTION
RP   WITH CTNNB1.
RX   PubMed=17113272; DOI=10.1016/j.mod.2006.09.006;
RA   Hoffmans R., Basler K.;
RT   "BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires
RT   Pygopus for its function in Wg/Wnt signaling.";
RL   Mech. Dev. 124:59-67(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-813, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-118; SER-1004; SER-1010 AND
RP   SER-1017, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-36; LYS-108 AND LYS-137, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88; SER-750; SER-813;
RP   SER-1004 AND SER-1010, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-25; SER-88; SER-116;
RP   SER-118 AND SER-975, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-25; SER-88; SER-424;
RP   THR-514; SER-750; SER-813; SER-915; SER-938; SER-947; SER-997; SER-1004 AND
RP   SER-1017, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21 AND SER-1017, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1344, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Transcriptional regulator that acts as an activator. Promotes
CC       beta-catenin transcriptional activity. Plays a role in tumorigenesis.
CC       Enhances the neoplastic transforming activity of CTNNB1 (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Found in a complex with CDC73; CTNNB1 and PYGO1. Interacts
CC       with CTNNB1. {ECO:0000269|PubMed:17052462,
CC       ECO:0000269|PubMed:17113272}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17129358,
CC       ECO:0000269|PubMed:17309600}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q86UU0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q86UU0-2; Sequence=VSP_030205;
CC       Name=3;
CC         IsoId=Q86UU0-3; Sequence=VSP_030207, VSP_030208;
CC       Name=4;
CC         IsoId=Q86UU0-4; Sequence=VSP_030206;
CC   -!- TISSUE SPECIFICITY: Expressed in breast, ductal and invasive ductal
CC       carcinomas of the breast, sporadic colorectal adenomas and carcinomas
CC       (at protein level). Expressed in fetal brain. Expressed in lung,
CC       amygdala, eye, prostate, pancreatic and prostate cancers, head and neck
CC       tumors and embryonal tumor. {ECO:0000269|PubMed:12964048,
CC       ECO:0000269|PubMed:17129358, ECO:0000269|PubMed:17309600}.
CC   -!- DOMAIN: Tne C-terminal domain is important for its transactivation
CC       activity. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the BCL9 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH33257.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAC85500.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAC85512.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY296059; AAQ62697.1; -; mRNA.
DR   EMBL; AB094091; BAC76045.1; -; mRNA.
DR   EMBL; CH471065; EAW67418.1; -; Genomic_DNA.
DR   EMBL; BC033257; AAH33257.1; ALT_INIT; mRNA.
DR   EMBL; AK122650; BAC85500.1; ALT_INIT; mRNA.
DR   EMBL; AK122882; BAC85512.1; ALT_INIT; mRNA.
DR   CCDS; CCDS8403.1; -. [Q86UU0-1]
DR   RefSeq; NP_872363.1; NM_182557.2. [Q86UU0-1]
DR   RefSeq; XP_005271568.1; XM_005271511.2. [Q86UU0-1]
DR   RefSeq; XP_006718878.1; XM_006718815.2. [Q86UU0-1]
DR   PDB; 2XB1; X-ray; 1.90 A; A/C=237-271.
DR   PDB; 4UP0; X-ray; 1.28 A; A=240-268.
DR   PDB; 4UP5; X-ray; 1.65 A; A=240-268.
DR   PDBsum; 2XB1; -.
DR   PDBsum; 4UP0; -.
DR   PDBsum; 4UP5; -.
DR   SMR; Q86UU0; -.
DR   BioGrid; 129475; 10.
DR   IntAct; Q86UU0; 5.
DR   MINT; Q86UU0; -.
DR   STRING; 9606.ENSP00000335320; -.
DR   iPTMnet; Q86UU0; -.
DR   PhosphoSitePlus; Q86UU0; -.
DR   BioMuta; BCL9L; -.
DR   DMDM; 74750433; -.
DR   EPD; Q86UU0; -.
DR   jPOST; Q86UU0; -.
DR   MassIVE; Q86UU0; -.
DR   MaxQB; Q86UU0; -.
DR   PaxDb; Q86UU0; -.
DR   PeptideAtlas; Q86UU0; -.
DR   PRIDE; Q86UU0; -.
DR   ProteomicsDB; 69890; -. [Q86UU0-1]
DR   ProteomicsDB; 69891; -. [Q86UU0-2]
DR   ProteomicsDB; 69892; -. [Q86UU0-3]
DR   ProteomicsDB; 69893; -. [Q86UU0-4]
DR   Antibodypedia; 32548; 125 antibodies.
DR   DNASU; 283149; -.
DR   Ensembl; ENST00000334801; ENSP00000335320; ENSG00000186174. [Q86UU0-1]
DR   GeneID; 283149; -.
DR   KEGG; hsa:283149; -.
DR   UCSC; uc001pug.5; human. [Q86UU0-1]
DR   CTD; 283149; -.
DR   DisGeNET; 283149; -.
DR   GeneCards; BCL9L; -.
DR   HGNC; HGNC:23688; BCL9L.
DR   HPA; ENSG00000186174; Low tissue specificity.
DR   MIM; 609004; gene.
DR   neXtProt; NX_Q86UU0; -.
DR   OpenTargets; ENSG00000186174; -.
DR   PharmGKB; PA134974002; -.
DR   eggNOG; ENOG410IEDB; Eukaryota.
DR   eggNOG; ENOG410XRMX; LUCA.
DR   GeneTree; ENSGT00730000110915; -.
DR   HOGENOM; CLU_004973_0_0_1; -.
DR   InParanoid; Q86UU0; -.
DR   KO; K22649; -.
DR   OMA; YHSKPGE; -.
DR   OrthoDB; 156519at2759; -.
DR   PhylomeDB; Q86UU0; -.
DR   TreeFam; TF331144; -.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   ChiTaRS; BCL9L; human.
DR   GenomeRNAi; 283149; -.
DR   Pharos; Q86UU0; Tbio.
DR   PRO; PR:Q86UU0; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q86UU0; protein.
DR   Bgee; ENSG00000186174; Expressed in cerebellum and 189 other tissues.
DR   ExpressionAtlas; Q86UU0; baseline and differential.
DR   Genevisible; Q86UU0; HS.
DR   GO; GO:1990907; C:beta-catenin-TCF complex; IDA:FlyBase.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:MGI.
DR   GO; GO:0003713; F:transcription coactivator activity; NAS:BHF-UCL.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0022604; P:regulation of cell morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR015668; Bcl-9/Bcl-9l.
DR   InterPro; IPR024670; BCL9_beta-catenin-bd_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR15185; PTHR15185; 1.
DR   Pfam; PF11502; BCL9; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Isopeptide bond; Methylation; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1499
FT                   /note="B-cell CLL/lymphoma 9-like protein"
FT                   /id="PRO_0000314079"
FT   REGION          304..533
FT                   /note="Necessary for interaction with CTNNB1"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        280..493
FT                   /note="Pro-rich"
FT   COMPBIAS        689..837
FT                   /note="Met-rich"
FT   COMPBIAS        891..1378
FT                   /note="Pro-rich"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         36
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         88
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:16964243,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         108
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         110
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q67FY2"
FT   MOD_RES         116
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692"
FT   MOD_RES         118
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:21406692"
FT   MOD_RES         137
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         424
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         514
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         680
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q67FY2"
FT   MOD_RES         750
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         813
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163"
FT   MOD_RES         915
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         926
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q67FY2"
FT   MOD_RES         938
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         942
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q67FY2"
FT   MOD_RES         947
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         975
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692"
FT   MOD_RES         987
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q67FY2"
FT   MOD_RES         991
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q67FY2"
FT   MOD_RES         997
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1004
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163"
FT   MOD_RES         1010
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231"
FT   MOD_RES         1017
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   CROSSLNK        1344
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         9..13
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15371335"
FT                   /id="VSP_030205"
FT   VAR_SEQ         1238..1283
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_030206"
FT   VAR_SEQ         1333..1394
FT                   /note="EKPSSTLQYFPKSENQPPKAQPPNLHLMNLQNMMAEQTPSRPPNLPGQQGVQ
FT                   RGLNMSMCHP -> WFLRTRPFSFCLYLLRILSLLMWLTPLPPLPAGGWPGGQVPAGAV
FT                   NRALRFCAGLCVCCISVF (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_030207"
FT   VAR_SEQ         1395..1499
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_030208"
FT   STRAND          241..243
FT                   /evidence="ECO:0000244|PDB:4UP0"
FT   HELIX           245..256
FT                   /evidence="ECO:0000244|PDB:4UP0"
FT   STRAND          259..262
FT                   /evidence="ECO:0000244|PDB:4UP0"
FT   HELIX           263..266
FT                   /evidence="ECO:0000244|PDB:4UP0"
SQ   SEQUENCE   1499 AA;  157129 MW;  8415C2EDB7AA9C0C CRC64;
     MRILANKTRL PHPRRREAPG SPPLSPRGHC PPAPAKPMHP ENKLTNHGKT GNGGAQSQHQ
     NVNQGPTCNV GSKGVGAGNH GAKANQISPS NSSLKNPQAG VPPFSSLKGK VKRDRSVSVD
     SGEQREAGTP SLDSEAKEVA PRSKRRCVLE RKQPYSGDEW CSGPDSEEDD KPIGATHNCN
     VADPAMAAPQ LGPGQTTQLP LSESSVPGAP HGPPPGLRPD APGGGGGGGG VPGKPPSQFV
     YVFTTHLANT AAEAVLQGRA DSILAYHQQN VPRAKLDQAP KVPPTPEPLP LSTPSAGTPQ
     SQPPPLPPPP PPAPGSAPPA LPPEGPPEDS SQDLAPNSVG AASTGGGTGG THPNTPTATT
     ANNPLPPGGD PSSAPGPALL GEAAAPGNGQ RSLVGSEGLS KEQLEHRERS LQTLRDIERL
     LLRSGETEPF LKGPPGGAGE GGPPAQAPPP PQQPPTAPPS GLKKYEEPLQ SMISQTQSLG
     GPPLEHEVPG HPPGGDMGQQ MNMMIQRLGQ DSLTPEQVAW RKLQEEYYEE KRRKEEQIGL
     HGSRPLQDMM GMGGMMVRGP PPPYHSKPGD QWPPGMGAQL RGPMDVQDPM QLRGGPPFPG
     PRFPGNQIQR VPGFGGMQSM PMEVPMNAMQ RPVRPGMGWT EDLPPMGGPS NFAQNTMPYP
     GGQGEAERFM TPRVREELLR HQLLEKRSMG MQRPLGMAGS GMGQSMEMER MMQAHRQMDP
     AMFPGQMAGG EGLAGTPMGM EFGGGRGLLS PPMGQSGLRE VDPPMGPGNL NMNMNVNMNM
     NMNLNVQMTP QQQMLMSQKM RGPGDLMGPQ GLSPEEMARV RAQNSSGVMG GPQKMLMPSQ
     FPNQGQQGFS GGQGPYQAMS QDMGNTQDMF SPDQSSMPMS NVGTTRLSHM PLPPASNPPG
     TVHSAPNRGL GRRPSDLTIS INQMGSPGMG HLKSPTLSQV HSPLVTSPSA NLKSPQTPSQ
     MVPLPSANPP GPLKSPQVLG SSLSVRSPTG SPSRLKSPSM AVPSPGWVAS PKTAMPSPGV
     SQNKQPPLNM NSSTTLSNME QGTLPPSGPR SSSSAPPANP PSGLMNPSLP FTSSPDPTPS
     QNPLSLMMTQ MSKYAMPSST PLYHNAIKTI ATSDDELLPD RPLLPPPPPP QGSGPGISNS
     QPSQMHLNSA AAQSPMGMNL PGQQPLSHEP PPAMLPSPTP LGSNIPLHPN AQGTGGPPQN
     SMMMAPGGPD SLNAPCGPVP SSSQMMPFPP RLQQPHGAMA PTGGGGGGPG LQQHYPSGMA
     LPPEDLPNQP PGPMPPQQHL MGKAMAGRMG DAYPPGVLPG VASVLNDPEL SEVIRPTPTG
     IPEFDLSRII PSEKPSSTLQ YFPKSENQPP KAQPPNLHLM NLQNMMAEQT PSRPPNLPGQ
     QGVQRGLNMS MCHPGQMSLL GRTGVPPQQG MVPHGLHQGV MSPPQGLMTQ QNFMLMKQRG
     VGGEVYSQPP HMLSPQGSLM GPPPQQNLMV SHPLRQRSVS LDSQMGYLPA PGGMANLPF
//
ID   BCORL_HUMAN             Reviewed;        1711 AA.
AC   Q5H9F3; B5MDQ8; Q5H9F2; Q5H9F4; Q6ZVE0; Q8TEN3; Q9Y528;
DT   04-DEC-2007, integrated into UniProtKB/Swiss-Prot.
DT   15-FEB-2005, sequence version 1.
DT   22-APR-2020, entry version 143.
DE   RecName: Full=BCL-6 corepressor-like protein 1;
DE            Short=BCoR-L1;
DE            Short=BCoR-like protein 1;
GN   Name=BCORL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 16-1711 (ISOFORM 1), AND VARIANT
RP   LEU-111.
RC   TISSUE=Spleen;
RX   PubMed=12693554; DOI=10.1093/dnares/10.1.49;
RA   Jikuya H., Takano J., Kikuno R., Hirosawa M., Nagase T., Nomura N.,
RA   Ohara O.;
RT   "Characterization of long cDNA clones from human adult spleen. II. The
RT   complete sequences of 81 cDNA clones.";
RL   DNA Res. 10:49-57(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 566-1435 (ISOFORM 2).
RA   Rhodes S.;
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1265-1711 (ISOFORM 2).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CTBP1; HDAC4; HDAC5 AND
RP   HDAC7, MUTAGENESIS OF 623-ASP-LEU-624, AND TISSUE SPECIFICITY.
RX   PubMed=17379597; DOI=10.1074/jbc.m700246200;
RA   Pagan J.K., Arnold J., Hanchard K.J., Kumar R., Bruno T., Jones M.J.,
RA   Richard D.J., Forrest A., Spurdle A., Verdin E., Crossley M., Fanciulli M.,
RA   Chenevix-Trench G., Young D.B., Khanna K.K.;
RT   "A novel corepressor, BCoR-L1, represses transcription through an
RT   interaction with CtBP.";
RL   J. Biol. Chem. 282:15248-15257(2007).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-613; SER-1033 AND SER-1162,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1476 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-496; SER-599; SER-1029;
RP   SER-1033 AND SER-1162, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1092, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [10]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1092, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [11]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-747 AND LYS-1092, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1634-1748 IN COMPLEX WITH PCGF1,
RP   INTERACTION WITH PCGF1, AND MUTAGENESIS OF LEU-1665.
RX   PubMed=23523425; DOI=10.1016/j.str.2013.02.013;
RA   Junco S.E., Wang R., Gaipa J.C., Taylor A.B., Schirf V., Gearhart M.D.,
RA   Bardwell V.J., Demeler B., Hart P.J., Kim C.A.;
RT   "Structure of the polycomb group protein PCGF1 in complex with BCOR reveals
RT   basis for binding selectivity of PCGF homologs.";
RL   Structure 21:665-671(2013).
RN   [13] {ECO:0000244|PDB:5JH5}
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 1594-1711, AND SUBUNIT.
RX   PubMed=27568929; DOI=10.1016/j.str.2016.07.011;
RA   Wong S.J., Gearhart M.D., Taylor A.B., Nanyes D.R., Ha D.J., Robinson A.K.,
RA   Artigas J.A., Lee O.J., Demeler B., Hart P.J., Bardwell V.J., Kim C.A.;
RT   "KDM2B Recruitment of the Polycomb Group Complex, PRC1.1, Requires
RT   Cooperation between PCGF1 and BCORL1.";
RL   Structure 24:1795-1801(2016).
RN   [14]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-832.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANT SHUVER SER-820, AND INVOLVEMENT IN SHUVER.
RX   PubMed=24123876; DOI=10.1136/jmedgenet-2013-101644;
RA   Schuurs-Hoeijmakers J.H., Vulto-van Silfhout A.T., Vissers L.E.,
RA   van de Vondervoort I.I., van Bon B.W., de Ligt J., Gilissen C.,
RA   Hehir-Kwa J.Y., Neveling K., del Rosario M., Hira G., Reitano S.,
RA   Vitello A., Failla P., Greco D., Fichera M., Galesi O., Kleefstra T.,
RA   Greally M.T., Ockeloen C.W., Willemsen M.H., Bongers E.M., Janssen I.M.,
RA   Pfundt R., Veltman J.A., Romano C., Willemsen M.A., van Bokhoven H.,
RA   Brunner H.G., de Vries B.B., de Brouwer A.P.;
RT   "Identification of pathogenic gene variants in small families with
RT   intellectually disabled siblings by exome sequencing.";
RL   J. Med. Genet. 50:802-811(2013).
RN   [16]
RP   VARIANT ILE-327.
RX   PubMed=26933038; DOI=10.1161/circgenetics.115.001193;
RA   Xue Y., Schoser B., Rao A.R., Quadrelli R., Vaglio A., Rupp V.,
RA   Beichler C., Nelson S.F., Schapacher-Tilp G., Windpassinger C.,
RA   Wilcox W.R.;
RT   "Exome sequencing identified a splice site mutation in FHL1 that causes
RT   Uruguay Syndrome, an X-linked disorder with skeletal muscle hypertrophy and
RT   premature cardiac death.";
RL   Circ. Cardiovasc. Genet. 9:130-135(2016).
RN   [17]
RP   VARIANTS SHUVER LEU-32; PHE-496 AND GLU-782, AND INVOLVEMENT IN SHUVER.
RX   PubMed=30941876; DOI=10.1002/ajmg.a.61118;
RA   Shukla A., Girisha K.M., Somashekar P.H., Nampoothiri S., McClellan R.,
RA   Vernon H.J.;
RT   "Variants in the transcriptional corepressor BCORL1 are associated with an
RT   X-linked disorder of intellectual disability, dysmorphic features, and
RT   behavioral abnormalities.";
RL   Am. J. Med. Genet. A 179:870-874(2019).
CC   -!- FUNCTION: Transcriptional corepressor. May specifically inhibit gene
CC       expression when recruited to promoter regions by sequence-specific DNA-
CC       binding proteins such as BCL6. This repression may be mediated at least
CC       in part by histone deacetylase activities which can associate with this
CC       corepressor. {ECO:0000269|PubMed:17379597}.
CC   -!- SUBUNIT: Interacts with PCGF1, forming heterodimers (PubMed:23523425,
CC       PubMed:27568929). The PCGF1-BCORL1 heterodimeric complex interacts with
CC       the KDM2B-SKP1 heterodimeric complex to form a homotetrameric polycomb
CC       repression complex 1 (PRC1.1) (PubMed:27568929). Interacts with CTBP1,
CC       HDAC4, HDAC5 and HDAC7 (PubMed:17379597). {ECO:0000269|PubMed:17379597,
CC       ECO:0000269|PubMed:23523425, ECO:0000269|PubMed:27568929}.
CC   -!- INTERACTION:
CC       Q5H9F3-1; Q9BSM1-1: PCGF1; NbExp=6; IntAct=EBI-16041827, EBI-16041863;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17379597}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q5H9F3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q5H9F3-2; Sequence=VSP_029778;
CC       Name=3;
CC         IsoId=Q5H9F3-3; Sequence=VSP_029779;
CC   -!- TISSUE SPECIFICITY: Detected in testis and prostate. Detected at lower
CC       levels in peripheral blood leukocytes and spleen.
CC       {ECO:0000269|PubMed:17379597}.
CC   -!- DISEASE: Shukla-Vernon syndrome (SHUVER) [MIM:301029]: An X-linked
CC       neurodevelopmental disorder manifesting in affected males with
CC       intellectual and learning disability, motor and language delay, autism
CC       spectrum disorder, attention deficit and hyperactivity disorder, and
CC       dysmorphic features. Some patients may have seizures and/or cerebellar
CC       atrophy on brain imaging. Carrier females may have mild disease
CC       manifestations. {ECO:0000269|PubMed:24123876,
CC       ECO:0000269|PubMed:30941876}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the BCOR family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC85922.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL034405; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL136450; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z82208; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK074089; BAB84915.1; -; mRNA.
DR   EMBL; AL096777; CAB46626.1; -; mRNA.
DR   EMBL; AK124676; BAC85922.1; ALT_INIT; mRNA.
DR   CCDS; CCDS14616.1; -. [Q5H9F3-1]
DR   RefSeq; NP_068765.3; NM_021946.4.
DR   PDB; 4HPM; X-ray; 1.85 A; A/C=1594-1711.
DR   PDB; 5JH5; X-ray; 2.55 A; D=1594-1711.
DR   PDBsum; 4HPM; -.
DR   PDBsum; 5JH5; -.
DR   SMR; Q5H9F3; -.
DR   BioGrid; 121961; 27.
DR   DIP; DIP-60148N; -.
DR   IntAct; Q5H9F3; 17.
DR   STRING; 9606.ENSP00000437775; -.
DR   iPTMnet; Q5H9F3; -.
DR   PhosphoSitePlus; Q5H9F3; -.
DR   BioMuta; BCORL1; -.
DR   DMDM; 74762178; -.
DR   EPD; Q5H9F3; -.
DR   jPOST; Q5H9F3; -.
DR   MassIVE; Q5H9F3; -.
DR   MaxQB; Q5H9F3; -.
DR   PaxDb; Q5H9F3; -.
DR   PeptideAtlas; Q5H9F3; -.
DR   PRIDE; Q5H9F3; -.
DR   ProteomicsDB; 62886; -. [Q5H9F3-1]
DR   ProteomicsDB; 62887; -. [Q5H9F3-2]
DR   ProteomicsDB; 62888; -. [Q5H9F3-3]
DR   Antibodypedia; 30129; 76 antibodies.
DR   DNASU; 63035; -.
DR   Ensembl; ENST00000218147; ENSP00000218147; ENSG00000085185.
DR   Ensembl; ENST00000540052; ENSP00000437775; ENSG00000085185.
DR   GeneID; 63035; -.
DR   KEGG; hsa:63035; -.
DR   UCSC; uc022cdu.1; human. [Q5H9F3-1]
DR   CTD; 63035; -.
DR   DisGeNET; 63035; -.
DR   GeneCards; BCORL1; -.
DR   HGNC; HGNC:25657; BCORL1.
DR   HPA; ENSG00000085185; Low tissue specificity.
DR   MalaCards; BCORL1; -.
DR   MIM; 300688; gene.
DR   MIM; 301029; phenotype.
DR   neXtProt; NX_Q5H9F3; -.
DR   eggNOG; ENOG410IFKH; Eukaryota.
DR   eggNOG; ENOG411028G; LUCA.
DR   InParanoid; Q5H9F3; -.
DR   OrthoDB; 85469at2759; -.
DR   PhylomeDB; Q5H9F3; -.
DR   TreeFam; TF333317; -.
DR   SIGNOR; Q5H9F3; -.
DR   ChiTaRS; BCORL1; human.
DR   GenomeRNAi; 63035; -.
DR   Pharos; Q5H9F3; Tbio.
DR   PRO; PR:Q5H9F3; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q5H9F3; protein.
DR   Bgee; ENSG00000085185; Expressed in placenta and 215 other tissues.
DR   ExpressionAtlas; Q5H9F3; baseline and differential.
DR   Genevisible; Q5H9F3; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   Gene3D; 1.25.40.20; -; 1.
DR   Gene3D; 3.10.260.40; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR031628; BCOR.
DR   InterPro; IPR032365; PUFD.
DR   InterPro; IPR038227; PUFD_som_sf.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF15808; BCOR; 1.
DR   Pfam; PF16553; PUFD; 1.
DR   SMART; SM00248; ANK; 2.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ANK repeat; Autism spectrum disorder;
KW   Chromatin regulator; Disease mutation; Isopeptide bond; Mental retardation;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Repressor; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1711
FT                   /note="BCL-6 corepressor-like protein 1"
FT                   /id="PRO_0000312268"
FT   REPEAT          1455..1484
FT                   /note="ANK 1"
FT   REPEAT          1488..1517
FT                   /note="ANK 2"
FT   REPEAT          1521..1549
FT                   /note="ANK 3"
FT   REGION          1594..1711
FT                   /note="PCGF Ub-like fold domain (PUFD); required for the
FT                   interaction with the KDM2B-SKP1 heterodimeric complex"
FT                   /evidence="ECO:0000269|PubMed:27568929"
FT   MOTIF           1328..1336
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        198..649
FT                   /note="Pro-rich"
FT   MOD_RES         496
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         599
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         613
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         1029
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1033
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         1162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   CROSSLNK        747
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1092
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:25755297, ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1230..1359
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.3"
FT                   /id="VSP_029778"
FT   VAR_SEQ         1434
FT                   /note="A -> AKGKGRWSQQKTRSPKSPTPVKPTEPCTPSKSRSASSEEASESPTAR
FT                   QIPPEARRLIVNKNAGETLLQRAARLGY (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_029779"
FT   VARIANT         32
FT                   /note="P -> L (in SHUVER; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30941876"
FT                   /id="VAR_082288"
FT   VARIANT         111
FT                   /note="F -> L (in dbSNP:rs4830173)"
FT                   /evidence="ECO:0000269|PubMed:12693554"
FT                   /id="VAR_061020"
FT   VARIANT         209
FT                   /note="G -> S (in dbSNP:rs5932715)"
FT                   /id="VAR_037467"
FT   VARIANT         327
FT                   /note="T -> I (found in a patient with Uruguay
FT                   faciocardiomusculoskeletal syndrome; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:26933038"
FT                   /id="VAR_080909"
FT   VARIANT         496
FT                   /note="S -> F (in SHUVER; unknown pathological
FT                   significance; dbSNP:rs1057521638)"
FT                   /evidence="ECO:0000269|PubMed:30941876"
FT                   /id="VAR_082289"
FT   VARIANT         782
FT                   /note="V -> E (in SHUVER; unknown pathological
FT                   significance; dbSNP:rs1488781894)"
FT                   /evidence="ECO:0000269|PubMed:30941876"
FT                   /id="VAR_082290"
FT   VARIANT         820
FT                   /note="N -> S (in SHUVER; unknown pathological
FT                   significance; dbSNP:rs398123004)"
FT                   /evidence="ECO:0000269|PubMed:24123876"
FT                   /id="VAR_070559"
FT   VARIANT         832
FT                   /note="G -> D (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_037468"
FT   MUTAGEN         623..624
FT                   /note="DL->AS: Strongly reduced repressor activity.
FT                   Interferes with CTBP1 binding."
FT                   /evidence="ECO:0000269|PubMed:17379597"
FT   MUTAGEN         1665
FT                   /note="L->D,R: Slightly inhibits interaction with PCGF1."
FT                   /evidence="ECO:0000269|PubMed:23523425"
FT   CONFLICT        1564
FT                   /note="V -> A (in Ref. 4; BAC85922)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1596..1603
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   STRAND          1609..1611
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   STRAND          1620..1624
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   HELIX           1625..1632
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   HELIX           1636..1642
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   STRAND          1648..1652
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   HELIX           1653..1660
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   STRAND          1664..1666
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   TURN            1668..1670
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   STRAND          1686..1691
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   HELIX           1694..1699
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   STRAND          1703..1707
FT                   /evidence="ECO:0000244|PDB:4HPM"
FT   MOD_RES         Q5H9F3-3:1476
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
SQ   SEQUENCE   1711 AA;  182526 MW;  DD78A00598703C53 CRC64;
     MISTAPLYSG VHNWTSSDRI RMCGINEERR APLSDEESTT GDCQHFGSQE FCVSSSFSKV
     ELTAVGSGSN ARGADPDGSA TEKLGHKSED KPDDPQPKMD YAGNVAEAEG FLVPLSSPGD
     GLKLPASDSA EASNSRADCS WTPLNTQMSK QVDCSPAGVK ALDSRQGVGE KNTFILATLG
     TGVPVEGTLP LVTTNFSPLP APICPPAPGS ASVPHSVPDA FQVPLSVPAP VPHSGLVPVQ
     VATSVPAPSP PLAPVPALAP APPSVPTLIS DSNPLSVSAS VLVPVPASAP PSGPVPLSAP
     APAPLSVPVS APPLALIQAP VPPSAPTLVL APVPTPVLAP MPASTPPAAP APPSVPMPTP
     TPSSGPPSTP TLIPAFAPTP VPAPTPAPIF TPAPTPMPAA TPAAIPTSAP IPASFSLSRV
     CFPAAQAPAM QKVPLSFQPG TVLTPSQPLV YIPPPSCGQP LSVATLPTTL GVSSTLTLPV
     LPSYLQDRCL PGVLASPELR SYPYAFSVAR PLTSDSKLVS LEVNRLPCTS PSGSTTTQPA
     PDGVPGPLAD TSLVTASAKV LPTPQPLLPA PSGSSAPPHP AKMPSGTEQQ TEGTSVTFSP
     LKSPPQLERE MASPPECSEM PLDLSSKSNR QKLPLPNQRK TPPMPVLTPV HTSSKALLST
     VLSRSQRTTQ AAGGNVTSCL GSTSSPFVIF PEIVRNGDPS TWVKNSTALI STIPGTYVGV
     ANPVPASLLL NKDPNLGLNR DPRHLPKQEP ISIIDQGEPK GTGATCGKKG SQAGAEGQPS
     TVKRYTPARI APGLPGCQTK ELSLWKPTGP ANIYPRCSVN GKPTSTQVLP VGWSPYHQAS
     LLSIGISSAG QLTPSQGAPI RPTSVVSEFS GVPSLSSSEA VHGLPEGQPR PGGSFVPEQD
     PVTKNKTCRI AAKPYEEQVN PVLLTLSPQT GTLALSVQPS GGDIRMNQGP EESESHLCSD
     STPKMEGPQG ACGLKLAGDT KPKNQVLATY MSHELVLATP QNLPKMPELP LLPHDSHPKE
     LILDVVPSSR RGSSTERPQL GSQVDLGRVK MEKVDGDVVF NLATCFRADG LPVAPQRGQA
     EVRAKAGQAR VKQESVGVFA CKNKWQPDDV TESLPPKKMK CGKEKDSEEQ QLQPQAKAVV
     RSSHRPKCRK LPSDPQESTK KSPRGASDSG KEHNGVRGKH KHRKPTKPES QSPGKRADSH
     EEGSLEKKAK SSFRDFIPVV LSTRTRSQSG SICSSFAGMA DSDMGSQEVF PTEEEEEVTP
     TPAKRRKVRK TQRDTQYRSH HAQDKSLLSQ GRRHLWRARE MPWRTEAARQ MWDTNEEEEE
     EEEEGLLKRK KRRRQKSRKY QTGEYLTEQE DEQRRKGRAD LKARKQKTSS SQSLEHRLRN
     RNLLLPNKVQ GISDSPNGFL PNNLEEPACL ENSEKPSGKR KCKTKHMATV SEEAKDVVLY
     CLQKDSEDVN HRDNAGYTAL HEACSRGWTD ILNILLEHGA NVNCSAQDGT RPVHDAVVND
     NLETIWLLLS YGADPTLATY SGQTAMKLAS SDTMKRFLSD HLSDLQGRAE GDPGVSWDFY
     SSSVLEEKDG FACDLLHNPP GSSDQEGDDP MEEDDFMFEL SDKPLLPCYN LQVSVSRGPC
     NWFLFSDVLK RLKLSSRIFQ ARFPHFEITT MPKAEFYRQV ASSQLLTPAE RPGGLDDRSP
     PGSSETVELV RYEPDLLRLL GSEVEFQSCN S
//
ID   BMR1A_HUMAN             Reviewed;         532 AA.
AC   P36894; A8K6U9; Q8NEN8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 2.
DT   22-APR-2020, entry version 229.
DE   RecName: Full=Bone morphogenetic protein receptor type-1A;
DE            Short=BMP type-1A receptor;
DE            Short=BMPR-1A;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor-like kinase 3;
DE            Short=ALK-3;
DE   AltName: Full=Serine/threonine-protein kinase receptor R5;
DE            Short=SKR5;
DE   AltName: CD_antigen=CD292;
DE   Flags: Precursor;
GN   Name=BMPR1A; Synonyms=ACVRLK3, ALK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-2.
RC   TISSUE=Placenta;
RX   PubMed=8397373;
RA   ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J., Toyoshima H.,
RA   Heldin C.-H., Miyazono K.;
RT   "Activin receptor-like kinases: a novel subclass of cell-surface receptors
RT   with predicted serine/threonine kinase activity.";
RL   Oncogene 8:2879-2887(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-2.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH BMP2, AND MUTAGENESIS OF 107-ASP--GLN-109.
RX   PubMed=22799562; DOI=10.1021/bi300942x;
RA   Mahlawat P., Ilangovan U., Biswas T., Sun L.Z., Hinck A.P.;
RT   "Structure of the Alk1 extracellular domain and characterization of its
RT   bone morphogenetic protein (BMP) binding properties.";
RL   Biochemistry 51:6328-6341(2012).
RN   [5]
RP   INTERACTION WITH GDF5.
RX   PubMed=24098149; DOI=10.1371/journal.pgen.1003846;
RA   Degenkolbe E., Konig J., Zimmer J., Walther M., Reissner C., Nickel J.,
RA   Ploger F., Raspopovic J., Sharpe J., Dathe K., Hecht J.T., Mundlos S.,
RA   Doelken S.C., Seemann P.;
RT   "A GDF5 point mutation strikes twice--causing BDA1 and SYNS2.";
RL   PLoS Genet. 9:E1003846-E1003846(2013).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 55-143 IN COMPLEX WITH BMP2,
RP   DISULFIDE BOND, AND INTERACTION WITH BMP2.
RX   PubMed=10881198; DOI=10.1038/75903;
RA   Kirsch T., Sebald W., Dreyer M.K.;
RT   "Crystal structure of the BMP-2-BRIA ectodomain complex.";
RL   Nat. Struct. Biol. 7:492-496(2000).
RN   [7]
RP   DISEASE.
RX   PubMed=11381269; DOI=10.1038/88919;
RA   Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A.,
RA   Petersen G.M., Velculescu V.E., Traverso G., Vogelstein B.;
RT   "Germline mutations of the gene encoding bone morphogenetic protein
RT   receptor 1A in juvenile polyposis.";
RL   Nat. Genet. 28:184-187(2001).
RN   [8]
RP   STRUCTURE BY NMR OF 51-152, DISULFIDE BONDS, AND INTERACTION WITH BMP2.
RX   PubMed=18937504; DOI=10.1021/bi801059j;
RA   Klages J., Kotzsch A., Coles M., Sebald W., Nickel J., Muller T.,
RA   Kessler H.;
RT   "The solution structure of BMPR-IA reveals a local disorder-to-order
RT   transition upon BMP-2 binding.";
RL   Biochemistry 47:11930-11939(2008).
RN   [9]
RP   VARIANTS JPS ARG-124; ASP-338 AND TYR-376.
RX   PubMed=11536076; DOI=10.1086/323703;
RA   Zhou X.-P., Woodford-Richens K., Lehtonen R., Kurose K., Aldred M.,
RA   Hampel H., Launonen V., Virta S., Pilarski R., Salovaara R., Bodmer W.F.,
RA   Conrad B.A., Dunlop M., Hodgson S.V., Iwama T., Jaervinen H.,
RA   Kellokumpu I., Kim J.C., Leggett B., Markie D., Mecklin J.-P., Neale K.,
RA   Phillips R., Piris J., Rozen P., Houlston R.S., Aaltonen L.A.,
RA   Tomlinson I.P.M., Eng C.;
RT   "Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile
RT   polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes.";
RL   Am. J. Hum. Genet. 69:704-711(2001).
RN   [10]
RP   VARIANTS JPS ASP-62; TYR-82 AND CYS-443.
RX   PubMed=12417513; DOI=10.1007/bf02557528;
RA   Sayed M.G., Ahmed A.F., Ringold J.R., Anderson M.E., Bair J.L.,
RA   Mitros F.A., Lynch H.T., Tinley S.T., Petersen G.M., Giardiello F.M.,
RA   Vogelstein B., Howe J.R.;
RT   "Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis.";
RL   Ann. Surg. Oncol. 9:901-906(2002).
RN   [11]
RP   VARIANT JPS ARG-130.
RX   PubMed=12136244; DOI=10.1007/s00439-002-0748-9;
RA   Friedl W., Uhlhaas S., Schulmann K., Stolte M., Loff S., Back W.,
RA   Mangold E., Stern M., Knaebel H.P., Sutter C., Weber R.G., Pistorius S.,
RA   Burger B., Propping P.;
RT   "Juvenile polyposis: massive gastric polyposis is more common in MADH4
RT   mutation carriers than in BMPR1A mutation carriers.";
RL   Hum. Genet. 111:108-111(2002).
RN   [12]
RP   VARIANT JPS THR-470.
RX   PubMed=12630959; DOI=10.1034/j.1399-0004.2003.00008.x;
RA   Kim I.J., Park J.H., Kang H.C., Kim K.H., Kim J.H., Ku J.L., Kang S.B.,
RA   Park S.Y., Lee J.S., Park J.G.;
RT   "Identification of a novel BMPR1A germline mutation in a Korean juvenile
RT   polyposis patient without SMAD4 mutation.";
RL   Clin. Genet. 63:126-130(2003).
RN   [13]
RP   INVOLVEMENT IN JUVENILE POLYPOSIS OF INFANCY.
RX   PubMed=16685657; DOI=10.1086/504301;
RA   Delnatte C., Sanlaville D., Mougenot J.-F., Vermeesch J.-R., Houdayer C.,
RA   Blois M.-C., Genevieve D., Goulet O., Fryns J.-P., Jaubert F., Vekemans M.,
RA   Lyonnet S., Romana S., Eng C., Stoppa-Lyonnet D.;
RT   "Contiguous gene deletion within chromosome arm 10q is associated with
RT   juvenile polyposis of infancy, reflecting cooperation between the BMPR1A
RT   and PTEN tumor-suppressor genes.";
RL   Am. J. Hum. Genet. 78:1066-1074(2006).
RN   [14]
RP   INVOLVEMENT IN HEREDITARY MIXED POLYPOSIS SYNDROME 2.
RX   PubMed=16525031; DOI=10.1136/jmg.2005.034827;
RA   Cao X., Eu K.W., Kumarasinghe M.P., Li H.H., Loi C., Cheah P.Y.;
RT   "Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23
RT   by genomewide high-density single nucleotide polymorphism (SNP) scan and
RT   identification of BMPR1A loss of function.";
RL   J. Med. Genet. 43:E13-E13(2006).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-2; TYR-58; CYS-443; MET-450 AND
RP   GLN-486.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [16]
RP   VARIANT THR-460.
RX   PubMed=25860647; DOI=10.1007/s10689-015-9803-2;
RA   Hansen M.F., Johansen J., Bjoernevoll I., Sylvander A.E., Steinsbekk K.S.,
RA   Saetrom P., Sandvik A.K., Drabloes F., Sjursen W.;
RT   "A novel POLE mutation associated with cancers of colon, pancreas, ovaries
RT   and small intestine.";
RL   Fam. Cancer 14:437-448(2015).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two
CC       type II and two type I transmembrane serine/threonine kinases. Type II
CC       receptors phosphorylate and activate type I receptors which
CC       autophosphorylate, then bind and activate SMAD transcriptional
CC       regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively
CC       regulates chondrocyte differentiation through GDF5 interaction.
CC       Mediates induction of adipogenesis by GDF6.
CC       {ECO:0000250|UniProtKB:P36895}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[receptor-protein]-L-threonine + ATP = [receptor-protein]-O-
CC         phospho-L-threonine + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA-
CC         COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977,
CC         ChEBI:CHEBI:456216; EC=2.7.11.30;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[receptor-protein]-L-serine + ATP = [receptor-protein]-O-
CC         phospho-L-serine + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA-
CC         COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421,
CC         ChEBI:CHEBI:456216; EC=2.7.11.30;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with BMP2 (PubMed:10881198, PubMed:18937504).
CC       Interacts with low affinity with GDF5; positively regulates chondrocyte
CC       differentiation (PubMed:24098149). {ECO:0000269|PubMed:10881198,
CC       ECO:0000269|PubMed:18937504, ECO:0000269|PubMed:24098149}.
CC   -!- INTERACTION:
CC       P36894; P12643: BMP2; NbExp=17; IntAct=EBI-1029237, EBI-1029262;
CC       P36894; P12644: BMP4; NbExp=2; IntAct=EBI-1029237, EBI-1998134;
CC       P36894; P43026: GDF5; NbExp=4; IntAct=EBI-1029237, EBI-8571476;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P36898};
CC       Single-pass type I membrane protein {ECO:0000255}. Cell surface
CC       {ECO:0000250|UniProtKB:P36895}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle.
CC   -!- PTM: Glycosylated. {ECO:0000250|UniProtKB:P36895}.
CC   -!- DISEASE: Juvenile polyposis syndrome (JPS) [MIM:174900]: Autosomal
CC       dominant gastrointestinal hamartomatous polyposis syndrome in which
CC       patients are at risk for developing gastrointestinal cancers. The
CC       lesions are typified by a smooth histological appearance, predominant
CC       stroma, cystic spaces and lack of a smooth muscle core. Multiple
CC       juvenile polyps usually occur in a number of Mendelian disorders.
CC       Sometimes, these polyps occur without associated features as in JPS;
CC       here, polyps tend to occur in the large bowel and are associated with
CC       an increased risk of colon and other gastrointestinal cancers.
CC       {ECO:0000269|PubMed:11536076, ECO:0000269|PubMed:12136244,
CC       ECO:0000269|PubMed:12417513, ECO:0000269|PubMed:12630959}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Polyposis syndrome, mixed hereditary 2 (HMPS2) [MIM:610069]: A
CC       disease is characterized by atypical juvenile polyps, colonic adenomas,
CC       and colorectal carcinomas. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and
CC       PTEN is a cause of chromosome 10q23 deletion syndrome, which shows
CC       overlapping features of the following three disorders: Bannayan-Zonana
CC       syndrome, Cowden disease and juvenile polyposis syndrome.
CC       {ECO:0000269|PubMed:11381269, ECO:0000269|PubMed:16525031}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z22535; CAA80257.1; -; mRNA.
DR   EMBL; AK291764; BAF84453.1; -; mRNA.
DR   EMBL; BC028383; AAH28383.1; -; mRNA.
DR   CCDS; CCDS7378.1; -.
DR   PIR; I37163; I37163.
DR   RefSeq; NP_004320.2; NM_004329.2.
DR   RefSeq; XP_011538405.1; XM_011540103.2.
DR   RefSeq; XP_011538406.1; XM_011540104.2.
DR   PDB; 1ES7; X-ray; 2.90 A; B/D=55-143.
DR   PDB; 1REW; X-ray; 1.86 A; C/D=24-152.
DR   PDB; 2GOO; X-ray; 2.20 A; B/E=24-152.
DR   PDB; 2H62; X-ray; 1.85 A; C=24-152.
DR   PDB; 2H64; X-ray; 1.92 A; B=24-152.
DR   PDB; 2K3G; NMR; -; A=51-152.
DR   PDB; 2QJ9; X-ray; 2.44 A; C/D=24-152.
DR   PDB; 2QJA; X-ray; 2.60 A; C/D=24-152.
DR   PDB; 2QJB; X-ray; 2.50 A; C/D=24-152.
DR   PDB; 3NH7; X-ray; 2.70 A; A/B/C/D=24-152.
DR   PDB; 3QB4; X-ray; 2.28 A; B/D=24-152.
DR   PDBsum; 1ES7; -.
DR   PDBsum; 1REW; -.
DR   PDBsum; 2GOO; -.
DR   PDBsum; 2H62; -.
DR   PDBsum; 2H64; -.
DR   PDBsum; 2K3G; -.
DR   PDBsum; 2QJ9; -.
DR   PDBsum; 2QJA; -.
DR   PDBsum; 2QJB; -.
DR   PDBsum; 3NH7; -.
DR   PDBsum; 3QB4; -.
DR   SMR; P36894; -.
DR   BioGrid; 107125; 127.
DR   CORUM; P36894; -.
DR   DIP; DIP-5793N; -.
DR   IntAct; P36894; 60.
DR   MINT; P36894; -.
DR   STRING; 9606.ENSP00000361107; -.
DR   BindingDB; P36894; -.
DR   ChEMBL; CHEMBL5275; -.
DR   DrugBank; DB11639; Dibotermin alfa.
DR   DrugCentral; P36894; -.
DR   GuidetoPHARMACOLOGY; 1786; -.
DR   iPTMnet; P36894; -.
DR   PhosphoSitePlus; P36894; -.
DR   BioMuta; BMPR1A; -.
DR   DMDM; 61252444; -.
DR   EPD; P36894; -.
DR   jPOST; P36894; -.
DR   MassIVE; P36894; -.
DR   MaxQB; P36894; -.
DR   PaxDb; P36894; -.
DR   PeptideAtlas; P36894; -.
DR   PRIDE; P36894; -.
DR   ProteomicsDB; 55228; -.
DR   ABCD; P36894; -.
DR   Antibodypedia; 4524; 747 antibodies.
DR   DNASU; 657; -.
DR   Ensembl; ENST00000372037; ENSP00000361107; ENSG00000107779.
DR   Ensembl; ENST00000635816; ENSP00000489707; ENSG00000107779.
DR   Ensembl; ENST00000636056; ENSP00000490273; ENSG00000107779.
DR   Ensembl; ENST00000638429; ENSP00000492290; ENSG00000107779.
DR   GeneID; 657; -.
DR   KEGG; hsa:657; -.
DR   UCSC; uc001kdy.4; human.
DR   CTD; 657; -.
DR   DisGeNET; 657; -.
DR   GeneCards; BMPR1A; -.
DR   GeneReviews; BMPR1A; -.
DR   HGNC; HGNC:1076; BMPR1A.
DR   HPA; ENSG00000107779; Low tissue specificity.
DR   MalaCards; BMPR1A; -.
DR   MIM; 174900; phenotype.
DR   MIM; 601299; gene.
DR   MIM; 610069; phenotype.
DR   MIM; 612242; phenotype.
DR   neXtProt; NX_P36894; -.
DR   OpenTargets; ENSG00000107779; -.
DR   Orphanet; 440437; Familial colorectal cancer Type X.
DR   Orphanet; 329971; Generalized juvenile polyposis/juvenile polyposis coli.
DR   Orphanet; 157794; Hereditary mixed polyposis syndrome.
DR   Orphanet; 79076; Juvenile polyposis of infancy.
DR   PharmGKB; PA25386; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   eggNOG; ENOG410XQT0; LUCA.
DR   GeneTree; ENSGT00940000156225; -.
DR   HOGENOM; CLU_000288_8_1_1; -.
DR   InParanoid; P36894; -.
DR   KO; K04673; -.
DR   OMA; TICCCTL; -.
DR   OrthoDB; 776697at2759; -.
DR   PhylomeDB; P36894; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; P36894; -.
DR   SIGNOR; P36894; -.
DR   ChiTaRS; BMPR1A; human.
DR   EvolutionaryTrace; P36894; -.
DR   GeneWiki; BMPR1A; -.
DR   GenomeRNAi; 657; -.
DR   Pharos; P36894; Tchem.
DR   PRO; PR:P36894; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P36894; protein.
DR   Bgee; ENSG00000107779; Expressed in intestine and 225 other tissues.
DR   ExpressionAtlas; P36894; baseline and differential.
DR   Genevisible; P36894; HS.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:1990712; C:HFE-transferrin receptor complex; IC:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC-UCL.
DR   GO; GO:0098821; F:BMP receptor activity; ISS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC-UCL.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC-UCL.
DR   GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IBA:GO_Central.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0061312; P:BMP signaling pathway involved in heart development; IC:BHF-UCL.
DR   GO; GO:0003161; P:cardiac conduction system development; ISS:BHF-UCL.
DR   GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0048589; P:developmental growth; IEA:Ensembl.
DR   GO; GO:0035912; P:dorsal aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IBA:GO_Central.
DR   GO; GO:0007398; P:ectoderm development; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0048568; P:embryonic organ development; IEA:Ensembl.
DR   GO; GO:0003272; P:endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1905285; P:fibrous ring of heart morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060914; P:heart formation; IEA:Ensembl.
DR   GO; GO:0035137; P:hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IMP:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0048368; P:lateral mesoderm development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0048382; P:mesendoderm development; IEA:Ensembl.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0003183; P:mitral valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001880; P:Mullerian duct regression; IEA:Ensembl.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IEA:Ensembl.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IMP:BHF-UCL.
DR   GO; GO:0014032; P:neural crest cell development; IEA:Ensembl.
DR   GO; GO:0021998; P:neural plate mediolateral regionalization; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048352; P:paraxial mesoderm structural organization; IEA:Ensembl.
DR   GO; GO:0061626; P:pharyngeal arch artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:1904414; P:positive regulation of cardiac ventricle development; ISS:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:HGNC-UCL.
DR   GO; GO:0060043; P:regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:2000772; P:regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:0048378; P:regulation of lateral mesodermal cell fate specification; IEA:Ensembl.
DR   GO; GO:0060021; P:roof of mouth development; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0019827; P:stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003223; P:ventricular compact myocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL.
DR   DisProt; DP01990; -.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Disease mutation; Disulfide bond;
KW   Glycoprotein; Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Polymorphism; Receptor; Reference proteome;
KW   Serine/threonine-protein kinase; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..532
FT                   /note="Bone morphogenetic protein receptor type-1A"
FT                   /id="PRO_0000024410"
FT   TOPO_DOM        24..152
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        153..176
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        177..532
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          204..233
FT                   /note="GS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00585"
FT   DOMAIN          234..525
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         240..248
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          107..109
FT                   /note="Mediates specificity for BMP ligand"
FT                   /evidence="ECO:0000269|PubMed:22799562"
FT   ACT_SITE        362
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         261
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   CARBOHYD        73
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        61..82
FT                   /evidence="ECO:0000269|PubMed:10881198,
FT                   ECO:0000269|PubMed:18937504"
FT   DISULFID        63..67
FT                   /evidence="ECO:0000269|PubMed:10881198,
FT                   ECO:0000269|PubMed:18937504"
FT   DISULFID        76..100
FT                   /evidence="ECO:0000269|PubMed:10881198,
FT                   ECO:0000269|PubMed:18937504"
FT   DISULFID        110..124
FT                   /evidence="ECO:0000269|PubMed:10881198,
FT                   ECO:0000269|PubMed:18937504"
FT   DISULFID        125..130
FT                   /evidence="ECO:0000269|PubMed:10881198,
FT                   ECO:0000269|PubMed:18937504"
FT   VARIANT         2
FT                   /note="P -> T (in dbSNP:rs11528010)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8397373"
FT                   /id="VAR_041397"
FT   VARIANT         58
FT                   /note="F -> Y (in a renal clear cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041398"
FT   VARIANT         62
FT                   /note="Y -> D (in JPS)"
FT                   /evidence="ECO:0000269|PubMed:12417513"
FT                   /id="VAR_022828"
FT   VARIANT         82
FT                   /note="C -> Y (in JPS)"
FT                   /evidence="ECO:0000269|PubMed:12417513"
FT                   /id="VAR_022829"
FT   VARIANT         124
FT                   /note="C -> R (in JPS; dbSNP:rs199476087)"
FT                   /evidence="ECO:0000269|PubMed:11536076"
FT                   /id="VAR_015533"
FT   VARIANT         130
FT                   /note="C -> R (in JPS; dbSNP:rs1131691168)"
FT                   /evidence="ECO:0000269|PubMed:12136244"
FT                   /id="VAR_022830"
FT   VARIANT         338
FT                   /note="A -> D (in JPS; dbSNP:rs199476086)"
FT                   /evidence="ECO:0000269|PubMed:11536076"
FT                   /id="VAR_015534"
FT   VARIANT         376
FT                   /note="C -> Y (in JPS; dbSNP:rs199476088)"
FT                   /evidence="ECO:0000269|PubMed:11536076"
FT                   /id="VAR_015535"
FT   VARIANT         443
FT                   /note="R -> C (in JPS; dbSNP:rs35619497)"
FT                   /evidence="ECO:0000269|PubMed:12417513,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_022831"
FT   VARIANT         450
FT                   /note="V -> M (in dbSNP:rs55932635)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041399"
FT   VARIANT         460
FT                   /note="M -> T (found in a patient with tubular adenoma and
FT                   rectal neuroendocrine tumor; unknown pathological
FT                   significance; dbSNP:rs758309022)"
FT                   /evidence="ECO:0000269|PubMed:25860647"
FT                   /id="VAR_077353"
FT   VARIANT         470
FT                   /note="M -> T (in JPS; dbSNP:rs199476089)"
FT                   /evidence="ECO:0000269|PubMed:12630959"
FT                   /id="VAR_022832"
FT   VARIANT         486
FT                   /note="R -> Q (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs752802257)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041400"
FT   MUTAGEN         107..109
FT                   /note="DFQ->REL: Affinity for BMP2 decreased by over 200-
FT                   fold."
FT                   /evidence="ECO:0000269|PubMed:22799562"
FT   STRAND          59..62
FT                   /evidence="ECO:0000244|PDB:2H62"
FT   STRAND          64..66
FT                   /evidence="ECO:0000244|PDB:2H62"
FT   STRAND          75..88
FT                   /evidence="ECO:0000244|PDB:2H62"
FT   STRAND          90..92
FT                   /evidence="ECO:0000244|PDB:2H62"
FT   STRAND          94..101
FT                   /evidence="ECO:0000244|PDB:2H62"
FT   HELIX           106..111
FT                   /evidence="ECO:0000244|PDB:2H62"
FT   STRAND          116..118
FT                   /evidence="ECO:0000244|PDB:2QJA"
FT   STRAND          120..125
FT                   /evidence="ECO:0000244|PDB:2H62"
FT   HELIX           130..133
FT                   /evidence="ECO:0000244|PDB:2H62"
SQ   SEQUENCE   532 AA;  60198 MW;  00CE2DDDA3A44170 CRC64;
     MPQLYIYIRL LGAYLFIISR VQGQNLDSML HGTGMKSDSD QKKSENGVTL APEDTLPFLK
     CYCSGHCPDD AINNTCITNG HCFAIIEEDD QGETTLASGC MKYEGSDFQC KDSPKAQLRR
     TIECCRTNLC NQYLQPTLPP VVIGPFFDGS IRWLVLLISM AVCIIAMIIF SSCFCYKHYC
     KSISSRRRYN RDLEQDEAFI PVGESLKDLI DQSQSSGSGS GLPLLVQRTI AKQIQMVRQV
     GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS WFRETEIYQT VLMRHENILG FIAADIKGTG
     SWTQLYLITD YHENGSLYDF LKCATLDTRA LLKLAYSAAC GLCHLHTEIY GTQGKPAIAH
     RDLKSKNILI KKNGSCCIAD LGLAVKFNSD TNEVDVPLNT RVGTKRYMAP EVLDESLNKN
     HFQPYIMADI YSFGLIIWEM ARRCITGGIV EEYQLPYYNM VPSDPSYEDM REVVCVKRLR
     PIVSNRWNSD ECLRAVLKLM SECWAHNPAS RLTALRIKKT LAKMVESQDV KI
//
ID   BTK_HUMAN               Reviewed;         659 AA.
AC   Q06187; B2RAW1; Q32ML5;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   22-APR-2020, entry version 246.
DE   RecName: Full=Tyrosine-protein kinase BTK;
DE            EC=2.7.10.2;
DE   AltName: Full=Agammaglobulinemia tyrosine kinase;
DE            Short=ATK;
DE   AltName: Full=B-cell progenitor kinase;
DE            Short=BPK;
DE   AltName: Full=Bruton tyrosine kinase;
GN   Name=BTK; Synonyms=AGMX1, ATK, BPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BTK-A).
RX   PubMed=8380905; DOI=10.1038/361226a0;
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A., Flinter F.,
RA   Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M., Smith C.I.E.,
RA   Bentley D.R.;
RT   "The gene involved in X-linked agammaglobulinaemia is a member of the src
RT   family of protein-tyrosine kinases.";
RL   Nature 361:226-233(1993).
RN   [2]
RP   ERRATUM OF PUBMED:8380905.
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A., Flinter F.,
RA   Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M., Smith C.I.E.,
RA   Bentley D.R.;
RL   Nature 364:362-362(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=8090769; DOI=10.1073/pnas.91.19.9062;
RA   Ohta Y., Haire R.N., Litman R.T., Fu S.M., Nelson R.P., Kratz J.,
RA   Kornfeld S.J., la Morena M., Good R.A., Litman G.W.;
RT   "Genomic organization and structure of Bruton agammaglobulinemia tyrosine
RT   kinase: localization of mutations associated with varied clinical
RT   presentations and course in X chromosome-linked agammaglobulinemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9062-9066(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7927535; DOI=10.1007/bf01246672;
RA   Rohrer J., Parolini O., Belmont J.W., Conley M.E.;
RT   "The genomic structure of human BTK, the defective gene in X-linked
RT   agammaglobulinemia.";
RL   Immunogenetics 40:319-324(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS XLA SER-334; ARG-506;
RP   GLN-520; TRP-562 AND LYS-630.
RX   PubMed=7880320; DOI=10.1093/hmg/3.10.1743;
RA   Hagemann T.L., Chen Y., Rosen F.S., Kwan S.-P.;
RT   "Genomic organization of the Btk gene and exon scanning for mutations in
RT   patients with X-linked agammaglobulinemia.";
RL   Hum. Mol. Genet. 3:1743-1749(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7626884; DOI=10.1007/bf00364796;
RA   Oeltjen J.C., Liu X., Lu J., Allen R.C., Muzny D.M., Belmont J.W.,
RA   Gibbs R.A.;
RT   "Sixty-nine kilobases of contiguous human genomic sequence containing the
RT   alpha-galactosidase A and Bruton's tyrosine kinase loci.";
RL   Mamm. Genome 6:334-338(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BTK-A).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BTK-A).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 1-442.
RX   PubMed=8425221; DOI=10.1016/0092-8674(93)90667-f;
RA   Tsukada S., Saffran D.C., Rawlings D.J., Parolini O., Allen R.C.,
RA   Klisak I., Sparkes R.S., Kubagawa H., Mohandas T., Quan S., Belmont J.W.,
RA   Cooper M.D., Conley M.E., Witte O.N.;
RT   "Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-
RT   linked agammaglobulinemia.";
RL   Cell 72:279-290(1993).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-12 AND 323-332, CLEAVAGE OF INITIATOR METHIONINE,
RP   ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 219-235, AND PHOSPHORYLATION AT TYR-223.
RX   PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1;
RA   Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A.,
RA   Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.;
RT   "Identification of phosphorylation sites within the SH3 domains of Tec
RT   family tyrosine kinases.";
RL   Biochim. Biophys. Acta 1645:123-132(2003).
RN   [13]
RP   INVOLVEMENT IN IGHD3.
RX   PubMed=8013627; DOI=10.1016/0014-5793(94)00457-9;
RA   Duriez B., Duquesnoy P., Dastot F., Bougneres P., Amselem S., Goossens M.;
RT   "An exon-skipping mutation in the btk gene of a patient with X-linked
RT   agammaglobulinemia and isolated growth hormone deficiency.";
RL   FEBS Lett. 346:165-170(1994).
RN   [14]
RP   DOMAIN PH.
RX   PubMed=8070576; DOI=10.1016/0014-5793(94)00783-7;
RA   Vihinen M., Nilsson L., Smith C.I.;
RT   "Tec homology (TH) adjacent to the PH domain.";
RL   FEBS Lett. 350:263-265(1994).
RN   [15]
RP   PHOSPHORYLATION AT TYR-223 AND TYR-551, MUTAGENESIS OF TYR-223, AND
RP   ACTIVITY REGULATION.
RX   PubMed=8630736; DOI=10.1016/s1074-7613(00)80417-3;
RA   Park H., Wahl M.I., Afar D.E., Turck C.W., Rawlings D.J., Tam C.,
RA   Scharenberg A.M., Kinet J.P., Witte O.N.;
RT   "Regulation of Btk function by a major autophosphorylation site within the
RT   SH3 domain.";
RL   Immunity 4:515-525(1996).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF GTF2I, PHOSPHORYLATION AT TYR-223 AND
RP   TYR-551, AND MUTAGENESIS OF GLU-41; PRO-189; TYR-223; TRP-251; ARG-307 AND
RP   TYR-551.
RX   PubMed=9012831; DOI=10.1073/pnas.94.2.604;
RA   Yang W., Desiderio S.;
RT   "BAP-135, a target for Bruton's tyrosine kinase in response to B cell
RT   receptor engagement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:604-609(1997).
RN   [17]
RP   MUTAGENESIS OF 251-TRP-TRP-252, AND INTERACTION WITH SH3BP5.
RX   PubMed=9571151; DOI=10.1006/bbrc.1998.8420;
RA   Matsushita M., Yamadori T., Kato S., Takemoto Y., Inazawa J., Baba Y.,
RA   Hashimoto S., Sekine S., Arai S., Kunikata T., Kurimoto M., Kishimoto T.,
RA   Tsukada S.;
RT   "Identification and characterization of a novel SH3-domain binding protein,
RT   Sab, which preferentially associates with Bruton's tyrosine kinase (Btk).";
RL   Biochem. Biophys. Res. Commun. 245:337-343(1998).
RN   [18]
RP   DOMAIN PH, AND SUBCELLULAR LOCATION.
RX   PubMed=10196179; DOI=10.1074/jbc.274.16.10983;
RA   Varnai P., Rother K.I., Balla T.;
RT   "Phosphatidylinositol 3-kinase-dependent membrane association of the
RT   Bruton's tyrosine kinase pleckstrin homology domain visualized in single
RT   living cells.";
RL   J. Biol. Chem. 274:10983-10989(1999).
RN   [19]
RP   INTERACTION WITH SH3BP5, AND ACTIVITY REGULATION.
RX   PubMed=10339589; DOI=10.1073/pnas.96.11.6341;
RA   Yamadori T., Baba Y., Mastushita M., Hashimoto S., Kurosaki M.,
RA   Kurosaki T., Kishimoto T., Tsukada S.;
RT   "Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-
RT   SH3 domain-binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6341-6346(1999).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10602036;
RX   DOI=10.1002/1521-4141(200001)30:1<145::aid-immu145>3.0.co;2-0;
RA   Nore B.F., Vargas L., Mohamed A.J., Branden L.J., Backesjo C.M.,
RA   Islam T.C., Mattsson P.T., Hultenby K., Christensson B., Smith C.I.;
RT   "Redistribution of Bruton's tyrosine kinase by activation of
RT   phosphatidylinositol 3-kinase and Rho-family GTPases.";
RL   Eur. J. Immunol. 30:145-154(2000).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11016936; DOI=10.1074/jbc.m006952200;
RA   Mohamed A.J., Vargas L., Nore B.F., Backesjo C.M., Christensson B.,
RA   Smith C.I.;
RT   "Nucleocytoplasmic shuttling of Bruton's tyrosine kinase.";
RL   J. Biol. Chem. 275:40614-40619(2000).
RN   [22]
RP   PHOSPHORYLATION AT SER-180, AND ACTIVITY REGULATION.
RX   PubMed=11598012; DOI=10.1093/emboj/20.20.5692;
RA   Kang S.W., Wahl M.I., Chu J., Kitaura J., Kawakami Y., Kato R.M.,
RA   Tabuchi R., Tarakhovsky A., Kawakami T., Turck C.W., Witte O.N.,
RA   Rawlings D.J.;
RT   "PKCbeta modulates antigen receptor signaling via regulation of Btk
RT   membrane localization.";
RL   EMBO J. 20:5692-5702(2001).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG2.
RX   PubMed=11606584; DOI=10.1074/jbc.m107577200;
RA   Rodriguez R., Matsuda M., Perisic O., Bravo J., Paul A., Jones N.P.,
RA   Light Y., Swann K., Williams R.L., Katan M.;
RT   "Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme
RT   function in B-cell signaling.";
RL   J. Biol. Chem. 276:47982-47992(2001).
RN   [24]
RP   INTERACTION WITH IBTK, AND ACTIVITY REGULATION.
RX   PubMed=11577348; DOI=10.1038/ni1001-939;
RA   Liu W., Quinto I., Chen X., Palmieri C., Rabin R.L., Schwartz O.M.,
RA   Nelson D.L., Scala G.;
RT   "Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding
RT   protein.";
RL   Nat. Immunol. 2:939-946(2001).
RN   [25]
RP   DOMAIN, INTERACTION WITH CAV1, SUBCELLULAR LOCATION, AND ACTIVITY
RP   REGULATION.
RX   PubMed=11751885; DOI=10.1074/jbc.m108537200;
RA   Vargas L., Nore B.F., Berglof A., Heinonen J.E., Mattsson P.T., Smith C.I.,
RA   Mohamed A.J.;
RT   "Functional interaction of caveolin-1 with Bruton's tyrosine kinase and
RT   Bmx.";
RL   J. Biol. Chem. 277:9351-9357(2002).
RN   [26]
RP   PHOSPHORYLATION AT TYR-617 AND SER-623, AND MUTAGENESIS OF TYR-617.
RX   PubMed=15375214; DOI=10.1073/pnas.0405878101;
RA   Guo S., Ferl G.Z., Deora R., Riedinger M., Yin S., Kerwin J.L., Loo J.A.,
RA   Witte O.N.;
RT   "A phosphorylation site in Bruton's tyrosine kinase selectively regulates B
RT   cell calcium signaling efficiency by altering phospholipase C-gamma
RT   activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:14180-14185(2004).
RN   [27]
RP   INTERACTION WITH PIN1, PHOSPHORYLATION AT SER-21 AND SER-115, AND ACTIVITY
RP   REGULATION.
RX   PubMed=16644721; DOI=10.1074/jbc.m603090200;
RA   Yu L., Mohamed A.J., Vargas L., Berglof A., Finn G., Lu K.P., Smith C.I.;
RT   "Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase
RT   Pin1.";
RL   J. Biol. Chem. 281:18201-18207(2006).
RN   [28]
RP   FUNCTION IN THE TLR PATHWAY.
RX   PubMed=16517732; DOI=10.4049/jimmunol.176.6.3635;
RA   Horwood N.J., Page T.H., McDaid J.P., Palmer C.D., Campbell J., Mahon T.,
RA   Brennan F.M., Webster D., Foxwell B.M.;
RT   "Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but
RT   not IL-6, production.";
RL   J. Immunol. 176:3635-3641(2006).
RN   [29]
RP   INTERACTION WITH GTF2I AND ARID3A, AND FUNCTION.
RX   PubMed=16738337; DOI=10.1128/mcb.02009-05;
RA   Rajaiya J., Nixon J.C., Ayers N., Desgranges Z.P., Roy A.L., Webb C.F.;
RT   "Induction of immunoglobulin heavy-chain transcription through the
RT   transcription factor Bright requires TFII-I.";
RL   Mol. Cell. Biol. 26:4758-4768(2006).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF TIRAP, AND ACTIVITY REGULATION.
RX   PubMed=16415872; DOI=10.1038/ni1299;
RA   Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J.,
RA   Nicholson S.E., Hilton D.J., O'Neill L.A., Hertzog P.J.;
RT   "Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor
RT   signaling by mediating Mal degradation.";
RL   Nat. Immunol. 7:148-155(2006).
RN   [31]
RP   FUNCTION, INTERACTION WITH TLR8 AND TLR9, ACTIVITY REGULATION, AND
RP   PHOSPHORYLATION AT TYR-223.
RX   PubMed=17932028; DOI=10.1074/jbc.m707682200;
RA   Doyle S.L., Jefferies C.A., Feighery C., O'Neill L.A.;
RT   "Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine
RT   kinase.";
RL   J. Biol. Chem. 282:36953-36960(2007).
RN   [32]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL (CD178) by
RT   phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [33]
RP   REVIEW ON FUNCTION IN REGULATION OF APOPTOSIS.
RX   PubMed=9751072; DOI=10.1016/s0006-2952(98)00122-1;
RA   Uckun F.M.;
RT   "Bruton's tyrosine kinase (BTK) as a dual-function regulator of
RT   apoptosis.";
RL   Biochem. Pharmacol. 56:683-691(1998).
RN   [34]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=19290921; DOI=10.1111/j.1600-065x.2008.00741.x;
RA   Mohamed A.J., Yu L., Backesjo C.M., Vargas L., Faryal R., Aints A.,
RA   Christensson B., Berglof A., Vihinen M., Nore B.F., Smith C.I.;
RT   "Bruton's tyrosine kinase (Btk): function, regulation, and transformation
RT   with special emphasis on the PH domain.";
RL   Immunol. Rev. 228:58-73(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55; THR-191; TYR-361 AND
RP   SER-659, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   ALTERNATIVE PROMOTER USAGE (ISOFORM BTK-C).
RX   PubMed=23913792; DOI=10.1002/gcc.22091;
RA   Eifert C., Wang X., Kokabee L., Kourtidis A., Jain R., Gerdes M.J.,
RA   Conklin D.S.;
RT   "A novel isoform of the B cell tyrosine kinase BTK protects breast cancer
RT   cells from apoptosis.";
RL   Genes Chromosomes Cancer 52:961-975(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-191; TYR-223 AND SER-604, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 2-170 IN COMPLEX WITH ZINC.
RX   PubMed=9218782; DOI=10.1093/emboj/16.12.3396;
RA   Hyvoenen M., Saraste M.;
RT   "Structure of the PH domain and Btk motif from Bruton's tyrosine kinase:
RT   molecular explanations for X-linked agammaglobulinaemia.";
RL   EMBO J. 16:3396-3404(1997).
RN   [41]
RP   STRUCTURE BY NMR OF 212-275.
RX   PubMed=9485443; DOI=10.1021/bi972409f;
RA   Hansson H., Mattsson P.T., Allard P., Haapaniemi P., Vihinen M.,
RA   Smith C.I.E., Haerd T.;
RT   "Solution structure of the SH3 domain from Bruton's tyrosine kinase.";
RL   Biochemistry 37:2912-2924(1998).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-170 IN COMPLEX WITH
RP   INOSITOL-(1,3,4,5)-TETRAKISPHOSPHATE AND ZINC, AND DOMAIN PH.
RX   PubMed=10196129; DOI=10.1016/s0969-2126(99)80057-4;
RA   Baraldi E., Carugo K.D., Hyvoenen M., Surdo P.L., Riley A.M.,
RA   Potter B.V.L., O'Brien R., Ladbury J.E., Saraste M.;
RT   "Structure of the PH domain from Bruton's tyrosine kinase in complex with
RT   inositol 1,3,4,5-tetrakisphosphate.";
RL   Structure 7:449-460(1999).
RN   [43]
RP   STRUCTURE BY NMR OF 216-273.
RX   PubMed=10826882; DOI=10.1023/a:1008376624863;
RA   Tzeng S.R., Lou Y.C., Pai M.T., Jain M.L., Cheng J.W.;
RT   "Solution structure of the human BTK SH3 domain complexed with a proline-
RT   rich peptide from p120cbl.";
RL   J. Biomol. NMR 16:303-312(2000).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 397-659.
RX   PubMed=11527964; DOI=10.1074/jbc.m104828200;
RA   Mao C., Zhou M., Uckun F.M.;
RT   "Crystal structure of Bruton's tyrosine kinase domain suggests a novel
RT   pathway for activation and provides insights into the molecular basis of X-
RT   linked agammaglobulinemia.";
RL   J. Biol. Chem. 276:41435-41443(2001).
RN   [45]
RP   STRUCTURE BY NMR OF 270-386.
RX   PubMed=16969585; DOI=10.1007/s10858-006-9064-3;
RA   Huang K.C., Cheng H.T., Pai M.T., Tzeng S.R., Cheng J.W.;
RT   "Solution structure and phosphopeptide binding of the SH2 domain from the
RT   human Bruton's tyrosine kinase.";
RL   J. Biomol. NMR 36:73-78(2006).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 393-656 IN COMPLEX WITH
RP   INHIBITOR.
RA   Di Paolo J.A., Huang T., Balazs M., Barbosa J., Barck K.H., Carano R.A.D.,
RA   Darrow J., Davies D.R., DeForge L.E., Dennis G. Jr., Diehl L., Ferrando R.;
RT   "A novel, specific Btk inhibitor antagonizes BCR and Fc[gamma]R signaling
RT   and suppresses inflammatory arthritis.";
RL   Submitted (AUG-2010) to the PDB data bank.
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF 2-170 IN COMPLEX WITH INHIBITOR
RP   AND ZINC.
RA   Murayama K., Kato-Murayama M., Mishima C., Shirouzu M., Yokoyama S.;
RT   "Crystal structure of PH domain of Bruton's tyrosine kinase.";
RL   Submitted (MAY-2007) to the PDB data bank.
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 382-659 IN COMPLEX WITH INHIBITOR
RP   DASATINIB.
RX   PubMed=20052711; DOI=10.1002/pro.321;
RA   Marcotte D.J., Liu Y.T., Arduini R.M., Hession C.A., Miatkowski K.,
RA   Wildes C.P., Cullen P.F., Hong V., Hopkins B.T., Mertsching E.,
RA   Jenkins T.J., Romanowski M.J., Baker D.P., Silvian L.F.;
RT   "Structures of human Bruton's tyrosine kinase in active and inactive
RT   conformations suggest a mechanism of activation for TEC family kinases.";
RL   Protein Sci. 19:429-439(2010).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 393-659.
RA   Di Paolo J., Huang T., Balazs M., Barbosa J., Barck K.H., Bravo B.,
RA   Carano R.A.D., Darrow J., Davies D.R., DeForge L.E., Diehl L., Ferrando R.,
RA   Gallion S.L., Gianetti A.M., Gribling P., Hurez V., Hymowitz S.G.,
RA   Jones R., Kropf J.E., Lee W.P., Maciejewski P.M., Mitchell S.A., Rong H.,
RA   Staker B.L., Whitney J.A., Yeh S., Young W., Yu C., Zhang J., Reif K.,
RA   Currie K.S.;
RT   "A novel, specific BTK inhibitor antagonizes BCR and FcgR signaling and
RT   suppresses inflammatory arthritis.";
RL   Submitted (SEP-2010) to the PDB data bank.
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 387-659 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=21280133; DOI=10.1002/pro.575;
RA   Kuglstatter A., Wong A., Tsing S., Lee S.W., Lou Y., Villasenor A.G.,
RA   Bradshaw J.M., Shaw D., Barnett J.W., Browner M.F.;
RT   "Insights into the conformational flexibility of Bruton's tyrosine kinase
RT   from multiple ligand complex structures.";
RL   Protein Sci. 20:428-436(2011).
RN   [51]
RP   REVIEW ON VARIANTS XLA.
RX   PubMed=8594569; DOI=10.1093/nar/24.1.160;
RA   Vihinen M., Iwata T., Kinnon C., Kwan S.-P., Ochs H.D., Vorechovsky I.,
RA   Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 24:160-165(1996).
RN   [52]
RP   REVIEW ON VARIANTS XLA.
RX   PubMed=9016530; DOI=10.1093/nar/25.1.166;
RA   Vihinen M., Belohradsky B.H., Haire R.N., Holinski-Feder E., Kwan S.-P.,
RA   Lappalainen I., Lehvaeslaiho H., Lester T., Meindl A., Ochs H.D.,
RA   Ollila J., Vorechovsky I., Weiss M., Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 25:166-171(1997).
RN   [53]
RP   VARIANTS XLA TRP-288; GLY-307; ASP-607 AND SER-VAL-PHE-SER-SER-THR-ARG-103
RP   INS.
RX   PubMed=8162056; DOI=10.1093/hmg/3.1.79;
RA   Bradley L.A.D., Sweatman A.K., Lovering R.C., Jones A.M., Morgan G.,
RA   Levinsky R.J., Kinnon C.;
RT   "Mutation detection in the X-linked agammaglobulinemia gene, BTK, using
RT   single strand conformation polymorphism analysis.";
RL   Hum. Mol. Genet. 3:79-83(1994).
RN   [54]
RP   VARIANTS XLA HIS-28 AND TRP-288.
RX   PubMed=8162018; DOI=10.1093/hmg/3.1.161;
RA   de Weers M., Mensink R.G.J., Kraakman M.E.M., Schuurman R.K.B.,
RA   Hendriks R.W.;
RT   "Mutation analysis of the Bruton's tyrosine kinase gene in X-linked
RT   agammaglobulinemia: identification of a mutation which affects the same
RT   codon as is altered in immunodeficient xid mice.";
RL   Hum. Mol. Genet. 3:161-166(1994).
RN   [55]
RP   VARIANTS XLA ASP-113; CYS-361; GLN-520; PRO-542; TRP-562; LYS-630 AND
RP   PRO-652.
RX   PubMed=7849697; DOI=10.1093/hmg/3.10.1751;
RA   Conley M.E., Fitch-Hilgenberg M.E., Cleveland J.L., Parolini O., Rohrer J.;
RT   "Screening of genomic DNA to identify mutations in the gene for Bruton's
RT   tyrosine kinase.";
RL   Hum. Mol. Genet. 3:1751-1756(1994).
RN   [56]
RP   VARIANTS XLA HIS-28; PRO-33; PRO-408; GLY-589; ASP-613 AND 260-GLN--GLU-280
RP   DEL.
RX   PubMed=7849721; DOI=10.1093/hmg/3.10.1899;
RA   Zhu Q., Zhang M., Winkelstein J., Chen S.-H., Ochs H.D.;
RT   "Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-
RT   linked agammaglobulinemia families.";
RL   Hum. Mol. Genet. 3:1899-1900(1994).
RN   [57]
RP   VARIANTS XLA GLU-430; GLN-520; GLN-525; PRO-562; VAL-582; GLY-589; GLU-594
RP   AND ASP-613.
RX   PubMed=7809124; DOI=10.1073/pnas.91.26.12803;
RA   Vihinen M., Vetrie D., Maniar H.S., Ochs H.D., Zhu Q., Vorechovsky I.,
RA   Webster A.D.B., Notarangelo L.D., Nilsson L., Sowadski J.M., Smith C.I.E.;
RT   "Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine
RT   kinase disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:12803-12807(1994).
RN   [58]
RP   VARIANT XLA PHE-64, AND CHARACTERIZATION OF OTHER XLA VARIANTS.
RX   PubMed=7849006; DOI=10.1021/bi00005a002;
RA   Vihinen M., Zvelebil J.J.M., Zhu Q., Brooimans R.A., Ochs H.D.,
RA   Zegers B.J.M., Nilsson L., Waterfield M.D., Smith C.I.E.;
RT   "Structural basis for pleckstrin homology domain mutations in X-linked
RT   agammaglobulinemia.";
RL   Biochemistry 34:1475-1481(1995).
RN   [59]
RP   VARIANTS XLA SER-25; TRP-288; MET-370; VAL-509; PRO-525; LYS-526; TRP-562;
RP   VAL-582 AND ARG-594.
RX   PubMed=7711734; DOI=10.1093/hmg/4.1.51;
RA   Vorechovsky I., Vihinen M., de Saint Basile G., Honsova S.,
RA   Hammarstroem L., Mueller S., Nilsson L., Fischer A., Smith C.I.E.;
RT   "DNA-based mutation analysis of Bruton's tyrosine kinase gene in patients
RT   with X-linked agammaglobulinaemia.";
RL   Hum. Mol. Genet. 4:51-58(1995).
RN   [60]
RP   VARIANTS XLA LYS-567; LEU-587 AND HIS-641.
RX   PubMed=7633420; DOI=10.1093/hmg/4.4.693;
RA   Jin H., Webster A.D.B., Vihinen M., Sideras P., Vorechovsky I.,
RA   Hammarstroem L., Bernatowska-Matuszkiewicz E., Smith C.I.E., Bobrow M.,
RA   Vetrie D.;
RT   "Identification of Btk mutations in 20 unrelated patients with X-linked
RT   agammaglobulinaemia (XLA).";
RL   Hum. Mol. Genet. 4:693-700(1995).
RN   [61]
RP   VARIANTS XLA PRO-33; GLY-302 DEL; GLN-520 AND CYS-641.
RX   PubMed=7633429; DOI=10.1093/hmg/4.4.755;
RA   Gaspar H.B., Bradley L.A.D., Katz F., Lovering R.C., Roifman C.M.,
RA   Morgan G., Levinsky R.J., Kinnon C.;
RT   "Mutation analysis in Bruton's tyrosine kinase, the X-linked
RT   agammaglobulinaemia gene, including identification of an insertional
RT   hotspot.";
RL   Hum. Mol. Genet. 4:755-757(1995).
RN   [62]
RP   VARIANTS XLA ASN-429 AND ARG-477.
RX   PubMed=8634718; DOI=10.1093/hmg/4.12.2403;
RA   Vorechovsky I., Luo L., de Saint Basile G., Hammarstroem L.,
RA   Webster A.D.B., Smith C.I.E.;
RT   "Improved oligonucleotide primer set for molecular diagnosis of X-linked
RT   agammaglobulinaemia: predominance of amino acid substitutions in the
RT   catalytic domain of Bruton's tyrosine kinase.";
RL   Hum. Mol. Genet. 4:2403-2405(1995).
RN   [63]
RP   VARIANTS XLA GLU-302 AND ASP-476.
RX   PubMed=7627183; DOI=10.1002/humu.1380050405;
RA   Hagemann T.L., Rosen F.S., Kwan S.-P.;
RT   "Characterization of germline mutations of the gene encoding Bruton's
RT   tyrosine kinase in families with X-linked agammaglobulinemia.";
RL   Hum. Mutat. 5:296-302(1995).
RN   [64]
RP   VARIANT XLA PHE-358.
RX   PubMed=7897635; DOI=10.1136/jmg.32.1.77;
RA   Ohashi Y., Tsuchiya S., Konno T.;
RT   "A new point mutation involving a highly conserved leucine in the Btk SH2
RT   domain in a family with X linked agammaglobulinaemia.";
RL   J. Med. Genet. 32:77-79(1995).
RN   [65]
RP   VARIANT XLA PRO-295.
RX   PubMed=8723128;
RX   DOI=10.1002/(sici)1096-8628(19960503)63:1<318::aid-ajmg53>3.0.co;2-n;
RA   Schuster V., Seidenspinner S., Kreth H.W.;
RT   "Detection of a novel mutation in the SRC homology domain 2 (SH2) of
RT   Bruton's tyrosine kinase and direct female carrier evaluation in a family
RT   with X-linked agammaglobulinemia.";
RL   Am. J. Med. Genet. 63:318-322(1996).
RN   [66]
RP   VARIANTS XLA ARG-12; PRO-28; GLU-302; TRP-502; HIS-521; TYR-633 AND
RP   SER-644.
RX   PubMed=8695804;
RA   Hashimoto S., Tsukada S., Matsushita M., Miyawaki T., Niida Y., Yachie A.,
RA   Kobayashi S., Iwata T., Hayakawa H., Matsuoka H., Tsuge I., Yamadori T.,
RA   Kunikata T., Arai S., Yoshizaki K., Taniguchi N., Kishimoto T.;
RT   "Identification of Bruton's tyrosine kinase (Btk) gene mutations and
RT   characterization of the derived proteins in 35 X-linked agammaglobulinemia
RT   families: a nationwide study of Btk deficiency in Japan.";
RL   Blood 88:561-573(1996).
RN   [67]
RP   VARIANTS XLA TRP-288; LYS-544 AND PRO-592.
RX   PubMed=8834236; DOI=10.1007/bf02267060;
RA   Kobayashi S., Iwata T., Saito M., Iwasaki R., Matsumoto H., Naritaka S.,
RA   Kono Y., Hayashi Y.;
RT   "Mutations of the Btk gene in 12 unrelated families with X-linked
RT   agammaglobulinemia in Japan.";
RL   Hum. Genet. 97:424-430(1996).
RN   [68]
RP   VARIANTS XLA SER-154 AND ARG-155.
RX   PubMed=9280283; DOI=10.1016/s0014-5793(97)00912-5;
RA   Vihinen M., Nore B., Mattsson P.T., Backesj C.-M., Nars M., Koutaniemi S.,
RA   Watanabe C., Lester T., Jones A.M., Ochs H.D., Smith C.I.E.;
RT   "Missense mutations affecting a conserved cysteine pair in the TH domain of
RT   Btk.";
RL   FEBS Lett. 413:205-210(1997).
RN   [69]
RP   VARIANTS XLA.
RX   PubMed=9260159; DOI=10.1007/bf03401694;
RA   Saha B.K., Curtis S.K., Vogler L.B., Vihinen M.;
RT   "Molecular and structural characterization of five novel mutations in the
RT   Bruton's tyrosine kinase gene from patients with X-linked
RT   agammaglobulinemia.";
RL   Mol. Med. 3:477-485(1997).
RN   [70]
RP   VARIANTS XLA GLN-288; THR-307; ARG-430; ASP-445; GLY-525; PHE-535; LEU-563
RP   AND PRO-622.
RX   PubMed=9545398; DOI=10.1086/301828;
RA   Conley M.E., Mathias D., Treadaway J., Minegishi Y., Rohrer J.;
RT   "Mutations in btk in patients with presumed X-linked agammaglobulinemia.";
RL   Am. J. Hum. Genet. 62:1034-1043(1998).
RN   [71]
RP   VARIANTS XLA GLU-19; HIS-28; ASN-61; PRO-117; HIS-127; ARG-155; PRO-295;
RP   PHE-369; GLY-372; ARG-414; TYR-506; GLY-521; GLN-525; SER-559; TRP-562;
RP   GLU-594; THR-619; GLY-626 AND HIS-641.
RX   PubMed=9445504; DOI=10.1542/peds.101.2.276;
RA   Holinski-Feder E., Weiss M., Brandau O., Jedele K.B., Nore B.,
RA   Baeckesjoe C.-M., Vihinen M., Hubbard S.R., Belohradsky B.H., Smith C.I.E.,
RA   Meindl A.;
RT   "Mutation screening of the BTK gene in 56 families with X-linked
RT   agammaglobulinemia (XLA): 47 unique mutations without correlation to
RT   clinical course.";
RL   Pediatrics 101:276-284(1998).
RN   [72]
RP   VARIANTS XLA.
RX   PubMed=10220140;
RX   DOI=10.1002/(sici)1098-1004(1999)13:4<280::aid-humu3>3.0.co;2-l;
RA   Vihinen M., Kwan S.-P., Lester T., Ochs H.D., Resnick I., Vaeliaho J.,
RA   Conley M.E., Smith C.I.E.;
RT   "Mutations of the human BTK gene coding for Bruton tyrosine kinase in X-
RT   linked agammaglobulinemia.";
RL   Hum. Mutat. 13:280-285(1999).
RN   [73]
RP   VARIANT XLA PRO-562.
RX   PubMed=10678660;
RX   DOI=10.1002/(sici)1096-8628(20000131)90:3<229::aid-ajmg8>3.0.co;2-q;
RA   Curtis S.K., Hebert M.D., Saha B.K.;
RT   "Twin carriers of X-linked agammaglobulinemia (XLA) due to germline
RT   mutation in the Btk gene.";
RL   Am. J. Med. Genet. 90:229-232(2000).
RN   [74]
RP   VARIANTS XLA SER-39; PRO-512; GLN-512; GLY-544; TYR-578 AND LYS-589.
RX   PubMed=10612838;
RX   DOI=10.1002/(sici)1098-1004(200001)15:1<117::aid-humu26>3.0.co;2-h;
RA   Orlandi P., Ritis K., Moschese V., Angelini F., Arvanitidis K.,
RA   Speletas M., Sideras P., Plebani A., Rossi P.;
RT   "Identification of nine novel mutations in the Bruton's tyrosine kinase
RT   gene in X-linked agammaglobulinaemia patients.";
RL   Hum. Mutat. 15:117-117(2000).
RN   [75]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-82 AND LYS-190.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [76]
RP   VARIANT SER-481, AND CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=24869598; DOI=10.1056/nejmoa1400029;
RA   Woyach J.A., Furman R.R., Liu T.M., Ozer H.G., Zapatka M., Ruppert A.S.,
RA   Xue L., Li D.H., Steggerda S.M., Versele M., Dave S.S., Zhang J.,
RA   Yilmaz A.S., Jaglowski S.M., Blum K.A., Lozanski A., Lozanski G.,
RA   James D.F., Barrientos J.C., Lichter P., Stilgenbauer S., Buggy J.J.,
RA   Chang B.Y., Johnson A.J., Byrd J.C.;
RT   "Resistance mechanisms for the Bruton's tyrosine kinase inhibitor
RT   ibrutinib.";
RL   N. Engl. J. Med. 370:2286-2294(2014).
RN   [77]
RP   CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=24869597; DOI=10.1056/nejmc1402716;
RA   Furman R.R., Cheng S., Lu P., Setty M., Perez A.R., Perez A.R., Guo A.,
RA   Racchumi J., Xu G., Wu H., Ma J., Steggerda S.M., Coleman M., Leslie C.,
RA   Wang Y.L.;
RT   "Ibrutinib resistance in chronic lymphocytic leukemia.";
RL   N. Engl. J. Med. 370:2352-2354(2014).
RN   [78]
RP   CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=25189416; DOI=10.1038/leu.2014.263;
RA   Cheng S., Guo A., Lu P., Ma J., Coleman M., Wang Y.L.;
RT   "Functional characterization of BTK(C481S) mutation that confers ibrutinib
RT   resistance: exploration of alternative kinase inhibitors.";
RL   Leukemia 29:895-900(2015).
CC   -!- FUNCTION: Non-receptor tyrosine kinase indispensable for B lymphocyte
CC       development, differentiation and signaling. Binding of antigen to the
CC       B-cell antigen receptor (BCR) triggers signaling that ultimately leads
CC       to B-cell activation. After BCR engagement and activation at the plasma
CC       membrane, phosphorylates PLCG2 at several sites, igniting the
CC       downstream signaling pathway through calcium mobilization, followed by
CC       activation of the protein kinase C (PKC) family members. PLCG2
CC       phosphorylation is performed in close cooperation with the adapter
CC       protein B-cell linker protein BLNK. BTK acts as a platform to bring
CC       together a diverse array of signaling proteins and is implicated in
CC       cytokine receptor signaling pathways. Plays an important role in the
CC       function of immune cells of innate as well as adaptive immunity, as a
CC       component of the Toll-like receptors (TLR) pathway. The TLR pathway
CC       acts as a primary surveillance system for the detection of pathogens
CC       and are crucial to the activation of host defense. Especially, is a
CC       critical molecule in regulating TLR9 activation in splenic B-cells.
CC       Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which
CC       leads to TIRAP degradation. BTK plays also a critical role in
CC       transcription regulation. Induces the activity of NF-kappa-B, which is
CC       involved in regulating the expression of hundreds of genes. BTK is
CC       involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B.
CC       Transiently phosphorylates transcription factor GTF2I on tyrosine
CC       residues in response to BCR. GTF2I then translocates to the nucleus to
CC       bind regulatory enhancer elements to modulate gene expression. ARID3A
CC       and NFAT are other transcriptional target of BTK. BTK is required for
CC       the formation of functional ARID3A DNA-binding complexes. There is
CC       however no evidence that BTK itself binds directly to DNA. BTK has a
CC       dual role in the regulation of apoptosis. {ECO:0000269|PubMed:11606584,
CC       ECO:0000269|PubMed:16415872, ECO:0000269|PubMed:16517732,
CC       ECO:0000269|PubMed:16738337, ECO:0000269|PubMed:17932028,
CC       ECO:0000269|PubMed:9012831}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation. In primary B
CC       lymphocytes, is almost always non-phosphorylated and is thus
CC       catalytically inactive. Stimulation of TLR8 and TLR9 causes BTK
CC       activation. As a negative feedback mechanism to fine-tune BCR
CC       signaling, activated PRKCB down-modulates BTK function via direct
CC       phosphorylation of BTK at Ser-180, resulting in translocation of BTK
CC       back to the cytoplasmic fraction. PIN1, SH3BP5, and IBTK were also
CC       identified as BTK activity inhibitors. Interaction with CAV1 leads to
CC       dramatic down-regulation of the kinase activity of BTK. LFM-13A is a
CC       specific inhibitor of BTK. Dasatinib, a cancer drug acting as a
CC       tyrosine kinase inhibitor, also blocks BTK activity.
CC       {ECO:0000269|PubMed:10339589, ECO:0000269|PubMed:11577348,
CC       ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:16415872, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:8630736}.
CC   -!- SUBUNIT: Binds GTF2I through the PH domain. Interacts with SH3BP5 via
CC       the SH3 domain. Interacts with IBTK via its PH domain. Interacts with
CC       ARID3A, CAV1, FASLG, PIN1, TLR8 and TLR9. {ECO:0000269|PubMed:10196129,
CC       ECO:0000269|PubMed:10339589, ECO:0000269|PubMed:11577348,
CC       ECO:0000269|PubMed:11751885, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:16738337, ECO:0000269|PubMed:17932028,
CC       ECO:0000269|PubMed:19807924, ECO:0000269|PubMed:20052711,
CC       ECO:0000269|PubMed:21280133, ECO:0000269|PubMed:9218782,
CC       ECO:0000269|PubMed:9571151, ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
CC   -!- INTERACTION:
CC       Q06187; Q06187; NbExp=2; IntAct=EBI-624835, EBI-624835;
CC       Q06187; Q13444: ADAM15; NbExp=2; IntAct=EBI-624835, EBI-77818;
CC       Q06187; Q99856: ARID3A; NbExp=3; IntAct=EBI-624835, EBI-5458244;
CC       Q06187; Q8WV28: BLNK; NbExp=2; IntAct=EBI-624835, EBI-2623522;
CC       Q06187; P78347: GTF2I; NbExp=6; IntAct=EBI-624835, EBI-359622;
CC       Q06187; P08238: HSP90AB1; NbExp=2; IntAct=EBI-624835, EBI-352572;
CC       Q06187; P21145: MAL; NbExp=5; IntAct=EBI-624835, EBI-3932027;
CC       Q06187; P50222: MEOX2; NbExp=3; IntAct=EBI-624835, EBI-748397;
CC       Q06187; Q04759: PRKCQ; NbExp=2; IntAct=EBI-624835, EBI-374762;
CC       Q06187; O60239: SH3BP5; NbExp=4; IntAct=EBI-624835, EBI-624860;
CC       Q06187; P42768: WAS; NbExp=4; IntAct=EBI-624835, EBI-346375;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral membrane
CC       protein. Nucleus. Note=In steady state, BTK is predominantly cytosolic.
CC       Following B-cell receptor (BCR) engagement by antigen, translocates to
CC       the plasma membrane through its PH domain. Plasma membrane localization
CC       is a critical step in the activation of BTK. A fraction of BTK also
CC       shuttles between the nucleus and the cytoplasm, and nuclear export is
CC       mediated by the nuclear export receptor CRM1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=BTK-A;
CC         IsoId=Q06187-1; Sequence=Displayed;
CC       Name=BTK-C;
CC         IsoId=Q06187-2; Sequence=VSP_053838;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in B-lymphocytes.
CC   -!- DOMAIN: The PH domain mediates the binding to inositol polyphosphate
CC       and phosphoinositides, leading to its targeting to the plasma membrane.
CC       It is extended in the BTK kinase family by a region designated the TH
CC       (Tec homology) domain, which consists of about 80 residues preceding
CC       the SH3 domain. {ECO:0000269|PubMed:10196129,
CC       ECO:0000269|PubMed:10196179, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:8070576}.
CC   -!- PTM: Following B-cell receptor (BCR) engagement, translocates to the
CC       plasma membrane where it gets phosphorylated at Tyr-551 by LYN and SYK.
CC       Phosphorylation at Tyr-551 is followed by autophosphorylation of Tyr-
CC       223 which may create a docking site for a SH2 containing protein.
CC       Phosphorylation at Ser-180 by PRKCB, leads in translocation of BTK back
CC       to the cytoplasmic fraction. Phosphorylation at Ser-21 and Ser-115
CC       creates a binding site for PIN1 at these Ser-Pro motifs, and promotes
CC       it's recruitment. {ECO:0000269|PubMed:11598012,
CC       ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:15375214,
CC       ECO:0000269|PubMed:16644721, ECO:0000269|PubMed:17932028,
CC       ECO:0000269|PubMed:8630736, ECO:0000269|PubMed:9012831}.
CC   -!- DISEASE: X-linked agammaglobulinemia (XLA) [MIM:300755]: Humoral
CC       immunodeficiency disease which results in developmental defects in the
CC       maturation pathway of B-cells. Affected boys have normal levels of pre-
CC       B-cells in their bone marrow but virtually no circulating mature B-
CC       lymphocytes. This results in a lack of immunoglobulins of all classes
CC       and leads to recurrent bacterial infections like otitis,
CC       conjunctivitis, dermatitis, sinusitis in the first few years of life,
CC       or even some patients present overwhelming sepsis or meningitis,
CC       resulting in death in a few hours. Treatment in most cases is by
CC       infusion of intravenous immunoglobulin. {ECO:0000269|PubMed:10220140,
CC       ECO:0000269|PubMed:10612838, ECO:0000269|PubMed:10678660,
CC       ECO:0000269|PubMed:7627183, ECO:0000269|PubMed:7633420,
CC       ECO:0000269|PubMed:7633429, ECO:0000269|PubMed:7711734,
CC       ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849006,
CC       ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7849721,
CC       ECO:0000269|PubMed:7880320, ECO:0000269|PubMed:7897635,
CC       ECO:0000269|PubMed:8013627, ECO:0000269|PubMed:8162018,
CC       ECO:0000269|PubMed:8162056, ECO:0000269|PubMed:8594569,
CC       ECO:0000269|PubMed:8634718, ECO:0000269|PubMed:8695804,
CC       ECO:0000269|PubMed:8723128, ECO:0000269|PubMed:8834236,
CC       ECO:0000269|PubMed:9016530, ECO:0000269|PubMed:9260159,
CC       ECO:0000269|PubMed:9280283, ECO:0000269|PubMed:9445504,
CC       ECO:0000269|PubMed:9545398}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Growth hormone deficiency, isolated, 3, with
CC       agammaglobulinemia (IGHD3) [MIM:307200]: An X-linked recessive disorder
CC       characterized by growth hormone deficiency, short stature, delayed bone
CC       age, agammaglobulinemia with markedly reduced numbers of B cells, and
CC       good response to treatment with growth hormone.
CC       {ECO:0000269|PubMed:8013627}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform BTK-C]: Produced by alternative promoter usage.
CC       Predominant form in many tumor cells where it may function as an anti-
CC       apoptotic cell survival factor. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BTKID851chXq22.html";
CC   -!- WEB RESOURCE: Name=BTKbase; Note=BTK mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/BTKbase/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X58957; CAA41728.1; -; mRNA.
DR   EMBL; U10087; AAB60639.1; -; Genomic_DNA.
DR   EMBL; U10084; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10085; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10086; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; L31572; AAA61479.1; -; Genomic_DNA.
DR   EMBL; L31557; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31558; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31559; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31561; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31563; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31564; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31565; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31566; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31567; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31568; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31569; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31570; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31571; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; U13433; AAC51347.1; -; Genomic_DNA.
DR   EMBL; U13410; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13412; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13413; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13414; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13415; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13416; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13417; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13422; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13423; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13424; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13425; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13427; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13428; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13429; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13430; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13431; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13432; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U78027; AAB64205.1; -; Genomic_DNA.
DR   EMBL; AK314382; BAG37008.1; -; mRNA.
DR   EMBL; AL035422; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC109079; AAI09080.1; -; mRNA.
DR   EMBL; BC109080; AAI09081.1; -; mRNA.
DR   CCDS; CCDS14482.1; -. [Q06187-1]
DR   CCDS; CCDS76003.1; -. [Q06187-2]
DR   PIR; I37212; A45184.
DR   RefSeq; NP_000052.1; NM_000061.2. [Q06187-1]
DR   RefSeq; NP_001274273.1; NM_001287344.1. [Q06187-2]
DR   RefSeq; NP_001274274.1; NM_001287345.1.
DR   PDB; 1AWW; NMR; -; A=212-275.
DR   PDB; 1AWX; NMR; -; A=212-275.
DR   PDB; 1B55; X-ray; 2.40 A; A/B=2-170.
DR   PDB; 1BTK; X-ray; 1.60 A; A/B=2-170.
DR   PDB; 1BWN; X-ray; 2.10 A; A/B=2-170.
DR   PDB; 1K2P; X-ray; 2.10 A; A/B=397-659.
DR   PDB; 1QLY; NMR; -; A=216-273.
DR   PDB; 2GE9; NMR; -; A=270-387.
DR   PDB; 2Z0P; X-ray; 2.58 A; A/B/C/D=2-170.
DR   PDB; 3GEN; X-ray; 1.60 A; A=382-659.
DR   PDB; 3K54; X-ray; 1.94 A; A=382-659.
DR   PDB; 3OCS; X-ray; 1.80 A; A=393-656.
DR   PDB; 3OCT; X-ray; 1.95 A; A=393-656.
DR   PDB; 3P08; X-ray; 2.30 A; A/B=393-659.
DR   PDB; 3PIX; X-ray; 1.85 A; A=387-659.
DR   PDB; 3PIY; X-ray; 2.55 A; A=387-659.
DR   PDB; 3PIZ; X-ray; 2.21 A; A=387-659.
DR   PDB; 3PJ1; X-ray; 2.00 A; A=387-659.
DR   PDB; 3PJ2; X-ray; 1.75 A; A=387-659.
DR   PDB; 3PJ3; X-ray; 1.85 A; A=387-659.
DR   PDB; 4NWM; X-ray; 2.03 A; A/B=396-657.
DR   PDB; 4OT5; X-ray; 1.55 A; A=378-659.
DR   PDB; 4OT6; X-ray; 2.05 A; A=378-659.
DR   PDB; 4OTF; X-ray; 1.95 A; A=393-657.
DR   PDB; 4OTQ; X-ray; 1.55 A; A=378-659.
DR   PDB; 4OTR; X-ray; 1.95 A; A=378-659.
DR   PDB; 4RFY; X-ray; 1.70 A; A=378-659.
DR   PDB; 4RFZ; X-ray; 1.17 A; A=378-659.
DR   PDB; 4RG0; X-ray; 2.50 A; A=378-659.
DR   PDB; 4RX5; X-ray; 1.36 A; A=393-657.
DR   PDB; 4YHF; X-ray; 2.20 A; A/B=382-659.
DR   PDB; 4Z3V; X-ray; 1.60 A; A=382-659.
DR   PDB; 4ZLY; X-ray; 1.65 A; A=389-658.
DR   PDB; 4ZLZ; X-ray; 2.00 A; A=389-658.
DR   PDB; 5BPY; X-ray; 2.31 A; A/B=396-659.
DR   PDB; 5BQ0; X-ray; 1.57 A; A=382-659.
DR   PDB; 5FBN; X-ray; 1.80 A; C/D=389-659.
DR   PDB; 5FBO; X-ray; 1.89 A; A=389-659.
DR   PDB; 5J87; X-ray; 1.59 A; A/B/C/D=385-658.
DR   PDB; 5JRS; X-ray; 1.97 A; A/B=396-659.
DR   PDB; 5KUP; X-ray; 1.39 A; A=393-657.
DR   PDB; 5P9F; X-ray; 1.71 A; A=382-659.
DR   PDB; 5P9G; X-ray; 1.75 A; A=382-659.
DR   PDB; 5P9H; X-ray; 1.95 A; A=382-659.
DR   PDB; 5P9I; X-ray; 1.11 A; A=382-659.
DR   PDB; 5P9J; X-ray; 1.08 A; A=382-659.
DR   PDB; 5P9K; X-ray; 1.28 A; A=382-659.
DR   PDB; 5P9L; X-ray; 1.25 A; A=382-659.
DR   PDB; 5P9M; X-ray; 1.41 A; A=382-659.
DR   PDB; 5T18; X-ray; 1.50 A; A=396-659.
DR   PDB; 5U9D; X-ray; 1.33 A; A=389-659.
DR   PDB; 5VFI; X-ray; 1.59 A; A=389-659.
DR   PDB; 5VGO; X-ray; 1.62 A; A=393-657.
DR   PDB; 5XYZ; X-ray; 2.64 A; A/B=393-656.
DR   PDB; 5ZZ4; X-ray; 2.90 A; A/B/C/D/E/F=393-656.
DR   PDB; 6AUA; X-ray; 1.66 A; A=394-656.
DR   PDB; 6AUB; X-ray; 1.65 A; A=395-657.
DR   PDB; 6BIK; X-ray; 1.90 A; A=392-657.
DR   PDB; 6BKE; X-ray; 1.95 A; A=392-657.
DR   PDB; 6BKH; X-ray; 1.79 A; A=392-657.
DR   PDB; 6BKW; X-ray; 1.50 A; A=392-657.
DR   PDB; 6BLN; X-ray; 1.30 A; A=392-657.
DR   PDB; 6DI0; X-ray; 1.30 A; A=389-659.
DR   PDB; 6DI1; X-ray; 1.10 A; A=389-659.
DR   PDB; 6DI3; X-ray; 2.00 A; A=389-659.
DR   PDB; 6DI5; X-ray; 1.42 A; A=389-659.
DR   PDB; 6DI9; X-ray; 1.25 A; A=389-659.
DR   PDB; 6E4F; X-ray; 1.15 A; A=387-659.
DR   PDB; 6EP9; X-ray; 2.01 A; A=378-659.
DR   PDB; 6HRP; X-ray; 1.12 A; A=378-659.
DR   PDB; 6HRT; X-ray; 1.36 A; A=378-659.
DR   PDB; 6J6M; X-ray; 1.25 A; A=393-659.
DR   PDB; 6N9P; X-ray; 2.23 A; A=389-659.
DR   PDB; 6NFH; X-ray; 1.40 A; A=389-659.
DR   PDB; 6NFI; X-ray; 2.41 A; A=392-659.
DR   PDB; 6NZM; X-ray; 1.72 A; A/D=382-659.
DR   PDB; 6O8I; X-ray; 1.42 A; A=391-659.
DR   PDB; 6OMU; X-ray; 1.41 A; A=389-659.
DR   PDB; 6S90; X-ray; 1.82 A; A/B=393-658.
DR   PDBsum; 1AWW; -.
DR   PDBsum; 1AWX; -.
DR   PDBsum; 1B55; -.
DR   PDBsum; 1BTK; -.
DR   PDBsum; 1BWN; -.
DR   PDBsum; 1K2P; -.
DR   PDBsum; 1QLY; -.
DR   PDBsum; 2GE9; -.
DR   PDBsum; 2Z0P; -.
DR   PDBsum; 3GEN; -.
DR   PDBsum; 3K54; -.
DR   PDBsum; 3OCS; -.
DR   PDBsum; 3OCT; -.
DR   PDBsum; 3P08; -.
DR   PDBsum; 3PIX; -.
DR   PDBsum; 3PIY; -.
DR   PDBsum; 3PIZ; -.
DR   PDBsum; 3PJ1; -.
DR   PDBsum; 3PJ2; -.
DR   PDBsum; 3PJ3; -.
DR   PDBsum; 4NWM; -.
DR   PDBsum; 4OT5; -.
DR   PDBsum; 4OT6; -.
DR   PDBsum; 4OTF; -.
DR   PDBsum; 4OTQ; -.
DR   PDBsum; 4OTR; -.
DR   PDBsum; 4RFY; -.
DR   PDBsum; 4RFZ; -.
DR   PDBsum; 4RG0; -.
DR   PDBsum; 4RX5; -.
DR   PDBsum; 4YHF; -.
DR   PDBsum; 4Z3V; -.
DR   PDBsum; 4ZLY; -.
DR   PDBsum; 4ZLZ; -.
DR   PDBsum; 5BPY; -.
DR   PDBsum; 5BQ0; -.
DR   PDBsum; 5FBN; -.
DR   PDBsum; 5FBO; -.
DR   PDBsum; 5J87; -.
DR   PDBsum; 5JRS; -.
DR   PDBsum; 5KUP; -.
DR   PDBsum; 5P9F; -.
DR   PDBsum; 5P9G; -.
DR   PDBsum; 5P9H; -.
DR   PDBsum; 5P9I; -.
DR   PDBsum; 5P9J; -.
DR   PDBsum; 5P9K; -.
DR   PDBsum; 5P9L; -.
DR   PDBsum; 5P9M; -.
DR   PDBsum; 5T18; -.
DR   PDBsum; 5U9D; -.
DR   PDBsum; 5VFI; -.
DR   PDBsum; 5VGO; -.
DR   PDBsum; 5XYZ; -.
DR   PDBsum; 5ZZ4; -.
DR   PDBsum; 6AUA; -.
DR   PDBsum; 6AUB; -.
DR   PDBsum; 6BIK; -.
DR   PDBsum; 6BKE; -.
DR   PDBsum; 6BKH; -.
DR   PDBsum; 6BKW; -.
DR   PDBsum; 6BLN; -.
DR   PDBsum; 6DI0; -.
DR   PDBsum; 6DI1; -.
DR   PDBsum; 6DI3; -.
DR   PDBsum; 6DI5; -.
DR   PDBsum; 6DI9; -.
DR   PDBsum; 6E4F; -.
DR   PDBsum; 6EP9; -.
DR   PDBsum; 6HRP; -.
DR   PDBsum; 6HRT; -.
DR   PDBsum; 6J6M; -.
DR   PDBsum; 6N9P; -.
DR   PDBsum; 6NFH; -.
DR   PDBsum; 6NFI; -.
DR   PDBsum; 6NZM; -.
DR   PDBsum; 6O8I; -.
DR   PDBsum; 6OMU; -.
DR   PDBsum; 6S90; -.
DR   SMR; Q06187; -.
DR   BioGrid; 107160; 88.
DR   CORUM; Q06187; -.
DR   DIP; DIP-34071N; -.
DR   ELM; Q06187; -.
DR   IntAct; Q06187; 58.
DR   MINT; Q06187; -.
DR   STRING; 9606.ENSP00000483570; -.
DR   BindingDB; Q06187; -.
DR   ChEMBL; CHEMBL5251; -.
DR   DrugBank; DB11703; Acalabrutinib.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB09053; Ibrutinib.
DR   DrugBank; DB01863; Inositol 1,3,4,5-Tetrakisphosphate.
DR   DrugBank; DB05204; XL418.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugCentral; Q06187; -.
DR   GuidetoPHARMACOLOGY; 1948; -.
DR   iPTMnet; Q06187; -.
DR   PhosphoSitePlus; Q06187; -.
DR   BioMuta; BTK; -.
DR   DMDM; 547759; -.
DR   EPD; Q06187; -.
DR   jPOST; Q06187; -.
DR   MassIVE; Q06187; -.
DR   MaxQB; Q06187; -.
DR   PaxDb; Q06187; -.
DR   PeptideAtlas; Q06187; -.
DR   PRIDE; Q06187; -.
DR   ProteomicsDB; 58419; -. [Q06187-1]
DR   Antibodypedia; 699; 1193 antibodies.
DR   DNASU; 695; -.
DR   Ensembl; ENST00000308731; ENSP00000308176; ENSG00000010671. [Q06187-1]
DR   Ensembl; ENST00000621635; ENSP00000483570; ENSG00000010671. [Q06187-2]
DR   GeneID; 695; -.
DR   KEGG; hsa:695; -.
DR   UCSC; uc004ehg.3; human. [Q06187-1]
DR   CTD; 695; -.
DR   DisGeNET; 695; -.
DR   GeneCards; BTK; -.
DR   GeneReviews; BTK; -.
DR   HGNC; HGNC:1133; BTK.
DR   HPA; ENSG00000010671; Group enriched (blood, lymphoid tissue).
DR   MalaCards; BTK; -.
DR   MIM; 300300; gene.
DR   MIM; 300755; phenotype.
DR   MIM; 307200; phenotype.
DR   neXtProt; NX_Q06187; -.
DR   OpenTargets; ENSG00000010671; -.
DR   Orphanet; 632; Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia.
DR   Orphanet; 47; X-linked agammaglobulinemia.
DR   PharmGKB; PA25454; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00940000158469; -.
DR   InParanoid; Q06187; -.
DR   KO; K07370; -.
DR   OMA; AMGCKIL; -.
DR   OrthoDB; 1047190at2759; -.
DR   PhylomeDB; Q06187; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-8964315; G beta:gamma signalling through BTK.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; Q06187; -.
DR   SIGNOR; Q06187; -.
DR   ChiTaRS; BTK; human.
DR   EvolutionaryTrace; Q06187; -.
DR   GeneWiki; Bruton%27s_tyrosine_kinase; -.
DR   GenomeRNAi; 695; -.
DR   Pharos; Q06187; Tclin.
DR   PRO; PR:Q06187; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q06187; protein.
DR   Bgee; ENSG00000010671; Expressed in small intestine Peyer's patch and 162 other tissues.
DR   ExpressionAtlas; Q06187; baseline and differential.
DR   Genevisible; Q06187; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0045121; C:membrane raft; IDA:HGNC-UCL.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; TAS:HGNC-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0002250; P:adaptive immune response; TAS:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0042113; P:B cell activation; TAS:UniProtKB.
DR   GO; GO:0002344; P:B cell affinity maturation; IEA:Ensembl.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; TAS:HGNC-UCL.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0098761; P:cellular response to interleukin-7; IEA:Ensembl.
DR   GO; GO:0071226; P:cellular response to molecule of fungal origin; IEA:Ensembl.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002553; P:histamine secretion by mast cell; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:HGNC-UCL.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0001818; P:negative regulation of cytokine production; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:CACAO.
DR   GO; GO:0045579; P:positive regulation of B cell differentiation; TAS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0001812; P:positive regulation of type I hypersensitivity; IEA:Ensembl.
DR   GO; GO:0001805; P:positive regulation of type III hypersensitivity; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:HGNC-UCL.
DR   GO; GO:0002902; P:regulation of B cell apoptotic process; TAS:UniProtKB.
DR   GO; GO:0002721; P:regulation of B cell cytokine production; TAS:UniProtKB.
DR   CDD; cd11906; SH3_BTK; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR035574; BTK_SH3.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00402; TECBTKDOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; Alternative promoter usage;
KW   Apoptosis; ATP-binding; Cell membrane; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Dwarfism; Immunity;
KW   Innate immunity; Kinase; Lipid-binding; Membrane; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; SH2 domain; SH3 domain; Transcription;
KW   Transcription regulation; Transferase; Tyrosine-protein kinase; Zinc;
KW   Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:25944712, ECO:0000269|Ref.11"
FT   CHAIN           2..659
FT                   /note="Tyrosine-protein kinase BTK"
FT                   /id="PRO_0000088065"
FT   DOMAIN          3..133
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          214..274
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          281..377
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          402..655
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         135..171
FT                   /note="Btk-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   NP_BIND         408..416
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          12..24
FT                   /note="Inositol-(1,3,4,5)-tetrakisphosphate 1-binding"
FT   REGION          474..479
FT                   /note="Inhibitor-binding"
FT   MOTIF           581..588
FT                   /note="CAV1-binding"
FT   ACT_SITE        521
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   METAL           143
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:10196129,
FT                   ECO:0000269|PubMed:9218782, ECO:0000269|Ref.47"
FT   METAL           154
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:10196129,
FT                   ECO:0000269|PubMed:9218782, ECO:0000269|Ref.47"
FT   METAL           155
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:10196129,
FT                   ECO:0000269|PubMed:9218782, ECO:0000269|Ref.47"
FT   METAL           165
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:10196129,
FT                   ECO:0000269|PubMed:9218782, ECO:0000269|Ref.47"
FT   BINDING         26
FT                   /note="Inositol-(1,3,4,5)-tetrakisphosphate"
FT                   /evidence="ECO:0000269|PubMed:10196129"
FT   BINDING         28
FT                   /note="Inositol-(1,3,4,5)-tetrakisphosphate"
FT                   /evidence="ECO:0000269|PubMed:10196129"
FT   BINDING         39
FT                   /note="Inositol-(1,3,4,5)-tetrakisphosphate"
FT                   /evidence="ECO:0000269|PubMed:10196129"
FT   BINDING         53
FT                   /note="Inositol-(1,3,4,5)-tetrakisphosphate; via carbonyl
FT                   oxygen"
FT                   /evidence="ECO:0000269|PubMed:10196129"
FT   BINDING         430
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         445
FT                   /note="Inhibitor"
FT                   /evidence="ECO:0000269|PubMed:21280133, ECO:0000269|Ref.46,
FT                   ECO:0000269|Ref.47"
FT   BINDING         461
FT                   /note="Inhibitor"
FT                   /evidence="ECO:0000269|PubMed:21280133, ECO:0000269|Ref.46,
FT                   ECO:0000269|Ref.47"
FT   BINDING         477
FT                   /note="Inhibitor"
FT                   /evidence="ECO:0000269|PubMed:21280133, ECO:0000269|Ref.46,
FT                   ECO:0000269|Ref.47"
FT   BINDING         538
FT                   /note="Inhibitor"
FT                   /evidence="ECO:0000269|PubMed:21280133, ECO:0000269|Ref.46,
FT                   ECO:0000269|Ref.47"
FT   BINDING         539
FT                   /note="Inhibitor; via amide nitrogen"
FT                   /evidence="ECO:0000269|PubMed:21280133, ECO:0000269|Ref.46,
FT                   ECO:0000269|Ref.47"
FT   BINDING         542
FT                   /note="Inhibitor; via carbonyl oxygen"
FT                   /evidence="ECO:0000269|PubMed:21280133, ECO:0000269|Ref.46,
FT                   ECO:0000269|Ref.47"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:25944712, ECO:0000269|Ref.11"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16644721"
FT   MOD_RES         40
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P35991"
FT   MOD_RES         55
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   MOD_RES         115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16644721"
FT   MOD_RES         180
FT                   /note="Phosphoserine; by PKC/PRKCB"
FT                   /evidence="ECO:0000269|PubMed:11598012"
FT   MOD_RES         191
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:19369195,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         223
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:17932028,
FT                   ECO:0000269|PubMed:8630736, ECO:0000269|PubMed:9012831"
FT   MOD_RES         344
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P35991"
FT   MOD_RES         361
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   MOD_RES         551
FT                   /note="Phosphotyrosine; by LYN and SYK"
FT                   /evidence="ECO:0000269|PubMed:8630736,
FT                   ECO:0000269|PubMed:9012831"
FT   MOD_RES         604
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         617
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:15375214"
FT   MOD_RES         623
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15375214"
FT   MOD_RES         659
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   VAR_SEQ         1
FT                   /note="M -> MASWSIQQMVIGCPLCGRHCSGGEHTGELQKEEAM (in isoform
FT                   BTK-C)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053838"
FT   VARIANT         11
FT                   /note="L -> P (in XLA)"
FT                   /id="VAR_006216"
FT   VARIANT         12
FT                   /note="K -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006217"
FT   VARIANT         14
FT                   /note="S -> F (in XLA)"
FT                   /id="VAR_006218"
FT   VARIANT         19
FT                   /note="K -> E (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008291"
FT   VARIANT         25
FT                   /note="F -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006219"
FT   VARIANT         27
FT                   /note="K -> R (in XLA)"
FT                   /id="VAR_008292"
FT   VARIANT         28
FT                   /note="R -> C (in XLA; no effect on phosphorylation of
FT                   GTF2I)"
FT                   /id="VAR_008293"
FT   VARIANT         28
FT                   /note="R -> H (in XLA; moderate; dbSNP:rs128620185)"
FT                   /evidence="ECO:0000269|PubMed:7849721,
FT                   ECO:0000269|PubMed:8162018, ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006220"
FT   VARIANT         28
FT                   /note="R -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006221"
FT   VARIANT         33
FT                   /note="T -> P (in XLA; severe; dbSNP:rs128620189)"
FT                   /evidence="ECO:0000269|PubMed:7633429,
FT                   ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006222"
FT   VARIANT         39
FT                   /note="Y -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008960"
FT   VARIANT         40
FT                   /note="Y -> C (in XLA; dbSNP:rs1555980875)"
FT                   /id="VAR_008294"
FT   VARIANT         40
FT                   /note="Y -> N (in XLA)"
FT                   /id="VAR_008295"
FT   VARIANT         61
FT                   /note="I -> N (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008296"
FT   VARIANT         64
FT                   /note="V -> D (in XLA)"
FT                   /id="VAR_008297"
FT   VARIANT         64
FT                   /note="V -> F (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7849006"
FT                   /id="VAR_006223"
FT   VARIANT         82
FT                   /note="R -> K (in dbSNP:rs56035945)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041676"
FT   VARIANT         103
FT                   /note="Q -> QSVFSSTR (in XLA)"
FT                   /id="VAR_006224"
FT   VARIANT         113
FT                   /note="V -> D (in XLA; dbSNP:rs128621190)"
FT                   /evidence="ECO:0000269|PubMed:7849697"
FT                   /id="VAR_006225"
FT   VARIANT         115
FT                   /note="S -> F (in XLA)"
FT                   /id="VAR_008298"
FT   VARIANT         117
FT                   /note="T -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008299"
FT   VARIANT         127
FT                   /note="Q -> H (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008300"
FT   VARIANT         154
FT                   /note="C -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9280283"
FT                   /id="VAR_008301"
FT   VARIANT         155
FT                   /note="C -> G (in XLA)"
FT                   /id="VAR_008302"
FT   VARIANT         155
FT                   /note="C -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9280283,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008303"
FT   VARIANT         184
FT                   /note="T -> P (in XLA)"
FT                   /id="VAR_008304"
FT   VARIANT         190
FT                   /note="P -> K (in a lung large cell carcinoma sample;
FT                   somatic mutation; requires 2 nucleotide substitutions)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041677"
FT   VARIANT         260..280
FT                   /note="Missing (in XLA; severe)"
FT                   /evidence="ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006226"
FT   VARIANT         288
FT                   /note="R -> Q (in XLA; dbSNP:rs1555978277)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008305"
FT   VARIANT         288
FT                   /note="R -> W (in XLA; dbSNP:rs128621194)"
FT                   /evidence="ECO:0000269|PubMed:7711734,
FT                   ECO:0000269|PubMed:8162018, ECO:0000269|PubMed:8162056,
FT                   ECO:0000269|PubMed:8834236"
FT                   /id="VAR_006227"
FT   VARIANT         295
FT                   /note="L -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8723128,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006228"
FT   VARIANT         302
FT                   /note="G -> E (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7627183,
FT                   ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006230"
FT   VARIANT         302
FT                   /note="G -> R (in XLA)"
FT                   /id="VAR_008306"
FT   VARIANT         302
FT                   /note="Missing (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7633429"
FT                   /id="VAR_006229"
FT   VARIANT         307
FT                   /note="R -> G (in XLA; loss of activity;
FT                   dbSNP:rs128621195)"
FT                   /evidence="ECO:0000269|PubMed:8162056"
FT                   /id="VAR_006231"
FT   VARIANT         307
FT                   /note="R -> T (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008307"
FT   VARIANT         308
FT                   /note="D -> E (in XLA)"
FT                   /id="VAR_008308"
FT   VARIANT         319
FT                   /note="V -> A (in XLA; moderate)"
FT                   /id="VAR_008309"
FT   VARIANT         334
FT                   /note="Y -> S (in XLA; dbSNP:rs128621196)"
FT                   /evidence="ECO:0000269|PubMed:7880320"
FT                   /id="VAR_006232"
FT   VARIANT         358
FT                   /note="L -> F (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7897635"
FT                   /id="VAR_006233"
FT   VARIANT         361
FT                   /note="Y -> C (in XLA; mild; dbSNP:rs28935478)"
FT                   /evidence="ECO:0000269|PubMed:7849697"
FT                   /id="VAR_006234"
FT   VARIANT         362
FT                   /note="H -> Q (in XLA)"
FT                   /id="VAR_006235"
FT   VARIANT         364
FT                   /note="H -> P (in XLA)"
FT                   /id="VAR_006236"
FT   VARIANT         365
FT                   /note="N -> Y (in XLA)"
FT                   /id="VAR_006237"
FT   VARIANT         366
FT                   /note="S -> F (in XLA)"
FT                   /id="VAR_008310"
FT   VARIANT         369
FT                   /note="L -> F (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008311"
FT   VARIANT         370
FT                   /note="I -> M (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006238"
FT   VARIANT         372
FT                   /note="R -> G (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008312"
FT   VARIANT         408
FT                   /note="L -> P (in XLA; moderate; dbSNP:rs128621198)"
FT                   /evidence="ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006239"
FT   VARIANT         414
FT                   /note="G -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008313"
FT   VARIANT         418
FT                   /note="Y -> H (in XLA; dbSNP:rs144079566)"
FT                   /id="VAR_006240"
FT   VARIANT         429
FT                   /note="I -> N (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8634718"
FT                   /id="VAR_006241"
FT   VARIANT         430
FT                   /note="K -> E (in XLA; loss of phosphorylation of GTF2I;
FT                   dbSNP:rs128620184)"
FT                   /evidence="ECO:0000269|PubMed:7809124"
FT                   /id="VAR_006242"
FT   VARIANT         430
FT                   /note="K -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008314"
FT   VARIANT         445
FT                   /note="E -> D (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008315"
FT   VARIANT         462
FT                   /note="G -> D (in XLA)"
FT                   /id="VAR_008316"
FT   VARIANT         462
FT                   /note="G -> V (in XLA)"
FT                   /id="VAR_008317"
FT   VARIANT         476
FT                   /note="Y -> D (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7627183"
FT                   /id="VAR_006243"
FT   VARIANT         477
FT                   /note="M -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8634718"
FT                   /id="VAR_006244"
FT   VARIANT         481
FT                   /note="C -> S (found in patients with chronic lymphocytic
FT                   leukemia; unknown pathological significance; results in
FT                   resistance to ibrutinib therapy; results in a protein that
FT                   is reversibly inhibited by ibrutinib; disrupts the covalent
FT                   binding between the enzyme and ibrutinib;
FT                   dbSNP:rs1057519825 and dbSNP:rs1057519826)"
FT                   /evidence="ECO:0000269|PubMed:24869597,
FT                   ECO:0000269|PubMed:24869598, ECO:0000269|PubMed:25189416"
FT                   /id="VAR_074309"
FT   VARIANT         502
FT                   /note="C -> F (in XLA)"
FT                   /id="VAR_006245"
FT   VARIANT         502
FT                   /note="C -> W (in XLA; dbSNP:rs41310709)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006246"
FT   VARIANT         506
FT                   /note="C -> R (in XLA; dbSNP:rs128621200)"
FT                   /evidence="ECO:0000269|PubMed:7880320"
FT                   /id="VAR_006247"
FT   VARIANT         506
FT                   /note="C -> Y (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006248"
FT   VARIANT         508
FT                   /note="A -> D (in XLA)"
FT                   /id="VAR_008318"
FT   VARIANT         509
FT                   /note="M -> I (in XLA)"
FT                   /id="VAR_008319"
FT   VARIANT         509
FT                   /note="M -> V (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006249"
FT   VARIANT         512
FT                   /note="L -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008961"
FT   VARIANT         512
FT                   /note="L -> Q (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008962"
FT   VARIANT         518
FT                   /note="L -> R (in XLA)"
FT                   /id="VAR_008320"
FT   VARIANT         520
FT                   /note="R -> Q (in XLA; severe; prevents activation due to
FT                   absence of contact between the catalytic loop and the
FT                   regulatory phosphorylated residue; dbSNP:rs128621202)"
FT                   /evidence="ECO:0000269|PubMed:7633429,
FT                   ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849697,
FT                   ECO:0000269|PubMed:7880320"
FT                   /id="VAR_006251"
FT   VARIANT         521
FT                   /note="D -> G (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008321"
FT   VARIANT         521
FT                   /note="D -> H (in XLA; severe)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006252"
FT   VARIANT         521
FT                   /note="D -> N (in XLA; severe)"
FT                   /id="VAR_006253"
FT   VARIANT         523
FT                   /note="A -> E (in XLA)"
FT                   /id="VAR_008322"
FT   VARIANT         525
FT                   /note="R -> G (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008323"
FT   VARIANT         525
FT                   /note="R -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006254"
FT   VARIANT         525
FT                   /note="R -> Q (in XLA; severe; disturbs ATP-binding;
FT                   dbSNP:rs128620183)"
FT                   /evidence="ECO:0000269|PubMed:7809124,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006255"
FT   VARIANT         526
FT                   /note="N -> K (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006256"
FT   VARIANT         535
FT                   /note="V -> F (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008324"
FT   VARIANT         542
FT                   /note="L -> P (in XLA; growth hormone deficiency;
FT                   dbSNP:rs128621203)"
FT                   /evidence="ECO:0000269|PubMed:7849697"
FT                   /id="VAR_006257"
FT   VARIANT         544
FT                   /note="R -> G (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008963"
FT   VARIANT         544
FT                   /note="R -> K (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8834236"
FT                   /id="VAR_006258"
FT   VARIANT         559
FT                   /note="F -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008325"
FT   VARIANT         562
FT                   /note="R -> P (in XLA; dbSNP:rs104894770)"
FT                   /evidence="ECO:0000269|PubMed:10678660,
FT                   ECO:0000269|PubMed:7809124"
FT                   /id="VAR_006259"
FT   VARIANT         562
FT                   /note="R -> W (in XLA; dbSNP:rs128621204)"
FT                   /evidence="ECO:0000269|PubMed:7711734,
FT                   ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7880320,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006260"
FT   VARIANT         563
FT                   /note="W -> L (in XLA; dbSNP:rs1555977474)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008326"
FT   VARIANT         567
FT                   /note="E -> K (in XLA; severe)"
FT                   /evidence="ECO:0000269|PubMed:7633420"
FT                   /id="VAR_006261"
FT   VARIANT         578
FT                   /note="S -> Y (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008964"
FT   VARIANT         581
FT                   /note="W -> R (in XLA; dbSNP:rs128621205)"
FT                   /id="VAR_006262"
FT   VARIANT         582
FT                   /note="A -> V (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734,
FT                   ECO:0000269|PubMed:7809124"
FT                   /id="VAR_006263"
FT   VARIANT         583
FT                   /note="F -> S (in XLA)"
FT                   /id="VAR_008327"
FT   VARIANT         587
FT                   /note="M -> L (in XLA; mild)"
FT                   /evidence="ECO:0000269|PubMed:7633420"
FT                   /id="VAR_006264"
FT   VARIANT         589
FT                   /note="E -> D (in XLA)"
FT                   /id="VAR_008328"
FT   VARIANT         589
FT                   /note="E -> G (in XLA; moderate; interferes with substrate
FT                   binding; dbSNP:rs128621206)"
FT                   /evidence="ECO:0000269|PubMed:7809124,
FT                   ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006265"
FT   VARIANT         589
FT                   /note="E -> K (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008965"
FT   VARIANT         592
FT                   /note="S -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8834236"
FT                   /id="VAR_006267"
FT   VARIANT         594
FT                   /note="G -> E (in XLA; mild; interferes with substrate
FT                   binding)"
FT                   /evidence="ECO:0000269|PubMed:7809124,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006268"
FT   VARIANT         594
FT                   /note="G -> R (in XLA; dbSNP:rs1555977339)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006269"
FT   VARIANT         598
FT                   /note="Y -> C (in XLA)"
FT                   /id="VAR_006270"
FT   VARIANT         607
FT                   /note="A -> D (in XLA; mild; dbSNP:rs128621208)"
FT                   /evidence="ECO:0000269|PubMed:8162056"
FT                   /id="VAR_006271"
FT   VARIANT         613
FT                   /note="G -> D (in XLA; mild; interferes with substrate
FT                   binding and/or domain interactions; dbSNP:rs128621209)"
FT                   /evidence="ECO:0000269|PubMed:7809124,
FT                   ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006272"
FT   VARIANT         619
FT                   /note="P -> A (in XLA)"
FT                   /id="VAR_008330"
FT   VARIANT         619
FT                   /note="P -> S (in XLA)"
FT                   /id="VAR_006273"
FT   VARIANT         619
FT                   /note="P -> T (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008331"
FT   VARIANT         622
FT                   /note="A -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008332"
FT   VARIANT         626
FT                   /note="V -> G (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008333"
FT   VARIANT         630
FT                   /note="M -> I (polymorphism, 35%)"
FT                   /id="VAR_006274"
FT   VARIANT         630
FT                   /note="M -> K (in XLA; dbSNP:rs128621210)"
FT                   /evidence="ECO:0000269|PubMed:7849697,
FT                   ECO:0000269|PubMed:7880320"
FT                   /id="VAR_006275"
FT   VARIANT         630
FT                   /note="M -> T (in XLA)"
FT                   /id="VAR_008334"
FT   VARIANT         633
FT                   /note="C -> Y (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006276"
FT   VARIANT         641
FT                   /note="R -> C (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7633429"
FT                   /id="VAR_006277"
FT   VARIANT         641
FT                   /note="R -> H (in XLA; severe)"
FT                   /evidence="ECO:0000269|PubMed:7633420,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006278"
FT   VARIANT         644
FT                   /note="F -> L (in XLA)"
FT                   /id="VAR_008335"
FT   VARIANT         644
FT                   /note="F -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006279"
FT   VARIANT         647
FT                   /note="L -> P (in XLA)"
FT                   /id="VAR_006280"
FT   VARIANT         652
FT                   /note="L -> P (in XLA; dbSNP:rs128622212)"
FT                   /evidence="ECO:0000269|PubMed:7849697"
FT                   /id="VAR_006281"
FT   MUTAGEN         41
FT                   /note="E->K: No effect on phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         189
FT                   /note="P->A: No effect on phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         223
FT                   /note="Y->F: Loss of phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:8630736,
FT                   ECO:0000269|PubMed:9012831"
FT   MUTAGEN         251..252
FT                   /note="WW->LL: Large decrease in binding by SH3BP5."
FT                   /evidence="ECO:0000269|PubMed:9571151"
FT   MUTAGEN         251
FT                   /note="W->L: No effect on phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         307
FT                   /note="R->K: Loss of phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         551
FT                   /note="Y->F: Loss of phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         617
FT                   /note="Y->E: Defective in mediating calcium response."
FT                   /evidence="ECO:0000269|PubMed:15375214"
FT   CONFLICT        253
FT                   /note="R -> K (in Ref. 7; BAG37008)"
FT                   /evidence="ECO:0000305"
FT   STRAND          6..13
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   STRAND          18..20
FT                   /evidence="ECO:0000244|PDB:2Z0P"
FT   STRAND          25..32
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   STRAND          34..43
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   TURN            44..47
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   STRAND          48..57
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   HELIX           58..60
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   STRAND          61..66
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   HELIX           75..77
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   HELIX           93..96
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   STRAND          100..106
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   STRAND          111..116
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   HELIX           118..132
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   STRAND          140..142
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   STRAND          149..152
FT                   /evidence="ECO:0000244|PDB:2Z0P"
FT   TURN            153..155
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   STRAND          165..167
FT                   /evidence="ECO:0000244|PDB:1BTK"
FT   TURN            212..215
FT                   /evidence="ECO:0000244|PDB:1AWX"
FT   STRAND          218..223
FT                   /evidence="ECO:0000244|PDB:1AWW"
FT   STRAND          228..232
FT                   /evidence="ECO:0000244|PDB:1AWW"
FT   STRAND          240..242
FT                   /evidence="ECO:0000244|PDB:1AWW"
FT   STRAND          248..252
FT                   /evidence="ECO:0000244|PDB:1AWW"
FT   TURN            257..259
FT                   /evidence="ECO:0000244|PDB:1QLY"
FT   STRAND          261..265
FT                   /evidence="ECO:0000244|PDB:1AWX"
FT   TURN            266..268
FT                   /evidence="ECO:0000244|PDB:1AWW"
FT   STRAND          279..282
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   HELIX           288..298
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   STRAND          303..308
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   STRAND          310..312
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   STRAND          315..326
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   STRAND          330..335
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   STRAND          337..339
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   TURN            340..342
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   STRAND          343..347
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   STRAND          350..354
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   HELIX           355..363
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   STRAND          373..376
FT                   /evidence="ECO:0000244|PDB:2GE9"
FT   HELIX           393..395
FT                   /evidence="ECO:0000244|PDB:6O8I"
FT   HELIX           399..401
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   STRAND          402..410
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   TURN            411..413
FT                   /evidence="ECO:0000244|PDB:3P08"
FT   STRAND          415..421
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   TURN            422..424
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   STRAND          425..431
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   TURN            434..436
FT                   /evidence="ECO:0000244|PDB:5FBO"
FT   HELIX           439..450
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   STRAND          460..464
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   STRAND          466..469
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   STRAND          471..474
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           482..487
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           489..491
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           495..514
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   TURN            524..526
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   STRAND          527..529
FT                   /evidence="ECO:0000244|PDB:6DI1"
FT   STRAND          535..537
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           542..545
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           549..551
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   STRAND          556..559
FT                   /evidence="ECO:0000244|PDB:6NFH"
FT   HELIX           561..563
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           566..571
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           576..591
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   TURN            592..594
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   TURN            597..600
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           603..611
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           624..632
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           638..640
FT                   /evidence="ECO:0000244|PDB:5P9J"
FT   HELIX           644..657
FT                   /evidence="ECO:0000244|PDB:5P9J"
SQ   SEQUENCE   659 AA;  76281 MW;  DF06B5D1FEC257CC CRC64;
     MAAVILESIF LKRSQQKKKT SPLNFKKRLF LLTVHKLSYY EYDFERGRRG SKKGSIDVEK
     ITCVETVVPE KNPPPERQIP RRGEESSEME QISIIERFPY PFQVVYDEGP LYVFSPTEEL
     RKRWIHQLKN VIRYNSDLVQ KYHPCFWIDG QYLCCSQTAK NAMGCQILEN RNGSLKPGSS
     HRKTKKPLPP TPEEDQILKK PLPPEPAAAP VSTSELKKVV ALYDYMPMNA NDLQLRKGDE
     YFILEESNLP WWRARDKNGQ EGYIPSNYVT EAEDSIEMYE WYSKHMTRSQ AEQLLKQEGK
     EGGFIVRDSS KAGKYTVSVF AKSTGDPQGV IRHYVVCSTP QSQYYLAEKH LFSTIPELIN
     YHQHNSAGLI SRLKYPVSQQ NKNAPSTAGL GYGSWEIDPK DLTFLKELGT GQFGVVKYGK
     WRGQYDVAIK MIKEGSMSED EFIEEAKVMM NLSHEKLVQL YGVCTKQRPI FIITEYMANG
     CLLNYLREMR HRFQTQQLLE MCKDVCEAME YLESKQFLHR DLAARNCLVN DQGVVKVSDF
     GLSRYVLDDE YTSSVGSKFP VRWSPPEVLM YSKFSSKSDI WAFGVLMWEI YSLGKMPYER
     FTNSETAEHI AQGLRLYRPH LASEKVYTIM YSCWHEKADE RPTFKILLSN ILDVMDEES
//
ID   Q5JY90_HUMAN            Unreviewed;       483 AA.
AC   Q5JY90;
DT   15-FEB-2005, integrated into UniProtKB/TrEMBL.
DT   15-FEB-2005, sequence version 1.
DT   22-APR-2020, entry version 154.
DE   RecName: Full=Tyrosine-protein kinase {ECO:0000256|RuleBase:RU362096};
DE            EC=2.7.10.2 {ECO:0000256|RuleBase:RU362096};
GN   Name=BTK {ECO:0000313|EMBL:EAX02857.1,
GN   ECO:0000313|Ensembl:ENSP00000361971};
GN   ORFNames=hCG_20400 {ECO:0000313|EMBL:EAX02857.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000361971, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|EMBL:EAX02857.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:BAG51864.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Small intestine {ECO:0000313|EMBL:BAG51864.1};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M.,
RA   Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S.,
RA   Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S.,
RA   Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H.,
RA   Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M.,
RA   Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M.,
RA   Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y.,
RA   Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N.,
RA   Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S.,
RA   Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T.,
RA   Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M.,
RA   Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y.,
RA   Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y.,
RA   Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T.,
RA   Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3] {ECO:0000313|Ensembl:ENSP00000361971, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4] {ECO:0000313|EMBL:EAX02857.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000213|PubMed:19369195}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [6] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [7] {ECO:0000313|Ensembl:ENSP00000361971}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (FEB-2012) to UniProtKB.
RN   [8] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9] {ECO:0000213|PubMed:25944712}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000256|RuleBase:RU362096};
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000256|RuleBase:RU362096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL035422; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK057105; BAG51864.1; -; mRNA.
DR   EMBL; CH471115; EAX02857.1; -; Genomic_DNA.
DR   RefSeq; NP_000052.1; NM_000061.2.
DR   RefSeq; NP_001274274.1; NM_001287345.1.
DR   ProteomicsDB; 63487; -.
DR   Antibodypedia; 699; 1193 antibodies.
DR   DNASU; 695; -.
DR   Ensembl; ENST00000372880; ENSP00000361971; ENSG00000010671.
DR   GeneID; 695; -.
DR   KEGG; hsa:695; -.
DR   UCSC; uc010nnn.2; human.
DR   CTD; 695; -.
DR   EuPathDB; HostDB:ENSG00000010671.15; -.
DR   HGNC; HGNC:1133; BTK.
DR   OpenTargets; ENSG00000010671; -.
DR   PharmGKB; PA25454; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00940000158469; -.
DR   KO; K07370; -.
DR   ChiTaRS; BTK; human.
DR   GenomeRNAi; 695; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000010671; Expressed in small intestine Peyer's patch and 162 other tissues.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   CDD; cd11906; SH3_BTK; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR035574; BTK_SH3.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00402; TECBTKDOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   ATP-binding {ECO:0000256|RuleBase:RU362096, ECO:0000256|SAAS:SAAS00990534};
KW   Kinase {ECO:0000256|RuleBase:RU362096, ECO:0000256|SAAS:SAAS00897698};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00432};
KW   Nucleotide-binding {ECO:0000256|RuleBase:RU362096,
KW   ECO:0000256|SAAS:SAAS00990534};
KW   Proteomics identification {ECO:0000213|EPD:Q5JY90,
KW   ECO:0000213|MaxQB:Q5JY90, ECO:0000213|PeptideAtlas:Q5JY90,
KW   ECO:0000213|ProteomicsDB:Q5JY90};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   SH2 domain {ECO:0000256|PROSITE-ProRule:PRU00191};
KW   SH3 domain {ECO:0000256|PROSITE-ProRule:PRU00192,
KW   ECO:0000256|SAAS:SAAS01042643};
KW   Transferase {ECO:0000256|RuleBase:RU362096, ECO:0000256|SAAS:SAAS00897698};
KW   Tyrosine-protein kinase {ECO:0000256|RuleBase:RU362096,
KW   ECO:0000256|SAAS:SAAS00897698};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00432};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00432}.
FT   DOMAIN          3..133
FT                   /note="PH"
FT                   /evidence="ECO:0000259|PROSITE:PS50003"
FT   DOMAIN          166..479
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000259|PROSITE:PS50011"
FT   DOMAIN          214..274
FT                   /note="SH3"
FT                   /evidence="ECO:0000259|PROSITE:PS50002"
FT   DOMAIN          281..349
FT                   /note="SH2"
FT                   /evidence="ECO:0000259|PROSITE:PS50001"
FT   REGION          171..210
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   483 AA;  55881 MW;  EC1A5FB717810D71 CRC64;
     MAAVILESIF LKRSQQKKKT SPLNFKKRLF LLTVHKLSYY EYDFERGRRG SKKGSIDVEK
     ITCVETVVPE KNPPPERQIP RRGEESSEME QISIIERFPY PFQVVYDEGP LYVFSPTEEL
     RKRWIHQLKN VIRYNSDLVQ KYHPCFWIDG QYLCCSQTAK NAMGCQILEN RNGSLKPGSS
     HRKTKKPLPP TPEEDQILKK PLPPEPAAAP VSTSELKKVV ALYDYMPMNA NDLQLRKGDE
     YFILEESNLP WWRARDKNGQ EGYIPSNYVT EAEDSIEMYE WYSKHMTRSQ AEQLLKQEGK
     EGGFIVRDSS KAGKYTVSVF AKSTGDPQGV IRHYVVCSTP QSQYYLAARN CLVNDQGVVK
     VSDFGLSRYV LDDEYTSSVG SKFPVRWSPP EVLMYSKFSS KSDIWAFGVL MWEIYSLGKM
     PYERFTNSET AEHIAQGLRL YRPHLASEKV YTIMYSCWHE KADERPTFKI LLSNILDVMD
     EES
//
ID   CBLC_HUMAN              Reviewed;         474 AA.
AC   Q9ULV8; Q8N1E5; Q9Y5Z2; Q9Y5Z3;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 3.
DT   22-APR-2020, entry version 186.
DE   RecName: Full=E3 ubiquitin-protein ligase CBL-C;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173};
DE   AltName: Full=RING finger protein 57;
DE   AltName: Full=RING-type E3 ubiquitin transferase CBL-C {ECO:0000305};
DE   AltName: Full=SH3-binding protein CBL-3;
DE   AltName: Full=SH3-binding protein CBL-C;
DE   AltName: Full=Signal transduction protein CBL-C;
GN   Name=CBLC; Synonyms=CBL3, RNF57;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT TYR-405.
RX   PubMed=10571044; DOI=10.1016/s0378-1119(99)00356-x;
RA   Kim M., Tezuka T., Suzuki Y., Sugano S., Hirai M., Yamamoto T.;
RT   "Molecular cloning and characterization of a novel cbl-family gene, cbl-
RT   c.";
RL   Gene 239:145-154(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), VARIANT TYR-405, FUNCTION AS
RP   EGF SIGNALING NEGATIVE REGULATOR, PHOSPHORYLATION BY EGFR (ISOFORM 1),
RP   TISSUE SPECIFICITY, AND INTERACTION WITH CRK AND LYN.
RC   TISSUE=Pancreatic adenocarcinoma;
RX   PubMed=10362357; DOI=10.1038/sj.onc.1202753;
RA   Keane M.M., Ettenberg S.A., Nau M.M., Banerjee P., Cuello M., Penninger J.,
RA   Lipkowitz S.;
RT   "cbl-3: a new mammalian cbl family protein.";
RL   Oncogene 18:3365-3375(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION AS E3 UBIQUITIN-PROTEIN LIGASE, CATALYTIC ACTIVITY, INTERACTION
RP   WITH SRC, AUTOUBIQUITINATION, AND MUTAGENESIS OF GLY-276; TYR-341 AND
RP   CYS-351.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent
RT   protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [5]
RP   FUNCTION IN RET STABILITY, INTERACTION WITH RET, AND MUTAGENESIS OF GLY-276
RP   AND CYS-351.
RX   PubMed=18753381; DOI=10.1523/jneurosci.2738-08.2008;
RA   Tsui C.C., Pierchala B.A.;
RT   "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation
RT   of ret signal transduction.";
RL   J. Neurosci. 28:8789-8800(2008).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, DOMAIN, INTERACTION WITH
RP   UBE2D2 AND UBE2D3, PHOSPHORYLATION AT TYR-341, AND MUTAGENESIS OF TYR-341.
RX   PubMed=20525694; DOI=10.1074/jbc.m109.091157;
RA   Ryan P.E., Sivadasan-Nair N., Nau M.M., Nicholas S., Lipkowitz S.;
RT   "The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating
RT   affinity for the ubiquitin-conjugating enzyme.";
RL   J. Biol. Chem. 285:23687-23698(2010).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOUBIQUITINATION, PHOSPHORYLATION AT
RP   TYR-341, INTERACTION WITH TGFB1I1, AND MUTAGENESIS OF TYR-341; CYS-351 AND
RP   CYS-366.
RX   PubMed=23145173; DOI=10.1371/journal.pone.0049428;
RA   Ryan P.E., Kales S.C., Yadavalli R., Nau M.M., Zhang H., Lipkowitz S.;
RT   "Cbl-c ubiquitin ligase activity is increased via the interaction of its
RT   RING finger domain with a LIM domain of the paxillin homolog, Hic 5.";
RL   PLoS ONE 7:E49428-E49428(2012).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 9-323 IN COMPLEX WITH EGFR
RP   PEPTIDE.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of Cbl-c (Cbl-3) TKB domain in complex with EGFR py1069
RT   peptide.";
RL   Submitted (OCT-2010) to the PDB data bank.
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.52 ANGSTROMS) OF 1-323 IN COMPLEX WITH CALCIUM;
RP   SRC AND EGFR PEPTIDES, CALCIUM-BINDING, INTERACTION WITH EGFR AND SRC, AND
RP   MUTAGENESIS OF TYR-244; ARG-264; PRO-265; SER-266; THR-268 AND GLY-276.
RX   PubMed=22888118; DOI=10.1093/jb/mvs085;
RA   Takeshita K., Tezuka T., Isozaki Y., Yamashita E., Suzuki M., Kim M.,
RA   Yamanashi Y., Yamamoto T., Nakagawa A.;
RT   "Structural flexibility regulates phosphopeptide-binding activity of the
RT   tyrosine kinase binding domain of Cbl-c.";
RL   J. Biochem. 152:487-495(2012).
CC   -!- FUNCTION: Acts as an E3 ubiquitin-protein ligase, which accepts
CC       ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then
CC       transfers it to substrates promoting their degradation by the
CC       proteasome. Functionally coupled with the E2 ubiquitin-protein ligases
CC       UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction;
CC       upon EGF activation, ubiquitinates EGFR. Isoform 1, but not isoform 2,
CC       inhibits EGF stimulated MAPK1 activation. Promotes ubiquitination of
CC       SRC phosphorylated at 'Tyr-419'. In collaboration with CD2AP may act as
CC       regulatory checkpoint for Ret signaling by modulating the rate of RET
CC       degradation after ligand activation; CD2AP converts it from an
CC       inhibitor to a promoter of RET degradation; the function limits the
CC       potency of GDNF on neuronal survival. {ECO:0000269|PubMed:10362357,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18753381,
CC       ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:14661060,
CC         ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173};
CC   -!- ACTIVITY REGULATION: Phosphorylation at Tyr-341 is necessary and
CC       sufficient for the activation of E3 activity.
CC       {ECO:0000269|PubMed:20525694}.
CC   -!- SUBUNIT: Interacts with ubiquitin-conjugating enzyme E2 UBE2D2 and
CC       UBE2D3. Isoform 1 interacts with EGFR (tyrosine phosphorylated).
CC       Interacts with the SH3 domain proteins LYN and CRK. Interacts (via
CC       RING-type zinc finger) with TGFB1I1 (via LIM zinc-binding domain 2);
CC       the interaction is direct and enhances the E3 activity. Interacts
CC       directly with RET (inactive) and CD2AP; dissociates from RET upon RET
CC       activation by GDNF which also increases the interaction with CD2AP
CC       suggesting dissociation as CBLC:CD2AP complex. Interacts with SRC; the
CC       interaction is enhanced when SRC is phosphorylated at 'Tyr-419'.
CC       {ECO:0000269|PubMed:10362357, ECO:0000269|PubMed:14661060,
CC       ECO:0000269|PubMed:18753381, ECO:0000269|PubMed:20525694,
CC       ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:23145173,
CC       ECO:0000269|Ref.8}.
CC   -!- INTERACTION:
CC       Q9ULV8; P07947: YES1; NbExp=3; IntAct=EBI-2341018, EBI-515331;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long;
CC         IsoId=Q9ULV8-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=Q9ULV8-2; Sequence=VSP_005732;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:10362357}.
CC   -!- DOMAIN: EF-hand-like and Sh2-like domains are required for N-terminal
CC       inhibition of E3 activity. {ECO:0000269|PubMed:20525694}.
CC   -!- DOMAIN: The N-terminus is composed of the phosphotyrosine binding (PTB)
CC       domain, a short linker region and the RING-type zinc finger. The PTB
CC       domain, which is also called TKB (tyrosine kinase binding) domain, is
CC       composed of three different subdomains: a four-helix bundle (4H), a
CC       calcium-binding EF hand and a divergent SH2 domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00839, ECO:0000269|PubMed:20525694}.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on multiple tyrosine residues by SRC. Isoform 1,
CC       but not isoform 2, is phosphorylated on tyrosines by EGFR.
CC   -!- PTM: Autoubiquitinated when phosphorylated at Tyr-341, enhanced by SRC;
CC       suggesting proteasomal degradation. {ECO:0000269|PubMed:14661060,
CC       ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173}.
CC   -!- MISCELLANEOUS: This protein has one functional calcium-binding site.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBLcID194.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB028645; BAA86298.1; -; mRNA.
DR   EMBL; AF117646; AAD34341.1; -; mRNA.
DR   EMBL; AF117647; AAD34342.1; -; mRNA.
DR   EMBL; BC028915; AAH28915.1; -; mRNA.
DR   CCDS; CCDS12643.1; -. [Q9ULV8-1]
DR   CCDS; CCDS46109.1; -. [Q9ULV8-2]
DR   RefSeq; NP_001124324.1; NM_001130852.1. [Q9ULV8-2]
DR   RefSeq; NP_036248.3; NM_012116.3. [Q9ULV8-1]
DR   PDB; 3OP0; X-ray; 2.52 A; A/B=9-323.
DR   PDB; 3VRN; X-ray; 1.64 A; A=1-323.
DR   PDB; 3VRO; X-ray; 1.80 A; A=1-323.
DR   PDB; 3VRP; X-ray; 1.52 A; A=1-323.
DR   PDB; 3VRQ; X-ray; 2.39 A; A/B=1-323.
DR   PDB; 3VRR; X-ray; 2.00 A; A=1-323.
DR   PDBsum; 3OP0; -.
DR   PDBsum; 3VRN; -.
DR   PDBsum; 3VRO; -.
DR   PDBsum; 3VRP; -.
DR   PDBsum; 3VRQ; -.
DR   PDBsum; 3VRR; -.
DR   SMR; Q9ULV8; -.
DR   BioGrid; 117156; 66.
DR   IntAct; Q9ULV8; 32.
DR   MINT; Q9ULV8; -.
DR   STRING; 9606.ENSP00000270279; -.
DR   iPTMnet; Q9ULV8; -.
DR   PhosphoSitePlus; Q9ULV8; -.
DR   BioMuta; CBLC; -.
DR   DMDM; 125987803; -.
DR   EPD; Q9ULV8; -.
DR   jPOST; Q9ULV8; -.
DR   MassIVE; Q9ULV8; -.
DR   PaxDb; Q9ULV8; -.
DR   PeptideAtlas; Q9ULV8; -.
DR   PRIDE; Q9ULV8; -.
DR   ProteomicsDB; 85137; -. [Q9ULV8-1]
DR   ProteomicsDB; 85138; -. [Q9ULV8-2]
DR   Antibodypedia; 3762; 363 antibodies.
DR   DNASU; 23624; -.
DR   Ensembl; ENST00000341505; ENSP00000340250; ENSG00000142273. [Q9ULV8-2]
DR   Ensembl; ENST00000647358; ENSP00000494162; ENSG00000142273. [Q9ULV8-1]
DR   GeneID; 23624; -.
DR   KEGG; hsa:23624; -.
DR   UCSC; uc002ozs.4; human. [Q9ULV8-1]
DR   CTD; 23624; -.
DR   DisGeNET; 23624; -.
DR   GeneCards; CBLC; -.
DR   HGNC; HGNC:15961; CBLC.
DR   HPA; ENSG00000142273; Tissue enhanced (intestine).
DR   MIM; 608453; gene.
DR   neXtProt; NX_Q9ULV8; -.
DR   OpenTargets; ENSG00000142273; -.
DR   PharmGKB; PA26117; -.
DR   eggNOG; KOG1785; Eukaryota.
DR   eggNOG; ENOG410YDNH; LUCA.
DR   GeneTree; ENSGT00940000162336; -.
DR   HOGENOM; CLU_013535_2_0_1; -.
DR   InParanoid; Q9ULV8; -.
DR   KO; K22518; -.
DR   OMA; QWAVGYV; -.
DR   OrthoDB; 540689at2759; -.
DR   PhylomeDB; Q9ULV8; -.
DR   TreeFam; TF314210; -.
DR   SignaLink; Q9ULV8; -.
DR   SIGNOR; Q9ULV8; -.
DR   GeneWiki; CBLC; -.
DR   GenomeRNAi; 23624; -.
DR   Pharos; Q9ULV8; Tbio.
DR   PRO; PR:Q9ULV8; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q9ULV8; protein.
DR   Bgee; ENSG00000142273; Expressed in mucosa of transverse colon and 76 other tissues.
DR   ExpressionAtlas; Q9ULV8; baseline and differential.
DR   Genevisible; Q9ULV8; HS.
DR   GO; GO:0045121; C:membrane raft; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IDA:BHF-UCL.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IDA:BHF-UCL.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007175; P:negative regulation of epidermal growth factor-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   CDD; cd09920; SH2_Cbl-b_TKB; 1.
DR   Gene3D; 1.20.930.20; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR024162; Adaptor_Cbl.
DR   InterPro; IPR014741; Adaptor_Cbl_EF_hand-like.
DR   InterPro; IPR036537; Adaptor_Cbl_N_dom_sf.
DR   InterPro; IPR003153; Adaptor_Cbl_N_hlx.
DR   InterPro; IPR014742; Adaptor_Cbl_SH2-like.
DR   InterPro; IPR024159; Cbl_PTB.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR23007; PTHR23007; 1.
DR   Pfam; PF02262; Cbl_N; 1.
DR   Pfam; PF02761; Cbl_N2; 1.
DR   Pfam; PF02762; Cbl_N3; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF47668; SSF47668; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS51506; CBL_PTB; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; SH3-binding; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..474
FT                   /note="E3 ubiquitin-protein ligase CBL-C"
FT                   /id="PRO_0000055866"
FT   DOMAIN          7..321
FT                   /note="Cbl-PTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00839"
FT   CA_BIND         199..210
FT   ZN_FING         351..390
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          7..145
FT                   /note="4H"
FT   REGION          146..218
FT                   /note="EF-hand-like"
FT   REGION          219..321
FT                   /note="SH2-like"
FT   REGION          322..350
FT                   /note="Linker"
FT   REGION          351..474
FT                   /note="Interaction with RET"
FT                   /evidence="ECO:0000269|PubMed:18753381"
FT   BINDING         264
FT                   /note="Phosphotyrosine"
FT   MOD_RES         341
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:20525694,
FT                   ECO:0000269|PubMed:23145173"
FT   VAR_SEQ         261..306
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10362357"
FT                   /id="VSP_005732"
FT   VARIANT         405
FT                   /note="H -> Y (in dbSNP:rs3208856)"
FT                   /evidence="ECO:0000269|PubMed:10362357,
FT                   ECO:0000269|PubMed:10571044"
FT                   /id="VAR_018298"
FT   MUTAGEN         244
FT                   /note="Y->A: Abolishes interaction with EGFR. Decreases
FT                   interaction with SRC and abolishes SRC ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:22888118"
FT   MUTAGEN         244
FT                   /note="Y->F: No effect on interaction with EGFR and SRC as
FT                   well as on SRC ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:22888118"
FT   MUTAGEN         264
FT                   /note="R->A: Abolishes interaction with EGFR. Decreases
FT                   interaction with SRC and abolishes SRC ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:22888118"
FT   MUTAGEN         265
FT                   /note="P->L: Enhances interaction with EGFR and SRC as well
FT                   as SRC ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:22888118"
FT   MUTAGEN         266
FT                   /note="S->A: Decreases interactions with EGFR and SRC as
FT                   well as SRC ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:22888118"
FT   MUTAGEN         268
FT                   /note="T->A: Abolishes interaction with EGFR. Decreases
FT                   interaction with and ubiquitination of SRC."
FT                   /evidence="ECO:0000269|PubMed:22888118"
FT   MUTAGEN         276
FT                   /note="G->E: No effect on interaction with RET. Binds
FT                   slightly to SRC, this interaction is independent of SRC
FT                   phosphorylation. Strongly decreases SRC ubiquitination.
FT                   Abolishes interaction with EGFR."
FT                   /evidence="ECO:0000269|PubMed:14661060,
FT                   ECO:0000269|PubMed:18753381, ECO:0000269|PubMed:22888118"
FT   MUTAGEN         341
FT                   /note="Y->E: Induces E3 activity and autoubiquitination.
FT                   Releases ubiquitin-conjugating enzyme E2 UBE2D2 faster."
FT                   /evidence="ECO:0000269|PubMed:14661060,
FT                   ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173"
FT   MUTAGEN         341
FT                   /note="Y->F: Abolishes activation by EGF stimulation and
FT                   enhancement by TGFB1I1 of E3 activity."
FT                   /evidence="ECO:0000269|PubMed:14661060,
FT                   ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173"
FT   MUTAGEN         341
FT                   /note="Missing: Abolishes E3 activity."
FT                   /evidence="ECO:0000269|PubMed:14661060,
FT                   ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173"
FT   MUTAGEN         351
FT                   /note="C->A: No effect on TGFB1I1 and SRC interactions.
FT                   Abolishes SRC ubiquitination. Abolishes interaction with
FT                   TGFB1I1; when associated with A-366. Abolishes interaction
FT                   with RET and inhibition of RET degradation."
FT                   /evidence="ECO:0000269|PubMed:14661060,
FT                   ECO:0000269|PubMed:18753381, ECO:0000269|PubMed:23145173"
FT   MUTAGEN         366
FT                   /note="C->A: Abolishes interaction with TGFB1I1. Abolishes
FT                   interaction with TGFB1I1; when associated with A-351."
FT                   /evidence="ECO:0000269|PubMed:23145173"
FT   CONFLICT        234
FT                   /note="N -> T (in Ref. 1; BAA86298)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        413
FT                   /note="S -> P (in Ref. 3; AAH28915)"
FT                   /evidence="ECO:0000305"
FT   HELIX           13..31
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          40..42
FT                   /evidence="ECO:0000244|PDB:3OP0"
FT   HELIX           44..62
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          64..66
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           76..97
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          100..102
FT                   /evidence="ECO:0000244|PDB:3OP0"
FT   HELIX           108..111
FT                   /evidence="ECO:0000244|PDB:3OP0"
FT   HELIX           116..138
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           140..142
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   TURN            146..148
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           154..164
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          168..171
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           172..179
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   TURN            180..182
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           189..198
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          203..207
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           208..217
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           221..223
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           224..232
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          238..241
FT                   /evidence="ECO:0000244|PDB:3VRQ"
FT   HELIX           244..251
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           252..254
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          260..265
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          267..269
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          273..278
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   STRAND          284..287
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           294..303
FT                   /evidence="ECO:0000244|PDB:3VRP"
FT   HELIX           320..323
FT                   /evidence="ECO:0000244|PDB:3OP0"
SQ   SEQUENCE   474 AA;  52456 MW;  202634AEDE434544 CRC64;
     MALAVAPWGR QWEEARALGR AVRMLQRLEE QCVDPRLSVS PPSLRDLLPR TAQLLREVAH
     SRRAAGGGGP GGPGGSGDFL LIYLANLEAK SRQVAALLPP RGRRSANDEL FRAGSRLRRQ
     LAKLAIIFSH MHAELHALFP GGKYCGHMYQ LTKAPAHTFW RESCGARCVL PWAEFESLLG
     TCHPVEPGCT ALALRTTIDL TCSGHVSIFE FDVFTRLFQP WPTLLKNWQL LAVNHPGYMA
     FLTYDEVQER LQACRDKPGS YIFRPSCTRL GQWAIGYVSS DGSILQTIPA NKPLSQVLLE
     GQKDGFYLYP DGKTHNPDLT ELGQAEPQQR IHVSEEQLQL YWAMDSTFEL CKICAESNKD
     VKIEPCGHLL CSCCLAAWQH SDSQTCPFCR CEIKGWEAVS IYQFHGQATA EDSGNSSDQE
     GRELELGQVP LSAPPLPPRP DLPPRKPRNA QPKVRLLKGN SPPAALGPQD PAPA
//
ID   CUX1_HUMAN              Reviewed;        1505 AA.
AC   P39880; B3KV79; J3KQV9; Q6NYH4; Q75LE5; Q75MT2; Q75MT3; Q86UJ7; Q9UEV5;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   22-APR-2020, entry version 190.
DE   RecName: Full=Homeobox protein cut-like 1;
DE   AltName: Full=CCAAT displacement protein;
DE            Short=CDP;
DE   AltName: Full=Homeobox protein cux-1;
GN   Name=CUX1; Synonyms=CUTL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Umbilical vein;
RX   PubMed=1301999; DOI=10.1038/ng0492-50;
RA   Neufeld E.J., Skalnik D.G., Lievens P.M.-J., Orkin S.H.;
RT   "Human CCAAT displacement protein is homologous to the Drosophila
RT   homeoprotein, cut.";
RL   Nat. Genet. 1:50-55(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 11).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 48-224 (ISOFORMS 1/2/3).
RX   PubMed=9799793; DOI=10.1101/gr.8.10.1060;
RA   Gloeckner G., Scherer S., Schattevoy R., Boright A.P., Weber J.,
RA   Tsui L.-C., Rosenthal A.;
RT   "Large-scale sequencing of two regions in human chromosome 7q22: analysis
RT   of 650 kb of genomic sequence around the EPO and CUTL1 loci reveals 17
RT   genes.";
RL   Genome Res. 8:1060-1073(1998).
RN   [6]
RP   ALTERNATIVE SPLICING (ISOFORMS 5; 6 AND 7).
RX   PubMed=10607901; DOI=10.1016/s0378-1119(99)00465-5;
RA   Rong Zeng W., Soucie E., Sung Moon N., Martin-Soudant N., Berube G.,
RA   Leduy L., Nepveu A.;
RT   "Exon/intron structure and alternative transcripts of the CUTL1 gene.";
RL   Gene 241:75-85(2000).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1059; SER-1270; SER-1455 AND
RP   SER-1486, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-540 (ISOFORM 11),
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-811, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [15]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-785, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-785; LYS-811; LYS-842 AND
RP   LYS-1284, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [18]
RP   INVOLVEMENT IN GDDI, AND VARIANT GDDI 862-GLN--PHE-1505 DEL.
RX   PubMed=30014507; DOI=10.1002/ana.25278;
RA   Platzer K., Cogne B., Hague J., Marcelis C.L., Mitter D., Oberndorff K.,
RA   Park S.M., Ploos van Amstel H.K., Simonic I., van der Smagt J.J.,
RA   Stegmann A.P.A., Stevens S.J.C., Stumpel C.T.R.M., Vincent M., Lemke J.R.,
RA   Jamra R.;
RT   "Haploinsufficiency of CUX1 causes nonsyndromic global developmental delay
RT   with possible catch-up development.";
RL   Ann. Neurol. 84:200-207(2018).
CC   -!- FUNCTION: Transcription factor involved in the control of neuronal
CC       differentiation in the brain. Regulates dendrite development and
CC       branching, and dendritic spine formation in cortical layers II-III.
CC       Also involved in the control of synaptogenesis. In addition, it has
CC       probably a broad role in mammalian development as a repressor of
CC       developmentally regulated gene expression. May act by preventing
CC       binding of positively-activing CCAAT factors to promoters. Component of
CC       nf-munr repressor; binds to the matrix attachment regions (MARs) (5'
CC       and 3') of the immunoglobulin heavy chain enhancer. Represses T-cell
CC       receptor (TCR) beta enhancer function by binding to MARbeta, an ATC-
CC       rich DNA sequence located upstream of the TCR beta enhancer. Binds to
CC       the TH enhancer; may require the basic helix-loop-helix protein TCF4 as
CC       a coactivator. {ECO:0000250|UniProtKB:P53564}.
CC   -!- SUBUNIT: Interacts with BANP. Interacts with SATB1 (via DNA-binding
CC       domains); the interaction inhibits the attachment of both proteins to
CC       DNA (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=P39880-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P39880-2; Sequence=VSP_002310;
CC       Name=3;
CC         IsoId=P39880-3; Sequence=VSP_015747;
CC       Name=5;
CC         IsoId=P39880-4; Sequence=VSP_017358;
CC       Name=6;
CC         IsoId=P39880-5; Sequence=VSP_017359;
CC       Name=7;
CC         IsoId=P39880-6; Sequence=VSP_017358, VSP_017359;
CC       Name=11;
CC         IsoId=P39880-9; Sequence=VSP_015747, VSP_045924, VSP_045925,
CC                                  VSP_045926;
CC       Name=4; Synonyms=CASP;
CC         IsoId=Q13948-1; Sequence=External;
CC       Name=8;
CC         IsoId=Q13948-2; Sequence=External;
CC       Name=9;
CC         IsoId=Q13948-9; Sequence=External;
CC       Name=10;
CC         IsoId=Q13948-10; Sequence=External;
CC   -!- DISEASE: Global developmental delay with or without impaired
CC       intellectual development (GDDI) [MIM:618330]: An autosomal dominant
CC       disorder characterized by global developmental delay associated with
CC       mild-to-moderate intellectual disability, hypotonia and short stature
CC       in some patients. {ECO:0000269|PubMed:30014507}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Asn-1290 may participate in regulating DNA-binding
CC       activity by promoting homo- and heterodimerization.
CC   -!- SIMILARITY: Belongs to the CUT homeobox family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M74099; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK122726; BAG53691.1; -; mRNA.
DR   EMBL; AC005072; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005086; AAP22331.1; -; Genomic_DNA.
DR   EMBL; AC005088; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005096; AAS07410.1; -; Genomic_DNA.
DR   EMBL; AC005103; AAS07388.1; -; Genomic_DNA.
DR   EMBL; AC092788; AAS07523.1; -; Genomic_DNA.
DR   EMBL; BC066592; AAH66592.1; -; mRNA.
DR   EMBL; AF047825; AAC78778.1; -; Genomic_DNA.
DR   CCDS; CCDS56498.1; -. [P39880-3]
DR   CCDS; CCDS56499.1; -. [P39880-9]
DR   CCDS; CCDS5721.1; -. [P39880-1]
DR   RefSeq; NP_001189472.1; NM_001202543.1. [P39880-3]
DR   RefSeq; NP_001189473.1; NM_001202544.2.
DR   RefSeq; NP_001189474.1; NM_001202545.2. [P39880-9]
DR   RefSeq; NP_852477.1; NM_181500.3.
DR   RefSeq; NP_853530.2; NM_181552.3. [P39880-1]
DR   SMR; P39880; -.
DR   BioGrid; 107903; 69.
DR   ELM; P39880; -.
DR   IntAct; P39880; 36.
DR   MINT; P39880; -.
DR   STRING; 9606.ENSP00000353401; -.
DR   iPTMnet; P39880; -.
DR   MetOSite; P39880; -.
DR   PhosphoSitePlus; P39880; -.
DR   BioMuta; CUX1; -.
DR   EPD; P39880; -.
DR   jPOST; P39880; -.
DR   MassIVE; P39880; -.
DR   PaxDb; P39880; -.
DR   PeptideAtlas; P39880; -.
DR   PRIDE; P39880; -.
DR   ProteomicsDB; 55321; -. [P39880-1]
DR   ProteomicsDB; 55322; -. [P39880-2]
DR   ProteomicsDB; 55323; -. [P39880-3]
DR   ProteomicsDB; 55324; -. [P39880-4]
DR   ProteomicsDB; 55325; -. [P39880-5]
DR   ProteomicsDB; 55326; -. [P39880-6]
DR   Antibodypedia; 48390; 386 antibodies.
DR   DNASU; 1523; -.
DR   Ensembl; ENST00000292535; ENSP00000292535; ENSG00000257923. [P39880-1]
DR   Ensembl; ENST00000360264; ENSP00000353401; ENSG00000257923. [P39880-3]
DR   Ensembl; ENST00000425244; ENSP00000409745; ENSG00000257923. [P39880-9]
DR   Ensembl; ENST00000546411; ENSP00000450125; ENSG00000257923. [P39880-1]
DR   Ensembl; ENST00000549414; ENSP00000446630; ENSG00000257923. [P39880-2]
DR   Ensembl; ENST00000550008; ENSP00000447373; ENSG00000257923. [P39880-5]
DR   Ensembl; ENST00000556210; ENSP00000451558; ENSG00000257923. [P39880-6]
DR   GeneID; 1523; -.
DR   UCSC; uc003uys.5; human. [P39880-1]
DR   CTD; 1523; -.
DR   DisGeNET; 1523; -.
DR   GeneCards; CUX1; -.
DR   HGNC; HGNC:2557; CUX1.
DR   HPA; ENSG00000257923; Low tissue specificity.
DR   MalaCards; CUX1; -.
DR   MIM; 116896; gene.
DR   MIM; 618330; phenotype.
DR   neXtProt; NX_P39880; -.
DR   OpenTargets; ENSG00000257923; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   PharmGKB; PA162382924; -.
DR   eggNOG; KOG0963; Eukaryota.
DR   eggNOG; KOG2252; Eukaryota.
DR   eggNOG; ENOG410XPKP; LUCA.
DR   GeneTree; ENSGT00940000159751; -.
DR   HOGENOM; CLU_016758_0_0_1; -.
DR   InParanoid; P39880; -.
DR   OMA; VANWRRT; -.
DR   OrthoDB; 181575at2759; -.
DR   PhylomeDB; P39880; -.
DR   TreeFam; TF318206; -.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   SIGNOR; P39880; -.
DR   ChiTaRS; CUX1; human.
DR   GeneWiki; CUTL1; -.
DR   GenomeRNAi; 1523; -.
DR   Pharos; P39880; Tbio.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P39880; protein.
DR   Bgee; ENSG00000257923; Expressed in secondary oocyte and 234 other tissues.
DR   ExpressionAtlas; P39880; baseline and differential.
DR   Genevisible; P39880; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000139; C:Golgi membrane; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0030674; F:protein binding, bridging; IEA:Ensembl.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0048193; P:Golgi vesicle transport; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0050775; P:positive regulation of dendrite morphogenesis; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:0000301; P:retrograde transport, vesicle recycling within Golgi; IEA:Ensembl.
DR   CDD; cd00086; homeodomain; 1.
DR   Gene3D; 1.10.260.40; -; 3.
DR   InterPro; IPR003350; CUT_dom.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR010982; Lambda_DNA-bd_dom_sf.
DR   Pfam; PF02376; CUT; 3.
DR   Pfam; PF00046; Homeodomain; 1.
DR   SMART; SM01109; CUT; 3.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   SUPFAM; SSF47413; SSF47413; 3.
DR   PROSITE; PS51042; CUT; 3.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; Developmental protein; Disease mutation;
KW   DNA-binding; Homeobox; Isopeptide bond; Mental retardation; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1505
FT                   /note="Homeobox protein cut-like 1"
FT                   /id="PRO_0000202393"
FT   DNA_BIND        542..629
FT                   /note="CUT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00374"
FT   DNA_BIND        934..1021
FT                   /note="CUT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00374"
FT   DNA_BIND        1117..1204
FT                   /note="CUT 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00374"
FT   DNA_BIND        1244..1303
FT                   /note="Homeobox"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT   COILED          56..407
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        1406..1438
FT                   /note="Ala-rich"
FT   MOD_RES         763
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         909
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P53565"
FT   MOD_RES         1059
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1069
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P53565"
FT   MOD_RES         1270
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1337
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P53564"
FT   MOD_RES         1455
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1486
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1496
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P53564"
FT   CROSSLNK        785
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25755297,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        811
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25772364,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        842
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1284
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1..10
FT                   /note="MLCVAGARLK -> MAANVGSMFQYWKRFDLQQLQ (in isoform 3
FT                   and isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015747"
FT   VAR_SEQ         90..135
FT                   /note="Missing (in isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045924"
FT   VAR_SEQ         408..509
FT                   /note="Missing (in isoform 5 and isoform 7)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_017358"
FT   VAR_SEQ         409..667
FT                   /note="SARRKGKDQPESRRPGSLPAPPPSQLPRNPGEQASNTNGTHQFSPAGLSQDF
FT                   FSSSLASPSLPLASTGKFALNSLLQRQLMQSFYSKAMQEAGSTSMIFSTGPYSTNSISS
FT                   QSPLQQSPDVNGMAPSPSQSESAGSVSEGEEMDTAEIARQVKEQLIKHNIGQRIFGHYV
FT                   LGLSQGSVSEILARPKPWNKLTVRGKEPFHKMKQFLSDEQNILALRSIQGRQRENPGQS
FT                   LNRLFQEVPKRRNGSEGNITTRIRASETGS -> RCAELQVRITEAVATATEQRELIAR
FT                   LEQDLSIIQSIQRPDAEGAAEHRLEKIPEPIKEATALFYGPAAPASGALPEGQVDSLLS
FT                   IISSQRERFRARNQELEAENRLAQHTLQALQSELDSLRADNIKLFEKIKFLQSYPGRGS
FT                   GSDDTELRYSSQYEERLDPFSSFSKRERQRKYLSLSPWDKATLSMGRLVLSNKMARTIG
FT                   FFYTLFLHCLVFLVLYKLAWSESMERDCATFCAKKFADHLHKFHENDNGAAAGDLWQ
FT                   (in isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045925"
FT   VAR_SEQ         632..687
FT                   /note="Missing (in isoform 6 and isoform 7)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_017359"
FT   VAR_SEQ         632..653
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1301999"
FT                   /id="VSP_002310"
FT   VAR_SEQ         668..1505
FT                   /note="Missing (in isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045926"
FT   VARIANT         862..1505
FT                   /note="Missing (in GDDI)"
FT                   /evidence="ECO:0000269|PubMed:30014507"
FT                   /id="VAR_081977"
FT   CONFLICT        5
FT                   /note="A -> R (in Ref. 1; M74099)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        145
FT                   /note="K -> I (in Ref. 2; BAG53691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        260
FT                   /note="A -> V (in Ref. 2; BAG53691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        704..705
FT                   /note="DA -> EP (in Ref. 1; M74099)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        844
FT                   /note="E -> R (in Ref. 1; M74099)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1436
FT                   /note="S -> T (in Ref. 1; M74099)"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         P39880-9:540
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
SQ   SEQUENCE   1505 AA;  164187 MW;  0F9027E5B8F08D95 CRC64;
     MLCVAGARLK RELDATATVL ANRQDESEQS RKRLIEQSRE FKKNTPEDLR KQVAPLLKSF
     QGEIDALSKR SKEAEAAFLN VYKRLIDVPD PVPALDLGQQ LQLKVQRLHD IETENQKLRE
     TLEEYNKEFA EVKNQEVTIK ALKEKIREYE QTLKNQAETI ALEKEQKLQN DFAEKERKLQ
     ETQMSTTSKL EEAEHKVQSL QTALEKTRTE LFDLKTKYDE ETTAKADEIE MIMTDLERAN
     QRAEVAQREA ETLREQLSSA NHSLQLASQI QKAPDVEQAI EVLTRSSLEV ELAAKEREIA
     QLVEDVQRLQ ASLTKLRENS ASQISQLEQQ LSAKNSTLKQ LEEKLKGQAD YEEVKKELNI
     LKSMEFAPSE GAGTQDAAKP LEVLLLEKNR SLQSENAALR ISNSDLSGSA RRKGKDQPES
     RRPGSLPAPP PSQLPRNPGE QASNTNGTHQ FSPAGLSQDF FSSSLASPSL PLASTGKFAL
     NSLLQRQLMQ SFYSKAMQEA GSTSMIFSTG PYSTNSISSQ SPLQQSPDVN GMAPSPSQSE
     SAGSVSEGEE MDTAEIARQV KEQLIKHNIG QRIFGHYVLG LSQGSVSEIL ARPKPWNKLT
     VRGKEPFHKM KQFLSDEQNI LALRSIQGRQ RENPGQSLNR LFQEVPKRRN GSEGNITTRI
     RASETGSDEA IKSILEQAKR ELQVQKTAEP AQPSSASGSG NSDDAIRSIL QQARREMEAQ
     QAALDPALKQ APLSQSDITI LTPKLLSTSP MPTVSSYPPL AISLKKPSAA PEAGASALPN
     PPALKKEAQD APGLDPQGAA DCAQGVLRQV KNEVGRSGAW KDHWWSAVQP ERRNAASSEE
     AKAEETGGGK EKGSGGSGGG SQPRAERSQL QGPSSSEYWK EWPSAESPYS QSSELSLTGA
     SRSETPQNSP LPSSPIVPMS KPTKPSVPPL TPEQYEVYMY QEVDTIELTR QVKEKLAKNG
     ICQRIFGEKV LGLSQGSVSD MLSRPKPWSK LTQKGREPFI RMQLWLNGEL GQGVLPVQGQ
     QQGPVLHSVT SLQDPLQQGC VSSESTPKTS ASCSPAPESP MSSSESVKSL TELVQQPCPP
     IEASKDSKPP EPSDPPASDS QPTTPLPLSG HSALSIQELV AMSPELDTYG ITKRVKEVLT
     DNNLGQRLFG ETILGLTQGS VSDLLARPKP WHKLSLKGRE PFVRMQLWLN DPNNVEKLMD
     MKRMEKKAYM KRRHSSVSDS QPCEPPSVGT EYSQGASPQP QHQLKKPRVV LAPEEKEALK
     RAYQQKPYPS PKTIEDLATQ LNLKTSTVIN WFHNYRSRIR RELFIEEIQA GSQGQAGASD
     SPSARSGRAA PSSEGDSCDG VEATEGPGSA DTEEPKSQGE AEREEVPRPA EQTEPPPSGT
     PGPDDARDDD HEGGPVEGPG PLPSPASATA TAAPAAPEDA ATSAAAAPGE GPAAPSSAPP
     PSNSSSSSAP RRPSSLQSLF GLPEAAGARD SRDNPLRKKK AANLNSIIHR LEKAASREEP
     IEWEF
//
ID   CASP_HUMAN              Reviewed;         678 AA.
AC   Q13948; B3KWH3; B3KWH8; B4DZZ2; G3V1Z6; J3KPQ6; Q53GU9; Q8TBS3;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   10-JAN-2006, sequence version 2.
DT   22-APR-2020, entry version 138.
DE   RecName: Full=Protein CASP;
GN   Name=CUX1; Synonyms=CUTL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical vein;
RX   PubMed=9332351; DOI=10.1016/s0378-1119(97)00243-6;
RA   Lievens P.M.-J., Tufarelli C., Donady J.J., Stagg A., Neufeld E.J.;
RT   "CASP, a novel, highly conserved alternative-splicing product of the
RT   CDP/cut/cux gene, lacks cut-repeat and homeo DNA-binding domains, and
RT   interacts with full-length CDP in vitro.";
RL   Gene 197:73-81(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 9 AND 10), AND VARIANT
RP   THR-464.
RC   TISSUE=Thalamus, Thymus, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-464.
RC   TISSUE=Liver;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT VAL-545.
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   ALTERNATIVE SPLICING.
RX   PubMed=10607901; DOI=10.1016/s0378-1119(99)00465-5;
RA   Rong Zeng W., Soucie E., Sung Moon N., Martin-Soudant N., Berube G.,
RA   Leduy L., Nepveu A.;
RT   "Exon/intron structure and alternative transcripts of the CUTL1 gene.";
RL   Gene 241:75-85(2000).
RN   [8]
RP   SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, SUBUNIT, AND MUTAGENESIS OF
RP   TYR-624 AND HIS-629.
RX   PubMed=12429822; DOI=10.1091/mbc.e02-06-0349;
RA   Gillingham A.K., Pfeifer A.C., Munro S.;
RT   "CASP, the alternatively spliced product of the gene encoding the CCAAT-
RT   displacement protein transcription factor, is a Golgi membrane protein
RT   related to giantin.";
RL   Mol. Biol. Cell 13:3761-3774(2002).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH GOLGA5.
RX   PubMed=15718469; DOI=10.1126/science.1108061;
RA   Malsam J., Satoh A., Pelletier L., Warren G.;
RT   "Golgin tethers define subpopulations of COPI vesicles.";
RL   Science 307:1095-1098(2005).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-586, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-490 AND CYS-609.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: May be involved in intra-Golgi retrograde transport.
CC       {ECO:0000269|PubMed:15718469}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Interacts with GOLGA5.
CC       {ECO:0000269|PubMed:12429822, ECO:0000269|PubMed:15718469}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:12429822}; Single-pass type IV membrane protein
CC       {ECO:0000269|PubMed:12429822}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=4; Synonyms=CASP;
CC         IsoId=Q13948-1; Sequence=Displayed;
CC       Name=11;
CC         IsoId=P39880-9; Sequence=External;
CC       Name=1;
CC         IsoId=P39880-1; Sequence=External;
CC       Name=2;
CC         IsoId=P39880-2; Sequence=External;
CC       Name=3;
CC         IsoId=P39880-3; Sequence=External;
CC       Name=5;
CC         IsoId=P39880-4; Sequence=External;
CC       Name=6;
CC         IsoId=P39880-5; Sequence=External;
CC       Name=7;
CC         IsoId=P39880-6; Sequence=External;
CC       Name=8;
CC         IsoId=Q13948-2; Sequence=VSP_040094;
CC       Name=9;
CC         IsoId=Q13948-9; Sequence=VSP_045593, VSP_040094;
CC       Name=10;
CC         IsoId=Q13948-10; Sequence=VSP_045927;
CC   -!- SIMILARITY: Belongs to the CASP family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CUX1ID403ch7q22.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L12579; AAA35654.1; -; mRNA.
DR   EMBL; AK125076; BAG54135.1; -; mRNA.
DR   EMBL; AK125097; BAG54140.1; -; mRNA.
DR   EMBL; AK303151; BAG64254.1; -; mRNA.
DR   EMBL; AK222832; BAD96552.1; -; mRNA.
DR   EMBL; AC005072; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005086; AAP22331.1; -; Genomic_DNA.
DR   EMBL; AC005088; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005096; AAS07410.1; -; Genomic_DNA.
DR   EMBL; AC005103; AAS07388.1; -; Genomic_DNA.
DR   EMBL; AC092788; AAS07523.1; -; Genomic_DNA.
DR   EMBL; CH471197; EAW50227.1; -; Genomic_DNA.
DR   EMBL; BC025422; AAH25422.1; -; mRNA.
DR   CCDS; CCDS47672.1; -. [Q13948-2]
DR   CCDS; CCDS56500.1; -. [Q13948-10]
DR   CCDS; CCDS5720.1; -. [Q13948-1]
DR   CCDS; CCDS59071.1; -. [Q13948-9]
DR   RefSeq; NP_001189473.1; NM_001202544.2. [Q13948-10]
DR   RefSeq; NP_001189474.1; NM_001202545.2.
DR   RefSeq; NP_001189475.1; NM_001202546.2. [Q13948-9]
DR   RefSeq; NP_001904.2; NM_001913.4. [Q13948-1]
DR   RefSeq; NP_852477.1; NM_181500.3. [Q13948-2]
DR   SMR; Q13948; -.
DR   BioGrid; 107903; 69.
DR   IntAct; Q13948; 13.
DR   MINT; Q13948; -.
DR   iPTMnet; Q13948; -.
DR   BioMuta; CUX1; -.
DR   DMDM; 85681028; -.
DR   EPD; Q13948; -.
DR   jPOST; Q13948; -.
DR   MassIVE; Q13948; -.
DR   MaxQB; Q13948; -.
DR   PeptideAtlas; Q13948; -.
DR   PRIDE; Q13948; -.
DR   ProteomicsDB; 32483; -.
DR   ProteomicsDB; 59765; -. [Q13948-1]
DR   ProteomicsDB; 59766; -. [Q13948-2]
DR   Antibodypedia; 48390; 386 antibodies.
DR   DNASU; 1523; -.
DR   Ensembl; ENST00000292538; ENSP00000292538; ENSG00000257923. [Q13948-1]
DR   Ensembl; ENST00000393824; ENSP00000377410; ENSG00000257923. [Q13948-9]
DR   Ensembl; ENST00000437600; ENSP00000414091; ENSG00000257923. [Q13948-2]
DR   Ensembl; ENST00000547394; ENSP00000449371; ENSG00000257923. [Q13948-10]
DR   Ensembl; ENST00000622516; ENSP00000484760; ENSG00000257923. [Q13948-1]
DR   GeneID; 1523; -.
DR   KEGG; hsa:1523; -.
DR   UCSC; uc003uyt.4; human. [Q13948-1]
DR   CTD; 1523; -.
DR   DisGeNET; 1523; -.
DR   GeneCards; CUX1; -.
DR   HGNC; HGNC:2557; CUX1.
DR   HPA; ENSG00000257923; Low tissue specificity.
DR   MalaCards; CUX1; -.
DR   MIM; 116896; gene.
DR   neXtProt; NX_Q13948; -.
DR   OpenTargets; ENSG00000257923; -.
DR   PharmGKB; PA162382924; -.
DR   eggNOG; KOG0963; Eukaryota.
DR   eggNOG; KOG2252; Eukaryota.
DR   eggNOG; ENOG410XPKP; LUCA.
DR   GeneTree; ENSGT00940000159751; -.
DR   KO; K09313; -.
DR   OrthoDB; 181575at2759; -.
DR   BioCyc; MetaCyc:ENSG00000170275-MONOMER; -.
DR   Reactome; R-HSA-6811438; Intra-Golgi traffic.
DR   SignaLink; Q13948; -.
DR   ChiTaRS; CUX1; human.
DR   GenomeRNAi; 1523; -.
DR   Pharos; Q13948; Tbio.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000257923; Expressed in secondary oocyte and 234 other tissues.
DR   ExpressionAtlas; Q13948; baseline and differential.
DR   Genevisible; Q13948; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0030173; C:integral component of Golgi membrane; IEA:InterPro.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0006891; P:intra-Golgi vesicle-mediated transport; IEA:InterPro.
DR   InterPro; IPR012955; CASP_C.
DR   Pfam; PF08172; CASP_C; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; Disulfide bond; Golgi apparatus;
KW   Membrane; Phosphoprotein; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..678
FT                   /note="Protein CASP"
FT                   /id="PRO_0000071790"
FT   TOPO_DOM        1..619
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        620..640
FT                   /note="Helical; Anchor for type IV membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        641..678
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   COILED          67..450
FT                   /evidence="ECO:0000255"
FT   COILED          502..556
FT                   /evidence="ECO:0000255"
FT   MOD_RES         586
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   VAR_SEQ         22..58
FT                   /note="Missing (in isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045593"
FT   VAR_SEQ         58..73
FT                   /note="Missing (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045927"
FT   VAR_SEQ         288..289
FT                   /note="Missing (in isoform 8 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_040094"
FT   VARIANT         464
FT                   /note="A -> T (in dbSNP:rs803064)"
FT                   /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.3"
FT                   /id="VAR_024923"
FT   VARIANT         490
FT                   /note="S -> G (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036285"
FT   VARIANT         545
FT                   /note="I -> V (in dbSNP:rs2230103)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_024924"
FT   VARIANT         609
FT                   /note="R -> C (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1287689842)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036286"
FT   MUTAGEN         624
FT                   /note="Y->L: Retained in the endoplasmic reticulum."
FT                   /evidence="ECO:0000269|PubMed:12429822"
FT   MUTAGEN         629
FT                   /note="H->L: No effect on subcellular location."
FT                   /evidence="ECO:0000269|PubMed:12429822"
FT   CONFLICT        407
FT                   /note="N -> S (in Ref. 6; AAH25422)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        455
FT                   /note="I -> V (in Ref. 2; BAG64254)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        525
FT                   /note="L -> V (in Ref. 2; BAG64254)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        551
FT                   /note="I -> V (in Ref. 3; BAD96552)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        613
FT                   /note="S -> P (in Ref. 2; BAG54140)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        657
FT                   /note="F -> L (in Ref. 1; AAA35654)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   678 AA;  77455 MW;  E587F222825EA47E CRC64;
     MAANVGSMFQ YWKRFDLQQL QRELDATATV LANRQDESEQ SRKRLIEQSR EFKKNTPEDL
     RKQVAPLLKS FQGEIDALSK RSKEAEAAFL NVYKRLIDVP DPVPALDLGQ QLQLKVQRLH
     DIETENQKLR ETLEEYNKEF AEVKNQEVTI KALKEKIREY EQTLKNQAET IALEKEQKLQ
     NDFAEKERKL QETQMSTTSK LEEAEHKVQS LQTALEKTRT ELFDLKTKYD EETTAKADEI
     EMIMTDLERA NQRAEVAQRE AETLREQLSS ANHSLQLASQ IQKAPDVEQA IEVLTRSSLE
     VELAAKEREI AQLVEDVQRL QASLTKLREN SASQISQLEQ QLSAKNSTLK QLEEKLKGQA
     DYEEVKKELN ILKSMEFAPS EGAGTQDAAK PLEVLLLEKN RSLQSENAAL RISNSDLSGR
     CAELQVRITE AVATATEQRE LIARLEQDLS IIQSIQRPDA EGAAEHRLEK IPEPIKEATA
     LFYGPAAPAS GALPEGQVDS LLSIISSQRE RFRARNQELE AENRLAQHTL QALQSELDSL
     RADNIKLFEK IKFLQSYPGR GSGSDDTELR YSSQYEERLD PFSSFSKRER QRKYLSLSPW
     DKATLSMGRL VLSNKMARTI GFFYTLFLHC LVFLVLYKLA WSESMERDCA TFCAKKFADH
     LHKFHENDNG AAAGDLWQ
//
ID   Q3LIA3_HUMAN            Unreviewed;       484 AA.
AC   Q3LIA3;
DT   08-NOV-2005, integrated into UniProtKB/TrEMBL.
DT   08-NOV-2005, sequence version 1.
DT   11-DEC-2019, entry version 67.
DE   SubName: Full=Uncharacterized protein Nbla10317 {ECO:0000313|EMBL:BAE45765.1};
GN   Name=Nbla10317 {ECO:0000313|EMBL:BAE45765.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAE45765.1};
RN   [1] {ECO:0000313|EMBL:BAE45765.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Ohira M., Morohashi A., Nakagawara A.;
RT   "A large-scale cloning from oligo-capping cDNA libraries of primary
RT   neuroblastoma.";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB075522; BAE45765.1; -; mRNA.
DR   RefSeq; NP_852477.1; NM_181500.3.
DR   PeptideAtlas; Q3LIA3; -.
DR   PRIDE; Q3LIA3; -.
DR   DNASU; 1523; -.
DR   GeneID; 1523; -.
DR   CTD; 1523; -.
DR   eggNOG; KOG0963; Eukaryota.
DR   eggNOG; KOG2252; Eukaryota.
DR   eggNOG; ENOG410XPKP; LUCA.
DR   OrthoDB; 181575at2759; -.
DR   ChiTaRS; CUX1; human.
DR   GenomeRNAi; 1523; -.
DR   Genevisible; Q3LIA3; HS.
DR   GO; GO:0030173; C:integral component of Golgi membrane; IEA:InterPro.
DR   GO; GO:0006891; P:intra-Golgi vesicle-mediated transport; IEA:InterPro.
DR   InterPro; IPR012955; CASP_C.
DR   Pfam; PF08172; CASP_C; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}; Membrane {ECO:0000256|SAM:Phobius};
KW   Transmembrane {ECO:0000256|SAM:Phobius};
KW   Transmembrane helix {ECO:0000256|SAM:Phobius}.
FT   TRANSMEM        422..443
FT                   /note="Helical"
FT                   /evidence="ECO:0000256|SAM:Phobius"
FT   DOMAIN          229..447
FT                   /note="CASP_C"
FT                   /evidence="ECO:0000259|Pfam:PF08172"
FT   COILED          7..34
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COILED          43..80
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COILED          102..136
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COILED          141..161
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COILED          234..254
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COILED          308..356
FT                   /evidence="ECO:0000256|SAM:Coils"
SQ   SEQUENCE   484 AA;  54552 MW;  741887B67FABD936 CRC64;
     MSTTSKLEEA EHKVQSLQTA LEKTRTELFD LKTKYDEETT AKADEIEMIM TDLERANQRA
     EVAQREAETL REQLSSANHS LQLASQIQKA PDVEQAIEVL TRSSLEVELA AKEREIAQLV
     EDVQRLQASL TKLRENSASQ ISQLEQQLSA KNSTLKQLEE KLKGQADYEE VKKELNILKS
     MEFAPSEGAG TQDAAKPLEV LLLEKNRSLQ SENAALRISN SGLSGRCAEL QVRITEAVAT
     ATEQRELIAR LEQDLSIIQS IQRPDAEGAA EHRLEKIPEP IKEATALFYG PAAPASGALP
     EGQVDSLLSI ISSQRERFRA RNQELEAENR LAQHTLQALQ SELDSLRADN IKLFEKIKFL
     QSYPGRGSGS DDTELRYSSQ YEERLDPFSS FSKRERQRKY LSLSPWDKAT LSMGRLVLSN
     KMARTIGFFY TLFLHCLVFL ALYKLAWSES MERDCATFCA KKFADHLHKF HENDNGAAAG
     DLWQ
//
ID   A0A024RCS3_HUMAN        Unreviewed;       740 AA.
AC   A0A024RCS3;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   22-APR-2020, entry version 46.
DE   SubName: Full=DAXX {ECO:0000313|EMBL:AQY76765.1};
DE   SubName: Full=Death-associated protein 6, isoform CRA_a {ECO:0000313|EMBL:EAX03723.1};
GN   Name=DAXX {ECO:0000313|EMBL:EAX03723.1};
GN   ORFNames=hCG_17515 {ECO:0000313|EMBL:EAX03723.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAX03723.1};
RN   [1] {ECO:0000313|EMBL:EAX03723.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAX03723.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:AQY76765.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Norman P.J., Norberg S.J., Nemat-Gorgani N., Ronaghi M., Parham P.;
RT   "CDS alleles of MHC region genes derived from homozygous individuals.";
RL   Submitted (MAR-2017) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KY500277; AQY76765.1; -; Genomic_DNA.
DR   EMBL; KY500278; AQY76766.1; -; Genomic_DNA.
DR   EMBL; KY500279; AQY76767.1; -; Genomic_DNA.
DR   EMBL; KY500281; AQY76769.1; -; Genomic_DNA.
DR   EMBL; KY500282; AQY76770.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03723.1; -; Genomic_DNA.
DR   RefSeq; NP_001135441.1; NM_001141969.1.
DR   RefSeq; NP_001341.1; NM_001350.4.
DR   Antibodypedia; 1411; 961 antibodies.
DR   GeneID; 1616; -.
DR   KEGG; hsa:1616; -.
DR   CTD; 1616; -.
DR   EuPathDB; HostDB:ENSG00000204209.10; -.
DR   eggNOG; ENOG410IGIP; Eukaryota.
DR   eggNOG; ENOG4111K0B; LUCA.
DR   HOGENOM; CLU_022811_1_0_1; -.
DR   KO; K02308; -.
DR   OMA; AMMQDKS; -.
DR   PhylomeDB; A0A024RCS3; -.
DR   ChiTaRS; DAXX; human.
DR   GenomeRNAi; 1616; -.
DR   Bgee; ENSG00000204209; Expressed in testis and 222 other tissues.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   CDD; cd13151; DAXX_helical_bundle; 1.
DR   Gene3D; 1.10.8.810; -; 1.
DR   InterPro; IPR005012; Daxx.
DR   InterPro; IPR031333; Daxx_N.
DR   InterPro; IPR038298; Daxx_N_sf.
DR   PANTHER; PTHR12766:SF7; PTHR12766:SF7; 1.
DR   Pfam; PF03344; Daxx; 1.
PE   4: Predicted;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN          50..145
FT                   /note="Daxx"
FT                   /evidence="ECO:0000259|Pfam:PF03344"
FT   REGION          1..55
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          147..185
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          384..724
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          188..208
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        147..184
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        434..487
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        496..529
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        580..619
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        677..724
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   740 AA;  81373 MW;  1B309ADDAA878040 CRC64;
     MATANSIIVL DDDDEDEAAA QPGPSHPLPN AASPGAEAPS SSEPHGARGS SSSGGKKCYK
     LENEKLFEEF LELCKMQTAD HPEVVPFLYN RQQRAHSLFL ASAEFCNILS RVLSRARSRP
     AKLYVYINEL CTVLKAHSAK KKLNLAPAAT TSNEPSGNNP PTHLSLDPTN AENTASQSPR
     TRGSRRQIQR LEQLLALYVA EIRRLQEKEL DLSELDDPDS AYLQEARLKR KLIRLFGRLC
     ELKDCSSLTG RVIEQRIPYR GTRYPEVNRR IERLINKPGP DTFPDYGDVL RAVEKAAARH
     SLGLPRQQLQ LMAQDAFRDV GIRLQERRHL DLIYNFGCHL TDDYRPGVDP ALSDPVLARR
     LRENRSLAMS RLDEVISKYA MLQDKSEEGE RKKRRARLQG TSSHSADTPE ASLDSGEGPS
     GMASQGCPSA SRAETDDEDD EESDEEEEEE EEEEEEEATD SEEEEDLEQM QEGQEDDEEE
     DEEEEAAAGK DGDKSPMSSL QISNEKNLEP GKQISRSSGE QQNKGRIVSP SLLSEEPLAP
     SSIDAESNGE QPEELTLEEE SPVSQLFELE IEALPLDTPS SVETDISSSR KQSEEPFTTV
     LENGAGMVSS TSFNGGVSPH NWGDSGPPCK KSRKEKKQTG SGPLGNSYVE RQRSVHEKNG
     KKICTLPSPP SPLASLAPVA DSSTRVDSPS HGLVTSSLCI PSPARLSQTP HSQPPRPGTC
     KTSVATQCDP EEIIVLSDSD
//
ID   B4E1C1_HUMAN            Unreviewed;       752 AA.
AC   B4E1C1;
DT   23-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   23-SEP-2008, sequence version 1.
DT   11-DEC-2019, entry version 63.
DE   SubName: Full=cDNA FLJ55943, highly similar to Death domain-associated protein 6 {ECO:0000313|EMBL:BAG64733.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG64733.1};
RN   [1] {ECO:0000313|EMBL:BAG64733.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver {ECO:0000313|EMBL:BAG64733.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A.,
RA   Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y.,
RA   Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T.,
RA   Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK303767; BAG64733.1; -; mRNA.
DR   RefSeq; NP_001135442.1; NM_001141970.1.
DR   MaxQB; B4E1C1; -.
DR   PeptideAtlas; B4E1C1; -.
DR   PRIDE; B4E1C1; -.
DR   DNASU; 1616; -.
DR   GeneID; 1616; -.
DR   CTD; 1616; -.
DR   PharmGKB; PA27148; -.
DR   eggNOG; ENOG410IGIP; Eukaryota.
DR   eggNOG; ENOG4111K0B; LUCA.
DR   OrthoDB; 557255at2759; -.
DR   GenomeRNAi; 1616; -.
DR   Genevisible; B4E1C1; HS.
DR   CDD; cd13151; DAXX_helical_bundle; 1.
DR   Gene3D; 1.10.8.810; -; 1.
DR   InterPro; IPR005012; Daxx.
DR   InterPro; IPR031333; Daxx_N.
DR   InterPro; IPR038298; Daxx_N_sf.
DR   PANTHER; PTHR12766:SF7; PTHR12766:SF7; 1.
DR   Pfam; PF03344; Daxx; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN          62..157
FT                   /note="Daxx"
FT                   /evidence="ECO:0000259|Pfam:PF03344"
FT   REGION          23..67
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          159..197
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          396..736
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          200..220
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        159..196
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        446..499
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        508..541
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        592..631
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        689..736
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   752 AA;  82876 MW;  564F283805B26479 CRC64;
     MRGSENCGEG RLERRFLSII VLDDDDEDEA AAQPGPSHPL PNAASPGAEA PSSSEPHGAR
     GSSSSGGKKC YKLENEKLFE EFLELCKMQT ADHPEVVPFL YNRQQRAHSL FLASAEFCNI
     LSRVLSRARS RPAKLYVYIN ELCTVLKAHS AKKKLNLAPA ATTSNEPSGN NPPTHLSLDP
     TNAENTASQS PRTRGSRRQI QRLEQLLALY VAEIRRLQEK ELDLSELDDP DSAYLQEARL
     KRKLIRLFGR LCELKDCSSL TGRVIEQRIP YRGTRYPEVN RRIERLINKP GPDTFPDYGD
     VLRAVEKAAA RHSLGLPRQQ LQLMAQDAFR DVGIRLQERR HLDLIYNFGC HLTDDYRPGV
     DPALSDPVLA RRLRENRSLA MSRLDEVISK YAMLQDKSEE GERKKRRARL QGTSSHSADT
     PEASLDSGEG PSGMASQGCP SASRAETDDE DDEESDEEEE EEEEEEEEEA TDSEEEEDLE
     QMQEGQEDDE EEDEEEEAAA GKDGDKSPMS SLQISNEKNL EPGKQISRSS GEQQNKGRIV
     SPSLLSEEPL APSSIDAESN GEQPEELTLE EESPVSQLFE LEIEALPLDT PSSVETDISS
     SRKQSEEPFT TVLENGAGMV SSTSFNGGVS PHNWGDSGPP CKKSRKEKKQ TGSGPLGNSY
     VERQRSVHEK NGKKICTLPS PPSPLASLAP VADSSTRVDS PSHGLVTSSL CIPSPARLSQ
     TPHSQPPRPG TCKTSVATQC DPEEIIVLSD SD
//
ID   Q53F85_HUMAN            Unreviewed;       740 AA.
AC   Q53F85;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   22-APR-2020, entry version 70.
DE   SubName: Full=Death-associated protein 6 variant {ECO:0000313|EMBL:BAD97124.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD97124.1};
RN   [1] {ECO:0000313|EMBL:BAD97124.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=8125298; DOI=10.1016/0378-1119(94)90802-8;
RA   Maruyama K., Sugano S.;
RT   "Oligo-capping: a simple method to replace the cap structure of eukaryotic
RT   mRNAs with oligoribonucleotides.";
RL   Gene 138:171-174(1994).
RN   [2] {ECO:0000313|EMBL:BAD97124.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=9373149; DOI=10.1016/S0378-1119(97)00411-3;
RA   Suzuki Y., Yoshitomo K., Maruyama K., Suyama A., Sugano S.;
RT   "Construction and characterization of a full length-enriched and a 5'-end-
RT   enriched cDNA library.";
RL   Gene 200:149-156(1997).
RN   [3] {ECO:0000313|EMBL:BAD97124.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK223404; BAD97124.1; -; mRNA.
DR   RefSeq; NP_001135441.1; NM_001141969.1.
DR   PeptideAtlas; Q53F85; -.
DR   PRIDE; Q53F85; -.
DR   DNASU; 1616; -.
DR   GeneID; 1616; -.
DR   KEGG; hsa:1616; -.
DR   CTD; 1616; -.
DR   PharmGKB; PA27148; -.
DR   eggNOG; ENOG410IGIP; Eukaryota.
DR   eggNOG; ENOG4111K0B; LUCA.
DR   KO; K02308; -.
DR   GenomeRNAi; 1616; -.
DR   Genevisible; Q53F85; HS.
DR   CDD; cd13151; DAXX_helical_bundle; 1.
DR   Gene3D; 1.10.8.810; -; 1.
DR   InterPro; IPR005012; Daxx.
DR   InterPro; IPR031333; Daxx_N.
DR   InterPro; IPR038298; Daxx_N_sf.
DR   PANTHER; PTHR12766:SF7; PTHR12766:SF7; 1.
DR   Pfam; PF03344; Daxx; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN          50..145
FT                   /note="Daxx"
FT                   /evidence="ECO:0000259|Pfam:PF03344"
FT   REGION          1..55
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          147..185
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          384..724
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          188..208
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        147..184
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        434..487
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        496..529
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        580..619
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        677..724
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:BAD97124.1"
SQ   SEQUENCE   740 AA;  81228 MW;  046B3A2A3BAC65E7 CRC64;
     MATANSIIVL DDDDEDEAAA QPGPSHPLPN AASPGAEAPS SSEPHGARGS SSSGGKKCYK
     LENEKLCEEF LGLCKMQTAD HPEVVPFLYN RQQRAHSLFL ASAEFCNILS RVLSRARSRP
     AKLYVYINEL CTVLKAHSAK KKLNLAPAAT TSNEPSGNNP PTHLSLDPTN AENTASQSPR
     TRGSRRQIQR LEQLLALYVA EIRRLQEKEL DLSELDDPDS AYLQEARLKR KLIRLFGRLC
     ELKDCSSLTG RVIEQRIPYR GTRYPEVNRR IERLINKPGP DTFPDYGDVL RAVEKAAARH
     SLGLPRQQLQ LMAQDAFRDA GIRLQERRHL DLIYNFGCHL TDDYRPGVDP ALSDPVLARR
     LRENRSLAMS RLDEVISKYA MLQDKSEEGE RKKRRARLQG TSSHSADTPE ASLDSGEGPS
     GMASQGCPSA SRAETDDEDD EESDEEEEEE EEEEEEEATD SEEEEDLEQM QEGQEDDEEE
     DEEEEAAAGK DGDKSPMSSL QISNEKNLEP GKQISRSSGE QQNKGRIVSP SLLSEEPLAP
     SSIDAESNGE QPEELTLEEE SPVSQLFELE IEALPLDTPS SVETDISSSR KQSEEPFTTV
     LENGAGMVSS TSFNGGVSPH NWGDSGPPCK KSRKEKKQTG SGPLGNSYVE RQRSVHEKNG
     KKICTLPSPP SPLASLAPVA DSSTRVDSPS HGLVTSSLCI PSPARLSQTP HSQPPRPGTC
     KTSVATQCDP EEIIVLSDSD
//
ID   DAXX_HUMAN              Reviewed;         740 AA.
AC   Q9UER7; B4E1I3; F5ANJ6; F5ANJ7; F5H082; O14747; O15141; O15208; Q5STK9;
AC   Q9BWI3;
DT   01-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-2002, sequence version 2.
DT   22-APR-2020, entry version 201.
DE   RecName: Full=Death domain-associated protein 6;
DE   AltName: Full=Daxx;
DE            Short=hDaxx;
DE   AltName: Full=ETS1-associated protein 1;
DE            Short=EAP1;
DE   AltName: Full=Fas death domain-associated protein;
GN   Name=DAXX; Synonyms=BING2, DAP6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9215629; DOI=10.1016/s0092-8674(00)80294-9;
RA   Yang X., Khosravi-Far R., Chang H.Y., Baltimore D.;
RT   "Daxx, a novel Fas-binding protein that activates JNK and apoptosis.";
RL   Cell 89:1067-1076(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=9407001; DOI=10.1089/dna.1997.16.1289;
RA   Kiriakidou M., Driscoll D.A., Lopez-Guisa J.M., Strauss J.F. III;
RT   "Cloning and expression of primate Daxx cDNAs and mapping of the human gene
RT   to chromosome 6p21.3 in the MHC region.";
RL   DNA Cell Biol. 16:1289-1298(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH CENPC, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9645950;
RA   Pluta A.F., Earnshaw W.C., Goldberg I.G.;
RT   "Interphase-specific association of intrinsic centromere protein CENP-C
RT   with HDaxx, a death domain-binding protein implicated in Fas-mediated cell
RT   death.";
RL   J. Cell Sci. 111:2029-2041(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=9545376; DOI=10.1006/jmbi.1998.1637;
RA   Herberg J.A., Beck S., Trowsdale J.;
RT   "TAPASIN, DAXX, RGL2, HKE2 and four new genes (BING 1, 3 to 5) form a dense
RT   cluster at the centromeric end of the MHC.";
RL   J. Mol. Biol. 277:839-857(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=10698492; DOI=10.1038/sj.onc.1203385;
RA   Li R., Pei H., Watson D.K., Papas T.S.;
RT   "EAP1/Daxx interacts with ETS1 and represses transcriptional activation of
RT   ETS1 target genes.";
RL   Oncogene 19:745-753(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS BETA AND GAMMA), SUBCELLULAR LOCATION
RP   (ISOFORMS BETA AND GAMMA), AND ALTERNATIVE SPLICING.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=21482821; DOI=10.1074/jbc.m110.196311;
RA   Wethkamp N., Hanenberg H., Funke S., Suschek C.V., Wetzel W., Heikaus S.,
RA   Grinstein E., Ramp U., Engers R., Gabbert H.E., Mahotka C.;
RT   "Daxx-beta and Daxx-gamma, two novel splice variants of the transcriptional
RT   co-repressor Daxx.";
RL   J. Biol. Chem. 286:19576-19588(2011).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Usui T.;
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 334-740 (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   INTERACTION WITH PAX3 AND PAX7, AND PHOSPHORYLATION.
RX   PubMed=10393185; DOI=10.1093/emboj/18.13.3702;
RA   Hollenbach A.D., Sublett J.E., McPherson C.J., Grosveld G.;
RT   "The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor
RT   hDaxx.";
RL   EMBO J. 18:3702-3711(1999).
RN   [14]
RP   INTERACTION WITH PML.
RX   PubMed=10684855; DOI=10.1084/jem.191.4.631;
RA   Zhong S., Salomoni P., Ronchetti S., Guo A., Ruggero D., Pandolfi P.P.;
RT   "Promyelocytic leukemia protein (PML) and Daxx participate in a novel
RT   nuclear pathway for apoptosis.";
RL   J. Exp. Med. 191:631-640(2000).
RN   [15]
RP   INTERACTION WITH SUMOYLATED PML; HDAC1; HDAC2 AND HDAC3, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10669754; DOI=10.1128/mcb.20.5.1784-1796.2000;
RA   Li H., Leo C., Zhu J., Wu X., O'Neil J., Park E.-J., Chen J.D.;
RT   "Sequestration and inhibition of Daxx-mediated transcriptional repression
RT   by PML.";
RL   Mol. Cell. Biol. 20:1784-1796(2000).
RN   [16]
RP   INTERACTION WITH HSPB1.
RX   PubMed=11003656; DOI=10.1128/mcb.20.20.7602-7612.2000;
RA   Charette S.J., Lavoie J.N., Lambert H., Landry J.;
RT   "Inhibition of Daxx-mediated apoptosis by heat shock protein 27.";
RL   Mol. Cell. Biol. 20:7602-7612(2000).
RN   [17]
RP   INTERACTION WITH MAP3K5, AND SUBCELLULAR LOCATION.
RX   PubMed=11495919; DOI=10.1074/jbc.m105928200;
RA   Ko Y.-G., Kang Y.-S., Park H., Seol W., Kim J., Kim T., Park H.-S.,
RA   Choi E.-J., Kim S.;
RT   "Apoptosis signal-regulating kinase 1 controls the proapoptotic function of
RT   death-associated protein (Daxx) in the cytoplasm.";
RL   J. Biol. Chem. 276:39103-39106(2001).
RN   [18]
RP   INTERACTION WITH TGFBR2.
RX   PubMed=11483955; DOI=10.1038/35087019;
RA   Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A.;
RT   "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that
RT   facilitates JNK activation.";
RL   Nat. Cell Biol. 3:708-714(2001).
RN   [19]
RP   SUMOYLATION AT LYS-630 AND LYS-631, AND MUTAGENESIS OF LYS-630 AND LYS-631.
RX   PubMed=12150977; DOI=10.1016/s0006-291x(02)00699-x;
RA   Jang M.-S., Ryu S.-W., Kim E.;
RT   "Modification of Daxx by small ubiquitin-related modifier-1.";
RL   Biochem. Biophys. Res. Commun. 295:495-500(2002).
RN   [20]
RP   INTERACTION WITH SLC2A4 AND UBE2I, SUMOYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=11842083; DOI=10.1074/jbc.m110294200;
RA   Lalioti V.S., Vergarajauregui S., Pulido D., Sandoval I.V.;
RT   "The insulin-sensitive glucose transporter, GLUT4, interacts physically
RT   with Daxx. Two proteins with capacity to bind Ubc9 and conjugated to
RT   SUMO1.";
RL   J. Biol. Chem. 277:19783-19791(2002).
RN   [21]
RP   INTERACTION WITH MCRS1.
RX   PubMed=11948183; DOI=10.1074/jbc.m200633200;
RA   Lin D.-Y., Shih H.-M.;
RT   "Essential role of the 58-kDa microspherule protein in the modulation of
RT   Daxx-dependent transcriptional repression as revealed by nucleolar
RT   sequestration.";
RL   J. Biol. Chem. 277:25446-25456(2002).
RN   [22]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH HDAC2; HISTONES AND DEK.
RX   PubMed=12140263;
RA   Hollenbach A.D., McPherson C.J., Mientjes E.J., Iyengar R., Grosveld G.;
RT   "Daxx and histone deacetylase II associate with chromatin through an
RT   interaction with core histones and the chromatin-associated protein Dek.";
RL   J. Cell Sci. 115:3319-3330(2002).
RN   [23]
RP   INTERACTION WITH HIPK2.
RX   PubMed=14678985;
RA   Hofmann T.G., Stollberg N., Schmitz M.L., Will H.;
RT   "HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-
RT   terminal kinase activation and apoptosis in human hepatoma cells.";
RL   Cancer Res. 63:8271-8277(2003).
RN   [24]
RP   OLIGOMERIZATION, SUBCELLULAR LOCATION, INTERACTION WITH MAP3K5, MUTAGENESIS
RP   OF SER-668 AND SER-671, AND PHOSPHORYLATION AT SER-668.
RX   PubMed=12968034; DOI=10.1074/jbc.m213201200;
RA   Song J.J., Lee Y.J.;
RT   "Role of the ASK1-SEK1-JNK1-HIPK1 signal in Daxx trafficking and ASK1
RT   oligomerization.";
RL   J. Biol. Chem. 278:47245-47252(2003).
RN   [25]
RP   INTERACTION WITH HIPK1.
RX   PubMed=12529400; DOI=10.1128/mcb.23.3.950-960.2003;
RA   Ecsedy J.A., Michaelson J.S., Leder P.;
RT   "Homeodomain-interacting protein kinase 1 modulates Daxx localization,
RT   phosphorylation, and transcriptional activity.";
RL   Mol. Cell. Biol. 23:950-960(2003).
RN   [26]
RP   INTERACTION WITH ATRX, AND SUBCELLULAR LOCATION.
RX   PubMed=12953102; DOI=10.1073/pnas.1937626100;
RA   Xue Y., Gibbons R., Yan Z., Yang D., McDowell T.L., Sechi S., Qin J.,
RA   Zhou S., Higgs D., Wang W.;
RT   "The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx
RT   and localizes in promyelocytic leukemia nuclear bodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:10635-10640(2003).
RN   [27]
RP   INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION).
RX   PubMed=14557665; DOI=10.1128/jvi.77.21.11809-11821.2003;
RA   Zhao L.Y., Colosimo A.L., Liu Y., Wan Y., Liao D.;
RT   "Adenovirus E1B 55-kilodalton oncoprotein binds to Daxx and eliminates
RT   enhancement of p53-dependent transcription by DAXX.";
RL   J. Virol. 77:11809-11821(2003).
RN   [28]
RP   INTERACTION WITH SPOP.
RX   PubMed=15240113; DOI=10.1016/j.bbrc.2004.06.022;
RA   La M., Kim K., Park J., Won J., Lee J.-H., Fu Y.M., Meadows G.G., Joe C.O.;
RT   "Daxx-mediated transcriptional repression of MMP1 gene is reversed by
RT   SPOP.";
RL   Biochem. Biophys. Res. Commun. 320:760-765(2004).
RN   [29]
RP   FUNCTION, INTERACTION WITH ATRX, AND SUBCELLULAR LOCATION.
RX   PubMed=14990586; DOI=10.1074/jbc.m401321200;
RA   Tang J., Wu S., Liu H., Stratt R., Barak O.G., Shiekhattar R.,
RA   Picketts D.J., Yang X.;
RT   "A novel transcription regulatory complex containing death domain-
RT   associated protein and the ATR-X syndrome protein.";
RL   J. Biol. Chem. 279:20369-20377(2004).
RN   [30]
RP   FUNCTION, AND INTERACTION WITH MDM2 AND TP53.
RX   PubMed=15364927; DOI=10.1074/jbc.m406743200;
RA   Zhao L.Y., Liu J., Sidhu G.S., Niu Y., Liu Y., Wang R., Liao D.;
RT   "Negative regulation of p53 functions by Daxx and the involvement of
RT   MDM2.";
RL   J. Biol. Chem. 279:50566-50579(2004).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH HSF1.
RX   PubMed=15016915; DOI=10.1073/pnas.0304768101;
RA   Boellmann F., Guettouche T., Guo Y., Fenna M., Mnayer L., Voellmy R.;
RT   "DAXX interacts with heat shock factor 1 during stress activation and
RT   enhances its transcriptional activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4100-4105(2004).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [33]
RP   IDENTIFICATION IN A COMPLEX WITH CUL3 AND SPOP, AND UBIQUITINATION.
RX   PubMed=16524876; DOI=10.1074/jbc.m600204200;
RA   Kwon J.E., La M., Oh K.H., Oh Y.M., Kim G.R., Seol J.H., Baek S.H.,
RA   Chiba T., Tanaka K., Bang O.S., Joe C.O., Chung C.H.;
RT   "BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor
RT   of Daxx for ubiquitination by Cul3-based ubiquitin ligase.";
RL   J. Biol. Chem. 281:12664-12672(2006).
RN   [34]
RP   FUNCTION, SUBCELLULAR LOCATION, SUMOYLATION, SUMO INTERACTION MOTIF, AND
RP   MUTAGENESIS OF 733-ILE--ASP-740.
RX   PubMed=17081986; DOI=10.1016/j.molcel.2006.10.019;
RA   Lin D.Y., Huang Y.S., Jeng J.C., Kuo H.Y., Chang C.C., Chao T.T., Ho C.C.,
RA   Chen Y.C., Lin T.P., Fang H.I., Hung C.C., Suen C.S., Hwang M.J.,
RA   Chang K.S., Maul G.G., Shih H.M.;
RT   "Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear
RT   localization, and repression of sumoylated transcription factors.";
RL   Mol. Cell 24:341-354(2006).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-702, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [36]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH MDM2 AND USP7, INTERACTION WITH
RP   MDM2; TP53 AND USP7, AND SUBCELLULAR LOCATION.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [37]
RP   INTERACTION WITH AXIN1.
RX   PubMed=17210684; DOI=10.1158/0008-5472.can-06-1671;
RA   Li Q., Wang X., Wu X., Rui Y., Liu W., Wang J., Wang X., Liou Y.C., Ye Z.,
RA   Lin S.C.;
RT   "Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death.";
RL   Cancer Res. 67:66-74(2007).
RN   [38]
RP   IDENTIFICATION IN A COMPLEX WITH MDM2; RASSF1 AND USP7, INTERACTION WITH
RP   RASSF1; USP7 AND MDM2, AND SUBCELLULAR LOCATION.
RX   PubMed=18566590; DOI=10.1038/emboj.2008.115;
RA   Song M.S., Song S.J., Kim S.Y., Oh H.J., Lim D.S.;
RT   "The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by
RT   disrupting the MDM2-DAXX-HAUSP complex.";
RL   EMBO J. 27:1863-1874(2008).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-671 AND SER-702, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [40]
RP   FUNCTION IN HCMV RESTRICTION.
RX   PubMed=17942542; DOI=10.1128/jvi.01685-07;
RA   Tavalai N., Papior P., Rechter S., Stamminger T.;
RT   "Nuclear domain 10 components promyelocytic leukemia protein and hDaxx
RT   independently contribute to an intrinsic antiviral defense against human
RT   cytomegalovirus infection.";
RL   J. Virol. 82:126-137(2008).
RN   [41]
RP   INTERACTION WITH HCMV PP71 (MICROBIAL INFECTION).
RX   PubMed=18922870; DOI=10.1128/jvi.01215-08;
RA   Lukashchuk V., McFarlane S., Everett R.D., Preston C.M.;
RT   "Human cytomegalovirus protein pp71 displaces the chromatin-associated
RT   factor ATRX from nuclear domain 10 at early stages of infection.";
RL   J. Virol. 82:12543-12554(2008).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-213; SER-495;
RP   SER-668; SER-671; SER-688; SER-702; SER-737 AND SER-739, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-702; SER-737 AND SER-739, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [45]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-512, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [46]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP7.
RX   PubMed=20153724; DOI=10.1016/j.bbrc.2010.02.051;
RA   Tang J., Qu L., Pang M., Yang X.;
RT   "Daxx is reciprocally regulated by Mdm2 and Hausp.";
RL   Biochem. Biophys. Res. Commun. 393:542-545(2010).
RN   [47]
RP   FUNCTION AS HISTONE CHAPERONE, FUNCTION OF THE ATRX:DAXX COMPLEX, AND
RP   INTERACTION WITH HISTONE H3.3.
RX   PubMed=20504901; DOI=10.1101/gad.566910;
RA   Drane P., Ouararhni K., Depaux A., Shuaib M., Hamiche A.;
RT   "The death-associated protein DAXX is a novel histone chaperone involved in
RT   the replication-independent deposition of H3.3.";
RL   Genes Dev. 24:1253-1265(2010).
RN   [48]
RP   INTERACTION WITH HHV-5 PROTEIN UL123.
RX   PubMed=20444888; DOI=10.1128/jvi.02231-09;
RA   Reeves M., Woodhall D., Compton T., Sinclair J.;
RT   "Human cytomegalovirus IE72 protein interacts with the transcriptional
RT   repressor hDaxx to regulate LUNA gene expression during lytic infection.";
RL   J. Virol. 84:7185-7194(2010).
RN   [49]
RP   FUNCTION AS HISTONE H3.3 CHAPERONE, AND INTERACTION WITH HISTONE H3.3.
RX   PubMed=20651253; DOI=10.1073/pnas.1008850107;
RA   Lewis P.W., Elsaesser S.J., Noh K.M., Stadler S.C., Allis C.D.;
RT   "Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in
RT   replication-independent chromatin assembly at telomeres.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14075-14080(2010).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495; SER-702; SER-737 AND
RP   SER-739, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495 AND SER-702, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [53]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23222847; DOI=10.1101/gr.142703.112;
RA   Delbarre E., Ivanauskiene K., Kuntziger T., Collas P.;
RT   "DAXX-dependent supply of soluble (H3.3-H4) dimers to PML bodies pending
RT   deposition into chromatin.";
RL   Genome Res. 23:440-451(2013).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-412; SER-424;
RP   SER-495; SER-671; SER-688 AND SER-702, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [55]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24200965; DOI=10.4161/cc.26988;
RA   Corpet A., Olbrich T., Gwerder M., Fink D., Stucki M.;
RT   "Dynamics of histone H3.3 deposition in proliferating and senescent cells
RT   reveals a DAXX-dependent targeting to PML-NBs important for pericentromeric
RT   heterochromatin organization.";
RL   Cell Cycle 13:249-267(2014).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-25, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [57]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS PROTEIN BNRF1 (MICROBIAL INFECTION),
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=25275136; DOI=10.1128/jvi.01895-14;
RA   Tsai K., Chan L., Gibeault R., Conn K., Dheekollu J., Domsic J.,
RA   Marmorstein R., Schang L.M., Lieberman P.M.;
RT   "Viral reprogramming of the Daxx histone H3.3 chaperone during early
RT   Epstein-Barr virus infection.";
RL   J. Virol. 88:14350-14363(2014).
RN   [58]
RP   FUNCTION.
RX   PubMed=24530302; DOI=10.1016/j.molcel.2014.01.018;
RA   Lacoste N., Woolfe A., Tachiwana H., Garea A.V., Barth T., Cantaloube S.,
RA   Kurumizaka H., Imhof A., Almouzni G.;
RT   "Mislocalization of the centromeric histone variant CenH3/CENP-A in human
RT   cells depends on the chaperone DAXX.";
RL   Mol. Cell 53:631-644(2014).
RN   [59]
RP   INTERACTION WITH SUMO1P1/SUMO5.
RX   PubMed=27211601; DOI=10.1038/srep26509;
RA   Liang Y.C., Lee C.C., Yao Y.L., Lai C.C., Schmitz M.L., Yang W.M.;
RT   "SUMO5, a novel poly-sumo isoform, regulates pml nuclear bodies.";
RL   Sci. Rep. 6:26509-26509(2016).
RN   [60]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-142, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [61]
RP   STRUCTURE BY NMR OF 55-144 IN COMPLEX WITH RASSF1, AND INTERACTION WITH
RP   RASSF1.
RX   PubMed=21134643; DOI=10.1016/j.str.2010.09.016;
RA   Escobar-Cabrera E., Lau D.K., Giovinazzi S., Ishov A.M., McIntosh L.P.;
RT   "Structural characterization of the DAXX N-terminal helical bundle domain
RT   and its complex with Rassf1C.";
RL   Structure 18:1642-1653(2010).
RN   [62]
RP   STRUCTURE BY NMR OF 721-740.
RX   PubMed=20927612; DOI=10.1007/s12104-010-9271-4;
RA   Naik M.T., Chang C.C., Naik N.M., Kung C.C., Shih H.M., Huang T.H.;
RT   "NMR chemical shift assignments of a complex between SUMO-1 and SIM peptide
RT   derived from the C-terminus of Daxx.";
RL   Biomol. NMR. Assign. 5:75-77(2011).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 184-390 IN COMPLEX WITH HISTONE
RP   H3.3/H4 DIMER, AND MUTAGENESIS OF TYR-222.
RX   PubMed=23142979; DOI=10.1038/nsmb.2439;
RA   Liu C.P., Xiong C., Wang M., Yu Z., Yang N., Chen P., Zhang Z., Li G.,
RA   Xu R.M.;
RT   "Structure of the variant histone H3.3-H4 heterodimer in complex with its
RT   chaperone DAXX.";
RL   Nat. Struct. Mol. Biol. 19:1287-1292(2012).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 178-389 IN COMPLEX WITH HISTONE
RP   H3.3/H4 DIMER, AND MUTAGENESIS OF GLN-206; SER-220; TYR-222; GLU-225;
RP   LYS-229; ARG-251; PHE-317; ARG-328 AND ASP-331.
RX   PubMed=23075851; DOI=10.1038/nature11608;
RA   Elsasser S.J., Huang H., Lewis P.W., Chin J.W., Allis C.D., Patel D.J.;
RT   "DAXX envelops a histone H3.3-H4 dimer for H3.3-specific recognition.";
RL   Nature 491:560-565(2012).
CC   -!- FUNCTION: Transcription corepressor known to repress transcriptional
CC       potential of several sumoylated transcription factors. Down-regulates
CC       basal and activated transcription. Its transcription repressor activity
CC       is modulated by recruiting it to subnuclear compartments like the
CC       nucleolus or PML/POD/ND10 nuclear bodies through interactions with
CC       MCSR1 and PML, respectively. Seems to regulate transcription in
CC       PML/POD/ND10 nuclear bodies together with PML and may influence
CC       TNFRSF6-dependent apoptosis thereby. Inhibits transcriptional
CC       activation of PAX3 and ETS1 through direct protein-protein
CC       interactions. Modulates PAX5 activity; the function seems to involve
CC       CREBBP. Acts as an adapter protein in a MDM2-DAXX-USP7 complex by
CC       regulating the RING-finger E3 ligase MDM2 ubiquitination activity.
CC       Under non-stress condition, in association with the deubiquitinating
CC       USP7, prevents MDM2 self-ubiquitination and enhances the intrinsic E3
CC       ligase activity of MDM2 towards TP53, thereby promoting TP53
CC       ubiquitination and subsequent proteasomal degradation. Upon DNA damage,
CC       its association with MDM2 and USP7 is disrupted, resulting in increased
CC       MDM2 autoubiquitination and consequently, MDM2 degradation, which leads
CC       to TP53 stabilization. Acts as histone chaperone that facilitates
CC       deposition of histone H3.3. Acts as targeting component of the
CC       chromatin remodeling complex ATRX:DAXX which has ATP-dependent DNA
CC       translocase activity and catalyzes the replication-independent
CC       deposition of histone H3.3 in pericentric DNA repeats outside S-phase
CC       and telomeres, and the in vitro remodeling of H3.3-containing
CC       nucleosomes. Does not affect the ATPase activity of ATRX but alleviates
CC       its transcription repression activity. Upon neuronal activation
CC       associates with regulatory elements of selected immediate early genes
CC       where it promotes deposition of histone H3.3 which may be linked to
CC       transcriptional induction of these genes. Required for the recruitment
CC       of histone H3.3:H4 dimers to PML-nuclear bodies (PML-NBs); the process
CC       is independent of ATRX and facilitated by ASF1A; PML-NBs are suggested
CC       to function as regulatory sites for the incorporation of newly
CC       synthesized histone H3.3 into chromatin. In case of overexpression of
CC       centromeric histone variant CENPA (as found in various tumors) is
CC       involved in its mislocalization to chromosomes; the ectopic
CC       localization involves a heterotypic tetramer containing CENPA, and
CC       histones H3.3 and H4 and decreases binding of CTCF to chromatin.
CC       Proposed to mediate activation of the JNK pathway and apoptosis via
CC       MAP3K5 in response to signaling from TNFRSF6 and TGFBR2. Interaction
CC       with HSPB1/HSP27 may prevent interaction with TNFRSF6 and MAP3K5 and
CC       block DAXX-mediated apoptosis. In contrast, in lymphoid cells JNC
CC       activation and TNFRSF6-mediated apoptosis may not involve DAXX. Shows
CC       restriction activity towards human cytomegalovirus (HCMV). Plays a role
CC       as a positive regulator of the heat shock transcription factor HSF1
CC       activity during the stress protein response (PubMed:15016915).
CC       {ECO:0000269|PubMed:12140263, ECO:0000269|PubMed:14990586,
CC       ECO:0000269|PubMed:15016915, ECO:0000269|PubMed:15364927,
CC       ECO:0000269|PubMed:16845383, ECO:0000269|PubMed:17081986,
CC       ECO:0000269|PubMed:17942542, ECO:0000269|PubMed:20504901,
CC       ECO:0000269|PubMed:20651253, ECO:0000269|PubMed:23222847,
CC       ECO:0000269|PubMed:24200965, ECO:0000269|PubMed:24530302}.
CC   -!- SUBUNIT: Homomultimer. Interacts (via C-terminus) with TNFRSF6 (via
CC       death domain). Interacts with PAX5, SLC2A4/GLUT4, MAP3K5, TGFBR2,
CC       phosphorylated dimeric HSPB1/HSP27, CENPC, ETS1, sumoylated PML, UBE2I,
CC       MCRS1 and TP53. Interacts (via N-terminus) with HIPK2 and HIPK3.
CC       Interacts with HIPK1, which induces translocation from PML/POD/ND10
CC       nuclear bodies to chromatin and enhances association with HDAC1.
CC       Interacts (non-phosphorylated) with PAX3, PAX7, DEK, HDAC1, HDAC2,
CC       HDAC3, acetylated histone H4 and histones H2A, H2B, H3, H3.3 and H4.
CC       Interacts with SPOP; mediating CUL3-dependent proteosomal degradation.
CC       Interacts with CBP; the interaction is dependent the sumoylation of CBP
CC       and suppresses CBP transcriptional activity via recruitment of HDAC2
CC       directly in the complex with TP53 and HIPK2. Interacts with AXIN1; the
CC       interaction stimulates the interaction of DAXX with TP53, stimulates
CC       'Ser-46' phosphorylation of TP53 on and induces cell death on UV
CC       irradiation. Interacts with MDM2; the interaction is direct. Interacts
CC       with USP7; the interaction is direct and independent of MDM2 and TP53.
CC       Part of a complex with DAXX, MDM2 and USP7 under non-stress conditions.
CC       Interacts (via N-terminus) with RASSF1 (via C-terminus); the
CC       interaction is independent of MDM2 and TP53; RASSF1 isoform A disrupts
CC       interactions among MDM2, DAXX and USP7, thus contributing to the
CC       efficient activation of TP53 by promoting MDM2 self-ubiquitination in
CC       cell-cycle checkpoint control in response to DNA damage. Interacts with
CC       ATRX to form the chromatin remodeling complex ATRX:DAXX. Interacts with
CC       HSF1 (via homotrimeric form preferentially); this interaction relieves
CC       homotrimeric HSF1 from repression of its transcriptional activity by
CC       HSP90-dependent multichaperone complex upon heat shock
CC       (PubMed:15016915). Interacts with SUMO1P1/SUMO5 (PubMed:27211601).
CC       {ECO:0000269|PubMed:10393185, ECO:0000269|PubMed:10669754,
CC       ECO:0000269|PubMed:10684855, ECO:0000269|PubMed:11003656,
CC       ECO:0000269|PubMed:11483955, ECO:0000269|PubMed:11495919,
CC       ECO:0000269|PubMed:11842083, ECO:0000269|PubMed:11948183,
CC       ECO:0000269|PubMed:12140263, ECO:0000269|PubMed:12529400,
CC       ECO:0000269|PubMed:12953102, ECO:0000269|PubMed:12968034,
CC       ECO:0000269|PubMed:14678985, ECO:0000269|PubMed:14990586,
CC       ECO:0000269|PubMed:15016915, ECO:0000269|PubMed:15240113,
CC       ECO:0000269|PubMed:15364927, ECO:0000269|PubMed:16524876,
CC       ECO:0000269|PubMed:16845383, ECO:0000269|PubMed:17210684,
CC       ECO:0000269|PubMed:18566590, ECO:0000269|PubMed:20444888,
CC       ECO:0000269|PubMed:20504901, ECO:0000269|PubMed:20651253,
CC       ECO:0000269|PubMed:21134643, ECO:0000269|PubMed:23075851,
CC       ECO:0000269|PubMed:23142979, ECO:0000269|PubMed:27211601,
CC       ECO:0000269|PubMed:9645950}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human
CC       cytomegalovirus/HHV-5 tegument phosphoprotein pp71 and protein UL123.
CC       {ECO:0000269|PubMed:18922870}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus
CC       protein BNRF1. {ECO:0000269|PubMed:25275136}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human adenovirus 5 E1B-
CC       55K protein; this interaction might alterate the normal interactions of
CC       DAXX, PML, and TP53, which may contribute to cell transformation.
CC       {ECO:0000269|PubMed:14557665}.
CC   -!- INTERACTION:
CC       Q9UER7; P03243; Xeno; NbExp=4; IntAct=EBI-77321, EBI-1561361;
CC       Q9UER7; O43918: AIRE; NbExp=5; IntAct=EBI-77321, EBI-1753081;
CC       Q9UER7; Q9Y2J4: AMOTL2; NbExp=3; IntAct=EBI-77321, EBI-746752;
CC       Q9UER7; P10275: AR; NbExp=5; IntAct=EBI-77321, EBI-608057;
CC       Q9UER7; P46100: ATRX; NbExp=7; IntAct=EBI-77321, EBI-396461;
CC       Q9UER7; P03179: BNRF1; Xeno; NbExp=5; IntAct=EBI-77321, EBI-9349301;
CC       Q9UER7; Q9H257: CARD9; NbExp=3; IntAct=EBI-77321, EBI-751319;
CC       Q9UER7; Q96GN5: CDCA7L; NbExp=3; IntAct=EBI-77321, EBI-5278764;
CC       Q9UER7; Q8N726: CDKN2A; NbExp=8; IntAct=EBI-77321, EBI-625922;
CC       Q9UER7; Q96MT8-3: CEP63; NbExp=3; IntAct=EBI-77321, EBI-11522539;
CC       Q9UER7; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-77321, EBI-739624;
CC       Q9UER7; Q92793: CREBBP; NbExp=2; IntAct=EBI-77321, EBI-81215;
CC       Q9UER7; Q9NPF5: DMAP1; NbExp=3; IntAct=EBI-77321, EBI-399105;
CC       Q9UER7; P03244: E1B; Xeno; NbExp=4; IntAct=EBI-77321, EBI-1561155;
CC       Q9UER7-1; P14921-1: ETS1; NbExp=3; IntAct=EBI-287635, EBI-913224;
CC       Q9UER7-1; P14921-2: ETS1; NbExp=2; IntAct=EBI-287635, EBI-913228;
CC       Q9UER7; Q8IZU0: FAM9B; NbExp=4; IntAct=EBI-77321, EBI-10175124;
CC       Q9UER7; P25445: FAS; NbExp=3; IntAct=EBI-77321, EBI-494743;
CC       Q9UER7; P25446: Fas; Xeno; NbExp=4; IntAct=EBI-77321, EBI-296206;
CC       Q9UER7; P02794: FTH1; NbExp=5; IntAct=EBI-77321, EBI-713259;
CC       Q9UER7; O95995: GAS8; NbExp=5; IntAct=EBI-77321, EBI-1052570;
CC       Q9UER7; Q96IK5: GMCL1; NbExp=3; IntAct=EBI-77321, EBI-2548508;
CC       Q9UER7; Q08379: GOLGA2; NbExp=8; IntAct=EBI-77321, EBI-618309;
CC       Q9UER7; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-77321, EBI-5916454;
CC       Q9UER7; Q4V328: GRIPAP1; NbExp=3; IntAct=EBI-77321, EBI-717919;
CC       Q9UER7; P84243: H3-3B; NbExp=5; IntAct=EBI-77321, EBI-120658;
CC       Q9UER7-1; P84243: H3-3B; NbExp=21; IntAct=EBI-287635, EBI-120658;
CC       Q9UER7-1; P68431: H3C12; NbExp=6; IntAct=EBI-287635, EBI-79722;
CC       Q9UER7; Q6NXT2: H3F3C; NbExp=3; IntAct=EBI-77321, EBI-2868501;
CC       Q9UER7; Q13547: HDAC1; NbExp=2; IntAct=EBI-77321, EBI-301834;
CC       Q9UER7; Q92769: HDAC2; NbExp=2; IntAct=EBI-77321, EBI-301821;
CC       Q9UER7; O88904: Hipk1; Xeno; NbExp=3; IntAct=EBI-77321, EBI-692945;
CC       Q9UER7-1; Q71DI3: HIST2H3A; NbExp=5; IntAct=EBI-287635, EBI-750650;
CC       Q9UER7; P04792: HSPB1; NbExp=4; IntAct=EBI-77321, EBI-352682;
CC       Q9UER7; P15991: HSPB1; Xeno; NbExp=3; IntAct=EBI-77321, EBI-1559114;
CC       Q9UER7; Q8WVF5: KCTD4; NbExp=3; IntAct=EBI-77321, EBI-741463;
CC       Q9UER7; Q9P2G9-2: KLHL8; NbExp=3; IntAct=EBI-77321, EBI-11959635;
CC       Q9UER7; Q99683: MAP3K5; NbExp=7; IntAct=EBI-77321, EBI-476263;
CC       Q9UER7; Q96EZ8: MCRS1; NbExp=11; IntAct=EBI-77321, EBI-348259;
CC       Q9UER7; Q00987: MDM2; NbExp=18; IntAct=EBI-77321, EBI-389668;
CC       Q9UER7; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-77321, EBI-2548751;
CC       Q9UER7; Q9UHC7: MKRN1; NbExp=3; IntAct=EBI-77321, EBI-373524;
CC       Q9UER7; Q8NCY6: MSANTD4; NbExp=3; IntAct=EBI-77321, EBI-7850168;
CC       Q9UER7; Q7Z6G3-2: NECAB2; NbExp=6; IntAct=EBI-77321, EBI-10172876;
CC       Q9UER7; Q9BZ95: NSD3; NbExp=2; IntAct=EBI-77321, EBI-3390132;
CC       Q9UER7; Q99497: PARK7; NbExp=3; IntAct=EBI-77321, EBI-1164361;
CC       Q9UER7; Q02650: Pax5; Xeno; NbExp=4; IntAct=EBI-77321, EBI-296260;
CC       Q9UER7; Q96AQ6: PBXIP1; NbExp=3; IntAct=EBI-77321, EBI-740845;
CC       Q9UER7; Q4G0R1: PIBF1; NbExp=3; IntAct=EBI-77321, EBI-14066006;
CC       Q9UER7; P29590: PML; NbExp=6; IntAct=EBI-77321, EBI-295890;
CC       Q9UER7; Q8ND90: PNMA1; NbExp=5; IntAct=EBI-77321, EBI-302345;
CC       Q9UER7; Q9NS23: RASSF1; NbExp=6; IntAct=EBI-77321, EBI-367363;
CC       Q9UER7; Q9NS23-4: RASSF1; NbExp=5; IntAct=EBI-77321, EBI-438710;
CC       Q9UER7; Q86WH2: RASSF3; NbExp=3; IntAct=EBI-77321, EBI-2845202;
CC       Q9UER7; Q04206: RELA; NbExp=5; IntAct=EBI-77321, EBI-73886;
CC       Q9UER7; Q9QZL0: Ripk3; Xeno; NbExp=2; IntAct=EBI-77321, EBI-2367423;
CC       Q9UER7; P78317: RNF4; NbExp=3; IntAct=EBI-77321, EBI-2340927;
CC       Q9UER7; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-77321, EBI-748621;
CC       Q9UER7; O43791: SPOP; NbExp=5; IntAct=EBI-77321, EBI-743549;
CC       Q9UER7; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-77321, EBI-2212028;
CC       Q9UER7; P40763: STAT3; NbExp=4; IntAct=EBI-77321, EBI-518675;
CC       Q9UER7; P63165: SUMO1; NbExp=7; IntAct=EBI-77321, EBI-80140;
CC       Q9UER7; Q86VP1: TAX1BP1; NbExp=3; IntAct=EBI-77321, EBI-529518;
CC       Q9UER7; Q9NQB0: TCF7L2; NbExp=5; IntAct=EBI-77321, EBI-924724;
CC       Q9UER7; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-77321, EBI-1105213;
CC       Q9UER7; P37173: TGFBR2; NbExp=2; IntAct=EBI-77321, EBI-296151;
CC       Q9UER7; P04637: TP53; NbExp=12; IntAct=EBI-77321, EBI-366083;
CC       Q9UER7; Q99816: TSG101; NbExp=4; IntAct=EBI-77321, EBI-346882;
CC       Q9UER7; P0CG48: UBC; NbExp=2; IntAct=EBI-77321, EBI-3390054;
CC       Q9UER7; P63279: UBE2I; NbExp=3; IntAct=EBI-77321, EBI-80168;
CC       Q9UER7; Q495M9: USH1G; NbExp=3; IntAct=EBI-77321, EBI-8601749;
CC       Q9UER7; Q93009: USP7; NbExp=13; IntAct=EBI-77321, EBI-302474;
CC       Q9UER7; Q8N680: ZBTB2; NbExp=3; IntAct=EBI-77321, EBI-2515601;
CC       Q9UER7; Q9HCK0: ZBTB26; NbExp=3; IntAct=EBI-77321, EBI-3918996;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11495919,
CC       ECO:0000269|PubMed:11842083, ECO:0000269|PubMed:12968034,
CC       ECO:0000269|PubMed:9407001}. Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:10669754, ECO:0000269|PubMed:16845383,
CC       ECO:0000269|PubMed:18566590, ECO:0000269|PubMed:23222847,
CC       ECO:0000269|PubMed:9407001}. Nucleus, PML body
CC       {ECO:0000269|PubMed:10669754, ECO:0000269|PubMed:11842083,
CC       ECO:0000269|PubMed:14990586, ECO:0000269|PubMed:17081986,
CC       ECO:0000269|PubMed:21482821, ECO:0000269|PubMed:23222847,
CC       ECO:0000269|PubMed:24200965, ECO:0000269|PubMed:25275136}. Nucleus,
CC       nucleolus {ECO:0000269|PubMed:23222847}. Chromosome, centromere
CC       {ECO:0000269|PubMed:24200965, ECO:0000269|PubMed:9645950}.
CC       Note=Dispersed throughout the nucleoplasm, in PML/POD/ND10 nuclear
CC       bodies, and in nucleoli (Probable). Colocalizes with histone H3.3,
CC       ATRX, HIRA and ASF1A at PML-nuclear bodies (PubMed:12953102,
CC       PubMed:14990586, PubMed:23222847, PubMed:24200965). Colocalizes with a
CC       subset of interphase centromeres, but is absent from mitotic
CC       centromeres (PubMed:9645950). Detected in cytoplasmic punctate
CC       structures (PubMed:11842083). Translocates from the nucleus to the
CC       cytoplasm upon glucose deprivation or oxidative stress
CC       (PubMed:12968034). Colocalizes with RASSF1 in the nucleus
CC       (PubMed:18566590). Colocalizes with USP7 in nucleoplasma with
CC       accumulation in speckled structures (PubMed:16845383).
CC       {ECO:0000269|PubMed:11842083, ECO:0000269|PubMed:12953102,
CC       ECO:0000269|PubMed:12968034, ECO:0000269|PubMed:14990586,
CC       ECO:0000269|PubMed:16845383, ECO:0000269|PubMed:18566590,
CC       ECO:0000269|PubMed:23222847, ECO:0000269|PubMed:24200965,
CC       ECO:0000269|PubMed:9645950, ECO:0000305|PubMed:10669754}.
CC   -!- SUBCELLULAR LOCATION: [Isoform beta]: Nucleus
CC       {ECO:0000269|PubMed:21482821}. Note=Diffuse nuclear distribution
CC       pattern and no comparable dot-like accumulation of isoform 1.
CC       {ECO:0000269|PubMed:21482821}.
CC   -!- SUBCELLULAR LOCATION: [Isoform gamma]: Nucleus
CC       {ECO:0000269|PubMed:21482821}. Note=Diffuse nuclear distribution
CC       pattern and no comparable dot-like accumulation of isoform 1.
CC       {ECO:0000269|PubMed:21482821}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q9UER7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UER7-2; Sequence=VSP_001270;
CC       Name=3;
CC         IsoId=Q9UER7-3; Sequence=VSP_045588;
CC       Name=beta;
CC         IsoId=Q9UER7-4; Sequence=VSP_057438, VSP_057440;
CC       Name=gamma;
CC         IsoId=Q9UER7-5; Sequence=VSP_057437, VSP_057439;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- INDUCTION: Upon mitogenic stimulation by concanavalin-A.
CC   -!- DOMAIN: The Sumo interaction motif mediates Sumo binding, and is
CC       required both for sumoylation and binding to sumoylated targets.
CC   -!- PTM: Sumoylated with SUMO1 on multiple lysine residues.
CC       {ECO:0000269|PubMed:11842083, ECO:0000269|PubMed:12150977,
CC       ECO:0000269|PubMed:17081986}.
CC   -!- PTM: Phosphorylated by HIPK1 upon glucose deprivation.
CC       {ECO:0000269|PubMed:10393185, ECO:0000269|PubMed:12140263,
CC       ECO:0000269|PubMed:12968034}.
CC   -!- PTM: Polyubiquitinated; which is promoted by CUL3 and SPOP and results
CC       in proteasomal degradation. Ubiquitinated by MDM2; inducing its
CC       degradation. Deubiquitinated by USP7; leading to stabilize it.
CC       {ECO:0000269|PubMed:16524876, ECO:0000269|PubMed:20153724}.
CC   -!- MISCELLANEOUS: [Isoform beta]: Markedly decreased affinity for PML and
CC       TP53/p53, unable to repress p53-mediated transcription. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform gamma]: Markedly decreased affinity for PML and
CC       TP53/p53, unable to repress p53-mediated transcription. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the DAXX family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DAXXID40265ch6p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF039136; AAB92671.1; -; mRNA.
DR   EMBL; AF006041; AAB63043.1; -; mRNA.
DR   EMBL; AF015956; AAB66585.2; -; mRNA.
DR   EMBL; AF050179; AAC39853.1; -; mRNA.
DR   EMBL; AF097742; AAC72843.1; -; mRNA.
DR   EMBL; HQ436528; AEC33235.1; -; mRNA.
DR   EMBL; HQ436529; AEC33236.1; -; mRNA.
DR   EMBL; AB015051; BAA34295.1; -; mRNA.
DR   EMBL; AK303854; BAG64795.1; -; mRNA.
DR   EMBL; CR457085; CAG33366.1; -; mRNA.
DR   EMBL; AL662820; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662827; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX248088; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR759793; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR759786; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR759817; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z97183; CAB09986.2; -; Genomic_DNA.
DR   EMBL; Z97184; CAB09986.2; JOINED; Genomic_DNA.
DR   EMBL; Z97184; CAB09989.2; -; Genomic_DNA.
DR   EMBL; Z97183; CAB09989.2; JOINED; Genomic_DNA.
DR   EMBL; CH471081; EAX03722.1; -; Genomic_DNA.
DR   EMBL; BC000220; AAH00220.1; -; mRNA.
DR   EMBL; BC109073; AAI09074.1; -; mRNA.
DR   EMBL; BC109074; AAI09075.1; -; mRNA.
DR   CCDS; CCDS4776.1; -. [Q9UER7-1]
DR   CCDS; CCDS59008.1; -. [Q9UER7-3]
DR   PIR; T03847; T03847.
DR   RefSeq; NP_001135441.1; NM_001141969.1. [Q9UER7-1]
DR   RefSeq; NP_001241646.1; NM_001254717.1. [Q9UER7-3]
DR   RefSeq; NP_001341.1; NM_001350.4. [Q9UER7-1]
DR   PDB; 2KQS; NMR; -; B=721-740.
DR   PDB; 2KZS; NMR; -; A=55-144.
DR   PDB; 2KZU; NMR; -; A=55-144.
DR   PDB; 4H9N; X-ray; 1.95 A; C=178-389.
DR   PDB; 4H9O; X-ray; 2.05 A; C=178-389.
DR   PDB; 4H9P; X-ray; 2.20 A; C=178-389.
DR   PDB; 4H9Q; X-ray; 1.95 A; C=178-389.
DR   PDB; 4H9R; X-ray; 2.20 A; C=178-389.
DR   PDB; 4H9S; X-ray; 2.60 A; E/F=183-398.
DR   PDB; 4HGA; X-ray; 2.80 A; A=184-390.
DR   PDB; 5GRQ; X-ray; 1.58 A; A=55-144, B=55-143.
DR   PDB; 5KDM; X-ray; 3.50 A; C=178-389.
DR   PDB; 5Y18; X-ray; 2.20 A; A=55-144.
DR   PDB; 5Y6O; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I=50-144.
DR   PDBsum; 2KQS; -.
DR   PDBsum; 2KZS; -.
DR   PDBsum; 2KZU; -.
DR   PDBsum; 4H9N; -.
DR   PDBsum; 4H9O; -.
DR   PDBsum; 4H9P; -.
DR   PDBsum; 4H9Q; -.
DR   PDBsum; 4H9R; -.
DR   PDBsum; 4H9S; -.
DR   PDBsum; 4HGA; -.
DR   PDBsum; 5GRQ; -.
DR   PDBsum; 5KDM; -.
DR   PDBsum; 5Y18; -.
DR   PDBsum; 5Y6O; -.
DR   SMR; Q9UER7; -.
DR   BioGrid; 107985; 248.
DR   CORUM; Q9UER7; -.
DR   DIP; DIP-27628N; -.
DR   IntAct; Q9UER7; 139.
DR   MINT; Q9UER7; -.
DR   STRING; 9606.ENSP00000363668; -.
DR   iPTMnet; Q9UER7; -.
DR   PhosphoSitePlus; Q9UER7; -.
DR   BioMuta; DAXX; -.
DR   DMDM; 24636785; -.
DR   EPD; Q9UER7; -.
DR   jPOST; Q9UER7; -.
DR   MassIVE; Q9UER7; -.
DR   PaxDb; Q9UER7; -.
DR   PeptideAtlas; Q9UER7; -.
DR   PRIDE; Q9UER7; -.
DR   ProteomicsDB; 25260; -.
DR   ProteomicsDB; 84150; -. [Q9UER7-1]
DR   ProteomicsDB; 84151; -. [Q9UER7-2]
DR   Antibodypedia; 1411; 961 antibodies.
DR   DNASU; 1616; -.
DR   Ensembl; ENST00000266000; ENSP00000266000; ENSG00000204209. [Q9UER7-1]
DR   Ensembl; ENST00000374542; ENSP00000363668; ENSG00000204209. [Q9UER7-1]
DR   Ensembl; ENST00000383062; ENSP00000372539; ENSG00000206206. [Q9UER7-1]
DR   Ensembl; ENST00000383194; ENSP00000372681; ENSG00000206279. [Q9UER7-1]
DR   Ensembl; ENST00000399060; ENSP00000382014; ENSG00000206206. [Q9UER7-1]
DR   Ensembl; ENST00000399344; ENSP00000382281; ENSG00000206279. [Q9UER7-1]
DR   Ensembl; ENST00000414083; ENSP00000396876; ENSG00000204209. [Q9UER7-3]
DR   Ensembl; ENST00000433482; ENSP00000404623; ENSG00000231617. [Q9UER7-1]
DR   Ensembl; ENST00000436311; ENSP00000404376; ENSG00000227046. [Q9UER7-1]
DR   Ensembl; ENST00000445009; ENSP00000394108; ENSG00000231617. [Q9UER7-1]
DR   Ensembl; ENST00000455860; ENSP00000410772; ENSG00000227046. [Q9UER7-1]
DR   Ensembl; ENST00000612868; ENSP00000479172; ENSG00000227046. [Q9UER7-3]
DR   Ensembl; ENST00000612888; ENSP00000483394; ENSG00000206206. [Q9UER7-3]
DR   Ensembl; ENST00000613912; ENSP00000477633; ENSG00000206206. [Q9UER7-4]
DR   Ensembl; ENST00000616312; ENSP00000483517; ENSG00000227046. [Q9UER7-4]
DR   Ensembl; ENST00000617660; ENSP00000480448; ENSG00000206279. [Q9UER7-3]
DR   Ensembl; ENST00000619421; ENSP00000478810; ENSG00000206279. [Q9UER7-4]
DR   Ensembl; ENST00000620164; ENSP00000482399; ENSG00000204209. [Q9UER7-4]
DR   Ensembl; ENST00000622655; ENSP00000484830; ENSG00000231617. [Q9UER7-4]
DR   GeneID; 1616; -.
DR   KEGG; hsa:1616; -.
DR   UCSC; uc003oec.4; human. [Q9UER7-1]
DR   UCSC; uc063nwl.1; human.
DR   CTD; 1616; -.
DR   DisGeNET; 1616; -.
DR   GeneCards; DAXX; -.
DR   HGNC; HGNC:2681; DAXX.
DR   HPA; ENSG00000204209; Low tissue specificity.
DR   MalaCards; DAXX; -.
DR   MIM; 603186; gene.
DR   neXtProt; NX_Q9UER7; -.
DR   OpenTargets; ENSG00000204209; -.
DR   Orphanet; 100075; Neuroendocrine tumor of stomach.
DR   PharmGKB; PA27148; -.
DR   eggNOG; ENOG410IGIP; Eukaryota.
DR   eggNOG; ENOG4111K0B; LUCA.
DR   GeneTree; ENSGT00390000009448; -.
DR   HOGENOM; CLU_022811_1_0_1; -.
DR   InParanoid; Q9UER7; -.
DR   KO; K02308; -.
DR   OMA; AMMQDKS; -.
DR   PhylomeDB; Q9UER7; -.
DR   TreeFam; TF325803; -.
DR   BRENDA; 2.7.7.19; 2681.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-9609690; HCMV Early Events.
DR   SignaLink; Q9UER7; -.
DR   SIGNOR; Q9UER7; -.
DR   ChiTaRS; DAXX; human.
DR   EvolutionaryTrace; Q9UER7; -.
DR   GeneWiki; Death-associated_protein_6; -.
DR   GenomeRNAi; 1616; -.
DR   Pharos; Q9UER7; Tbio.
DR   PRO; PR:Q9UER7; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q9UER7; protein.
DR   Bgee; ENSG00000204209; Expressed in testis and 222 other tissues.
DR   ExpressionAtlas; Q9UER7; baseline and differential.
DR   Genevisible; Q9UER7; HS.
DR   GO; GO:0000775; C:chromosome, centromeric region; IDA:CACAO.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0050681; F:androgen receptor binding; IPI:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0031072; F:heat shock protein binding; TAS:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0030295; F:protein kinase activator activity; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0032183; F:SUMO binding; IPI:CAFA.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; TAS:ProtInc.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IDA:UniProtKB.
DR   GO; GO:0071280; P:cellular response to copper ion; IDA:UniProtKB.
DR   GO; GO:0072738; P:cellular response to diamide; IDA:UniProtKB.
DR   GO; GO:0034605; P:cellular response to heat; IDA:UniProtKB.
DR   GO; GO:1903936; P:cellular response to sodium arsenite; IDA:UniProtKB.
DR   GO; GO:0034620; P:cellular response to unfolded protein; IDA:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IDA:UniProtKB.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; TAS:ProtInc.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006334; P:nucleosome assembly; IDA:UniProtKB.
DR   GO; GO:1901216; P:positive regulation of neuron death; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd13151; DAXX_helical_bundle; 1.
DR   DisProt; DP00707; -.
DR   Gene3D; 1.10.8.810; -; 1.
DR   InterPro; IPR005012; Daxx.
DR   InterPro; IPR031333; Daxx_N.
DR   InterPro; IPR038298; Daxx_N_sf.
DR   PANTHER; PTHR12766:SF7; PTHR12766:SF7; 1.
DR   Pfam; PF03344; Daxx; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; Centromere;
KW   Chaperone; Chromatin regulator; Chromosome; Coiled coil; Cytoplasm;
KW   Host-virus interaction; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Reference proteome; Repressor; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..740
FT                   /note="Death domain-associated protein 6"
FT                   /id="PRO_0000151258"
FT   REGION          1..160
FT                   /note="Necessary for interaction with USP7 and ATRX"
FT   REGION          183..417
FT                   /note="Interaction with histone H3.3"
FT   REGION          347..570
FT                   /note="Necessary for interaction with USP7"
FT   REGION          501..625
FT                   /note="Interaction with MAP3K5"
FT   REGION          626..740
FT                   /note="Interaction with SPOP"
FT                   /evidence="ECO:0000269|PubMed:15240113"
FT   REGION          733..740
FT                   /note="Sumo interaction motif (SIM)"
FT   COILED          180..217
FT                   /evidence="ECO:0000255"
FT   COILED          358..399
FT                   /evidence="ECO:0000255"
FT   COILED          430..489
FT                   /evidence="ECO:0000255"
FT   MOTIF           391..395
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOTIF           628..634
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        11..16
FT                   /note="Poly-Asp"
FT   COMPBIAS        434..572
FT                   /note="Asp/Glu-rich (acidic)"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         213
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         412
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         424
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         459
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O35613"
FT   MOD_RES         495
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         498
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VIB2"
FT   MOD_RES         512
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         561
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VIB2"
FT   MOD_RES         580
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VIB2"
FT   MOD_RES         668
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000269|PubMed:12968034"
FT   MOD_RES         671
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336,
FT                   ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:23186163"
FT   MOD_RES         688
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         702
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:16964243,
FT                   ECO:0000244|PubMed:18220336, ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163"
FT   MOD_RES         737
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231"
FT   MOD_RES         739
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231"
FT   CROSSLNK        142
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        630
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000269|PubMed:12150977"
FT   CROSSLNK        631
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000269|PubMed:12150977"
FT   VAR_SEQ         1..75
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045588"
FT   VAR_SEQ         648..682
FT                   /note="YVERQRSVHEKNGKKICTLPSPPSPLASLAPVADS -> PAVPNPPFTASSA
FT                   WYLQDKCGHTMRSRRDHRALRL (in isoform gamma)"
FT                   /evidence="ECO:0000303|PubMed:21482821"
FT                   /id="VSP_057437"
FT   VAR_SEQ         653..688
FT                   /note="RSVHEKNGKKICTLPSPPSPLASLAPVADSSTRVDS -> SPAVPNPPFTAS
FT                   SAWYLQDKCGHTMRSRRDHRALRL (in isoform beta)"
FT                   /evidence="ECO:0000303|PubMed:21482821"
FT                   /id="VSP_057438"
FT   VAR_SEQ         683..740
FT                   /note="Missing (in isoform gamma)"
FT                   /evidence="ECO:0000303|PubMed:21482821"
FT                   /id="VSP_057439"
FT   VAR_SEQ         689..740
FT                   /note="Missing (in isoform beta)"
FT                   /evidence="ECO:0000303|PubMed:21482821"
FT                   /id="VSP_057440"
FT   VAR_SEQ         696..740
FT                   /note="SSLCIPSPARLSQTPHSQPPRPGTCKTSVATQCDPEEIIVLSDSD -> PAK
FT                   NLGRRRSKQDQG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_001270"
FT   MUTAGEN         206
FT                   /note="Q->L: Impairs interaction with histones H3 and H4."
FT                   /evidence="ECO:0000269|PubMed:23075851"
FT   MUTAGEN         220
FT                   /note="S->A: Abolishes interaction with histones H3 and
FT                   H4."
FT                   /evidence="ECO:0000269|PubMed:23075851"
FT   MUTAGEN         222
FT                   /note="Y->A,S: Abolishes interaction with histones H3 and
FT                   H4."
FT                   /evidence="ECO:0000269|PubMed:23075851,
FT                   ECO:0000269|PubMed:23142979"
FT   MUTAGEN         222
FT                   /note="Y->E: Abolishes interaction with histone H3.3."
FT                   /evidence="ECO:0000269|PubMed:23075851,
FT                   ECO:0000269|PubMed:23142979"
FT   MUTAGEN         225
FT                   /note="E->L: Impairs interaction with histones H3 and H4."
FT                   /evidence="ECO:0000269|PubMed:23075851"
FT   MUTAGEN         229
FT                   /note="K->A,L: Impairs interaction with histones H3 and
FT                   H4."
FT                   /evidence="ECO:0000269|PubMed:23075851"
FT   MUTAGEN         251
FT                   /note="R->A: Abolishes interaction with histones H3 and
FT                   H4."
FT                   /evidence="ECO:0000269|PubMed:23075851"
FT   MUTAGEN         317
FT                   /note="F->A: Abolishes interaction with histones H3 and
FT                   H4."
FT                   /evidence="ECO:0000269|PubMed:23075851"
FT   MUTAGEN         328
FT                   /note="R->A: Abolishes interaction with histones H3 and
FT                   H4."
FT                   /evidence="ECO:0000269|PubMed:23075851"
FT   MUTAGEN         331
FT                   /note="D->A: Abolishes interaction with histones H3 and
FT                   H4."
FT                   /evidence="ECO:0000269|PubMed:23075851"
FT   MUTAGEN         630
FT                   /note="K->A: Abolishes sumoylation; when associated with A-
FT                   631."
FT                   /evidence="ECO:0000269|PubMed:12150977"
FT   MUTAGEN         631
FT                   /note="K->A: Abolishes sumoylation; when associated with A-
FT                   630."
FT                   /evidence="ECO:0000269|PubMed:12150977"
FT   MUTAGEN         668
FT                   /note="S->A: No translocation to the cytosol upon glucose
FT                   deprivation."
FT                   /evidence="ECO:0000269|PubMed:12968034"
FT   MUTAGEN         671
FT                   /note="S->A: No effect on cytosol translocation. upon
FT                   glucose deprivation."
FT                   /evidence="ECO:0000269|PubMed:12968034"
FT   MUTAGEN         733..740
FT                   /note="Missing: Abolishes sumoylation."
FT                   /evidence="ECO:0000269|PubMed:17081986"
FT   CONFLICT        177
FT                   /note="Q -> R (in Ref. 2; AAB66585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        263
FT                   /note="R -> H (in Ref. 5; AAC72843)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        323
FT                   /note="R -> W (in Ref. 2; AAB66585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        365
FT                   /note="R -> Q (in Ref. 2; AAB66585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        382
FT                   /note="L -> S (in Ref. 2; AAB66585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        505
FT                   /note="E -> G (in Ref. 8; BAG64795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        647
FT                   /note="S -> R (in Ref. 10; CAB09986/CAB09989)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        722
FT                   /note="T -> A (in Ref. 10; CAB09986/CAB09989)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        731..732
FT                   /note="EE -> KK (in Ref. 5; AAC72843)"
FT                   /evidence="ECO:0000305"
FT   HELIX           60..77
FT                   /evidence="ECO:0000244|PDB:5GRQ"
FT   TURN            78..80
FT                   /evidence="ECO:0000244|PDB:2KZU"
FT   HELIX           84..93
FT                   /evidence="ECO:0000244|PDB:5GRQ"
FT   HELIX           97..100
FT                   /evidence="ECO:0000244|PDB:5GRQ"
FT   HELIX           103..118
FT                   /evidence="ECO:0000244|PDB:5GRQ"
FT   HELIX           120..122
FT                   /evidence="ECO:0000244|PDB:5GRQ"
FT   HELIX           123..136
FT                   /evidence="ECO:0000244|PDB:5GRQ"
FT   STRAND          138..140
FT                   /evidence="ECO:0000244|PDB:2KZS"
FT   HELIX           185..206
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   HELIX           214..216
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   HELIX           221..242
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   HELIX           252..254
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   HELIX           265..275
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   STRAND          278..280
FT                   /evidence="ECO:0000244|PDB:4H9S"
FT   HELIX           286..299
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   HELIX           306..333
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   HELIX           339..341
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   HELIX           346..348
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   HELIX           350..353
FT                   /evidence="ECO:0000244|PDB:4H9N"
FT   HELIX           355..384
FT                   /evidence="ECO:0000244|PDB:4H9N"
SQ   SEQUENCE   740 AA;  81373 MW;  1B309ADDAA878040 CRC64;
     MATANSIIVL DDDDEDEAAA QPGPSHPLPN AASPGAEAPS SSEPHGARGS SSSGGKKCYK
     LENEKLFEEF LELCKMQTAD HPEVVPFLYN RQQRAHSLFL ASAEFCNILS RVLSRARSRP
     AKLYVYINEL CTVLKAHSAK KKLNLAPAAT TSNEPSGNNP PTHLSLDPTN AENTASQSPR
     TRGSRRQIQR LEQLLALYVA EIRRLQEKEL DLSELDDPDS AYLQEARLKR KLIRLFGRLC
     ELKDCSSLTG RVIEQRIPYR GTRYPEVNRR IERLINKPGP DTFPDYGDVL RAVEKAAARH
     SLGLPRQQLQ LMAQDAFRDV GIRLQERRHL DLIYNFGCHL TDDYRPGVDP ALSDPVLARR
     LRENRSLAMS RLDEVISKYA MLQDKSEEGE RKKRRARLQG TSSHSADTPE ASLDSGEGPS
     GMASQGCPSA SRAETDDEDD EESDEEEEEE EEEEEEEATD SEEEEDLEQM QEGQEDDEEE
     DEEEEAAAGK DGDKSPMSSL QISNEKNLEP GKQISRSSGE QQNKGRIVSP SLLSEEPLAP
     SSIDAESNGE QPEELTLEEE SPVSQLFELE IEALPLDTPS SVETDISSSR KQSEEPFTTV
     LENGAGMVSS TSFNGGVSPH NWGDSGPPCK KSRKEKKQTG SGPLGNSYVE RQRSVHEKNG
     KKICTLPSPP SPLASLAPVA DSSTRVDSPS HGLVTSSLCI PSPARLSQTP HSQPPRPGTC
     KTSVATQCDP EEIIVLSDSD
//
ID   DDB2_HUMAN              Reviewed;         427 AA.
AC   Q92466; B2R875; Q76E54; Q76E55; Q76E56; Q76E57;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1997, sequence version 1.
DT   22-APR-2020, entry version 199.
DE   RecName: Full=DNA damage-binding protein 2;
DE   AltName: Full=DDB p48 subunit;
DE            Short=DDBb;
DE   AltName: Full=Damage-specific DNA-binding protein 2;
DE   AltName: Full=UV-damaged DNA-binding protein 2;
DE            Short=UV-DDB 2;
GN   Name=DDB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Epidermis;
RX   PubMed=8530102; DOI=10.1006/geno.1995.1215;
RA   Dualan R., Brody T., Keeney S., Nichols A.F., Admon A., Linn S.;
RT   "Chromosomal localization and cDNA cloning of the genes (DDB1 and DDB2) for
RT   the p127 and p48 subunits of a human damage-specific DNA binding protein.";
RL   Genomics 29:62-69(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS D1; D2; D3 AND D4), FUNCTION,
RP   INTERACTION WITH DDB1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Epithelium;
RX   PubMed=14751237; DOI=10.1016/j.bbrc.2004.01.003;
RA   Inoki T., Yamagami S., Inoki Y., Tsuru T., Hamamoto T., Kagawa Y., Mori T.,
RA   Endo H.;
RT   "Human DDB2 splicing variants are dominant negative inhibitors of UV-
RT   damaged DNA repair.";
RL   Biochem. Biophys. Res. Commun. 314:1036-1043(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-215 AND THR-293.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH DDB1, DNA-BINDING, AND CHARACTERIZATION OF VARIANTS
RP   GLU-244 AND HIS-273.
RX   PubMed=9632823; DOI=10.1128/mcb.18.7.4391;
RA   Hwang B.J., Toering S., Francke U., Chu G.;
RT   "p48 Activates a UV-damaged-DNA binding factor and is defective in
RT   xeroderma pigmentosum group E cells that lack binding activity.";
RL   Mol. Cell. Biol. 18:4391-4399(1998).
RN   [9]
RP   FUNCTION, AND DNA-BINDING.
RX   PubMed=9892649; DOI=10.1073/pnas.96.2.424;
RA   Hwang B.J., Ford J.M., Hanawalt P.C., Chu G.;
RT   "Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is
RT   involved in global genomic repair.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:424-428(1999).
RN   [10]
RP   DNA-BINDING, SUBCELLULAR LOCATION, INDUCTION, AND CHARACTERIZATION OF
RP   VARIANTS GLU-244 AND HIS-273.
RX   PubMed=10777490; DOI=10.1074/jbc.m000960200;
RA   Nichols A.F., Itoh T., Graham J.A., Liu W., Yamaizumi M., Linn S.;
RT   "Human damage-specific DNA-binding protein p48. Characterization of XPE
RT   mutations and regulation following UV irradiation.";
RL   J. Biol. Chem. 275:21422-21428(2000).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10777491; DOI=10.1074/jbc.m000961200;
RA   Liu W., Nichols A.F., Graham J.A., Dualan R., Abbas A., Linn S.;
RT   "Nuclear transport of human DDB protein induced by ultraviolet light.";
RL   J. Biol. Chem. 275:21429-21434(2000).
RN   [12]
RP   FUNCTION.
RX   PubMed=10882109; DOI=10.1016/s1097-2765(00)80252-x;
RA   Tang J.Y., Hwang B.J., Ford J.M., Hanawalt P.C., Chu G.;
RT   "Xeroderma pigmentosum p48 gene enhances global genomic repair and
RT   suppresses UV-induced mutagenesis.";
RL   Mol. Cell 5:737-744(2000).
RN   [13]
RP   FUNCTION, AND DNA-BINDING.
RX   PubMed=11278856; DOI=10.1074/jbc.m011177200;
RA   Wakasugi M., Shimizu M., Morioka H., Linn S., Nikaido O., Matsunaga T.;
RT   "Damaged DNA-binding protein DDB stimulates the excision of cyclobutane
RT   pyrimidine dimers in vitro in concert with XPA and replication protein A.";
RL   J. Biol. Chem. 276:15434-15440(2001).
RN   [14]
RP   INTERACTION WITH CUL4A, UBIQUITINATION, AND CHARACTERIZATION OF VARIANT
RP   HIS-273.
RX   PubMed=11673459; DOI=10.1074/jbc.m106808200;
RA   Chen X., Zhang Y., Douglas L., Zhou P.;
RT   "UV-damaged DNA-binding proteins are targets of CUL-4A-mediated
RT   ubiquitination and degradation.";
RL   J. Biol. Chem. 276:48175-48182(2001).
RN   [15]
RP   FUNCTION, DNA-BINDING, AND SUBCELLULAR LOCATION.
RX   PubMed=11705987; DOI=10.1074/jbc.c100610200;
RA   Wakasugi M., Kawashima A., Morioka H., Linn S., Sancar A., Mori T.,
RA   Nikaido O., Matsunaga T.;
RT   "DDB accumulates at DNA damage sites immediately after UV irradiation and
RT   directly stimulates nucleotide excision repair.";
RL   J. Biol. Chem. 277:1637-1640(2002).
RN   [16]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN A COMPLEX
RP   WITH CUL4A; DDB1 AND RBX1 AND THE COP9 SIGNALOSOME, AND DNA-BINDING.
RX   PubMed=12732143; DOI=10.1016/s0092-8674(03)00316-7;
RA   Groisman R., Polanowska J., Kuraoka I., Sawada J., Saijo M., Drapkin R.,
RA   Kisselev A.F., Tanaka K., Nakatani Y.;
RT   "The ubiquitin ligase activity in the DDB2 and CSA complexes is
RT   differentially regulated by the COP9 signalosome in response to DNA
RT   damage.";
RL   Cell 113:357-367(2003).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12944386; DOI=10.1074/jbc.m307254200;
RA   Fitch M.E., Nakajima S., Yasui A., Ford J.M.;
RT   "In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by
RT   the DDB2 gene product.";
RL   J. Biol. Chem. 278:46906-46910(2003).
RN   [18]
RP   FUNCTION, INTERACTION WITH CUL4A; DDB1; RBX1 AND XPC, DNA-BINDING, AND
RP   UBIQUITINATION.
RX   PubMed=15882621; DOI=10.1016/j.cell.2005.02.035;
RA   Sugasawa K., Okuda Y., Saijo M., Nishi R., Matsuda N., Chu G., Mori T.,
RA   Iwai S., Tanaka K., Tanaka K., Hanaoka F.;
RT   "UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin
RT   ligase complex.";
RL   Cell 121:387-400(2005).
RN   [19]
RP   INTERACTION WITH DDB1, DNA-BINDING, AND CHARACTERIZATION OF VARIANTS
RP   GLU-244 AND HIS-273.
RX   PubMed=16223728; DOI=10.1074/jbc.m507854200;
RA   Wittschieben B.O., Iwai S., Wood R.D.;
RT   "DDB1-DDB2 (xeroderma pigmentosum group E) protein complex recognizes a
RT   cyclobutane pyrimidine dimer, mismatches, apurinic/apyrimidinic sites, and
RT   compound lesions in DNA.";
RL   J. Biol. Chem. 280:39982-39989(2005).
RN   [20]
RP   FUNCTION, INTERACTION WITH CUL4A; DDB1; RBX1 AND THE COP9 SIGNALOSOME, AND
RP   DNA-BINDING.
RX   PubMed=16260596; DOI=10.1128/mcb.25.22.9784-9792.2005;
RA   Kulaksiz G., Reardon J.T., Sancar A.;
RT   "Xeroderma pigmentosum complementation group E protein (XPE/DDB2):
RT   purification of various complexes of XPE and analyses of their damaged DNA
RT   binding and putative DNA repair properties.";
RL   Mol. Cell. Biol. 25:9784-9792(2005).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24 AND SER-26, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [22]
RP   INTERACTION WITH CUL4A AND DDB1, DOMAIN DWD BOX MOTIF, AND MUTAGENESIS OF
RP   LEU-258; SER-262; ASP-264; ILE-269; TRP-270; LEU-272 AND ARG-273.
RX   PubMed=17079684; DOI=10.1101/gad.1483206;
RA   He Y.J., McCall C.M., Hu J., Zeng Y., Xiong Y.;
RT   "DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1
RT   ubiquitin ligases.";
RL   Genes Dev. 20:2949-2954(2006).
RN   [23]
RP   INTERACTION WITH CUL4A AND DDB1, AND UBIQUITINATION.
RX   PubMed=16527807; DOI=10.1074/jbc.m511834200;
RA   El-Mahdy M.A., Zhu Q., Wang Q.-E., Wani G., Praetorius-Ibba M., Wani A.A.;
RT   "Cullin 4A-mediated proteolysis of DDB2 protein at DNA damage sites
RT   regulates in vivo lesion recognition by XPC.";
RL   J. Biol. Chem. 281:13404-13411(2006).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN A COMPLEX WITH DDB1;
RP   CUL4A; CUL4B AND RBX1, AND FUNCTION.
RX   PubMed=16678110; DOI=10.1016/j.molcel.2006.03.035;
RA   Wang H., Zhai L., Xu J., Joo H.-Y., Jackson S., Erdjument-Bromage H.,
RA   Tempst P., Xiong Y., Zhang Y.;
RT   "Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase
RT   facilitates cellular response to DNA damage.";
RL   Mol. Cell 22:383-394(2006).
RN   [25]
RP   SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=16713579; DOI=10.1016/j.molcel.2006.04.021;
RA   Chen X., Zhang J., Lee J., Lin P.S., Ford J.M., Zheng N., Zhou P.;
RT   "A kinase-independent function of c-Abl in promoting proteolytic
RT   destruction of damaged DNA binding proteins.";
RL   Mol. Cell 22:489-499(2006).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH DDB1, MUTAGENESIS OF
RP   LEU-350, AND CHARACTERIZATION OF VARIANT HIS-273.
RX   PubMed=16949367; DOI=10.1016/j.molcel.2006.08.010;
RA   Jin J., Arias E.E., Chen J., Harper J.W., Walter J.C.;
RT   "A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is
RT   required for S phase destruction of the replication factor Cdt1.";
RL   Mol. Cell 23:709-721(2006).
RN   [27]
RP   INTERACTION WITH DDB1, AND CHARACTERIZATION OF VARIANT HIS-273.
RX   PubMed=16964240; DOI=10.1038/nature05175;
RA   Angers S., Li T., Yi X., MacCoss M.J., Moon R.T., Zheng N.;
RT   "Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase
RT   machinery.";
RL   Nature 443:590-593(2006).
RN   [28]
RP   INTERACTION WITH CUL4A AND CUL4B.
RX   PubMed=17041588; DOI=10.1038/ncb1490;
RA   Higa L.A., Wu M., Ye T., Kobayashi R., Sun H., Zhang H.;
RT   "CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins
RT   and regulates histone methylation.";
RL   Nat. Cell Biol. 8:1277-1283(2006).
RN   [29]
RP   FUNCTION, INTERACTION WITH CUL4A; DDB1; HISTONE H2A AND RBX1, DNA-BINDING,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=16473935; DOI=10.1073/pnas.0511160103;
RA   Kapetanaki M.G., Guerrero-Santoro J., Bisi D.C., Hsieh C.L.,
RA   Rapic-Otrin V., Levine A.S.;
RT   "The DDB1-CUL4ADDB2 ubiquitin ligase is deficient in xeroderma pigmentosum
RT   group E and targets histone H2A at UV-damaged DNA sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:2588-2593(2006).
RN   [30]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17635991; DOI=10.1242/jcs.008367;
RA   Luijsterburg M.S., Goedhart J., Moser J., Kool H., Geverts B.,
RA   Houtsmuller A.B., Mullenders L.H.F., Vermeulen W., van Driel R.;
RT   "Dynamic in vivo interaction of DDB2 E3 ubiquitin ligase with UV-damaged
RT   DNA is independent of damage-recognition protein XPC.";
RL   J. Cell Sci. 120:2706-2716(2007).
RN   [31]
RP   FUNCTION, INTERACTION WITH CUL4A; CUL4B AND DDB1, AND SUBCELLULAR LOCATION.
RX   PubMed=18593899; DOI=10.1158/0008-5472.can-07-6162;
RA   Guerrero-Santoro J., Kapetanaki M.G., Hsieh C.L., Gorbachinsky I.,
RA   Levine A.S., Rapic-Otrin V.;
RT   "The cullin 4B-based UV-damaged DNA-binding protein ligase binds to UV-
RT   damaged chromatin and ubiquitinates histone H2A.";
RL   Cancer Res. 68:5014-5022(2008).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [36]
RP   DEUBIQUITINATION BY USP24.
RX   PubMed=23159851; DOI=10.4161/cc.22688;
RA   Zhang L., Lubin A., Chen H., Sun Z., Gong F.;
RT   "The deubiquitinating protein USP24 interacts with DDB2 and regulates DDB2
RT   stability.";
RL   Cell Cycle 11:4378-4384(2012).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24 AND SER-26, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 10-427 IN COMPLEX WITH DDB1 AND
RP   DNA, AND WD REPEATS.
RX   PubMed=19109893; DOI=10.1016/j.cell.2008.10.045;
RA   Scrima A., Konickova R., Czyzewski B.K., Kawasaki Y., Jeffrey P.D.,
RA   Groisman R., Nakatani Y., Iwai S., Pavletich N.P., Thoma N.H.;
RT   "Structural basis of UV DNA-damage recognition by the DDB1-DDB2 complex.";
RL   Cell 135:1213-1223(2008).
RN   [39]
RP   FUNCTION.
RX   PubMed=26572825; DOI=10.1128/mcb.00809-15;
RA   Matsunuma R., Niida H., Ohhata T., Kitagawa K., Sakai S., Uchida C.,
RA   Shiotani B., Matsumoto M., Nakayama K.I., Ogura H., Shiiya N., Kitagawa M.;
RT   "UV damage-induced phosphorylation of HBO1 triggers CRL4DDB2-mediated
RT   degradation to regulate cell proliferation.";
RL   Mol. Cell. Biol. 36:394-406(2016).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 68-81 IN COMPLEX WITH DDB1.
RX   PubMed=19966799; DOI=10.1038/nsmb.1719;
RA   Li T., Robert E.I., van Breugel P.C., Strubin M., Zheng N.;
RT   "A promiscuous alpha-helical motif anchors viral hijackers and substrate
RT   receptors to the CUL4-DDB1 ubiquitin ligase machinery.";
RL   Nat. Struct. Mol. Biol. 17:105-111(2010).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) IN COMPLEX WITH DDB1.
RX   PubMed=22822215; DOI=10.1073/pnas.1110067109;
RA   Yeh J.I., Levine A.S., Du S., Chinte U., Ghodke H., Wang H., Shi H.,
RA   Hsieh C.L., Conway J.F., Van Houten B., Rapic-Otrin V.;
RT   "Damaged DNA induced UV-damaged DNA-binding protein (UV-DDB) dimerization
RT   and its roles in chromatinized DNA repair.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:E2737-E2746(2012).
RN   [42]
RP   VARIANTS XP-E GLU-244 AND HIS-273.
RX   PubMed=8798680; DOI=10.1074/jbc.271.40.24317;
RA   Nichols A.F., Ong P., Linn S.;
RT   "Mutations specific to the xeroderma pigmentosum group E Ddb-phenotype.";
RL   J. Biol. Chem. 271:24317-24320(1996).
CC   -!- FUNCTION: Protein, which is both involved in DNA repair and protein
CC       ubiquitination, as part of the UV-DDB complex and DCX (DDB1-CUL4-X-box)
CC       complexes, respectively (PubMed:10882109, PubMed:11278856,
CC       PubMed:11705987, PubMed:9892649, PubMed:12732143, PubMed:15882621,
CC       PubMed:16473935, PubMed:18593899). Core component of the UV-DDB complex
CC       (UV-damaged DNA-binding protein complex), a complex that recognizes UV-
CC       induced DNA damage and recruit proteins of the nucleotide excision
CC       repair pathway (the NER pathway) to initiate DNA repair
CC       (PubMed:10882109, PubMed:11278856, PubMed:11705987, PubMed:16260596,
CC       PubMed:12944386, PubMed:14751237). The UV-DDB complex preferentially
CC       binds to cyclobutane pyrimidine dimers (CPD), 6-4 photoproducts (6-4
CC       PP), apurinic sites and short mismatches (PubMed:10882109,
CC       PubMed:11278856, PubMed:11705987, PubMed:16260596, PubMed:12944386).
CC       Also functions as the substrate recognition module for the DCX (DDB2-
CC       CUL4-X-box) E3 ubiquitin-protein ligase complex DDB2-CUL4-ROC1 (also
CC       known as CUL4-DDB-ROC1 and CUL4-DDB-RBX1) (PubMed:12732143,
CC       PubMed:15882621, PubMed:16473935, PubMed:18593899, PubMed:26572825).
CC       The DDB2-CUL4-ROC1 complex may ubiquitinate histone H2A, histone H3 and
CC       histone H4 at sites of UV-induced DNA damage (PubMed:16678110,
CC       PubMed:16473935). The ubiquitination of histones may facilitate their
CC       removal from the nucleosome and promote subsequent DNA repair
CC       (PubMed:16678110, PubMed:16473935). The DDB2-CUL4-ROC1 complex also
CC       ubiquitinates XPC, which may enhance DNA-binding by XPC and promote NER
CC       (PubMed:15882621). The DDB2-CUL4-ROC1 complex also ubiquitinates
CC       KAT7/HBO1 in response to DNA damage, leading to its degradation:
CC       recognizes KAT7/HBO1 following phosphorylation by ATR
CC       (PubMed:26572825). {ECO:0000269|PubMed:10882109,
CC       ECO:0000269|PubMed:11278856, ECO:0000269|PubMed:11705987,
CC       ECO:0000269|PubMed:12732143, ECO:0000269|PubMed:12944386,
CC       ECO:0000269|PubMed:14751237, ECO:0000269|PubMed:15882621,
CC       ECO:0000269|PubMed:16260596, ECO:0000269|PubMed:16473935,
CC       ECO:0000269|PubMed:16678110, ECO:0000269|PubMed:18593899,
CC       ECO:0000269|PubMed:26572825, ECO:0000269|PubMed:9892649}.
CC   -!- FUNCTION: [Isoform D1]: Inhibits UV-damaged DNA repair.
CC       {ECO:0000269|PubMed:14751237}.
CC   -!- FUNCTION: [Isoform D2]: Inhibits UV-damaged DNA repair.
CC       {ECO:0000269|PubMed:14751237}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Component of the UV-DDB complex which includes DDB1 and DDB2.
CC       The UV-DDB complex interacts with monoubiquitinated histone H2A and
CC       binds to XPC via the DDB2 subunit. Component of the DCX (DDB1-CUL4-X-
CC       box) E3 ubiquitin-protein ligase complex DDB1-CUL4-ROC1 (also known as
CC       CUL4-DDB-ROC1 and CUL4-DDB-RBX1), which includes CUL4A or CUL4B, DDB1,
CC       DDB2 and RBX1. DDB2 may function as the substrate recognition module
CC       within this complex. The DDB1-CUL4-ROC1 complex may associate with the
CC       COP9 signalosome, and this inhibits the E3 ubiquitin-protein ligase
CC       activity of the complex. A large number of other DCX complexes may also
CC       exist in which an alternate substrate targeting subunit replaces DDB2.
CC       These targeting subunits are generally known as DCAF (DDB1- and CUL4-
CC       associated factor) or CDW (CUL4-DDB1-associated WD40-repeat) proteins.
CC       Isoform D1 and isoform D2 do not interact with DDB1.
CC       {ECO:0000269|PubMed:11673459, ECO:0000269|PubMed:12732143,
CC       ECO:0000269|PubMed:14751237, ECO:0000269|PubMed:15882621,
CC       ECO:0000269|PubMed:16223728, ECO:0000269|PubMed:16260596,
CC       ECO:0000269|PubMed:16473935, ECO:0000269|PubMed:16527807,
CC       ECO:0000269|PubMed:16678110, ECO:0000269|PubMed:16949367,
CC       ECO:0000269|PubMed:16964240, ECO:0000269|PubMed:17041588,
CC       ECO:0000269|PubMed:17079684, ECO:0000269|PubMed:18593899,
CC       ECO:0000269|PubMed:19109893, ECO:0000269|PubMed:19966799,
CC       ECO:0000269|PubMed:22822215, ECO:0000269|PubMed:9632823}.
CC   -!- INTERACTION:
CC       Q92466; Q13619: CUL4A; NbExp=10; IntAct=EBI-1176171, EBI-456106;
CC       Q92466; Q16531: DDB1; NbExp=20; IntAct=EBI-1176171, EBI-350322;
CC       Q92466; Q01094: E2F1; NbExp=2; IntAct=EBI-1176171, EBI-448924;
CC       Q92466; Q01831-1: XPC; NbExp=4; IntAct=EBI-1176171, EBI-15950383;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10777490,
CC       ECO:0000269|PubMed:10777491, ECO:0000269|PubMed:11705987,
CC       ECO:0000269|PubMed:12944386, ECO:0000269|PubMed:14751237,
CC       ECO:0000269|PubMed:16473935, ECO:0000269|PubMed:16713579,
CC       ECO:0000269|PubMed:17635991, ECO:0000269|PubMed:18593899}.
CC       Note=Accumulates at sites of DNA damage following UV irradiation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q92466-1; Sequence=Displayed;
CC       Name=D1;
CC         IsoId=Q92466-2; Sequence=VSP_014675;
CC       Name=D2;
CC         IsoId=Q92466-3; Sequence=VSP_014676, VSP_014677;
CC       Name=D3;
CC         IsoId=Q92466-4; Sequence=VSP_014674;
CC       Name=D4;
CC         IsoId=Q92466-5; Sequence=VSP_014678, VSP_014679;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed; with highest levels in
CC       corneal endothelium and lowest levels in brain. Isoform D1 is highly
CC       expressed in brain and heart. Isoform D2, isoform D3 and isoform D4 are
CC       weakly expressed. {ECO:0000269|PubMed:14751237}.
CC   -!- INDUCTION: Expression is induced in response to treatment with IR or UV
CC       and this requires p53/TP53 activity. {ECO:0000269|PubMed:10777490}.
CC   -!- DOMAIN: The DWD box is required for interaction with DDB1.
CC       {ECO:0000269|PubMed:17079684}.
CC   -!- DOMAIN: Interblade loops of the WD repeat region mediate most of the
CC       interaction with DNA. A hairpin between blades 5 and 6 inserts into DNA
CC       minor groove and mediates recognition of lesions and separation of the
CC       damaged and undamaged strands. {ECO:0000269|PubMed:17079684}.
CC   -!- PTM: Phosphorylation by ABL1 negatively regulate UV-DDB activity.
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by CUL4A in response to UV irradiation.
CC       Ubiquitination appears to both impair DNA-binding and promotes
CC       ubiquitin-dependent proteolysis. Degradation of DDB2 at sites of DNA
CC       damage may be a prerequisite for their recognition by XPC and
CC       subsequent repair. CUL4A-mediated degradation appears to be promoted by
CC       ABL1. {ECO:0000269|PubMed:23159851}.
CC   -!- PTM: Ubiquitinated, leading to proteasomal degradation, and
CC       deubiquitinated by USP24. {ECO:0000269|PubMed:23159851}.
CC   -!- DISEASE: Xeroderma pigmentosum complementation group E (XP-E)
CC       [MIM:278740]: An autosomal recessive pigmentary skin disorder
CC       characterized by solar hypersensitivity of the skin, high
CC       predisposition for developing cancers on areas exposed to sunlight and,
CC       in some cases, neurological abnormalities. The skin develops marked
CC       freckling and other pigmentation abnormalities. XP-E patients show a
CC       mild phenotype with minimal or no neurologic features.
CC       {ECO:0000269|PubMed:8798680}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the WD repeat DDB2/WDR76 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/XPEID298.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ddb2/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U18300; AAB07897.1; -; mRNA.
DR   EMBL; AB107037; BAD12557.1; -; mRNA.
DR   EMBL; AB107038; BAD12558.1; -; mRNA.
DR   EMBL; AB107039; BAD12559.1; -; mRNA.
DR   EMBL; AB107040; BAD12560.1; -; mRNA.
DR   EMBL; BT007139; AAP35803.1; -; mRNA.
DR   EMBL; AY220533; AAO25655.1; -; Genomic_DNA.
DR   EMBL; AK313262; BAG36072.1; -; mRNA.
DR   EMBL; CH471064; EAW67952.1; -; Genomic_DNA.
DR   EMBL; BC000093; AAH00093.1; -; mRNA.
DR   CCDS; CCDS73284.1; -. [Q92466-2]
DR   CCDS; CCDS7927.1; -. [Q92466-1]
DR   PIR; I38909; I38909.
DR   RefSeq; NP_000098.1; NM_000107.2. [Q92466-1]
DR   RefSeq; NP_001287663.1; NM_001300734.1. [Q92466-2]
DR   PDB; 3EI4; X-ray; 3.30 A; B/D/F=10-427.
DR   PDB; 3I7L; X-ray; 2.80 A; B=68-81.
DR   PDB; 4E54; X-ray; 2.85 A; B=2-427.
DR   PDB; 4E5Z; X-ray; 3.22 A; B=2-427.
DR   PDB; 6R8Y; EM; 4.30 A; L=1-427.
DR   PDB; 6R8Z; EM; 3.90 A; L=1-427.
DR   PDB; 6R90; EM; 4.50 A; L=1-427.
DR   PDB; 6R91; EM; 4.10 A; L=1-427.
DR   PDB; 6R92; EM; 4.80 A; L=1-427.
DR   PDBsum; 3EI4; -.
DR   PDBsum; 3I7L; -.
DR   PDBsum; 4E54; -.
DR   PDBsum; 4E5Z; -.
DR   PDBsum; 6R8Y; -.
DR   PDBsum; 6R8Z; -.
DR   PDBsum; 6R90; -.
DR   PDBsum; 6R91; -.
DR   PDBsum; 6R92; -.
DR   SMR; Q92466; -.
DR   BioGrid; 108010; 103.
DR   ComplexPortal; CPX-308; UV DNA damage recognition complex DBB1-DBB2.
DR   ComplexPortal; CPX-477; CRL4-DDB2 E3 ubiquitin ligase complex, CUL4A variant.
DR   ComplexPortal; CPX-648; CRL4-DDB2 E3 ubiquitin ligase complex, CUL4B variant.
DR   CORUM; Q92466; -.
DR   DIP; DIP-36670N; -.
DR   IntAct; Q92466; 49.
DR   STRING; 9606.ENSP00000256996; -.
DR   iPTMnet; Q92466; -.
DR   PhosphoSitePlus; Q92466; -.
DR   BioMuta; DDB2; -.
DR   DMDM; 12230033; -.
DR   EPD; Q92466; -.
DR   jPOST; Q92466; -.
DR   MassIVE; Q92466; -.
DR   MaxQB; Q92466; -.
DR   PaxDb; Q92466; -.
DR   PeptideAtlas; Q92466; -.
DR   PRIDE; Q92466; -.
DR   ProteomicsDB; 75255; -. [Q92466-1]
DR   ProteomicsDB; 75256; -. [Q92466-2]
DR   ProteomicsDB; 75257; -. [Q92466-3]
DR   ProteomicsDB; 75258; -. [Q92466-4]
DR   ProteomicsDB; 75259; -. [Q92466-5]
DR   Antibodypedia; 13582; 257 antibodies.
DR   DNASU; 1643; -.
DR   Ensembl; ENST00000256996; ENSP00000256996; ENSG00000134574. [Q92466-1]
DR   Ensembl; ENST00000378600; ENSP00000367863; ENSG00000134574. [Q92466-2]
DR   Ensembl; ENST00000378601; ENSP00000367864; ENSG00000134574. [Q92466-5]
DR   Ensembl; ENST00000378603; ENSP00000367866; ENSG00000134574. [Q92466-4]
DR   Ensembl; ENST00000616278; ENSP00000478411; ENSG00000134574. [Q92466-3]
DR   GeneID; 1643; -.
DR   KEGG; hsa:1643; -.
DR   UCSC; uc001neb.3; human. [Q92466-1]
DR   CTD; 1643; -.
DR   DisGeNET; 1643; -.
DR   GeneCards; DDB2; -.
DR   GeneReviews; DDB2; -.
DR   HGNC; HGNC:2718; DDB2.
DR   HPA; ENSG00000134574; Low tissue specificity.
DR   MalaCards; DDB2; -.
DR   MIM; 278740; phenotype.
DR   MIM; 600811; gene.
DR   neXtProt; NX_Q92466; -.
DR   OpenTargets; ENSG00000134574; -.
DR   Orphanet; 910; Xeroderma pigmentosum.
DR   PharmGKB; PA27188; -.
DR   eggNOG; ENOG410IMQS; Eukaryota.
DR   eggNOG; COG2319; LUCA.
DR   GeneTree; ENSGT00510000047881; -.
DR   HOGENOM; CLU_036401_1_0_1; -.
DR   InParanoid; Q92466; -.
DR   KO; K10140; -.
DR   OMA; FIKGKGP; -.
DR   OrthoDB; 559605at2759; -.
DR   PhylomeDB; Q92466; -.
DR   TreeFam; TF331587; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5696394; DNA Damage Recognition in GG-NER.
DR   Reactome; R-HSA-5696395; Formation of Incision Complex in GG-NER.
DR   Reactome; R-HSA-5696400; Dual Incision in GG-NER.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   SignaLink; Q92466; -.
DR   SIGNOR; Q92466; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; DDB2; human.
DR   EvolutionaryTrace; Q92466; -.
DR   GeneWiki; DDB2; -.
DR   GenomeRNAi; 1643; -.
DR   Pharos; Q92466; Tbio.
DR   PRO; PR:Q92466; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q92466; protein.
DR   Bgee; ENSG00000134574; Expressed in skin of abdomen and 183 other tissues.
DR   ExpressionAtlas; Q92466; baseline and differential.
DR   Genevisible; Q92466; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0080008; C:Cul4-RING E3 ubiquitin ligase complex; IMP:UniProtKB.
DR   GO; GO:0031465; C:Cul4B-RING E3 ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; TAS:ProtInc.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IBA:GO_Central.
DR   GO; GO:0070911; P:global genome nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0035518; P:histone H2A monoubiquitination; IDA:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; TAS:ProtInc.
DR   GO; GO:0000715; P:nucleotide-excision repair, DNA damage recognition; TAS:Reactome.
DR   GO; GO:0000717; P:nucleotide-excision repair, DNA duplex unwinding; TAS:Reactome.
DR   GO; GO:0033683; P:nucleotide-excision repair, DNA incision; TAS:Reactome.
DR   GO; GO:0006295; P:nucleotide-excision repair, DNA incision, 3'-to lesion; TAS:Reactome.
DR   GO; GO:0006296; P:nucleotide-excision repair, DNA incision, 5'-to lesion; TAS:Reactome.
DR   GO; GO:0006294; P:nucleotide-excision repair, preincision complex assembly; TAS:Reactome.
DR   GO; GO:0006293; P:nucleotide-excision repair, preincision complex stabilization; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0006290; P:pyrimidine dimer repair; IEA:Ensembl.
DR   GO; GO:0009411; P:response to UV; IDA:UniProtKB.
DR   GO; GO:0070914; P:UV-damage excision repair; IDA:UniProtKB.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR033312; DDB2.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   PANTHER; PTHR15169; PTHR15169; 1.
DR   Pfam; PF00400; WD40; 1.
DR   SMART; SM00320; WD40; 5.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 1.
DR   PROSITE; PS50082; WD_REPEATS_2; 1.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Disease mutation; DNA damage;
KW   DNA repair; DNA-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Ubl conjugation; Ubl conjugation pathway;
KW   WD repeat; Xeroderma pigmentosum.
FT   CHAIN           1..427
FT                   /note="DNA damage-binding protein 2"
FT                   /id="PRO_0000050953"
FT   REPEAT          116..151
FT                   /note="WD 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00221,
FT                   ECO:0000269|PubMed:19109893"
FT   REPEAT          159..194
FT                   /note="WD 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00221,
FT                   ECO:0000269|PubMed:19109893"
FT   REPEAT          203..238
FT                   /note="WD 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00221,
FT                   ECO:0000269|PubMed:19109893"
FT   REPEAT          244..287
FT                   /note="WD 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00221,
FT                   ECO:0000269|PubMed:19109893"
FT   REPEAT          290..329
FT                   /note="WD 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00221,
FT                   ECO:0000269|PubMed:19109893"
FT   REPEAT          343..386
FT                   /note="WD 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00221,
FT                   ECO:0000269|PubMed:19109893"
FT   REPEAT          396..420
FT                   /note="WD 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00221,
FT                   ECO:0000269|PubMed:19109893"
FT   REGION          68..79
FT                   /note="Required for interaction with DDB1"
FT   REGION          87..98
FT                   /note="Required for interaction with DDB1"
FT   REGION          334..336
FT                   /note="Photolesion recognition"
FT   MOTIF           256..274
FT                   /note="DWD box"
FT   MOD_RES         24
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         26
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163"
FT   VAR_SEQ         89..152
FT                   /note="Missing (in isoform D3)"
FT                   /evidence="ECO:0000303|PubMed:14751237"
FT                   /id="VSP_014674"
FT   VAR_SEQ         153..341
FT                   /note="Missing (in isoform D1)"
FT                   /evidence="ECO:0000303|PubMed:14751237"
FT                   /id="VSP_014675"
FT   VAR_SEQ         153..156
FT                   /note="IGAG -> HLVL (in isoform D2)"
FT                   /evidence="ECO:0000303|PubMed:14751237"
FT                   /id="VSP_014676"
FT   VAR_SEQ         157..427
FT                   /note="Missing (in isoform D2)"
FT                   /evidence="ECO:0000303|PubMed:14751237"
FT                   /id="VSP_014677"
FT   VAR_SEQ         236..244
FT                   /note="WNLRMHKKK -> VSVPMEPGS (in isoform D4)"
FT                   /evidence="ECO:0000303|PubMed:14751237"
FT                   /id="VSP_014678"
FT   VAR_SEQ         245..427
FT                   /note="Missing (in isoform D4)"
FT                   /evidence="ECO:0000303|PubMed:14751237"
FT                   /id="VSP_014679"
FT   VARIANT         215
FT                   /note="M -> T (in dbSNP:rs4647750)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_016337"
FT   VARIANT         244
FT                   /note="K -> E (in XP-E; impairs DNA-binding of the UV-DDB
FT                   complex; dbSNP:rs121434639)"
FT                   /evidence="ECO:0000269|PubMed:10777490,
FT                   ECO:0000269|PubMed:16223728, ECO:0000269|PubMed:8798680,
FT                   ECO:0000269|PubMed:9632823"
FT                   /id="VAR_010141"
FT   VARIANT         273
FT                   /note="R -> H (in XP-E; impairs interaction with DDB1 and
FT                   CUL4A; dbSNP:rs121434640)"
FT                   /evidence="ECO:0000269|PubMed:10777490,
FT                   ECO:0000269|PubMed:11673459, ECO:0000269|PubMed:16223728,
FT                   ECO:0000269|PubMed:16949367, ECO:0000269|PubMed:16964240,
FT                   ECO:0000269|PubMed:8798680, ECO:0000269|PubMed:9632823"
FT                   /id="VAR_010142"
FT   VARIANT         293
FT                   /note="A -> T (in dbSNP:rs4647751)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_016338"
FT   MUTAGEN         258
FT                   /note="L->A: Impairs interaction with DDB1."
FT                   /evidence="ECO:0000269|PubMed:17079684"
FT   MUTAGEN         262
FT                   /note="S->A: Impairs interaction with DDB1."
FT                   /evidence="ECO:0000269|PubMed:17079684"
FT   MUTAGEN         264
FT                   /note="D->A: Impairs interaction with DDB1."
FT                   /evidence="ECO:0000269|PubMed:17079684"
FT   MUTAGEN         269
FT                   /note="I->A: Impairs interaction with DDB1."
FT                   /evidence="ECO:0000269|PubMed:17079684"
FT   MUTAGEN         270
FT                   /note="W->A: Impairs interaction with DDB1."
FT                   /evidence="ECO:0000269|PubMed:17079684"
FT   MUTAGEN         272
FT                   /note="L->A: Impairs interaction with DDB1."
FT                   /evidence="ECO:0000269|PubMed:17079684"
FT   MUTAGEN         273
FT                   /note="R->A: Impairs interaction with DDB1."
FT                   /evidence="ECO:0000269|PubMed:17079684"
FT   MUTAGEN         350
FT                   /note="L->P: Impairs interaction with DDB1."
FT                   /evidence="ECO:0000269|PubMed:16949367"
FT   HELIX           21..25
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          30..32
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   HELIX           39..42
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            44..47
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          49..51
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   HELIX           58..62
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            63..65
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   HELIX           69..77
FT                   /evidence="ECO:0000244|PDB:3I7L"
FT   HELIX           83..91
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            92..94
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            96..102
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          106..109
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          114..119
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          127..131
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          136..139
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          148..150
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          154..156
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          161..164
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          171..175
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          177..179
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          181..185
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            186..188
FT                   /evidence="ECO:0000244|PDB:3EI4"
FT   STRAND          190..195
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          198..201
FT                   /evidence="ECO:0000244|PDB:4E5Z"
FT   STRAND          207..210
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            211..214
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          215..219
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          221..232
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          241..243
FT                   /evidence="ECO:0000244|PDB:4E5Z"
FT   STRAND          245..250
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            252..254
FT                   /evidence="ECO:0000244|PDB:4E5Z"
FT   STRAND          255..262
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            263..265
FT                   /evidence="ECO:0000244|PDB:4E5Z"
FT   STRAND          269..271
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            272..274
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          277..279
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          282..286
FT                   /evidence="ECO:0000244|PDB:3EI4"
FT   STRAND          291..293
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          300..310
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          312..326
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          335..337
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          346..349
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          351..354
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          359..361
FT                   /evidence="ECO:0000244|PDB:4E5Z"
FT   STRAND          364..366
FT                   /evidence="ECO:0000244|PDB:3EI4"
FT   STRAND          372..375
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          377..379
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          382..386
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   TURN            389..391
FT                   /evidence="ECO:0000244|PDB:3EI4"
FT   STRAND          397..400
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          407..410
FT                   /evidence="ECO:0000244|PDB:4E54"
FT   STRAND          412..417
FT                   /evidence="ECO:0000244|PDB:4E54"
SQ   SEQUENCE   427 AA;  47864 MW;  E881F21242CA44D2 CRC64;
     MAPKKRPETQ KTSEIVLRPR NKRSRSPLEL EPEAKKLCAK GSGPSRRCDS DCLWVGLAGP
     QILPPCRSIV RTLHQHKLGR ASWPSVQQGL QQSFLHTLDS YRILQKAAPF DRRATSLAWH
     PTHPSTVAVG SKGGDIMLWN FGIKDKPTFI KGIGAGGSIT GLKFNPLNTN QFYASSMEGT
     TRLQDFKGNI LRVFASSDTI NIWFCSLDVS ASSRMVVTGD NVGNVILLNM DGKELWNLRM
     HKKKVTHVAL NPCCDWFLAT ASVDQTVKIW DLRQVRGKAS FLYSLPHRHP VNAACFSPDG
     ARLLTTDQKS EIRVYSASQW DCPLGLIPHP HRHFQHLTPI KAAWHPRYNL IVVGRYPDPN
     FKSCTPYELR TIDVFDGNSG KMMCQLYDPE SSGISSLNEF NPMGDTLASA MGYHILIWSQ
     EEARTRK
//
ID   B3KW07_HUMAN            Unreviewed;       336 AA.
AC   B3KW07;
DT   02-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   02-SEP-2008, sequence version 1.
DT   11-DEC-2019, entry version 60.
DE   SubName: Full=cDNA FLJ41851 fis, clone NT2RI3003925, highly similar to Endothelial PAS domain-containing protein 1 {ECO:0000313|EMBL:BAG53969.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG53969.1};
RN   [1] {ECO:0000313|EMBL:BAG53969.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M.,
RA   Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S.,
RA   Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S.,
RA   Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H.,
RA   Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M.,
RA   Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M.,
RA   Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y.,
RA   Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N.,
RA   Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S.,
RA   Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T.,
RA   Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M.,
RA   Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y.,
RA   Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y.,
RA   Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T.,
RA   Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK123845; BAG53969.1; -; mRNA.
DR   RefSeq; NP_001421.2; NM_001430.4.
DR   PeptideAtlas; B3KW07; -.
DR   PRIDE; B3KW07; -.
DR   GeneID; 2034; -.
DR   KEGG; hsa:2034; -.
DR   CTD; 2034; -.
DR   PharmGKB; PA27809; -.
DR   eggNOG; KOG3558; Eukaryota.
DR   eggNOG; ENOG410YK57; LUCA.
DR   KO; K09095; -.
DR   OrthoDB; 547545at2759; -.
DR   GenomeRNAi; 2034; -.
DR   Genevisible; B3KW07; HS.
DR   InterPro; IPR014887; HIF-1_TAD_C.
DR   InterPro; IPR021537; HIF_alpha_subunit.
DR   Pfam; PF11413; HIF-1; 1.
DR   Pfam; PF08778; HIF-1a_CTAD; 1.
PE   2: Evidence at transcript level;
FT   DOMAIN          299..335
FT                   /note="HIF-1a_CTAD"
FT                   /evidence="ECO:0000259|Pfam:PF08778"
SQ   SEQUENCE   336 AA;  36509 MW;  D5C86DD03FDE0B34 CRC64;
     MDGEDFQLSP ICPEERLLAE NPQSTPQHCF SAMTNIFQPL APVAPHSPFL LDKFQQQLES
     KKTEPEHRPM SSIFFDAGSK ASLPPCCGQA STPLSSMGGR SNTQWPPDPP LHFGPTKWAV
     GDQRTEFLGA APLGPPVSPP HVSTFKTRSA KGFGARGPDV LSPAMVALSN KLKLKRQLEY
     EEQAFQDLSG GDPPGGSTSH LMWKRMKNLR GGSCPLMPDK PLSANVPNDK FTQNPMRGLG
     HPLRHLPLPQ PPSAISPGEN SKSRFPPQCY ATQYQDYSLS SAHKVSGMAS RLLGPSFESY
     LLPELTRYDC EVNVPVLGSS TLLQGGDLLR ALDQAT
//
ID   EPAS1_HUMAN             Reviewed;         870 AA.
AC   Q99814; Q86VA2; Q99630;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   03-JUL-2003, sequence version 3.
DT   22-APR-2020, entry version 211.
DE   RecName: Full=Endothelial PAS domain-containing protein 1;
DE            Short=EPAS-1;
DE   AltName: Full=Basic-helix-loop-helix-PAS protein MOP2;
DE   AltName: Full=Class E basic helix-loop-helix protein 73;
DE            Short=bHLHe73;
DE   AltName: Full=HIF-1-alpha-like factor;
DE            Short=HLF;
DE   AltName: Full=Hypoxia-inducible factor 2-alpha;
DE            Short=HIF-2-alpha;
DE            Short=HIF2-alpha;
DE   AltName: Full=Member of PAS protein 2;
DE   AltName: Full=PAS domain-containing protein 2;
GN   Name=EPAS1; Synonyms=BHLHE73, HIF2A, MOP2, PASD2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9000051; DOI=10.1101/gad.11.1.72;
RA   Tian H., McKnight S.L., Russell D.W.;
RT   "Endothelial PAS domain protein 1 (EPAS1), a transcription factor
RT   selectively expressed in endothelial cells.";
RL   Genes Dev. 11:72-82(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hepatoma;
RX   PubMed=9079689; DOI=10.1074/jbc.272.13.8581;
RA   Hogenesch J.B., Chan W.K., Jackiw V.H., Brown R.C., Gu Y.-Z.,
RA   Pray-Grant M., Perdew G.H., Bradfield C.A.;
RT   "Characterization of a subset of the basic-helix-loop-helix-PAS superfamily
RT   that interacts with components of the dioxin signaling pathway.";
RL   J. Biol. Chem. 272:8581-8593(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   TRANSACTIVATION DOMAINS NTAD AND CTAD, INTERACTION WITH APEX, AND
RP   MUTAGENESIS OF CYS-844.
RX   PubMed=10202154; DOI=10.1093/emboj/18.7.1905;
RA   Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K., Poellinger L.,
RA   Fujii-Kuriyama Y.;
RT   "Molecular mechanisms of transcription activation by HLF and HIF1alpha in
RT   response to hypoxia: their stabilization and redox signal-induced
RT   interaction with CBP/p300.";
RL   EMBO J. 18:1905-1914(1999).
RN   [5]
RP   INTERACTION WITH EGLN1 AND VHL, VARIANT ECYT4 LEU-534, AND CHARACTERIZATION
RP   OF VARIANTS ECYT4 LEU-534; VAL-535 AND ARG-537.
RX   PubMed=19208626; DOI=10.1074/jbc.m808737200;
RA   Furlow P.W., Percy M.J., Sutherland S., Bierl C., McMullin M.F.,
RA   Master S.R., Lappin T.R., Lee F.S.;
RT   "Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role
RT   for residues C-terminal to the hydroxylacceptor proline.";
RL   J. Biol. Chem. 284:9050-9058(2009).
RN   [6] {ECO:0000244|PDB:2A24}
RP   STRUCTURE BY NMR OF 356-470 IN COMPLEX WITH ARNT, AND INTERACTION WITH
RP   ARNT.
RX   PubMed=16181639; DOI=10.1016/j.jmb.2005.08.043;
RA   Card P.B., Erbel P.J., Gardner K.H.;
RT   "Structural basis of ARNT PAS-B dimerization: use of a common beta-sheet
RT   interface for hetero- and homodimerization.";
RL   J. Mol. Biol. 353:664-677(2005).
RN   [7]
RP   VARIANTS ECYT4 VAL-535 AND ARG-537.
RX   PubMed=18378852; DOI=10.1182/blood-2008-02-137703;
RA   Percy M.J., Beer P.A., Campbell G., Dekker A.W., Green A.R., Oscier D.,
RA   Rainey M.G., van Wijk R., Wood M., Lappin T.R., McMullin M.F., Lee F.S.;
RT   "Novel exon 12 mutations in the HIF2A gene associated with
RT   erythrocytosis.";
RL   Blood 111:5400-5402(2008).
RN   [8]
RP   VARIANT ECYT4 TRP-537, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   CHARACTERIZATION OF VARIANT ECYT4 TRP-537.
RX   PubMed=18184961; DOI=10.1056/nejmoa073123;
RA   Percy M.J., Furlow P.W., Lucas G.S., Li X., Lappin T.R., McMullin M.F.,
RA   Lee F.S.;
RT   "A gain-of-function mutation in the HIF2A gene in familial
RT   erythrocytosis.";
RL   N. Engl. J. Med. 358:162-168(2008).
RN   [9]
RP   VARIANTS ECYT4 THR-535 AND LEU-540, AND CHARACTERIZATION OF VARIANT ECYT4
RP   LEU-540.
RX   PubMed=22367913; DOI=10.1002/ajh.23123;
RA   Percy M.J., Chung Y.J., Harrison C., Mercieca J., Hoffbrand A.V.,
RA   Dinardo C.L., Santos P.C., Fonseca G.H., Gualandro S.F., Pereira A.C.,
RA   Lappin T.R., McMullin M.F., Lee F.S.;
RT   "Two new mutations in the HIF2A gene associated with erythrocytosis.";
RL   Am. J. Hematol. 87:439-442(2012).
CC   -!- FUNCTION: Transcription factor involved in the induction of oxygen
CC       regulated genes. Heterodimerizes with ARNT; heterodimer binds to core
CC       DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of
CC       target gene promoters (By similarity). Regulates the vascular
CC       endothelial growth factor (VEGF) expression and seems to be implicated
CC       in the development of blood vessels and the tubular system of lung. May
CC       also play a role in the formation of the endothelium that gives rise to
CC       the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase
CC       expression. Activation requires recruitment of transcriptional
CC       coactivators such as CREBBP and probably EP300. Interaction with redox
CC       regulatory protein APEX seems to activate CTAD (By similarity).
CC       {ECO:0000250, ECO:0000250|UniProtKB:P97481}.
CC   -!- SUBUNIT: Interacts with HIF3A (By similarity). Efficient DNA binding
CC       requires dimerization with another bHLH protein. Heterodimerizes with
CC       ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the
CC       hypoxia response element (HRE) of target gene promoters
CC       (PubMed:16181639). Interacts with CREBBP (By similarity). Interacts
CC       with EGLN1. Interacts with VHL (PubMed:19208626).
CC       {ECO:0000250|UniProtKB:P97481, ECO:0000269|PubMed:10202154,
CC       ECO:0000269|PubMed:16181639, ECO:0000269|PubMed:19208626}.
CC   -!- INTERACTION:
CC       Q99814; P27540: ARNT; NbExp=7; IntAct=EBI-447470, EBI-80809;
CC       Q99814; O00327-8: ARNTL; NbExp=3; IntAct=EBI-447470, EBI-11991546;
CC       Q99814; Q8WYA1-3: ARNTL2; NbExp=3; IntAct=EBI-447470, EBI-12268276;
CC       Q99814; Q96RK4: BBS4; NbExp=2; IntAct=EBI-447470, EBI-1805814;
CC       Q99814; Q9GZT9: EGLN1; NbExp=3; IntAct=EBI-447470, EBI-1174818;
CC       Q99814; P60228: EIF3E; NbExp=10; IntAct=EBI-447470, EBI-347740;
CC       Q99814; O60573: EIF4E2; NbExp=2; IntAct=EBI-447470, EBI-398610;
CC       Q99814; P09467: FBP1; NbExp=4; IntAct=EBI-447470, EBI-712740;
CC       Q99814; P61244: MAX; NbExp=2; IntAct=EBI-447470, EBI-751711;
CC       Q99814; Q9BWF3-1: RBM4; NbExp=6; IntAct=EBI-447470, EBI-15621561;
CC       Q99814; P84022: SMAD3; NbExp=2; IntAct=EBI-447470, EBI-347161;
CC       Q99814; P08047: SP1; NbExp=2; IntAct=EBI-447470, EBI-298336;
CC       Q99814; A0A024R8A9: USP20; NbExp=3; IntAct=EBI-447470, EBI-14096082;
CC       Q99814; P40818: USP8; NbExp=2; IntAct=EBI-447470, EBI-1050865;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P97481,
CC       ECO:0000255|PROSITE-ProRule:PRU00981}. Nucleus speckle
CC       {ECO:0000250|UniProtKB:P97481}. Note=Colocalizes with HIF3A in the
CC       nucleus and speckles. {ECO:0000250|UniProtKB:P97481}.
CC   -!- TISSUE SPECIFICITY: Expressed in most tissues, with highest levels in
CC       placenta, lung and heart. Selectively expressed in endothelial cells.
CC   -!- PTM: In normoxia, is probably hydroxylated on Pro-405 and Pro-531 by
CC       EGLN1/PHD1, EGLN2/PHD2 and/or EGLN3/PHD3. The hydroxylated prolines
CC       promote interaction with VHL, initiating rapid ubiquitination and
CC       subsequent proteasomal degradation. Under hypoxia, proline
CC       hydroxylation is impaired and ubiquitination is attenuated, resulting
CC       in stabilization (By similarity). {ECO:0000250}.
CC   -!- PTM: In normoxia, is hydroxylated on Asn-847 by HIF1AN thus probably
CC       abrogating interaction with CREBBP and EP300 and preventing
CC       transcriptional activation. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on multiple sites in the CTAD. {ECO:0000250}.
CC   -!- PTM: The iron and 2-oxoglutarate dependent 3-hydroxylation of
CC       asparagine is (S) stereospecific within HIF CTAD domains.
CC       {ECO:0000250}.
CC   -!- DISEASE: Erythrocytosis, familial, 4 (ECYT4) [MIM:611783]: An autosomal
CC       dominant disorder characterized by elevated serum hemoglobin and
CC       hematocrit, and normal platelet and leukocyte counts.
CC       {ECO:0000269|PubMed:18184961, ECO:0000269|PubMed:18378852,
CC       ECO:0000269|PubMed:19208626, ECO:0000269|PubMed:22367913}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U81984; AAB41495.1; -; mRNA.
DR   EMBL; U51626; AAC51212.1; -; mRNA.
DR   EMBL; BC051338; AAH51338.1; -; mRNA.
DR   CCDS; CCDS1825.1; -.
DR   RefSeq; NP_001421.2; NM_001430.4.
DR   PDB; 1P97; NMR; -; A=240-350.
DR   PDB; 2A24; NMR; -; A=242-348.
DR   PDB; 3F1N; X-ray; 1.48 A; A=239-350.
DR   PDB; 3F1O; X-ray; 1.60 A; A=239-350.
DR   PDB; 3F1P; X-ray; 1.17 A; A=239-350.
DR   PDB; 3H7W; X-ray; 1.65 A; A=239-350.
DR   PDB; 3H82; X-ray; 1.50 A; A=239-350.
DR   PDB; 4GHI; X-ray; 1.50 A; A=239-350.
DR   PDB; 4GS9; X-ray; 1.72 A; A=239-350.
DR   PDB; 4PKY; X-ray; 3.20 A; G=239-350.
DR   PDB; 4XT2; X-ray; 1.70 A; A/C=239-350.
DR   PDB; 5KIZ; NMR; -; A=239-349.
DR   PDB; 5TBM; X-ray; 1.85 A; A=239-348.
DR   PDB; 5UFP; X-ray; 1.90 A; A=239-348.
DR   PDB; 6BVB; X-ray; 2.00 A; H=523-540.
DR   PDB; 6CZW; X-ray; 1.60 A; A=239-350.
DR   PDB; 6D09; X-ray; 1.85 A; A=239-350.
DR   PDB; 6D0B; X-ray; 1.60 A; A=239-350.
DR   PDB; 6D0C; X-ray; 1.50 A; A=239-350.
DR   PDB; 6I7Q; X-ray; 1.80 A; H=523-541.
DR   PDB; 6I7R; X-ray; 1.95 A; H=523-542.
DR   PDBsum; 1P97; -.
DR   PDBsum; 2A24; -.
DR   PDBsum; 3F1N; -.
DR   PDBsum; 3F1O; -.
DR   PDBsum; 3F1P; -.
DR   PDBsum; 3H7W; -.
DR   PDBsum; 3H82; -.
DR   PDBsum; 4GHI; -.
DR   PDBsum; 4GS9; -.
DR   PDBsum; 4PKY; -.
DR   PDBsum; 4XT2; -.
DR   PDBsum; 5KIZ; -.
DR   PDBsum; 5TBM; -.
DR   PDBsum; 5UFP; -.
DR   PDBsum; 6BVB; -.
DR   PDBsum; 6CZW; -.
DR   PDBsum; 6D09; -.
DR   PDBsum; 6D0B; -.
DR   PDBsum; 6D0C; -.
DR   PDBsum; 6I7Q; -.
DR   PDBsum; 6I7R; -.
DR   SMR; Q99814; -.
DR   BioGrid; 108348; 127.
DR   CORUM; Q99814; -.
DR   DIP; DIP-32857N; -.
DR   ELM; Q99814; -.
DR   IntAct; Q99814; 38.
DR   MINT; Q99814; -.
DR   STRING; 9606.ENSP00000263734; -.
DR   BindingDB; Q99814; -.
DR   ChEMBL; CHEMBL1744522; -.
DR   DrugBank; DB15463; PT2977.
DR   iPTMnet; Q99814; -.
DR   PhosphoSitePlus; Q99814; -.
DR   BioMuta; EPAS1; -.
DR   DMDM; 32470617; -.
DR   jPOST; Q99814; -.
DR   MassIVE; Q99814; -.
DR   MaxQB; Q99814; -.
DR   PaxDb; Q99814; -.
DR   PeptideAtlas; Q99814; -.
DR   PRIDE; Q99814; -.
DR   ProteomicsDB; 78489; -.
DR   Antibodypedia; 29965; 689 antibodies.
DR   Ensembl; ENST00000263734; ENSP00000263734; ENSG00000116016.
DR   GeneID; 2034; -.
DR   KEGG; hsa:2034; -.
DR   UCSC; uc002ruv.3; human.
DR   CTD; 2034; -.
DR   DisGeNET; 2034; -.
DR   GeneCards; EPAS1; -.
DR   HGNC; HGNC:3374; EPAS1.
DR   HPA; ENSG00000116016; Tissue enhanced (lung).
DR   MalaCards; EPAS1; -.
DR   MIM; 603349; gene.
DR   MIM; 611783; phenotype.
DR   neXtProt; NX_Q99814; -.
DR   OpenTargets; ENSG00000116016; -.
DR   Orphanet; 247511; Autosomal dominant secondary polycythemia.
DR   Orphanet; 324299; Multiple paragangliomas associated with polycythemia.
DR   Orphanet; 276624; Sporadic pheochromocytoma.
DR   Orphanet; 276627; Sporadic secreting paraganglioma.
DR   PharmGKB; PA27809; -.
DR   eggNOG; KOG3558; Eukaryota.
DR   eggNOG; ENOG410YK57; LUCA.
DR   GeneTree; ENSGT00940000155930; -.
DR   HOGENOM; CLU_010044_3_1_1; -.
DR   InParanoid; Q99814; -.
DR   KO; K09095; -.
DR   OMA; MNSIFDN; -.
DR   OrthoDB; 547545at2759; -.
DR   PhylomeDB; Q99814; -.
DR   TreeFam; TF317772; -.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-1234174; Cellular response to hypoxia.
DR   Reactome; R-HSA-1234176; Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha.
DR   Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells.
DR   Reactome; R-HSA-8849473; PTK6 Expression.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   SignaLink; Q99814; -.
DR   SIGNOR; Q99814; -.
DR   ChiTaRS; EPAS1; human.
DR   EvolutionaryTrace; Q99814; -.
DR   GeneWiki; EPAS1; -.
DR   GenomeRNAi; 2034; -.
DR   Pharos; Q99814; Tchem.
DR   PRO; PR:Q99814; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q99814; protein.
DR   Bgee; ENSG00000116016; Expressed in visceral pleura and 233 other tissues.
DR   ExpressionAtlas; Q99814; baseline and differential.
DR   Genevisible; Q99814; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005667; C:transcription factor complex; IDA:MGI.
DR   GO; GO:0003677; F:DNA binding; IGI:MGI.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0055072; P:iron ion homeostasis; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0007005; P:mitochondrion organization; IEA:Ensembl.
DR   GO; GO:0048625; P:myoblast fate commitment; ISS:BHF-UCL.
DR   GO; GO:0042415; P:norepinephrine metabolic process; IEA:Ensembl.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:Reactome.
DR   GO; GO:0002027; P:regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0043619; P:regulation of transcription from RNA polymerase II promoter in response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IDA:MGI.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0043129; P:surfactant homeostasis; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:0007601; P:visual perception; IEA:Ensembl.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR014887; HIF-1_TAD_C.
DR   InterPro; IPR021537; HIF_alpha_subunit.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   InterPro; IPR013655; PAS_fold_3.
DR   Pfam; PF11413; HIF-1; 1.
DR   Pfam; PF08778; HIF-1a_CTAD; 1.
DR   Pfam; PF00989; PAS; 1.
DR   Pfam; PF08447; PAS_3; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   TIGRFAMs; TIGR00229; sensory_box; 2.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Angiogenesis; Congenital erythrocytosis;
KW   Developmental protein; Differentiation; Disease mutation; DNA-binding;
KW   Hydroxylation; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..870
FT                   /note="Endothelial PAS domain-containing protein 1"
FT                   /id="PRO_0000127419"
FT   DOMAIN          14..67
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   DOMAIN          84..154
FT                   /note="PAS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          230..300
FT                   /note="PAS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          304..347
FT                   /note="PAC"
FT   REGION          26..53
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000250|UniProtKB:P97481"
FT   REGION          171..192
FT                   /note="Required for heterodimer formation with ARNT"
FT                   /evidence="ECO:0000250|UniProtKB:P97481"
FT   REGION          496..542
FT                   /note="NTAD"
FT   REGION          830..870
FT                   /note="CTAD"
FT   COMPBIAS        474..480
FT                   /note="Poly-Ser"
FT   MOD_RES         405
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         531
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         840
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P97481"
FT   MOD_RES         847
FT                   /note="(3S)-3-hydroxyasparagine"
FT                   /evidence="ECO:0000250"
FT   VARIANT         534
FT                   /note="P -> L (in ECYT4; impairs interaction with EGLN1 and
FT                   VHL)"
FT                   /evidence="ECO:0000269|PubMed:19208626"
FT                   /id="VAR_067358"
FT   VARIANT         535
FT                   /note="M -> T (in ECYT4)"
FT                   /evidence="ECO:0000269|PubMed:22367913"
FT                   /id="VAR_067359"
FT   VARIANT         535
FT                   /note="M -> V (in ECYT4; impairs interaction with EGLN1;
FT                   dbSNP:rs137853037)"
FT                   /evidence="ECO:0000269|PubMed:18378852,
FT                   ECO:0000269|PubMed:19208626"
FT                   /id="VAR_067360"
FT   VARIANT         537
FT                   /note="G -> R (in ECYT4; impairs interaction with EGLN1 and
FT                   VHL; dbSNP:rs137853036)"
FT                   /evidence="ECO:0000269|PubMed:18378852,
FT                   ECO:0000269|PubMed:19208626"
FT                   /id="VAR_067361"
FT   VARIANT         537
FT                   /note="G -> W (in ECYT4; gain of function; affects
FT                   hydroxylation; dbSNP:rs137853036)"
FT                   /evidence="ECO:0000269|PubMed:18184961"
FT                   /id="VAR_042443"
FT   VARIANT         540
FT                   /note="F -> L (in ECYT4; affects the interaction with EGLN1
FT                   and VHL)"
FT                   /evidence="ECO:0000269|PubMed:22367913"
FT                   /id="VAR_067362"
FT   VARIANT         766
FT                   /note="T -> P (in dbSNP:rs59901247)"
FT                   /id="VAR_061261"
FT   VARIANT         785
FT                   /note="P -> T (in dbSNP:rs61518065)"
FT                   /id="VAR_061262"
FT   MUTAGEN         844
FT                   /note="C->S: Abolishes hypoxia-inducible transcriptional
FT                   activation of ctaD."
FT                   /evidence="ECO:0000269|PubMed:10202154"
FT   CONFLICT        60
FT                   /note="A -> E (in Ref. 1; AAB41495)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        539
FT                   /note="D -> G (in Ref. 2; AAC51212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        601
FT                   /note="H -> R (in Ref. 2; AAC51212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        693
FT                   /note="D -> N (in Ref. 2; AAC51212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        716
FT                   /note="E -> K (in Ref. 2; AAC51212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        722
FT                   /note="L -> P (in Ref. 2; AAC51212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        765
FT                   /note="F -> L (in Ref. 2; AAC51212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        769
FT                   /note="P -> S (in Ref. 2; AAC51212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        844
FT                   /note="C -> R (in Ref. 2; AAC51212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        847
FT                   /note="N -> K (in Ref. 2; AAC51212)"
FT                   /evidence="ECO:0000305"
FT   HELIX           240..242
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   STRAND          243..248
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   TURN            250..252
FT                   /evidence="ECO:0000244|PDB:2A24"
FT   STRAND          253..257
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   HELIX           260..265
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   HELIX           269..272
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   HELIX           277..280
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   HELIX           283..285
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   HELIX           286..299
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   STRAND          300..303
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   STRAND          307..310
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   STRAND          314..327
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   TURN            329..331
FT                   /evidence="ECO:0000244|PDB:3F1P"
FT   STRAND          334..343
FT                   /evidence="ECO:0000244|PDB:3F1P"
SQ   SEQUENCE   870 AA;  96459 MW;  4838989598234FC1 CRC64;
     MTADKEKKRS SSERRKEKSR DAARCRRSKE TEVFYELAHE LPLPHSVSSH LDKASIMRLA
     ISFLRTHKLL SSVCSENESE AEADQQMDNL YLKALEGFIA VVTQDGDMIF LSENISKFMG
     LTQVELTGHS IFDFTHPCDH EEIRENLSLK NGSGFGKKSK DMSTERDFFM RMKCTVTNRG
     RTVNLKSATW KVLHCTGQVK VYNNCPPHNS LCGYKEPLLS CLIIMCEPIQ HPSHMDIPLD
     SKTFLSRHSM DMKFTYCDDR ITELIGYHPE ELLGRSAYEF YHALDSENMT KSHQNLCTKG
     QVVSGQYRML AKHGGYVWLE TQGTVIYNPR NLQPQCIMCV NYVLSEIEKN DVVFSMDQTE
     SLFKPHLMAM NSIFDSSGKG AVSEKSNFLF TKLKEEPEEL AQLAPTPGDA IISLDFGNQN
     FEESSAYGKA ILPPSQPWAT ELRSHSTQSE AGSLPAFTVP QAAAPGSTTP SATSSSSSCS
     TPNSPEDYYT SLDNDLKIEV IEKLFAMDTE AKDQCSTQTD FNELDLETLA PYIPMDGEDF
     QLSPICPEER LLAENPQSTP QHCFSAMTNI FQPLAPVAPH SPFLLDKFQQ QLESKKTEPE
     HRPMSSIFFD AGSKASLPPC CGQASTPLSS MGGRSNTQWP PDPPLHFGPT KWAVGDQRTE
     FLGAAPLGPP VSPPHVSTFK TRSAKGFGAR GPDVLSPAMV ALSNKLKLKR QLEYEEQAFQ
     DLSGGDPPGG STSHLMWKRM KNLRGGSCPL MPDKPLSANV PNDKFTQNPM RGLGHPLRHL
     PLPQPPSAIS PGENSKSRFP PQCYATQYQD YSLSSAHKVS GMASRLLGPS FESYLLPELT
     RYDCEVNVPV LGSSTLLQGG DLLRALDQAT
//
ID   ERBB4_HUMAN             Reviewed;        1308 AA.
AC   Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   22-APR-2020, entry version 223.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-4;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene-like protein c-ErbB-4;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER4;
DE   AltName: Full=p180erbB4;
DE   Contains:
DE     RecName: Full=ERBB4 intracellular domain;
DE              Short=4ICD;
DE              Short=E4ICD;
DE     AltName: Full=s80HER4;
DE   Flags: Precursor;
GN   Name=ERBB4; Synonyms=HER4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1), FUNCTION AS CELL SURFACE
RP   RECEPTOR, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=8383326; DOI=10.1073/pnas.90.5.1746;
RA   Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W.,
RA   Foy L., Neubauer M.G., Shoyab M.;
RT   "Ligand-specific activation of HER4/p180erbB4, a fourth member of the
RT   epidermal growth factor receptor family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1), TISSUE
RP   SPECIFICITY, FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND BTC,
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND PROTEOLYTIC PROCESSING.
RC   TISSUE=Fetal brain;
RX   PubMed=9334263; DOI=10.1074/jbc.272.42.26761;
RA   Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D.,
RA   Klagsbrun M.;
RT   "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific
RT   tissue distribution and differential processing in response to phorbol
RT   ester.";
RL   J. Biol. Chem. 272:26761-26768(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B CYT-1;
RP   JM-A CYT-2 AND JM-B CYT-2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A CYT-2).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION.
RX   PubMed=7689552;
RA   Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.;
RT   "Characterization of a breast cancer cell differentiation factor that
RT   specifically activates the HER4/p180erbB4 receptor.";
RL   J. Biol. Chem. 268:18407-18410(1993).
RN   [6]
RP   INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION.
RX   PubMed=7902537; DOI=10.1038/366473a0;
RA   Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M.,
RA   Buckley S.;
RT   "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.";
RL   Nature 366:473-475(1993).
RN   [7]
RP   FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION, CATALYTIC
RP   ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT
RP   TYR-1056; TYR-1188 AND TYR-1242, AND INTERACTION WITH EGFR; SHC1 AND
RP   PIK3R1.
RX   PubMed=8617750; DOI=10.1074/jbc.271.9.4813;
RA   Cohen B.D., Green J.M., Foy L., Fell H.P.;
RT   "HER4-mediated biological and biochemical properties in NIH 3T3 cells.
RT   Evidence for HER1-HER4 heterodimers.";
RL   J. Biol. Chem. 271:4813-4818(1996).
RN   [8]
RP   INTERACTION WITH BTC, AND AUTOPHOSPHORYLATION.
RX   PubMed=8570211;
RA   Riese D.J. II, Bermingham Y., van Raaij T.M., Buckley S., Plowman G.D.,
RA   Stern D.F.;
RT   "Betacellulin activates the epidermal growth factor receptor and erbB-4,
RT   and induces cellular response patterns distinct from those stimulated by
RT   epidermal growth factor or neuregulin-beta.";
RL   Oncogene 12:345-353(1996).
RN   [9]
RP   FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND IN
RP   ACTIVATION OF PIK3R1, INTERACTION WITH HBEGF AND PIK3R1, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=9135143; DOI=10.1093/emboj/16.6.1268;
RA   Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.;
RT   "Activation of HER4 by heparin-binding EGF-like growth factor stimulates
RT   chemotaxis but not proliferation.";
RL   EMBO J. 16:1268-1278(1997).
RN   [10]
RP   INTERACTION WITH NRG2, FUNCTION AS NRG2 RECEPTOR, AND PHOSPHORYLATION.
RX   PubMed=9168115; DOI=10.1038/387512a0;
RA   Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M.,
RA   Lai C.;
RT   "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.";
RL   Nature 387:512-516(1997).
RN   [11]
RP   INTERACTION WITH EREG, AND AUTOPHOSPHORYLATION.
RX   PubMed=9419975; DOI=10.1038/sj.onc.1201458;
RA   Komurasaki T., Toyoda H., Uchida D., Morimoto S.;
RT   "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and
RT   induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-
RT   2, ErbB-3 and ErbB-4.";
RL   Oncogene 15:2841-2848(1997).
RN   [12]
RP   INTERACTION WITH NRG3, AND AUTOPHOSPHORYLATION.
RX   PubMed=9275162; DOI=10.1073/pnas.94.18.9562;
RA   Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Hillan K.,
RA   Crowley C., Brush J., Godowski P.J.;
RT   "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and
RT   activates ErbB4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997).
RN   [13]
RP   INTERACTION WITH GRB7.
RX   PubMed=9516479; DOI=10.1074/jbc.273.13.7717;
RA   Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H.,
RA   Wallasch C., Daly R.J.;
RT   "Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals
RT   a novel target selectivity for erbB3.";
RL   J. Biol. Chem. 273:7717-7724(1998).
RN   [14]
RP   INTERACTION WITH ERBB2, AND FUNCTION IN ACTIVATION OF STAT5A.
RX   PubMed=10358079; DOI=10.1074/jbc.274.24.17209;
RA   Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.;
RT   "ErbB receptor-induced activation of stat transcription factors is mediated
RT   by Src tyrosine kinases.";
RL   J. Biol. Chem. 274:17209-17218(1999).
RN   [15]
RP   ALTERNATIVE SPLICING, FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PIK3R1,
RP   INTERACTION WITH NRG1 AND PIKR3R1, AUTOPHOSPHORYLATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=10353604; DOI=10.1038/sj.onc.1202612;
RA   Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E., Klagsbrun M.;
RT   "Characterization of a naturally occurring ErbB4 isoform that does not bind
RT   or activate phosphatidyl inositol 3-kinase.";
RL   Oncogene 18:2607-2615(1999).
RN   [16]
RP   FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1 AND IN
RP   CELL PROLIFERATION, INTERACTION WITH NRG4, AND SUBCELLULAR LOCATION.
RX   PubMed=10348342; DOI=10.1038/sj.onc.1202631;
RA   Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C.,
RA   Yarden Y.;
RT   "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor
RT   tyrosine kinase.";
RL   Oncogene 18:2681-2689(1999).
RN   [17]
RP   FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL AND IN
RP   PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=10722704; DOI=10.1074/jbc.275.12.8641;
RA   Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E., Klagsbrun M.,
RA   Elenius K.;
RT   "A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase
RT   mediates proliferation but not survival or chemotaxis.";
RL   J. Biol. Chem. 275:8641-8649(2000).
RN   [18]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=10744726; DOI=10.1074/jbc.275.14.10379;
RA   Rio C., Buxbaum J.D., Peschon J.J., Corfas G.;
RT   "Tumor necrosis factor-alpha-converting enzyme is required for cleavage of
RT   erbB4/HER4.";
RL   J. Biol. Chem. 275:10379-10387(2000).
RN   [19]
RP   FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1, INTERACTION WITH
RP   PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3, AND LIGAND-SPECIFIC
RP   AUTOPHOSPHORYLATION.
RX   PubMed=10867024; DOI=10.1074/jbc.c901015199;
RA   Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C.,
RA   Carraway K.L. III;
RT   "Ligand discrimination in signaling through an ErbB4 receptor homodimer.";
RL   J. Biol. Chem. 275:19803-19807(2000).
RN   [20]
RP   INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2.
RX   PubMed=10725395; DOI=10.1073/pnas.97.7.3596;
RA   Garcia R.A., Vasudevan K., Buonanno A.;
RT   "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at
RT   neuronal synapses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000).
RN   [21]
RP   FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES,
RP   AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION.
RX   PubMed=11178955; DOI=10.1006/bbrc.2001.4302;
RA   Egeblad M., Mortensen O.H., van Kempen L.C., Jaattela M.;
RT   "BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at
RT   different concentrations in intact cells.";
RL   Biochem. Biophys. Res. Commun. 281:25-31(2001).
RN   [22]
RP   MUTAGENESIS OF LYS-751, AND FUNCTION IN PROMOTING CELL DIFFERENTIATION AND
RP   INHIBITING CELL PROLIFERATION.
RX   PubMed=11390655; DOI=10.1128/mcb.21.13.4265-4275.2001;
RA   Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L.,
RA   Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III;
RT   "Her4 mediates ligand-dependent antiproliferative and differentiation
RT   responses in human breast cancer cells.";
RL   Mol. Cell. Biol. 21:4265-4275(2001).
RN   [23]
RP   FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION WITH
RP   YAP1, AND MUTAGENESIS OF TYR-1301.
RX   PubMed=12807903; DOI=10.1074/jbc.m305597200;
RA   Komuro A., Nagai M., Navin N.E., Sudol M.;
RT   "WW domain-containing protein YAP associates with ErbB-4 and acts as a co-
RT   transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that
RT   translocates to the nucleus.";
RL   J. Biol. Chem. 278:33334-33341(2003).
RN   [24]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent
RT   on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [25]
RP   INTERACTION WITH STAT5A, SUBCELLULAR LOCATION, FUNCTION IN NUCLEAR
RP   LOCALIZATION OF STAT5A, DNA-BINDING, AND MUTAGENESIS OF 681-LYS--ARG-684.
RX   PubMed=15534001; DOI=10.1083/jcb.200403155;
RA   Williams C.C., Allison J.G., Vidal G.A., Burow M.E., Beckman B.S.,
RA   Marrero L., Jones F.E.;
RT   "The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by
RT   functioning as a STAT5A nuclear chaperone.";
RL   J. Cell Biol. 167:469-478(2004).
RN   [26]
RP   INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND TYR-1301.
RX   PubMed=16061658; DOI=10.1158/0008-5472.can-05-1150;
RA   Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y.,
RA   Sudol M., Croce C.M.;
RT   "WW domain-containing proteins, WWOX and YAP, compete for interaction with
RT   ErbB-4 and modulate its transcriptional function.";
RL   Cancer Res. 65:6764-6772(2005).
RN   [27]
RP   FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF VAL-675.
RX   PubMed=15746097; DOI=10.1074/jbc.m412457200;
RA   Vidal G.A., Naresh A., Marrero L., Jones F.E.;
RT   "Presenilin-dependent gamma-secretase processing regulates multiple
RT   ERBB4/HER4 activities.";
RL   J. Biol. Chem. 280:19777-19783(2005).
RN   [28]
RP   FUNCTION IN PROMOTING APOPTOSIS, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   BCL2.
RX   PubMed=16778220; DOI=10.1158/0008-5472.can-05-2368;
RA   Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I.,
RA   Tovey S., Cooke T.G., Bartlett J.M., Jones F.E.;
RT   "The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting
RT   apoptosis of breast cancer cells.";
RL   Cancer Res. 66:6412-6420(2006).
RN   [29]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=16815842; DOI=10.1074/jbc.m603998200;
RA   Linggi B., Carpenter G.;
RT   "ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional
RT   repression.";
RL   J. Biol. Chem. 281:25373-25380(2006).
RN   [30]
RP   FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=16251361; DOI=10.1091/mbc.e05-05-0402;
RA   Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J., Isola J.,
RA   Egeblad M., Elenius K.;
RT   "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4
RT   isoform promote ligand-independent survival and cancer cell growth.";
RL   Mol. Biol. Cell 17:67-79(2006).
RN   [31]
RP   FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM, PROTEOLYTIC PROCESSING,
RP   AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH STAT5A.
RX   PubMed=16837552; DOI=10.1091/mbc.e06-02-0101;
RA   Muraoka-Cook R.S., Sandahl M., Husted C., Hunter D., Miraglia L.,
RA   Feng S.M., Elenius K., Earp H.S. III;
RT   "The intracellular domain of ErbB4 induces differentiation of mammary
RT   epithelial cells.";
RL   Mol. Biol. Cell 17:4118-4129(2006).
RN   [32]
RP   MUTAGENESIS OF GLN-646, AND PHOSPHORYLATION AT TYR-1056.
RX   PubMed=17120616; DOI=10.3727/000000006783981134;
RA   Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. II;
RT   "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling
RT   to inhibition of colony formation by human mammary cell lines.";
RL   Oncol. Res. 16:179-193(2006).
RN   [33]
RP   FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING, SUBCELLULAR
RP   LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN, AND MUTAGENESIS OF
RP   VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000.
RX   PubMed=17638867; DOI=10.1158/0008-5472.can-06-4145;
RA   Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A.,
RA   Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.;
RT   "HER4 D-box sequences regulate mitotic progression and degradation of the
RT   nuclear HER4 cleavage product s80HER4.";
RL   Cancer Res. 67:6582-6590(2007).
RN   [34]
RP   INTERACTION WITH ERBB2, MUTAGENESIS OF ASP-843, AND AUTOPHOSPHORYLATION IN
RP   TRANS.
RX   PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020;
RA   Li Z., Mei Y., Liu X., Zhou M.;
RT   "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor
RT   heterodimer partners.";
RL   Cell. Signal. 19:466-471(2007).
RN   [35]
RP   FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND
RP   MUTAGENESIS OF LYS-751.
RX   PubMed=17486069; DOI=10.1038/sj.onc.1210501;
RA   Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I., Savisalo M.,
RA   Silvennoinen O., Yarden Y., Elenius K.;
RT   "Differential nuclear localization and kinase activity of alternative ErbB4
RT   intracellular domains.";
RL   Oncogene 26:6905-6914(2007).
RN   [36]
RP   PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162;
RP   TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284, INTERACTION WITH
RP   PIK3R1 AND STAT1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006;
RA   Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G.;
RT   "System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation
RT   that are unusually selective in their recruitment properties.";
RL   Chem. Biol. 15:808-817(2008).
RN   [37]
RP   INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF E4ICD1.
RX   PubMed=19193720; DOI=10.1096/fj.08-121947;
RA   Zeng F., Xu J., Harris R.C.;
RT   "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK
RT   II cells.";
RL   FASEB J. 23:1935-1945(2009).
RN   [38]
RP   FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION WITH ERBB2,
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY ERBB2, ACTIVITY
RP   REGULATION, AND MUTAGENESIS OF VAL-721; ALA-773; ARG-782; GLU-810; PRO-854;
RP   ASP-861; GLU-872 AND THR-926.
RX   PubMed=19098003; DOI=10.1074/jbc.m805438200;
RA   Tvorogov D., Sundvall M., Kurppa K., Hollmen M., Repo S., Johnson M.S.,
RA   Elenius K.;
RT   "Somatic mutations of ErbB4: selective loss-of-function phenotype affecting
RT   signal transduction pathways in cancer.";
RL   J. Biol. Chem. 284:5582-5591(2009).
RN   [39]
RP   INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301.
RX   PubMed=19561640; DOI=10.1038/onc.2009.162;
RA   Li Y., Zhou Z., Alimandi M., Chen C.;
RT   "WW domain containing E3 ubiquitin protein ligase 1 targets the full-length
RT   ErbB4 for ubiquitin-mediated degradation in breast cancer.";
RL   Oncogene 28:2948-2958(2009).
RN   [40]
RP   INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1; U2SURP;
RP   ITCH; HNRNPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND ARS2, FUNCTION,
RP   SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=20858735; DOI=10.1158/1541-7786.mcr-10-0042;
RA   Gilmore-Hebert M., Ramabhadran R., Stern D.F.;
RT   "Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage
RT   response pathways.";
RL   Mol. Cancer Res. 8:1388-1398(2010).
RN   [41]
RP   ACTIVITY REGULATION.
RX   PubMed=21439954; DOI=10.1016/j.yexcr.2011.03.015;
RA   Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L., Conde M.,
RA   Gomez-Martinez A., Garcia-Morales P., Ferragut J.A., Martinez-Lacaci I.;
RT   "Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting
RT   with erbB3 and erbB4 in glioblastoma cell lines.";
RL   Exp. Cell Res. 317:1476-1489(2011).
RN   [42]
RP   REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT.
RX   PubMed=14504474;
RA   Jones F.E., Golding J.P., Gassmann M.;
RT   "ErbB4 signaling during breast and neural development: novel genetic models
RT   reveal unique ErbB4 activities.";
RL   Cell Cycle 2:555-559(2003).
RN   [43]
RP   REVIEW.
RX   PubMed=15944951; DOI=10.14670/hh-20.1005;
RA   Zaczek A., Brandt B., Bielawski K.P.;
RT   "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase
RT   receptors and the consequences for therapeutic approaches.";
RL   Histol. Histopathol. 20:1005-1015(2005).
RN   [44]
RP   REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT.
RX   PubMed=18437540; DOI=10.1007/s10911-008-9080-x;
RA   Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. III;
RT   "ErbB4/HER4: role in mammary gland development, differentiation and growth
RT   inhibition.";
RL   J. Mammary Gland Biol. Neoplasia 13:235-246(2008).
RN   [45]
RP   REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN.
RX   PubMed=18473151; DOI=10.1007/s10911-008-9076-6;
RA   Jones F.E.;
RT   "HER4 intracellular domain (4ICD) activity in the developing mammary gland
RT   and breast cancer.";
RL   J. Mammary Gland Biol. Neoplasia 13:247-258(2008).
RN   [46]
RP   REVIEW ON LIGAND SPECIFICITY AND SIGNALING.
RX   PubMed=18454307; DOI=10.1007/s10911-008-9079-3;
RA   Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K.;
RT   "Role of ErbB4 in breast cancer.";
RL   J. Mammary Gland Biol. Neoplasia 13:259-268(2008).
RN   [47]
RP   REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH.
RX   PubMed=20933198; DOI=10.1016/s1054-3589(10)59002-1;
RA   Xu Y., Li X., Liu X., Zhou M.;
RT   "Neuregulin-1/ErbB signaling and chronic heart failure.";
RL   Adv. Pharmacol. 59:31-51(2010).
RN   [48]
RP   REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE
RP   SPECIFICITY; SIGNALING AND ROLE IN DISEASE.
RX   PubMed=21811097; DOI=10.4161/cc.10.16.17194;
RA   Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M.,
RA   Elenius K.;
RT   "Function of ERBB4 is determined by alternative splicing.";
RL   Cell Cycle 10:2647-2657(2011).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473;
RP   ASN-495 AND ASN-576.
RX   PubMed=16203964; DOI=10.1073/pnas.0507591102;
RA   Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.;
RT   "The extracellular region of ErbB4 adopts a tethered conformation in the
RT   absence of ligand.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH INHIBITOR,
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-710;
RP   MET-766; LEU-864 AND ILE-947.
RX   PubMed=18287036; DOI=10.1073/pnas.0708281105;
RA   Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L.,
RA   Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M.,
RA   Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G., Reno M.J.,
RA   Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D., Vanderwall D.E.,
RA   Waterson A.G., Williams J.D., White W.L., Uehling D.E.;
RT   "6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as
RT   tunable covalent modifiers of ErbB kinases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2773-2778(2008).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN
RP   COMPLEX WITH LAPATINIB, CATALYTIC ACTIVITY, ACTIVITY REGULATION,
RP   AUTOPHOSPHORYLATION, AND SUBUNIT.
RX   PubMed=18334220; DOI=10.1016/j.str.2007.12.016;
RA   Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S.,
RA   Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., Leahy D.J.;
RT   "Mechanism of activation and inhibition of the HER4/ErbB4 kinase.";
RL   Structure 16:460-467(2008).
RN   [52]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [53]
RP   VARIANTS ALS19 GLN-927 AND TRP-1275, AND CHARACTERIZATION OF VARIANTS ASL19
RP   GLN-927 AND TRP-1275.
RX   PubMed=24119685; DOI=10.1016/j.ajhg.2013.09.008;
RA   Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K., Moritoyo H.,
RA   Belzil V.V., Dion P.A., Higasa K., Doi K., Ishiura H., Mitsui J., Date H.,
RA   Ahsan B., Matsukawa T., Ichikawa Y., Moritoyo T., Ikoma M., Hashimoto T.,
RA   Kimura F., Murayama S., Onodera O., Nishizawa M., Yoshida M., Atsuta N.,
RA   Sobue G., Fifita J.A., Williams K.L., Blair I.P., Nicholson G.A.,
RA   Gonzalez-Perez P., Brown R.H. Jr., Nomoto M., Elenius K., Rouleau G.A.,
RA   Fujiyama A., Morishita S., Goto J., Tsuji S., Nakamura R., Watanabe H.,
RA   Izumi Y., Kaji R., Morita M., Ogaki K., Taniguchi A., Aiba I.,
RA   Mizoguchi K., Okamoto K., Hasegawa K., Aoki M., Kawata A., Nakano I.,
RA   Abe K., Oda M., Konagaya M., Imai T., Nakagawa M., Fujita T., Sasaki H.,
RA   Nishizawa M.;
RT   "ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause
RT   amyotrophic lateral sclerosis type 19.";
RL   Am. J. Hum. Genet. 93:900-905(2013).
CC   -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as cell
CC       surface receptor for neuregulins and EGF family members and regulates
CC       development of the heart, the central nervous system and the mammary
CC       gland, gene transcription, cell proliferation, differentiation,
CC       migration and apoptosis. Required for normal cardiac muscle
CC       differentiation during embryonic development, and for postnatal
CC       cardiomyocyte proliferation. Required for normal development of the
CC       embryonic central nervous system, especially for normal neural crest
CC       cell migration and normal axon guidance. Required for mammary gland
CC       differentiation, induction of milk proteins and lactation. Acts as
CC       cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and
CC       the EGF family members BTC, EREG and HBEGF. Ligand binding triggers
CC       receptor dimerization and autophosphorylation at specific tyrosine
CC       residues that then serve as binding sites for scaffold proteins and
CC       effectors. Ligand specificity and signaling is modulated by alternative
CC       splicing, proteolytic processing, and by the formation of heterodimers
CC       with other ERBB family members, thereby creating multiple combinations
CC       of intracellular phosphotyrosines that trigger ligand- and context-
CC       specific cellular responses. Mediates phosphorylation of SHC1 and
CC       activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A
CC       CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the
CC       activation of phosphatidylinositol 3-kinase and AKT1 and protect cells
CC       against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate
CC       reorganization of the actin cytoskeleton and promote cell migration in
CC       response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the
CC       phosphotyrosine that mediates interaction with PIK3R1, and hence do not
CC       phosphorylate PIK3R1, do not protect cells against apoptosis, and do
CC       not promote reorganization of the actin cytoskeleton and cell
CC       migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-
CC       A CYT-2 gives rise to the corresponding soluble intracellular domains
CC       (4ICD) that translocate to the nucleus, promote nuclear import of
CC       STAT5A, activation of STAT5A, mammary epithelium differentiation, cell
CC       proliferation and activation of gene expression. The ERBB4 soluble
CC       intracellular domains (4ICD) colocalize with STAT5A at the CSN2
CC       promoter to regulate transcription of milk proteins during lactation.
CC       The ERBB4 soluble intracellular domains can also translocate to
CC       mitochondria and promote apoptosis. {ECO:0000269|PubMed:10348342,
CC       ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079,
CC       ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024,
CC       ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655,
CC       ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001,
CC       ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361,
CC       ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867,
CC       ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750,
CC       ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115,
CC       ECO:0000269|PubMed:9334263}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:18287036, ECO:0000269|PubMed:18334220,
CC         ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750};
CC   -!- ACTIVITY REGULATION: Binding of a cognate ligand leads to dimerization
CC       and activation by autophosphorylation on tyrosine residues. In vitro
CC       kinase activity is increased by Mg(2+). Inhibited by PD153035,
CC       lapatinib, gefitinib (iressa, ZD1839), AG1478 and BIBX1382BS.
CC       {ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:18334220,
CC       ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:21439954,
CC       ECO:0000269|PubMed:8617750}.
CC   -!- SUBUNIT: Monomer in the absence of bound ligand. Homodimer or
CC       heterodimer with another ERBB family member upon ligand binding, thus
CC       forming heterotetramers. Interacts with EGFR and ERBB2. Interacts with
CC       CBFA2T3 (By similarity). Interacts with DLG2 (via its PDZ domain), DLG3
CC       (via its PDZ domain), DLG4 (via its PDZ domain) and SNTB2 (via its PDZ
CC       domain). Interacts with MUC1. Interacts (via its PPxy motifs) with
CC       WWOX. Interacts (via the PPxY motif 3 of isoform JM-A CYT-2) with YAP1
CC       (via the WW domain 1 of isoform 1). Interacts (isoform JM-A CYT-1 and
CC       isoform JM-B CYT-1) with WWP1. Interacts (via its intracellular domain)
CC       with TRIM28. Interacts (via the intracellular domains of both CYT-1 and
CC       CYT-2 isoforms) with KAP1; the interaction does not phosphorylate KAP1
CC       but represses ERBB4-mediated transcriptional activity. Interacts with
CC       PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH, HNRNPU,
CC       AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 AND ARS2. Interacts
CC       (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-1) with PIK3R1.
CC       Interacts with SHC1. Interacts with GRB2. Interacts (soluble
CC       intracellular domain) with STAT5A. Interacts (soluble intracellular
CC       domain) with BCL2. Interacts (phosphorylated) with STAT1. {ECO:0000250,
CC       ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604,
CC       ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10725395,
CC       ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:12807903,
CC       ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15534001,
CC       ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16778220,
CC       ECO:0000269|PubMed:16815842, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18287036,
CC       ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:18721752,
CC       ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:19193720,
CC       ECO:0000269|PubMed:19561640, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:7689552, ECO:0000269|PubMed:7902537,
CC       ECO:0000269|PubMed:8570211, ECO:0000269|PubMed:8617750,
CC       ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115,
CC       ECO:0000269|PubMed:9275162, ECO:0000269|PubMed:9419975,
CC       ECO:0000269|PubMed:9516479}.
CC   -!- INTERACTION:
CC       Q15303; P42684: ABL2; NbExp=4; IntAct=EBI-80371, EBI-1102694;
CC       Q15303; Q13895: BYSL; NbExp=3; IntAct=EBI-80371, EBI-358049;
CC       Q15303; P78352: DLG4; NbExp=6; IntAct=EBI-80371, EBI-80389;
CC       Q15303; P00533: EGFR; NbExp=2; IntAct=EBI-80371, EBI-297353;
CC       Q15303; P04626: ERBB2; NbExp=4; IntAct=EBI-80371, EBI-641062;
CC       Q15303; P21860: ERBB3; NbExp=4; IntAct=EBI-80371, EBI-720706;
CC       Q15303; Q99075: HBEGF; NbExp=2; IntAct=EBI-80371, EBI-7211558;
CC       Q15303; P08238: HSP90AB1; NbExp=2; IntAct=EBI-80371, EBI-352572;
CC       Q15303; Q96J02-2: ITCH; NbExp=3; IntAct=EBI-80371, EBI-6672198;
CC       Q15303-3; Q96J02-2: ITCH; NbExp=2; IntAct=EBI-15692884, EBI-6672198;
CC       Q15303; P26447: S100A4; NbExp=4; IntAct=EBI-80371, EBI-717058;
CC       Q15303; P29353: SHC1; NbExp=2; IntAct=EBI-80371, EBI-78835;
CC       Q15303; Q12815: TROAP; NbExp=3; IntAct=EBI-80371, EBI-2349743;
CC       Q15303; P46937: YAP1; NbExp=3; IntAct=EBI-80371, EBI-1044059;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10348342,
CC       ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001,
CC       ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220,
CC       ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069,
CC       ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720,
CC       ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326,
CC       ECO:0000269|PubMed:9334263}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:12807903,
CC       ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:16251361,
CC       ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867,
CC       ECO:0000269|PubMed:19193720, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}. Note=In
CC       response to NRG1 treatment, the activated receptor is internalized.
CC   -!- SUBCELLULAR LOCATION: [ERBB4 intracellular domain]: Nucleus
CC       {ECO:0000269|PubMed:17486069}. Mitochondrion
CC       {ECO:0000269|PubMed:17486069}. Note=Following proteolytical processing
CC       E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is
CC       translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is
CC       found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=JM-A CYT-1;
CC         IsoId=Q15303-1; Sequence=Displayed;
CC       Name=JM-B CYT-1;
CC         IsoId=Q15303-2; Sequence=VSP_002895;
CC       Name=JM-A CYT-2;
CC         IsoId=Q15303-3; Sequence=VSP_022148;
CC       Name=JM-B CYT-2;
CC         IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148;
CC   -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart,
CC       kidney, in addition to skeletal muscle, parathyroid, cerebellum,
CC       pituitary, spleen, testis and breast. Lower levels in thymus, lung,
CC       salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1
CC       are expressed in cerebellum, but only the isoform JM-B is expressed in
CC       the heart. {ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:8383326,
CC       ECO:0000269|PubMed:9334263}.
CC   -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17.
CC       Proteolytic processing in response to ligand or 12-O-
CC       tetradecanoylphorbol-13-acetate stimulation results in the production
CC       of 120 kDa soluble receptor forms and intermediate membrane-anchored 80
CC       kDa fragments (m80HER4), which are further processed by a presenilin-
CC       dependent gamma-secretase to release a cytoplasmic intracellular domain
CC       (E4ICD; E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform).
CC       Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1
CC       are more readily degraded by the proteasome than fragments of isoform
CC       JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B
CC       CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not
CC       processed by ADAM17, precluding further processing by gamma-secretase.
CC       {ECO:0000269|PubMed:10744726, ECO:0000269|PubMed:12807903,
CC       ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:9334263}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other subunit.
CC       Ligands trigger phosphorylation at specific tyrosine residues, thereby
CC       creating binding sites for scaffold proteins and effectors.
CC       Constitutively phosphorylated at a basal level when overexpressed in
CC       heterologous systems; ligand binding leads to increased
CC       phosphorylation. Phosphorylation at Tyr-1035 is important for
CC       interaction with STAT1. Phosphorylation at Tyr-1056 is important for
CC       interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for
CC       interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute
CC       to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively
CC       phosphorylated on tyrosine residues in a ligand-independent manner.
CC       E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues.
CC       {ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:17120616,
CC       ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:18721752,
CC       ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750,
CC       ECO:0000269|PubMed:9168115}.
CC   -!- PTM: Ubiquitinated. During mitosis, the ERBB4 intracellular domain is
CC       ubiquitinated by the APC/C complex and targeted to proteasomal
CC       degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are
CC       ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is
CC       ubiquitinated, and this involves NEDD4. {ECO:0000269|PubMed:17638867,
CC       ECO:0000269|PubMed:19193720}.
CC   -!- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A
CC       neurodegenerative disorder affecting upper motor neurons in the brain
CC       and lower motor neurons in the brain stem and spinal cord, resulting in
CC       fatal paralysis. Sensory abnormalities are absent. The pathologic
CC       hallmarks of the disease include pallor of the corticospinal tract due
CC       to loss of motor neurons, presence of ubiquitin-positive inclusions
CC       within surviving motor neurons, and deposition of pathologic
CC       aggregates. The etiology of amyotrophic lateral sclerosis is likely to
CC       be multifactorial, involving both genetic and environmental factors.
CC       The disease is inherited in 5-10% of the cases.
CC       {ECO:0000269|PubMed:24119685}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform JM-A CYT-1]: Proteolytical processing generates
CC       E4ICD1 (s80Cyt1).
CC   -!- MISCELLANEOUS: [Isoform JM-A CYT-2]: Proteolytical processing generates
CC       E4ICD2 (s80Cyt2). {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- CAUTION: Conflicting reports about the role of ERBB4 in mediating
CC       apoptosis, differentiation, or tumor cell proliferation may be
CC       explained by the opposite functions of the different isoforms and their
CC       intracellular fragments, and by the formation of heterodimers with
CC       other EGF receptor family members (PubMed:18454307 and
CC       PubMed:21811097). Thus, heterodimer formation of a kinase-dead ERBB4
CC       mutant with ERBB2 is sufficient for the activation of AKT1, MAPK1/ERK2
CC       and MAPK3/ERK1 (PubMed:19098003). {ECO:0000305|PubMed:19098003}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L07868; AAB59446.1; -; mRNA.
DR   EMBL; BC112199; AAI12200.1; -; mRNA.
DR   EMBL; BC143741; AAI43742.1; -; mRNA.
DR   EMBL; BC143747; AAI43748.1; -; mRNA.
DR   EMBL; BC143749; AAI43750.1; -; mRNA.
DR   EMBL; AB209697; BAD92934.1; -; mRNA.
DR   CCDS; CCDS2394.1; -. [Q15303-1]
DR   CCDS; CCDS42811.1; -. [Q15303-3]
DR   PIR; A47253; A47253.
DR   RefSeq; NP_001036064.1; NM_001042599.1. [Q15303-3]
DR   RefSeq; NP_005226.1; NM_005235.2. [Q15303-1]
DR   RefSeq; XP_005246433.1; XM_005246376.2. [Q15303-2]
DR   RefSeq; XP_005246434.1; XM_005246377.2. [Q15303-4]
DR   PDB; 2AHX; X-ray; 2.40 A; A/B=26-641.
DR   PDB; 2L2T; NMR; -; A/B=642-685.
DR   PDB; 2LCX; NMR; -; A/B=642-685.
DR   PDB; 2R4B; X-ray; 2.40 A; A/B=690-999.
DR   PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029.
DR   PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029.
DR   PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029.
DR   PDB; 3U2P; X-ray; 2.57 A; A=26-522.
DR   PDB; 3U7U; X-ray; 3.03 A; A/B/C/D/E/F=26-640.
DR   PDB; 3U9U; X-ray; 3.42 A; E/F=26-650.
DR   PDBsum; 2AHX; -.
DR   PDBsum; 2L2T; -.
DR   PDBsum; 2LCX; -.
DR   PDBsum; 2R4B; -.
DR   PDBsum; 3BBT; -.
DR   PDBsum; 3BBW; -.
DR   PDBsum; 3BCE; -.
DR   PDBsum; 3U2P; -.
DR   PDBsum; 3U7U; -.
DR   PDBsum; 3U9U; -.
DR   SMR; Q15303; -.
DR   BioGrid; 108378; 89.
DR   DIP; DIP-29650N; -.
DR   ELM; Q15303; -.
DR   IntAct; Q15303; 99.
DR   MINT; Q15303; -.
DR   STRING; 9606.ENSP00000342235; -.
DR   BindingDB; Q15303; -.
DR   ChEMBL; CHEMBL3009; -.
DR   DrugBank; DB08916; Afatinib.
DR   DrugBank; DB12267; Brigatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugCentral; Q15303; -.
DR   GuidetoPHARMACOLOGY; 1799; -.
DR   TCDB; 8.A.23.1.17; the basigin (basigin) family.
DR   iPTMnet; Q15303; -.
DR   PhosphoSitePlus; Q15303; -.
DR   BioMuta; ERBB4; -.
DR   DMDM; 3913590; -.
DR   jPOST; Q15303; -.
DR   MassIVE; Q15303; -.
DR   MaxQB; Q15303; -.
DR   PaxDb; Q15303; -.
DR   PeptideAtlas; Q15303; -.
DR   PRIDE; Q15303; -.
DR   ProteomicsDB; 60520; -. [Q15303-1]
DR   ProteomicsDB; 60521; -. [Q15303-2]
DR   ProteomicsDB; 60522; -. [Q15303-3]
DR   ProteomicsDB; 60523; -. [Q15303-4]
DR   ABCD; Q15303; -.
DR   Antibodypedia; 1602; 1379 antibodies.
DR   DNASU; 2066; -.
DR   Ensembl; ENST00000342788; ENSP00000342235; ENSG00000178568. [Q15303-1]
DR   Ensembl; ENST00000436443; ENSP00000403204; ENSG00000178568. [Q15303-3]
DR   GeneID; 2066; -.
DR   KEGG; hsa:2066; -.
DR   UCSC; uc002veg.2; human. [Q15303-1]
DR   CTD; 2066; -.
DR   DisGeNET; 2066; -.
DR   GeneCards; ERBB4; -.
DR   HGNC; HGNC:3432; ERBB4.
DR   HPA; ENSG00000178568; Tissue enhanced (fallopian).
DR   MalaCards; ERBB4; -.
DR   MIM; 600543; gene.
DR   MIM; 615515; phenotype.
DR   neXtProt; NX_Q15303; -.
DR   OpenTargets; ENSG00000178568; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   PharmGKB; PA27847; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   GeneTree; ENSGT00940000154695; -.
DR   InParanoid; Q15303; -.
DR   KO; K05085; -.
DR   OMA; PASHDCI; -.
DR   OrthoDB; 81952at2759; -.
DR   PhylomeDB; Q15303; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1236394; Signaling by ERBB4.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling.
DR   Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling.
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   Reactome; R-HSA-9620244; Long-term potentiation.
DR   Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants.
DR   SignaLink; Q15303; -.
DR   SIGNOR; Q15303; -.
DR   ChiTaRS; ERBB4; human.
DR   EvolutionaryTrace; Q15303; -.
DR   GeneWiki; ERBB4; -.
DR   GenomeRNAi; 2066; -.
DR   Pharos; Q15303; Tclin.
DR   PRO; PR:Q15303; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q15303; protein.
DR   Bgee; ENSG00000178568; Expressed in oviduct epithelium and 167 other tissues.
DR   ExpressionAtlas; Q15303; baseline and differential.
DR   Genevisible; Q15303; HS.
DR   GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0099061; C:integral component of postsynaptic density membrane; IEA:Ensembl.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IMP:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0061026; P:cardiac muscle tissue regeneration; ISS:UniProtKB.
DR   GO; GO:0045165; P:cell fate commitment; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0021551; P:central nervous system morphogenesis; ISS:UniProtKB.
DR   GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0007595; P:lactation; IMP:UniProtKB.
DR   GO; GO:0060749; P:mammary gland alveolus development; ISS:UniProtKB.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; ISS:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB.
DR   GO; GO:0021889; P:olfactory bulb interneuron differentiation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; TAS:Reactome.
DR   GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:UniProtKB.
DR   GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0007416; P:synapse assembly; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB.
DR   CDD; cd00064; FU; 3.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR036941; Rcpt_L-dom_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 5.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing;
KW   Amyotrophic lateral sclerosis; Apoptosis; ATP-binding; Cell membrane;
KW   Developmental protein; Disease mutation; Disulfide bond; Glycoprotein;
KW   Kinase; Lactation; Membrane; Mitochondrion; Neurodegeneration;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Signal; Transcription;
KW   Transcription regulation; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..1308
FT                   /note="Receptor tyrosine-protein kinase erbB-4"
FT                   /id="PRO_0000016674"
FT   CHAIN           676..1308
FT                   /note="ERBB4 intracellular domain"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000396797"
FT   TOPO_DOM        26..651
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        652..675
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        676..1308
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          718..985
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         724..732
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         797..799
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         843..848
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOTIF           676..684
FT                   /note="Nuclear localization signal"
FT   MOTIF           1032..1035
FT                   /note="PPxY motif 1"
FT   MOTIF           1053..1056
FT                   /note="PPxY motif 2"
FT   MOTIF           1298..1301
FT                   /note="PPxY motif 3"
FT   MOTIF           1306..1308
FT                   /note="PDZ-binding"
FT   COMPBIAS        186..334
FT                   /note="Cys-rich"
FT   COMPBIAS        496..633
FT                   /note="Cys-rich"
FT   ACT_SITE        843
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         751
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         875
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18721752"
FT   MOD_RES         1035
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18721752"
FT   MOD_RES         1056
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17120616,
FT                   ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:8617750"
FT   MOD_RES         1150
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18721752"
FT   MOD_RES         1162
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18721752"
FT   MOD_RES         1188
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18721752,
FT                   ECO:0000269|PubMed:8617750"
FT   MOD_RES         1202
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18721752"
FT   MOD_RES         1242
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18721752,
FT                   ECO:0000269|PubMed:8617750"
FT   MOD_RES         1258
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18721752"
FT   MOD_RES         1284
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18721752"
FT   CARBOHYD        138
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   CARBOHYD        174
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   CARBOHYD        181
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        253
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   CARBOHYD        358
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   CARBOHYD        410
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   CARBOHYD        473
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   CARBOHYD        495
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   CARBOHYD        548
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        576
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   CARBOHYD        620
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        29..56
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        156..186
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        189..197
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        193..205
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        213..221
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        217..229
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        230..238
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        234..246
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        249..258
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        262..289
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        293..304
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        308..323
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        326..330
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        503..512
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        507..520
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        523..532
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        536..552
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        555..569
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        559..577
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        580..589
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        593..614
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        617..625
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   DISULFID        621..633
FT                   /evidence="ECO:0000269|PubMed:16203964"
FT   VAR_SEQ         626..648
FT                   /note="NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD (in isoform
FT                   JM-B CYT-1 and isoform JM-B CYT-2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9334263"
FT                   /id="VSP_002895"
FT   VAR_SEQ         1046..1061
FT                   /note="Missing (in isoform JM-A CYT-2 and isoform JM-B CYT-
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4"
FT                   /id="VSP_022148"
FT   VARIANT         140
FT                   /note="T -> I (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042113"
FT   VARIANT         303
FT                   /note="S -> Y (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042114"
FT   VARIANT         927
FT                   /note="R -> Q (in ALS19; reduces autophosphorylation upon
FT                   NRG1 stimulation; dbSNP:rs397514262)"
FT                   /evidence="ECO:0000269|PubMed:24119685"
FT                   /id="VAR_070810"
FT   VARIANT         1275
FT                   /note="R -> W (in ALS19; reduces autophosphorylation upon
FT                   NRG1 stimulation; dbSNP:rs397514263)"
FT                   /evidence="ECO:0000269|PubMed:24119685"
FT                   /id="VAR_070811"
FT   MUTAGEN         646
FT                   /note="Q->C: Constitutively activated kinase."
FT                   /evidence="ECO:0000269|PubMed:17120616"
FT   MUTAGEN         675
FT                   /note="V->A: Abolishes proteolytic processing and nuclear
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:15746097,
FT                   ECO:0000269|PubMed:17638867"
FT   MUTAGEN         681..684
FT                   /note="KKKR->EIMG: Abolishes nuclear localization of the
FT                   ERBB4 intracellular domain."
FT                   /evidence="ECO:0000269|PubMed:15534001"
FT   MUTAGEN         710
FT                   /note="L->N: Strongly reduced autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:18287036"
FT   MUTAGEN         721
FT                   /note="V->I: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19098003"
FT   MUTAGEN         751
FT                   /note="K->R: Abolishes kinase activity. Abolishes
FT                   phosphorylation, proteolytic processing and nuclear
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:11390655,
FT                   ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867"
FT   MUTAGEN         766
FT                   /note="M->R: Strongly reduced autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:18287036"
FT   MUTAGEN         773
FT                   /note="A->S: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19098003"
FT   MUTAGEN         782
FT                   /note="R->Q: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19098003"
FT   MUTAGEN         810
FT                   /note="E->K: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19098003"
FT   MUTAGEN         843
FT                   /note="D->N: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:16978839"
FT   MUTAGEN         854
FT                   /note="P->Q: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19098003"
FT   MUTAGEN         861
FT                   /note="D->Y: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19098003"
FT   MUTAGEN         864
FT                   /note="L->R: Strongly reduced autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:18287036"
FT   MUTAGEN         872
FT                   /note="E->K: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19098003"
FT   MUTAGEN         926
FT                   /note="T->M: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19098003"
FT   MUTAGEN         947
FT                   /note="I->R: Constitutively autophosphorylated."
FT                   /evidence="ECO:0000269|PubMed:18287036"
FT   MUTAGEN         992
FT                   /note="R->A: Abolishes APC/C-mediated degradation; when
FT                   associated with A-995 and A-1000."
FT                   /evidence="ECO:0000269|PubMed:17638867"
FT   MUTAGEN         995
FT                   /note="L->A: Abolishes APC/C-mediated degradation; when
FT                   associated with A-992 and A-1000."
FT                   /evidence="ECO:0000269|PubMed:17638867"
FT   MUTAGEN         1000
FT                   /note="D->A: Abolishes APC/C-mediated degradation; when
FT                   associated with A-992 and A-995."
FT                   /evidence="ECO:0000269|PubMed:17638867"
FT   MUTAGEN         1035
FT                   /note="Y->A: No effect on interaction with WWOX. Abolishes
FT                   interaction with WWOX; when associated with A-1301."
FT                   /evidence="ECO:0000269|PubMed:16061658"
FT   MUTAGEN         1056
FT                   /note="Y->A: Abolishes interaction with NEDD4 and impairs
FT                   ubiquitination. Promotes nuclear translocation of ERBB4
FT                   intracellular domain E4ICD1."
FT                   /evidence="ECO:0000269|PubMed:19561640"
FT   MUTAGEN         1056
FT                   /note="Y->F: Abolishes interaction with WWP1; when
FT                   associated with F-1301."
FT                   /evidence="ECO:0000269|PubMed:19561640"
FT   MUTAGEN         1301
FT                   /note="Y->A: Abolishes interaction with NEDD4 and impairs
FT                   ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:12807903,
FT                   ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640"
FT   MUTAGEN         1301
FT                   /note="Y->A: No effect on interaction with WWOX. Abolishes
FT                   interaction with WWOX; when associated with A-1035. Loss of
FT                   interaction with YAP1 and stimulation of transcription."
FT                   /evidence="ECO:0000269|PubMed:12807903,
FT                   ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640"
FT   MUTAGEN         1301
FT                   /note="Y->F: Abolishes interaction with WWP1; when
FT                   associated with F-1056."
FT                   /evidence="ECO:0000269|PubMed:12807903,
FT                   ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640"
FT   STRAND          28..30
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          38..41
FT                   /evidence="ECO:0000244|PDB:3U7U"
FT   HELIX           42..53
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          57..61
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          63..67
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           75..79
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          82..85
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          87..91
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          95..98
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   TURN            112..114
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          115..120
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          125..128
FT                   /evidence="ECO:0000244|PDB:3U2P"
FT   STRAND          133..135
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          144..150
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           158..160
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           163..165
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           173..175
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          176..178
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   TURN            191..193
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          197..201
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           202..204
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          221..225
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           226..228
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          234..242
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          245..254
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          257..261
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          265..269
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   TURN            270..273
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          274..277
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          283..285
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          288..292
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          298..300
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          303..307
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          312..317
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          320..325
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          327..329
FT                   /evidence="ECO:0000244|PDB:3U2P"
FT   STRAND          333..335
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           340..342
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   TURN            350..352
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           353..356
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          360..364
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          366..368
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           370..374
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           377..379
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           386..394
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          397..400
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          402..405
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           415..417
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          432..438
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          455..461
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           469..471
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           474..476
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          479..482
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          485..487
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          489..491
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           493..497
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   TURN            498..500
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          512..516
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          519..528
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          531..534
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          537..543
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          545..548
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          551..554
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          568..573
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          576..585
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          588..592
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          595..608
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          612..616
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   STRAND          625..629
FT                   /evidence="ECO:0000244|PDB:2AHX"
FT   HELIX           651..676
FT                   /evidence="ECO:0000244|PDB:2L2T"
FT   HELIX           715..717
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   STRAND          718..729
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   STRAND          731..737
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   STRAND          740..743
FT                   /evidence="ECO:0000244|PDB:3BBT"
FT   STRAND          746..752
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           762..773
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   STRAND          778..780
FT                   /evidence="ECO:0000244|PDB:3BBT"
FT   STRAND          783..787
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   STRAND          789..791
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   STRAND          793..797
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           804..810
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           812..814
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           817..836
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           846..848
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   STRAND          849..853
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   STRAND          856..859
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           864..869
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           884..886
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           889..893
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           899..914
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   TURN            920..923
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   TURN            926..928
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           929..934
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           947..955
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           961..963
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           967..977
FT                   /evidence="ECO:0000244|PDB:2R4B"
FT   HELIX           981..983
FT                   /evidence="ECO:0000244|PDB:2R4B"
SQ   SEQUENCE   1308 AA;  146808 MW;  5E4AE80985D88761 CRC64;
     MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM
     GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF
     LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST
     NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG
     PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD
     SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT
     KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL
     VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST
     INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD
     GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA
     NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG
     LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR
     VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL
     VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV
     HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ
     SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID
     ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE
     EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP
     YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS
     PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED
     EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ
     EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV
//
ID   A0A090N8E9_HUMAN        Unreviewed;       751 AA.
AC   A0A090N8E9;
DT   26-NOV-2014, integrated into UniProtKB/TrEMBL.
DT   26-NOV-2014, sequence version 1.
DT   22-APR-2020, entry version 44.
DE   SubName: Full=Enhancer of zeste homolog 2 (Drosophila) {ECO:0000313|EMBL:EAL24424.1};
GN   Name=EZH2 {ECO:0000313|EMBL:EAL24424.1};
GN   ORFNames=tcag7.507 {ECO:0000313|EMBL:EAL24424.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAL24424.1};
RN   [1] {ECO:0000313|EMBL:EAL24424.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J., Grzeschik K.H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Dohner H.,
RA   Dohner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [2] {ECO:0000313|EMBL:EAL24424.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Nusskern D., Zhang Q., Gu Z., Lu F., Zeesman S., Teshima I.,
RA   Chitayat D., Shuman C., Weksberg R., Zackai E.H., Grebe T.A., Cox S.R.,
RA   Kirkpatrick S.J., Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.,
RA   Lococo F., Belloni E., Shaffer L.G., Morton C.C., Pober B., Gusella J.,
RA   Bruns G., Korf B.R., Quade B.J., Ligon A.H., Ferguson H., Higgins A.W.,
RA   Leach N.T., Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M.,
RA   Gripp K.W., Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H.,
RA   Teebi A., Minassian B.A., Kere J., Armengol L., Pujana M.Angel.,
RA   Estivill X., Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P.,
RA   Zlotorynski E., Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J.,
RA   Doehner H., Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
CC   -!- CAUTION: The sequence shown here is derived from an EMBL/GenBank/DDBJ
CC       whole genome shotgun (WGS) entry which is preliminary data.
CC       {ECO:0000313|EMBL:EAL24424.1}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AACC02000041; EAL24424.1; -; Genomic_DNA.
DR   RefSeq; NP_004447.2; NM_004456.4.
DR   RefSeq; XP_011514186.1; XM_011515884.2.
DR   SMR; A0A090N8E9; -.
DR   PRIDE; A0A090N8E9; -.
DR   Antibodypedia; 32761; 796 antibodies.
DR   GeneID; 2146; -.
DR   CTD; 2146; -.
DR   EuPathDB; HostDB:ENSG00000106462.10; -.
DR   eggNOG; KOG1079; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   OMA; IKEAWIK; -.
DR   OrthoDB; 875190at2759; -.
DR   PhylomeDB; A0A090N8E9; -.
DR   ChiTaRS; EZH2; human.
DR   GenomeRNAi; 2146; -.
DR   Bgee; ENSG00000106462; Expressed in lung and 156 other tissues.
DR   ExpressionAtlas; A0A090N8E9; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0035098; C:ESC/E(Z) complex; IEA:Ensembl.
DR   GO; GO:0000790; C:nuclear chromatin; IEA:Ensembl.
DR   GO; GO:0045120; C:pronucleus; IEA:Ensembl.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IEA:InterPro.
DR   GO; GO:0070878; F:primary miRNA binding; IEA:Ensembl.
DR   GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:Ensembl.
DR   GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0035984; P:cellular response to trichostatin A; IEA:Ensembl.
DR   GO; GO:0021695; P:cerebellar cortex development; IEA:Ensembl.
DR   GO; GO:0006306; P:DNA methylation; IEA:Ensembl.
DR   GO; GO:0070314; P:G1 to G0 transition; IEA:Ensembl.
DR   GO; GO:0036333; P:hepatocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0098532; P:histone H3-K27 trimethylation; IEA:Ensembl.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0045605; P:negative regulation of epidermal cell differentiation; IEA:Ensembl.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0051154; P:negative regulation of striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:1900006; P:positive regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0071168; P:protein localization to chromatin; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IEA:Ensembl.
DR   GO; GO:0014013; P:regulation of gliogenesis; IEA:Ensembl.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:1904772; P:response to tetrachloromethane; IEA:Ensembl.
DR   GO; GO:0014834; P:skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration; IEA:Ensembl.
DR   CDD; cd00167; SANT; 1.
DR   InterPro; IPR026489; CXC_dom.
DR   InterPro; IPR021654; EZH1/EZH2.
DR   InterPro; IPR041343; PRC2_HTH_1.
DR   InterPro; IPR041355; Pre-SET_CXC.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR033467; Tesmin/TSO1-like_CXC.
DR   Pfam; PF11616; EZH2_WD-Binding; 1.
DR   Pfam; PF18118; PRC2_HTH_1; 1.
DR   Pfam; PF18264; preSET_CXC; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM01114; CXC; 1.
DR   SMART; SM00717; SANT; 2.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51633; CXC; 1.
DR   PROSITE; PS50280; SET; 1.
PE   4: Predicted;
FT   DOMAIN          508..610
FT                   /note="CXC"
FT                   /evidence="ECO:0000259|PROSITE:PS51633"
FT   DOMAIN          617..732
FT                   /note="SET"
FT                   /evidence="ECO:0000259|PROSITE:PS50280"
FT   REGION          180..221
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          345..431
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        180..195
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        196..220
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        364..379
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        380..412
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   751 AA;  86018 MW;  D885CF02E60EF836 CRC64;
     MGQTGKKSEK GPVCWRKRVK SEYMRLRQLK RFRRADEVKS MFSSNRQKIL ERTEILNQEW
     KQRRIQPVHI LTSVSSLRGT RECSVTSDLD FPTQVIPLKT LNAVASVPIM YSWSPLQQNF
     MVEDETVLHN IPYMGDEVLD QDGTFIEELI KNYDGKVHGD RECGFINDEI FVELVNALGQ
     YNDDDDDDDG DDPEEREEKQ KDLEDHRDDK ESRPPRKFPS DKIFEAISSM FPDKGTAEEL
     KEKYKELTEQ QLPGALPPEC TPNIDGPNAK SVQREQSLHS FHTLFCRRCF KYDCFLHRKC
     NYSFHATPNT YKRKNTETAL DNKPCGPQCY QHLEGAKEFA AALTAERIKT PPKRPGGRRR
     GRLPNNSSRP STPTINVLES KDTDSDREAG TETGGENNDK EEEEKKDETS SSSEANSRCQ
     TPIKMKPNIE PPENVEWSGA EASMFRVLIG TYYDNFCAIA RLIGTKTCRQ VYEFRVKESS
     IIAPAPAEDV DTPPRKKKRK HRLWAAHCRK IQLKKDGSSN HVYNYQPCDH PRQPCDSSCP
     CVIAQNFCEK FCQCSSECQN RFPGCRCKAQ CNTKQCPCYL AVRECDPDLC LTCGAADHWD
     SKNVSCKNCS IQRGSKKHLL LAPSDVAGWG IFIKDPVQKN EFISEYCGEI ISQDEADRRG
     KVYDKYMCSF LFNLNNDFVV DATRKGNKIR FANHSVNPNC YAKVMMVNGD HRIGIFAKRA
     IQTGEELFFD YRYSQADALK YVGIEREMEI P
//
ID   EZH2_HUMAN              Reviewed;         746 AA.
AC   Q15910; B2RAQ1; B3KS30; B7Z1D6; B7Z7L6; Q15755; Q75MG3; Q92857; Q96FI6;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   22-APR-2020, entry version 199.
DE   RecName: Full=Histone-lysine N-methyltransferase EZH2 {ECO:0000305};
DE            EC=2.1.1.356 {ECO:0000269|PubMed:22323599};
DE   AltName: Full=ENX-1;
DE   AltName: Full=Enhancer of zeste homolog 2 {ECO:0000303|PubMed:28229514};
DE   AltName: Full=Lysine N-methyltransferase 6;
GN   Name=EZH2 {ECO:0000312|HGNC:HGNC:3527}; Synonyms=KMT6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8954776; DOI=10.1006/geno.1996.0588;
RA   Chen H., Rossier C., Antonarakis S.E.;
RT   "Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2)
RT   that maps to chromosome 21q22.2.";
RL   Genomics 38:30-37(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9214638; DOI=10.1093/emboj/16.11.3219;
RA   Laible G., Wolf A., Dorn R., Reuter G., Nislow C., Lebersorger A.,
RA   Popkin D., Pillus L., Jenuwein T.;
RT   "Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate
RT   gene silencing in Drosophila heterochromatin and at S. cerevisiae
RT   telomeres.";
RL   EMBO J. 16:3219-3232(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 4 AND 5).
RC   TISSUE=Brain, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 134-746.
RX   PubMed=8649418; DOI=10.1128/mcb.16.6.3066;
RA   Hobert O., Jallal B., Ullrich A.;
RT   "Interaction of Vav with ENX-1, a putative transcriptional regulator of
RT   homeobox gene expression.";
RL   Mol. Cell. Biol. 16:3066-3073(1996).
RN   [8]
RP   INTERACTION WITH ATRX.
RX   PubMed=9499421; DOI=10.1093/hmg/7.4.679;
RA   Cardoso C., Timsit S., Villard L., Khrestchatisky M., Fontes M.,
RA   Colleaux L.;
RT   "Specific interaction between the XNP/ATR-X gene product and the SET domain
RT   of the human EZH2 protein.";
RL   Hum. Mol. Genet. 7:679-684(1998).
RN   [9]
RP   INTERACTION WITH EED, AND SUBCELLULAR LOCATION.
RX   PubMed=9584199; DOI=10.1128/mcb.18.6.3586;
RA   Sewalt R.G.A.B., van der Vlag J., Gunster M.J., Hamer K.M.,
RA   den Blaauwen J.L., Satijn D.P.E., Hendrix T., van Driel R., Otte A.P.;
RT   "Characterization of interactions between the mammalian polycomb-group
RT   proteins Enx1/EZH2 and EED suggests the existence of different mammalian
RT   polycomb-group protein complexes.";
RL   Mol. Cell. Biol. 18:3586-3595(1998).
RN   [10]
RP   INTERACTION WITH EED; HDAC1 AND HDAC2.
RX   PubMed=10581039; DOI=10.1038/70602;
RA   van der Vlag J., Otte A.P.;
RT   "Transcriptional repression mediated by the human polycomb-group protein
RT   EED involves histone deacetylation.";
RL   Nat. Genet. 23:474-478(1999).
RN   [11]
RP   INTERACTION WITH EED.
RX   PubMed=11158321; DOI=10.1128/mcb.21.4.1360-1369.2001;
RA   Satijn D.P.E., Hamer K.M., den Blaauwen J., Otte A.P.;
RT   "The polycomb group protein EED interacts with YY1, and both proteins
RT   induce neural tissue in Xenopus embryos.";
RL   Mol. Cell. Biol. 21:1360-1369(2001).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2 COMPLEX
RP   WITH EED; RBBP4; RBBP7 AND SUZ12, METHYLTRANSFERASE ACTIVITY OF THE PRC2
RP   COMPLEX, AND MUTAGENESIS OF CYS-588 AND HIS-689.
RX   PubMed=12435631; DOI=10.1101/gad.1035902;
RA   Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P., Reinberg D.;
RT   "Histone methyltransferase activity associated with a human multiprotein
RT   complex containing the Enhancer of Zeste protein.";
RL   Genes Dev. 16:2893-2905(2002).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12101246; DOI=10.1128/mcb.22.15.5539-5553.2002;
RA   Sewalt R.G.A.B., Lachner M., Vargas M., Hamer K.M., den Blaauwen J.L.,
RA   Hendrix T., Melcher M., Schweizer D., Jenuwein T., Otte A.P.;
RT   "Selective interactions between vertebrate polycomb homologs and the
RT   SUV39H1 histone lysine methyltransferase suggest that histone H3-K9
RT   methylation contributes to chromosomal targeting of Polycomb group
RT   proteins.";
RL   Mol. Cell. Biol. 22:5539-5553(2002).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2 COMPLEX
RP   WITH EED; RBBP4; RBBP7 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE
RP   PRC2 COMPLEX.
RX   PubMed=12351676; DOI=10.1126/science.1076997;
RA   Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P.,
RA   Jones R.S., Zhang Y.;
RT   "Role of histone H3 lysine 27 methylation in Polycomb-group silencing.";
RL   Science 298:1039-1043(2002).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, INDUCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=14532106; DOI=10.1093/emboj/cdg542;
RA   Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K.;
RT   "EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and
RT   amplified in cancer.";
RL   EMBO J. 22:5323-5335(2003).
RN   [16]
RP   FUNCTION, INTERACTION WITH EED AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF
RP   THE PRC2 COMPLEX.
RX   PubMed=15385962; DOI=10.1038/sj.emboj.7600402;
RA   Pasini D., Bracken A.P., Jensen M.R., Lazzerini Denchi E., Helin K.;
RT   "Suz12 is essential for mouse development and for EZH2 histone
RT   methyltransferase activity.";
RL   EMBO J. 23:4061-4071(2004).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15231737; DOI=10.1101/gad.1200204;
RA   Kirmizis A., Bartley S.M., Kuzmichev A., Margueron R., Reinberg D.,
RA   Green R., Farnham P.J.;
RT   "Silencing of human polycomb target genes is associated with methylation of
RT   histone H3 Lys 27.";
RL   Genes Dev. 18:1592-1605(2004).
RN   [18]
RP   CHARACTERIZATION OF THE PRC2 AND PRC3 COMPLEXES INCLUDING EED; EZH2; RBBP4;
RP   RBBP7 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 AND PRC3
RP   COMPLEXES.
RX   PubMed=15099518; DOI=10.1016/s1097-2765(04)00185-6;
RA   Kuzmichev A., Jenuwein T., Tempst P., Reinberg D.;
RT   "Different EZH2-containing complexes target methylation of histone H1 or
RT   nucleosomal histone H3.";
RL   Mol. Cell 14:183-193(2004).
RN   [19]
RP   FUNCTION, CHARACTERIZATION OF THE PRC2 COMPLEX INCLUDING AEBP2; EED; EZH2;
RP   RBBP4 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=15225548; DOI=10.1016/j.molcel.2004.06.020;
RA   Cao R., Zhang Y.;
RT   "SUZ12 is required for both the histone methyltransferase activity and the
RT   silencing function of the EED-EZH2 complex.";
RL   Mol. Cell 15:57-67(2004).
RN   [20]
RP   DEVELOPMENTAL STAGE, AND INDUCTION.
RX   PubMed=15208672; DOI=10.1038/sj.onc.1207706;
RA   Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., Rotter V.;
RT   "Activated p53 suppresses the histone methyltransferase EZH2 gene.";
RL   Oncogene 23:5759-5769(2004).
RN   [21]
RP   FUNCTION IN RETINOIC ACID SIGNALING, AND INTERACTION WITH PRAME.
RX   PubMed=16179254; DOI=10.1016/j.cell.2005.07.003;
RA   Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., Bernards R.;
RT   "The human tumor antigen PRAME is a dominant repressor of retinoic acid
RT   receptor signaling.";
RL   Cell 122:835-847(2005).
RN   [22]
RP   CHARACTERIZATION OF THE PRC4 COMPLEX INCLUDING EED; EZH2; RBBP4; RBBP7;
RP   SUZ12 AND SIRT1, AND METHYLTRANSFERASE ACTIVITY OF THE PRC4 COMPLEX.
RX   PubMed=15684044; DOI=10.1073/pnas.0409875102;
RA   Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M.,
RA   Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P.J.,
RA   Reinberg D.;
RT   "Composition and histone substrates of polycomb repressive group complexes
RT   change during cellular differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1859-1864(2005).
RN   [23]
RP   INTERACTION WITH EED AND SUZ12, PHOSPHORYLATION AT SER-21 BY AKT1, AND
RP   MUTAGENESIS OF SER-21.
RX   PubMed=16224021; DOI=10.1126/science.1118947;
RA   Cha T.-L., Zhou B.P., Xia W., Wu Y., Yang C.-C., Chen C.-T., Ping B.,
RA   Otte A.P., Hung M.-C.;
RT   "Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27
RT   in histone H3.";
RL   Science 310:306-310(2005).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [25]
RP   FUNCTION.
RX   PubMed=16618801; DOI=10.1101/gad.381706;
RA   Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K.;
RT   "Genome-wide mapping of Polycomb target genes unravels their roles in cell
RT   fate transitions.";
RL   Genes Dev. 20:1123-1136(2006).
RN   [26]
RP   METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=16431907; DOI=10.1074/jbc.m513425200;
RA   Martin C., Cao R., Zhang Y.;
RT   "Substrate preferences of the EZH2 histone methyltransferase complex.";
RL   J. Biol. Chem. 281:8365-8370(2006).
RN   [27]
RP   FUNCTION.
RX   PubMed=16717091; DOI=10.1074/jbc.m603722200;
RA   Etchegaray J.P., Yang X., DeBruyne J.P., Peters A.H., Weaver D.R.,
RA   Jenuwein T., Reppert S.M.;
RT   "The polycomb group protein EZH2 is required for mammalian circadian clock
RT   function.";
RL   J. Biol. Chem. 281:21209-21215(2006).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [29]
RP   FUNCTION, AND INTERACTION OF THE PRC2 COMPLEX WITH DNMT1; DNMT3A AND
RP   DNMT3B.
RX   PubMed=16357870; DOI=10.1038/nature04431;
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RT   "The Polycomb group protein EZH2 directly controls DNA methylation.";
RL   Nature 439:871-874(2006).
RN   [30]
RP   ERRATUM OF PUBMED:16357870.
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RL   Nature 446:824-824(2006).
RN   [31]
RP   FUNCTION.
RX   PubMed=16936726; DOI=10.1038/nsmb1142;
RA   Kim D.H., Villeneuve L.M., Morris K.V., Rossi J.J.;
RT   "Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human
RT   cells.";
RL   Nat. Struct. Mol. Biol. 13:793-797(2006).
RN   [32]
RP   FUNCTION.
RX   PubMed=17210787; DOI=10.1101/gad.1499407;
RA   Kotake Y., Cao R., Viatour P., Sage J., Zhang Y., Xiong Y.;
RT   "pRB family proteins are required for H3K27 trimethylation and Polycomb
RT   repression complexes binding to and silencing p16INK4alpha tumor suppressor
RT   gene.";
RL   Genes Dev. 21:49-54(2007).
RN   [33]
RP   FUNCTION, DEVELOPMENTAL STAGE, AND INDUCTION.
RX   PubMed=17344414; DOI=10.1101/gad.415507;
RA   Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D., Gargiulo G.,
RA   Beekman C., Theilgaard-Moench K., Minucci S., Porse B.T., Marine J.-C.,
RA   Hansen K.H., Helin K.;
RT   "The Polycomb group proteins bind throughout the INK4A-ARF locus and are
RT   disassociated in senescent cells.";
RL   Genes Dev. 21:525-530(2007).
RN   [34]
RP   DE NOVO DNA METHYLATION OF PRC2 TARGET GENES.
RX   PubMed=17200670; DOI=10.1038/ng1950;
RA   Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M.,
RA   Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E.,
RA   Bergman Y., Simon I., Cedar H.;
RT   "Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for
RT   de novo methylation in cancer.";
RL   Nat. Genet. 39:232-236(2007).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [37]
RP   FUNCTION, AND IDENTIFICATION IN THE PRC2/EED-EZH1 COMPLEX.
RX   PubMed=19026781; DOI=10.1016/j.molcel.2008.11.004;
RA   Margueron R., Li G., Sarma K., Blais A., Zavadil J., Woodcock C.L.,
RA   Dynlacht B.D., Reinberg D.;
RT   "Ezh1 and Ezh2 maintain repressive chromatin through different
RT   mechanisms.";
RL   Mol. Cell 32:503-518(2008).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2 COMPLEX,
RP   AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=18086877; DOI=10.1128/mcb.01589-07;
RA   Cao R., Wang H., He J., Erdjument-Bromage H., Tempst P., Zhang Y.;
RT   "Role of hPHF1 in H3K27 methylation and Hox gene silencing.";
RL   Mol. Cell. Biol. 28:1862-1872(2008).
RN   [39]
RP   FUNCTION, INTERACTION WITH EED; SUZ12 AND PHF1, METHYLTRANSFERASE ACTIVITY
RP   OF THE PRC2 COMPLEX, AND MUTAGENESIS OF HIS-689.
RX   PubMed=18285464; DOI=10.1128/mcb.02017-07;
RA   Sarma K., Margueron R., Ivanov A., Pirrotta V., Reinberg D.;
RT   "Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in
RT   vivo.";
RL   Mol. Cell. Biol. 28:2718-2731(2008).
RN   [40]
RP   SUMOYLATION.
RX   PubMed=18628979; DOI=10.1371/journal.pone.0002704;
RA   Riising E.M., Boggio R., Chiocca S., Helin K., Pasini D.;
RT   "The polycomb repressive complex 2 is a potential target of SUMO
RT   modifications.";
RL   PLoS ONE 3:E2704-E2704(2008).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-366; THR-367 AND THR-487, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [44]
RP   FUNCTION, PHOSPHORYLATION AT THR-345 BY CDK1 AND CDK2, AND MUTAGENESIS OF
RP   THR-345.
RX   PubMed=20935635; DOI=10.1038/ncb2116;
RA   Chen S., Bohrer L.R., Rai A.N., Pan Y., Gan L., Zhou X., Bagchi A.,
RA   Simon J.A., Huang H.;
RT   "Cyclin-dependent kinases regulate epigenetic gene silencing through
RT   phosphorylation of EZH2.";
RL   Nat. Cell Biol. 12:1108-1114(2010).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [46]
RP   INTERACTION WITH CDYL.
RX   PubMed=22009739; DOI=10.1074/jbc.m111.271064;
RA   Zhang Y., Yang X., Gui B., Xie G., Zhang D., Shang Y., Liang J.;
RT   "Corepressor protein CDYL functions as a molecular bridge between polycomb
RT   repressor complex 2 and repressive chromatin mark trimethylated histone
RT   lysine 27.";
RL   J. Biol. Chem. 286:42414-42425(2011).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [48]
RP   FUNCTION.
RX   PubMed=23063525; DOI=10.1016/j.molcel.2012.09.004;
RA   Lee J.M., Lee J.S., Kim H., Kim K., Park H., Kim J.Y., Lee S.H., Kim I.S.,
RA   Kim J., Lee M., Chung C.H., Seo S.B., Yoon J.B., Ko E., Noh D.Y., Kim K.I.,
RA   Kim K.K., Baek S.H.;
RT   "EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4
RT   E3 ubiquitin ligase complex.";
RL   Mol. Cell 48:572-586(2012).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; THR-339; SER-363; THR-367
RP   AND THR-487, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [50]
RP   GLYCOSYLATION AT SER-75, MUTAGENESIS OF SER-75, AND FUNCTION.
RX   PubMed=24474760; DOI=10.1073/pnas.1323226111;
RA   Chu C.S., Lo P.W., Yeh Y.H., Hsu P.H., Peng S.H., Teng Y.C., Kang M.L.,
RA   Wong C.H., Juan L.J.;
RT   "O-GlcNAcylation regulates EZH2 protein stability and function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:1355-1360(2014).
RN   [51]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-634, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [52]
RP   FUNCTION, AND INTERACTION WITH EZHIP.
RX   PubMed=30923826; DOI=10.1093/neuonc/noz058;
RA   Huebner J.M., Mueller T., Papageorgiou D.N., Mauermann M., Krijgsveld J.,
RA   Russell R.B., Ellison D.W., Pfister S.M., Pajtler K.W., Kool M.;
RT   "EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an
RT   intrinsic inhibitor of PRC2 function in aggressive posterior fossa
RT   ependymoma.";
RL   Neuro-oncol. 0:0-0(2019).
RN   [53]
RP   VARIANTS PHE-641; SER-641; ASN-641; HIS-641 AND CYS-641.
RX   PubMed=20081860; DOI=10.1038/ng.518;
RA   Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R.,
RA   Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., Yap D., Humphries R.K.,
RA   Griffith O.L., Shah S., Zhu H., Kimbara M., Shashkin P., Charlot J.F.,
RA   Tcherpakov M., Corbett R., Tam A., Varhol R., Smailus D., Moksa M.,
RA   Zhao Y., Delaney A., Qian H., Birol I., Schein J., Moore R., Holt R.,
RA   Horsman D.E., Connors J.M., Jones S., Aparicio S., Hirst M., Gascoyne R.D.,
RA   Marra M.A.;
RT   "Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large
RT   B-cell lymphomas of germinal-center origin.";
RL   Nat. Genet. 42:181-185(2010).
RN   [54]
RP   VARIANTS TRP-571; CYS-641; CYS-685 AND ASP-726, AND CHARACTERIZATION OF
RP   VARIANTS TRP-571; CYS-641; CYS-685 AND ASP-726.
RX   PubMed=20601953; DOI=10.1038/ng.621;
RA   Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V.,
RA   Waghorn K., Zoi K., Ross F.M., Reiter A., Hochhaus A., Drexler H.G.,
RA   Duncombe A., Cervantes F., Oscier D., Boultwood J., Grand F.H., Cross N.C.;
RT   "Inactivating mutations of the histone methyltransferase gene EZH2 in
RT   myeloid disorders.";
RL   Nat. Genet. 42:722-726(2010).
RN   [55]
RP   CHARACTERIZATION OF VARIANTS PHE-641 AND ASN-641.
RX   PubMed=21190999; DOI=10.1182/blood-2010-11-321208;
RA   Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A.,
RA   Morin R.D., Mungall A.J., Meissner B., Boyle M., Marquez V.E., Marra M.A.,
RA   Gascoyne R.D., Humphries R.K., Arrowsmith C.H., Morin G.B., Aparicio S.A.;
RT   "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of
RT   selectively altered PRC2 catalytic activity, to increase H3K27
RT   trimethylation.";
RL   Blood 117:2451-2459(2011).
RN   [56]
RP   VARIANT HIS-685.
RX   PubMed=21828135; DOI=10.1182/blood-2010-10-311019;
RA   Jankowska A.M., Makishima H., Tiu R.V., Szpurka H., Huang Y., Traina F.,
RA   Visconte V., Sugimoto Y., Prince C., O'Keefe C., Hsi E.D., List A.,
RA   Sekeres M.A., Rao A., McDevitt M.A., Maciejewski J.P.;
RT   "Mutational spectrum analysis of chronic myelomonocytic leukemia includes
RT   genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.";
RL   Blood 118:3932-3941(2011).
RN   [57]
RP   VARIANTS WVS THR-134; GLU-156; ARG-279; MET-621; ASN-658; THR-677; CYS-679;
RP   LEU-690; 728-TYR--PRO-746 DEL AND CYS-736.
RX   PubMed=22190405; DOI=10.18632/oncotarget.385;
RG   Childhood Overgrowth Collaboration;
RA   Tatton-Brown K., Hanks S., Ruark E., Zachariou A., Duarte S.V., Ramsay E.,
RA   Snape K., Murray A., Perdeaux E.R., Seal S., Loveday C., Banka S.,
RA   Clericuzio C., Flinter F., Magee A., McConnell V., Patton M., Raith W.,
RA   Rankin J., Splitt M., Strenger V., Taylor C., Wheeler P., Temple K.I.,
RA   Cole T., Douglas J., Rahman N.;
RT   "Germline mutations in the oncogene EZH2 cause Weaver syndrome and
RT   increased human height.";
RL   Oncotarget 2:1127-1133(2011).
RN   [58]
RP   VARIANTS WVS SER-132; TYR-153 DEL AND TYR-689.
RX   PubMed=22177091; DOI=10.1016/j.ajhg.2011.11.018;
RA   Gibson W.T., Hood R.L., Zhan S.H., Bulman D.E., Fejes A.P., Moore R.,
RA   Mungall A.J., Eydoux P., Babul-Hirji R., An J., Marra M.A., Chitayat D.,
RA   Boycott K.M., Weaver D.D., Jones S.J.;
RT   "Mutations in EZH2 cause Weaver syndrome.";
RL   Am. J. Hum. Genet. 90:110-118(2012).
RN   [59]
RP   VARIANT GLY-677, CHARACTERIZATION OF VARIANTS ASN-641; CYS-641; HIS-641;
RP   PHE-641 AND GLY-677, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22323599; DOI=10.1073/pnas.1116418109;
RA   McCabe M.T., Graves A.P., Ganji G., Diaz E., Halsey W.S., Jiang Y.,
RA   Smitheman K.N., Ott H.M., Pappalardi M.B., Allen K.E., Chen S.B.,
RA   Della Pietra A. III, Dul E., Hughes A.M., Gilbert S.A., Thrall S.H.,
RA   Tummino P.J., Kruger R.G., Brandt M., Schwartz B., Creasy C.L.;
RT   "Mutation of A677 in histone methyltransferase EZH2 in human B-cell
RT   lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:2989-2994(2012).
RN   [60]
RP   VARIANT WVS LYS-740.
RX   PubMed=23239504; DOI=10.1002/ajmg.a.35660;
RA   Al-Salem A., Alshammari M.J., Hassan H., Alazami A.M., Alkuraya F.S.;
RT   "Weaver syndrome and defective cortical development: a rare association.";
RL   Am. J. Med. Genet. A 161A:225-227(2013).
RN   [61]
RP   VARIANTS WVS CYS-133 AND CYS-679, CHARACTERIZATION OF VARIANTS WVS SER-132;
RP   CYS-133; TYR-153 DEL; CYS-679 AND TYR-689, VARIANT HIS-185,
RP   CHARACTERIZATION OF VARIANT HIS-185, AND MUTAGENESIS OF PHE-667.
RX   PubMed=26694085; DOI=10.1002/humu.22946;
RA   Cohen A.S., Yap D.B., Lewis M.E., Chijiwa C., Ramos-Arroyo M.A.,
RA   Tkachenko N., Milano V., Fradin M., McKinnon M.L., Townsend K.N., Xu J.,
RA   Van Allen M.I., Ross C.J., Dobyns W.B., Weaver D.D., Gibson W.T.;
RT   "Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone
RT   Methyltransferase Function In Vitro.";
RL   Hum. Mutat. 37:301-307(2016).
RN   [62]
RP   INVOLVEMENT IN WVS.
RX   PubMed=28229514; DOI=10.1002/humu.23200;
RA   Imagawa E., Higashimoto K., Sakai Y., Numakura C., Okamoto N.,
RA   Matsunaga S., Ryo A., Sato Y., Sanefuji M., Ihara K., Takada Y.,
RA   Nishimura G., Saitsu H., Mizuguchi T., Miyatake S., Nakashima M.,
RA   Miyake N., Soejima H., Matsumoto N.;
RT   "Mutations in genes encoding polycomb repressive complex 2 subunits cause
RT   Weaver syndrome.";
RL   Hum. Mutat. 38:637-648(2017).
CC   -!- FUNCTION: Polycomb group (PcG) protein. Catalytic subunit of the
CC       PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27'
CC       (H3K27me) of histone H3, leading to transcriptional repression of the
CC       affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of
CC       histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively.
CC       Displays a preference for substrates with less methylation, loses
CC       activity when progressively more methyl groups are incorporated into
CC       H3K27, H3K27me0 > H3K27me1 > H3K27me2 (PubMed:22323599,
CC       PubMed:30923826). Compared to EZH1-containing complexes, it is more
CC       abundant in embryonic stem cells and plays a major role in forming
CC       H3K27me3, which is required for embryonic stem cell identity and proper
CC       differentiation. The PRC2/EED-EZH2 complex may also serve as a
CC       recruiting platform for DNA methyltransferases, thereby linking two
CC       epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2
CC       complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target
CC       genes. EZH2 can also methylate non-histone proteins such as the
CC       transcription factor GATA4 and the nuclear receptor RORA. Regulates the
CC       circadian clock via histone methylation at the promoter of the
CC       circadian genes. Essential for the CRY1/2-mediated repression of the
CC       transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1
CC       heterodimer; involved in the di and trimethylation of 'Lys-27' of
CC       histone H3 on PER1/2 promoters which is necessary for the CRY1/2
CC       proteins to inhibit transcription. {ECO:0000269|PubMed:14532106,
CC       ECO:0000269|PubMed:15225548, ECO:0000269|PubMed:15231737,
CC       ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16179254,
CC       ECO:0000269|PubMed:16357870, ECO:0000269|PubMed:16618801,
CC       ECO:0000269|PubMed:16717091, ECO:0000269|PubMed:16936726,
CC       ECO:0000269|PubMed:17210787, ECO:0000269|PubMed:17344414,
CC       ECO:0000269|PubMed:18285464, ECO:0000269|PubMed:19026781,
CC       ECO:0000269|PubMed:20935635, ECO:0000269|PubMed:22323599,
CC       ECO:0000269|PubMed:23063525, ECO:0000269|PubMed:24474760,
CC       ECO:0000269|PubMed:30923826}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-lysyl(27)-[histone H3] + 3 S-adenosyl-L-methionine = 3 H(+)
CC         + N(6),N(6),N(6)-trimethyl-L-lysyl(27)-[histone H3] + 3 S-adenosyl-L-
CC         homocysteine; Xref=Rhea:RHEA:60292, Rhea:RHEA-COMP:15535, Rhea:RHEA-
CC         COMP:15548, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57856,
CC         ChEBI:CHEBI:59789, ChEBI:CHEBI:61961; EC=2.1.1.356;
CC         Evidence={ECO:0000269|PubMed:22323599};
CC   -!- SUBUNIT: Binds ATRX via the SET domain (Probable). Component of the
CC       PRC2/EED-EZH2 complex, which includes EED, EZH2, SUZ12, RBBP4 and RBBP7
CC       and possibly AEBP2. The minimum components required for
CC       methyltransferase activity of the PRC2/EED-EZH2 complex are EED, EZH2
CC       and SUZ12. The PRC2 complex may also interact with DNMT1, DNMT3A,
CC       DNMT3B and PHF1 via the EZH2 subunit and with SIRT1 via the SUZ12
CC       subunit. Interacts with HDAC1 and HDAC2. Interacts with PRAME.
CC       Interacts with CDYL. Interacts with CLOCK, ARNTL/BMAL1 and CRY1 (By
CC       similarity). Interacts with DNMT3L; the interaction is direct (By
CC       similarity). Interacts with EZHIP; the interaction blocks EZH2
CC       methyltransferase activity (PubMed:30923826).
CC       {ECO:0000250|UniProtKB:Q61188, ECO:0000269|PubMed:10581039,
CC       ECO:0000269|PubMed:11158321, ECO:0000269|PubMed:12351676,
CC       ECO:0000269|PubMed:12435631, ECO:0000269|PubMed:15385962,
CC       ECO:0000269|PubMed:16179254, ECO:0000269|PubMed:16224021,
CC       ECO:0000269|PubMed:16357870, ECO:0000269|PubMed:18086877,
CC       ECO:0000269|PubMed:18285464, ECO:0000269|PubMed:19026781,
CC       ECO:0000269|PubMed:22009739, ECO:0000269|PubMed:30923826,
CC       ECO:0000269|PubMed:9499421, ECO:0000269|PubMed:9584199, ECO:0000305}.
CC   -!- INTERACTION:
CC       Q15910; Q8IXJ9: ASXL1; NbExp=6; IntAct=EBI-530054, EBI-1646500;
CC       Q15910; P46100: ATRX; NbExp=2; IntAct=EBI-530054, EBI-396461;
CC       Q15910; Q96MT8: CEP63; NbExp=4; IntAct=EBI-530054, EBI-741977;
CC       Q15910; P26358: DNMT1; NbExp=8; IntAct=EBI-530054, EBI-719459;
CC       Q15910; Q9Y6K1: DNMT3A; NbExp=6; IntAct=EBI-530054, EBI-923653;
CC       Q15910; Q9UBC3: DNMT3B; NbExp=14; IntAct=EBI-530054, EBI-80125;
CC       Q15910; Q9CWR8: Dnmt3l; Xeno; NbExp=2; IntAct=EBI-530054, EBI-3043871;
CC       Q15910; O75530: EED; NbExp=11; IntAct=EBI-530054, EBI-923794;
CC       Q15910-2; O75530-2: EED; NbExp=3; IntAct=EBI-10699473, EBI-11132357;
CC       Q15910; Q92833-1: JARID2; NbExp=7; IntAct=EBI-530054, EBI-15825247;
CC       Q15910-2; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-10699473, EBI-10172052;
CC       Q15910; O43189: PHF1; NbExp=5; IntAct=EBI-530054, EBI-530034;
CC       Q15910; Q15156: PML-RAR; NbExp=8; IntAct=EBI-530054, EBI-867256;
CC       Q15910; P10276: RARA; NbExp=2; IntAct=EBI-530054, EBI-413374;
CC       Q15910; P40763: STAT3; NbExp=5; IntAct=EBI-530054, EBI-518675;
CC       Q15910; O43463: SUV39H1; NbExp=2; IntAct=EBI-530054, EBI-349968;
CC       Q15910; Q15022: SUZ12; NbExp=22; IntAct=EBI-530054, EBI-1264675;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12101246,
CC       ECO:0000269|PubMed:14532106, ECO:0000269|PubMed:15231737,
CC       ECO:0000269|PubMed:9584199}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q15910-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15910-2; Sequence=VSP_038815;
CC       Name=3;
CC         IsoId=Q15910-3; Sequence=VSP_038814;
CC       Name=4;
CC         IsoId=Q15910-4; Sequence=VSP_038813;
CC       Name=5;
CC         IsoId=Q15910-5; Sequence=VSP_038813, VSP_038816;
CC   -!- TISSUE SPECIFICITY: Expressed in many tissues. Overexpressed in
CC       numerous tumor types including carcinomas of the breast, colon, larynx,
CC       lymphoma and testis. {ECO:0000269|PubMed:14532106}.
CC   -!- DEVELOPMENTAL STAGE: Expression decreases during senescence of
CC       embryonic fibroblasts (HEFs). Expression peaks at the G1/S phase
CC       boundary. {ECO:0000269|PubMed:14532106, ECO:0000269|PubMed:15208672,
CC       ECO:0000269|PubMed:17344414}.
CC   -!- INDUCTION: Expression is induced by E2F1, E2F2 and E2F3. Expression is
CC       reduced in cells subject to numerous types of stress including UV-,
CC       IR- and bleomycin-induced DNA damage and by activation of p53/TP53.
CC       {ECO:0000269|PubMed:14532106, ECO:0000269|PubMed:15208672,
CC       ECO:0000269|PubMed:17344414}.
CC   -!- PTM: Phosphorylated by AKT1. Phosphorylation by AKT1 reduces
CC       methyltransferase activity. Phosphorylation at Thr-345 by CDK1 and CDK2
CC       promotes maintenance of H3K27me3 levels at EZH2-target loci, thus
CC       leading to epigenetic gene silencing. {ECO:0000269|PubMed:16224021,
CC       ECO:0000269|PubMed:20935635}.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:18628979}.
CC   -!- PTM: Glycosylated: O-GlcNAcylation at Ser-75 by OGT increases stability
CC       of EZH2 and facilitates the formation of H3K27me3 by the PRC2/EED-EZH2
CC       complex. {ECO:0000269|PubMed:24474760}.
CC   -!- DISEASE: Weaver syndrome (WVS) [MIM:277590]: A syndrome of accelerated
CC       growth and osseous maturation, unusual craniofacial appearance, hoarse
CC       and low-pitched cry, and hypertonia with camptodactyly. Distinguishing
CC       features of Weaver syndrome include broad forehead and face, ocular
CC       hypertelorism, prominent wide philtrum, micrognathia, deep horizontal
CC       chin groove, and deep-set nails. In addition, carpal bone development
CC       is advanced over the rest of the hand. {ECO:0000269|PubMed:22177091,
CC       ECO:0000269|PubMed:22190405, ECO:0000269|PubMed:23239504,
CC       ECO:0000269|PubMed:26694085, ECO:0000269|PubMed:28229514}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding methyltransferase
CC       superfamily. Histone-lysine methyltransferase family. EZ subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00190}.
CC   -!- CAUTION: Two variants of the PRC2 complex have been described, termed
CC       PRC3 and PRC4. Each of the three complexes may include a different
CC       complement of EED isoforms, although the precise sequences of the
CC       isoforms in each complex have not been determined. The PRC2 and PRC4
CC       complexes may also methylate 'Lys-26' of histone H1 in addition to
CC       'Lys-27' of histone H3 (PubMed:15099518 and PubMed:15684044), although
CC       other studies have demonstrated no methylation of 'Lys-26' of histone
CC       H1 by PRC2 (PubMed:16431907). {ECO:0000305|PubMed:16431907}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAS07448.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X95653; CAA64955.1; -; mRNA.
DR   EMBL; U61145; AAC51520.1; -; mRNA.
DR   EMBL; AK302216; BAH13652.1; -; mRNA.
DR   EMBL; AK092676; BAG52592.1; -; mRNA.
DR   EMBL; AK293239; BAH11472.1; -; mRNA.
DR   EMBL; AK314291; BAG36948.1; -; mRNA.
DR   EMBL; AC006323; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073140; AAS07448.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471146; EAW80067.1; -; Genomic_DNA.
DR   EMBL; CH471146; EAW80070.1; -; Genomic_DNA.
DR   EMBL; BC010858; AAH10858.1; -; mRNA.
DR   EMBL; U52965; AAC50591.1; -; Genomic_DNA.
DR   CCDS; CCDS56516.1; -. [Q15910-1]
DR   CCDS; CCDS56517.1; -. [Q15910-5]
DR   CCDS; CCDS56518.1; -. [Q15910-4]
DR   CCDS; CCDS5891.1; -. [Q15910-2]
DR   CCDS; CCDS5892.1; -. [Q15910-3]
DR   PIR; G02838; G02838.
DR   RefSeq; NP_001190176.1; NM_001203247.1. [Q15910-1]
DR   RefSeq; NP_001190177.1; NM_001203248.1. [Q15910-4]
DR   RefSeq; NP_001190178.1; NM_001203249.1. [Q15910-5]
DR   RefSeq; NP_004447.2; NM_004456.4. [Q15910-2]
DR   RefSeq; NP_694543.1; NM_152998.2. [Q15910-3]
DR   RefSeq; XP_011514186.1; XM_011515884.2. [Q15910-2]
DR   PDB; 2C6V; Model; -; A=508-734.
DR   PDB; 4MI0; X-ray; 2.00 A; A=520-746.
DR   PDB; 4MI5; X-ray; 2.00 A; A=521-746.
DR   PDB; 5GSA; X-ray; 2.49 A; C/D=40-68.
DR   PDB; 5H14; X-ray; 1.90 A; C/D=40-68.
DR   PDB; 5H15; X-ray; 2.27 A; C/D=40-68.
DR   PDB; 5H17; X-ray; 2.30 A; B=40-68.
DR   PDB; 5H19; X-ray; 1.90 A; B=40-68.
DR   PDB; 5H24; X-ray; 2.50 A; C/D=40-68.
DR   PDB; 5H25; X-ray; 2.88 A; C/D=40-68.
DR   PDB; 5HYN; X-ray; 2.95 A; A/F/K/Q=1-746.
DR   PDB; 5IJ7; X-ray; 2.62 A; A/B=429-487, A/B=511-746.
DR   PDB; 5IJ8; X-ray; 2.99 A; A/B=429-487, A/B=511-531, A/B=533-746.
DR   PDB; 5LS6; X-ray; 3.47 A; A/D/G/J=1-385, A/D/G/J=421-746.
DR   PDB; 5U5T; X-ray; 1.60 A; C/D=39-68.
DR   PDB; 5U62; X-ray; 1.90 A; C/D=39-68.
DR   PDB; 5WG6; X-ray; 3.90 A; A/C=2-746.
DR   PDB; 5WUK; X-ray; 2.03 A; B=41-68.
DR   PDB; 6C23; EM; 3.90 A; C/K=1-746.
DR   PDB; 6C24; EM; 3.50 A; C/K=1-746.
DR   PDBsum; 2C6V; -.
DR   PDBsum; 4MI0; -.
DR   PDBsum; 4MI5; -.
DR   PDBsum; 5GSA; -.
DR   PDBsum; 5H14; -.
DR   PDBsum; 5H15; -.
DR   PDBsum; 5H17; -.
DR   PDBsum; 5H19; -.
DR   PDBsum; 5H24; -.
DR   PDBsum; 5H25; -.
DR   PDBsum; 5HYN; -.
DR   PDBsum; 5IJ7; -.
DR   PDBsum; 5IJ8; -.
DR   PDBsum; 5LS6; -.
DR   PDBsum; 5U5T; -.
DR   PDBsum; 5U62; -.
DR   PDBsum; 5WG6; -.
DR   PDBsum; 5WUK; -.
DR   PDBsum; 6C23; -.
DR   PDBsum; 6C24; -.
DR   SMR; Q15910; -.
DR   BioGrid; 108446; 730.
DR   CORUM; Q15910; -.
DR   DIP; DIP-34002N; -.
DR   IntAct; Q15910; 119.
DR   MINT; Q15910; -.
DR   STRING; 9606.ENSP00000320147; -.
DR   BindingDB; Q15910; -.
DR   ChEMBL; CHEMBL2189110; -.
DR   DrugBank; DB14581; CPI-1205.
DR   DrugBank; DB12887; Tazemetostat.
DR   GuidetoPHARMACOLOGY; 2654; -.
DR   iPTMnet; Q15910; -.
DR   PhosphoSitePlus; Q15910; -.
DR   SwissPalm; Q15910; -.
DR   BioMuta; EZH2; -.
DR   DMDM; 3334180; -.
DR   EPD; Q15910; -.
DR   jPOST; Q15910; -.
DR   MassIVE; Q15910; -.
DR   MaxQB; Q15910; -.
DR   PaxDb; Q15910; -.
DR   PeptideAtlas; Q15910; -.
DR   PRIDE; Q15910; -.
DR   ProteomicsDB; 60809; -. [Q15910-1]
DR   ProteomicsDB; 60810; -. [Q15910-2]
DR   ProteomicsDB; 60811; -. [Q15910-3]
DR   ProteomicsDB; 60812; -. [Q15910-4]
DR   ProteomicsDB; 60813; -. [Q15910-5]
DR   Antibodypedia; 32761; 796 antibodies.
DR   DNASU; 2146; -.
DR   Ensembl; ENST00000320356; ENSP00000320147; ENSG00000106462. [Q15910-2]
DR   Ensembl; ENST00000350995; ENSP00000223193; ENSG00000106462. [Q15910-3]
DR   Ensembl; ENST00000460911; ENSP00000419711; ENSG00000106462. [Q15910-1]
DR   Ensembl; ENST00000476773; ENSP00000419050; ENSG00000106462. [Q15910-5]
DR   Ensembl; ENST00000478654; ENSP00000417062; ENSG00000106462. [Q15910-5]
DR   Ensembl; ENST00000483967; ENSP00000419856; ENSG00000106462. [Q15910-4]
DR   GeneID; 2146; -.
DR   KEGG; hsa:2146; -.
DR   UCSC; uc003wfb.3; human. [Q15910-1]
DR   CTD; 2146; -.
DR   DisGeNET; 2146; -.
DR   GeneCards; EZH2; -.
DR   GeneReviews; EZH2; -.
DR   HGNC; HGNC:3527; EZH2.
DR   HPA; ENSG00000106462; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MalaCards; EZH2; -.
DR   MIM; 277590; phenotype.
DR   MIM; 601573; gene.
DR   neXtProt; NX_Q15910; -.
DR   OpenTargets; ENSG00000106462; -.
DR   Orphanet; 3447; Weaver syndrome.
DR   PharmGKB; PA27939; -.
DR   eggNOG; KOG1079; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   GeneTree; ENSGT00940000155013; -.
DR   HOGENOM; CLU_011342_0_0_1; -.
DR   InParanoid; Q15910; -.
DR   KO; K11430; -.
DR   OMA; IKEAWIK; -.
DR   OrthoDB; 875190at2759; -.
DR   PhylomeDB; Q15910; -.
DR   TreeFam; TF314509; -.
DR   Reactome; R-HSA-212300; PRC2 methylates histones and DNA.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-8953750; Transcriptional Regulation by E2F6.
DR   Reactome; R-HSA-9609690; HCMV Early Events.
DR   SignaLink; Q15910; -.
DR   SIGNOR; Q15910; -.
DR   ChiTaRS; EZH2; human.
DR   GeneWiki; EZH2; -.
DR   GenomeRNAi; 2146; -.
DR   Pharos; Q15910; Tchem.
DR   PRO; PR:Q15910; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q15910; protein.
DR   Bgee; ENSG00000106462; Expressed in lung and 156 other tissues.
DR   ExpressionAtlas; Q15910; baseline and differential.
DR   Genevisible; Q15910; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IGI:ARUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0035098; C:ESC/E(Z) complex; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0045120; C:pronucleus; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISM:NTNU_SB.
DR   GO; GO:0042054; F:histone methyltransferase activity; IDA:MGI.
DR   GO; GO:0046976; F:histone methyltransferase activity (H3-K27 specific); IDA:UniProtKB.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IDA:MGI.
DR   GO; GO:0070878; F:primary miRNA binding; IEA:Ensembl.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0016279; F:protein-lysine N-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:Ensembl.
DR   GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0035984; P:cellular response to trichostatin A; IEA:Ensembl.
DR   GO; GO:0021695; P:cerebellar cortex development; IEA:Ensembl.
DR   GO; GO:0006325; P:chromatin organization; TAS:ProtInc.
DR   GO; GO:0006348; P:chromatin silencing at telomere; IGI:ARUK-UCL.
DR   GO; GO:0006306; P:DNA methylation; IEA:Ensembl.
DR   GO; GO:0070314; P:G1 to G0 transition; IEA:Ensembl.
DR   GO; GO:0036333; P:hepatocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0070734; P:histone H3-K27 methylation; IDA:UniProtKB.
DR   GO; GO:0098532; P:histone H3-K27 trimethylation; IEA:Ensembl.
DR   GO; GO:0016571; P:histone methylation; IMP:UniProtKB.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0045605; P:negative regulation of epidermal cell differentiation; IEA:Ensembl.
DR   GO; GO:0070317; P:negative regulation of G0 to G1 transition; TAS:Reactome.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; IDA:UniProtKB.
DR   GO; GO:0048387; P:negative regulation of retinoic acid receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051154; P:negative regulation of striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:1902808; P:positive regulation of cell cycle G1/S phase transition; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:1900006; P:positive regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0071168; P:protein localization to chromatin; IEA:Ensembl.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IMP:UniProtKB.
DR   GO; GO:0014013; P:regulation of gliogenesis; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:1904772; P:response to tetrachloromethane; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0014834; P:skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration; IEA:Ensembl.
DR   CDD; cd00167; SANT; 1.
DR   DisProt; DP01817; -.
DR   InterPro; IPR026489; CXC_dom.
DR   InterPro; IPR021654; EZH1/EZH2.
DR   InterPro; IPR041343; PRC2_HTH_1.
DR   InterPro; IPR041355; Pre-SET_CXC.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR033467; Tesmin/TSO1-like_CXC.
DR   Pfam; PF11616; EZH2_WD-Binding; 1.
DR   Pfam; PF18118; PRC2_HTH_1; 1.
DR   Pfam; PF18264; preSET_CXC; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM01114; CXC; 1.
DR   SMART; SM00717; SANT; 2.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51633; CXC; 1.
DR   PROSITE; PS50280; SET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Biological rhythms;
KW   Chromatin regulator; Disease mutation; Glycoprotein; Isopeptide bond;
KW   Methyltransferase; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repressor; S-adenosyl-L-methionine; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN           1..746
FT                   /note="Histone-lysine N-methyltransferase EZH2"
FT                   /id="PRO_0000213992"
FT   DOMAIN          503..605
FT                   /note="CXC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00970"
FT   DOMAIN          612..727
FT                   /note="SET"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT   REGION          1..340
FT                   /note="Interaction with DNMT1, DNMT3A and DNMT3B"
FT   REGION          39..68
FT                   /note="Interaction with EED"
FT                   /evidence="ECO:0000250"
FT   REGION          329..522
FT                   /note="Interaction with CDYL"
FT                   /evidence="ECO:0000269|PubMed:22009739"
FT   COMPBIAS        523..605
FT                   /note="Cys-rich"
FT   MOD_RES         21
FT                   /note="Phosphoserine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:16224021"
FT   MOD_RES         76
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         339
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         345
FT                   /note="Phosphothreonine; by CDK1 and CDK2"
FT                   /evidence="ECO:0000269|PubMed:20935635"
FT   MOD_RES         363
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         366
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         367
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         487
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:16964243,
FT                   ECO:0000244|PubMed:17081983, ECO:0000244|PubMed:18220336,
FT                   ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:18691976,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163"
FT   CARBOHYD        75
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000269|PubMed:24474760"
FT   CROSSLNK        634
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         74..82
FT                   /note="Missing (in isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038813"
FT   VAR_SEQ         83..121
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038814"
FT   VAR_SEQ         297..298
FT                   /note="HP -> HRKCNYS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_038815"
FT   VAR_SEQ         511..553
FT                   /note="DGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSSEC -> G (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038816"
FT   VARIANT         132
FT                   /note="P -> S (in WVS; decreased histone methyltransferase
FT                   activity; dbSNP:rs193921148)"
FT                   /evidence="ECO:0000269|PubMed:22177091,
FT                   ECO:0000269|PubMed:26694085"
FT                   /id="VAR_067595"
FT   VARIANT         133
FT                   /note="Y -> C (in WVS; decreased histone methyltransferase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:26694085"
FT                   /id="VAR_078320"
FT   VARIANT         134
FT                   /note="M -> T (in WVS)"
FT                   /evidence="ECO:0000269|PubMed:22190405"
FT                   /id="VAR_078321"
FT   VARIANT         153
FT                   /note="Missing (in WVS; decreased histone methyltransferase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:22177091,
FT                   ECO:0000269|PubMed:26694085"
FT                   /id="VAR_067596"
FT   VARIANT         156
FT                   /note="K -> E (in WVS)"
FT                   /evidence="ECO:0000269|PubMed:22190405"
FT                   /id="VAR_078322"
FT   VARIANT         185
FT                   /note="D -> H (polymorphism; decreased histone
FT                   methyltransferase activity; dbSNP:rs2302427)"
FT                   /evidence="ECO:0000269|PubMed:26694085"
FT                   /id="VAR_055795"
FT   VARIANT         279
FT                   /note="H -> R (in WVS)"
FT                   /evidence="ECO:0000269|PubMed:22190405"
FT                   /id="VAR_078323"
FT   VARIANT         571
FT                   /note="C -> W (found in a patient with myelodysplastic
FT                   syndrome and myelodysplastic-myeloproliferative neoplasms;
FT                   somatic mutation; loss of histone methyltransferase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:20601953"
FT                   /id="VAR_078324"
FT   VARIANT         621
FT                   /note="V -> M (in WVS; unknown pathological significance;
FT                   dbSNP:rs587783625)"
FT                   /evidence="ECO:0000269|PubMed:22190405"
FT                   /id="VAR_078325"
FT   VARIANT         641
FT                   /note="Y -> C (in a patient with diffuse large B-cell
FT                   lymphoma; somatic mutation; changed substrate preferences;
FT                   prefers substrates with greater methylation
FT                   H3K27me0<me1<me2)"
FT                   /evidence="ECO:0000269|PubMed:20081860,
FT                   ECO:0000269|PubMed:20601953, ECO:0000269|PubMed:22323599"
FT                   /id="VAR_067228"
FT   VARIANT         641
FT                   /note="Y -> F (found in a patient with follicular lymphoma;
FT                   also in diffuse large B-cell lymphoma; somatic mutation;
FT                   changed substrate preferences; prefers substrates with
FT                   greater methylation H3K27me0<me1<me2; dbSNP:rs267601394)"
FT                   /evidence="ECO:0000269|PubMed:20081860,
FT                   ECO:0000269|PubMed:22323599"
FT                   /id="VAR_067229"
FT   VARIANT         641
FT                   /note="Y -> H (found in patients with follicular lymphoma;
FT                   also in diffuse large B-cell lymphoma; somatic mutation;
FT                   changed substrate preferences; prefers substrates with
FT                   greater methylation H3K27me0<me1<me2; dbSNP:rs267601395)"
FT                   /evidence="ECO:0000269|PubMed:20081860,
FT                   ECO:0000269|PubMed:22323599"
FT                   /id="VAR_067230"
FT   VARIANT         641
FT                   /note="Y -> N (found in patients with follicular lymphoma;
FT                   also in diffuse large B-cell lymphoma; somatic mutation;
FT                   changed substrate preferences; prefers substrates with
FT                   greater methylation H3K27me0<me1<me2; dbSNP:rs267601395)"
FT                   /evidence="ECO:0000269|PubMed:20081860,
FT                   ECO:0000269|PubMed:22323599"
FT                   /id="VAR_067231"
FT   VARIANT         641
FT                   /note="Y -> S (found in patients with follicular lymphoma;
FT                   also in diffuse large B-cell lymphoma; somatic mutation;
FT                   dbSNP:rs267601394)"
FT                   /evidence="ECO:0000269|PubMed:20081860"
FT                   /id="VAR_067232"
FT   VARIANT         658
FT                   /note="Y -> N (in WVS)"
FT                   /evidence="ECO:0000269|PubMed:22190405"
FT                   /id="VAR_078326"
FT   VARIANT         677
FT                   /note="A -> G (found in a patient with B-cell lymphoma;
FT                   increased hypertrimethylation of H3K27; changed substrate
FT                   preferences; confers biochemical activity independent of
FT                   H3K27 methylation state; dbSNP:rs1057519833)"
FT                   /evidence="ECO:0000269|PubMed:22323599"
FT                   /id="VAR_078327"
FT   VARIANT         677
FT                   /note="A -> T (in WVS; dbSNP:rs397515547)"
FT                   /evidence="ECO:0000269|PubMed:22190405"
FT                   /id="VAR_078328"
FT   VARIANT         679
FT                   /note="R -> C (in WVS; decreased histone methyltransferase
FT                   activity; dbSNP:rs587783626)"
FT                   /evidence="ECO:0000269|PubMed:22190405,
FT                   ECO:0000269|PubMed:26694085"
FT                   /id="VAR_078329"
FT   VARIANT         685
FT                   /note="R -> C (found in a patient with myeloid disorders;
FT                   somatic mutation; loss of histone methyltransferase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:20601953"
FT                   /id="VAR_078330"
FT   VARIANT         685
FT                   /note="R -> H (in a patient with chronic myelomonocytic
FT                   leukemia; dbSNP:rs1554481435)"
FT                   /evidence="ECO:0000269|PubMed:21828135"
FT                   /id="VAR_067233"
FT   VARIANT         689
FT                   /note="H -> Y (in WVS; decreased histone methyltransferase
FT                   activity; dbSNP:rs193921147)"
FT                   /evidence="ECO:0000269|PubMed:22177091,
FT                   ECO:0000269|PubMed:26694085"
FT                   /id="VAR_067597"
FT   VARIANT         690
FT                   /note="S -> L (in WVS)"
FT                   /evidence="ECO:0000269|PubMed:22190405"
FT                   /id="VAR_078331"
FT   VARIANT         726
FT                   /note="Y -> D (found in a patient with chronic
FT                   myelomonocytic leukemia; somatic mutation; loss of histone
FT                   methyltransferase activity)"
FT                   /evidence="ECO:0000269|PubMed:20601953"
FT                   /id="VAR_078332"
FT   VARIANT         728..746
FT                   /note="Missing (in WVS)"
FT                   /evidence="ECO:0000269|PubMed:22190405"
FT                   /id="VAR_078333"
FT   VARIANT         736
FT                   /note="Y -> C (in WVS)"
FT                   /evidence="ECO:0000269|PubMed:22190405"
FT                   /id="VAR_078334"
FT   VARIANT         740
FT                   /note="E -> K (in WVS; unknown pathological significance;
FT                   dbSNP:rs397515548)"
FT                   /evidence="ECO:0000269|PubMed:23239504"
FT                   /id="VAR_078335"
FT   MUTAGEN         21
FT                   /note="S->A: Enhances methyltransferase activity towards
FT                   'Lys-27' of histone H3 and abrogates phosphorylation by
FT                   PKB/AKT1."
FT                   /evidence="ECO:0000269|PubMed:16224021"
FT   MUTAGEN         21
FT                   /note="S->D: Reduces methyltransferase activity towards
FT                   'Lys-27' of histone H3 and abrogates phosphorylation by
FT                   PKB/AKT1."
FT                   /evidence="ECO:0000269|PubMed:16224021"
FT   MUTAGEN         75
FT                   /note="S->A: Reduced protein stability."
FT                   /evidence="ECO:0000269|PubMed:24474760"
FT   MUTAGEN         345
FT                   /note="T->A: Impaired CDK1- and CDK-2 mediated
FT                   phosphorylation and subsequent gene silencing. Altered
FT                   EZH2-mediated cell proliferation and migration."
FT                   /evidence="ECO:0000269|PubMed:20935635"
FT   MUTAGEN         588
FT                   /note="C->Y: Strongly impairs methyltransferase activity
FT                   towards 'Lys-27' of histone H3."
FT                   /evidence="ECO:0000269|PubMed:12435631"
FT   MUTAGEN         667
FT                   /note="F->I: Strongly decreases histone methyltransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26694085"
FT   MUTAGEN         689
FT                   /note="H->A: Abrogates methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:12435631,
FT                   ECO:0000269|PubMed:18285464"
FT   CONFLICT        39
FT                   /note="K -> N (in Ref. 3; BAG52592)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        224
FT                   /note="F -> L (in Ref. 1; CAA64955)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        724
FT                   /note="F -> V (in Ref. 1; CAA64955)"
FT                   /evidence="ECO:0000305"
FT   HELIX           44..62
FT                   /evidence="ECO:0000244|PDB:5U5T"
FT   STRAND          82..87
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   STRAND          94..97
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   STRAND          99..101
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   STRAND          126..129
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   HELIX           135..138
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   TURN            139..143
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   HELIX           144..152
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   TURN            153..155
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   STRAND          161..163
FT                   /evidence="ECO:0000244|PDB:5LS6"
FT   HELIX           168..181
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   HELIX           221..230
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   TURN            232..234
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   HELIX           237..248
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   STRAND          264..266
FT                   /evidence="ECO:0000244|PDB:5LS6"
FT   HELIX           274..284
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   TURN            287..289
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   STRAND          291..293
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   TURN            304..306
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   HELIX           332..343
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   HELIX           434..447
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   HELIX           451..458
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   HELIX           463..474
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   STRAND          526..528
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   HELIX           535..538
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          563..565
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          568..571
FT                   /evidence="ECO:0000244|PDB:6C24"
FT   HELIX           572..575
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   TURN            582..584
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          587..589
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          590..592
FT                   /evidence="ECO:0000244|PDB:5LS6"
FT   STRAND          594..596
FT                   /evidence="ECO:0000244|PDB:5HYN"
FT   STRAND          600..603
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   HELIX           605..608
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          614..618
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          620..630
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          637..640
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          643..647
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   HELIX           648..656
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          666..668
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          670..676
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   TURN            678..680
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   HELIX           683..686
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          687..689
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          694..702
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          705..714
FT                   /evidence="ECO:0000244|PDB:4MI0"
FT   STRAND          721..723
FT                   /evidence="ECO:0000244|PDB:5LS6"
SQ   SEQUENCE   746 AA;  85363 MW;  1B5029EB9D509BE5 CRC64;
     MGQTGKKSEK GPVCWRKRVK SEYMRLRQLK RFRRADEVKS MFSSNRQKIL ERTEILNQEW
     KQRRIQPVHI LTSVSSLRGT RECSVTSDLD FPTQVIPLKT LNAVASVPIM YSWSPLQQNF
     MVEDETVLHN IPYMGDEVLD QDGTFIEELI KNYDGKVHGD RECGFINDEI FVELVNALGQ
     YNDDDDDDDG DDPEEREEKQ KDLEDHRDDK ESRPPRKFPS DKIFEAISSM FPDKGTAEEL
     KEKYKELTEQ QLPGALPPEC TPNIDGPNAK SVQREQSLHS FHTLFCRRCF KYDCFLHPFH
     ATPNTYKRKN TETALDNKPC GPQCYQHLEG AKEFAAALTA ERIKTPPKRP GGRRRGRLPN
     NSSRPSTPTI NVLESKDTDS DREAGTETGG ENNDKEEEEK KDETSSSSEA NSRCQTPIKM
     KPNIEPPENV EWSGAEASMF RVLIGTYYDN FCAIARLIGT KTCRQVYEFR VKESSIIAPA
     PAEDVDTPPR KKKRKHRLWA AHCRKIQLKK DGSSNHVYNY QPCDHPRQPC DSSCPCVIAQ
     NFCEKFCQCS SECQNRFPGC RCKAQCNTKQ CPCYLAVREC DPDLCLTCGA ADHWDSKNVS
     CKNCSIQRGS KKHLLLAPSD VAGWGIFIKD PVQKNEFISE YCGEIISQDE ADRRGKVYDK
     YMCSFLFNLN NDFVVDATRK GNKIRFANHS VNPNCYAKVM MVNGDHRIGI FAKRAIQTGE
     ELFFDYRYSQ ADALKYVGIE REMEIP
//
ID   S4S3R8_HUMAN            Unreviewed;       707 AA.
AC   S4S3R8;
DT   16-OCT-2013, integrated into UniProtKB/TrEMBL.
DT   16-OCT-2013, sequence version 1.
DT   22-APR-2020, entry version 55.
DE   SubName: Full=EZH2b {ECO:0000313|EMBL:AEN79481.1};
DE   SubName: Full=Enhancer of zeste homolog 2 (Drosophila) {ECO:0000313|EMBL:EAL24423.1};
GN   Name=EZH2 {ECO:0000313|EMBL:EAL24423.1};
GN   ORFNames=tcag7.507 {ECO:0000313|EMBL:EAL24423.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AEN79481.1};
RN   [1] {ECO:0000313|EMBL:EAL24423.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J., Grzeschik K.H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Dohner H.,
RA   Dohner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [2] {ECO:0000313|EMBL:EAL24423.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Nusskern D., Zhang Q., Gu Z., Lu F., Zeesman S., Teshima I.,
RA   Chitayat D., Shuman C., Weksberg R., Zackai E.H., Grebe T.A., Cox S.R.,
RA   Kirkpatrick S.J., Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.,
RA   Lococo F., Belloni E., Shaffer L.G., Morton C.C., Pober B., Gusella J.,
RA   Bruns G., Korf B.R., Quade B.J., Ligon A.H., Ferguson H., Higgins A.W.,
RA   Leach N.T., Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M.,
RA   Gripp K.W., Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H.,
RA   Teebi A., Minassian B.A., Kere J., Armengol L., Pujana M.Angel.,
RA   Estivill X., Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P.,
RA   Zlotorynski E., Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J.,
RA   Doehner H., Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:AEN79481.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Grzenda A.L., Urrutia R.A., Gwen L.A.;
RT   "Polycomb repressive complexes utilize distinct EZH2 isoforms to mediate
RT   gene silencing.";
RL   Submitted (MAY-2011) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; JF939048; AEN79481.1; -; Genomic_RNA.
DR   EMBL; AACC02000041; EAL24423.1; -; Genomic_DNA.
DR   RefSeq; NP_694543.1; NM_152998.2.
DR   Antibodypedia; 32761; 796 antibodies.
DR   GeneID; 2146; -.
DR   UCSC; uc003wfc.3; human.
DR   CTD; 2146; -.
DR   EuPathDB; HostDB:ENSG00000106462.10; -.
DR   HOGENOM; CLU_011342_0_0_1; -.
DR   OrthoDB; 875190at2759; -.
DR   ChiTaRS; EZH2; human.
DR   GenomeRNAi; 2146; -.
DR   Bgee; ENSG00000106462; Expressed in lung and 156 other tissues.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IEA:InterPro.
DR   CDD; cd00167; SANT; 1.
DR   InterPro; IPR026489; CXC_dom.
DR   InterPro; IPR021654; EZH1/EZH2.
DR   InterPro; IPR041343; PRC2_HTH_1.
DR   InterPro; IPR041355; Pre-SET_CXC.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR033467; Tesmin/TSO1-like_CXC.
DR   Pfam; PF11616; EZH2_WD-Binding; 1.
DR   Pfam; PF18118; PRC2_HTH_1; 1.
DR   Pfam; PF18264; preSET_CXC; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM01114; CXC; 1.
DR   SMART; SM00717; SANT; 2.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51633; CXC; 1.
DR   PROSITE; PS50280; SET; 1.
PE   4: Predicted;
FT   DOMAIN          464..566
FT                   /note="CXC"
FT                   /evidence="ECO:0000259|PROSITE:PS51633"
FT   DOMAIN          573..688
FT                   /note="SET"
FT                   /evidence="ECO:0000259|PROSITE:PS50280"
FT   REGION          141..183
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          301..387
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        141..156
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        157..181
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        320..335
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        336..368
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   707 AA;  81038 MW;  48EAF1393A9EA4F2 CRC64;
     MGQTGKKSEK GPVCWRKRVK SEYMRLRQLK RFRRADEVKS MFSSNRQKIL ERTEILNQEW
     KQRRIQPVHI LTSVSSLRGT REVEDETVLH NIPYMGDEVL DQDGTFIEEL IKNYDGKVHG
     DRECGFINDE IFVELVNALG QYNDDDDDDD GDDPEEREEK QKDLEDHRDD KESRPPRKFP
     SDKIFEAISS MFPDKGTAEE LKEKYKELTE QQLPGALPPE CTPNIDGPNA KSVQREQSLH
     SFHTLFCRRC FKYDCFLHPF HATPNTYKRK NTETALDNKP CGPQCYQHLE GAKEFAAALT
     AERIKTPPKR PGGRRRGRLP NNSSRPSTPT INVLESKDTD SDREAGTETG GENNDKEEEE
     KKDETSSSSE ANSRCQTPIK MKPNIEPPEN VEWSGAEASM FRVLIGTYYD NFCAIARLIG
     TKTCRQVYEF RVKESSIIAP APAEDVDTPP RKKKRKHRLW AAHCRKIQLK KDGSSNHVYN
     YQPCDHPRQP CDSSCPCVIA QNFCEKFCQC SSECQNRFPG CRCKAQCNTK QCPCYLAVRE
     CDPDLCLTCG AADHWDSKNV SCKNCSIQRG SKKHLLLAPS DVAGWGIFIK DPVQKNEFIS
     EYCGEIISQD EADRRGKVYD KYMCSFLFNL NNDFVVDATR KGNKIRFANH SVNPNCYAKV
     MMVNGDHRIG IFAKRAIQTG EELFFDYRYS QADALKYVGI EREMEIP
//
ID   A0A024RC92_HUMAN        Unreviewed;       822 AA.
AC   A0A024RC92;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   22-APR-2020, entry version 54.
DE   RecName: Full=Tyrosine-protein kinase {ECO:0000256|PIRNR:PIRNR000632};
DE            EC=2.7.10.2 {ECO:0000256|PIRNR:PIRNR000632};
GN   Name=FES {ECO:0000313|EMBL:EAX02116.1};
GN   ORFNames=hCG_32581 {ECO:0000313|EMBL:EAX02116.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAX02116.1};
RN   [1] {ECO:0000313|EMBL:EAX02116.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAX02116.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000256|PIRNR:PIRNR000632,
CC         ECO:0000256|SAAS:SAAS01115681};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton
CC       {ECO:0000256|PIRNR:PIRNR000632}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fes/fps subfamily. {ECO:0000256|PIRNR:PIRNR000632}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH471101; EAX02115.1; -; Genomic_DNA.
DR   EMBL; CH471101; EAX02116.1; -; Genomic_DNA.
DR   RefSeq; NP_001996.1; NM_002005.3.
DR   RefSeq; XP_016877494.1; XM_017022005.1.
DR   RefSeq; XP_016877498.1; XM_017022009.1.
DR   Antibodypedia; 734; 427 antibodies.
DR   GeneID; 2242; -.
DR   KEGG; hsa:2242; -.
DR   CTD; 2242; -.
DR   EuPathDB; HostDB:ENSG00000182511.11; -.
DR   eggNOG; KOG0194; Eukaryota.
DR   eggNOG; ENOG410Y6RP; LUCA.
DR   HOGENOM; CLU_005265_0_1_1; -.
DR   KO; K07527; -.
DR   OMA; HFIIQSA; -.
DR   OrthoDB; 556386at2759; -.
DR   ChiTaRS; FES; human.
DR   GenomeRNAi; 2242; -.
DR   Bgee; ENSG00000182511; Expressed in spleen and 113 other tissues.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008017; F:microtubule binding; IEA:Ensembl.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0007098; P:centrosome cycle; IEA:Ensembl.
DR   GO; GO:0001578; P:microtubule bundle formation; IEA:Ensembl.
DR   CDD; cd10361; SH2_Fps_family; 1.
DR   Gene3D; 1.20.1270.60; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR027267; AH/BAR_dom_sf.
DR   InterPro; IPR031160; F_BAR.
DR   InterPro; IPR001060; FCH_dom.
DR   InterPro; IPR035849; Fes/Fps/Fer_SH2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR016250; Tyr-prot_kinase_Fes/Fps.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PIRSF; PIRSF000632; TyrPK_fps; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00055; FCH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF103657; SSF103657; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51741; F_BAR; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   3: Inferred from homology;
KW   ATP-binding {ECO:0000256|PIRNR:PIRNR000632, ECO:0000256|PIRSR:PIRSR000632-
KW   2, ECO:0000256|SAAS:SAAS00990534};
KW   Coiled coil {ECO:0000256|PROSITE-ProRule:PRU01077, ECO:0000256|SAM:Coils};
KW   Cytoplasm {ECO:0000256|PIRNR:PIRNR000632};
KW   Cytoskeleton {ECO:0000256|PIRNR:PIRNR000632};
KW   Kinase {ECO:0000256|PIRNR:PIRNR000632, ECO:0000256|SAAS:SAAS00897698};
KW   Nucleotide-binding {ECO:0000256|PIRNR:PIRNR000632,
KW   ECO:0000256|PIRSR:PIRSR000632-2, ECO:0000256|SAAS:SAAS00990534};
KW   SH2 domain {ECO:0000256|PROSITE-ProRule:PRU00191};
KW   Transferase {ECO:0000256|PIRNR:PIRNR000632, ECO:0000256|SAAS:SAAS00897698};
KW   Tyrosine-protein kinase {ECO:0000256|PIRNR:PIRNR000632,
KW   ECO:0000256|SAAS:SAAS00897698}.
FT   DOMAIN          1..260
FT                   /note="F-BAR"
FT                   /evidence="ECO:0000259|PROSITE:PS51741"
FT   DOMAIN          460..549
FT                   /note="SH2"
FT                   /evidence="ECO:0000259|PROSITE:PS50001"
FT   DOMAIN          561..822
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000259|PROSITE:PS50011"
FT   NP_BIND         567..575
FT                   /note="ATP"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR000632-2"
FT   REGION          394..421
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          135..169
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COILED          324..344
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   ACT_SITE        683
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR000632-1"
FT   BINDING         590
FT                   /note="ATP"
FT                   /evidence="ECO:0000256|PIRSR:PIRSR000632-2"
SQ   SEQUENCE   822 AA;  93497 MW;  4C2A90555857F045 CRC64;
     MGFSSELCSP QGHGVLQQMQ EAELRLLEGM RKWMAQRVKS DREYAGLLHH MSLQDSGGQS
     RAISPDSPIS QSWAEITSQT EGLSRLLRQH AEDLNSGPLS KLSLLIRERQ QLRKTYSEQW
     QQLQQELTKT HSQDIEKLKS QYRALARDSA QAKRKYQEAS KDKDRDKAKD KYVRSLWKLF
     AHHNRYVLGV RAAQLHHQHH HQLLLPGLLR SLQDLHEEMA CILKEILQEY LEISSLVQDE
     VVAIHREMAA AAARIQPEAE YQGFLRQYGS APDVPPCVTF DESLLEEGEP LEPGELQLNE
     LTVESVQHTL TSVTDELAVA TEMVFRRQEM VTQLQQELRN EEENTHPRER VQLLGKRQVL
     QEALQGLQVA LCSQAKLQAQ QELLQTKLEH LGPGEPPPVL LLQDDRHSTS SSEQEREGGR
     TPTLEILKSH ISGIFRPKFS LPPPLQLIPE VQKPLHEQLW YHGAIPRAEV AELLVHSGDF
     LVRESQGKQE YVLSVLWDGL PRHFIIQSLD NLYRLEGEGF PSIPLLIDHL LSTQQPLTKK
     SGVVLHRAVP KDKWVLNHED LVLGEQIGRG NFGEVFSGRL RADNTLVAVK SCRETLPPDL
     KAKFLQEARI LKQYSHPNIV RLIGVCTQKQ PIYIVMELVQ GGDFLTFLRT EGARLRVKTL
     LQMVGDAAAG MEYLESKCCI HRDLAARNCL VTEKNVLKIS DFGMSREEAD GVYAASGGLR
     QVPVKWTAPE ALNYGRYSSE SDVWSFGILL WETFSLGASP YPNLSNQQTR EFVEKGGRLP
     CPELCPDAVF RLMEQCWAYE PGQRPSFSTI YQELQSIRKR HR
//
ID   FES_HUMAN               Reviewed;         822 AA.
AC   P07332; B2R6E6; B4DUD0; E9PC94; E9PC95; Q2VXS7; Q2VXS8; Q2VXT0; Q6GTU5;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 3.
DT   22-APR-2020, entry version 218.
DE   RecName: Full=Tyrosine-protein kinase Fes/Fps;
DE            EC=2.7.10.2;
DE   AltName: Full=Feline sarcoma/Fujinami avian sarcoma oncogene homolog;
DE   AltName: Full=Proto-oncogene c-Fes;
DE   AltName: Full=Proto-oncogene c-Fps;
DE   AltName: Full=p93c-fes;
GN   Name=FES; Synonyms=FPS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2179816;
RA   Alcalay M., Antolini F., van de Ven W.J.M., Lanfrancone L., Grignani F.,
RA   Pelicci P.G.;
RT   "Characterization of human and mouse c-fes cDNA clones and identification
RT   of the 5' end of the gene.";
RL   Oncogene 5:267-275(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=4065096; DOI=10.1002/j.1460-2075.1985.tb04020.x;
RA   Roebroek A.J.M., Schalken J.A., Verbeek J.S., van den Ouweland A.M.W.,
RA   Onnekink C., Bloemers H.P.J., van de Ven W.J.M.;
RT   "The structure of the human c-fes/fps proto-oncogene.";
RL   EMBO J. 4:2897-2903(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4).
RA   Lefebvre J.-C.;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION IN CELL DIFFERENTIATION AND AS TUMOR SUPPRESSOR, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=2656706;
RA   Yu G., Smithgall T.E., Glazer R.I.;
RT   "K562 leukemia cells transfected with the human c-fes gene acquire the
RT   ability to undergo myeloid differentiation.";
RL   J. Biol. Chem. 264:10276-10281(1989).
RN   [9]
RP   PHOSPHORYLATION AT TYR-713, CATALYTIC ACTIVITY, AND MUTAGENESIS OF TYR-713.
RX   PubMed=7687763;
RA   Hjermstad S.J., Peters K.L., Briggs S.D., Glazer R.I., Smithgall T.E.;
RT   "Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its
RT   src homology 2 domain and major autophosphorylation site (Tyr-713).";
RL   Oncogene 8:2283-2292(1993).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF BCR, AUTOPHOSPHORYLATION, AND ACTIVITY
RP   REGULATION.
RX   PubMed=8955135; DOI=10.1074/jbc.271.51.32930;
RA   Li J., Smithgall T.E.;
RT   "Co-expression with BCR induces activation of the FES tyrosine kinase and
RT   phosphorylation of specific N-terminal BCR tyrosine residues.";
RL   J. Biol. Chem. 271:32930-32936(1996).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11339827; DOI=10.1006/excr.2001.5217;
RA   Zirngibl R., Schulze D., Mirski S.E., Cole S.P., Greer P.A.;
RT   "Subcellular localization analysis of the closely related Fps/Fes and Fer
RT   protein-tyrosine kinases suggests a distinct role for Fps/Fes in vesicular
RT   trafficking.";
RL   Exp. Cell Res. 266:87-94(2001).
RN   [12]
RP   FUNCTION IN CELL PROLIFERATION AND CELL SPREADING, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, SUBUNIT, DOMAIN, AND MUTAGENESIS OF LEU-145 AND
RP   LEU-334.
RX   PubMed=11509660; DOI=10.1128/mcb.21.18.6170-6180.2001;
RA   Cheng H.Y., Schiavone A.P., Smithgall T.E.;
RT   "A point mutation in the N-terminal coiled-coil domain releases c-Fes
RT   tyrosine kinase activity and survival signaling in myeloid leukemia
RT   cells.";
RL   Mol. Cell. Biol. 21:6170-6180(2001).
RN   [13]
RP   REVIEW.
RX   PubMed=11994747; DOI=10.1038/nrm783;
RA   Greer P.;
RT   "Closing in on the biological functions of Fps/Fes and Fer.";
RL   Nat. Rev. Mol. Cell Biol. 3:278-289(2002).
RN   [14]
RP   FUNCTION IN REORGANIZATION OF THE ACTIN CYTOSKELETON AND CELL
RP   DIFFERENTIATION, AND INTERACTION WITH BCR.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster region
RT   protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent
RT   manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH TUBULIN AND MICROTUBULES,
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-713, PHOSPHORYLATION BY HCK,
RP   AND MUTAGENESIS OF LEU-145; ARG-483 AND LYS-590.
RX   PubMed=15485904; DOI=10.1128/mcb.24.21.9351-9358.2004;
RA   Laurent C.E., Delfino F.J., Cheng H.Y., Smithgall T.E.;
RT   "The human c-Fes tyrosine kinase binds tubulin and microtubules through
RT   separate domains and promotes microtubule assembly.";
RL   Mol. Cell. Biol. 24:9351-9358(2004).
RN   [16]
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF MET-704;
RP   ARG-706; VAL-743 AND SER-759.
RX   PubMed=15867340; DOI=10.1158/0008-5472.can-04-3468;
RA   Sangrar W., Zirgnibl R.A., Gao Y., Muller W.J., Jia Z., Greer P.A.;
RT   "An identity crisis for fps/fes: oncogene or tumor suppressor?";
RL   Cancer Res. 65:3518-3522(2005).
RN   [17]
RP   ALTERNATIVE SPLICING.
RX   PubMed=15869408; DOI=10.1089/dna.2005.24.311;
RA   Carlson A., Berkowitz J.M., Browning D., Slamon D.J., Gasson J.C.,
RA   Yates K.E.;
RT   "Expression of c-Fes protein isoforms correlates with differentiation in
RT   myeloid leukemias.";
RL   DNA Cell Biol. 24:311-316(2005).
RN   [18]
RP   INTERACTION WITH TRIM28.
RX   PubMed=16792528; DOI=10.1042/bj20060194;
RA   Delfino F.J., Shaffer J.M., Smithgall T.E.;
RT   "The KRAB-associated co-repressor KAP-1 is a coiled-coil binding partner,
RT   substrate and activator of the c-Fes protein tyrosine kinase.";
RL   Biochem. J. 399:141-150(2006).
RN   [19]
RP   FUNCTION IN STAT3 PHOSPHORYLATION, ROLE AS PUTATIVE TUMOR SUPPRESSOR IN
RP   COLON CANCER, MUTAGENESIS OF MET-704; ARG-706; VAL-743 AND SER-759,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16455651; DOI=10.1074/jbc.m507331200;
RA   Delfino F.J., Stevenson H., Smithgall T.E.;
RT   "A growth-suppressive function for the c-fes protein-tyrosine kinase in
RT   colorectal cancer.";
RL   J. Biol. Chem. 281:8829-8835(2006).
RN   [20]
RP   FUNCTION IN KIT SIGNALING, AND POSSIBLE ROLE IN CANCER CELL PROLIFERATION.
RX   PubMed=17595334; DOI=10.1182/blood-2007-02-076471;
RA   Voisset E., Lopez S., Dubreuil P., De Sepulveda P.;
RT   "The tyrosine kinase FES is an essential effector of KITD816V proliferation
RT   signal.";
RL   Blood 110:2593-2599(2007).
RN   [21]
RP   FUNCTION IN CYTOSKELETON REORGANIZATION, INTERACTION WITH EZR,
RP   PHOSPHORYLATION AT TYR-713, AND SUBCELLULAR LOCATION.
RX   PubMed=18046454; DOI=10.1038/sj.emboj.7601943;
RA   Naba A., Reverdy C., Louvard D., Arpin M.;
RT   "Spatial recruitment and activation of the Fes kinase by ezrin promotes
RT   HGF-induced cell scattering.";
RL   EMBO J. 27:38-50(2008).
RN   [22]
RP   SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-713, PHOSPHORYLATION
RP   BY HCK, AND DOMAIN.
RX   PubMed=19382747; DOI=10.1021/bi900238f;
RA   Shaffer J.M., Hellwig S., Smithgall T.E.;
RT   "Bimolecular fluorescence complementation demonstrates that the c-Fes
RT   protein-tyrosine kinase forms constitutive oligomers in living cells.";
RL   Biochemistry 48:4780-4788(2009).
RN   [23]
RP   FUNCTION, TISSUE SPECIFICITY, AND ROLE AS PUTATIVE TUMOR SUPPRESSOR IN
RP   COLON CANCER.
RX   PubMed=19051325; DOI=10.1002/gcc.20638;
RA   Shaffer J.M., Smithgall T.E.;
RT   "Promoter methylation blocks FES protein-tyrosine kinase gene expression in
RT   colorectal cancer.";
RL   Genes Chromosomes Cancer 48:272-284(2009).
RN   [24]
RP   PUTATIVE ROLE IN RENAL CARCINOMA.
RX   PubMed=19082481;
RA   Kanda S., Miyata Y., Kanetake H., Smithgall T.E.;
RT   "Downregulation of the c-Fes protein-tyrosine kinase inhibits the
RT   proliferation of human renal carcinoma cells.";
RL   Int. J. Oncol. 34:89-96(2009).
RN   [25]
RP   FUNCTION, INTERACTION WITH MS4A2/FCER1B AND HCLS1/HS1, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION, INTERACTION WITH PHOSPHOINOSITIDE-CONTAINING
RP   MEMBRANES, AND MUTAGENESIS OF 113-ARG-LYS-114.
RX   PubMed=19001085; DOI=10.1128/mcb.00904-08;
RA   McPherson V.A., Everingham S., Karisch R., Smith J.A., Udell C.M.,
RA   Zheng J., Jia Z., Craig A.W.;
RT   "Contributions of F-BAR and SH2 domains of Fes protein tyrosine kinase for
RT   coupling to the FcepsilonRI pathway in mast cells.";
RL   Mol. Cell. Biol. 29:389-401(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64; SER-67; TYR-261; TYR-713
RP   AND SER-716, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   FUNCTION, PHOSPHORYLATION AT THR-421, AND INTERACTION WITH FLT3.
RX   PubMed=20111072; DOI=10.1038/leu.2009.301;
RA   Voisset E., Lopez S., Chaix A., Georges C., Hanssens K., Prebet T.,
RA   Dubreuil P., De Sepulveda P.;
RT   "FES kinases are required for oncogenic FLT3 signaling.";
RL   Leukemia 24:721-728(2010).
RN   [28]
RP   REVIEW.
RX   PubMed=21622225; DOI=10.2741/3902;
RA   Hellwig S., Smithgall T.E.;
RT   "Structure and regulation of the c-Fes protein-tyrosine kinase.";
RL   Front. Biosci. 16:3146-3155(2011).
RN   [29]
RP   POSSIBLE ROLE IN PROSTATE CANCER.
RX   PubMed=21563194; DOI=10.1002/pros.21422;
RA   Miyata Y., Watanabe S.I., Matsuo T., Hayashi T., Sakai H., Xuan J.W.,
RA   Greer P.A., Kanda S.;
RT   "Pathological significance and predictive value for biochemical recurrence
RT   of c-Fes expression in prostate cancer.";
RL   Prostate 72:201-208(2012).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-408 AND SER-411, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   TISSUE SPECIFICITY, ROLE AS TUMOR SUPPRESSOR IN MELANOMA, AND MUTAGENESIS
RP   OF LYS-590.
RX   PubMed=28463229; DOI=10.1172/jci91291;
RA   Olvedy M., Tisserand J.C., Luciani F., Boeckx B., Wouters J., Lopez S.,
RA   Rambow F., Aibar S., Thienpont B., Barra J., Koehler C., Radaelli E.,
RA   Tartare-Deckert S., Aerts S., Dubreuil P., van den Oord J.J.,
RA   Lambrechts D., De Sepulveda P., Marine J.C.;
RT   "Comparative oncogenomics identifies tyrosine kinase FES as a tumor
RT   suppressor in melanoma.";
RL   J. Clin. Invest. 127:2310-2325(2017).
RN   [32]
RP   STRUCTURE BY NMR OF 450-550.
RX   PubMed=15929003; DOI=10.1007/s10858-005-0946-6;
RA   Scott A., Pantoja-Uceda D., Koshiba S., Inoue M., Kigawa T., Terada T.,
RA   Shirouzu M., Tanaka A., Sugano S., Yokoyama S., Guentert P.;
RT   "Solution structure of the Src homology 2 domain from the human feline
RT   sarcoma oncogene Fes.";
RL   J. Biomol. NMR 31:357-361(2005).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.78 ANGSTROMS) OF 448-822 OF UNPHOSPHORYLATED
RP   APOPROTEIN AND IN COMPLEX WITH STAUROSPORINE AND A SUBSTRATE PEPTIDE,
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT TYR-713, NMR
RP   SPECTROSCOPY, AND MUTAGENESIS OF GLY-463 AND ARG-483.
RX   PubMed=18775312; DOI=10.1016/j.cell.2008.07.047;
RA   Filippakopoulos P., Kofler M., Hantschel O., Gish G.D., Grebien F.,
RA   Salah E., Neudecker P., Kay L.E., Turk B.E., Superti-Furga G., Pawson T.,
RA   Knapp S.;
RT   "Structural coupling of SH2-kinase domains links Fes and Abl substrate
RT   recognition and kinase activation.";
RL   Cell 134:793-803(2008).
RN   [34]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-85; GLN-246 AND VAL-323.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts downstream of cell surface
CC       receptors and plays a role in the regulation of the actin cytoskeleton,
CC       microtubule assembly, cell attachment and cell spreading. Plays a role
CC       in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated
CC       signaling in mast cells. Acts down-stream of the activated FCER1
CC       receptor and the mast/stem cell growth factor receptor KIT. Plays a
CC       role in the regulation of mast cell degranulation. Plays a role in the
CC       regulation of cell differentiation and promotes neurite outgrowth in
CC       response to NGF signaling. Plays a role in cell scattering and cell
CC       migration in response to HGF-induced activation of EZR. Phosphorylates
CC       BCR and down-regulates BCR kinase activity. Phosphorylates HCLS1/HS1,
CC       PECAM1, STAT3 and TRIM28. {ECO:0000269|PubMed:11509660,
CC       ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15485904,
CC       ECO:0000269|PubMed:16455651, ECO:0000269|PubMed:17595334,
CC       ECO:0000269|PubMed:18046454, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19051325, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:2656706, ECO:0000269|PubMed:8955135}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:11509660, ECO:0000269|PubMed:15485904,
CC         ECO:0000269|PubMed:15867340, ECO:0000269|PubMed:18775312,
CC         ECO:0000269|PubMed:2656706, ECO:0000269|PubMed:7687763};
CC   -!- ACTIVITY REGULATION: Kinase activity is tightly regulated. Activated in
CC       response to signaling from a cell surface receptor. Activation probably
CC       requires binding of a substrate via the SH2 domain, plus
CC       autophosphorylation at Tyr-713. Present in an inactive form in the
CC       absence of activating stimuli. {ECO:0000269|PubMed:18775312,
CC       ECO:0000269|PubMed:8955135}.
CC   -!- SUBUNIT: Homooligomer. Interacts with BCR. Interacts (when activated,
CC       via coiled coil domain) with TRIM28. Interacts (via SH2 domain) with
CC       phosphorylated EZR, MS4A2/FCER1B and HCLS1/HS1. Interacts with
CC       phosphorylated KIT. Interacts with FLT3. Interacts (via F-BAR domain)
CC       with soluble tubulin. Interacts (via SH2 domain) with microtubules.
CC       {ECO:0000269|PubMed:11509660, ECO:0000269|PubMed:15302586,
CC       ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:16792528,
CC       ECO:0000269|PubMed:18046454, ECO:0000269|PubMed:18775312,
CC       ECO:0000269|PubMed:19001085, ECO:0000269|PubMed:19382747,
CC       ECO:0000269|PubMed:20111072}.
CC   -!- INTERACTION:
CC       P07332; P10275: AR; NbExp=3; IntAct=EBI-1055635, EBI-608057;
CC       P07332; P15311: EZR; NbExp=8; IntAct=EBI-1055635, EBI-1056902;
CC       P07332; Q13480: GAB1; NbExp=2; IntAct=EBI-1055635, EBI-517684;
CC       P07332; P10721: KIT; NbExp=2; IntAct=EBI-1055635, EBI-1379503;
CC       P07332; P54274: TERF1; NbExp=2; IntAct=EBI-1055635, EBI-710997;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cytoplasm, cytoskeleton. Cell
CC       membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasmic
CC       vesicle. Golgi apparatus. Cell junction, focal adhesion.
CC       Note=Distributed throughout the cytosol when the kinase is not
CC       activated. Association with microtubules requires activation of the
CC       kinase activity. Shuttles between focal adhesions and cell-cell
CC       contacts in epithelial cells. Recruited to the lateral cell membrane in
CC       polarized epithelial cells by interaction with phosphorylated EZR.
CC       Detected at tubular membrane structures in the cytoplasm and at the
CC       cell periphery.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P07332-1; Sequence=Displayed;
CC       Name=2; Synonyms=Variant 1;
CC         IsoId=P07332-2; Sequence=VSP_041748, VSP_041749;
CC       Name=3; Synonyms=Variant 3;
CC         IsoId=P07332-3; Sequence=VSP_041748;
CC       Name=4; Synonyms=Variant 4;
CC         IsoId=P07332-4; Sequence=VSP_041749;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Detected in adult colon
CC       epithelium (at protein level) (PubMed:16455651, PubMed:19051325).
CC       Expressed in melanocytes (at protein level) (PubMed:28463229).
CC       {ECO:0000269|PubMed:16455651, ECO:0000269|PubMed:19051325,
CC       ECO:0000269|PubMed:28463229}.
CC   -!- DOMAIN: The coiled coil domains are important for regulating the kinase
CC       activity. They mediate homooligomerization and probably also
CC       interaction with other proteins.
CC   -!- DOMAIN: The N-terminal region including the first coiled coil domain
CC       mediates interaction with phosphoinositide-containing membranes.
CC   -!- PTM: Autophosphorylated on Tyr-713. Phosphorylated by LYN in response
CC       to FCER1 activation. Phosphorylated by HCK.
CC       {ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:18046454,
CC       ECO:0000269|PubMed:18775312, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19382747, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:7687763}.
CC   -!- DISEASE: Note=Has been shown to act as proto-oncogene in some types of
CC       cancer, possibly due to abnormal activation of the kinase. Has been
CC       shown to act as tumor suppressor in other types of cancer. Expressed
CC       and present as activated kinase in a subset of acute myeloid leukemia
CC       patients; promotes survival of leukemia cells (PubMed:20111072).
CC       Expression is absent in K562 leukemia cells; ectopic expression of
CC       FSP/FES restores myeloid differentiation (PubMed:2656706). May function
CC       as tumor suppressor in colorectal cancer; expression is reduced or
CC       absent in samples from some colon cancer patients (PubMed:16455651).
CC       May function as tumor suppressor in melanoma by preventing melanoma
CC       cell proliferation; expression is reduced or absent in samples from
CC       some melanoma patients (PubMed:28463229). Ectopic expression of FSP/FES
CC       suppresses anchorage-independent growth in colon cancer cell lines
CC       (PubMed:16455651). Up-regulated in prostate cancer, and might be a
CC       predictor of recurrence after radical surgery (PubMed:16455651). May
CC       promote growth of renal carcinoma cells (PubMed:19082481).
CC       {ECO:0000269|PubMed:16455651, ECO:0000269|PubMed:19082481,
CC       ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:2656706,
CC       ECO:0000269|PubMed:28463229}.
CC   -!- MISCELLANEOUS: Cellular homolog of retroviral oncogenes. In contrast to
CC       the viral oncoproteins, the kinase activity of cellular FSP/FES is
CC       tightly regulated, and the kinase is inactive in normal cells in the
CC       absence of activating stimuli (PubMed:15485904).
CC       {ECO:0000305|PubMed:15485904}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fes/fps subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X52192; CAA36438.1; -; mRNA.
DR   EMBL; X06292; CAA29619.1; -; Genomic_DNA.
DR   EMBL; AY513654; AAS82866.1; -; mRNA.
DR   EMBL; AY513656; AAS82868.1; -; mRNA.
DR   EMBL; AY513657; AAS82869.1; -; mRNA.
DR   EMBL; AK300595; BAG62292.1; -; mRNA.
DR   EMBL; AK312545; BAG35443.1; -; mRNA.
DR   EMBL; AC124248; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471101; EAX02114.1; -; Genomic_DNA.
DR   EMBL; BC035357; AAH35357.1; -; mRNA.
DR   CCDS; CCDS10365.1; -. [P07332-1]
DR   CCDS; CCDS45349.1; -. [P07332-4]
DR   CCDS; CCDS45350.1; -. [P07332-3]
DR   CCDS; CCDS45351.1; -. [P07332-2]
DR   PIR; A24673; TVHUFF.
DR   RefSeq; NP_001137255.1; NM_001143783.1. [P07332-3]
DR   RefSeq; NP_001137256.1; NM_001143784.1. [P07332-4]
DR   RefSeq; NP_001137257.1; NM_001143785.1. [P07332-2]
DR   RefSeq; NP_001996.1; NM_002005.3. [P07332-1]
DR   RefSeq; XP_005254937.1; XM_005254880.1. [P07332-3]
DR   RefSeq; XP_005254939.1; XM_005254882.1. [P07332-4]
DR   RefSeq; XP_016877494.1; XM_017022005.1. [P07332-1]
DR   RefSeq; XP_016877495.1; XM_017022006.1. [P07332-3]
DR   RefSeq; XP_016877496.1; XM_017022007.1. [P07332-4]
DR   RefSeq; XP_016877497.1; XM_017022008.1. [P07332-2]
DR   RefSeq; XP_016877498.1; XM_017022009.1. [P07332-1]
DR   RefSeq; XP_016877499.1; XM_017022010.1. [P07332-3]
DR   PDB; 1WQU; NMR; -; A=450-550.
DR   PDB; 2DCR; NMR; -; A=450-550.
DR   PDB; 3BKB; X-ray; 1.78 A; A=448-822.
DR   PDB; 3CBL; X-ray; 1.75 A; A=448-822.
DR   PDB; 3CD3; X-ray; 1.98 A; A=448-822.
DR   PDB; 4DYL; X-ray; 2.18 A; A=1-405.
DR   PDB; 4E93; X-ray; 1.84 A; A=448-822.
DR   PDB; 6JMF; X-ray; 2.00 A; A=449-822.
DR   PDBsum; 1WQU; -.
DR   PDBsum; 2DCR; -.
DR   PDBsum; 3BKB; -.
DR   PDBsum; 3CBL; -.
DR   PDBsum; 3CD3; -.
DR   PDBsum; 4DYL; -.
DR   PDBsum; 4E93; -.
DR   PDBsum; 6JMF; -.
DR   SMR; P07332; -.
DR   BioGrid; 108533; 25.
DR   IntAct; P07332; 32.
DR   MINT; P07332; -.
DR   STRING; 9606.ENSP00000331504; -.
DR   BindingDB; P07332; -.
DR   ChEMBL; CHEMBL5455; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P07332; -.
DR   GuidetoPHARMACOLOGY; 2023; -.
DR   iPTMnet; P07332; -.
DR   PhosphoSitePlus; P07332; -.
DR   BioMuta; FES; -.
DR   DMDM; 115502390; -.
DR   CPTAC; CPTAC-1778; -.
DR   EPD; P07332; -.
DR   jPOST; P07332; -.
DR   MassIVE; P07332; -.
DR   MaxQB; P07332; -.
DR   PaxDb; P07332; -.
DR   PeptideAtlas; P07332; -.
DR   PRIDE; P07332; -.
DR   ProteomicsDB; 51989; -. [P07332-1]
DR   ProteomicsDB; 51990; -. [P07332-2]
DR   ProteomicsDB; 51991; -. [P07332-3]
DR   ProteomicsDB; 51992; -. [P07332-4]
DR   Antibodypedia; 734; 427 antibodies.
DR   DNASU; 2242; -.
DR   Ensembl; ENST00000328850; ENSP00000331504; ENSG00000182511. [P07332-1]
DR   Ensembl; ENST00000394300; ENSP00000377837; ENSG00000182511. [P07332-3]
DR   Ensembl; ENST00000414248; ENSP00000414629; ENSG00000182511. [P07332-2]
DR   Ensembl; ENST00000444422; ENSP00000400868; ENSG00000182511. [P07332-4]
DR   GeneID; 2242; -.
DR   KEGG; hsa:2242; -.
DR   UCSC; uc002bpv.4; human. [P07332-1]
DR   CTD; 2242; -.
DR   DisGeNET; 2242; -.
DR   GeneCards; FES; -.
DR   HGNC; HGNC:3657; FES.
DR   HPA; ENSG00000182511; Tissue enhanced (blood, lymphoid tissue).
DR   MIM; 190030; gene.
DR   neXtProt; NX_P07332; -.
DR   OpenTargets; ENSG00000182511; -.
DR   PharmGKB; PA28098; -.
DR   eggNOG; KOG0194; Eukaryota.
DR   eggNOG; ENOG410Y6RP; LUCA.
DR   GeneTree; ENSGT00940000158881; -.
DR   HOGENOM; CLU_005265_0_1_1; -.
DR   InParanoid; P07332; -.
DR   KO; K07527; -.
DR   OMA; HFIIQSA; -.
DR   PhylomeDB; P07332; -.
DR   TreeFam; TF315363; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR   Reactome; R-HSA-399956; CRMPs in Sema3A signaling.
DR   SignaLink; P07332; -.
DR   SIGNOR; P07332; -.
DR   ChiTaRS; FES; human.
DR   EvolutionaryTrace; P07332; -.
DR   GeneWiki; Feline_sarcoma_oncogene; -.
DR   GenomeRNAi; 2242; -.
DR   Pharos; P07332; Tchem.
DR   PRO; PR:P07332; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P07332; protein.
DR   Bgee; ENSG00000182511; Expressed in spleen and 113 other tissues.
DR   ExpressionAtlas; P07332; baseline and differential.
DR   Genevisible; P07332; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0034987; F:immunoglobulin receptor binding; IDA:UniProtKB.
DR   GO; GO:0008017; F:microtubule binding; IEA:Ensembl.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0035091; F:phosphatidylinositol binding; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0071305; P:cellular response to vitamin D; IMP:ARUK-UCL.
DR   GO; GO:0007098; P:centrosome cycle; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0001578; P:microtubule bundle formation; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IMP:UniProtKB.
DR   GO; GO:0045657; P:positive regulation of monocyte differentiation; IMP:ARUK-UCL.
DR   GO; GO:0045639; P:positive regulation of myeloid cell differentiation; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; IMP:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0043304; P:regulation of mast cell degranulation; IMP:UniProtKB.
DR   GO; GO:0060627; P:regulation of vesicle-mediated transport; TAS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10361; SH2_Fps_family; 1.
DR   Gene3D; 1.20.1270.60; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR027267; AH/BAR_dom_sf.
DR   InterPro; IPR031160; F_BAR.
DR   InterPro; IPR001060; FCH_dom.
DR   InterPro; IPR035849; Fes/Fps/Fer_SH2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR016250; Tyr-prot_kinase_Fes/Fps.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PIRSF; PIRSF000632; TyrPK_fps; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00055; FCH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF103657; SSF103657; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51741; F_BAR; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell junction;
KW   Cell membrane; Coiled coil; Cytoplasm; Cytoplasmic vesicle; Cytoskeleton;
KW   Golgi apparatus; Kinase; Lipid-binding; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   SH2 domain; Transferase; Tumor suppressor; Tyrosine-protein kinase.
FT   CHAIN           1..822
FT                   /note="Tyrosine-protein kinase Fes/Fps"
FT                   /id="PRO_0000088088"
FT   DOMAIN          1..260
FT                   /note="F-BAR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01077"
FT   DOMAIN          460..549
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          561..822
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         567..575
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..300
FT                   /note="Important for interaction with membranes containing
FT                   phosphoinositides"
FT   COILED          125..169
FT                   /evidence="ECO:0000255"
FT   COILED          324..368
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        683
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         590
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         64
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   MOD_RES         67
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   MOD_RES         261
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   MOD_RES         408
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         411
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         421
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:20111072"
FT   MOD_RES         713
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000244|PubMed:19369195,
FT                   ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:18046454,
FT                   ECO:0000269|PubMed:18775312, ECO:0000269|PubMed:19382747,
FT                   ECO:0000269|PubMed:7687763"
FT   MOD_RES         716
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   VAR_SEQ         72..129
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.3"
FT                   /id="VSP_041748"
FT   VAR_SEQ         441..510
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.3"
FT                   /id="VSP_041749"
FT   VARIANT         85
FT                   /note="R -> C (in dbSNP:rs56041861)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041697"
FT   VARIANT         246
FT                   /note="R -> Q (in dbSNP:rs34573430)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041698"
FT   VARIANT         323
FT                   /note="M -> V (in dbSNP:rs56296062)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041699"
FT   MUTAGEN         113..114
FT                   /note="RK->EE: Reduced binding to membranes containing
FT                   phosphoinositides."
FT                   /evidence="ECO:0000269|PubMed:19001085"
FT   MUTAGEN         113..114
FT                   /note="RK->QQ: Reduced binding to membranes containing
FT                   phosphoinositides."
FT                   /evidence="ECO:0000269|PubMed:19001085"
FT   MUTAGEN         145
FT                   /note="L->P: Constitutively activated kinase that can act
FT                   as oncogene. Promotes myeloid cell survival and
FT                   proliferation."
FT                   /evidence="ECO:0000269|PubMed:11509660,
FT                   ECO:0000269|PubMed:15485904"
FT   MUTAGEN         334
FT                   /note="L->P: Abolishes autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11509660"
FT   MUTAGEN         463
FT                   /note="G->V: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:18775312"
FT   MUTAGEN         483
FT                   /note="R->M: Abolishes pTyr binding. Abolishes association
FT                   with microtubules. Abolishes autophosphorylation. Reduced
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15485904,
FT                   ECO:0000269|PubMed:18775312"
FT   MUTAGEN         590
FT                   /note="K->E: Abolishes kinase activity. Fails to inhibit
FT                   proliferation of melanoma cells."
FT                   /evidence="ECO:0000269|PubMed:15485904,
FT                   ECO:0000269|PubMed:28463229"
FT   MUTAGEN         704
FT                   /note="M->V: Reduced autophosphorylation and strongly
FT                   reduced kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15867340,
FT                   ECO:0000269|PubMed:16455651"
FT   MUTAGEN         706
FT                   /note="R->Q: Negligible effect on autophosphorylation and
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15867340,
FT                   ECO:0000269|PubMed:16455651"
FT   MUTAGEN         713
FT                   /note="Y->F: Reduces kinase activity by over 90%."
FT                   /evidence="ECO:0000269|PubMed:7687763"
FT   MUTAGEN         743
FT                   /note="V->M: Strongly reduced autophosphorylation and
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15867340,
FT                   ECO:0000269|PubMed:16455651"
FT   MUTAGEN         759
FT                   /note="S->F: Reduced autophosphorylation and strongly
FT                   reduced kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15867340,
FT                   ECO:0000269|PubMed:16455651"
FT   CONFLICT        719
FT                   /note="L -> S (in Ref. 1; CAA36438 and 3; AAS82866/
FT                   AAS82869/AAS82868)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..6
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           10..51
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           68..96
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           98..131
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           133..154
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           167..202
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           204..234
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   STRAND          236..238
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           239..254
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           257..259
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           262..268
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   TURN            300..302
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           303..344
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           350..353
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           354..389
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   TURN            390..393
FT                   /evidence="ECO:0000244|PDB:4DYL"
FT   HELIX           450..452
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           455..457
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          461..464
FT                   /evidence="ECO:0000244|PDB:1WQU"
FT   HELIX           467..473
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          479..484
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   TURN            486..489
FT                   /evidence="ECO:0000244|PDB:3BKB"
FT   STRAND          491..494
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          503..506
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          507..509
FT                   /evidence="ECO:0000244|PDB:3BKB"
FT   STRAND          512..517
FT                   /evidence="ECO:0000244|PDB:3BKB"
FT   STRAND          520..522
FT                   /evidence="ECO:0000244|PDB:3BKB"
FT   HELIX           523..533
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   TURN            539..541
FT                   /evidence="ECO:0000244|PDB:3BKB"
FT   HELIX           558..560
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          561..570
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          573..580
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   TURN            581..583
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          586..591
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           598..601
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           602..605
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           606..611
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          622..626
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          628..631
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          633..637
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           644..651
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           652..654
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           657..676
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           686..688
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          689..691
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          697..699
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           702..704
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          711..714
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          720..723
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           724..726
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           729..734
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   STRAND          736..738
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           739..754
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   TURN            755..757
FT                   /evidence="ECO:0000244|PDB:4E93"
FT   HELIX           766..774
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           787..796
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           801..803
FT                   /evidence="ECO:0000244|PDB:3CBL"
FT   HELIX           807..820
FT                   /evidence="ECO:0000244|PDB:3CBL"
SQ   SEQUENCE   822 AA;  93497 MW;  4C2A90555857F045 CRC64;
     MGFSSELCSP QGHGVLQQMQ EAELRLLEGM RKWMAQRVKS DREYAGLLHH MSLQDSGGQS
     RAISPDSPIS QSWAEITSQT EGLSRLLRQH AEDLNSGPLS KLSLLIRERQ QLRKTYSEQW
     QQLQQELTKT HSQDIEKLKS QYRALARDSA QAKRKYQEAS KDKDRDKAKD KYVRSLWKLF
     AHHNRYVLGV RAAQLHHQHH HQLLLPGLLR SLQDLHEEMA CILKEILQEY LEISSLVQDE
     VVAIHREMAA AAARIQPEAE YQGFLRQYGS APDVPPCVTF DESLLEEGEP LEPGELQLNE
     LTVESVQHTL TSVTDELAVA TEMVFRRQEM VTQLQQELRN EEENTHPRER VQLLGKRQVL
     QEALQGLQVA LCSQAKLQAQ QELLQTKLEH LGPGEPPPVL LLQDDRHSTS SSEQEREGGR
     TPTLEILKSH ISGIFRPKFS LPPPLQLIPE VQKPLHEQLW YHGAIPRAEV AELLVHSGDF
     LVRESQGKQE YVLSVLWDGL PRHFIIQSLD NLYRLEGEGF PSIPLLIDHL LSTQQPLTKK
     SGVVLHRAVP KDKWVLNHED LVLGEQIGRG NFGEVFSGRL RADNTLVAVK SCRETLPPDL
     KAKFLQEARI LKQYSHPNIV RLIGVCTQKQ PIYIVMELVQ GGDFLTFLRT EGARLRVKTL
     LQMVGDAAAG MEYLESKCCI HRDLAARNCL VTEKNVLKIS DFGMSREEAD GVYAASGGLR
     QVPVKWTAPE ALNYGRYSSE SDVWSFGILL WETFSLGASP YPNLSNQQTR EFVEKGGRLP
     CPELCPDAVF RLMEQCWAYE PGQRPSFSTI YQELQSIRKR HR
//
ID   FOXL2_HUMAN             Reviewed;         376 AA.
AC   P58012; Q4ZGJ3;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   27-APR-2001, sequence version 1.
DT   22-APR-2020, entry version 189.
DE   RecName: Full=Forkhead box protein L2;
GN   Name=FOXL2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT BPES
RP   ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-234 INS.
RX   PubMed=11175783; DOI=10.1038/84781;
RA   Crisponi L., Deiana M., Loi A., Chiappe F., Uda M., Amati P., Bisceglia L.,
RA   Zelante L., Nagaraja R., Porcu S., Ristaldi M.S., Marzella R., Rocchi M.,
RA   Nicolino M., Lienhardt-Roussie A., Nivelon A., Verloes A., Schlessinger D.,
RA   Gasparini P., Bonneau D., Cao A., Pilia G.;
RT   "The putative forkhead transcription factor FOXL2 is mutated in
RT   blepharophimosis/ptosis/epicanthus inversus syndrome.";
RL   Nat. Genet. 27:159-166(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT BPES
RP   ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-234 INS.
RA   Xu Y.;
RT   "Study of mutations of FOXL2 gene in a Chinese TongHai family with
RT   blepharophimosis-ptosis-epicanthus inversus syndrome.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION IN APOPTOSIS, AND INTERACTION WITH DDX20.
RX   PubMed=16153597; DOI=10.1016/j.bbrc.2005.08.184;
RA   Lee K., Pisarska M.D., Ko J.J., Kang Y., Yoon S., Ryou S.M., Cha K.Y.,
RA   Bae J.;
RT   "Transcriptional factor FOXL2 interacts with DP103 and induces apoptosis.";
RL   Biochem. Biophys. Res. Commun. 336:876-881(2005).
RN   [5]
RP   FUNCTION AS TRANSCRIPTIONAL REPRESSOR OF STAR, INTERACTION WITH UBE2I,
RP   SUMOYLATION AT LYS-25, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-25.
RX   PubMed=19744555; DOI=10.1016/j.cellsig.2009.09.001;
RA   Kuo F.T., Bentsi-Barnes I.K., Barlow G.M., Bae J., Pisarska M.D.;
RT   "Sumoylation of forkhead L2 by Ubc9 is required for its activity as a
RT   transcriptional repressor of the steroidogenic acute regulatory gene.";
RL   Cell. Signal. 21:1935-1944(2009).
RN   [6]
RP   FUNCTION AS TRANSCRIPTIONAL ACTIVATOR OF SIRT1, AND INDUCTION.
RX   PubMed=19010791; DOI=10.1093/hmg/ddn389;
RA   Benayoun B.A., Batista F., Auer J., Dipietromaria A., L'Hote D.,
RA   De Baere E., Veitia R.A.;
RT   "Positive and negative feedback regulates the transcription factor FOXL2 in
RT   response to cell stress: evidence for a regulatory imbalance induced by
RT   disease-causing mutations.";
RL   Hum. Mol. Genet. 18:632-644(2009).
RN   [7]
RP   FUNCTION AS TRANSCRIPTIONAL ACTIVATOR OF OSR2, VARIANT POF3 ASP-187, AND
RP   CHARACTERIZATION OF VARIANT POF3 ASP-187.
RX   PubMed=19429596; DOI=10.1136/jmg.2008.065086;
RA   Laissue P., Lakhal B., Benayoun B.A., Dipietromaria A., Braham R.,
RA   Elghezal H., Philibert P., Saad A., Sultan C., Fellous M., Veitia R.A.;
RT   "Functional evidence implicating FOXL2 in non-syndromic premature ovarian
RT   failure and in the regulation of the transcription factor OSR2.";
RL   J. Med. Genet. 46:455-457(2009).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-33, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   DATABASE OF FOXL2 VARIANTS.
RX   PubMed=15300845; DOI=10.1002/humu.20079;
RA   Beysen D., Vandesompele J., Messiaen L., De Paepe A., De Baere E.;
RT   "The human FOXL2 mutation database.";
RL   Hum. Mutat. 24:189-193(2004).
RN   [10]
RP   VARIANTS BPES ILE-85 DEL AND PHE-217.
RX   PubMed=11468277; DOI=10.1093/hmg/10.15.1591;
RA   De Baere E., Dixon M.J., Small K.W., Jabs E.W., Leroy B.P., Devriendt K.,
RA   Gillerot Y., Mortier G., Meire F., Van Maldergem L., Courtens W.,
RA   Hjalgrim H., Huang S., Liebaers I., Van Regemorter N., Touraine P.,
RA   Praphanphoj V., Verloes A., Udar N., Yellore V., Chalukya M., Yelchits S.,
RA   De Paepe A., Kuttenn F., Fellous M., Veitia R., Messiaen L.;
RT   "Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus
RT   inversus (BPES) families demonstrates a genotype -- phenotype
RT   correlation.";
RL   Hum. Mol. Genet. 10:1591-1600(2001).
RN   [11]
RP   VARIANT BPES ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-234 INS.
RX   PubMed=12400065; DOI=10.1002/ajmg.10741;
RA   Ramirez-Castro J.L., Pineda-Trujillo N., Valencia A.V., Muneton C.M.,
RA   Botero O., Trujillo O., Vasquez G., Mora B.E., Durango N., Bedoya G.,
RA   Ruiz-Linares A.;
RT   "Mutations in FOXL2 underlying BPES (types 1 and 2) in Colombian
RT   families.";
RL   Am. J. Med. Genet. 113:47-51(2002).
RN   [12]
RP   VARIANTS ASP-187 AND SER-285.
RX   PubMed=12161610; DOI=10.1136/jmg.39.8.e43;
RA   De Baere E., Lemercier B., Christin-Maitre S., Durval D., Messiaen L.,
RA   Fellous M., Veitia R.;
RT   "FOXL2 mutation screening in a large panel of POF patients and XX males.";
RL   J. Med. Genet. 39:E43-E43(2002).
RN   [13]
RP   VARIANTS POF3 221-ALA--ALA-230 DEL AND ASN-258, AND VARIANT GLY-179.
RX   PubMed=12149404; DOI=10.1093/molehr/8.8.729;
RA   Harris S.E., Chand A.L., Winship I.M., Gersak K., Aittomaeki K.,
RA   Shelling A.N.;
RT   "Identification of novel mutations in FOXL2 associated with premature
RT   ovarian failure.";
RL   Mol. Hum. Reprod. 8:729-733(2002).
RN   [14]
RP   VARIANTS BPES PHE-106; LYS-109 AND PHE-217.
RX   PubMed=12529855; DOI=10.1086/346118;
RA   De Baere E., Beysen D., Oley C., Lorenz B., Cocquet J., De Sutter P.,
RA   Devriendt K., Dixon M.J., Fellous M., Fryns J.-P., Garza A., Jonsrud C.,
RA   Koivisto P.A., Krause A., Leroy B.P., Meire F., Plomp A., Van Maldergem L.,
RA   De Paepe A., Veitia R., Messiaen L.;
RT   "FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision
RT   of the genotype-phenotype correlation.";
RL   Am. J. Hum. Genet. 72:478-487(2003).
RN   [15]
RP   VARIANT BPES SER-84.
RX   PubMed=12630957; DOI=10.1034/j.1399-0004.2003.00011.x;
RA   Dollfus H., Stoetzel C., Riehm S., Lahlou Boukoffa W., Bediard Boulaneb F.,
RA   Quillet R., Abu-Eid M., Speeg-Schatz C., Francfort J.J., Flament J.,
RA   Veillon F., Perrin-Schmitt F.;
RT   "Sporadic and familial blepharophimosis -ptosis-epicanthus inversus
RT   syndrome: FOXL2 mutation screen and MRI study of the superior levator
RT   eyelid muscle.";
RL   Clin. Genet. 63:117-120(2003).
RN   [16]
RP   VARIANT BPES ARG-104.
RX   PubMed=12938087; DOI=10.1002/humu.10251;
RA   Udar N., Yellore V., Chalukya M., Yelchits S., Silva-Garcia R., Small K.;
RT   "Comparative analysis of the FOXL2 gene and characterization of mutations
RT   in BPES patients.";
RL   Hum. Mutat. 22:222-228(2003).
RN   [17]
RP   VARIANT BPES CYS-215.
RX   PubMed=15257268;
RA   Kumar A., Babu M., Raghunath A., Venkatesh C.P.;
RT   "Genetic analysis of a five generation Indian family with BPES: a novel
RT   missense mutation (p.Y215C).";
RL   Mol. Vis. 10:445-449(2004).
RN   [18]
RP   VARIANT BPES THR-63.
RX   PubMed=16454982;
RA   Or S.F., Tong M.F., Lo F.M., Lam T.S.;
RT   "Three novel FOXL2 gene mutations in Chinese patients with
RT   blepharophimosis-ptosis-epicanthus inversus syndrome.";
RL   Chin. Med. J. 119:49-52(2006).
RN   [19]
RP   VARIANT BPES ALA-ALA-ALA-ALA-ALA-234 INS, AND CHARACTERIZATION OF VARIANT
RP   BPES ALA-ALA-ALA-ALA-ALA-234 INS.
RX   PubMed=17089161; DOI=10.1007/s00439-006-0276-0;
RA   Nallathambi J., Moumne L., De Baere E., Beysen D., Usha K., Sundaresan P.,
RA   Veitia R.A.;
RT   "A novel polyalanine expansion in FOXL2: the first evidence for a recessive
RT   form of the blepharophimosis syndrome (BPES) associated with ovarian
RT   dysfunction.";
RL   Hum. Genet. 121:107-112(2007).
RN   [20]
RP   CHARACTERIZATION OF VARIANTS BPES LEU-58; VAL-66; LYS-69; THR-80; ASN-84;
RP   SER-90; GLY-98; ARG-101; THR-102; CYS-103; ARG-104; PHE-106; PRO-106;
RP   LYS-109 AND PHE-217.
RX   PubMed=18372316; DOI=10.1093/hmg/ddn100;
RA   Beysen D., Moumne L., Veitia R., Peters H., Leroy B.P., De Paepe A.,
RA   De Baere E.;
RT   "Missense mutations in the forkhead domain of FOXL2 lead to subcellular
RT   mislocalization, protein aggregation and impaired transactivation.";
RL   Hum. Mol. Genet. 17:2030-2038(2008).
RN   [21]
RP   VARIANTS BPES ARG-98; PRO-108; CYS-215; CYS-217 AND
RP   ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-234 INS, VARIANT GLY-179, AND
RP   CHARACTERIZATION OF VARIANTS BPES PRO-108 AND CYS-217.
RX   PubMed=18484667; DOI=10.1002/humu.20809;
RA   Nallathambi J., Laissue P., Batista F., Benayoun B.A., Lesaffre C.,
RA   Moumne L., Pandaranayaka P.E., Usha K., Krishnaswamy S., Sundaresan P.,
RA   Veitia R.A.;
RT   "Differential functional effects of novel mutations of the transcription
RT   factor FOXL2 in BPES patients.";
RL   Hum. Mutat. 29:E123-E131(2008).
RN   [22]
RP   VARIANTS BPES LEU-58; VAL-65; VAL-66; LYS-69; THR-80; ASN-84; SER-90;
RP   GLY-98; ARG-101; THR-102; CYS-103 AND PRO-106.
RX   PubMed=18642388; DOI=10.1002/humu.20819;
RA   Beysen D., De Jaegere S., Amor D., Bouchard P., Christin-Maitre S.,
RA   Fellous M., Touraine P., Grix A.W., Hennekam R., Meire F., Oyen N.,
RA   Wilson L.C., Barel D., Clayton-Smith J., de Ravel T., Decock C.,
RA   Delbeke P., Ensenauer R., Ebinger F., Gillessen-Kaesbach G., Hendriks Y.,
RA   Kimonis V., Laframboise R., Laissue P., Leppig K., Leroy B.P., Miller D.T.,
RA   Mowat D., Neumann L., Plomp A., Van Regemorter N., Wieczorek D.,
RA   Veitia R.A., De Paepe A., De Baere E.;
RT   "Identification of 34 novel and 56 known FOXL2 mutations in patients with
RT   blepharophimosis syndrome.";
RL   Hum. Mutat. 29:E205-E219(2008).
RN   [23]
RP   VARIANT TRP-134.
RX   PubMed=19516027; DOI=10.1056/nejmoa0902542;
RA   Shah S.P., Kobel M., Senz J., Morin R.D., Clarke B.A., Wiegand K.C.,
RA   Leung G., Zayed A., Mehl E., Kalloger S.E., Sun M., Giuliany R., Yorida E.,
RA   Jones S., Varhol R., Swenerton K.D., Miller D., Clement P.B., Crane C.,
RA   Madore J., Provencher D., Leung P., DeFazio A., Khattra J., Turashvili G.,
RA   Zhao Y., Zeng T., Glover J.N., Vanderhyden B., Zhao C., Parkinson C.A.,
RA   Jimenez-Linan M., Bowtell D.D., Mes-Masson A.M., Brenton J.D.,
RA   Aparicio S.A., Boyd N., Hirst M., Gilks C.B., Marra M., Huntsman D.G.;
RT   "Mutation of FOXL2 in granulosa-cell tumors of the ovary.";
RL   N. Engl. J. Med. 360:2719-2729(2009).
RN   [24]
RP   VARIANT TRP-134.
RX   PubMed=19956657; DOI=10.1371/journal.pone.0007988;
RA   Schrader K.A., Gorbatcheva B., Senz J., Heravi-Moussavi A., Melnyk N.,
RA   Salamanca C., Maines-Bandiera S., Cooke S.L., Leung P., Brenton J.D.,
RA   Gilks C.B., Monahan J., Huntsman D.G.;
RT   "The specificity of the FOXL2 c.402C>G Somatic mutation: a survey of solid
RT   tumors.";
RL   PLoS ONE 4:E7988-E7988(2009).
RN   [25]
RP   VARIANT GLY-349.
RX   PubMed=27610946; DOI=10.1002/humu.23116;
RA   Igarashi M., Takasawa K., Hakoda A., Kanno J., Takada S., Miyado M.,
RA   Baba T., Morohashi K.I., Tajima T., Hata K., Nakabayashi K., Matsubara Y.,
RA   Sekido R., Ogata T., Kashimada K., Fukami M.;
RT   "Identical NR5A1 missense mutations in two unrelated 46,XX individuals with
RT   testicular tissues.";
RL   Hum. Mutat. 38:39-42(2017).
CC   -!- FUNCTION: Transcriptional regulator. Critical factor essential for
CC       ovary differentiation and maintenance, and repression of the genetic
CC       program for somatic testis determination. Prevents trans-
CC       differentiation of ovary to testis through transcriptional repression
CC       of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic
CC       activity in ovarian cells. Suppresses ESR1-mediated transcription of
CC       PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of
CC       CYP19 expression (By similarity). Participates in SMAD3-dependent
CC       transcription of FST via the intronic SMAD-binding element (By
CC       similarity). Is a transcriptional repressor of STAR. Activates SIRT1
CC       transcription under cellular stress conditions. Activates transcription
CC       of OSR2. {ECO:0000250, ECO:0000269|PubMed:16153597,
CC       ECO:0000269|PubMed:19010791, ECO:0000269|PubMed:19429596,
CC       ECO:0000269|PubMed:19744555}.
CC   -!- SUBUNIT: Interacts with ESR1 (By similarity). Interacts with SMAD3 (By
CC       similarity). Interacts with DDX20. Interacts with UBE2I/UBC9.
CC       {ECO:0000250, ECO:0000269|PubMed:16153597,
CC       ECO:0000269|PubMed:19744555}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00089,
CC       ECO:0000269|PubMed:19744555}.
CC   -!- TISSUE SPECIFICITY: In addition to its expression in the developing
CC       eyelid, it is transcribed very early in somatic cells of the developing
CC       gonad (before sex determination) and its expression persists in the
CC       follicular cells of the adult ovary.
CC   -!- INDUCTION: In granulosa-like cells, up-regulated at transcript and
CC       protein levels under oxidative stress and heat-shock conditions. Down-
CC       regulated by SIRT1. {ECO:0000269|PubMed:19010791}.
CC   -!- PTM: Sumoylated with SUMO1; sumoylation is required for transcriptional
CC       repression activity. {ECO:0000269|PubMed:19744555}.
CC   -!- DISEASE: Blepharophimosis, ptosis, and epicanthus inversus syndrome
CC       (BPES) [MIM:110100]: A disorder characterized by eyelid dysplasia,
CC       small palpebral fissures, drooping eyelids and a skin fold curving in
CC       the mediolateral direction, inferior to the inner canthus. In type I
CC       BPSE (BPES1) eyelid abnormalities are associated with female
CC       infertility. Affected females show an ovarian deficit due to primary
CC       amenorrhea or to premature ovarian failure (POF). In type II BPSE
CC       (BPES2) affected individuals show only the eyelid defects.
CC       {ECO:0000269|PubMed:11175783, ECO:0000269|PubMed:11468277,
CC       ECO:0000269|PubMed:12400065, ECO:0000269|PubMed:12529855,
CC       ECO:0000269|PubMed:12630957, ECO:0000269|PubMed:12938087,
CC       ECO:0000269|PubMed:15257268, ECO:0000269|PubMed:16454982,
CC       ECO:0000269|PubMed:17089161, ECO:0000269|PubMed:18372316,
CC       ECO:0000269|PubMed:18484667, ECO:0000269|PubMed:18642388,
CC       ECO:0000269|Ref.2}. Note=The disease is caused by mutations affecting
CC       the gene represented in this entry. There is a mutational hotspot in
CC       the region coding for the poly-Ala domain, since 30% of all mutations
CC       in the ORF lead to poly-Ala expansions, resulting mainly in BPES type
CC       II.
CC   -!- DISEASE: Premature ovarian failure 3 (POF3) [MIM:608996]: An ovarian
CC       disorder defined as the cessation of ovarian function under the age of
CC       40 years. It is characterized by oligomenorrhea or amenorrhea, in the
CC       presence of elevated levels of serum gonadotropins and low estradiol.
CC       {ECO:0000269|PubMed:12149404, ECO:0000269|PubMed:19429596}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=Forkhead box L2 (FOXL2); Note=Leiden Open Variation
CC       Database (LOVD);
CC       URL="https://lovd.cmgg.be/index.php?select_db=FOXL2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF301906; AAK01352.1; -; mRNA.
DR   EMBL; DQ016609; AAY21823.1; -; Genomic_DNA.
DR   EMBL; BC062549; AAH62549.1; -; mRNA.
DR   CCDS; CCDS3105.1; -.
DR   RefSeq; NP_075555.1; NM_023067.3.
DR   SMR; P58012; -.
DR   BioGrid; 107136; 66.
DR   IntAct; P58012; 53.
DR   MINT; P58012; -.
DR   STRING; 9606.ENSP00000333188; -.
DR   iPTMnet; P58012; -.
DR   PhosphoSitePlus; P58012; -.
DR   BioMuta; FOXL2; -.
DR   DMDM; 13626838; -.
DR   jPOST; P58012; -.
DR   MassIVE; P58012; -.
DR   PaxDb; P58012; -.
DR   PeptideAtlas; P58012; -.
DR   PRIDE; P58012; -.
DR   ProteomicsDB; 57047; -.
DR   Antibodypedia; 17961; 354 antibodies.
DR   Ensembl; ENST00000648323; ENSP00000497217; ENSG00000183770.
DR   GeneID; 668; -.
DR   KEGG; hsa:668; -.
DR   CTD; 668; -.
DR   DisGeNET; 668; -.
DR   GeneCards; FOXL2; -.
DR   GeneReviews; FOXL2; -.
DR   HGNC; HGNC:1092; FOXL2.
DR   HPA; ENSG00000183770; Tissue enhanced (cervix, uterine, ovary, parathyroid gland).
DR   MalaCards; FOXL2; -.
DR   MIM; 110100; phenotype.
DR   MIM; 605597; gene.
DR   MIM; 608996; phenotype.
DR   neXtProt; NX_P58012; -.
DR   OpenTargets; ENSG00000183770; -.
DR   Orphanet; 261559; Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.
DR   Orphanet; 261572; Blepharophimosis-epicanthus inversus-ptosis due to a point mutation syndrome.
DR   Orphanet; 261579; Blepharophimosis-epicanthus inversus-ptosis due to copy number variations.
DR   Orphanet; 99915; Maligant granulosa cell tumor of the ovary.
DR   Orphanet; 619; NON RARE IN EUROPE: Primary ovarian failure.
DR   PharmGKB; PA28235; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   GeneTree; ENSGT00940000162075; -.
DR   HOGENOM; CLU_023357_1_0_1; -.
DR   InParanoid; P58012; -.
DR   KO; K09405; -.
DR   OMA; SMMHCSY; -.
DR   OrthoDB; 1270467at2759; -.
DR   PhylomeDB; P58012; -.
DR   TreeFam; TF316127; -.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   SIGNOR; P58012; -.
DR   GeneWiki; Forkhead_box_L2; -.
DR   GenomeRNAi; 668; -.
DR   Pharos; P58012; Tbio.
DR   PRO; PR:P58012; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P58012; protein.
DR   Bgee; ENSG00000183770; Expressed in female gonad and 48 other tissues.
DR   ExpressionAtlas; P58012; baseline and differential.
DR   Genevisible; P58012; HS.
DR   GO; GO:0045171; C:intercellular bridge; IDA:HPA.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043028; F:cysteine-type endopeptidase regulator activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0030331; F:estrogen receptor binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central.
DR   GO; GO:0006309; P:apoptotic DNA fragmentation; IMP:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0048048; P:embryonic eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0002074; P:extraocular skeletal muscle development; IMP:UniProtKB.
DR   GO; GO:0019101; P:female somatic sex determination; IEA:Ensembl.
DR   GO; GO:0060014; P:granulosa cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0001555; P:oocyte growth; IEA:Ensembl.
DR   GO; GO:0001541; P:ovarian follicle development; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0046881; P:positive regulation of follicle-stimulating hormone secretion; IEA:Ensembl.
DR   GO; GO:0033686; P:positive regulation of luteinizing hormone secretion; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0007338; P:single fertilization; IEA:Ensembl.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   CDD; cd00059; FH; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR018122; TF_fork_head_CS_1.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00657; FORK_HEAD_1; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   1: Evidence at protein level;
KW   Differentiation; Disease mutation; DNA-binding; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Polymorphism; Premature ovarian failure;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Triplet repeat expansion; Ubl conjugation.
FT   CHAIN           1..376
FT                   /note="Forkhead box protein L2"
FT                   /id="PRO_0000091861"
FT   DNA_BIND        54..148
FT                   /note="Fork-head"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00089"
FT   COMPBIAS        35..43
FT                   /note="Poly-Gly"
FT   COMPBIAS        221..234
FT                   /note="Poly-Ala"
FT   COMPBIAS        284..292
FT                   /note="Poly-Pro"
FT   COMPBIAS        301..304
FT                   /note="Poly-Ala"
FT   MOD_RES         33
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   CROSSLNK        25
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT   VARIANT         58
FT                   /note="S -> L (in BPES; sporadic; nuclear and cytoplasmic
FT                   aggregation; impaired transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_021196"
FT   VARIANT         63
FT                   /note="I -> T (in BPES; dbSNP:rs1315073489)"
FT                   /evidence="ECO:0000269|PubMed:16454982"
FT                   /id="VAR_062545"
FT   VARIANT         65
FT                   /note="M -> V (in BPES)"
FT                   /evidence="ECO:0000269|PubMed:18642388"
FT                   /id="VAR_046490"
FT   VARIANT         66
FT                   /note="A -> V (in BPES; nuclear and cytoplasmic
FT                   aggregation; impaired transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_021197"
FT   VARIANT         69
FT                   /note="E -> K (in BPES; sporadic; nuclear aggregation;
FT                   normal transactivation activity; dbSNP:rs387906920)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_021198"
FT   VARIANT         80
FT                   /note="I -> T (in BPES; nuclear and cytoplasmic
FT                   aggregation; impaired transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_046491"
FT   VARIANT         84
FT                   /note="I -> N (in BPES; nuclear and cytoplasmic
FT                   aggregation; impaired transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_046492"
FT   VARIANT         84
FT                   /note="I -> S (in BPES; type I; dbSNP:rs28937884)"
FT                   /evidence="ECO:0000269|PubMed:12630957"
FT                   /id="VAR_016883"
FT   VARIANT         85
FT                   /note="Missing (in BPES; sporadic)"
FT                   /evidence="ECO:0000269|PubMed:11468277"
FT                   /id="VAR_016884"
FT   VARIANT         90
FT                   /note="F -> S (in BPES; nuclear and cytoplasmic
FT                   aggregation; impaired transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_046493"
FT   VARIANT         98
FT                   /note="W -> G (in BPES; nuclear and cytoplasmic
FT                   aggregation; impaired transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_046494"
FT   VARIANT         98
FT                   /note="W -> R (in BPES; dbSNP:rs1057516149)"
FT                   /evidence="ECO:0000269|PubMed:18484667"
FT                   /id="VAR_062546"
FT   VARIANT         101
FT                   /note="S -> R (in BPES; nuclear aggregation; impaired
FT                   transactivation activity; dbSNP:rs1057516151)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_046495"
FT   VARIANT         102
FT                   /note="I -> T (in BPES; nuclear and cytoplasmic
FT                   aggregation; impaired transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_046496"
FT   VARIANT         103
FT                   /note="R -> C (in BPES; nuclear and cytoplasmic
FT                   aggregation; normal transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_046497"
FT   VARIANT         104
FT                   /note="H -> R (in BPES; diffuse nuclear localization as
FT                   wild type; normal transactivation activity;
FT                   dbSNP:rs1057516153)"
FT                   /evidence="ECO:0000269|PubMed:12938087,
FT                   ECO:0000269|PubMed:18372316"
FT                   /id="VAR_021199"
FT   VARIANT         105
FT                   /note="N -> S (in BPES; type II)"
FT                   /id="VAR_021200"
FT   VARIANT         106
FT                   /note="L -> F (in BPES; sporadic; nuclear and cytoplasmic
FT                   aggregation; impaired transactivation activity;
FT                   dbSNP:rs1057516156)"
FT                   /evidence="ECO:0000269|PubMed:12529855,
FT                   ECO:0000269|PubMed:18372316"
FT                   /id="VAR_016885"
FT   VARIANT         106
FT                   /note="L -> P (in BPES; nuclear and cytoplasmic
FT                   aggregation; impaired transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18372316,
FT                   ECO:0000269|PubMed:18642388"
FT                   /id="VAR_046498"
FT   VARIANT         108
FT                   /note="L -> P (in BPES; nuclear aggregation and cytoplasmic
FT                   mislocalization; impaired transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:18484667"
FT                   /id="VAR_062547"
FT   VARIANT         109
FT                   /note="N -> K (in BPES; type II; diffuse nuclear
FT                   localization as wild type; impaired transactivation
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:12529855,
FT                   ECO:0000269|PubMed:18372316"
FT                   /id="VAR_016886"
FT   VARIANT         134
FT                   /note="C -> W (in granulosa-cell tumors of the ovary; not
FT                   commonly found in other tumor types; dbSNP:rs1057519865)"
FT                   /evidence="ECO:0000269|PubMed:19516027,
FT                   ECO:0000269|PubMed:19956657"
FT                   /id="VAR_062548"
FT   VARIANT         179
FT                   /note="A -> G (in dbSNP:rs7432551)"
FT                   /evidence="ECO:0000269|PubMed:12149404,
FT                   ECO:0000269|PubMed:18484667"
FT                   /id="VAR_021201"
FT   VARIANT         187
FT                   /note="G -> D (in POF3; does not affect nuclear
FT                   localization; reduces transcriptional activation of OSR2;
FT                   dbSNP:rs121908359)"
FT                   /evidence="ECO:0000269|PubMed:12161610,
FT                   ECO:0000269|PubMed:19429596"
FT                   /id="VAR_015181"
FT   VARIANT         193
FT                   /note="K -> R (in BPES; type II; dbSNP:rs1057516162)"
FT                   /id="VAR_021202"
FT   VARIANT         215
FT                   /note="Y -> C (in BPES; dbSNP:rs1057516168)"
FT                   /evidence="ECO:0000269|PubMed:15257268,
FT                   ECO:0000269|PubMed:18484667"
FT                   /id="VAR_021203"
FT   VARIANT         217
FT                   /note="S -> C (in BPES; diffuse nuclear localization;
FT                   normal transcriptional activation)"
FT                   /evidence="ECO:0000269|PubMed:18484667"
FT                   /id="VAR_062549"
FT   VARIANT         217
FT                   /note="S -> F (in BPES; diffuse nuclear localization;
FT                   increased transactivation activity; dbSNP:rs797044527)"
FT                   /evidence="ECO:0000269|PubMed:11468277,
FT                   ECO:0000269|PubMed:12529855, ECO:0000269|PubMed:18372316"
FT                   /id="VAR_016887"
FT   VARIANT         234
FT                   /note="A -> AAAAAA (in BPES; significant higher cytoplasmic
FT                   retention compared to the wild-type protein)"
FT                   /evidence="ECO:0000269|PubMed:17089161"
FT                   /id="VAR_037303"
FT   VARIANT         234
FT                   /note="A -> AAAAAAAAAAA (in BPES; type II)"
FT                   /evidence="ECO:0000269|PubMed:11175783,
FT                   ECO:0000269|PubMed:12400065"
FT                   /id="VAR_010782"
FT   VARIANT         234
FT                   /note="A -> AAAAAAAAAAAA (in BPES)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_025306"
FT   VARIANT         258
FT                   /note="Y -> N (in POF3; dbSNP:rs28937885)"
FT                   /evidence="ECO:0000269|PubMed:12149404"
FT                   /id="VAR_021204"
FT   VARIANT         285
FT                   /note="P -> S"
FT                   /evidence="ECO:0000269|PubMed:12161610"
FT                   /id="VAR_015182"
FT   VARIANT         349
FT                   /note="R -> G (in dbSNP:rs201840174)"
FT                   /evidence="ECO:0000269|PubMed:27610946"
FT                   /id="VAR_078138"
FT   MUTAGEN         25
FT                   /note="K->R: Results in reduced sumoylation. Loss of
FT                   transcriptional repression activity."
FT                   /evidence="ECO:0000269|PubMed:19744555"
SQ   SEQUENCE   376 AA;  38772 MW;  B4952F2A0380E533 CRC64;
     MMASYPEPED AAGALLAPET GRTVKEPEGP PPSPGKGGGG GGGTAPEKPD PAQKPPYSYV
     ALIAMAIRES AEKRLTLSGI YQYIIAKFPF YEKNKKGWQN SIRHNLSLNE CFIKVPREGG
     GERKGNYWTL DPACEDMFEK GNYRRRRRMK RPFRPPPAHF QPGKGLFGAG GAAGGCGVAG
     AGADGYGYLA PPKYLQSGFL NNSWPLPQPP SPMPYASCQM AAAAAAAAAA AAAAGPGSPG
     AAAVVKGLAG PAASYGPYTR VQSMALPPGV VNSYNGLGGP PAAPPPPPHP HPHPHAHHLH
     AAAAPPPAPP HHGAAAPPPG QLSPASPATA APPAPAPTSA PGLQFACARQ PELAMMHCSY
     WDHDSKTGAL HSRLDL
//
ID   Q53ZD3_HUMAN            Unreviewed;       376 AA.
AC   Q53ZD3;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   22-APR-2020, entry version 139.
DE   SubName: Full=FOXL2 {ECO:0000313|EMBL:AAY21821.1};
DE   SubName: Full=Forkhead box L2 {ECO:0000313|EMBL:AAQ01519.1};
GN   Name=FOXL2 {ECO:0000313|EMBL:AAQ01519.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAQ01519.1};
RN   [1] {ECO:0000313|EMBL:AAQ01519.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Crisponi L., Loi A., Deiana M., Pilia G.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2] {ECO:0000313|EMBL:AAQ01519.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Brathwaite M.E., Uda M., Nagaraja R., Schlessinger D.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:AAQ01519.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Uda M., Nagaraja R., Schlessinger D.;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000313|EMBL:AAQ01519.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=15081106; DOI=10.1016/j.ygeno.2003.11.010;
RA   Crisponi L., Uda M., Deiana M., Loi A., Nagaraja R., Chiappe F.,
RA   Schlessinger D., Cao A., Pilia G.;
RT   "FOXL2 inactivation by a translocation 171 kb away: analysis of 500 kb of
RT   chromosome 3 for candidate long-range regulatory sequences.";
RL   Genomics 83:757-764(2004).
RN   [5] {ECO:0000313|EMBL:AAY21821.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Mutant 101 {ECO:0000313|EMBL:AAY21821.1}, and
RC   Mutant 102 {ECO:0000313|EMBL:AAY21822.1};
RA   Xu Y.;
RT   "Study of mutations of FOXL2 gene in a Chinese TongHai family with
RT   blepharophimosis-ptosis-epicanthus inversus syndrome.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-ProRule:PRU00089}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY331134; AAQ01519.1; -; Genomic_DNA.
DR   EMBL; DQ016593; AAY21821.1; -; Genomic_DNA.
DR   EMBL; DQ016608; AAY21822.1; -; Genomic_DNA.
DR   RefSeq; NP_075555.1; NM_023067.3.
DR   Antibodypedia; 17961; 354 antibodies.
DR   GeneID; 668; -.
DR   KEGG; hsa:668; -.
DR   UCSC; uc003esw.3; human.
DR   CTD; 668; -.
DR   EuPathDB; HostDB:ENSG00000183770.5; -.
DR   PharmGKB; PA28235; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   HOGENOM; CLU_023357_1_0_1; -.
DR   KO; K09405; -.
DR   OMA; SMMHCSY; -.
DR   OrthoDB; 1270467at2759; -.
DR   GenomeRNAi; 668; -.
DR   Bgee; ENSG00000183770; Expressed in female gonad and 48 other tissues.
DR   GO; GO:0045171; C:intercellular bridge; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0030331; F:estrogen receptor binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0048048; P:embryonic eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0019101; P:female somatic sex determination; IEA:Ensembl.
DR   GO; GO:0060014; P:granulosa cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0001555; P:oocyte growth; IEA:Ensembl.
DR   GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
DR   GO; GO:0046881; P:positive regulation of follicle-stimulating hormone secretion; IEA:Ensembl.
DR   GO; GO:0033686; P:positive regulation of luteinizing hormone secretion; IEA:Ensembl.
DR   GO; GO:0007338; P:single fertilization; IEA:Ensembl.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   CDD; cd00059; FH; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR018122; TF_fork_head_CS_1.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00657; FORK_HEAD_1; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   4: Predicted;
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00089,
KW   ECO:0000256|SAAS:SAAS00582228};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00089}.
FT   DOMAIN          54..148
FT                   /note="Fork-head"
FT                   /evidence="ECO:0000259|PROSITE:PS50039"
FT   DNA_BIND        54..148
FT                   /note="Fork-head"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00089"
FT   REGION          1..53
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          276..342
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        303..339
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   376 AA;  38772 MW;  B4952F2A0380E533 CRC64;
     MMASYPEPED AAGALLAPET GRTVKEPEGP PPSPGKGGGG GGGTAPEKPD PAQKPPYSYV
     ALIAMAIRES AEKRLTLSGI YQYIIAKFPF YEKNKKGWQN SIRHNLSLNE CFIKVPREGG
     GERKGNYWTL DPACEDMFEK GNYRRRRRMK RPFRPPPAHF QPGKGLFGAG GAAGGCGVAG
     AGADGYGYLA PPKYLQSGFL NNSWPLPQPP SPMPYASCQM AAAAAAAAAA AAAAGPGSPG
     AAAVVKGLAG PAASYGPYTR VQSMALPPGV VNSYNGLGGP PAAPPPPPHP HPHPHAHHLH
     AAAAPPPAPP HHGAAAPPPG QLSPASPATA APPAPAPTSA PGLQFACARQ PELAMMHCSY
     WDHDSKTGAL HSRLDL
//
ID   GATA1_HUMAN             Reviewed;         413 AA.
AC   P15976; Q96GB8;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   22-APR-2020, entry version 211.
DE   RecName: Full=Erythroid transcription factor;
DE   AltName: Full=Eryf1;
DE   AltName: Full=GATA-binding factor 1;
DE            Short=GATA-1;
DE            Short=GF-1;
DE   AltName: Full=NF-E1 DNA-binding protein;
GN   Name=GATA1; Synonyms=ERYF1, GF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=2104960; DOI=10.1038/343092a0;
RA   Trainor C.D., Evans T., Felsenfeld G., Boguski M.S.;
RT   "Structure and evolution of a human erythroid transcription factor.";
RL   Nature 343:92-96(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Erythrocyte;
RX   PubMed=2300555; DOI=10.1073/pnas.87.2.668;
RA   Zon L.I., Tsai S.-F., Burgess S., Matsudaira P., Bruns G.A.P., Orkin S.H.;
RT   "The major human erythroid DNA-binding protein (GF-1): primary sequence and
RT   localization of the gene to the X chromosome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:668-672(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Bone marrow;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   ALTERNATIVE INITIATION (ISOFORM 3), SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=8524811; DOI=10.1073/pnas.92.25.11598;
RA   Calligaris R., Bottardi S., Cogoi S., Apezteguia I., Santoro C.;
RT   "Alternative translation initiation site usage results in two functionally
RT   distinct forms of the GATA-1 transcription factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:11598-11602(1995).
RN   [6]
RP   INTERACTION WITH EP300, AND ACETYLATION AT LYS-233; LYS-245 AND LYS-246.
RX   PubMed=9859997; DOI=10.1038/25166;
RA   Boyes J., Byfield P., Nakatani Y., Ogryzko V.;
RT   "Regulation of activity of the transcription factor GATA-1 by
RT   acetylation.";
RL   Nature 396:594-598(1998).
RN   [7]
RP   INVOLVEMENT IN XLAWT.
RX   PubMed=16783379; DOI=10.1038/ng1825;
RA   Hollanda L.M., Lima C.S., Cunha A.F., Albuquerque D.M., Vassallo J.,
RA   Ozelo M.C., Joazeiro P.P., Saad S.T., Costa F.F.;
RT   "An inherited mutation leading to production of only the short isoform of
RT   GATA-1 is associated with impaired erythropoiesis.";
RL   Nat. Genet. 38:807-812(2006).
RN   [8]
RP   SUMOYLATION AT LYS-137, PHOSPHORYLATION AT SER-142, AND MUTAGENESIS OF
RP   LYS-137 AND SER-142.
RX   PubMed=16371476; DOI=10.1073/pnas.0503698102;
RA   Hietakangas V., Anckar J., Blomster H.A., Fujimoto M., Palvimo J.J.,
RA   Nakai A., Sistonen L.;
RT   "PDSM, a motif for phosphorylation-dependent SUMO modification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:45-50(2006).
RN   [9]
RP   INTERACTION WITH GFI1B.
RX   PubMed=17420275; DOI=10.1128/mcb.02212-06;
RA   Kuo Y.-Y., Chang Z.-F.;
RT   "GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription.";
RL   Mol. Cell. Biol. 27:4261-4272(2007).
RN   [10]
RP   FUNCTION, AND DNA-BINDING.
RX   PubMed=22235304; DOI=10.1371/journal.pone.0029518;
RA   Zeng Y., Wang W., Ma J., Wang X., Guo M., Li W.;
RT   "Knockdown of ZNF268, which is transcriptionally downregulated by GATA-1,
RT   promotes proliferation of K562 cells.";
RL   PLoS ONE 7:E29518-E29518(2012).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-116 AND SER-131, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH MED1; CCAR1 AND CALCOCO1.
RX   PubMed=24245781; DOI=10.1111/gtc.12104;
RA   Mizuta S., Minami T., Fujita H., Kaminaga C., Matsui K., Ishino R.,
RA   Fujita A., Oda K., Kawai A., Hasegawa N., Urahama N., Roeder R.G., Ito M.;
RT   "CCAR1/CoCoA pair-mediated recruitment of the Mediator defines a novel
RT   pathway for GATA1 function.";
RL   Genes Cells 19:28-51(2014).
RN   [13]
RP   INTERACTION WITH CEBPE.
RX   PubMed=26019275; DOI=10.4049/jimmunol.1402222;
RA   Wada T., Akagi T., Muraoka M., Toma T., Kaji K., Agematsu K.,
RA   Koeffler H.P., Yokota T., Yachie A.;
RT   "A novel in-frame deletion in the leucine zipper domain of C/EBPepsilon
RT   leads to neutrophil-specific granule deficiency.";
RL   J. Immunol. 195:80-86(2015).
RN   [14]
RP   VARIANT XDAT MET-205, INTERACTION WITH ZFPM1, CHARACTERIZATION OF VARIANT
RP   XDAT MET-205, AND MUTAGENESIS OF CYS-204.
RC   TISSUE=Peripheral blood;
RX   PubMed=10700180; DOI=10.1038/73480;
RA   Nichols K.E., Crispino J.D., Poncz M., White J.G., Orkin S.H., Maris J.M.,
RA   Weiss M.J.;
RT   "Familial dyserythropoietic anaemia and thrombocytopenia due to an
RT   inherited mutation in GATA1.";
RL   Nat. Genet. 24:266-270(2000).
RN   [15]
RP   VARIANT XDAT GLY-218, INTERACTION WITH ZFPM1, AND CHARACTERIZATION OF
RP   VARIANT XDAT GLY-218.
RX   PubMed=11418466; DOI=10.1182/blood.v98.1.85;
RA   Freson K., Devriendt K., Matthijs G., Van Hoof A., De Vos R., Thys C.,
RA   Minner K., Hoylaerts M.F., Vermylen J., Van Geet C.;
RT   "Platelet characteristics in patients with X-linked macrothrombocytopenia
RT   because of a novel GATA1 mutation.";
RL   Blood 98:85-92(2001).
RN   [16]
RP   VARIANT XDAT SER-208, INTERACTION WITH ZFPM1, AND CHARACTERIZATION OF
RP   VARIANT XDAT SER-208.
RX   PubMed=11675338; DOI=10.1182/blood.v98.9.2681;
RA   Mehaffey M.G., Newton A.L., Gandhi M.J., Crossley M., Drachman J.G.;
RT   "X-linked thrombocytopenia caused by a novel mutation of GATA-1.";
RL   Blood 98:2681-2688(2001).
RN   [17]
RP   VARIANT XLTT GLN-216, INTERACTION WITH ZFPM1, AND CHARACTERIZATION OF
RP   VARIANT XLTT GLN-216.
RX   PubMed=12200364; DOI=10.1182/blood-2002-02-0387;
RA   Yu C., Niakan K.K., Matsushita M., Stamatoyannopoulos G., Orkin S.H.,
RA   Raskind W.H.;
RT   "X-linked thrombocytopenia with thalassemia from a mutation in the amino
RT   finger of GATA-1 affecting DNA binding rather than FOG-1 interaction.";
RL   Blood 100:2040-2045(2002).
RN   [18]
RP   VARIANT XDAT TYR-218, INTERACTION WITH ZFPM1, AND CHARACTERIZATION OF
RP   VARIANT XDAT TYR-218.
RX   PubMed=11809723; DOI=10.1093/hmg/11.2.147;
RA   Freson K., Matthijs G., Thys C., Marieen P., Hoylaerts M.F., Vermylen J.,
RA   Van Geet C.;
RT   "Different substitutions at residue D218 of the X-linked transcription
RT   factor GATA1 lead to altered clinical severity of macrothrombocytopenia and
RT   anemia and are associated with variable skewed X inactivation.";
RL   Hum. Mol. Genet. 11:147-152(2002).
CC   -!- FUNCTION: Transcriptional activator or repressor which probably serves
CC       as a general switch factor for erythroid development. It binds to DNA
CC       sites with the consensus sequence 5'-[AT]GATA[AG]-3' within regulatory
CC       regions of globin genes and of other genes expressed in erythroid
CC       cells. Activates the transcription of genes involved in erythroid
CC       differentiation of K562 erythroleukemia cells, including HBB, HBG1/2,
CC       ALAS2 and HMBS (PubMed:24245781). {ECO:0000269|PubMed:22235304,
CC       ECO:0000269|PubMed:24245781}.
CC   -!- SUBUNIT: May form homodimers or heterodimers with other isoforms.
CC       Interacts (via the N-terminal zinc finger) with ZFPM1. Interacts with
CC       GFI1B. Interacts with PIAS4; the interaction enhances sumoylation and
CC       represses the transactivational activity in a sumoylation-independent
CC       manner. Interacts with LMCD1. Interacts with BRD3 (By similarity).
CC       Interacts with CREBBP; the interaction stimulates acetylation and
CC       transcriptional activity in vivo (By similarity). Interacts with EP300.
CC       Interacts with MED1, CCAR1 and CALCOCO1. Interacts with CEBPE
CC       (PubMed:26019275). {ECO:0000250|UniProtKB:P17679,
CC       ECO:0000269|PubMed:10700180, ECO:0000269|PubMed:11418466,
CC       ECO:0000269|PubMed:11675338, ECO:0000269|PubMed:11809723,
CC       ECO:0000269|PubMed:12200364, ECO:0000269|PubMed:17420275,
CC       ECO:0000269|PubMed:24245781, ECO:0000269|PubMed:26019275,
CC       ECO:0000269|PubMed:8524811, ECO:0000269|PubMed:9859997}.
CC   -!- INTERACTION:
CC       P15976-2; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-9090198, EBI-742909;
CC       P15976; Q8N4L8: CCDC24; NbExp=3; IntAct=EBI-3909284, EBI-1104933;
CC       P15976-2; Q8N4L8: CCDC24; NbExp=3; IntAct=EBI-9090198, EBI-1104933;
CC       P15976-2; Q9H2X0: CHRD; NbExp=3; IntAct=EBI-9090198, EBI-947551;
CC       P15976-2; Q9BY27: DGCR6L; NbExp=3; IntAct=EBI-9090198, EBI-742953;
CC       P15976-2; Q9NW38: FANCL; NbExp=3; IntAct=EBI-9090198, EBI-2339898;
CC       P15976; Q8TES7-6: FBF1; NbExp=3; IntAct=EBI-3909284, EBI-10244131;
CC       P15976-2; Q13643: FHL3; NbExp=4; IntAct=EBI-9090198, EBI-741101;
CC       P15976; O43559: FRS3; NbExp=3; IntAct=EBI-3909284, EBI-725515;
CC       P15976-2; O43559: FRS3; NbExp=5; IntAct=EBI-9090198, EBI-725515;
CC       P15976; Q96MH2: HEXIM2; NbExp=3; IntAct=EBI-3909284, EBI-5460660;
CC       P15976; P49639: HOXA1; NbExp=3; IntAct=EBI-3909284, EBI-740785;
CC       P15976-2; P49639: HOXA1; NbExp=3; IntAct=EBI-9090198, EBI-740785;
CC       P15976; P08107: HSPA1B; NbExp=5; IntAct=EBI-3909284, EBI-629985;
CC       P15976-2; Q63ZY3: KANK2; NbExp=3; IntAct=EBI-9090198, EBI-2556193;
CC       P15976; P60370: KRTAP10-5; NbExp=3; IntAct=EBI-3909284, EBI-10172150;
CC       P15976-2; Q9BYR7: KRTAP3-2; NbExp=3; IntAct=EBI-9090198, EBI-751260;
CC       P15976-2; Q9BYQ6: KRTAP4-11; NbExp=3; IntAct=EBI-9090198, EBI-10302392;
CC       P15976-2; Q9BYR2: KRTAP4-5; NbExp=3; IntAct=EBI-9090198, EBI-11993254;
CC       P15976; Q9BYQ4: KRTAP9-2; NbExp=3; IntAct=EBI-3909284, EBI-1044640;
CC       P15976-2; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-9090198, EBI-741037;
CC       P15976-2; Q99750: MDFI; NbExp=5; IntAct=EBI-9090198, EBI-724076;
CC       P15976; Q15648: MED1; NbExp=6; IntAct=EBI-3909284, EBI-394459;
CC       P15976-2; Q13064: MKRN3; NbExp=3; IntAct=EBI-9090198, EBI-2340269;
CC       P15976-2; P78337: PITX1; NbExp=3; IntAct=EBI-9090198, EBI-748265;
CC       P15976-2; Q9NRQ2: PLSCR4; NbExp=3; IntAct=EBI-9090198, EBI-769257;
CC       P15976; O43741: PRKAB2; NbExp=3; IntAct=EBI-3909284, EBI-1053424;
CC       P15976-2; O43741: PRKAB2; NbExp=6; IntAct=EBI-9090198, EBI-1053424;
CC       P15976; Q96JH8: RADIL; NbExp=3; IntAct=EBI-3909284, EBI-744267;
CC       P15976; P06400: RB1; NbExp=2; IntAct=EBI-3909284, EBI-491274;
CC       P15976; P13405: Rb1; Xeno; NbExp=2; IntAct=EBI-3909284, EBI-971782;
CC       P15976-2; Q8WW24: TEKT4; NbExp=5; IntAct=EBI-9090198, EBI-750487;
CC       P15976-2; Q08117-2: TLE5; NbExp=5; IntAct=EBI-9090198, EBI-11741437;
CC       P15976-2; Q13077: TRAF1; NbExp=3; IntAct=EBI-9090198, EBI-359224;
CC       P15976-2; Q15654: TRIP6; NbExp=4; IntAct=EBI-9090198, EBI-742327;
CC       P15976; Q8IX07: ZFPM1; NbExp=2; IntAct=EBI-3909284, EBI-3942619;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=3;
CC       Name=1;
CC         IsoId=P15976-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15976-2; Sequence=VSP_014782;
CC       Name=3; Synonyms=GATA-1s;
CC         IsoId=P15976-3; Sequence=VSP_041451;
CC   -!- TISSUE SPECIFICITY: Erythrocytes. {ECO:0000269|PubMed:8524811}.
CC   -!- DOMAIN: The two fingers are functionally distinct and cooperate to
CC       achieve specific, stable DNA binding. The first finger is necessary
CC       only for full specificity and stability of binding, whereas the second
CC       one is required for binding (By similarity). {ECO:0000250}.
CC   -!- PTM: Highly phosphorylated on serine residues. Phosphorylation on Ser-
CC       310 is enhanced on erythroid differentiation. Phosphorylation on Ser-
CC       142 promotes sumoylation on Lys-137 (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylation on Lys-137 is enhanced by phosphorylation on Ser-142
CC       and by interaction with PIAS4. Sumoylation with SUMO1 has no effect on
CC       transcriptional activity (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated at 2 conserved lysine-rich motifs by CREBBP in vitro.
CC       Acetylation does not affect DNA-binding in vitro but is essential to
CC       induce erythroid differentiation and for binding chromatin in vivo (By
CC       similarity). Acetylated on Lys-233, Lys-245 Lys-246 by EP300.
CC       {ECO:0000250, ECO:0000269|PubMed:9859997}.
CC   -!- DISEASE: X-linked dyserythropoietic anemia and thrombocytopenia (XDAT)
CC       [MIM:300367]: Disorder characterized by erythrocytes with abnormal size
CC       and shape, and paucity of platelets in peripheral blood. The bone
CC       marrow contains abundant and abnormally small megakaryocytes.
CC       {ECO:0000269|PubMed:10700180, ECO:0000269|PubMed:11418466,
CC       ECO:0000269|PubMed:11675338, ECO:0000269|PubMed:11809723}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Thrombocytopenia with beta-thalassemia, X-linked (XLTT)
CC       [MIM:314050]: An unusual form of thrombocytopenia associated with beta-
CC       thalassemia. Patients have splenomegaly and petechiae, moderate
CC       thrombocytopenia, prolonged bleeding time due to platelet dysfunction,
CC       reticulocytosis and unbalanced (hemo)globin chain synthesis resembling
CC       that of beta-thalassemia minor. {ECO:0000269|PubMed:12200364}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Anemia without thrombocytopenia, X-linked (XLAWT)
CC       [MIM:300835]: A form of anemia characterized by abnormal morphology of
CC       erythrocytes and granulocytes in peripheral blood, bone marrow
CC       dysplasia with hypocellularity of erythroid and granulocytic lineages,
CC       and normal or increased number of megakaryocytes. Neutropenia of a
CC       variable degree is present in affected individuals.
CC       {ECO:0000269|PubMed:16783379}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative initiation at Met-
CC       84 of isoform 1. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GATA1ID40689chXp11.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X17254; CAA35120.1; -; mRNA.
DR   EMBL; M30601; AAA35885.1; -; mRNA.
DR   EMBL; AF196971; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009797; AAH09797.1; -; mRNA.
DR   CCDS; CCDS14305.1; -. [P15976-1]
DR   PIR; A34888; A34888.
DR   RefSeq; NP_002040.1; NM_002049.3. [P15976-1]
DR   PDB; 6G0Q; X-ray; 1.40 A; B=309-319.
DR   PDBsum; 6G0Q; -.
DR   SMR; P15976; -.
DR   BioGrid; 108893; 76.
DR   DIP; DIP-41431N; -.
DR   IntAct; P15976; 57.
DR   MINT; P15976; -.
DR   STRING; 9606.ENSP00000365858; -.
DR   iPTMnet; P15976; -.
DR   PhosphoSitePlus; P15976; -.
DR   BioMuta; GATA1; -.
DR   DMDM; 120956; -.
DR   MassIVE; P15976; -.
DR   MaxQB; P15976; -.
DR   PaxDb; P15976; -.
DR   PeptideAtlas; P15976; -.
DR   PRIDE; P15976; -.
DR   ProteomicsDB; 53260; -. [P15976-1]
DR   ProteomicsDB; 53261; -. [P15976-2]
DR   ProteomicsDB; 53262; -. [P15976-3]
DR   Antibodypedia; 372; 930 antibodies.
DR   DNASU; 2623; -.
DR   Ensembl; ENST00000376670; ENSP00000365858; ENSG00000102145. [P15976-1]
DR   Ensembl; ENST00000651144; ENSP00000498550; ENSG00000102145. [P15976-3]
DR   GeneID; 2623; -.
DR   KEGG; hsa:2623; -.
DR   UCSC; uc004dkq.5; human. [P15976-1]
DR   CTD; 2623; -.
DR   DisGeNET; 2623; -.
DR   GeneCards; GATA1; -.
DR   GeneReviews; GATA1; -.
DR   HGNC; HGNC:4170; GATA1.
DR   HPA; ENSG00000102145; Group enriched (blood, bone marrow).
DR   MalaCards; GATA1; -.
DR   MIM; 300367; phenotype.
DR   MIM; 300835; phenotype.
DR   MIM; 305371; gene.
DR   MIM; 314050; phenotype.
DR   neXtProt; NX_P15976; -.
DR   OpenTargets; ENSG00000102145; -.
DR   Orphanet; 86849; Acute basophilic leukemia.
DR   Orphanet; 99887; Acute megakaryoblastic leukemia in Down syndrome.
DR   Orphanet; 231393; Beta-thalassemia-X-linked thrombocytopenia syndrome.
DR   Orphanet; 124; Blackfan-Diamond anemia.
DR   Orphanet; 79277; Congenital erythropoietic porphyria.
DR   Orphanet; 67044; Thrombocytopenia with congenital dyserythropoietic anemia.
DR   Orphanet; 420611; Transient myeloproliferative syndrome.
DR   Orphanet; 363727; X-linked dyserythropoietic anemia with abnormal platelets and neutropenia.
DR   PharmGKB; PA28584; -.
DR   eggNOG; KOG1601; Eukaryota.
DR   eggNOG; COG5641; LUCA.
DR   GeneTree; ENSGT00940000161156; -.
DR   HOGENOM; CLU_027524_1_1_1; -.
DR   InParanoid; P15976; -.
DR   KO; K09182; -.
DR   OMA; YSKTGLY; -.
DR   OrthoDB; 807790at2759; -.
DR   PhylomeDB; P15976; -.
DR   TreeFam; TF315391; -.
DR   Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P15976; -.
DR   SIGNOR; P15976; -.
DR   ChiTaRS; GATA1; human.
DR   GeneWiki; GATA1; -.
DR   GenomeRNAi; 2623; -.
DR   Pharos; P15976; Tbio.
DR   PRO; PR:P15976; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P15976; protein.
DR   Bgee; ENSG00000102145; Expressed in liver and 59 other tissues.
DR   ExpressionAtlas; P15976; baseline and differential.
DR   Genevisible; P15976; HS.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:BHF-UCL.
DR   GO; GO:0070742; F:C2H2 zinc finger domain binding; IPI:BHF-UCL.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0002039; F:p53 binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IMP:BHF-UCL.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IMP:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030221; P:basophil differentiation; IEP:BHF-UCL.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0045165; P:cell fate commitment; IBA:GO_Central.
DR   GO; GO:0007267; P:cell-cell signaling; IEA:Ensembl.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IDA:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IEA:Ensembl.
DR   GO; GO:0030222; P:eosinophil differentiation; IEP:BHF-UCL.
DR   GO; GO:0035854; P:eosinophil fate commitment; IDA:BHF-UCL.
DR   GO; GO:0048821; P:erythrocyte development; IMP:BHF-UCL.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEP:BHF-UCL.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IMP:BHF-UCL.
DR   GO; GO:0030219; P:megakaryocyte differentiation; IMP:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030502; P:negative regulation of bone mineralization; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:2000678; P:negative regulation of transcription regulatory region DNA binding; IDA:BHF-UCL.
DR   GO; GO:0070527; P:platelet aggregation; IMP:BHF-UCL.
DR   GO; GO:0030220; P:platelet formation; IMP:BHF-UCL.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0010724; P:regulation of definitive erythrocyte differentiation; IDA:BHF-UCL.
DR   GO; GO:0010559; P:regulation of glycoprotein biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0045652; P:regulation of megakaryocyte differentiation; TAS:Reactome.
DR   GO; GO:0010725; P:regulation of primitive erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0071733; P:transcriptional activation by promoter-enhancer looping; ISS:BHF-UCL.
DR   CDD; cd00202; ZnF_GATA; 2.
DR   Gene3D; 3.30.50.10; -; 2.
DR   InterPro; IPR029524; GATA-1.
DR   InterPro; IPR039355; Transcription_factor_GATA.
DR   InterPro; IPR000679; Znf_GATA.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR10071; PTHR10071; 1.
DR   PANTHER; PTHR10071:SF190; PTHR10071:SF190; 1.
DR   Pfam; PF00320; GATA; 2.
DR   PRINTS; PR00619; GATAZNFINGER.
DR   SMART; SM00401; ZnF_GATA; 2.
DR   PROSITE; PS00344; GATA_ZN_FINGER_1; 2.
DR   PROSITE; PS50114; GATA_ZN_FINGER_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative initiation;
KW   Alternative splicing; Direct protein sequencing; Disease mutation;
KW   DNA-binding; Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..413
FT                   /note="Erythroid transcription factor"
FT                   /id="PRO_0000083397"
FT   ZN_FING         204..228
FT                   /note="GATA-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00094"
FT   ZN_FING         258..282
FT                   /note="GATA-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00094"
FT   REGION          200..330
FT                   /note="Interaction with MED1 and CCAR1"
FT                   /evidence="ECO:0000269|PubMed:24245781"
FT   REGION          203..222
FT                   /note="Required for interaction with ZFPM1"
FT   REGION          249..315
FT                   /note="Interaction with CALCOCO1"
FT                   /evidence="ECO:0000269|PubMed:24245781"
FT   MOD_RES         26
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         72
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         116
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         131
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         142
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16371476"
FT   MOD_RES         178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         187
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         233
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000305|PubMed:9859997"
FT   MOD_RES         245
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000305|PubMed:9859997"
FT   MOD_RES         246
FT                   /note="N6-acetyllysine; by CREBBP"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         246
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000305|PubMed:9859997"
FT   MOD_RES         252
FT                   /note="N6-acetyllysine; by CREBBP"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         308
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         310
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         312
FT                   /note="N6-acetyllysine; by CREBBP"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         314
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   MOD_RES         315
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17679"
FT   CROSSLNK        137
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:16371476"
FT   VAR_SEQ         1..83
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_041451"
FT   VAR_SEQ         290..413
FT                   /note="QVNRPLTMRKDGIQTRNRKASGKGKKKRGSSLGGTGAAEGPAGGFMVVAGGS
FT                   GSGNCGEVASGLTLGPPGTAHLYQGLGPVVLSGPVSHLMPFPGPLLGSPTGSFPTGPMP
FT                   PTTSTTVVAPLSS -> HQHYCGGSAQLMRAQSMASRGGVVSFSSCSQNSGQPKSLGPR
FT                   HPLA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014782"
FT   VARIANT         205
FT                   /note="V -> M (in XDAT; severe impairment of ZFPM1 binding
FT                   and erythroid differentiation in vitro; dbSNP:rs104894815)"
FT                   /evidence="ECO:0000269|PubMed:10700180"
FT                   /id="VAR_010115"
FT   VARIANT         208
FT                   /note="G -> S (in XDAT; partially disrupts the interaction
FT                   with ZFPM1; dbSNP:rs137852312)"
FT                   /evidence="ECO:0000269|PubMed:11675338"
FT                   /id="VAR_012706"
FT   VARIANT         216
FT                   /note="R -> Q (in XLTT; does not affect ZFPM1 binding;
FT                   reduced affinity to palindromic GATA sites; supports
FT                   erythroid maturation less efficiently than wild-type GATA1;
FT                   dbSNP:rs104894809)"
FT                   /evidence="ECO:0000269|PubMed:12200364"
FT                   /id="VAR_033114"
FT   VARIANT         218
FT                   /note="D -> G (in XDAT; partially disrupts the interaction
FT                   with ZFPM1; dbSNP:rs104894816)"
FT                   /evidence="ECO:0000269|PubMed:11418466"
FT                   /id="VAR_012707"
FT   VARIANT         218
FT                   /note="D -> Y (in XDAT; stronger loss of affinity than of
FT                   G-218-GATA1 for ZFPM1 and disturbed GATA1 self-association;
FT                   dbSNP:rs104894808)"
FT                   /evidence="ECO:0000269|PubMed:11809723"
FT                   /id="VAR_033115"
FT   MUTAGEN         137
FT                   /note="K->R: Abolishes sumoylation."
FT                   /evidence="ECO:0000269|PubMed:16371476"
FT   MUTAGEN         142
FT                   /note="S->A: Loss of sumoylation."
FT                   /evidence="ECO:0000269|PubMed:16371476"
FT   MUTAGEN         142
FT                   /note="S->D: Increased sumoylation in vitro."
FT                   /evidence="ECO:0000269|PubMed:16371476"
FT   MUTAGEN         204
FT                   /note="C->R: Increase of dissociation rate from bound DNA."
FT                   /evidence="ECO:0000269|PubMed:10700180"
SQ   SEQUENCE   413 AA;  42751 MW;  822BD2DE14B908AD CRC64;
     MEFPGLGSLG TSEPLPQFVD PALVSSTPES GVFFPSGPEG LDAAASSTAP STATAAAAAL
     AYYRDAEAYR HSPVFQVYPL LNCMEGIPGG SPYAGWAYGK TGLYPASTVC PTREDSPPQA
     VEDLDGKGST SFLETLKTER LSPDLLTLGP ALPSSLPVPN SAYGGPDFSS TFFSPTGSPL
     NSAAYSSPKL RGTLPLPPCE ARECVNCGAT ATPLWRRDRT GHYLCNACGL YHKMNGQNRP
     LIRPKKRLIV SKRAGTQCTN CQTTTTTLWR RNASGDPVCN ACGLYYKLHQ VNRPLTMRKD
     GIQTRNRKAS GKGKKKRGSS LGGTGAAEGP AGGFMVVAGG SGSGNCGEVA SGLTLGPPGT
     AHLYQGLGPV VLSGPVSHLM PFPGPLLGSP TGSFPTGPMP PTTSTTVVAP LSS
//
ID   GATA3_HUMAN             Reviewed;         443 AA.
AC   P23771; Q5VWG7; Q5VWG8; Q96J16;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 1.
DT   22-APR-2020, entry version 205.
DE   RecName: Full=Trans-acting T-cell-specific transcription factor GATA-3;
DE   AltName: Full=GATA-binding factor 3;
GN   Name=GATA3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=2050118; DOI=10.1002/j.1460-2075.1991.tb07706.x;
RA   Joulin V., Bories D., Eleouet J.-F., Labastie M.-C., Chretien S.,
RA   Mattei M.-G., Romeo P.-H.;
RT   "A T-cell specific TCR delta DNA binding protein is a member of the human
RT   GATA family.";
RL   EMBO J. 10:1809-1816(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=1827068; DOI=10.1002/j.1460-2075.1991.tb08059.x;
RA   Ho I.-C., Vorhees P., Marin N., Oakley B.K., Tsai S.-F., Orkin S.H.,
RA   Leiden J.M.;
RT   "Human GATA-3: a lineage-restricted transcription factor that regulates the
RT   expression of the T cell receptor alpha gene.";
RL   EMBO J. 10:1187-1192(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=T-cell;
RX   PubMed=2017177; DOI=10.1128/mcb.11.5.2778;
RA   Ko L.J., Yamamoto M., Leonard M.W., George K.M., Ting P., Engel J.D.;
RT   "Murine and human T-lymphocyte GATA-3 factors mediate transcription through
RT   a cis-regulatory element within the human T-cell receptor delta gene
RT   enhancer.";
RL   Mol. Cell. Biol. 11:2778-2784(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1871134; DOI=10.1073/pnas.88.16.7284;
RA   Marine J., Winoto A.;
RT   "The human enhancer-binding protein Gata3 binds to several T-cell receptor
RT   regulatory elements.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:7284-7288(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT SER-242.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cervix, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INVOLVEMENT IN HDR.
RX   PubMed=10935639; DOI=10.1038/35019088;
RA   Van Esch H., Groenen P., Nesbit M.A., Schuffenhauer S., Lichtner P.,
RA   Vanderlinden G., Harding B., Beetz R., Bilous R.W., Holdaway I., Shaw N.J.,
RA   Fryns J.-P., Van de Ven W., Thakker R.V., Devriendt K.;
RT   "GATA3 haplo-insufficiency causes human HDR syndrome.";
RL   Nature 406:419-422(2000).
RN   [10]
RP   INTERACTION WITH TBX21.
RX   PubMed=15662016; DOI=10.1126/science.1103336;
RA   Hwang E.S., Szabo S.J., Schwartzberg P.L., Glimcher L.H.;
RT   "T helper cell fate specified by kinase-mediated interaction of T-bet with
RT   GATA-3.";
RL   Science 307:430-433(2005).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115 AND SER-162, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=23824597; DOI=10.1371/journal.pone.0066468;
RA   Sasaki T., Onodera A., Hosokawa H., Watanabe Y., Horiuchi S., Yamashita J.,
RA   Tanaka H., Ogawa Y., Suzuki Y., Nakayama T.;
RT   "Genome-wide gene expression profiling revealed a critical role for GATA3
RT   in the maintenance of the Th2 cell identity.";
RL   PLoS ONE 8:E66468-E66468(2013).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 260-370 IN COMPLEX WITH DNA, AND
RP   GATA-TYPE ZINC FINGERS.
RX   PubMed=23142663; DOI=10.1016/j.celrep.2012.10.012;
RA   Chen Y., Bates D.L., Dey R., Chen P.H., Machado A.C., Laird-Offringa I.A.,
RA   Rohs R., Chen L.;
RT   "DNA binding by GATA transcription factor suggests mechanisms of DNA
RT   looping and long-range gene regulation.";
RL   Cell Rep. 2:1197-1206(2012).
RN   [14]
RP   VARIANT HDR ARG-274.
RX   PubMed=11389161; DOI=10.1136/jmg.38.6.374;
RA   Muroya K., Hasegawa T., Ito Y., Nagai T., Isotani H., Iwata Y.,
RA   Yamamoto K., Fujimoto S., Seishu S., Fukushima Y., Hasegawa Y., Ogata T.;
RT   "GATA3 abnormalities and the phenotypic spectrum of HDR syndrome.";
RL   J. Med. Genet. 38:374-380(2001).
RN   [15]
RP   VARIANT LEU-366.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S.,
RA   Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M.,
RA   Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by expression
RT   profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [16]
RP   VARIANT HDR GLN-298, AND CHARACTERIZATION OF VARIANT HDR GLN-298.
RX   PubMed=26514990; DOI=10.1186/s12902-015-0065-7;
RA   Okawa T., Yoshida M., Usui T., Kudou T., Iwasaki Y., Fukuoka K.,
RA   Takahashi N., Uehara Y., Oiso Y.;
RT   "A novel loss-of-function mutation of GATA3 (p.R299Q) in a Japanese family
RT   with Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) syndrome.";
RL   BMC Endocr. Disord. 15:66-66(2015).
CC   -!- FUNCTION: Transcriptional activator which binds to the enhancer of the
CC       T-cell receptor alpha and delta genes. Binds to the consensus sequence
CC       5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process
CC       following immune and inflammatory responses.
CC       {ECO:0000269|PubMed:23824597}.
CC   -!- SUBUNIT: Interacts with TBX21 ('Tyr-530' phosphorylated form).
CC       {ECO:0000269|PubMed:15662016}.
CC   -!- INTERACTION:
CC       P23771; P35609: ACTN2; NbExp=3; IntAct=EBI-6664760, EBI-77797;
CC       P23771-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-6672518, EBI-3867333;
CC       P23771; Q96KQ7: EHMT2; NbExp=20; IntAct=EBI-6664760, EBI-744366;
CC       P23771; O15379: HDAC3; NbExp=7; IntAct=EBI-6664760, EBI-607682;
CC       P23771; Q9UQL6: HDAC5; NbExp=4; IntAct=EBI-6664760, EBI-715576;
CC       P23771; Q16665: HIF1A; NbExp=3; IntAct=EBI-6664760, EBI-447269;
CC       P23771-2; P59990: KRTAP12-1; NbExp=3; IntAct=EBI-6672518, EBI-10210845;
CC       P23771-2; Q52LG2: KRTAP13-2; NbExp=3; IntAct=EBI-6672518, EBI-11953846;
CC       P23771-2; Q3LI66: KRTAP6-2; NbExp=3; IntAct=EBI-6672518, EBI-11962084;
CC       P23771; P06239: LCK; NbExp=3; IntAct=EBI-6664760, EBI-1348;
CC       P23771; Q9BTC8: MTA3; NbExp=18; IntAct=EBI-6664760, EBI-2461787;
CC       P23771-2; Q58EX7: PLEKHG4; NbExp=3; IntAct=EBI-6672518, EBI-949255;
CC       P23771; P25788: PSMA3; NbExp=3; IntAct=EBI-6664760, EBI-348380;
CC       P23771; Q9UL17: TBX21; NbExp=6; IntAct=EBI-6664760, EBI-3922312;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P23771-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P23771-2; Sequence=VSP_001598;
CC   -!- TISSUE SPECIFICITY: T-cells and endothelial cells.
CC   -!- DOMAIN: Binds DNA via the 2 GATA-type zinc fingers. Each zinc finger
CC       may bind either adjacent sites in a palindromic motif, or a different
CC       DNA molecule allowing looping and long-range gene regulation.
CC   -!- DOMAIN: The YxKxHxxxRP motif is critical for DNA-binding and function.
CC       {ECO:0000250}.
CC   -!- DISEASE: Hypoparathyroidism, sensorineural deafness, and renal disease
CC       (HDR) [MIM:146255]: A disease characterized by steroid-resistant
CC       nephrosis with progressive renal failure, hypoparathyroidism,
CC       sensorineural deafness, and renal dysplasia.
CC       {ECO:0000269|PubMed:10935639, ECO:0000269|PubMed:11389161,
CC       ECO:0000269|PubMed:26514990}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/gata3/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GATA3ID107ch10p14.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X58072; CAA41102.1; -; mRNA.
DR   EMBL; X55037; CAA38877.1; -; mRNA.
DR   EMBL; X55122; CAA38916.1; -; mRNA.
DR   EMBL; M69106; AAA35870.1; -; mRNA.
DR   EMBL; AY497006; AAR32096.1; -; Genomic_DNA.
DR   EMBL; AL390294; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW86367.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86368.1; -; Genomic_DNA.
DR   EMBL; BC003070; AAH03070.1; -; mRNA.
DR   EMBL; BC006793; AAH06793.1; -; mRNA.
DR   CCDS; CCDS31143.1; -. [P23771-2]
DR   CCDS; CCDS7083.1; -. [P23771-1]
DR   PIR; A39794; A39794.
DR   RefSeq; NP_001002295.1; NM_001002295.1. [P23771-2]
DR   RefSeq; NP_002042.1; NM_002051.2. [P23771-1]
DR   RefSeq; XP_005252499.1; XM_005252442.2. [P23771-2]
DR   RefSeq; XP_005252500.1; XM_005252443.4. [P23771-2]
DR   PDB; 4HC7; X-ray; 2.65 A; A/B=260-370.
DR   PDB; 4HC9; X-ray; 1.60 A; A=260-370.
DR   PDB; 4HCA; X-ray; 2.80 A; A=260-370.
DR   PDBsum; 4HC7; -.
DR   PDBsum; 4HC9; -.
DR   PDBsum; 4HCA; -.
DR   SMR; P23771; -.
DR   BioGrid; 108895; 32.
DR   DIP; DIP-61302N; -.
DR   IntAct; P23771; 42.
DR   MINT; P23771; -.
DR   STRING; 9606.ENSP00000368632; -.
DR   iPTMnet; P23771; -.
DR   PhosphoSitePlus; P23771; -.
DR   BioMuta; GATA3; -.
DR   DMDM; 120962; -.
DR   EPD; P23771; -.
DR   jPOST; P23771; -.
DR   MassIVE; P23771; -.
DR   MaxQB; P23771; -.
DR   PaxDb; P23771; -.
DR   PeptideAtlas; P23771; -.
DR   PRIDE; P23771; -.
DR   ProteomicsDB; 54162; -. [P23771-1]
DR   ProteomicsDB; 54163; -. [P23771-2]
DR   Antibodypedia; 11113; 925 antibodies.
DR   DNASU; 2625; -.
DR   Ensembl; ENST00000346208; ENSP00000341619; ENSG00000107485. [P23771-1]
DR   Ensembl; ENST00000379328; ENSP00000368632; ENSG00000107485. [P23771-2]
DR   GeneID; 2625; -.
DR   KEGG; hsa:2625; -.
DR   UCSC; uc001ijz.4; human. [P23771-1]
DR   CTD; 2625; -.
DR   DisGeNET; 2625; -.
DR   GeneCards; GATA3; -.
DR   HGNC; HGNC:4172; GATA3.
DR   HPA; ENSG00000107485; Tissue enhanced (seminal vesicle, skin).
DR   MalaCards; GATA3; -.
DR   MIM; 131320; gene.
DR   MIM; 146255; phenotype.
DR   neXtProt; NX_P23771; -.
DR   OpenTargets; ENSG00000107485; -.
DR   Orphanet; 2237; Hypoparathyroidism-sensorineural deafness-renal disease syndrome.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA28586; -.
DR   eggNOG; KOG1601; Eukaryota.
DR   eggNOG; COG5641; LUCA.
DR   GeneTree; ENSGT00940000159247; -.
DR   HOGENOM; CLU_027524_1_0_1; -.
DR   InParanoid; P23771; -.
DR   KO; K17895; -.
DR   OMA; TDQPRWV; -.
DR   OrthoDB; 1240204at2759; -.
DR   PhylomeDB; P23771; -.
DR   TreeFam; TF315391; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P23771; -.
DR   SIGNOR; P23771; -.
DR   ChiTaRS; GATA3; human.
DR   GeneWiki; GATA3; -.
DR   GenomeRNAi; 2625; -.
DR   Pharos; P23771; Tbio.
DR   PRO; PR:P23771; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P23771; protein.
DR   Bgee; ENSG00000107485; Expressed in endometrium epithelium and 165 other tissues.
DR   ExpressionAtlas; P23771; baseline and differential.
DR   Genevisible; P23771; HS.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IMP:UniProtKB.
DR   GO; GO:0070888; F:E-box binding; IDA:BHF-UCL.
DR   GO; GO:0071837; F:HMG box domain binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0005134; F:interleukin-2 receptor binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; ISS:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0003180; P:aortic valve morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0061290; P:canonical Wnt signaling pathway involved in metanephric kidney development; ISS:UniProtKB.
DR   GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:UniProtKB.
DR   GO; GO:0045165; P:cell fate commitment; IBA:GO_Central.
DR   GO; GO:0001709; P:cell fate determination; ISS:UniProtKB.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IEA:Ensembl.
DR   GO; GO:0035457; P:cellular response to interferon-alpha; IEP:UniProtKB.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IEP:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR   GO; GO:0090102; P:cochlea development; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006952; P:defense response; TAS:ProtInc.
DR   GO; GO:0048589; P:developmental growth; IEA:Ensembl.
DR   GO; GO:0043583; P:ear development; IMP:UniProtKB.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IEA:Ensembl.
DR   GO; GO:0048568; P:embryonic organ development; IBA:GO_Central.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0002520; P:immune system development; IBA:GO_Central.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0072643; P:interferon-gamma secretion; IEA:Ensembl.
DR   GO; GO:0072602; P:interleukin-4 secretion; IEA:Ensembl.
DR   GO; GO:0001822; P:kidney development; IMP:UniProtKB.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0072676; P:lymphocyte migration; IDA:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; ISS:UniProtKB.
DR   GO; GO:0060374; P:mast cell differentiation; IEA:Ensembl.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; IDA:UniProtKB.
DR   GO; GO:0001823; P:mesonephros development; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:2000146; P:negative regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:2000607; P:negative regulation of cell proliferation involved in mesonephros development; ISS:UniProtKB.
DR   GO; GO:1901536; P:negative regulation of DNA demethylation; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IMP:UniProtKB.
DR   GO; GO:2000703; P:negative regulation of fibroblast growth factor receptor signaling pathway involved in ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:2000734; P:negative regulation of glial cell-derived neurotrophic factor receptor signaling pathway involved in ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:UniProtKB.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; IEA:Ensembl.
DR   GO; GO:0033600; P:negative regulation of mammary gland epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0072179; P:nephric duct formation; ISS:UniProtKB.
DR   GO; GO:0072178; P:nephric duct morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0042421; P:norepinephrine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0071599; P:otic vesicle development; IEA:Ensembl.
DR   GO; GO:0060017; P:parathyroid gland development; IEA:Ensembl.
DR   GO; GO:0035898; P:parathyroid hormone secretion; IEA:Ensembl.
DR   GO; GO:0060037; P:pharyngeal system development; ISS:UniProtKB.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0071442; P:positive regulation of histone H3-K14 acetylation; IEA:Ensembl.
DR   GO; GO:2000617; P:positive regulation of histone H3-K9 acetylation; IEA:Ensembl.
DR   GO; GO:2000667; P:positive regulation of interleukin-13 secretion; IDA:UniProtKB.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:2000664; P:positive regulation of interleukin-5 secretion; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0009967; P:positive regulation of signal transduction; IMP:UniProtKB.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; IEA:Ensembl.
DR   GO; GO:2000611; P:positive regulation of thyroid hormone generation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0072107; P:positive regulation of ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0002572; P:pro-T cell differentiation; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0043370; P:regulation of CD4-positive, alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:2000683; P:regulation of cellular response to X-ray; IMP:UniProtKB.
DR   GO; GO:0042035; P:regulation of cytokine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0030856; P:regulation of epithelial cell differentiation; IBA:GO_Central.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; IEA:Ensembl.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0061085; P:regulation of histone H3-K27 methylation; IEA:Ensembl.
DR   GO; GO:0051569; P:regulation of histone H3-K4 methylation; IEA:Ensembl.
DR   GO; GO:0072182; P:regulation of nephron tubule epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0010975; P:regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEP:UniProtKB.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; ISS:UniProtKB.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045064; P:T-helper 2 cell differentiation; IEA:Ensembl.
DR   GO; GO:0045061; P:thymic T cell selection; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0031929; P:TOR signaling; ISS:UniProtKB.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:0001806; P:type IV hypersensitivity; IEA:Ensembl.
DR   GO; GO:0035799; P:ureter maturation; IEA:Ensembl.
DR   GO; GO:0072197; P:ureter morphogenesis; IEA:Ensembl.
DR   GO; GO:0060676; P:ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:0060065; P:uterus development; ISS:UniProtKB.
DR   GO; GO:0003281; P:ventricular septum development; ISS:UniProtKB.
DR   CDD; cd00202; ZnF_GATA; 2.
DR   Gene3D; 3.30.50.10; -; 2.
DR   InterPro; IPR029521; GATA-3.
DR   InterPro; IPR016374; TF_GATA-2/3.
DR   InterPro; IPR039355; Transcription_factor_GATA.
DR   InterPro; IPR000679; Znf_GATA.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR10071; PTHR10071; 1.
DR   PANTHER; PTHR10071:SF106; PTHR10071:SF106; 1.
DR   Pfam; PF00320; GATA; 2.
DR   PIRSF; PIRSF003027; TF_GATA-1/2/3; 1.
DR   PRINTS; PR00619; GATAZNFINGER.
DR   SMART; SM00401; ZnF_GATA; 2.
DR   PROSITE; PS00344; GATA_ZN_FINGER_1; 2.
DR   PROSITE; PS50114; GATA_ZN_FINGER_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Deafness; Disease mutation;
KW   DNA-binding; Immunity; Innate immunity; Metal-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN           1..443
FT                   /note="Trans-acting T-cell-specific transcription factor
FT                   GATA-3"
FT                   /id="PRO_0000083408"
FT   ZN_FING         263..287
FT                   /note="GATA-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00094"
FT   ZN_FING         317..341
FT                   /note="GATA-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00094"
FT   REGION          1..258
FT                   /note="Interaction with TBX21"
FT                   /evidence="ECO:0000250|UniProtKB:P23772"
FT   REGION          288..316
FT                   /note="Flexible linker"
FT   MOTIF           344..353
FT                   /note="YxKxHxxxRP"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        137..142
FT                   /note="Poly-Ser"
FT   COMPBIAS        322..326
FT                   /note="Poly-Thr"
FT   MOD_RES         115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   VAR_SEQ         259
FT                   /note="T -> TE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:1871134, ECO:0000303|PubMed:2017177"
FT                   /id="VSP_001598"
FT   VARIANT         242
FT                   /note="G -> S (in dbSNP:rs11567901)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_019202"
FT   VARIANT         274
FT                   /note="W -> R (in HDR; dbSNP:rs104894163)"
FT                   /evidence="ECO:0000269|PubMed:11389161"
FT                   /id="VAR_017818"
FT   VARIANT         298
FT                   /note="R -> Q (in HDR; loss of enhancer activity on PTH
FT                   gene promoter and on GATA responsive element)"
FT                   /evidence="ECO:0000269|PubMed:26514990"
FT                   /id="VAR_075427"
FT   VARIANT         366
FT                   /note="R -> L (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033025"
FT   CONFLICT        11
FT                   /note="V -> L (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        102
FT                   /note="A -> V (in Ref. 2; CAA38877)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        173
FT                   /note="A -> G (in Ref. 2; CAA38877)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        219
FT                   /note="I -> Y (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        225..226
FT                   /note="YV -> TC (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        285..286
FT                   /note="NA -> RR (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        425
FT                   /note="P -> A (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        441
FT                   /note="A -> G (in Ref. 4; AAA35870)"
FT                   /evidence="ECO:0000305"
FT   TURN            264..266
FT                   /evidence="ECO:0000244|PDB:4HC9"
FT   HELIX           285..294
FT                   /evidence="ECO:0000244|PDB:4HC9"
FT   STRAND          307..313
FT                   /evidence="ECO:0000244|PDB:4HC7"
FT   TURN            318..320
FT                   /evidence="ECO:0000244|PDB:4HC9"
FT   HELIX           339..348
FT                   /evidence="ECO:0000244|PDB:4HC9"
FT   HELIX           354..356
FT                   /evidence="ECO:0000244|PDB:4HC9"
SQ   SEQUENCE   443 AA;  47916 MW;  F24C58681E1D02A5 CRC64;
     MEVTADQPRW VSHHHPAVLN GQHPDTHHPG LSHSYMDAAQ YPLPEEVDVL FNIDGQGNHV
     PPYYGNSVRA TVQRYPPTHH GSQVCRPPLL HGSLPWLDGG KALGSHHTAS PWNLSPFSKT
     SIHHGSPGPL SVYPPASSSS LSGGHASPHL FTFPPTPPKD VSPDPSLSTP GSAGSARQDE
     KECLKYQVPL PDSMKLESSH SRGSMTALGG ASSSTHHPIT TYPPYVPEYS SGLFPPSSLL
     GGSPTGFGCK SRPKARSSTG RECVNCGATS TPLWRRDGTG HYLCNACGLY HKMNGQNRPL
     IKPKRRLSAA RRAGTSCANC QTTTTTLWRR NANGDPVCNA CGLYYKLHNI NRPLTMKKEG
     IQTRNRKMSS KSKKCKKVHD SLEDFPKNSS FNPAALSRHM SSLSHISPFS HSSHMLTTPT
     PMHPPSSLSF GPHHPSSMVT AMG
//
ID   B4DTD8_HUMAN            Unreviewed;       564 AA.
AC   B4DTD8;
DT   23-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   23-SEP-2008, sequence version 1.
DT   22-APR-2020, entry version 59.
DE   SubName: Full=cDNA FLJ53916, highly similar to Glypican-3 {ECO:0000313|EMBL:BAG61950.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG61950.1};
RN   [1] {ECO:0000313|EMBL:BAG61950.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Placenta {ECO:0000313|EMBL:BAG61950.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A.,
RA   Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y.,
RA   Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T.,
RA   Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Cell surface proteoglycan that bears heparan sulfate.
CC       {ECO:0000256|RuleBase:RU003519}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000256|RuleBase:RU003519};
CC       Lipid-anchor, GPI-anchor {ECO:0000256|RuleBase:RU003519}.
CC   -!- SIMILARITY: Belongs to the glypican family.
CC       {ECO:0000256|RuleBase:RU003518}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK300168; BAG61950.1; -; mRNA.
DR   RefSeq; NP_001158090.1; NM_001164618.1.
DR   SMR; B4DTD8; -.
DR   MaxQB; B4DTD8; -.
DR   PeptideAtlas; B4DTD8; -.
DR   PRIDE; B4DTD8; -.
DR   DNASU; 2719; -.
DR   GeneID; 2719; -.
DR   CTD; 2719; -.
DR   PharmGKB; PA28832; -.
DR   GenomeRNAi; 2719; -.
DR   Genevisible; B4DTD8; HS.
DR   GO; GO:0046658; C:anchored component of plasma membrane; IEA:InterPro.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IEA:InterPro.
DR   GO; GO:0009966; P:regulation of signal transduction; IEA:InterPro.
DR   InterPro; IPR001863; Glypican.
DR   InterPro; IPR015501; Glypican-3.
DR   InterPro; IPR019803; Glypican_CS.
DR   PANTHER; PTHR10822; PTHR10822; 1.
DR   PANTHER; PTHR10822:SF4; PTHR10822:SF4; 1.
DR   Pfam; PF01153; Glypican; 1.
DR   PROSITE; PS01207; GLYPICAN; 1.
PE   2: Evidence at transcript level;
KW   Glycoprotein {ECO:0000256|RuleBase:RU003519};
KW   GPI-anchor {ECO:0000256|RuleBase:RU003519};
KW   Heparan sulfate {ECO:0000256|RuleBase:RU003519};
KW   Lipoprotein {ECO:0000256|RuleBase:RU003519};
KW   Membrane {ECO:0000256|RuleBase:RU003519};
KW   Proteoglycan {ECO:0000256|RuleBase:RU003519};
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT   CHAIN           25..564
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT                   /id="PRO_5002801027"
SQ   SEQUENCE   564 AA;  63728 MW;  FC5B36FD989E8414 CRC64;
     MAGTVRTACL VVAMLLSLDF PGQAQPPPPP PDATCHQVRS FFQRLQPGLK WVPETPVPGS
     DLQVCLPKGP TCCSRKMEEK YQLTARLNME QLLQSAKAFE IVVRHAKNYT NAMFKNNYPS
     LTPQAFEFVG EFFTDVSLYI LGSDINVDDM VNELFDSLFP VIYTQLMNPG LPDSALDINE
     CLRGARRDLK VFGNFPKLIM TQVSKSLQVT RIFLQALNLG IEVINTTDHL KFSKDCGRML
     TRMWYCSYCQ GLMMVKPCGG YCNVVMQGCM AGVVEIDKYW REYILSLEEL VNGMYRIYDM
     ENVLLGLFST IHDSIQYVQK NAGKLTTTIG KLCAHSQQRQ YRSAYYPEDL FIDKKVLKVA
     HVEHEETLSS RRRELIQKLK SFISFYSALP GYICSHSPVA ENDTLCWNGQ ELVERYSQKA
     ARNGMKNQFN LHELKMKGPE PVVSQIIDKL KHINQLLRTM SMPKGRVLDK NLDEEGFESG
     DCGDDEDECI GGSGDGMIKV KNQLRFLAEL AYDLDVDDAP GNSQQATPKD NEISTFHNLG
     NVHSPLKLLT SMAISVVCFF FLVH
//
ID   I6QTG3_HUMAN            Unreviewed;       580 AA.
AC   I6QTG3;
DT   03-OCT-2012, integrated into UniProtKB/TrEMBL.
DT   03-OCT-2012, sequence version 1.
DT   22-APR-2020, entry version 59.
DE   SubName: Full=Glypican 3 isoform 2 {ECO:0000313|EMBL:AFM30911.1};
DE   SubName: Full=Glypican 3, isoform CRA_b {ECO:0000313|EMBL:EAX11770.1};
GN   Name=GPC3 {ECO:0000313|EMBL:AFM30911.1};
GN   ORFNames=hCG_14619 {ECO:0000313|EMBL:EAX11770.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AFM30911.1};
RN   [1] {ECO:0000313|EMBL:EAX11770.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAX11770.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:AFM30911.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Hepatocellular carcinoma {ECO:0000313|EMBL:AFM30911.1};
RA   Gao W., Ho M.;
RT   "Discovery of monoclonal antibodies to glypican-3.";
RL   Submitted (APR-2012) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Cell surface proteoglycan that bears heparan sulfate.
CC       {ECO:0000256|RuleBase:RU003519}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000256|RuleBase:RU003519};
CC       Lipid-anchor, GPI-anchor {ECO:0000256|RuleBase:RU003519}.
CC   -!- SIMILARITY: Belongs to the glypican family.
CC       {ECO:0000256|RuleBase:RU003518}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; JQ943686; AFM30911.1; -; mRNA.
DR   EMBL; CH471107; EAX11770.1; -; Genomic_DNA.
DR   RefSeq; NP_004475.1; NM_004484.3.
DR   Antibodypedia; 424; 1347 antibodies.
DR   GeneID; 2719; -.
DR   KEGG; hsa:2719; -.
DR   CTD; 2719; -.
DR   EuPathDB; HostDB:ENSG00000147257.13; -.
DR   eggNOG; KOG3821; Eukaryota.
DR   eggNOG; ENOG410XST2; LUCA.
DR   HOGENOM; CLU_024658_4_2_1; -.
DR   KO; K08109; -.
DR   ChiTaRS; GPC3; human.
DR   GenomeRNAi; 2719; -.
DR   Bgee; ENSG00000147257; Expressed in kidney and 171 other tissues.
DR   GO; GO:0046658; C:anchored component of plasma membrane; IEA:InterPro.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IEA:InterPro.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0009966; P:regulation of signal transduction; IEA:InterPro.
DR   InterPro; IPR001863; Glypican.
DR   InterPro; IPR015501; Glypican-3.
DR   InterPro; IPR019803; Glypican_CS.
DR   PANTHER; PTHR10822; PTHR10822; 1.
DR   PANTHER; PTHR10822:SF4; PTHR10822:SF4; 1.
DR   Pfam; PF01153; Glypican; 1.
DR   PROSITE; PS01207; GLYPICAN; 1.
PE   2: Evidence at transcript level;
KW   Glycoprotein {ECO:0000256|RuleBase:RU003519};
KW   GPI-anchor {ECO:0000256|RuleBase:RU003519};
KW   Heparan sulfate {ECO:0000256|RuleBase:RU003519};
KW   Lipoprotein {ECO:0000256|RuleBase:RU003519};
KW   Membrane {ECO:0000256|RuleBase:RU003519};
KW   Proteoglycan {ECO:0000256|RuleBase:RU003519};
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT   CHAIN           25..580
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT                   /id="PRO_5010125021"
SQ   SEQUENCE   580 AA;  65563 MW;  19485B76D3CE15FC CRC64;
     MAGTVRTACL VVAMLLSLDF PGQAQPPPPP PDATCHQVRS FFQRLQPGLK WVPETPVPGS
     DLQVCLPKGP TCCSRKMEEK YQLTARLNME QLLQSASMEL KFLIIQNAAV FQEAFEIVVR
     HAKNYTNAMF KNNYPSLTPQ AFEFVGEFFT DVSLYILGSD INVDDMVNEL FDSLFPVIYT
     QLMNPGLPDS ALDINECLRG ARRDLKVFGN FPKLIMTQVS KSLQVTRIFL QALNLGIEVI
     NTTDHLKFSK DCGRMLTRMW YCSYCQGLMM VKPCGGYCNV VMQGCMAGVV EIDKYWREYI
     LSLEELVNGM YRIYDMENVL LGLFSTIHDS IQYVQKNAGK LTTTIGKLCA HSQQRQYRSA
     YYPEDLFIDK KVLKVAHVEH EETLSSRRRE LIQKLKSFIS FYSALPGYIC SHSPVAENDT
     LCWNGQELVE RYSQKAARNG MKNQFNLHEL KMKGPEPVVS QIIDKLKHIN QLLRTMSMPK
     GRVLDKNLDE EGFESGDCGD DEDECIGGSG DGMIKVKNQL RFLAELAYDL DVDDAPGNSQ
     QATPKDNEIS TFHNLGNVHS PLKLLTSMAI SVVCFFFLVH
//
ID   GPC3_HUMAN              Reviewed;         580 AA.
AC   P51654; C9JLE3; G3V1R0; Q2L880; Q2L882;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   22-APR-2020, entry version 187.
DE   RecName: Full=Glypican-3;
DE   AltName: Full=GTR2-2;
DE   AltName: Full=Intestinal protein OCI-5;
DE   AltName: Full=MXR7;
DE   Contains:
DE     RecName: Full=Glypican-3 alpha subunit {ECO:0000303|PubMed:14610063};
DE   Contains:
DE     RecName: Full=Glypican-3 beta subunit {ECO:0000303|PubMed:14610063};
DE   Flags: Precursor;
GN   Name=GPC3; Synonyms=OCI5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9021160; DOI=10.1007/s003359900357;
RA   Shen T., Sonoda G., Hamid J., Li M., Filmus J., Buick R.N., Testa J.R.;
RT   "Mapping of the Simpson-Golabi-Behmel overgrowth syndrome gene (GPC3) to
RT   chromosome X in human and rat by fluorescence in situ hybridization.";
RL   Mamm. Genome 8:72-72(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   AND DISEASE.
RC   TISSUE=Embryo;
RX   PubMed=8589713; DOI=10.1038/ng0396-241;
RA   Pilia G., Hughes-Benzie R.M., Mackenzie A., Baybayan P., Chen E.Y.,
RA   Huber R., Neri G., Cao A., Forabosco A., Schlessinger D.;
RT   "Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel
RT   overgrowth syndrome.";
RL   Nat. Genet. 12:241-247(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9133586; DOI=10.1016/s0378-1119(96)00689-0;
RA   Lage H., Dietel M.;
RT   "Cloning and characterization of human cDNAs encoding a protein with high
RT   homology to rat intestinal development protein OCI-5.";
RL   Gene 188:151-156(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), AND VARIANT MET-429.
RA   Grozdanov P.N., Yovchev M.I., Dabeva M.D.;
RT   "Expression of the Glypican-3 protein in hepatoma cells.";
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-58.
RX   PubMed=9339360; DOI=10.1006/geno.1997.4916;
RA   Huber R., Crisponi L., Mazzarella R., Chen C.N., Su Y., Shizuya H.,
RA   Chen E.Y., Cao A., Pilia G.;
RT   "Analysis of exon/intron structure and 400 kb of genomic sequence
RT   surrounding the 5'-promoter and 3'-terminal ends of the human glypican 3
RT   (GPC3) gene.";
RL   Genomics 45:48-58(1997).
RN   [8]
RP   MARKER FOR HEPATOCELLULAR CARCINOMA.
RX   PubMed=12851874; DOI=10.1016/s0016-5085(03)00689-9;
RA   Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E.,
RA   Filmus J.;
RT   "Glypican-3: a novel serum and histochemical marker for hepatocellular
RT   carcinoma.";
RL   Gastroenterology 125:89-97(2003).
RN   [9]
RP   FUNCTION, SUBUNIT, INTERACTION WITH WNT5A, SUBCELLULAR LOCATION,
RP   GLYCOSYLATION, CLEAVAGE, AND MUTAGENESIS OF 355-ARG--ARG-358;
RP   370-LYS--LYS-374; 387-ARG--ARG-389 AND 394-LYS--LYS-396.
RX   PubMed=14610063; DOI=10.1083/jcb.200302152;
RA   De Cat B., Muyldermans S.Y., Coomans C., Degeest G., Vanderschueren B.,
RA   Creemers J., Biemar F., Peers B., David G.;
RT   "Processing by proprotein convertases is required for glypican-3 modulation
RT   of cell survival, Wnt signaling, and gastrulation movements.";
RL   J. Cell Biol. 163:625-635(2003).
RN   [10]
RP   PROTEIN SEQUENCE OF 359-367.
RX   PubMed=15059894; DOI=10.1158/0008-5472.can-03-2191;
RA   Hippo Y., Watanabe K., Watanabe A., Midorikawa Y., Yamamoto S., Ihara S.,
RA   Tokita S., Iwanari H., Ito Y., Nakano K., Nezu J., Tsunoda H., Yoshino T.,
RA   Ohizumi I., Tsuchiya M., Ohnishi S., Makuuchi M., Hamakubo T., Kodama T.,
RA   Aburatani H.;
RT   "Identification of soluble NH2-terminal fragment of glypican-3 as a
RT   serological marker for early-stage hepatocellular carcinoma.";
RL   Cancer Res. 64:2418-2423(2004).
RN   [11]
RP   ROLE IN HEPATOCELLULAR CARCINOMA GROWTH.
RX   PubMed=16024626; DOI=10.1158/0008-5472.can-04-4244;
RA   Capurro M.I., Xiang Y.Y., Lobe C., Filmus J.;
RT   "Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating
RT   canonical Wnt signaling.";
RL   Cancer Res. 65:6245-6254(2005).
RN   [12]
RP   FUNCTION, INTERACTION WITH WNT3A AND WNT7B, MUTAGENESIS OF
RP   355-ARG--ARG-358, AND ROLE IN HEPATOCELLULAR CARCINOMA GROWTH.
RX   PubMed=16227623; DOI=10.1074/jbc.m507004200;
RA   Capurro M.I., Shi W., Sandal S., Filmus J.;
RT   "Processing by convertases is not required for glypican-3-induced
RT   stimulation of hepatocellular carcinoma growth.";
RL   J. Biol. Chem. 280:41201-41206(2005).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH DPP4.
RX   PubMed=17549790; DOI=10.1002/pmic.200600654;
RA   Davoodi J., Kelly J., Gendron N.H., MacKenzie A.E.;
RT   "The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and
RT   inhibits the dipeptidyl peptidase activity of CD26.";
RL   Proteomics 7:2300-2310(2007).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH FZD4; FZD7 AND FZD8.
RX   PubMed=24496449; DOI=10.1242/jcs.140871;
RA   Capurro M., Martin T., Shi W., Filmus J.;
RT   "Glypican-3 binds to Frizzled and plays a direct role in the stimulation of
RT   canonical Wnt signaling.";
RL   J. Cell Sci. 127:1565-1575(2014).
RN   [16]
RP   PHOSPHORYLATION AT SER-352.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [17]
RP   CLEAVAGE, AND MUTAGENESIS OF 355-ARG--ARG-358.
RX   PubMed=25653284; DOI=10.1074/jbc.m114.612705;
RA   Capurro M., Shi W., Izumikawa T., Kitagawa H., Filmus J.;
RT   "Processing by convertases is required for glypican-3-induced inhibition of
RT   Hedgehog signaling.";
RL   J. Biol. Chem. 290:7576-7585(2015).
RN   [18]
RP   GLYCOSYLATION AT ASN-124; ASN-241 AND ASN-418, PYROGLUTAMATE FORMATION AT
RP   GLN-25, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=29345911; DOI=10.1021/acs.biochem.7b01208;
RA   Saad A., Liet B., Joucla G., Santarelli X., Charpentier J., Claverol S.,
RA   Grosset C.F., Trezeguet V.;
RT   "Role of glycanation and convertase maturation of soluble glypican-3 in
RT   inhibiting proliferation of hepatocellular carcinoma cells.";
RL   Biochemistry 57:1201-1211(2018).
RN   [19]
RP   VARIANT SGBS1 ARG-296.
RX   PubMed=10814714; DOI=10.1093/hmg/9.9.1321;
RA   Veugelers M., Cat B.D., Muyldermans S.Y., Reekmans G., Delande N.,
RA   Frints S., Legius E., Fryns J.-P., Schrander-Stumpel C., Weidle B.,
RA   Magdalena N., David G.;
RT   "Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in
RT   patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-
RT   function mutations in the GPC3 gene.";
RL   Hum. Mol. Genet. 9:1321-1328(2000).
CC   -!- FUNCTION: Cell surface proteoglycan that bears heparan sulfate
CC       (PubMed:14610063). Negatively regulates the hedgehog signaling pathway
CC       when attached via the GPI-anchor to the cell surface by competing with
CC       the hedgehog receptor PTC1 for binding to hedgehog proteins (By
CC       similarity). Binding to the hedgehog protein SHH triggers
CC       internalization of the complex by endocytosis and its subsequent
CC       lysosomal degradation (By similarity). Positively regulates the
CC       canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled
CC       and stimulating the binding of the Frizzled receptor to Wnt ligands
CC       (PubMed:16227623, PubMed:24496449). Positively regulates the non-
CC       canonical Wnt signaling pathway (By similarity). Binds to CD81 which
CC       decreases the availability of free CD81 for binding to the
CC       transcriptional repressor HHEX, resulting in nuclear translocation of
CC       HHEX and transcriptional repression (By similarity). Inhibits the
CC       dipeptidyl peptidase activity of DPP4 (PubMed:17549790). Plays a role
CC       in limb patterning and skeletal development by controlling the cellular
CC       response to BMP4 (By similarity). Modulates the effects of growth
CC       factors BMP2, BMP7 and FGF7 on renal branching morphogenesis (By
CC       similarity). Required for coronary vascular development (By
CC       similarity). Plays a role in regulating cell movements during
CC       gastrulation (By similarity). {ECO:0000250|UniProtKB:Q6V9Y8,
CC       ECO:0000250|UniProtKB:Q8CFZ4, ECO:0000269|PubMed:14610063,
CC       ECO:0000269|PubMed:16227623, ECO:0000269|PubMed:17549790,
CC       ECO:0000269|PubMed:24496449}.
CC   -!- SUBUNIT: Heterodimer; disulfide-linked (PubMed:14610063). Cleavage by a
CC       furin-like convertase results in production of alpha and beta chains
CC       which form a disulfide-linked heterodimer (PubMed:14610063). Interacts
CC       with DPP4 (PubMed:17549790). Interacts with FGF2 (By similarity).
CC       Interacts with WNT5A (PubMed:14610063). Also interacts with WNT3A and
CC       WNT7B (PubMed:16227623). Interacts with hedgehog protein SHH; the
CC       heparan sulfate chains are not required for the interaction (By
CC       similarity). Also interacts with hedgehog protein IHH (By similarity).
CC       Interacts with CD81 (By similarity). Interacts with Wnt receptors FZD4,
CC       FZD7 and FZD8; the heparan sulfate chains are required for the
CC       interaction (PubMed:24496449). {ECO:0000250|UniProtKB:P13265,
CC       ECO:0000250|UniProtKB:Q8CFZ4, ECO:0000269|PubMed:14610063,
CC       ECO:0000269|PubMed:16227623, ECO:0000269|PubMed:17549790,
CC       ECO:0000269|PubMed:24496449}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:14610063};
CC       Lipid-anchor, GPI-anchor {ECO:0000250|UniProtKB:P13265}; Extracellular
CC       side {ECO:0000250|UniProtKB:P13265}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P51654-1; Sequence=Displayed;
CC       Name=2; Synonyms=Variant B;
CC         IsoId=P51654-2; Sequence=VSP_046117;
CC       Name=3; Synonyms=Variant C;
CC         IsoId=P51654-3; Sequence=VSP_046703;
CC   -!- TISSUE SPECIFICITY: Highly expressed in lung, liver and kidney.
CC       {ECO:0000269|PubMed:8589713}.
CC   -!- PTM: O-glycosylated; contains heparan sulfate.
CC       {ECO:0000269|PubMed:14610063}.
CC   -!- PTM: Cleaved intracellularly by a furin-like convertase to generate 2
CC       subunits, alpha and beta, which remain associated through disulfide
CC       bonds and are associated with the cell surface via the GPI-anchor
CC       (PubMed:14610063). This processing is essential for its role in
CC       inhibition of hedgehog signaling (PubMed:25653284). A second
CC       proteolytic event may result in cleavage of the protein on the cell
CC       surface, separating it from the GPI-anchor and leading to its shedding
CC       from the cell surface (PubMed:14610063). {ECO:0000269|PubMed:14610063,
CC       ECO:0000269|PubMed:25653284}.
CC   -!- DISEASE: Simpson-Golabi-Behmel syndrome 1 (SGBS1) [MIM:312870]: A
CC       condition characterized by pre- and postnatal overgrowth (gigantism),
CC       facial dysmorphism and a variety of inconstant visceral and skeletal
CC       malformations. Characteristic dysmorphic features include macrocephaly
CC       with coarse, distinctive facies with a large protruding jaw, broad
CC       nasal bridge and cleft palate. Cardiac defects are frequent.
CC       {ECO:0000269|PubMed:10814714}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Used as a marker for hepatocellular carcinoma (HCC) as
CC       it is expressed in HCC but is not detectable in hepatocytes from normal
CC       or benign liver diseases (PubMed:12851874). When attached to the cell
CC       surface, stimulates the growth of HCC cells by increasing canonical Wnt
CC       signaling (PubMed:16024626). Cleavage is not required for stimulation
CC       of Wnt signaling or HCC growth (PubMed:16227623).
CC       {ECO:0000269|PubMed:12851874, ECO:0000269|PubMed:16024626,
CC       ECO:0000269|PubMed:16227623}.
CC   -!- SIMILARITY: Belongs to the glypican family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GPC3ID156.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U50410; AAA93471.1; -; mRNA.
DR   EMBL; L47124; AAA98131.1; -; Genomic_DNA.
DR   EMBL; L47125; AAA98132.1; -; mRNA.
DR   EMBL; L47176; AAB58806.1; -; mRNA.
DR   EMBL; Z37987; CAA86069.1; -; mRNA.
DR   EMBL; DQ349136; ABC72125.1; -; mRNA.
DR   EMBL; DQ349138; ABC72127.1; -; mRNA.
DR   EMBL; AL008712; CAI43110.1; -; Genomic_DNA.
DR   EMBL; AC002420; CAI43110.1; JOINED; Genomic_DNA.
DR   EMBL; AF003529; CAI43110.1; JOINED; Genomic_DNA.
DR   EMBL; AL009174; CAI43110.1; JOINED; Genomic_DNA.
DR   EMBL; Z99570; CAI43110.1; JOINED; Genomic_DNA.
DR   EMBL; AL009174; CAI42761.1; -; Genomic_DNA.
DR   EMBL; AC002420; CAI42761.1; JOINED; Genomic_DNA.
DR   EMBL; AF003529; CAI42761.1; JOINED; Genomic_DNA.
DR   EMBL; AL008712; CAI42761.1; JOINED; Genomic_DNA.
DR   EMBL; Z99570; CAI42761.1; JOINED; Genomic_DNA.
DR   EMBL; Z99570; CAI42277.1; -; Genomic_DNA.
DR   EMBL; AC002420; CAI42277.1; JOINED; Genomic_DNA.
DR   EMBL; AF003529; CAI42277.1; JOINED; Genomic_DNA.
DR   EMBL; AL008712; CAI42277.1; JOINED; Genomic_DNA.
DR   EMBL; AL009174; CAI42277.1; JOINED; Genomic_DNA.
DR   EMBL; AL034401; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662851; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z97196; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471107; EAX11771.1; -; Genomic_DNA.
DR   EMBL; AF003529; AAB87062.1; -; Genomic_DNA.
DR   CCDS; CCDS14638.1; -. [P51654-1]
DR   CCDS; CCDS55495.1; -. [P51654-2]
DR   CCDS; CCDS55496.1; -. [P51654-3]
DR   RefSeq; NP_001158089.1; NM_001164617.1. [P51654-3]
DR   RefSeq; NP_001158091.1; NM_001164619.1. [P51654-2]
DR   RefSeq; NP_004475.1; NM_004484.3. [P51654-1]
DR   SMR; P51654; -.
DR   BioGrid; 108983; 26.
DR   DIP; DIP-61509N; -.
DR   IntAct; P51654; 22.
DR   STRING; 9606.ENSP00000377836; -.
DR   iPTMnet; P51654; -.
DR   PhosphoSitePlus; P51654; -.
DR   SwissPalm; P51654; -.
DR   BioMuta; GPC3; -.
DR   DMDM; 1708022; -.
DR   EPD; P51654; -.
DR   jPOST; P51654; -.
DR   MassIVE; P51654; -.
DR   MaxQB; P51654; -.
DR   PaxDb; P51654; -.
DR   PeptideAtlas; P51654; -.
DR   PRIDE; P51654; -.
DR   ProteomicsDB; 10697; -.
DR   ProteomicsDB; 32411; -.
DR   ProteomicsDB; 56359; -. [P51654-1]
DR   TopDownProteomics; P51654-1; -. [P51654-1]
DR   ABCD; P51654; -.
DR   Antibodypedia; 424; 1347 antibodies.
DR   DNASU; 2719; -.
DR   Ensembl; ENST00000370818; ENSP00000359854; ENSG00000147257. [P51654-1]
DR   Ensembl; ENST00000394299; ENSP00000377836; ENSG00000147257. [P51654-3]
DR   Ensembl; ENST00000631057; ENSP00000486325; ENSG00000147257. [P51654-2]
DR   GeneID; 2719; -.
DR   KEGG; hsa:2719; -.
DR   UCSC; uc004exe.4; human. [P51654-1]
DR   CTD; 2719; -.
DR   DisGeNET; 2719; -.
DR   GeneCards; GPC3; -.
DR   GeneReviews; GPC3; -.
DR   HGNC; HGNC:4451; GPC3.
DR   HPA; ENSG00000147257; Tissue enriched (placenta).
DR   MalaCards; GPC3; -.
DR   MIM; 300037; gene.
DR   MIM; 312870; phenotype.
DR   neXtProt; NX_P51654; -.
DR   OpenTargets; ENSG00000147257; -.
DR   Orphanet; 654; Nephroblastoma.
DR   Orphanet; 373; Simpson-Golabi-Behmel syndrome.
DR   PharmGKB; PA28832; -.
DR   eggNOG; KOG3821; Eukaryota.
DR   eggNOG; ENOG410XST2; LUCA.
DR   GeneTree; ENSGT00950000182687; -.
DR   HOGENOM; CLU_024658_4_2_1; -.
DR   InParanoid; P51654; -.
DR   KO; K08109; -.
DR   OMA; VEMTECL; -.
DR   PhylomeDB; P51654; -.
DR   TreeFam; TF105317; -.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-3560783; Defective B4GALT7 causes EDS, progeroid type.
DR   Reactome; R-HSA-3560801; Defective B3GAT3 causes JDSSDHD.
DR   Reactome; R-HSA-3656237; Defective EXT2 causes exostoses 2.
DR   Reactome; R-HSA-3656253; Defective EXT1 causes exostoses 1, TRPS2 and CHDS.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-4420332; Defective B3GALT6 causes EDSP2 and SEMDJL1.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SignaLink; P51654; -.
DR   SIGNOR; P51654; -.
DR   ChiTaRS; GPC3; human.
DR   GeneWiki; Glypican_3; -.
DR   GenomeRNAi; 2719; -.
DR   Pharos; P51654; Tbio.
DR   PRO; PR:P51654; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P51654; protein.
DR   Bgee; ENSG00000147257; Expressed in kidney and 171 other tissues.
DR   ExpressionAtlas; P51654; baseline and differential.
DR   Genevisible; P51654; HS.
DR   GO; GO:0046658; C:anchored component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IBA:GO_Central.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IEA:InterPro.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; IBA:GO_Central.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; TAS:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0060422; F:peptidyl-dipeptidase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl.
DR   GO; GO:0010171; P:body morphogenesis; IEA:Ensembl.
DR   GO; GO:0030282; P:bone mineralization; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0042074; P:cell migration involved in gastrulation; ISS:UniProtKB.
DR   GO; GO:0072111; P:cell proliferation involved in kidney development; ISS:UniProtKB.
DR   GO; GO:0072203; P:cell proliferation involved in metanephros development; IEA:Ensembl.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0060976; P:coronary vasculature development; ISS:UniProtKB.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; TAS:Reactome.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0072138; P:mesenchymal cell proliferation involved in ureteric bud development; ISS:UniProtKB.
DR   GO; GO:0072180; P:mesonephric duct morphogenesis; ISS:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl.
DR   GO; GO:0045879; P:negative regulation of smoothened signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045807; P:positive regulation of endocytosis; ISS:UniProtKB.
DR   GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:2000096; P:positive regulation of Wnt signaling pathway, planar cell polarity pathway; IEA:Ensembl.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0060828; P:regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:2000050; P:regulation of non-canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:1905475; P:regulation of protein localization to membrane; IBA:GO_Central.
DR   GO; GO:0009617; P:response to bacterium; IEA:Ensembl.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   InterPro; IPR001863; Glypican.
DR   InterPro; IPR015501; Glypican-3.
DR   InterPro; IPR019803; Glypican_CS.
DR   PANTHER; PTHR10822; PTHR10822; 1.
DR   PANTHER; PTHR10822:SF4; PTHR10822:SF4; 1.
DR   Pfam; PF01153; Glypican; 1.
DR   PROSITE; PS01207; GLYPICAN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; GPI-anchor;
KW   Heparan sulfate; Lipoprotein; Membrane; Phosphoprotein; Protease inhibitor;
KW   Proteoglycan; Pyrrolidone carboxylic acid; Reference proteome; Signal.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000269|PubMed:29345911"
FT   CHAIN           25..358
FT                   /note="Glypican-3 alpha subunit"
FT                   /evidence="ECO:0000305|PubMed:14610063"
FT                   /id="PRO_0000445410"
FT   CHAIN           359..554
FT                   /note="Glypican-3 beta subunit"
FT                   /evidence="ECO:0000305|PubMed:14610063"
FT                   /id="PRO_0000445411"
FT   PROPEP          555..580
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000012310"
FT   SITE            358..359
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000269|PubMed:14610063,
FT                   ECO:0000269|PubMed:15059894"
FT   MOD_RES         25
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000269|PubMed:29345911"
FT   MOD_RES         352
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039"
FT   LIPID           554
FT                   /note="GPI-anchor amidated asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        124
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:29345911"
FT   CARBOHYD        241
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:29345911"
FT   CARBOHYD        418
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:29345911"
FT   CARBOHYD        495
FT                   /note="O-linked (Xyl...) (heparan sulfate) serine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        509
FT                   /note="O-linked (Xyl...) (heparan sulfate) serine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        35..72
FT                   /evidence="ECO:0000250|UniProtKB:P35052"
FT   DISULFID        65..262
FT                   /evidence="ECO:0000250|UniProtKB:P35052"
FT   DISULFID        73..265
FT                   /evidence="ECO:0000250|UniProtKB:P35052"
FT   DISULFID        197..349
FT                   /evidence="ECO:0000250|UniProtKB:P35052"
FT   DISULFID        252..285
FT                   /evidence="ECO:0000250|UniProtKB:P35052"
FT   DISULFID        274..422
FT                   /note="Interchain (between alpha and beta chains)"
FT                   /evidence="ECO:0000250|UniProtKB:P35052"
FT   DISULFID        278..410
FT                   /note="Interchain (between alpha and beta chains)"
FT                   /evidence="ECO:0000250|UniProtKB:P35052"
FT   VAR_SEQ         59..112
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_046117"
FT   VAR_SEQ         344
FT                   /note="T -> TETEKKIWHFKYPIFFLCIGLDLQ (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_046703"
FT   VARIANT         296
FT                   /note="W -> R (in SGBS1; dbSNP:rs104894854)"
FT                   /evidence="ECO:0000269|PubMed:10814714"
FT                   /id="VAR_021385"
FT   VARIANT         429
FT                   /note="V -> M (in dbSNP:rs11539789)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_069139"
FT   MUTAGEN         355..358
FT                   /note="RQYR->AQYA: Abolishes proteolytic processing.
FT                   Abolishes interaction with WNT5A and ability to regulate
FT                   Wnt signaling. Increases binding of hedgehog protein SHH to
FT                   the PTC1 receptor and abolishes ability to inhibit hedgehog
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:14610063,
FT                   ECO:0000269|PubMed:16227623, ECO:0000269|PubMed:25653284"
FT   MUTAGEN         355
FT                   /note="R->A: No effect on proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:14610063"
FT   MUTAGEN         358
FT                   /note="R->A: No effect on proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:14610063"
FT   MUTAGEN         371..374
FT                   /note="KVLK->AVLA: No effect on proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:14610063"
FT   MUTAGEN         387..389
FT                   /note="RRR->AAA: No effect on proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:14610063"
FT   MUTAGEN         394..396
FT                   /note="KLK->ALA: No effect on proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:14610063"
SQ   SEQUENCE   580 AA;  65563 MW;  19485B76D3CE15FC CRC64;
     MAGTVRTACL VVAMLLSLDF PGQAQPPPPP PDATCHQVRS FFQRLQPGLK WVPETPVPGS
     DLQVCLPKGP TCCSRKMEEK YQLTARLNME QLLQSASMEL KFLIIQNAAV FQEAFEIVVR
     HAKNYTNAMF KNNYPSLTPQ AFEFVGEFFT DVSLYILGSD INVDDMVNEL FDSLFPVIYT
     QLMNPGLPDS ALDINECLRG ARRDLKVFGN FPKLIMTQVS KSLQVTRIFL QALNLGIEVI
     NTTDHLKFSK DCGRMLTRMW YCSYCQGLMM VKPCGGYCNV VMQGCMAGVV EIDKYWREYI
     LSLEELVNGM YRIYDMENVL LGLFSTIHDS IQYVQKNAGK LTTTIGKLCA HSQQRQYRSA
     YYPEDLFIDK KVLKVAHVEH EETLSSRRRE LIQKLKSFIS FYSALPGYIC SHSPVAENDT
     LCWNGQELVE RYSQKAARNG MKNQFNLHEL KMKGPEPVVS QIIDKLKHIN QLLRTMSMPK
     GRVLDKNLDE EGFESGDCGD DEDECIGGSG DGMIKVKNQL RFLAELAYDL DVDDAPGNSQ
     QATPKDNEIS TFHNLGNVHS PLKLLTSMAI SVVCFFFLVH
//
ID   Q53H15_HUMAN            Unreviewed;       580 AA.
AC   Q53H15;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   11-DEC-2019, entry version 83.
DE   SubName: Full=Glypican 3 variant {ECO:0000313|EMBL:BAD96486.1};
DE   SubName: Full=Glypican-3 splice variant A {ECO:0000313|EMBL:ABC72126.1};
DE   Flags: Fragment;
GN   Name=GPC3 {ECO:0000313|EMBL:ABC72126.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD96486.1};
RN   [1] {ECO:0000313|EMBL:BAD96486.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver {ECO:0000313|EMBL:BAD96486.1};
RX   PubMed=8125298; DOI=10.1016/0378-1119(94)90802-8;
RA   Maruyama K., Sugano S.;
RT   "Oligo-capping: a simple method to replace the cap structure of eukaryotic
RT   mRNAs with oligoribonucleotides.";
RL   Gene 138:171-174(1994).
RN   [2] {ECO:0000313|EMBL:BAD96486.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver {ECO:0000313|EMBL:BAD96486.1};
RX   PubMed=9373149; DOI=10.1016/S0378-1119(97)00411-3;
RA   Suzuki Y., Yoshitomo K., Maruyama K., Suyama A., Sugano S.;
RT   "Construction and characterization of a full length-enriched and a 5'-end-
RT   enriched cDNA library.";
RL   Gene 200:149-156(1997).
RN   [3] {ECO:0000313|EMBL:BAD96486.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver {ECO:0000313|EMBL:BAD96486.1};
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000313|EMBL:ABC72126.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Grozdanov P.N., Yovchev M.I., Dabeva M.D.;
RT   "Expression of the Glypican-3 protein in hepatoma cells.";
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Cell surface proteoglycan that bears heparan sulfate.
CC       {ECO:0000256|RuleBase:RU003519}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000256|RuleBase:RU003519};
CC       Lipid-anchor, GPI-anchor {ECO:0000256|RuleBase:RU003519}.
CC   -!- SIMILARITY: Belongs to the glypican family.
CC       {ECO:0000256|RuleBase:RU003518}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ349137; ABC72126.1; -; mRNA.
DR   EMBL; AK222761; BAD96481.1; -; mRNA.
DR   EMBL; AK222766; BAD96486.1; -; mRNA.
DR   RefSeq; NP_001158089.1; NM_001164617.1.
DR   RefSeq; NP_001158090.1; NM_001164618.1.
DR   RefSeq; NP_001158091.1; NM_001164619.1.
DR   RefSeq; NP_004475.1; NM_004484.3.
DR   PeptideAtlas; Q53H15; -.
DR   PRIDE; Q53H15; -.
DR   DNASU; 2719; -.
DR   GeneID; 2719; -.
DR   KEGG; hsa:2719; -.
DR   CTD; 2719; -.
DR   PharmGKB; PA28832; -.
DR   eggNOG; KOG3821; Eukaryota.
DR   eggNOG; ENOG410XST2; LUCA.
DR   KO; K08109; -.
DR   OrthoDB; 1097767at2759; -.
DR   ChiTaRS; GPC3; human.
DR   GenomeRNAi; 2719; -.
DR   GO; GO:0046658; C:anchored component of plasma membrane; IEA:InterPro.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IEA:InterPro.
DR   GO; GO:0009966; P:regulation of signal transduction; IEA:InterPro.
DR   InterPro; IPR001863; Glypican.
DR   InterPro; IPR015501; Glypican-3.
DR   InterPro; IPR019803; Glypican_CS.
DR   PANTHER; PTHR10822; PTHR10822; 1.
DR   PANTHER; PTHR10822:SF4; PTHR10822:SF4; 1.
DR   Pfam; PF01153; Glypican; 1.
DR   PROSITE; PS01207; GLYPICAN; 1.
PE   2: Evidence at transcript level;
KW   Glycoprotein {ECO:0000256|RuleBase:RU003519};
KW   GPI-anchor {ECO:0000256|RuleBase:RU003519};
KW   Heparan sulfate {ECO:0000256|RuleBase:RU003519};
KW   Lipoprotein {ECO:0000256|RuleBase:RU003519};
KW   Membrane {ECO:0000256|RuleBase:RU003519};
KW   Proteoglycan {ECO:0000256|RuleBase:RU003519};
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT   CHAIN           25..580
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT                   /id="PRO_5010139063"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:BAD96486.1"
SQ   SEQUENCE   580 AA;  65595 MW;  ECA8BADDD3D4A45C CRC64;
     MAGTVRTACL VVAMLLSLDF PGQAQPPPPP PDATCHQVRS FFQRLQPGLK WVPETPVPGS
     DLQVCLPKGP TCCSRKMEEK YQLTARLNME QLLQSASMEL KFLIIQNAAV FQEAFEIVVR
     HAKNYTNAMF KNNYPSLTPQ AFEFVGEFFT DVSLYILGSD INVDDMVNEL FDSLFPVIYT
     QLMNPGLPDS ALDINECLRG ARRDLKVFGN FPKLIMTQVS KSLQVTRIFL QALNLGIEVI
     NTTDHLKFSK DCGRMLTRMW YCSYCQGLMM VKPCGGYCNV VMQGCMAGVV EIDKYWREYI
     LSLEELVNGM YRIYDMENVL LGLFSTIHDS IQYVQKNAGK LTTTIGKLCA HSQQRQYRSA
     YYPEDLFIDK KVLKVAHVEH EETLSSRRRE LIQKLKSFIS FYSALPGYIC SHSPVAENDT
     LCWNGQELME RYSQKAARNG MKNQFNLHEL KMKGPEPVVS QIIDKLKHIN QLLRTMSMPK
     GRVLDKNLDE EGFESGDCGD DEDECIGGSG DGMIKVKNQL RFLAELAYDL DVDDAPGNSQ
     QATPKDNEIS TFHNLGNVHS PLKLLTSMAI SVVCFFFLVH
//
ID   IRS4_HUMAN              Reviewed;        1257 AA.
AC   O14654;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   22-APR-2020, entry version 171.
DE   RecName: Full=Insulin receptor substrate 4;
DE            Short=IRS-4;
DE   AltName: Full=160 kDa phosphotyrosine protein;
DE            Short=py160;
DE   AltName: Full=Phosphoprotein of 160 kDa;
DE            Short=pp160;
GN   Name=IRS4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 100-117; 233-240; 613-618;
RP   836-843 AND 844-852, AND PHOSPHORYLATION.
RC   TISSUE=Kidney;
RX   PubMed=9261155; DOI=10.1074/jbc.272.34.21403;
RA   Lavan B.E., Fantin V.R., Chang E.T., Lane W.S., Keller S.R., Lienhard G.E.;
RT   "A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic
RT   kidney cells is a new member of the insulin receptor substrate family.";
RL   J. Biol. Chem. 272:21403-21407(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH GRB2 AND PIK3R1, AND
RP   PHOSPHORYLATION.
RX   PubMed=9553137; DOI=10.1074/jbc.273.17.10726;
RA   Fantin V.R., Sparling J.D., Slot J.W., Keller S.R., Lienhard G.E.,
RA   Lavan B.E.;
RT   "Characterization of insulin receptor substrate 4 in human embryonic kidney
RT   293 cells.";
RL   J. Biol. Chem. 273:10726-10732(1998).
RN   [5]
RP   INTERACTION WITH CRK AND CRKL.
RX   PubMed=9614078; DOI=10.1074/jbc.273.24.14780;
RA   Koval A.P., Karas M., Zick Y., LeRoith D.;
RT   "Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like
RT   growth factor-I receptor-mediated signal transduction.";
RL   J. Biol. Chem. 273:14780-14787(1998).
RN   [6]
RP   FUNCTION.
RX   PubMed=10531310; DOI=10.1074/jbc.274.44.31179;
RA   Qu B.-H., Karas M., Koval A., LeRoith D.;
RT   "Insulin receptor substrate-4 enhances insulin-like growth factor-I-induced
RT   cell proliferation.";
RL   J. Biol. Chem. 274:31179-31184(1999).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH GRB2 AND PIK3R1.
RX   PubMed=10594015; DOI=10.1128/MCB.20.1.126-138.2000;
RA   Uchida T., Myers M.G. Jr., White M.F.;
RT   "IRS-4 mediates protein kinase B signaling during insulin stimulation
RT   without promoting antiapoptosis.";
RL   Mol. Cell. Biol. 20:126-138(2000).
RN   [8]
RP   INTERACTION WITH CRK, AND MUTAGENESIS OF TYR-700; TYR-717; TYR-743 AND
RP   TYR-779.
RX   PubMed=11316748; DOI=10.1210/endo.142.5.8135;
RA   Karas M., Koval A.P., Zick Y., LeRoith D.;
RT   "The insulin-like growth factor I receptor-induced interaction of insulin
RT   receptor substrate-4 and Crk-II.";
RL   Endocrinology 142:1835-1840(2001).
RN   [9]
RP   INTERACTION WITH NISCH.
RX   PubMed=11912194; DOI=10.1074/jbc.m111838200;
RA   Sano H., Liu S.C.H., Lane W.S., Piletz J.E., Lienhard G.E.;
RT   "Insulin receptor substrate 4 associates with the protein IRAS.";
RL   J. Biol. Chem. 277:19439-19447(2002).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=12639902; DOI=10.1210/en.2002-220723;
RA   Schreyer S., Ledwig D., Rakatzi I., Kloeting I., Eckel J.;
RT   "Insulin receptor substrate-4 is expressed in muscle tissue without acting
RT   as a substrate for the insulin receptor.";
RL   Endocrinology 144:1211-1218(2003).
RN   [11]
RP   PHOSPHORYLATION AT TYR-921, INTERACTION WITH SHC1; GRB2; PHOSPHOLIPASE
RP   C-GAMMA AND PHOSPHATIDYLINOSITOL 3-KINASE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=15316024; DOI=10.1074/jbc.m404537200;
RA   Hinsby A.M., Olsen J.V., Mann M.;
RT   "Tyrosine phosphoproteomics of fibroblast growth factor signaling: a role
RT   for insulin receptor substrate-4.";
RL   J. Biol. Chem. 279:46438-46447(2004).
RN   [12]
RP   INTERACTION WITH PPP4C, INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15331607; DOI=10.1074/jbc.m408067200;
RA   Mihindukulasuriya K.A., Zhou G., Qin J., Tan T.-H.;
RT   "Protein phosphatase 4 interacts with and down-regulates insulin receptor
RT   substrate 4 following tumor necrosis factor-alpha stimulation.";
RL   J. Biol. Chem. 279:46588-46594(2004).
RN   [13]
RP   INTERACTION WITH PTK6, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15870689; DOI=10.1038/sj.onc.1208721;
RA   Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.;
RT   "Interaction between Brk kinase and insulin receptor substrate-4.";
RL   Oncogene 24:5656-5664(2005).
RN   [14]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=17408801; DOI=10.1016/j.jhep.2007.01.031;
RA   Cuevas E.P., Escribano O., Chiloeches A., Ramirez Rubio S., Roman I.D.,
RA   Fernandez-Moreno M.D., Guijarro L.G.;
RT   "Role of insulin receptor substrate-4 in IGF-I-stimulated HEPG2
RT   proliferation.";
RL   J. Hepatol. 46:1089-1098(2007).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-20; GLU-215 AND ARG-557.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Acts as an interface between multiple growth factor receptors
CC       possessing tyrosine kinase activity, such as insulin receptor, IGF1R
CC       and FGFR1, and a complex network of intracellular signaling molecules
CC       containing SH2 domains. Involved in the IGF1R mitogenic signaling
CC       pathway. Promotes the AKT1 signaling pathway and BAD phosphorylation
CC       during insulin stimulation without activation of RPS6KB1 or the
CC       inhibition of apoptosis. Interaction with GRB2 enhances insulin-
CC       stimulated mitogen-activated protein kinase activity. May be involved
CC       in nonreceptor tyrosine kinase signaling in myoblasts. Plays a pivotal
CC       role in the proliferation/differentiation of hepatoblastoma cell
CC       through EPHB2 activation upon IGF1 stimulation. May play a role in the
CC       signal transduction in response to insulin and to a lesser extent in
CC       response to IL4 and GH on mitogenesis. Plays a role in growth,
CC       reproduction and glucose homeostasis. May act as negative regulators of
CC       the IGF1 signaling pathway by suppressing the function of IRS1 and
CC       IRS2. {ECO:0000269|PubMed:10531310, ECO:0000269|PubMed:10594015,
CC       ECO:0000269|PubMed:12639902, ECO:0000269|PubMed:17408801,
CC       ECO:0000269|PubMed:9553137}.
CC   -!- SUBUNIT: Interacts with SOCS6 in response to stimulation with either
CC       insulin or IGF1 (By similarity). Interacts with CRK and CRKL.
CC       Interaction with CRK is stronger than with CRKL. Interacts with CRK via
CC       the phosphorylated YXXM motifs. Interacts with GRB2 and PIK3R1.
CC       Interacts with PLC-gamma, SHC1, PTK6, PPP4C and NISCH. {ECO:0000250,
CC       ECO:0000269|PubMed:10594015, ECO:0000269|PubMed:11316748,
CC       ECO:0000269|PubMed:11912194, ECO:0000269|PubMed:15316024,
CC       ECO:0000269|PubMed:15331607, ECO:0000269|PubMed:15870689,
CC       ECO:0000269|PubMed:9553137, ECO:0000269|PubMed:9614078}.
CC   -!- INTERACTION:
CC       O14654; P46108: CRK; NbExp=8; IntAct=EBI-356594, EBI-886;
CC       O14654; P00533: EGFR; NbExp=2; IntAct=EBI-356594, EBI-297353;
CC       O14654; Q15185: PTGES3; NbExp=2; IntAct=EBI-356594, EBI-1049387;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:9553137};
CC       Peripheral membrane protein {ECO:0000269|PubMed:9553137}; Cytoplasmic
CC       side {ECO:0000269|PubMed:9553137}.
CC   -!- TISSUE SPECIFICITY: Expressed in myoblasts. Expressed in liver and
CC       hepatocellular carcinoma. {ECO:0000269|PubMed:12639902,
CC       ECO:0000269|PubMed:17408801}.
CC   -!- INDUCTION: Down-regulated by PPP4C in a phosphatase activity-dependent
CC       manner. {ECO:0000269|PubMed:15331607}.
CC   -!- PTM: Phosphorylated on tyrosine residues in response to both insulin
CC       and IGF1 signaling. Phosphorylated on Tyr-921 in response to FGF2
CC       signaling. Phosphorylation of Tyr-921 is required for GRB2,
CC       phospholipase C-gamma and phosphatidylinositol 3-kinase interaction.
CC       {ECO:0000269|PubMed:15316024, ECO:0000269|PubMed:9261155,
CC       ECO:0000269|PubMed:9553137}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF007567; AAC51738.1; -; mRNA.
DR   EMBL; AL035425; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471120; EAX02682.1; -; Genomic_DNA.
DR   CCDS; CCDS14544.1; -.
DR   RefSeq; NP_003595.1; NM_003604.2.
DR   BioGrid; 114048; 146.
DR   IntAct; O14654; 110.
DR   MINT; O14654; -.
DR   STRING; 9606.ENSP00000361202; -.
DR   iPTMnet; O14654; -.
DR   PhosphoSitePlus; O14654; -.
DR   BioMuta; IRS4; -.
DR   jPOST; O14654; -.
DR   MassIVE; O14654; -.
DR   MaxQB; O14654; -.
DR   PaxDb; O14654; -.
DR   PeptideAtlas; O14654; -.
DR   PRIDE; O14654; -.
DR   ProteomicsDB; 48151; -.
DR   Antibodypedia; 15310; 163 antibodies.
DR   DNASU; 8471; -.
DR   Ensembl; ENST00000372129; ENSP00000361202; ENSG00000133124.
DR   GeneID; 8471; -.
DR   KEGG; hsa:8471; -.
DR   UCSC; uc004eoc.3; human.
DR   CTD; 8471; -.
DR   DisGeNET; 8471; -.
DR   GeneCards; IRS4; -.
DR   HGNC; HGNC:6128; IRS4.
DR   HPA; ENSG00000133124; Tissue enriched (pituitary).
DR   MIM; 300904; gene.
DR   neXtProt; NX_O14654; -.
DR   OpenTargets; ENSG00000133124; -.
DR   PharmGKB; PA29923; -.
DR   eggNOG; ENOG410IXEK; Eukaryota.
DR   eggNOG; ENOG410Z9EP; LUCA.
DR   GeneTree; ENSGT00940000160883; -.
DR   HOGENOM; CLU_290952_0_0_1; -.
DR   InParanoid; O14654; -.
DR   KO; K17446; -.
DR   OMA; EDSRGYM; -.
DR   OrthoDB; 298675at2759; -.
DR   PhylomeDB; O14654; -.
DR   TreeFam; TF325994; -.
DR   Reactome; R-HSA-2428928; IRS-related events triggered by IGF1R.
DR   SignaLink; O14654; -.
DR   SIGNOR; O14654; -.
DR   GeneWiki; IRS4; -.
DR   GenomeRNAi; 8471; -.
DR   Pharos; O14654; Tbio.
DR   PRO; PR:O14654; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; O14654; protein.
DR   Bgee; ENSG00000133124; Expressed in adenohypophysis and 22 other tissues.
DR   Genevisible; O14654; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005158; F:insulin receptor binding; IBA:GO_Central.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IBA:GO_Central.
DR   GO; GO:0005070; F:SH3/SH2 adaptor activity; TAS:ProtInc.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd01204; PTB_IRS; 1.
DR   Gene3D; 2.30.29.30; -; 2.
DR   InterPro; IPR039011; IRS.
DR   InterPro; IPR002404; IRS_PTB.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   PANTHER; PTHR10614; PTHR10614; 1.
DR   Pfam; PF02174; IRS; 1.
DR   PRINTS; PR00628; INSULINRSI.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00310; PTBI; 1.
DR   PROSITE; PS51064; IRS_PTB; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Direct protein sequencing; Membrane; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Transducer.
FT   CHAIN           1..1257
FT                   /note="Insulin receptor substrate 4"
FT                   /id="PRO_0000314678"
FT   DOMAIN          78..199
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          231..335
FT                   /note="IRS-type PTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00389"
FT   REGION          678..800
FT                   /note="CRK-binding"
FT   REGION          895..897
FT                   /note="GRB2-binding"
FT   MOTIF           487..490
FT                   /note="YXXM motif 1"
FT   MOTIF           700..703
FT                   /note="YXXM motif 2"
FT   MOTIF           717..720
FT                   /note="YXXM motif 3"
FT   MOTIF           743..746
FT                   /note="YXXM motif 4"
FT   MOTIF           779..782
FT                   /note="YXXM motif 5"
FT   MOTIF           828..831
FT                   /note="YXXM motif 6"
FT   MOTIF           921..924
FT                   /note="YXXM motif 7"
FT   COMPBIAS        18..28
FT                   /note="Poly-Ala"
FT   COMPBIAS        124..137
FT                   /note="Ala-rich"
FT   COMPBIAS        218..226
FT                   /note="Poly-Ala"
FT   COMPBIAS        628..639
FT                   /note="Pro-rich"
FT   COMPBIAS        1094..1212
FT                   /note="Ala-rich"
FT   MOD_RES         921
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:15316024"
FT   VARIANT         20
FT                   /note="A -> V (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_038042"
FT   VARIANT         34
FT                   /note="L -> F (in dbSNP:rs1801162)"
FT                   /id="VAR_051078"
FT   VARIANT         215
FT                   /note="G -> E (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_038043"
FT   VARIANT         508
FT                   /note="N -> K (in dbSNP:rs34287560)"
FT                   /id="VAR_051079"
FT   VARIANT         557
FT                   /note="G -> R (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_038044"
FT   VARIANT         879
FT                   /note="H -> D (in dbSNP:rs1801164)"
FT                   /id="VAR_051080"
FT   VARIANT         1230
FT                   /note="D -> Y (in dbSNP:rs28546943)"
FT                   /id="VAR_061669"
FT   MUTAGEN         700
FT                   /note="Y->F: No effect. Reduces interaction with CRK by
FT                   50%; when associated with F-717. Abolishes interaction with
FT                   CRK; when associated with F-717; F-743 and F-779."
FT                   /evidence="ECO:0000269|PubMed:11316748"
FT   MUTAGEN         717
FT                   /note="Y->F: No effect. Reduces interaction with CRK by
FT                   50%; when associated with F-700. Abolishes interaction with
FT                   CRK; when associated with F-700; F-743 and F-779."
FT                   /evidence="ECO:0000269|PubMed:11316748"
FT   MUTAGEN         743
FT                   /note="Y->F: No effect. Reduces interaction with CRK by
FT                   50%; when associated with F-779. Abolishes interaction with
FT                   CRK; when associated with F-700; F-717 and F-779."
FT                   /evidence="ECO:0000269|PubMed:11316748"
FT   MUTAGEN         779
FT                   /note="Y->F: No effect. Reduces interaction with CRK by
FT                   50%; when associated with F-743. Abolishes interaction with
FT                   CRK; when associated with F-700; F-717 and F-743."
FT                   /evidence="ECO:0000269|PubMed:11316748"
SQ   SEQUENCE   1257 AA;  133768 MW;  4D512D65A7A80374 CRC64;
     MASCSFTRDQ ATRRLRGAAA AAAAALAAVV TTPLLSSGTP TALIGTGSSC PGAMWLSTAT
     GSRSDSESEE EDLPVGEEVC KRGYLRKQKH GHRRYFVLKL ETADAPARLE YYENARKFRH
     SVRAAAAAAA AAASGAAIPP LIPPRRVITL YQCFSVSQRA DARYRHLIAL FTQDEYFAMV
     AENESEQESW YLLLSRLILE SKRRRCGTLG AQPDGEPAAL AAAAAAEPPF YKDVWQVIVK
     PRGLGHRKEL SGVFRLCLTD EEVVFVRLNT EVASVVVQLL SIRRCGHSEQ YFFLEVGRST
     VIGPGELWMQ VDDCVVAQNM HELFLEKMRA LCADEYRARC RSYSISIGAH LLTLLSARRH
     LGLVPLEPGG WLRRSRFEQF CHLRAIGDGE DEMLFTRRFV TPSEPVAHSR RGRLHLPRGR
     RSRRAVSVPA SFFRRLAPSP ARPRHPAEAP NNGARLSSEV SGSGSGNFGE EGNPQGKEDQ
     EGSGGDYMPM NNWGSGNGRG SGGGQGSNGQ GSSSHSSGGN QCSGEGQGSR GGQGSNGQGS
     GGNQCSRDGQ GTAGGHGSGG GQRPGGGHGS GGGQGPGDGH GSGGGKNSGG GKGSGSGKGS
     DGDGERGKSL KKRSYFGKLT QSKQQQMPPP PPPPPPPPPA GGTGGKGKSG GRFRLYFCVD
     RGATKECKEA KEVKDAEIPE GAARGPHRAR AFDEDEDDPY VPMRPGVATP LVSSSDYMPM
     APQNVSASKK RHSRSPFEDS RGYMMMFPRV SPPPAPSPPK APDTNKEDDS KDNDSESDYM
     FMAPGAGAIP KNPRNPQGGS SSKSWSSYFS LPNPFRSSPL GQNDNSEYVP MLPGKFLGRG
     LDKEVSYNWD PKDAASKPSG EGSFSKPGDG GSPSKPSDHE PPKNKAKRPN RLSFITKGYK
     IKPKPQKPTH EQREADSSSD YVNMDFTKRE SNTPAPSTQG LPDSWGIIAE PRQSAFSNYV
     NVEFGVPFPN PANDLSDLLR AIPRANPLSL DSARWPLPPL PLSATGSNAI EEEGDYIEVI
     FNSAMTPAMA LADSAIRYDA ETGRIYVVDP FSECCMDISL SPSRCSEPPP VARLLQEEEQ
     ERRRPQSRSQ SFFAAARAAV SAFPTDSLER DLSPSSAPAV ASAAEPTLAL SQVVAAASAL
     AAAPGIGAAA AAAGFDSASA RWFQPVANAA DAEAVRGAQD VAGGSNPGAH NPSANLARGD
     NQAGGAAAAA AAPEPPPRSR RVPRPPERED SDNDDDTHVR MDFARRDNQF DSPKRGR
//
ID   JAK1_HUMAN              Reviewed;        1154 AA.
AC   P23458; Q59GQ2; Q9UD26;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   22-APR-2020, entry version 218.
DE   RecName: Full=Tyrosine-protein kinase JAK1;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:1848670, ECO:0000269|PubMed:7615558};
DE   AltName: Full=Janus kinase 1;
DE            Short=JAK-1;
GN   Name=JAK1; Synonyms=JAK1A, JAK1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY.
RX   PubMed=1848670; DOI=10.1128/mcb.11.4.2057;
RA   Wilks A.F., Harpur A.G., Kurban R.R., Ralph S.J., Zuercher G.,
RA   Ziemiecki A.;
RT   "Two novel protein-tyrosine kinases, each with a second phosphotransferase-
RT   related catalytic domain, define a new class of protein kinase.";
RL   Mol. Cell. Biol. 11:2057-2065(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1005-1062.
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1008-1062, AND TISSUE SPECIFICITY.
RC   TISSUE=Colon tumor;
RX   PubMed=7896447; DOI=10.1002/ijc.2910600611;
RA   Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A., Srivastava S.,
RA   Varnum B., Liu E.T., Cance W.G.;
RT   "Receptor tyrosine kinases expressed in metastatic colon cancer.";
RL   Int. J. Cancer 60:791-797(1995).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH IFNGR1, AND
RP   PHOSPHORYLATION.
RX   PubMed=7615558; DOI=10.1074/jbc.270.29.17528;
RA   Sakatsume M., Igarashi K., Winestock K.D., Garotta G., Larner A.C.,
RA   Finbloom D.S.;
RT   "The Jak kinases differentially associate with the alpha and beta
RT   (accessory factor) chains of the interferon gamma receptor to form a
RT   functional receptor unit capable of activating STAT transcription
RT   factors.";
RL   J. Biol. Chem. 270:17528-17534(1995).
RN   [9]
RP   INTERACTION WITH IFNAR2.
RX   PubMed=7759950; DOI=10.1002/jlb.57.5.712;
RA   Novick D., Cohen B., Tal N., Rubinstein M.;
RT   "Soluble and membrane-anchored forms of the human IFN-alpha/beta
RT   receptor.";
RL   J. Leukoc. Biol. 57:712-718(1995).
RN   [10]
RP   INTERACTION WITH SHB.
RX   PubMed=12200137; DOI=10.1016/s0006-291x(02)02016-8;
RA   Lindholm C.K.;
RT   "IL-2 receptor signaling through the Shb adapter protein in T and NK
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 296:929-936(2002).
RN   [11]
RP   FUNCTION IN CYTOKINE SIGNALING, PHOSPHORYLATION AT TYR-1034 AND TYR-1035,
RP   AND DEPHOSPHORYLATION AT TYR-1034 AND TYR-1035 BY PTPN2.
RX   PubMed=11909529; DOI=10.1016/s0960-9822(02)00697-8;
RA   Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J.;
RT   "The T cell protein tyrosine phosphatase is a negative regulator of janus
RT   family kinases 1 and 3.";
RL   Curr. Biol. 12:446-453(2002).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH IL2RB AND IL10RA.
RX   PubMed=12133952; DOI=10.4049/jimmunol.169.3.1302;
RA   Usacheva A., Kotenko S., Witte M.M., Colamonici O.R.;
RT   "Two distinct domains within the N-terminal region of Janus kinase 1
RT   interact with cytokine receptors.";
RL   J. Immunol. 169:1302-1308(2002).
RN   [13]
RP   INTERACTION WITH IL31RA.
RX   PubMed=15194700; DOI=10.1074/jbc.m401122200;
RA   Dreuw A., Radtke S., Pflanz S., Lippok B.E., Heinrich P.C., Hermanns H.M.;
RT   "Characterization of the signaling capacities of the novel gp130-like
RT   cytokine receptor.";
RL   J. Biol. Chem. 279:36112-36120(2004).
RN   [14]
RP   INTERACTION WITH JAKMIP1.
RX   PubMed=15277531; DOI=10.1074/jbc.m401915200;
RA   Steindler C., Li Z., Algarte M., Alcover A., Libri V., Ragimbeau J.,
RA   Pellegrini S.;
RT   "Jamip1 (marlin-1) defines a family of proteins interacting with Janus
RT   kinases and microtubules.";
RL   J. Biol. Chem. 279:43168-43177(2004).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT TYR-3 AND SER-228, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   UBIQUITINATION.
RX   PubMed=26027934; DOI=10.1016/j.celrep.2015.04.049;
RA   Kim H., Frederick D.T., Levesque M.P., Cooper Z.A., Feng Y., Krepler C.,
RA   Brill L., Samuels Y., Hayward N.K., Perlina A., Piris A., Zhang T.,
RA   Halaban R., Herlyn M.M., Brown K.M., Wargo J.A., Dummer R., Flaherty K.T.,
RA   Ronai Z.A.;
RT   "Downregulation of the ubiquitin ligase RNF125 underlies resistance of
RT   melanoma cells to BRAF inhibitors via JAK1 deregulation.";
RL   Cell Rep. 11:1458-1473(2015).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 865-1154 IN COMPLEXES WITH
RP   SYNTHETIC INHIBITORS CMP6 AND CP-690,550.
RX   PubMed=19361440; DOI=10.1016/j.jmb.2009.01.041;
RA   Williams N.K., Bamert R.S., Patel O., Wang C., Walden P.M., Wilks A.F.,
RA   Fantino E., Rossjohn J., Lucet I.S.;
RT   "Dissecting specificity in the Janus kinases: the structures of JAK-
RT   specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase
RT   domains.";
RL   J. Mol. Biol. 387:219-232(2009).
RN   [20]
RP   VARIANT [LARGE SCALE ANALYSIS] LYS-973.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine kinase of the non-receptor type, involved in the
CC       IFN-alpha/beta/gamma signal pathway (PubMed:7615558). Kinase partner
CC       for the interleukin (IL)-2 receptor (PubMed:11909529) as well as
CC       interleukin (IL)-10 receptor (PubMed:12133952).
CC       {ECO:0000269|PubMed:11909529, ECO:0000269|PubMed:7615558}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:1848670, ECO:0000269|PubMed:7615558};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000305|PubMed:7615558};
CC       Note=Mn(2+) was used in the in vitro kinase assay but Mg(2+) is likely
CC       to be the in vivo cofactor. {ECO:0000305|PubMed:7615558};
CC   -!- SUBUNIT: Interacts with IL31RA (PubMed:15194700). Interacts with IFNAR2
CC       (PubMed:7759950). Interacts with IFNGR1 (PubMed:7615558). Interacts
CC       with JAKMIP1 (PubMed:15277531). Interacts with SHB (PubMed:12200137).
CC       Interacts (via N-terminus) with IL2RB and IL10RA (via its cytoplasmic
CC       domain) (PubMed:12133952). Interacts with FER (By similarity).
CC       {ECO:0000250|UniProtKB:P52332, ECO:0000269|PubMed:12133952,
CC       ECO:0000269|PubMed:12200137, ECO:0000269|PubMed:15194700,
CC       ECO:0000269|PubMed:15277531, ECO:0000269|PubMed:7615558,
CC       ECO:0000269|PubMed:7759950}.
CC   -!- INTERACTION:
CC       P23458; P04626: ERBB2; NbExp=2; IntAct=EBI-1383438, EBI-641062;
CC       P23458; P48551: IFNAR2; NbExp=3; IntAct=EBI-1383438, EBI-958408;
CC       P23458; P40189-1: IL6ST; NbExp=3; IntAct=EBI-1383438, EBI-15742214;
CC       P23458; O60674: JAK2; NbExp=4; IntAct=EBI-1383438, EBI-518647;
CC       P23458; P40763: STAT3; NbExp=2; IntAct=EBI-1383438, EBI-518675;
CC   -!- SUBCELLULAR LOCATION: Endomembrane system; Peripheral membrane protein.
CC       Note=Wholly intracellular, possibly membrane associated.
CC   -!- TISSUE SPECIFICITY: Expressed at higher levels in primary colon tumors
CC       than in normal colon tissue. The expression level in metastatic colon
CC       tumors is comparable to the expression level in normal colon tissue.
CC       {ECO:0000269|PubMed:7896447}.
CC   -!- DOMAIN: Possesses two phosphotransferase domains. The second one
CC       probably contains the catalytic domain, while the presence of slight
CC       differences suggest a different role for domain 1. {ECO:0000250}.
CC   -!- DOMAIN: The FERM domain mediates interaction with JAKMIP1.
CC   -!- PTM: Autophosphorylated (PubMed:7615558). Phosphorylated on tyrosine
CC       residues in response to interferon gamma signaling (PubMed:7615558).
CC       Dephosphorylation of Tyr-1034 and Tyr-1035 by PTPN2 negatively
CC       regulates cytokine-mediated signaling (PubMed:11909529).
CC       {ECO:0000269|PubMed:11909529, ECO:0000269|PubMed:7615558}.
CC   -!- PTM: Ubiquitinated by RNF125; leading to its degradation by the
CC       proteasome. {ECO:0000269|PubMed:26027934}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. JAK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA36527.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAA36527.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JAK1ID41031ch1p31.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M64174; AAA36527.1; ALT_SEQ; mRNA.
DR   EMBL; AB209057; BAD92294.1; -; mRNA.
DR   EMBL; AC093427; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX06547.1; -; Genomic_DNA.
DR   EMBL; BC132729; AAI32730.1; -; mRNA.
DR   CCDS; CCDS41346.1; -.
DR   PIR; A39577; A39577.
DR   RefSeq; NP_001307852.1; NM_001320923.1.
DR   RefSeq; NP_001308781.1; NM_001321852.1.
DR   RefSeq; NP_001308782.1; NM_001321853.1.
DR   RefSeq; NP_001308783.1; NM_001321854.1.
DR   RefSeq; NP_001308784.1; NM_001321855.1.
DR   RefSeq; NP_001308785.1; NM_001321856.1.
DR   RefSeq; NP_002218.2; NM_002227.3.
DR   PDB; 3EYG; X-ray; 1.90 A; A=865-1154.
DR   PDB; 3EYH; X-ray; 2.00 A; A=865-1154.
DR   PDB; 4E4L; X-ray; 2.00 A; A/B/D/E=854-1154.
DR   PDB; 4E4N; X-ray; 1.90 A; A/B=854-1154.
DR   PDB; 4E5W; X-ray; 1.86 A; A/B=854-1154.
DR   PDB; 4EHZ; X-ray; 2.17 A; A/B/C/D=854-1154.
DR   PDB; 4EI4; X-ray; 2.22 A; A/B=854-1154.
DR   PDB; 4FK6; X-ray; 2.20 A; A/B=854-1154.
DR   PDB; 4GS0; X-ray; 1.80 A; C=1033-1036.
DR   PDB; 4I5C; X-ray; 2.10 A; A/B=854-1154.
DR   PDB; 4IVB; X-ray; 1.90 A; A/B=854-1154.
DR   PDB; 4IVC; X-ray; 2.35 A; A/B=854-1154.
DR   PDB; 4IVD; X-ray; 1.93 A; A/B=854-1154.
DR   PDB; 4K6Z; X-ray; 2.73 A; A=854-1154.
DR   PDB; 4K77; X-ray; 2.40 A; A/B=854-1154.
DR   PDB; 4L00; X-ray; 1.80 A; A/B=561-860.
DR   PDB; 4L01; X-ray; 1.90 A; A/B=561-860.
DR   PDB; 5E1E; X-ray; 2.30 A; A/B=865-1154.
DR   PDB; 5HX8; X-ray; 2.20 A; A/B=854-1154.
DR   PDB; 5IXD; X-ray; 2.85 A; A=35-559.
DR   PDB; 5IXI; X-ray; 2.57 A; A=35-559.
DR   PDB; 5KHW; X-ray; 2.47 A; A/B=841-1154.
DR   PDB; 5KHX; X-ray; 2.40 A; A=841-1154.
DR   PDB; 5L04; X-ray; 2.10 A; A=31-577.
DR   PDB; 5WO4; X-ray; 1.84 A; A/B=854-1154.
DR   PDB; 6AAH; X-ray; 1.83 A; A/B=865-1154.
DR   PDB; 6BBU; X-ray; 2.08 A; A=841-1154.
DR   PDB; 6C7Y; X-ray; 2.50 A; A=869-1153.
DR   PDB; 6DBN; X-ray; 2.48 A; A=841-1154.
DR   PDB; 6ELR; X-ray; 1.80 A; A/B=854-1154.
DR   PDB; 6GGH; X-ray; 1.70 A; A/B=863-1154.
DR   PDB; 6HZU; X-ray; 2.20 A; A/B=854-1154.
DR   PDB; 6N77; X-ray; 1.64 A; A/B=854-1154.
DR   PDB; 6N78; X-ray; 1.83 A; A=854-1154.
DR   PDB; 6N79; X-ray; 2.27 A; A=854-1154.
DR   PDB; 6N7A; X-ray; 1.33 A; A/B=854-1154.
DR   PDB; 6N7B; X-ray; 1.81 A; A=854-1154.
DR   PDB; 6N7C; X-ray; 1.69 A; A/B=854-1154.
DR   PDB; 6N7D; X-ray; 1.78 A; A=854-1154.
DR   PDBsum; 3EYG; -.
DR   PDBsum; 3EYH; -.
DR   PDBsum; 4E4L; -.
DR   PDBsum; 4E4N; -.
DR   PDBsum; 4E5W; -.
DR   PDBsum; 4EHZ; -.
DR   PDBsum; 4EI4; -.
DR   PDBsum; 4FK6; -.
DR   PDBsum; 4GS0; -.
DR   PDBsum; 4I5C; -.
DR   PDBsum; 4IVB; -.
DR   PDBsum; 4IVC; -.
DR   PDBsum; 4IVD; -.
DR   PDBsum; 4K6Z; -.
DR   PDBsum; 4K77; -.
DR   PDBsum; 4L00; -.
DR   PDBsum; 4L01; -.
DR   PDBsum; 5E1E; -.
DR   PDBsum; 5HX8; -.
DR   PDBsum; 5IXD; -.
DR   PDBsum; 5IXI; -.
DR   PDBsum; 5KHW; -.
DR   PDBsum; 5KHX; -.
DR   PDBsum; 5L04; -.
DR   PDBsum; 5WO4; -.
DR   PDBsum; 6AAH; -.
DR   PDBsum; 6BBU; -.
DR   PDBsum; 6C7Y; -.
DR   PDBsum; 6DBN; -.
DR   PDBsum; 6ELR; -.
DR   PDBsum; 6GGH; -.
DR   PDBsum; 6HZU; -.
DR   PDBsum; 6N77; -.
DR   PDBsum; 6N78; -.
DR   PDBsum; 6N79; -.
DR   PDBsum; 6N7A; -.
DR   PDBsum; 6N7B; -.
DR   PDBsum; 6N7C; -.
DR   PDBsum; 6N7D; -.
DR   SMR; P23458; -.
DR   BioGrid; 109919; 118.
DR   CORUM; P23458; -.
DR   DIP; DIP-133N; -.
DR   IntAct; P23458; 80.
DR   MINT; P23458; -.
DR   STRING; 9606.ENSP00000343204; -.
DR   BindingDB; P23458; -.
DR   ChEMBL; CHEMBL2835; -.
DR   DrugBank; DB04716; 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE.
DR   DrugBank; DB11817; Baricitinib.
DR   DrugBank; DB12500; Fedratinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB02375; Myricetin.
DR   DrugBank; DB08877; Ruxolitinib.
DR   DrugBank; DB08895; Tofacitinib.
DR   DrugBank; DB15091; Upadacitinib.
DR   DrugCentral; P23458; -.
DR   GuidetoPHARMACOLOGY; 2047; -.
DR   CarbonylDB; P23458; -.
DR   GlyConnect; 1869; -.
DR   iPTMnet; P23458; -.
DR   PhosphoSitePlus; P23458; -.
DR   SwissPalm; P23458; -.
DR   BioMuta; JAK1; -.
DR   DMDM; 215274013; -.
DR   CPTAC; CPTAC-1251; -.
DR   EPD; P23458; -.
DR   jPOST; P23458; -.
DR   MassIVE; P23458; -.
DR   MaxQB; P23458; -.
DR   PaxDb; P23458; -.
DR   PeptideAtlas; P23458; -.
DR   PRIDE; P23458; -.
DR   ProteomicsDB; 54097; -.
DR   Antibodypedia; 3400; 577 antibodies.
DR   Ensembl; ENST00000342505; ENSP00000343204; ENSG00000162434.
DR   Ensembl; ENST00000671929; ENSP00000500485; ENSG00000162434.
DR   Ensembl; ENST00000671954; ENSP00000500841; ENSG00000162434.
DR   Ensembl; ENST00000672179; ENSP00000500296; ENSG00000162434.
DR   Ensembl; ENST00000672247; ENSP00000499884; ENSG00000162434.
DR   Ensembl; ENST00000672434; ENSP00000499900; ENSG00000162434.
DR   GeneID; 3716; -.
DR   KEGG; hsa:3716; -.
DR   UCSC; uc001dbu.2; human.
DR   CTD; 3716; -.
DR   DisGeNET; 3716; -.
DR   GeneCards; JAK1; -.
DR   HGNC; HGNC:6190; JAK1.
DR   HPA; ENSG00000162434; Low tissue specificity.
DR   MIM; 147795; gene.
DR   neXtProt; NX_P23458; -.
DR   OpenTargets; ENSG00000162434; -.
DR   PharmGKB; PA29988; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00940000157092; -.
DR   HOGENOM; CLU_008155_1_0_1; -.
DR   InParanoid; P23458; -.
DR   KO; K11217; -.
DR   OMA; VFCDFHE; -.
DR   OrthoDB; 58906at2759; -.
DR   PhylomeDB; P23458; -.
DR   TreeFam; TF327041; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-449836; Other interleukin signaling.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6783783; Interleukin-10 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-6788467; IL-6-type cytokine receptor ligand interactions.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling.
DR   Reactome; R-HSA-8854691; Interleukin-20 family signaling.
DR   Reactome; R-HSA-8983432; Interleukin-15 signaling.
DR   Reactome; R-HSA-8984722; Interleukin-35 Signalling.
DR   Reactome; R-HSA-8985947; Interleukin-9 signaling.
DR   Reactome; R-HSA-9020558; Interleukin-2 signaling.
DR   Reactome; R-HSA-9020591; Interleukin-12 signaling.
DR   Reactome; R-HSA-9020956; Interleukin-27 signaling.
DR   Reactome; R-HSA-9020958; Interleukin-21 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912694; Regulation of IFNA signaling.
DR   SignaLink; P23458; -.
DR   SIGNOR; P23458; -.
DR   ChiTaRS; JAK1; human.
DR   EvolutionaryTrace; P23458; -.
DR   GeneWiki; Janus_kinase_1; -.
DR   GenomeRNAi; 3716; -.
DR   Pharos; P23458; Tclin.
DR   PRO; PR:P23458; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P23458; protein.
DR   Bgee; ENSG00000162434; Expressed in blood and 234 other tissues.
DR   Genevisible; P23458; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005131; F:growth hormone receptor binding; ISS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035722; P:interleukin-12-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035723; P:interleukin-15-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038110; P:interleukin-2-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0038114; P:interleukin-21-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070106; P:interleukin-27-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070757; P:interleukin-35-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038111; P:interleukin-7-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038113; P:interleukin-9-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0034112; P:positive regulation of homotypic cell-cell adhesion; IMP:ARUK-UCL.
DR   GO; GO:1903672; P:positive regulation of sprouting angiogenesis; IGI:BHF-UCL.
DR   GO; GO:0150105; P:protein localization to cell-cell junction; IMP:ARUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0060334; P:regulation of interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0046677; P:response to antibiotic; IDA:MGI.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   CDD; cd14473; FERM_B-lobe; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR035963; FERM_2.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR041155; FERM_F1.
DR   InterPro; IPR041046; FERM_F2.
DR   InterPro; IPR041381; Jak1_PHL_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016251; Tyr_kinase_non-rcpt_Jak/Tyk2.
DR   InterPro; IPR020776; Tyr_kinase_non-rcpt_Jak1.
DR   Pfam; PF18379; FERM_F1; 1.
DR   Pfam; PF18377; FERM_F2; 1.
DR   Pfam; PF17887; Jak1_Phl; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 2.
DR   PIRSF; PIRSF000636; TyrPK_Jak; 1.
DR   PRINTS; PR01823; JANUSKINASE.
DR   PRINTS; PR01824; JANUSKINASE1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 2.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Kinase; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; SH2 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   CHAIN           1..1154
FT                   /note="Tyrosine-protein kinase JAK1"
FT                   /id="PRO_0000088108"
FT   DOMAIN          34..420
FT                   /note="FERM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00084"
FT   DOMAIN          439..544
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          583..855
FT                   /note="Protein kinase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          875..1153
FT                   /note="Protein kinase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         881..889
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        1003
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         908
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   MOD_RES         3
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   MOD_RES         228
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19369195"
FT   MOD_RES         1034
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11909529"
FT   MOD_RES         1035
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11909529"
FT   VARIANT         973
FT                   /note="N -> K (in dbSNP:rs34680086)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041715"
FT   CONFLICT        350
FT                   /note="H -> D (in Ref. 1; AAA36527)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        368
FT                   /note="Y -> F (in Ref. 1; AAA36527)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        898
FT                   /note="Missing (in Ref. 1; AAA36527)"
FT                   /evidence="ECO:0000305"
FT   STRAND          36..39
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          43..45
FT                   /evidence="ECO:0000244|PDB:5IXI"
FT   STRAND          48..50
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          52..56
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           57..67
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   TURN            72..74
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           75..77
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          78..82
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   TURN            83..86
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          94..97
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          103..109
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   TURN            114..117
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          121..123
FT                   /evidence="ECO:0000244|PDB:5IXI"
FT   STRAND          149..151
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           152..167
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           179..204
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   TURN            208..210
FT                   /evidence="ECO:0000244|PDB:5IXD"
FT   HELIX           217..220
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           223..230
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           234..252
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           254..259
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           263..277
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          278..280
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          284..289
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          291..293
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          299..304
FT                   /evidence="ECO:0000244|PDB:5IXI"
FT   STRAND          313..318
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   TURN            319..321
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          322..327
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          364..367
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           369..371
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          372..378
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          381..386
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          391..395
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           399..416
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           425..427
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           430..437
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           446..456
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          463..467
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          472..482
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          493..503
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          506..509
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          516..518
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           519..527
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          529..533
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          536..538
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   STRAND          555..557
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           559..562
FT                   /evidence="ECO:0000244|PDB:5L04"
FT   HELIX           569..572
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   STRAND          575..578
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           580..582
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   STRAND          583..592
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   STRAND          595..603
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   STRAND          616..624
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           629..644
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   STRAND          653..659
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   STRAND          662..668
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           675..682
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   TURN            683..685
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           688..707
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           717..719
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   STRAND          720..724
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   STRAND          727..731
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   STRAND          734..737
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           744..746
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           749..754
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   TURN            755..758
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           761..765
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           767..769
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           774..787
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   TURN            788..790
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   TURN            793..796
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           799..807
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           818..827
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           832..834
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           838..848
FT                   /evidence="ECO:0000244|PDB:4L00"
FT   HELIX           872..874
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          875..883
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          885..894
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          898..900
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          902..910
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           919..930
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          940..944
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          947..949
FT                   /evidence="ECO:0000244|PDB:6HZU"
FT   STRAND          953..957
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           964..970
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   TURN            972..974
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           977..996
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          998..1000
FT                   /evidence="ECO:0000244|PDB:4K6Z"
FT   HELIX           1006..1008
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          1009..1013
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          1016..1019
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          1033..1036
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          1039..1041
FT                   /evidence="ECO:0000244|PDB:5KHX"
FT   HELIX           1045..1047
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           1050..1055
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   STRAND          1057..1059
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           1060..1075
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   TURN            1076..1078
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           1080..1082
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           1084..1092
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   TURN            1097..1099
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           1100..1109
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           1122..1129
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           1130..1132
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           1136..1138
FT                   /evidence="ECO:0000244|PDB:6N7A"
FT   HELIX           1142..1153
FT                   /evidence="ECO:0000244|PDB:6N7A"
SQ   SEQUENCE   1154 AA;  133277 MW;  A2C4BE27851ACABB CRC64;
     MQYLNIKEDC NAMAFCAKMR SSKKTEVNLE APEPGVEVIF YLSDREPLRL GSGEYTAEEL
     CIRAAQACRI SPLCHNLFAL YDENTKLWYA PNRTITVDDK MSLRLHYRMR FYFTNWHGTN
     DNEQSVWRHS PKKQKNGYEK KKIPDATPLL DASSLEYLFA QGQYDLVKCL APIRDPKTEQ
     DGHDIENECL GMAVLAISHY AMMKKMQLPE LPKDISYKRY IPETLNKSIR QRNLLTRMRI
     NNVFKDFLKE FNNKTICDSS VSTHDLKVKY LATLETLTKH YGAEIFETSM LLISSENEMN
     WFHSNDGGNV LYYEVMVTGN LGIQWRHKPN VVSVEKEKNK LKRKKLENKH KKDEEKNKIR
     EEWNNFSYFP EITHIVIKES VVSINKQDNK KMELKLSSHE EALSFVSLVD GYFRLTADAH
     HYLCTDVAPP LIVHNIQNGC HGPICTEYAI NKLRQEGSEE GMYVLRWSCT DFDNILMTVT
     CFEKSEQVQG AQKQFKNFQI EVQKGRYSLH GSDRSFPSLG DLMSHLKKQI LRTDNISFML
     KRCCQPKPRE ISNLLVATKK AQEWQPVYPM SQLSFDRILK KDLVQGEHLG RGTRTHIYSG
     TLMDYKDDEG TSEEKKIKVI LKVLDPSHRD ISLAFFEAAS MMRQVSHKHI VYLYGVCVRD
     VENIMVEEFV EGGPLDLFMH RKSDVLTTPW KFKVAKQLAS ALSYLEDKDL VHGNVCTKNL
     LLAREGIDSE CGPFIKLSDP GIPITVLSRQ ECIERIPWIA PECVEDSKNL SVAADKWSFG
     TTLWEICYNG EIPLKDKTLI EKERFYESRC RPVTPSCKEL ADLMTRCMNY DPNQRPFFRA
     IMRDINKLEE QNPDIVSEKK PATEVDPTHF EKRFLKRIRD LGEGHFGKVE LCRYDPEGDN
     TGEQVAVKSL KPESGGNHIA DLKKEIEILR NLYHENIVKY KGICTEDGGN GIKLIMEFLP
     SGSLKEYLPK NKNKINLKQQ LKYAVQICKG MDYLGSRQYV HRDLAARNVL VESEHQVKIG
     DFGLTKAIET DKEYYTVKDD RDSPVFWYAP ECLMQSKFYI ASDVWSFGVT LHELLTYCDS
     DSSPMALFLK MIGPTHGQMT VTRLVNTLKE GKRLPCPPNC PDEVYQLMRK CWEFQPSNRT
     SFQNLIEGFE ALLK
//
ID   Q6P669_HUMAN            Unreviewed;       351 AA.
AC   Q6P669;
DT   05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   05-JUL-2004, sequence version 1.
DT   11-DEC-2019, entry version 73.
DE   SubName: Full=JAK1 protein {ECO:0000313|EMBL:AAH62431.1};
DE   Flags: Fragment;
GN   Name=JAK1 {ECO:0000313|EMBL:AAH62431.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH62431.1};
RN   [1] {ECO:0000313|EMBL:AAH62431.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung {ECO:0000313|EMBL:AAH62431.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC062431; AAH62431.1; -; mRNA.
DR   RefSeq; NP_001307852.1; NM_001320923.1.
DR   PeptideAtlas; Q6P669; -.
DR   PRIDE; Q6P669; -.
DR   GeneID; 3716; -.
DR   KEGG; hsa:3716; -.
DR   CTD; 3716; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   KO; K11217; -.
DR   OrthoDB; 58906at2759; -.
DR   ChiTaRS; JAK1; human.
DR   GenomeRNAi; 3716; -.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   CDD; cd14473; FERM_B-lobe; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR035963; FERM_2.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR041155; FERM_F1.
DR   InterPro; IPR041046; FERM_F2.
DR   InterPro; IPR041381; Jak1_PHL_dom.
DR   Pfam; PF18379; FERM_F1; 1.
DR   Pfam; PF18377; FERM_F2; 1.
DR   Pfam; PF17887; Jak1_Phl; 1.
DR   SMART; SM00295; B41; 1.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   PROSITE; PS50057; FERM_3; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN          34..351
FT                   /note="FERM"
FT                   /evidence="ECO:0000259|PROSITE:PS50057"
FT   COILED          331..351
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   NON_TER         351
FT                   /evidence="ECO:0000313|EMBL:AAH62431.1"
SQ   SEQUENCE   351 AA;  40931 MW;  9763318A8CBF7B3E CRC64;
     MQYLNIKEDC NAMAFCAKMR SSKKTEVNLE APEPGVEVIF YLSDREPLRL GSGEYTAEEL
     CIRAAQACRI SPLCHNLFAL YDENTKLWYA PNRTITVDDK MSLRLHYRMR FYFTNWHGTN
     DNEQSVWRHS PKKQKNGYEK KKIPDATPLL DASSLEYLFA QGQYDLVKCL APIRDPKTEQ
     DGHDIENECL GMAVLAISHY AMMKKMQLPE LPKDISYKRY IPETLNKSIR QRNLLTRMRI
     NNVFKDFLKE FNNKTICDSS VSTHDLKVKY LATLETLTKH YGAEIFETSM LLISSENEMN
     WFHSNDGGNV LYYEVMVTGN LGIQWRHKPN VVSVEKEKNK LKKKKKKKKK K
//
ID   B4E0L8_HUMAN            Unreviewed;      1040 AA.
AC   B4E0L8;
DT   23-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   23-SEP-2008, sequence version 1.
DT   26-FEB-2020, entry version 59.
DE   SubName: Full=cDNA FLJ54396, highly similar to Ubiquitously transcribed X chromosome tetratricopeptide repeat protein {ECO:0000313|EMBL:BAG64480.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG64480.1};
RN   [1] {ECO:0000313|EMBL:BAG64480.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAG64480.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A.,
RA   Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y.,
RA   Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T.,
RA   Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK303430; BAG64480.1; -; mRNA.
DR   RefSeq; NP_001278346.1; NM_001291417.1.
DR   PeptideAtlas; B4E0L8; -.
DR   PRIDE; B4E0L8; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   OrthoDB; 268901at2759; -.
DR   GenomeRNAi; 7403; -.
DR   Gene3D; 1.25.40.10; -; 1.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   Pfam; PF02373; JmjC; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SUPFAM; SSF48452; SSF48452; 1.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
FT   DOMAIN          1..51
FT                   /note="TPR_REGION"
FT                   /evidence="ECO:0000259|PROSITE:PS50293"
FT   DOMAIN          734..897
FT                   /note="JmjC"
FT                   /evidence="ECO:0000259|PROSITE:PS51184"
FT   REGION          96..137
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          263..385
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          397..417
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          449..503
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          553..579
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          682..718
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        449..501
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        556..576
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        685..715
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   1040 AA;  113266 MW;  3F1788AB9AD07098 CRC64;
     MDALQAYICA VQLDHGHAAA WMDLGTLYES CNQPQDAIKC YLNATRSKSC SNTSALAARI
     KYLQACKPHH PNTEPVLGLS QTPISQQSLP LHMIPSSQVD DLSSPAKRKR TSSPTKNTSD
     NWSGGHAVSH PPVQQQAHSW CLTPQKLQMR PTGVAQVRST GIPNGPTADS SLPTNSVSGQ
     QPQLALTRVP SVSQPGVRPA CPGQPLANGP FSAGHVPCST SRTLGSTDTI LIGNNHITGS
     GSNGNVPYLQ RNALTLPHNR TNLTSSAEEP WKNQLSNSTQ GLHKGQSSHS AGPNGERPLS
     STGPSQHLQA AGSGIQNQNG HPTLPSNSVT QGAALNHLSS HTATSGGQQG ITLTKESKPS
     GNILTVPETS RHTGETPNST ASVEGLPNHV HQMTADAVCS PSHGDSKSPG LLSSDNPQLS
     ALLMGKANNN VGTGTCDKVN NIHPAVHTKT DNSVASSPSS AISTATPSPK STEQTTTNSV
     TSLNSPHSGL HTINGEGMEE SQSPMKTDLL LVNHKPSPQI IPSMSVSIYP SSAEVLKACR
     NLGKNGLSNS SILLDKCPPP RPPSSPYPPL PKDKLNPPTP SIYLENKRDA FFPPLHQFCT
     NPNNPVTVIR GLAGALKLDL GLFSTKTLVE ANNEHMVEVR TQLLQPADEN WDPTGTKKIW
     HCESNRSHTT IAKYAQYQAS SFQESLREEN EKRSHHKDHS DSESTSSDNS GRRRKGPFKT
     IKFGTNIDLS DDKKWKLQLH ELTKLPAFVR VVSAGNLLSH VGHTILGMNT VQLYMKVPGS
     RTPGHQENNN FCSVNINIGP GDCEWFVVPE GYWGVLNDFC EKNNLNFLMG SWWPNLEDLY
     EANVPVYRFI QRPGDLVWIN AGTVHWVQAI GWCNNIAWNV GPLTACQYKL AVERYEWNKL
     QSVKSIVPMV HLSWNMARNI KVSDPKLFEM IKYCLLRTLK QCQTLREALI AAGKEIIWHG
     RTKEEPAHYC SICEVEVFDL LFVTNESNSR KTYIVHCQDC ARKTSGNLEN FVVLEQYKME
     DLMQVYDQFT LAPPLPSASS
//
ID   B7ZKN1_HUMAN            Unreviewed;      1408 AA.
AC   B7ZKN1;
DT   03-MAR-2009, integrated into UniProtKB/TrEMBL.
DT   03-MAR-2009, sequence version 1.
DT   11-DEC-2019, entry version 62.
DE   SubName: Full=UTX protein {ECO:0000313|EMBL:AAI43273.1};
GN   Name=UTX {ECO:0000313|EMBL:AAI43273.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAI43273.1};
RN   [1] {ECO:0000313|EMBL:AAI43273.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAI43273.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC143272; AAI43273.1; -; mRNA.
DR   RefSeq; NP_001278345.1; NM_001291416.1.
DR   MaxQB; B7ZKN1; -.
DR   PeptideAtlas; B7ZKN1; -.
DR   PRIDE; B7ZKN1; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   OrthoDB; 268901at2759; -.
DR   ChiTaRS; KDM6A; human.
DR   GenomeRNAi; 7403; -.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 1.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN          93..385
FT                   /note="TPR_REGION"
FT                   /evidence="ECO:0000259|PROSITE:PS50293"
FT   REPEAT          93..126
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          130..163
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          205..238
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          250..283
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          284..317
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          318..351
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          352..385
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   DOMAIN          1102..1265
FT                   /note="JmjC"
FT                   /evidence="ECO:0000259|PROSITE:PS51184"
FT   REGION          430..471
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          631..753
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          765..785
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          817..871
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          921..948
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1050..1086
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        817..869
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        924..944
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1053..1083
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   1408 AA;  154955 MW;  F6DFF398109BE162 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASPS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLYGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIQFH IAHLYETQRK YHSAKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQAC KPHHPNTEPV LGLSQTPISQ
     QSLPLHMIPS SQVDDLSSPA KRKRTSSPTK NTSDNWSGGH AVSHPPVQQQ AHSWCLTPQK
     LQHLEQLRAN RNNLNPAQKL MLEQLESQFV LMQQHQMRPT GVAQVRSTGI PNGPTADSSL
     PTNSVSGQQP QLALTRVPSV SQPGVRPACP GQPLANGPFS AGHVPCSTSR TLGSTDTILI
     GNNHITGSGS NGNVPYLQRN ALTLPHNRTN LTSSAEEPWK NQLSNSTQGL HKGQSSHSAG
     PNGERPLSST GPSQHLQAAG SGIQNQNGHP TLPSNSVTQG AALNHLSSHT ATSGGQQGIT
     LTKESKPSGN ILKVPETSRH TGETPNSTAS VEGLPNHVHQ MTADAVCSPS HGDSKSPGLL
     SSDNPQLSAL LMGKANNNVG TGTCDKVNNI HPAVHTKTDN SVASSPSSAI STATPSPKST
     EQTTTNSVTS LNSPHSGLHT INGEGMEESQ SPMKTDLLLV NHKPSPQIIP SMSVSIYPSS
     AEVLKACRNL GKNGLSNSSI LLDKCPPPRP PSSPYPPLPK DKLNPPTPSI YLENKRDAFF
     PPLHQFCTNP NNPVTVIRGL AGALKLDLGL FSTKTLVEAN NEHMVEVRTQ LLQPADENWD
     PTGTKKIWHC ESNRSHTTIA KYAQYQASSF QESLREENEK RSHHKDHSDS ESTSSDNSGR
     RRKGPFKTIK FGTNIDLSDD KKWKLQLHEL TKLPAFVRVV SAGNLLSHVG HTILGMNTVQ
     LYMKVPGSRT PGHQENNNFC SVNINIGPGD CEWFVVPEGY WGVLNDFCEK NNLNFLMGSW
     WPNLEDLYEA NVPVYRFIQR PGDLVWINAG TVHWVQAIGW CNNIAWNVGP LTACQYKLAV
     ERYEWNKLQS VKSIVPMVHL SWNMARNIKV SDPKLFEMIK YCLLRTLKQC QTLREALIAA
     GKEIIWHGRT KEEPAHYCSI CEVEVFDLLF VTNESNSRKT YIVHCQDCAR KTSGNLENFV
     VLEQYKMEDL MQVYDQFTLA PPLPSASS
//
ID   B7ZKN5_HUMAN            Unreviewed;      1453 AA.
AC   B7ZKN5;
DT   03-MAR-2009, integrated into UniProtKB/TrEMBL.
DT   03-MAR-2009, sequence version 1.
DT   26-FEB-2020, entry version 67.
DE   SubName: Full=UTX protein {ECO:0000313|EMBL:AAI43278.1};
GN   Name=UTX {ECO:0000313|EMBL:AAI43278.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAI43278.1};
RN   [1] {ECO:0000313|EMBL:AAI43278.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAI43278.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC143277; AAI43278.1; -; mRNA.
DR   RefSeq; NP_001278344.1; NM_001291415.1.
DR   SMR; B7ZKN5; -.
DR   MaxQB; B7ZKN5; -.
DR   PeptideAtlas; B7ZKN5; -.
DR   PRIDE; B7ZKN5; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   OrthoDB; 268901at2759; -.
DR   ChiTaRS; KDM6A; human.
DR   GenomeRNAi; 7403; -.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN          93..385
FT                   /note="TPR_REGION"
FT                   /evidence="ECO:0000259|PROSITE:PS50293"
FT   REPEAT          93..126
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          130..163
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          205..238
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          250..283
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          284..317
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          318..351
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          352..385
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   DOMAIN          1147..1310
FT                   /note="JmjC"
FT                   /evidence="ECO:0000259|PROSITE:PS51184"
FT   REGION          439..458
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          475..514
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          676..798
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          810..830
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          862..916
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          966..992
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1095..1131
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        862..914
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        969..989
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1098..1128
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   1453 AA;  159815 MW;  3E833ACA6C55C587 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASPS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLYGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIQFH IAHLYETQRK YHSAKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQAQ LCNLPQGSLQ NKTKLLPSIE
     EAWSLPIPAE LTSRQGAMNT AQQACKPHHP NTEPVLGLSQ TPISQQSLPL HMIPSSQVDD
     LSSPAKRKRT SSPTKNTSDN WSGGHAVSHP PVQQQAHSWC LTPQKLQHLE QLRANRNNLN
     PAQKLMLEQL ESQFVLMQQH QMRPTGVAQV RSTGIPNGPT ADSSLPTNSV SGQQPQLALT
     RVPSVSQPGV RPACPGQPLA NGPFSAGHVP CSTSRTLGST DTILIGNNHI TGSGSNGNVP
     YLQRNALTLP HNRTNLTSSA EEPWKNQLSN STQGLHKGQS SHSAGPNGER PLSSTGPSQH
     LQAAGSGIQN QNGHPTLPSN SVTQGAALNH LSSHTATSGG QQGITLTKES KPSGNILKVP
     ETSRHTGETP NSTASVEGLP NHVHQMTADA VCSPSHGDSK SPGLLSSDNP QLSALLMGKA
     NNNVGTGTCD KVNNIHPAVH TKTDNSVASS PSSAISTATP SPKSTEQTTT NSVTSLNSPH
     SGLHTINGEG MEESQSPMKT DLLLVNHKPS PQIIPSMSVS IYPSSAEVLK ACRNLGKNGL
     SNSSILLDKC PPPRPPSSPY PPLPKDKLNP PTPSIYLENK RDAFFPPLHQ FCTNPNNPVT
     VIRGLAGALK LDLGLFSTKT LVEANNEHMV EVRTQLLQPA DENWDPTGTK KIWHCESNRS
     HTTIAKYAQY QASSFQESLR EENEKRSHHK DHSDSESTSS DNSGRRRKGP FKTIKFGTNI
     DLSDDKKWKL QLHELTKLPA FVRVVSAGNL LSHVGHTILG MNTVQLYMKV PGSRTPGHQE
     NNNFCSVNIN IGPGDCEWFV VPEGYWGVLN DFCEKNNLNF LMGSWWPNLE DLYEANVPVY
     RFIQRPGDLV WINAGTVHWV QAIGWCNNIA WNVGPLTACQ YKLAVERYEW NKLQSVKSIV
     PMVHLSWNMA RNIKVSDPKL FEMIKYCLLR TLKQCQTLRE ALIAAGKEII WHGRTKEEPA
     HYCSICEVEV FDLLFVTNES NSRKTYIVHC QDCARKTSGN LENFVVLEQY KMEDLMQVYD
     QFTLAPPLPS ASS
//
ID   B7ZKN6_HUMAN            Unreviewed;      1356 AA.
AC   B7ZKN6;
DT   03-MAR-2009, integrated into UniProtKB/TrEMBL.
DT   03-MAR-2009, sequence version 1.
DT   11-DEC-2019, entry version 58.
DE   SubName: Full=UTX protein {ECO:0000313|EMBL:AAI43279.1};
GN   Name=UTX {ECO:0000313|EMBL:AAI43279.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAI43279.1};
RN   [1] {ECO:0000313|EMBL:AAI43279.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAI43279.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC143278; AAI43279.1; -; mRNA.
DR   RefSeq; NP_001278344.1; NM_001291415.1.
DR   RefSeq; NP_001278345.1; NM_001291416.1.
DR   RefSeq; NP_001278346.1; NM_001291417.1.
DR   RefSeq; NP_001278347.1; NM_001291418.1.
DR   RefSeq; NP_001278350.1; NM_001291421.1.
DR   PeptideAtlas; B7ZKN6; -.
DR   PRIDE; B7ZKN6; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   OrthoDB; 268901at2759; -.
DR   ChiTaRS; KDM6A; human.
DR   GenomeRNAi; 7403; -.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN          93..385
FT                   /note="TPR_REGION"
FT                   /evidence="ECO:0000259|PROSITE:PS50293"
FT   REPEAT          93..126
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          130..163
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          205..238
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          250..283
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          284..317
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          318..351
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          352..385
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   DOMAIN          1050..1213
FT                   /note="JmjC"
FT                   /evidence="ECO:0000259|PROSITE:PS51184"
FT   REGION          579..701
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          713..733
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          765..819
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          869..895
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          998..1034
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        765..817
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        872..892
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1001..1031
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   1356 AA;  149287 MW;  C64C8E56F8301807 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASPS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLYGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIQFH IAHLYETQRK YHSAKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQNT SDNWSGGHAV SHPPVQQQAH
     SWCLTPQKLQ HLEQLRANRN NLNPAQKLML EQLESQFVLM QQHQMRPTGV AQVRSTGIPN
     GPTADSSLPT NSVSGQQPQL ALTRVPSVSQ PGVRPACPGQ PLANGPFSAG HVPCSTSRTL
     GSTDTILIGN NHITGSGSNG NVPYLQRNAL TLPHNRTNLT SSAEEPWKNQ LSNSTQGLHK
     GQSSHSAGPN GERPLSSTGP SQHLQAAGSG IQNQNGHPTL PSNSVTQGAA LNHLSSHTAT
     SGGQQGITLT KESKPSGNIL TVPETSRHTG ETPNSTASVE GLPNHVHQMT ADAVCSPSHG
     DSKSPGLLSS DNPQLSALLM GKANNNVGTG TCDKVNNIHP AVHTKTDNSV ASSPSSAIST
     ATPSPKSTEQ TTTNSVTSLN SPHSGLHTIN GEGMEESQSP MKTDLLLVNH KPSPQIIPSM
     SVSIYPSSAE VLKACRNLGK NGLSNSSILL DKCPPPRPPS SPYPPLPKDK LNPPTPSIYL
     ENKRDAFFPP LHQFCTNPNN PVTVIRGLAG ALKLDLGLFS TKTLVEANNE HMVEVRTQLL
     QPADENWDPT GTKKIWHCES NRSHTTIAKY AQYQASSFQE SLREENEKRS HHKDHSDSES
     TSSDNSGRRR KGPFKTIKFG TNIDLSDDKK WKLQLHELTK LPAFVRVVSA GNLLSHVGHT
     ILGTNTVQLY MKVPGSRTPG HQENNNFCSV NINIGPGDCE WFVVPEGYWG VLNDFCEKNN
     LNFLMGSWWP NLEDLYEANV PVYRFIQRPG DLVWINAGTV HWVQAIGWCN NIAWNVGPLT
     ACQYKLAVER YEWNKLQSVK SIVPMVHLSW NMARNIKVSD PKLFEMIKYC LLRTLKQCQT
     LREALIAAGK EIIWHGRTKE EPAHYCSICE VEVFDLLFVT NESNSRKTYI VHCQDCARKT
     SGNLENFVVL EQYKMEDLMQ VYDQFTLAPP LPSASS
//
ID   E1U0S6_HUMAN            Unreviewed;      1322 AA.
AC   E1U0S6;
DT   30-NOV-2010, integrated into UniProtKB/TrEMBL.
DT   30-NOV-2010, sequence version 1.
DT   11-DEC-2019, entry version 47.
DE   SubName: Full=Ubiquitously transcribed tetratricopeptide repeat protein X-linked, transcript variant 5 {ECO:0000313|EMBL:AAZ06656.1};
GN   Name=UTX {ECO:0000313|EMBL:AAZ06656.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAZ06656.1};
RN   [1] {ECO:0000313|EMBL:AAZ06656.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Laaser I., Kolb H.-J., Adamski J.;
RT   "Splice variants of human UTX.";
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ062677; AAZ06656.1; -; mRNA.
DR   RefSeq; NP_001278347.1; NM_001291418.1.
DR   PeptideAtlas; E1U0S6; -.
DR   PRIDE; E1U0S6; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   OrthoDB; 268901at2759; -.
DR   ChiTaRS; KDM6A; human.
DR   GenomeRNAi; 7403; -.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   Pfam; PF02373; JmjC; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN          93..385
FT                   /note="TPR_REGION"
FT                   /evidence="ECO:0000259|PROSITE:PS50293"
FT   REPEAT          93..126
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          130..163
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          205..238
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          250..283
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          284..317
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          318..351
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          352..385
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   DOMAIN          1016..1179
FT                   /note="JmjC"
FT                   /evidence="ECO:0000259|PROSITE:PS51184"
FT   REGION          545..667
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          679..699
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          731..785
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          835..863
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          964..1000
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        731..783
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        838..858
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        967..997
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   1322 AA;  145156 MW;  90449E57B0D81F04 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASLS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLHGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIPFH IAHLYETQRK YHSTKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQNT SDNWSGGHAV SHPPVQQQAH
     SWCLTPQKLQ MSPTGVAQVR STGIPNGPTA DSSLPTNSVS GQQPRLALTR VPSVSQPGVR
     PACPGQPLAN GPFSAGHVPC STSRTLGSTD TILIGNNHIT GSGSNGNVPY LQRNALTLPH
     NRTNLTSSAE EPWKNQLSNS TQGLHKGQSS HSAGPNGERP LSSTGPSQHL QAAGSGIQNQ
     NGHPTLPSNS VTQGAALNHL SSHTATSGGQ QGITLTKESK PSGNILTVPE TSRHTGETPN
     STASVEGLPN HVHQMTADAV CSPSHGDSKS PGLLSSDNPQ LSALLMGKAN NNVGTGTCDK
     VNNIHPAVHT KTDNSVASSP SSAISTATPS PKSTEQTTTN SVTSLNSPHS GLHTINGEGM
     EESQSPMKTD LLLVNHKPSP QIIPSMSVSI YPSSAEVLKA CRNLGKNGLS NSSILLDKCP
     PPRPPSSPYP PLPKDKLNPP TPSIYLENKR DAFFPPLHQF CTNPNNPVTV IRGLAGALKL
     DLGLFSTKTL VEANNEHMVE VRTQSLQPAD ENWDPTGTKK IWHCESNRSH TTIAKYAQYQ
     ASSFQESLRE ENEKRSHHKD HSDSESTSSD NSGRRRKGPF KTIKFGTNID LSDDKKWKLQ
     LHELTKLPAF VRVVSAGNLL SHVGHTILGM NTVQLYMKVP GSRTPGHQEN NNFCSVNINI
     GPGDCEWFVV PEGYWGVLND FCEKNNLNFL MGSWWPNLED LYEANVPVYR FIQRPGDLVW
     INAGTVHWVQ AIGWCNNIAW NVGPLTACQY KLAVERYEWN KLQSVKSIVP MVHLSWNMAR
     NIKVSDPKLF EMIKYCLLRT LKQCQTLREA LIAAGKEIIW HGRTKEEPAH YCSICEVEVF
     DLLFVTNESN SRKTYIVHCQ DCARKTSGNL ENFVVLEQYK MEDLMQVYDQ FTLAPPLPSA
     SS
//
ID   KDM6A_HUMAN             Reviewed;        1401 AA.
AC   O15550; Q52LL9; Q5JVQ7;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 2.
DT   22-APR-2020, entry version 193.
DE   RecName: Full=Lysine-specific demethylase 6A;
DE            EC=1.14.11.- {ECO:0000269|PubMed:17713478, ECO:0000269|PubMed:17761849, ECO:0000269|PubMed:17851529, ECO:0000269|PubMed:18003914};
DE   AltName: Full=Histone demethylase UTX;
DE   AltName: Full=Ubiquitously-transcribed TPR protein on the X chromosome;
DE   AltName: Full=Ubiquitously-transcribed X chromosome tetratricopeptide repeat protein;
GN   Name=KDM6A; Synonyms=UTX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9381176; DOI=10.1126/science.278.5338.675;
RA   Lahn B.T., Page D.C.;
RT   "Functional coherence of the human Y chromosome.";
RL   Science 278:675-680(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-726.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MLL2/3
RP   COMPLEX.
RX   PubMed=17500065; DOI=10.1074/jbc.m701574200;
RA   Cho Y.-W., Hong T., Hong S., Guo H., Yu H., Kim D., Guszczynski T.,
RA   Dressler G.R., Copeland T.D., Kalkum M., Ge K.;
RT   "PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4
RT   methyltransferase complex.";
RL   J. Biol. Chem. 282:20395-20406(2007).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-1146.
RX   PubMed=17851529; DOI=10.1038/nature06192;
RA   Lan F., Bayliss P.E., Rinn J.L., Whetstine J.R., Wang J.K., Chen S.,
RA   Iwase S., Alpatov R., Issaeva I., Canaani E., Roberts T.M., Chang H.Y.,
RA   Shi Y.;
RT   "A histone H3 lysine 27 demethylase regulates animal posterior
RT   development.";
RL   Nature 449:689-694(2007).
RN   [7]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=17713478; DOI=10.1038/nature06145;
RA   Agger K., Cloos P.A., Christensen J., Pasini D., Rose S., Rappsilber J.,
RA   Issaeva I., Canaani E., Salcini A.E., Helin K.;
RT   "UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene
RT   regulation and development.";
RL   Nature 449:731-734(2007).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-1146.
RX   PubMed=18003914; DOI=10.1073/pnas.0707292104;
RA   Hong S., Cho Y.W., Yu L.-R., Yu H., Veenstra T.D., Ge K.;
RT   "Identification of JmjC domain-containing UTX and JMJD3 as histone H3
RT   lysine 27 demethylases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:18439-18444(2007).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, MUTAGENESIS OF HIS-1146, AND
RP   IDENTIFICATION IN THE MLL2/3 COMPLEX.
RX   PubMed=17761849; DOI=10.1126/science.1149042;
RA   Lee M.G., Villa R., Trojer P., Norman J., Yan K.P., Reinberg D.,
RA   Di Croce L., Shiekhattar R.;
RT   "Demethylation of H3K27 regulates polycomb recruitment and H2A
RT   ubiquitination.";
RL   Science 318:447-450(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-769 AND SER-829, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   INVOLVEMENT IN KABUK2.
RX   PubMed=22197486; DOI=10.1016/j.ajhg.2011.11.021;
RA   Lederer D., Grisart B., Digilio M.C., Benoit V., Crespin M., Ghariani S.C.,
RA   Maystadt I., Dallapiccola B., Verellen-Dumoulin C.;
RT   "Deletion of KDM6A, a histone demethylase interacting with MLL2, in three
RT   patients with Kabuki syndrome.";
RL   Am. J. Hum. Genet. 90:119-124(2012).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-829, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 880-1401 IN COMPLEX WITH HISTONE
RP   H3 PEPTIDE, IRON-BINDING SITES, AND ZINC-BINDING SITES.
RX   PubMed=22002947; DOI=10.1101/gad.172296.111;
RA   Sengoku T., Yokoyama S.;
RT   "Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A.";
RL   Genes Dev. 25:2266-2277(2011).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-1106.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [16]
RP   VARIANTS VAL-270; ASP-834 AND LYS-922.
RX   PubMed=21828135; DOI=10.1182/blood-2010-10-311019;
RA   Jankowska A.M., Makishima H., Tiu R.V., Szpurka H., Huang Y., Traina F.,
RA   Visconte V., Sugimoto Y., Prince C., O'Keefe C., Hsi E.D., List A.,
RA   Sekeres M.A., Rao A., McDevitt M.A., Maciejewski J.P.;
RT   "Mutational spectrum analysis of chronic myelomonocytic leukemia includes
RT   genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.";
RL   Blood 118:3932-3941(2011).
CC   -!- FUNCTION: Histone demethylase that specifically demethylates 'Lys-27'
CC       of histone H3, thereby playing a central role in histone code
CC       (PubMed:17851529, PubMed:17713478, PubMed:17761849). Demethylates
CC       trimethylated and dimethylated but not monomethylated H3 'Lys-27'
CC       (PubMed:17851529, PubMed:17713478, PubMed:17761849). Plays a central
CC       role in regulation of posterior development, by regulating HOX gene
CC       expression (PubMed:17851529). Demethylation of 'Lys-27' of histone H3
CC       is concomitant with methylation of 'Lys-4' of histone H3, and regulates
CC       the recruitment of the PRC1 complex and monoubiquitination of histone
CC       H2A (PubMed:17761849). Plays a demethylase-independent role in
CC       chromatin remodeling to regulate T-box family member-dependent gene
CC       expression (By similarity). {ECO:0000250|UniProtKB:O70546,
CC       ECO:0000269|PubMed:17713478, ECO:0000269|PubMed:17761849,
CC       ECO:0000269|PubMed:17851529, ECO:0000269|PubMed:18003914}.
CC   -!- COFACTOR:
CC       Name=L-ascorbate; Xref=ChEBI:CHEBI:38290;
CC         Evidence={ECO:0000269|PubMed:17761849};
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:17761849};
CC   -!- SUBUNIT: Interacts with TLE1 (By similarity). Component of the MLL2/3
CC       complex (also named ASCOM complex), at least composed of KMT2D/MLL2 or
CC       KMT2C/MLL3, ASH2L, RBBP5, WDR5, NCOA6, DPY30, KDM6A (or KDM6B),
CC       PAXIP1/PTIP, PAGR1 and alpha- and beta-tubulin (PubMed:17500065,
CC       PubMed:17713478). Interacts with SUPT6H. Interacts with SMARCA4 (By
CC       similarity). {ECO:0000250|UniProtKB:O70546,
CC       ECO:0000269|PubMed:17500065, ECO:0000269|PubMed:17713478}.
CC   -!- INTERACTION:
CC       O15550; O15499: GSC2; NbExp=3; IntAct=EBI-4292203, EBI-19954058;
CC       O15550; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-4292203, EBI-16439278;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- DISEASE: Kabuki syndrome 2 (KABUK2) [MIM:300867]: A congenital mental
CC       retardation syndrome with additional features, including postnatal
CC       dwarfism, a peculiar facies characterized by long palpebral fissures
CC       with eversion of the lateral third of the lower eyelids, a broad and
CC       depressed nasal tip, large prominent earlobes, a cleft or high-arched
CC       palate, scoliosis, short fifth finger, persistence of fingerpads,
CC       radiographic abnormalities of the vertebrae, hands, and hip joints, and
CC       recurrent otitis media in infancy. {ECO:0000269|PubMed:22197486}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: Escapes X chromosome inactivation.
CC   -!- SIMILARITY: Belongs to the UTX family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF000992; AAC51839.1; -; mRNA.
DR   EMBL; AF000993; AAC51840.1; -; mRNA.
DR   EMBL; AC136488; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133545; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL138744; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471141; EAW59368.1; -; Genomic_DNA.
DR   EMBL; BC093868; AAH93868.1; -; mRNA.
DR   EMBL; BC113381; AAI13382.1; -; mRNA.
DR   CCDS; CCDS14265.1; -.
DR   PIR; T02255; T02255.
DR   RefSeq; NP_066963.2; NM_021140.3.
DR   PDB; 3AVR; X-ray; 1.80 A; A=880-1401.
DR   PDB; 3AVS; X-ray; 1.85 A; A=880-1401.
DR   PDB; 6FUK; X-ray; 2.00 A; A=877-1401.
DR   PDB; 6FUL; X-ray; 1.65 A; A=877-1401.
DR   PDBsum; 3AVR; -.
DR   PDBsum; 3AVS; -.
DR   PDBsum; 6FUK; -.
DR   PDBsum; 6FUL; -.
DR   SMR; O15550; -.
DR   BioGrid; 113246; 58.
DR   CORUM; O15550; -.
DR   DIP; DIP-46192N; -.
DR   IntAct; O15550; 19.
DR   MINT; O15550; -.
DR   STRING; 9606.ENSP00000367203; -.
DR   BindingDB; O15550; -.
DR   ChEMBL; CHEMBL2069164; -.
DR   GuidetoPHARMACOLOGY; 2684; -.
DR   iPTMnet; O15550; -.
DR   PhosphoSitePlus; O15550; -.
DR   BioMuta; KDM6A; -.
DR   EPD; O15550; -.
DR   jPOST; O15550; -.
DR   MassIVE; O15550; -.
DR   MaxQB; O15550; -.
DR   PaxDb; O15550; -.
DR   PeptideAtlas; O15550; -.
DR   PRIDE; O15550; -.
DR   ProteomicsDB; 48752; -.
DR   Antibodypedia; 639; 189 antibodies.
DR   Ensembl; ENST00000377967; ENSP00000367203; ENSG00000147050.
DR   GeneID; 7403; -.
DR   KEGG; hsa:7403; -.
DR   UCSC; uc004dge.5; human.
DR   CTD; 7403; -.
DR   DisGeNET; 7403; -.
DR   GeneCards; KDM6A; -.
DR   GeneReviews; KDM6A; -.
DR   HGNC; HGNC:12637; KDM6A.
DR   HPA; ENSG00000147050; Low tissue specificity.
DR   MalaCards; KDM6A; -.
DR   MIM; 300128; gene.
DR   MIM; 300867; phenotype.
DR   neXtProt; NX_O15550; -.
DR   OpenTargets; ENSG00000147050; -.
DR   Orphanet; 2322; Kabuki syndrome.
DR   PharmGKB; PA37262; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   GeneTree; ENSGT00940000155202; -.
DR   InParanoid; O15550; -.
DR   KO; K11447; -.
DR   OrthoDB; 268901at2759; -.
DR   PhylomeDB; O15550; -.
DR   TreeFam; TF317405; -.
DR   Reactome; R-HSA-3214842; HDMs demethylate histones.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   ChiTaRS; KDM6A; human.
DR   GeneWiki; UTX_(gene); -.
DR   GenomeRNAi; 7403; -.
DR   Pharos; O15550; Tchem.
DR   PRO; PR:O15550; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; O15550; protein.
DR   Bgee; ENSG00000147050; Expressed in kidney and 222 other tissues.
DR   ExpressionAtlas; O15550; baseline and differential.
DR   Genevisible; O15550; HS.
DR   GO; GO:0035097; C:histone methyltransferase complex; IDA:MGI.
DR   GO; GO:0044666; C:MLL3/4 complex; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0031490; F:chromatin DNA binding; IBA:GO_Central.
DR   GO; GO:0051213; F:dioxygenase activity; IEA:UniProtKB-KW.
DR   GO; GO:0071558; F:histone demethylase activity (H3-K27 specific); IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0072358; P:cardiovascular system development; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB.
DR   GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0051568; P:histone H3-K4 methylation; ISS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0048333; P:mesodermal cell differentiation; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0001843; P:neural tube closure; IEA:Ensembl.
DR   GO; GO:0048570; P:notochord morphogenesis; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0003016; P:respiratory system process; IEA:Ensembl.
DR   GO; GO:0032525; P:somite rostral/caudal axis specification; IEA:Ensembl.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chromatin regulator; Dioxygenase; Iron; Mental retardation;
KW   Metal-binding; Methylation; Nucleus; Oxidoreductase; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; TPR repeat; Zinc.
FT   CHAIN           1..1401
FT                   /note="Lysine-specific demethylase 6A"
FT                   /id="PRO_0000106409"
FT   REPEAT          93..126
FT                   /note="TPR 1"
FT   REPEAT          130..163
FT                   /note="TPR 2"
FT   REPEAT          170..199
FT                   /note="TPR 3"
FT   REPEAT          205..238
FT                   /note="TPR 4"
FT   REPEAT          250..283
FT                   /note="TPR 5"
FT   REPEAT          284..317
FT                   /note="TPR 6"
FT   REPEAT          318..351
FT                   /note="TPR 7"
FT   REPEAT          352..385
FT                   /note="TPR 8"
FT   DOMAIN          1095..1258
FT                   /note="JmjC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00538"
FT   REGION          1..1095
FT                   /note="Interaction with SUPT6H"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        9..17
FT                   /note="Poly-Ala"
FT   METAL           1146
FT                   /note="Iron"
FT                   /evidence="ECO:0000269|PubMed:22002947"
FT   METAL           1148
FT                   /note="Iron"
FT                   /evidence="ECO:0000269|PubMed:22002947"
FT   METAL           1226
FT                   /note="Iron"
FT                   /evidence="ECO:0000269|PubMed:22002947"
FT   METAL           1331
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:22002947"
FT   METAL           1334
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:22002947"
FT   METAL           1358
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:22002947"
FT   METAL           1361
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:22002947"
FT   MOD_RES         519
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:O70546"
FT   MOD_RES         549
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:O70546"
FT   MOD_RES         769
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         827
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O70546"
FT   MOD_RES         829
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:23186163"
FT   VARIANT         30
FT                   /note="A -> T (in dbSNP:rs6529)"
FT                   /id="VAR_014492"
FT   VARIANT         270
FT                   /note="I -> V (in a patient with chronic myelomonocytic
FT                   leukemia)"
FT                   /evidence="ECO:0000269|PubMed:21828135"
FT                   /id="VAR_067225"
FT   VARIANT         497
FT                   /note="Q -> H (in dbSNP:rs6530)"
FT                   /id="VAR_014493"
FT   VARIANT         581
FT                   /note="T -> A (in dbSNP:rs34922269)"
FT                   /id="VAR_046527"
FT   VARIANT         726
FT                   /note="T -> K (in dbSNP:rs2230018)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_020313"
FT   VARIANT         834
FT                   /note="E -> D (in a patient with chronic myelomonocytic
FT                   leukemia)"
FT                   /evidence="ECO:0000269|PubMed:21828135"
FT                   /id="VAR_067226"
FT   VARIANT         922
FT                   /note="R -> K (in a patient with chronic myelomonocytic
FT                   leukemia)"
FT                   /evidence="ECO:0000269|PubMed:21828135"
FT                   /id="VAR_067227"
FT   VARIANT         1106
FT                   /note="L -> R (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035871"
FT   MUTAGEN         1146
FT                   /note="H->A: Abolishes histone demethylase activity."
FT                   /evidence="ECO:0000269|PubMed:17761849,
FT                   ECO:0000269|PubMed:17851529, ECO:0000269|PubMed:18003914"
FT   CONFLICT        173
FT                   /note="L -> V (in Ref. 1; AAC51839/AAC51840)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        585
FT                   /note="L -> R (in Ref. 1; AAC51839/AAC51840)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        601
FT                   /note="S -> N (in Ref. 1; AAC51839/AAC51840)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        629
FT                   /note="E -> K (in Ref. 1; AAC51839/AAC51840)"
FT                   /evidence="ECO:0000305"
FT   HELIX           893..900
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           933..935
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          942..944
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           948..951
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           955..961
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          966..971
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           973..977
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           981..984
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           986..993
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          997..1004
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1016..1019
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1025..1031
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1032..1047
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1081..1089
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   TURN            1093..1095
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1097..1103
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1108..1110
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1118..1121
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1122..1124
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   TURN            1127..1129
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1133..1137
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1142..1146
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1149..1151
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1153..1162
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1164..1169
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1171..1173
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1174..1183
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   TURN            1188..1190
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1197..1202
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1208..1212
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1217..1220
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1225..1241
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1243..1245
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1246..1262
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1270..1280
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1286..1312
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1317..1319
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   TURN            1332..1334
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1340..1345
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1346..1350
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1351..1357
FT                   /evidence="ECO:0000244|PDB:3AVR"
FT   HELIX           1359..1365
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   STRAND          1372..1376
FT                   /evidence="ECO:0000244|PDB:6FUL"
FT   HELIX           1380..1389
FT                   /evidence="ECO:0000244|PDB:6FUL"
SQ   SEQUENCE   1401 AA;  154177 MW;  9DD7EA6C61E79229 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASPS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLYGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIQFH IAHLYETQRK YHSAKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQAQ LCNLPQGSLQ NKTKLLPSIE
     EAWSLPIPAE LTSRQGAMNT AQQNTSDNWS GGHAVSHPPV QQQAHSWCLT PQKLQHLEQL
     RANRNNLNPA QKLMLEQLES QFVLMQQHQM RPTGVAQVRS TGIPNGPTAD SSLPTNSVSG
     QQPQLALTRV PSVSQPGVRP ACPGQPLANG PFSAGHVPCS TSRTLGSTDT ILIGNNHITG
     SGSNGNVPYL QRNALTLPHN RTNLTSSAEE PWKNQLSNST QGLHKGQSSH SAGPNGERPL
     SSTGPSQHLQ AAGSGIQNQN GHPTLPSNSV TQGAALNHLS SHTATSGGQQ GITLTKESKP
     SGNILTVPET SRHTGETPNS TASVEGLPNH VHQMTADAVC SPSHGDSKSP GLLSSDNPQL
     SALLMGKANN NVGTGTCDKV NNIHPAVHTK TDNSVASSPS SAISTATPSP KSTEQTTTNS
     VTSLNSPHSG LHTINGEGME ESQSPMKTDL LLVNHKPSPQ IIPSMSVSIY PSSAEVLKAC
     RNLGKNGLSN SSILLDKCPP PRPPSSPYPP LPKDKLNPPT PSIYLENKRD AFFPPLHQFC
     TNPNNPVTVI RGLAGALKLD LGLFSTKTLV EANNEHMVEV RTQLLQPADE NWDPTGTKKI
     WHCESNRSHT TIAKYAQYQA SSFQESLREE NEKRSHHKDH SDSESTSSDN SGRRRKGPFK
     TIKFGTNIDL SDDKKWKLQL HELTKLPAFV RVVSAGNLLS HVGHTILGMN TVQLYMKVPG
     SRTPGHQENN NFCSVNINIG PGDCEWFVVP EGYWGVLNDF CEKNNLNFLM GSWWPNLEDL
     YEANVPVYRF IQRPGDLVWI NAGTVHWVQA IGWCNNIAWN VGPLTACQYK LAVERYEWNK
     LQSVKSIVPM VHLSWNMARN IKVSDPKLFE MIKYCLLRTL KQCQTLREAL IAAGKEIIWH
     GRTKEEPAHY CSICEVEVFD LLFVTNESNS RKTYIVHCQD CARKTSGNLE NFVVLEQYKM
     EDLMQVYDQF TLAPPLPSAS S
//
ID   Q59HG3_HUMAN            Unreviewed;      1406 AA.
AC   Q59HG3;
DT   26-APR-2005, integrated into UniProtKB/TrEMBL.
DT   26-APR-2005, sequence version 1.
DT   26-FEB-2020, entry version 96.
DE   SubName: Full=Ubiquitously transcribed tetratricopeptide repeat variant {ECO:0000313|EMBL:BAD92032.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD92032.1};
RN   [1] {ECO:0000313|EMBL:BAD92032.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:BAD92032.1};
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB208795; BAD92032.1; -; mRNA.
DR   RefSeq; NP_001278347.1; NM_001291418.1.
DR   RefSeq; NP_066963.2; NM_021140.3.
DR   PRIDE; Q59HG3; -.
DR   GeneID; 7403; -.
DR   KEGG; hsa:7403; -.
DR   CTD; 7403; -.
DR   PharmGKB; PA37262; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   KO; K11447; -.
DR   OrthoDB; 268901at2759; -.
DR   GenomeRNAi; 7403; -.
DR   Genevisible; Q59HG3; HS.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN          98..390
FT                   /note="TPR_REGION"
FT                   /evidence="ECO:0000259|PROSITE:PS50293"
FT   REPEAT          98..131
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          135..168
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          210..243
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          255..288
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          289..322
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          323..356
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   REPEAT          357..390
FT                   /note="TPR"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00339"
FT   DOMAIN          1100..1263
FT                   /note="JmjC"
FT                   /evidence="ECO:0000259|PROSITE:PS51184"
FT   REGION          442..462
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          526..546
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          629..751
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          763..783
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          815..869
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          919..945
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1048..1084
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        815..867
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        922..942
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1051..1081
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:BAD92032.1"
SQ   SEQUENCE   1406 AA;  154735 MW;  ECB54A9C1B838DC3 CRC64;
     IRCVSMKSCG VSLATAAAAA AAFGDEEKKM AAGKASGESE EASPSLTAEE REALGGLDSR
     LFGFVRFHED GARTKALLGK AVRCYESLIL KAEGKVESDF FCQLGHFNLL LEDYPKALSA
     YQRYYSLQSD YWKNAAFLYG LGLVYFHYNA FQWAIKAFQE VLYVDPSFCR AKEIHLRLGL
     MFKVNTDYES SLKHFQLALV DCNPCTLSNA EIQFHIAHLY ETQRKYHSAK EAYEQLLQTE
     NLSAQVKATV LQQLGWMHHT VDLLGDKATK ESYAIQYLQK SLEADPNSGQ SWYFLGRCYS
     SIGKVQDAFI SYRQSIDKSE ASADTWCSIG VLYQQQNQPM DALQAYICAV QLDHGHAAAW
     MDLGTLYESC NQPQDAIKCY LNATRSKSCS NTSALAARIK YLQAQLCNLP QGSLQNKTKL
     LPSIEEAWSL PIPAELTSRQ GAMNTAQQNT SDNWSGGHAV SHPPVQQQAH SWCLTPQKLQ
     HLEQLRANRN NLNPAQKLML EQLESQFVLM QQHQMRPTGV AQVRSTGIPN GPTADSSLPT
     NSVSGQQPQL ALTRVPSVSQ PGVRPACPGQ PLANGPFSAG HVPCSTSRTL GSTDTILIGN
     NHITGSGSNG NVPYLQRNAL TLPHNRTNLT SSAEEPWKNQ LSNSTQGLHK GQSSHSAGPN
     GERPLSSTGP SQHLQAAGSG IQNQNGHPTL PSNSVTQGAA LNHLSSHTAT SGGQQGITLT
     KESKPSGNIL TVPETSRHTG ETPNSTASVE GLPNHVHQMT ADAVCSPSHG DSKSPGLLSS
     DNPQLSALLM GKANNNVGTG TCDKVNNIHP AVHTKTDNSV ASSPSSAIST ATPSPKSTEQ
     TTTNSVTSLN SPHSGLHTIN GEGMEESQSP MKTDLLLVNH KPSPQIIPSM SVSIYPSSAE
     VLKACRNLGK NGLSNSSILL DKCPPPRPPS SPYPPLPKDK LNPPTPSIYL ENKRDAFFPP
     LHQFCTNPNN PVTVIRGLAG ALKLDLGLFS TKTLVEANNE HMVEVRTQLL QPADENWDPT
     GTKKIWHCES NRSHTTIAKY AQYQASSFQE SLREENEKRS HHKDHSDSES TSSDNSGRRR
     KGPFKTIKFG TNIDLSDDKK WKLQLHELTK LPAFVRVVSA GNLLSHVGHT ILGMNTVQLY
     MKVPGSRTPG HQENNNFCSV NINIGPGDCE WFVVPEGYWG VLNDFCEKNN LNFLMGSWWP
     NLEDLYEANV PVYRFIQRPG DLVWINAGTV HWVQAIGWCN NIAWNVGPLT ACQYKLAVER
     YEWNKLQSVK SIVPMVHLSW NMARNIKVSD PKLFEMIKYC LLRTLKQCQT LREALIAAGK
     EIIWHGRTKE EPAHYCSICE VEVFDLLFVT NESNSRKTYI VHCQDCARKT SGNLENFVVL
     EQYKMEDLMQ VYDQFTLAPP LPSASS
//
ID   Q86TD1_HUMAN            Unreviewed;      1035 AA.
AC   Q86TD1;
DT   01-JUN-2003, integrated into UniProtKB/TrEMBL.
DT   01-JUN-2003, sequence version 1.
DT   11-DEC-2019, entry version 71.
DE   SubName: Full=Uncharacterized protein DKFZp451J023 {ECO:0000313|EMBL:CAD89904.1};
DE   Flags: Fragment;
GN   Name=DKFZp451J023 {ECO:0000313|EMBL:CAD89904.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:CAD89904.1};
RN   [1] {ECO:0000313|EMBL:CAD89904.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Human skeletal muscle {ECO:0000313|EMBL:CAD89904.1};
RA   Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A., Fobo G.,
RA   Han M., Wiemann S.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL831996; CAD89904.1; -; mRNA.
DR   RefSeq; NP_001278344.1; NM_001291415.1.
DR   RefSeq; NP_001278345.1; NM_001291416.1.
DR   RefSeq; NP_001278346.1; NM_001291417.1.
DR   RefSeq; NP_001278350.1; NM_001291421.1.
DR   PeptideAtlas; Q86TD1; -.
DR   PRIDE; Q86TD1; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   OrthoDB; 268901at2759; -.
DR   GenomeRNAi; 7403; -.
DR   InterPro; IPR003347; JmjC_dom.
DR   Pfam; PF02373; JmjC; 1.
DR   SMART; SM00558; JmjC; 1.
DR   PROSITE; PS51184; JMJC; 1.
PE   2: Evidence at transcript level;
FT   DOMAIN          729..892
FT                   /note="JmjC"
FT                   /evidence="ECO:0000259|PROSITE:PS51184"
FT   REGION          18..40
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          57..97
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          258..380
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          392..412
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          444..498
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          548..575
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          677..713
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        444..496
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        551..571
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        680..710
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:CAD89904.1"
SQ   SEQUENCE   1035 AA;  113020 MW;  9E77CD6FEA9B1495 CRC64;
     IEEAWSLPIP AELTSRQGAM NTAQQACKPH HPNTEPVLGL SQTPISQQSL PLHMIPSSQV
     DDLSSPAKRK RTSSPTKNTS DNWSGGHAVS HPPVQQQAHS WCLTPQKLQH LEQLRANRNN
     LNPAQKLMLE QLESQFVLMQ QHQMRPTGVA QVRSTGIPNG PTADSSLPTN SVSGQQPQLA
     LTRVPSVSQP GVRPACPGQP LANGPFSAGH VPCSTSRTLG STDTILIGNN HITGSGSNGN
     VPYLQRNALT LPHNRTNLTS SAEEPWKNQL SNSTQGLHKG QSSHSAGPNG ERPLSSTGPS
     QHLQAAGSGI QNQNGHPTLP SNSVTQGAAL NHLSSHTATS GGQQGITLTK ESKPSGNILK
     VPETSRHTGE TPNSTASVEG LPNHVHQMTA DAVCSPSHGD SKSPGLLSSD NPQLSALLMG
     KANNNVGTGT CDKVNNIHPA VHTKTDNSVA SSPSSAISTA TPSPKSTEQT TTNSVTSLNS
     PHSGLHTING EGMEESQSPM KTDLLLVNHK PSPQIIPSMS VSIYPSSAEV LKACRNLGKN
     GLSNSSILLD KCPPPRPPSS PYPPLPKDKL NPPTPSIYLE NKRDAFFPPL HQFCTNPNNP
     VTVIRGLAGA LKLDLGLFST KTLVEANNEH MVEVRTQLLQ PADENWDPTG TKKIWHCESN
     RSHTTIAKYA QYQASSFQES LREENEKRSH HKDHSDSEST SSDNSGRRRK GPFKTIKFGT
     NIDLSDDKKW KLQLHELTKL PAFVRVVSAG NLLSHVGHTI LGMNTVQLYM KVPGSRTPGH
     QENNNFCSVN INIGPGDCEW FVVPEGYWGV LNDFCEKNNL NFLMGSWWPN LEDLYEANVP
     VYRFIQRPGD LVWINAGTVH WVQAIGWCNN IAWNVGPLTA CQYKLAVERY EWNKLQSVKS
     IVPMVHLSWN MARNIKVSDP KLFEMIKYCL LRTLKQCQTL REALIAAGKE IIWHGRTKEE
     PAHYCSICEV EVFDLLFVTN ESNSRKTYIV HCQDCARKTS GNLENFVVLE QYKMEDLMQV
     CDQFTLAPPL PSASS
//
ID   KLF4_HUMAN              Reviewed;         513 AA.
AC   O43474; B2R8S4; B3KT79; L0R3I6; L0R4N5; P78338; Q5T3J8; Q5T3J9; Q8N717;
AC   Q9UNP3;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   10-FEB-2009, sequence version 3.
DT   22-APR-2020, entry version 193.
DE   RecName: Full=Krueppel-like factor 4;
DE   AltName: Full=Epithelial zinc finger protein EZF;
DE   AltName: Full=Gut-enriched krueppel-like factor;
GN   Name=KLF4; Synonyms=EZF, GKLF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=9422764; DOI=10.1074/jbc.273.2.1026;
RA   Yet S.-F., McA'Nulty M.M., Folta S.C., Yen H.-W., Yoshizumi M.,
RA   Hsieh C.-M., Layne M.D., Chin M.T., Wang H., Perrella M.A., Jain M.K.,
RA   Lee M.-E.;
RT   "Human EZF, a Kruppel-like zinc finger protein, is expressed in vascular
RT   endothelial cells and contains transcriptional activation and repression
RT   domains.";
RL   J. Biol. Chem. 273:1026-1031(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=10392904;
RA   Foster K.W., Ren S., Louro I.D., Lobo-Ruppert S.M., McKie-Bell P.,
RA   Grizzle W., Hayes M.R., Broker T.R., Chow L.T., Ruppert J.M.;
RT   "Oncogene expression cloning by retroviral transduction of adenovirus E1A-
RT   immortalized rat kidney RK3E cells: transformation of a host with
RT   epithelial features by c-MYC and the zinc finger protein GKLF.";
RL   Cell Growth Differ. 10:423-434(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5), AND ALTERNATIVE SPLICING.
RX   PubMed=23134681; DOI=10.1096/fj.12-220319;
RA   Camacho-Vanegas O., Till J., Miranda-Lorenzo I., Ozturk B., Camacho S.C.,
RA   Martignetti J.A.;
RT   "Shaking the family tree: Identification of novel and biologically active
RT   alternatively spliced isoforms across the KLF family of transcription
RT   factors.";
RL   FASEB J. 27:432-436(2013).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS SER-315 AND PHE-321.
RC   TISSUE=Placenta;
RA   Garrett-Sinha L.A., de Crombrugghe B.;
RL   Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Substantia nigra, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cervix, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH MUC1, AND FUNCTION.
RX   PubMed=17308127; DOI=10.1158/0008-5472.can-06-3063;
RA   Wei X., Xu H., Kufe D.;
RT   "Human mucin 1 oncoprotein represses transcription of the p53 tumor
RT   suppressor gene.";
RL   Cancer Res. 67:1853-1858(2007).
RN   [11]
RP   BIOTECHNOLOGY.
RX   PubMed=18035408; DOI=10.1016/j.cell.2007.11.019;
RA   Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K.,
RA   Yamanaka S.;
RT   "Induction of pluripotent stem cells from adult human fibroblasts by
RT   defined factors.";
RL   Cell 131:861-872(2007).
RN   [12]
RP   9AATAD MOTIF.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-32, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=18655026; DOI=10.1002/pmic.200700887;
RA   Tan F., Lu L., Cai Y., Wang J., Xie Y., Wang L., Gong Y., Xu B.-E., Wu J.,
RA   Luo Y., Qiang B., Yuan J., Sun X., Peng X.;
RT   "Proteomic analysis of ubiquitinated proteins in normal hepatocyte cell
RT   line Chang liver cells.";
RL   Proteomics 8:2885-2896(2008).
RN   [15]
RP   FUNCTION.
RX   PubMed=20071344; DOI=10.1074/jbc.m109.077958;
RA   Zhang P., Andrianakos R., Yang Y., Liu C., Lu W.;
RT   "Kruppel-like factor 4 (Klf4) prevents embryonic stem (ES) cell
RT   differentiation by regulating Nanog gene expression.";
RL   J. Biol. Chem. 285:9180-9189(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-254, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   INTERACTION WITH PBX1 AND MEIS2.
RX   PubMed=21746878; DOI=10.1128/mcb.01456-10;
RA   Bjerke G.A., Hyman-Walsh C., Wotton D.;
RT   "Cooperative transcriptional activation by Klf4, Meis2, and Pbx1.";
RL   Mol. Cell. Biol. 31:3723-3733(2011).
RN   [18]
RP   INTERACTION WITH GLIS1.
RX   PubMed=21654807; DOI=10.1038/nature10106;
RA   Maekawa M., Yamaguchi K., Nakamura T., Shibukawa R., Kodanaka I.,
RA   Ichisaka T., Kawamura Y., Mochizuki H., Goshima N., Yamanaka S.;
RT   "Direct reprogramming of somatic cells is promoted by maternal
RT   transcription factor Glis1.";
RL   Nature 474:225-229(2011).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   9AATAD MOTIF.
RX   PubMed=31375868; DOI=10.1007/s00018-019-03251-w;
RA   Piskacek M., Havelka M., Jendruchova K., Knight A., Keegan L.P.;
RT   "The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with
RT   valines and intron reservoirs.";
RL   Cell. Mol. Life Sci. 0:0-0(2019).
CC   -!- FUNCTION: Transcription factor; can act both as activator and as
CC       repressor. Binds the 5'-CACCC-3' core sequence. Binds to the promoter
CC       region of its own gene and can activate its own transcription.
CC       Regulates the expression of key transcription factors during embryonic
CC       development. Plays an important role in maintaining embryonic stem
CC       cells, and in preventing their differentiation. Required for
CC       establishing the barrier function of the skin and for postnatal
CC       maturation and maintenance of the ocular surface. Involved in the
CC       differentiation of epithelial cells and may also function in skeletal
CC       and kidney development. Contributes to the down-regulation of p53/TP53
CC       transcription. {ECO:0000269|PubMed:17308127,
CC       ECO:0000269|PubMed:20071344}.
CC   -!- SUBUNIT: Interacts with POU5F1/OCT4 and SOX2 (By similarity). Interacts
CC       with MUC1 (via the C-terminal domain) (PubMed:17308127). Interacts with
CC       MEIS2 isoform 4 and PBX1 isoform PBX1a (PubMed:21746878). Interacts
CC       with ZNF296 (By similarity). Interacts with GLIS1 (PubMed:21654807).
CC       {ECO:0000250|UniProtKB:Q60793, ECO:0000269|PubMed:17308127,
CC       ECO:0000269|PubMed:21654807, ECO:0000269|PubMed:21746878}.
CC   -!- INTERACTION:
CC       O43474; Q13363: CTBP1; NbExp=4; IntAct=EBI-7232405, EBI-908846;
CC       O43474; Q92997: DVL3; NbExp=3; IntAct=EBI-7232405, EBI-739789;
CC       O43474; P13807: GYS1; NbExp=5; IntAct=EBI-7232405, EBI-740553;
CC       O43474; A0A024R8L2: hCG_1987119; NbExp=3; IntAct=EBI-7232405, EBI-14103818;
CC       O43474; O14964: HGS; NbExp=3; IntAct=EBI-7232405, EBI-740220;
CC       O43474; O75031: HSF2BP; NbExp=3; IntAct=EBI-7232405, EBI-7116203;
CC       O43474; O95983: MBD3; NbExp=3; IntAct=EBI-7232405, EBI-1783068;
CC       O43474; P55771: PAX9; NbExp=3; IntAct=EBI-7232405, EBI-12111000;
CC       O43474; Q08117-2: TLE5; NbExp=3; IntAct=EBI-7232405, EBI-11741437;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O43474-3; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43474-1; Sequence=VSP_036399;
CC       Name=3;
CC         IsoId=O43474-4; Sequence=VSP_040569, VSP_036399;
CC       Name=4; Synonyms=1a;
CC         IsoId=O43474-5; Sequence=VSP_047470, VSP_047473;
CC       Name=5;
CC         IsoId=O43474-6; Sequence=VSP_047471, VSP_047472;
CC   -!- DOMAIN: the 9aaTAD motif is a transactivation domain present in a large
CC       number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:17467953, ECO:0000269|PubMed:31375868}.
CC   -!- BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the four
CC       Yamanaka factors. When combined, these factors are sufficient to
CC       reprogram differentiated cells to an embryonic-like state designated
CC       iPS (induced pluripotent stem) cells. iPS cells exhibit the morphology
CC       and growth properties of ES cells and express ES cell marker genes.
CC       {ECO:0000269|PubMed:18035408}.
CC   -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB48399.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAC03462.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAD42165.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH29923.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH30811.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=ABG25917.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAG36271.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=EAW59020.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW59021.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/KLF4ID44316ch9q31.html";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/klf4/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF022184; AAC03462.1; ALT_INIT; mRNA.
DR   EMBL; AF105036; AAD42165.1; ALT_INIT; mRNA.
DR   EMBL; HF546201; CCO02787.1; -; mRNA.
DR   EMBL; HF546202; CCO02788.1; -; mRNA.
DR   EMBL; U70663; AAB48399.1; ALT_INIT; mRNA.
DR   EMBL; AK095134; BAG52991.1; -; mRNA.
DR   EMBL; AK313489; BAG36271.1; ALT_INIT; mRNA.
DR   EMBL; DQ658241; ABG25917.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL360218; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471105; EAW59020.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471105; EAW59021.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; BC029923; AAH29923.1; ALT_INIT; mRNA.
DR   EMBL; BC030811; AAH30811.1; ALT_INIT; mRNA.
DR   CCDS; CCDS6770.2; -. [O43474-1]
DR   RefSeq; NP_001300981.1; NM_001314052.1. [O43474-3]
DR   RefSeq; NP_004226.3; NM_004235.5. [O43474-1]
DR   SMR; O43474; -.
DR   BioGrid; 114726; 34.
DR   DIP; DIP-57667N; -.
DR   IntAct; O43474; 20.
DR   MINT; O43474; -.
DR   STRING; 9606.ENSP00000363804; -.
DR   iPTMnet; O43474; -.
DR   PhosphoSitePlus; O43474; -.
DR   BioMuta; KLF4; -.
DR   jPOST; O43474; -.
DR   MassIVE; O43474; -.
DR   MaxQB; O43474; -.
DR   PeptideAtlas; O43474; -.
DR   PRIDE; O43474; -.
DR   ProteomicsDB; 48962; -. [O43474-3]
DR   ProteomicsDB; 48963; -. [O43474-1]
DR   ProteomicsDB; 48964; -. [O43474-4]
DR   Antibodypedia; 14888; 873 antibodies.
DR   DNASU; 9314; -.
DR   Ensembl; ENST00000374672; ENSP00000363804; ENSG00000136826. [O43474-1]
DR   GeneID; 9314; -.
DR   KEGG; hsa:9314; -.
DR   UCSC; uc004bdg.4; human. [O43474-3]
DR   CTD; 9314; -.
DR   DisGeNET; 9314; -.
DR   GeneCards; KLF4; -.
DR   HGNC; HGNC:6348; KLF4.
DR   HPA; ENSG00000136826; Tissue enhanced (skin).
DR   MIM; 602253; gene.
DR   neXtProt; NX_O43474; -.
DR   OpenTargets; ENSG00000136826; -.
DR   PharmGKB; PA30138; -.
DR   GeneTree; ENSGT00940000156229; -.
DR   HOGENOM; CLU_002678_33_1_1; -.
DR   InParanoid; O43474; -.
DR   KO; K17846; -.
DR   OMA; TLNMGEY; -.
DR   OrthoDB; 1591573at2759; -.
DR   PhylomeDB; O43474; -.
DR   TreeFam; TF350556; -.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells.
DR   Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes.
DR   SignaLink; O43474; -.
DR   SIGNOR; O43474; -.
DR   ChiTaRS; KLF4; human.
DR   GeneWiki; KLF4; -.
DR   GenomeRNAi; 9314; -.
DR   Pharos; O43474; Tbio.
DR   PRO; PR:O43474; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; O43474; protein.
DR   Bgee; ENSG00000136826; Expressed in colonic mucosa and 233 other tissues.
DR   ExpressionAtlas; O43474; baseline and differential.
DR   Genevisible; O43474; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005719; C:nuclear euchromatin; IEA:Ensembl.
DR   GO; GO:0044798; C:nuclear transcription factor complex; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:Ensembl.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IMP:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0042826; F:histone deacetylase binding; IEA:Ensembl.
DR   GO; GO:0035014; F:phosphatidylinositol 3-kinase regulator activity; IEA:Ensembl.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001010; F:RNA polymerase II sequence-specific DNA-binding transcription factor recruiting activity; ISS:BHF-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001221; F:transcription cofactor binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; NAS:UniProtKB.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0071409; P:cellular response to cycloheximide; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:BHF-UCL.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:1901653; P:cellular response to peptide; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0009913; P:epidermal cell differentiation; IEA:Ensembl.
DR   GO; GO:0048730; P:epidermis morphogenesis; IEA:Ensembl.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0007500; P:mesodermal cell fate determination; TAS:ProtInc.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:2000342; P:negative regulation of chemokine (C-X-C motif) ligand 2 production; IDA:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IGI:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; TAS:BHF-UCL.
DR   GO; GO:0045415; P:negative regulation of interleukin-8 biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:1904998; P:negative regulation of leukocyte adhesion to arterial endothelial cell; IGI:BHF-UCL.
DR   GO; GO:0014740; P:negative regulation of muscle hyperplasia; IEA:Ensembl.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0014067; P:negative regulation of phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0060761; P:negative regulation of response to cytokine stimulus; IDA:BHF-UCL.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; IMP:BHF-UCL.
DR   GO; GO:1904798; P:positive regulation of core promoter binding; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IGI:BHF-UCL.
DR   GO; GO:0046985; P:positive regulation of hemoglobin biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; IGI:BHF-UCL.
DR   GO; GO:1903672; P:positive regulation of sprouting angiogenesis; IGI:BHF-UCL.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0031077; P:post-embryonic camera-type eye development; IEA:Ensembl.
DR   GO; GO:0035166; P:post-embryonic hemopoiesis; IMP:BHF-UCL.
DR   GO; GO:0061614; P:pri-miRNA transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0048679; P:regulation of axon regeneration; IEA:Ensembl.
DR   GO; GO:0045595; P:regulation of cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; TAS:Reactome.
DR   GO; GO:0019827; P:stem cell population maintenance; ISS:UniProtKB.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISS:BHF-UCL.
DR   DisProt; DP01174; -.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00096; zf-C2H2; 3.
DR   SMART; SM00355; ZnF_C2H2; 3.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; DNA-binding; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..513
FT                   /note="Krueppel-like factor 4"
FT                   /id="PRO_0000047167"
FT   ZN_FING         430..454
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         460..484
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         490..512
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          416..513
FT                   /note="Interaction with ZNF296"
FT                   /evidence="ECO:0000250|UniProtKB:Q60793"
FT   REGION          473..504
FT                   /note="Interaction with target DNA"
FT                   /evidence="ECO:0000250"
FT   MOTIF           101..109
FT                   /note="9aaTAD"
FT                   /evidence="ECO:0000269|PubMed:31375868"
FT   COMPBIAS        125..149
FT                   /note="Ser-rich"
FT   COMPBIAS        179..415
FT                   /note="Pro-rich"
FT   MOD_RES         254
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   CROSSLNK        32
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:18655026"
FT   VAR_SEQ         1..50
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_040569"
FT   VAR_SEQ         43..118
FT                   /note="RWREELSHMKRLPPVLPGRPYDLAAATVATDLESGGAGAACGGSNLAPLPRR
FT                   ETEEFNDLLDLDFILSNSLTHPPE -> SSCHPVPACQRSPSQRGEDDRGPGKGPPPTL
FT                   VITRAAAKPTQRVPISRHTCEPTQVRNLTTVTGTAVDGNSPAQMN (in isoform
FT                   4)"
FT                   /evidence="ECO:0000303|PubMed:23134681"
FT                   /id="VSP_047470"
FT   VAR_SEQ         43..63
FT                   /note="RWREELSHMKRLPPVLPGRPY -> VRNLTTVTGTAVDGNSPAQMN (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:23134681"
FT                   /id="VSP_047471"
FT   VAR_SEQ         64..513
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:23134681"
FT                   /id="VSP_047472"
FT   VAR_SEQ         119..513
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:23134681"
FT                   /id="VSP_047473"
FT   VAR_SEQ         367..400
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10392904,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9422764, ECO:0000303|Ref.4"
FT                   /id="VSP_036399"
FT   VARIANT         315
FT                   /note="T -> S (in dbSNP:rs1059913)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_059888"
FT   VARIANT         321
FT                   /note="L -> F (in dbSNP:rs1059914)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_059889"
FT   CONFLICT        60..61
FT                   /note="GR -> AG (in Ref. 1; AAC03462)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        77
FT                   /note="G -> A (in Ref. 1; AAC03462)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        251
FT                   /note="S -> T (in Ref. 1; AAC03462)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        304
FT                   /note="D -> N (in Ref. 4; AAB48399)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        329
FT                   /note="D -> E (in Ref. 4; AAB48399)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   513 AA;  54671 MW;  3B6113A3EF333935 CRC64;
     MRQPPGESDM AVSDALLPSF STFASGPAGR EKTLRQAGAP NNRWREELSH MKRLPPVLPG
     RPYDLAAATV ATDLESGGAG AACGGSNLAP LPRRETEEFN DLLDLDFILS NSLTHPPESV
     AATVSSSASA SSSSSPSSSG PASAPSTCSF TYPIRAGNDP GVAPGGTGGG LLYGRESAPP
     PTAPFNLADI NDVSPSGGFV AELLRPELDP VYIPPQQPQP PGGGLMGKFV LKASLSAPGS
     EYGSPSVISV SKGSPDGSHP VVVAPYNGGP PRTCPKIKQE AVSSCTHLGA GPPLSNGHRP
     AAHDFPLGRQ LPSRTTPTLG LEEVLSSRDC HPALPLPPGF HPHPGPNYPS FLPDQMQPQV
     PPLHYQGQSR GFVARAGEPC VCWPHFGTHG MMLTPPSSPL ELMPPGSCMP EEPKPKRGRR
     SWPRKRTATH TCDYAGCGKT YTKSSHLKAH LRTHTGEKPY HCDWDGCGWK FARSDELTRH
     YRKHTGHRPF QCQKCDRAFS RSDHLALHMK RHF
//
ID   KMT2D_HUMAN             Reviewed;        5537 AA.
AC   O14686; O14687;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 2.
DT   22-APR-2020, entry version 191.
DE   RecName: Full=Histone-lysine N-methyltransferase 2D;
DE            Short=Lysine N-methyltransferase 2D;
DE            EC=2.1.1.354 {ECO:0000269|PubMed:17500065, ECO:0000305|PubMed:16603732};
DE   AltName: Full=ALL1-related protein;
DE   AltName: Full=Myeloid/lymphoid or mixed-lineage leukemia protein 2;
GN   Name=KMT2D; Synonyms=ALR, MLL2, MLL4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RX   PubMed=9247308; DOI=10.1038/sj.onc.1201211;
RA   Prasad R., Zhadanov A.B., Sedkov Y., Bullrich F., Druck T., Rallapalli R.,
RA   Yano T., Alder H., Croce C.M., Huebner K., Mazo A., Canaani E.;
RT   "Structure and expression pattern of human ALR, a novel gene with strong
RT   homology to ALL-1 involved in acute leukemia and to Drosophila trithorax.";
RL   Oncogene 15:549-560(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   IDENTIFICATION IN THE MLL2/3 COMPLEX.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12482968; DOI=10.1128/mcb.23.1.140-149.2003;
RA   Goo Y.-H., Sohn Y.C., Kim D.-H., Kim S.-W., Kang M.-J., Jung D.-J.,
RA   Kwak E., Barlev N.A., Berger S.L., Chow V.T., Roeder R.G., Azorsa D.O.,
RA   Meltzer P.S., Suh P.-G., Song E.J., Lee K.-J., Lee Y.C., Lee J.W.;
RT   "Activating signal cointegrator 2 belongs to a novel steady-state complex
RT   that contains a subset of trithorax group proteins.";
RL   Mol. Cell. Biol. 23:140-149(2003).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3130, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [5]
RP   FUNCTION, ENZYME ACTIVITY, IDENTIFICATION IN THE MLL2 COMPLEX, LXXLL
RP   MOTIFS, AND INTERACTION WITH ESR1.
RX   PubMed=16603732; DOI=10.1074/jbc.m513245200;
RA   Mo R., Rao S.M., Zhu Y.-J.;
RT   "Identification of the MLL2 complex as a coactivator for estrogen receptor
RT   alpha.";
RL   J. Biol. Chem. 281:15714-15720(2006).
RN   [6]
RP   IDENTIFICATION IN THE MLL2/3 (ASCOM) COMPLEX.
RX   PubMed=17021013; DOI=10.1073/pnas.0607313103;
RA   Lee S., Lee D.K., Dou Y., Lee J., Lee B., Kwak E., Kong Y.Y., Lee S.K.,
RA   Roeder R.G., Lee J.W.;
RT   "Coactivator as a target gene specificity determinant for histone H3 lysine
RT   4 methyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15392-15397(2006).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   IDENTIFICATION IN THE MLL2/3 COMPLEX.
RX   PubMed=17500065; DOI=10.1074/jbc.m701574200;
RA   Cho Y.-W., Hong T., Hong S., Guo H., Yu H., Kim D., Guszczynski T.,
RA   Dressler G.R., Copeland T.D., Kalkum M., Ge K.;
RT   "PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4
RT   methyltransferase complex.";
RL   J. Biol. Chem. 282:20395-20406(2007).
RN   [8]
RP   FUNCTION, AND IDENTIFICATION IN THE MLL2/3 COMPLEX.
RX   PubMed=17851529; DOI=10.1038/nature06192;
RA   Lan F., Bayliss P.E., Rinn J.L., Whetstine J.R., Wang J.K., Chen S.,
RA   Iwase S., Alpatov R., Issaeva I., Canaani E., Roberts T.M., Chang H.Y.,
RA   Shi Y.;
RT   "A histone H3 lysine 27 demethylase regulates animal posterior
RT   development.";
RL   Nature 449:689-694(2007).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [10]
RP   IDENTIFICATION IN THE MLL2/3 COMPLEX.
RX   PubMed=17761849; DOI=10.1126/science.1149042;
RA   Lee M.G., Villa R., Trojer P., Norman J., Yan K.P., Reinberg D.,
RA   Di Croce L., Shiekhattar R.;
RT   "Demethylation of H3K27 regulates polycomb recruitment and H2A
RT   ubiquitination.";
RL   Science 318:447-450(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4738, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-2274; SER-2309;
RP   SER-2311; THR-3197 AND SER-4822, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1671; SER-2274; THR-3197;
RP   SER-4359 AND SER-4822, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-2246; LYS-3079; LYS-3433;
RP   LYS-4465 AND LYS-4776, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1606; THR-3197; SER-3199;
RP   SER-4215; SER-4359 AND SER-4738, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1671; SER-2274 AND SER-4738,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1606; SER-1671; SER-1820;
RP   SER-1834; THR-1843; THR-2240; SER-2260; SER-2274; SER-2640; SER-3130;
RP   SER-3199; SER-4359; SER-4738; SER-4822 AND SER-4849, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1151; THR-1195; SER-1249;
RP   SER-2239 AND SER-4738, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-3727, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-4756, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-4756 AND LYS-4880, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [23] {ECO:0000244|PDB:4ERQ}
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 5333-5346 IN COMPLEX WITH WDR5,
RP   INTERACTION WITH WDR5, AND MOTIF WIN.
RX   PubMed=22665483; DOI=10.1074/jbc.m112.364125;
RA   Dharmarajan V., Lee J.H., Patel A., Skalnik D.G., Cosgrove M.S.;
RT   "Structural basis for WDR5 interaction (Win) motif recognition in human
RT   SET1 family histone methyltransferases.";
RL   J. Biol. Chem. 287:27275-27289(2012).
RN   [24] {ECO:0000244|PDB:3UVK}
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 5337-5347 IN COMPLEX WITH WDR5,
RP   INTERACTION WITH WDR5, AND MOTIF WIN.
RX   PubMed=22266653; DOI=10.1093/nar/gkr1235;
RA   Zhang P., Lee H., Brunzelle J.S., Couture J.F.;
RT   "The plasticity of WDR5 peptide-binding cleft enables the binding of the
RT   SET1 family of histone methyltransferases.";
RL   Nucleic Acids Res. 40:4237-4246(2012).
RN   [25]
RP   VARIANTS KABUK1 PHE-5109; HIS-5179; HIS-5214; LEU-5340 AND MET-5464, AND
RP   INVOLVEMENT IN KABUK1.
RX   PubMed=20711175; DOI=10.1038/ng.646;
RA   Ng S.B., Bigham A.W., Buckingham K.J., Hannibal M.C., McMillin M.J.,
RA   Gildersleeve H.I., Beck A.E., Tabor H.K., Cooper G.M., Mefford H.C.,
RA   Lee C., Turner E.H., Smith J.D., Rieder M.J., Yoshiura K., Matsumoto N.,
RA   Ohta T., Niikawa N., Nickerson D.A., Bamshad M.J., Shendure J.;
RT   "Exome sequencing identifies MLL2 mutations as a cause of Kabuki
RT   syndrome.";
RL   Nat. Genet. 42:790-793(2010).
RN   [26]
RP   VARIANTS KABUK1 LEU-1388; ARG-1430; TYR-1471; CYS-5048; PHE-5109; HIS-5179;
RP   CYS-5214; HIS-5214; LEU-5340; MET-5464 AND THR-5471.
RX   PubMed=21671394; DOI=10.1002/ajmg.a.34074;
RA   Hannibal M.C., Buckingham K.J., Ng S.B., Ming J.E., Beck A.E.,
RA   McMillin M.J., Gildersleeve H.I., Bigham A.W., Tabor H.K., Mefford H.C.,
RA   Cook J., Yoshiura K., Matsumoto T., Matsumoto N., Miyake N., Tonoki H.,
RA   Naritomi K., Kaname T., Nagai T., Ohashi H., Kurosawa K., Hou J.W.,
RA   Ohta T., Liang D., Sudo A., Morris C.A., Banka S., Black G.C.,
RA   Clayton-Smith J., Nickerson D.A., Zackai E.H., Shaikh T.H., Donnai D.,
RA   Niikawa N., Shendure J., Bamshad M.J.;
RT   "Spectrum of MLL2 (ALR) mutations in 110 cases of Kabuki syndrome.";
RL   Am. J. Med. Genet. A 155A:1511-1516(2011).
RN   [27]
RP   VARIANTS KABUK1 LEU-543; GLN-647; MET-1192; ARG-1453; VAL-1718; GLN-5154
RP   AND PHE-5498.
RX   PubMed=21607748; DOI=10.1007/s00439-011-1004-y;
RA   Li Y., Boegershausen N., Alanay Y., Simsek Kiper P.O., Plume N., Keupp K.,
RA   Pohl E., Pawlik B., Rachwalski M., Milz E., Thoenes M., Albrecht B.,
RA   Prott E.C., Lehmkuehler M., Demuth S., Utine G.E., Boduroglu K.,
RA   Frankenbusch K., Borck G., Gillessen-Kaesbach G., Yigit G., Wieczorek D.,
RA   Wollnik B.;
RT   "A mutation screen in patients with Kabuki syndrome.";
RL   Hum. Genet. 130:715-724(2011).
RN   [28]
RP   VARIANTS KABUK1 CYS-5210 AND ASP-5428, AND VARIANTS THR-692; LEU-813;
RP   SER-2382; CYS-2460; LEU-2557; VAL-3398; GLY-3419 AND SER-4357.
RX   PubMed=21280141; DOI=10.1002/humu.21416;
RA   Paulussen A.D., Stegmann A.P., Blok M.J., Tserpelis D., Posma-Velter C.,
RA   Detisch Y., Smeets E.E., Wagemans A., Schrander J.J.,
RA   van den Boogaard M.J., van der Smagt J., van Haeringen A.,
RA   Stolte-Dijkstra I., Kerstjens-Frederikse W.S., Mancini G.M., Wessels M.W.,
RA   Hennekam R.C., Vreeburg M., Geraedts J., de Ravel T., Fryns J.P.,
RA   Smeets H.J., Devriendt K., Schrander-Stumpel C.T.;
RT   "MLL2 mutation spectrum in 45 patients with Kabuki syndrome.";
RL   Hum. Mutat. 32:E2018-E2025(2011).
RN   [29]
RP   VARIANTS KABUK1 GLN-1258; VAL-1417; MET-1418; ARG-1522; THR-2841; GLU-5028;
RP   VAL-5034; PRO-5059 AND GLN-5340.
RX   PubMed=21658225; DOI=10.1186/1750-1172-6-38;
RA   Micale L., Augello B., Fusco C., Selicorni A., Loviglio M.N., Silengo M.C.,
RA   Reymond A., Gumiero B., Zucchetti F., D'Addetta E.V., Belligni E.,
RA   Calcagni A., Digilio M.C., Dallapiccola B., Faravelli F., Forzano F.,
RA   Accadia M., Bonfante A., Clementi M., Daolio C., Douzgou S., Ferrari P.,
RA   Fischetto R., Garavelli L., Lapi E., Mattina T., Melis D., Patricelli M.G.,
RA   Priolo M., Prontera P., Renieri A., Mencarelli M.A., Scarano G.,
RA   della Monica M., Toschi B., Turolla L., Vancini A., Zatterale A.,
RA   Gabrielli O., Zelante L., Merla G.;
RT   "Mutation spectrum of MLL2 in a cohort of Kabuki syndrome patients.";
RL   Orphanet J. Rare Dis. 6:38-38(2011).
RN   [30]
RP   VARIANTS KABUK1 LEU-337; LEU-4353; VAL-5047; CYS-5048; CYS-5214; THR-5471
RP   AND TYR-5481.
RX   PubMed=22126750; DOI=10.1038/ejhg.2011.220;
RA   Banka S., Veeramachaneni R., Reardon W., Howa rd E., Bunstone S., Ragge N.,
RA   Parker M.J., Crow Y.J., Kerr B., Kingston H., Metcalfe K., Chandler K.,
RA   Magee A., Stewart F., McConnell V.P., Donnelly D.E., Berland S., Houge G.,
RA   Morton J.E., Oley C., Revencu N., Park S.M., Davies S.J., Fry A.E.,
RA   Lynch S.A., Gill H., Schweiger S., Lam W.W., Tolmie J., Mohammed S.N.,
RA   Hobson E., Smith A., Blyth M., Bennett C., Vasudevan P.C.,
RA   Garcia-Minaur S., Henderson A., Goodship J., Wright M.J., Fisher R.,
RA   Gibbons R., Price S.M., C de Silva D., Temple I.K., Collins A.L.,
RA   Lachlan K., Elmslie F., McEntagart M., Castle B., Clayton-Smith J.,
RA   Black G.C., Donnai D.;
RT   "How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116
RT   patients, review and analyses of mutation and phenotypic spectrum.";
RL   Eur. J. Hum. Genet. 20:381-388(2012).
RN   [31]
RP   VARIANTS KABUK1 ARG-1376; CYS-1423; GLY-1445; PHE-1526; CYS-5030; GLY-5040;
RP   CYS-5048; HIS-5048; GLN-5154; HIS-5179; ARG-5189 AND GLN-5351.
RX   PubMed=23913813; DOI=10.1002/ajmg.a.36072;
RA   Miyake N., Koshimizu E., Okamoto N., Mizuno S., Ogata T., Nagai T.,
RA   Kosho T., Ohashi H., Kato M., Sasaki G., Mabe H., Watanabe Y., Yoshino M.,
RA   Matsuishi T., Takanashi J., Shotelersuk V., Tekin M., Ochi N., Kubota M.,
RA   Ito N., Ihara K., Hara T., Tonoki H., Ohta T., Saito K., Matsuo M.,
RA   Urano M., Enokizono T., Sato A., Tanaka H., Ogawa A., Fujita T., Hiraki Y.,
RA   Kitanaka S., Matsubara Y., Makita T., Taguri M., Nakashima M.,
RA   Tsurusaki Y., Saitsu H., Yoshiura K., Matsumoto N., Niikawa N.;
RT   "MLL2 and KDM6A mutations in patients with Kabuki syndrome.";
RL   Am. J. Med. Genet. A 161A:2234-2243(2013).
RN   [32]
RP   VARIANTS KABUK1 PHE-1424 AND GLN-4420.
RX   PubMed=24739679; DOI=10.1038/jhg.2014.25;
RA   Cheon C.K., Sohn Y.B., Ko J.M., Lee Y.J., Song J.S., Moon J.W., Yang B.K.,
RA   Ha I.S., Bae E.J., Jin H.S., Jeong S.Y.;
RT   "Identification of KMT2D and KDM6A mutations by exome sequencing in Korean
RT   patients with Kabuki syndrome.";
RL   J. Hum. Genet. 59:321-325(2014).
RN   [33]
RP   VARIANTS KABUK1 HIS-170; LEU-170; GLN-647; ARG-1380; ARG-1471; ARG-3876;
RP   SER-3897; CYS-5030; CYS-5048; HIS-5048; CYS-5214; TRP-5432 AND PHE-5498,
RP   AND VARIANTS LEU-2557; LEU-2652 AND PRO-4010.
RX   PubMed=23320472; DOI=10.1111/cge.12081;
RA   Makrythanasis P., van Bon B.W., Steehouwer M., Rodriguez-Santiago B.,
RA   Simpson M., Dias P., Anderlid B.M., Arts P., Bhat M., Augello B.,
RA   Biamino E., Bongers E.M., Del Campo M., Cordeiro I., Cueto-Gonzalez A.M.,
RA   Cusco I., Deshpande C., Frysira E., Izatt L., Flores R., Galan E.,
RA   Gener B., Gilissen C., Granneman S.M., Hoyer J., Yntema H.G., Kets C.M.,
RA   Koolen D.A., Marcelis C.L., Medeira A., Micale L., Mohammed S.,
RA   de Munnik S.A., Nordgren A., Psoni S., Reardon W., Revencu N., Roscioli T.,
RA   Ruiterkamp-Versteeg M., Santos H.G., Schoumans J.,
RA   Schuurs-Hoeijmakers J.H., Silengo M.C., Toledo L., Vendrell T.,
RA   van der Burgt I., van Lier B., Zweier C., Reymond A., Trembath R.C.,
RA   Perez-Jurado L., Dupont J., de Vries B.B., Brunner H.G., Veltman J.A.,
RA   Merla G., Antonarakis S.E., Hoischen A.;
RT   "MLL2 mutation detection in 86 patients with Kabuki syndrome: a genotype-
RT   phenotype study.";
RL   Clin. Genet. 84:539-545(2013).
CC   -!- FUNCTION: Histone methyltransferase. Methylates 'Lys-4' of histone H3
CC       (H3K4me). H3K4me represents a specific tag for epigenetic
CC       transcriptional activation. Acts as a coactivator for estrogen receptor
CC       by being recruited by ESR1, thereby activating transcription.
CC       {ECO:0000269|PubMed:16603732, ECO:0000269|PubMed:17500065,
CC       ECO:0000269|PubMed:17851529}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-lysyl(4)-[histone H3] + 3 S-adenosyl-L-methionine = 3 H(+) +
CC         N(6),N(6),N(6)-trimethyl-L-lysyl(4)-[histone H3] + 3 S-adenosyl-L-
CC         homocysteine; Xref=Rhea:RHEA:60260, Rhea:RHEA-COMP:15537, Rhea:RHEA-
CC         COMP:15547, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57856,
CC         ChEBI:CHEBI:59789, ChEBI:CHEBI:61961; EC=2.1.1.354;
CC         Evidence={ECO:0000269|PubMed:17500065, ECO:0000305|PubMed:16603732};
CC   -!- SUBUNIT: Component of the MLL2/3 complex (also named ASCOM complex), at
CC       least composed of KMT2D/MLL2 or KMT2C/MLL3, ASH2L, RBBP5, WDR5, NCOA6,
CC       DPY30, KDM6A, PAXIP1/PTIP, PAGR1 and alpha- and beta-tubulin. Interacts
CC       with ESR1; interaction is direct. Interacts (via WIN motif) with WDR5
CC       (PubMed:22665483, PubMed:22266653). {ECO:0000269|PubMed:12482968,
CC       ECO:0000269|PubMed:16603732, ECO:0000269|PubMed:17021013,
CC       ECO:0000269|PubMed:17500065, ECO:0000269|PubMed:17761849,
CC       ECO:0000269|PubMed:17851529, ECO:0000269|PubMed:22266653,
CC       ECO:0000269|PubMed:22665483}.
CC   -!- INTERACTION:
CC       O14686; P10275: AR; NbExp=2; IntAct=EBI-996065, EBI-608057;
CC       O14686; Q9UBL3-3: ASH2L; NbExp=2; IntAct=EBI-996065, EBI-16130425;
CC       O14686; P03372: ESR1; NbExp=3; IntAct=EBI-996065, EBI-78473;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O14686-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=O14686-3; Sequence=VSP_008560;
CC   -!- TISSUE SPECIFICITY: Expressed in most adult tissues, including a
CC       variety of hematoipoietic cells, with the exception of the liver.
CC   -!- DOMAIN: LXXLL motifs 5 and 6 are essential for the association with
CC       ESR1 nuclear receptor.
CC   -!- DISEASE: Kabuki syndrome 1 (KABUK1) [MIM:147920]: A congenital mental
CC       retardation syndrome with additional features, including postnatal
CC       dwarfism, a peculiar facies characterized by long palpebral fissures
CC       with eversion of the lateral third of the lower eyelids, a broad and
CC       depressed nasal tip, large prominent earlobes, a cleft or high-arched
CC       palate, scoliosis, short fifth finger, persistence of fingerpads,
CC       radiographic abnormalities of the vertebrae, hands, and hip joints, and
CC       recurrent otitis media in infancy. {ECO:0000269|PubMed:20711175,
CC       ECO:0000269|PubMed:21280141, ECO:0000269|PubMed:21607748,
CC       ECO:0000269|PubMed:21658225, ECO:0000269|PubMed:21671394,
CC       ECO:0000269|PubMed:22126750, ECO:0000269|PubMed:23320472,
CC       ECO:0000269|PubMed:23913813, ECO:0000269|PubMed:24739679}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: This gene mapped to a chromosomal region involved in
CC       duplications and translocations associated with cancer.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding methyltransferase
CC       superfamily. Histone-lysine methyltransferase family. TRX/MLL
CC       subfamily. {ECO:0000255|PROSITE-ProRule:PRU00190}.
CC   -!- CAUTION: Another protein KMT2B/MLL4, located on chromosome 19, was
CC       first named MLL2 (see AC Q9UMN6). Thus, KMT2B/MLL4 is often referred to
CC       as MLL2 and vice versa in the literature. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF010403; AAC51734.1; -; mRNA.
DR   EMBL; AF010404; AAC51735.1; -; mRNA.
DR   EMBL; AC011603; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS44873.1; -. [O14686-1]
DR   PIR; T03454; T03454.
DR   PIR; T03455; T03455.
DR   RefSeq; NP_003473.3; NM_003482.3. [O14686-1]
DR   RefSeq; XP_005269219.1; XM_005269162.4. [O14686-1]
DR   RefSeq; XP_006719677.1; XM_006719614.3. [O14686-3]
DR   PDB; 3UVK; X-ray; 1.40 A; B=5337-5347.
DR   PDB; 4ERQ; X-ray; 1.91 A; D/E/F=5333-5346.
DR   PDB; 4Z4P; X-ray; 2.20 A; A=5382-5536.
DR   PDB; 6O7G; NMR; -; B=1503-1562.
DR   PDBsum; 3UVK; -.
DR   PDBsum; 4ERQ; -.
DR   PDBsum; 4Z4P; -.
DR   PDBsum; 6O7G; -.
DR   SMR; O14686; -.
DR   BioGrid; 113758; 46.
DR   CORUM; O14686; -.
DR   DIP; DIP-37875N; -.
DR   ELM; O14686; -.
DR   IntAct; O14686; 29.
DR   MINT; O14686; -.
DR   STRING; 9606.ENSP00000301067; -.
DR   BindingDB; O14686; -.
DR   ChEMBL; CHEMBL2189114; -.
DR   iPTMnet; O14686; -.
DR   PhosphoSitePlus; O14686; -.
DR   BioMuta; KMT2D; -.
DR   CPTAC; CPTAC-978; -.
DR   EPD; O14686; -.
DR   jPOST; O14686; -.
DR   MassIVE; O14686; -.
DR   MaxQB; O14686; -.
DR   PaxDb; O14686; -.
DR   PeptideAtlas; O14686; -.
DR   PRIDE; O14686; -.
DR   ProteomicsDB; 48168; -. [O14686-1]
DR   ProteomicsDB; 48169; -. [O14686-3]
DR   Antibodypedia; 25797; 134 antibodies.
DR   Ensembl; ENST00000301067; ENSP00000301067; ENSG00000167548. [O14686-1]
DR   GeneID; 8085; -.
DR   KEGG; hsa:8085; -.
DR   UCSC; uc001rta.4; human. [O14686-1]
DR   CTD; 8085; -.
DR   DisGeNET; 8085; -.
DR   GeneCards; KMT2D; -.
DR   GeneReviews; KMT2D; -.
DR   HGNC; HGNC:7133; KMT2D.
DR   HPA; ENSG00000167548; Low tissue specificity.
DR   MalaCards; KMT2D; -.
DR   MIM; 147920; phenotype.
DR   MIM; 602113; gene.
DR   neXtProt; NX_O14686; -.
DR   OpenTargets; ENSG00000167548; -.
DR   Orphanet; 2322; Kabuki syndrome.
DR   PharmGKB; PA30846; -.
DR   eggNOG; KOG4443; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   GeneTree; ENSGT00940000156707; -.
DR   HOGENOM; CLU_000065_0_0_1; -.
DR   InParanoid; O14686; -.
DR   KO; K09187; -.
DR   OMA; LPGVGVM; -.
DR   OrthoDB; 61027at2759; -.
DR   PhylomeDB; O14686; -.
DR   TreeFam; TF354317; -.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function.
DR   SIGNOR; O14686; -.
DR   ChiTaRS; KMT2D; human.
DR   GeneWiki; MLL2; -.
DR   GenomeRNAi; 8085; -.
DR   Pharos; O14686; Tbio.
DR   PRO; PR:O14686; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; O14686; protein.
DR   Bgee; ENSG00000167548; Expressed in left lobe of thyroid gland and 99 other tissues.
DR   ExpressionAtlas; O14686; baseline and differential.
DR   Genevisible; O14686; HS.
DR   GO; GO:0035097; C:histone methyltransferase complex; IPI:MGI.
DR   GO; GO:0044666; C:MLL3/4 complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IBA:GO_Central.
DR   GO; GO:0042800; F:histone methyltransferase activity (H3-K4 specific); IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003713; F:transcription coactivator activity; IBA:GO_Central.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0006342; P:chromatin silencing; ISS:UniProtKB.
DR   GO; GO:0044648; P:histone H3-K4 dimethylation; IDA:CACAO.
DR   GO; GO:0051568; P:histone H3-K4 methylation; ISS:UniProtKB.
DR   GO; GO:0097692; P:histone H3-K4 monomethylation; IDA:CACAO.
DR   GO; GO:0080182; P:histone H3-K4 trimethylation; IDA:CACAO.
DR   GO; GO:0001555; P:oocyte growth; ISS:UniProtKB.
DR   GO; GO:0048477; P:oogenesis; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0045652; P:regulation of megakaryocyte differentiation; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0043627; P:response to estrogen; IDA:UniProtKB.
DR   CDD; cd15695; ePHD1_KMT2D; 1.
DR   CDD; cd15698; ePHD2_KMT2D; 1.
DR   Gene3D; 1.10.30.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 6.
DR   InterPro; IPR034732; EPHD.
DR   InterPro; IPR003889; FYrich_C.
DR   InterPro; IPR003888; FYrich_N.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR037890; KMT2D.
DR   InterPro; IPR041961; KMT2D_ePHD1.
DR   InterPro; IPR041964; KMT2D_ePHD2.
DR   InterPro; IPR003616; Post-SET_dom.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR45888:SF2; PTHR45888:SF2; 2.
DR   Pfam; PF05965; FYRC; 1.
DR   Pfam; PF05964; FYRN; 1.
DR   Pfam; PF00628; PHD; 3.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM00542; FYRC; 1.
DR   SMART; SM00541; FYRN; 1.
DR   SMART; SM00398; HMG; 1.
DR   SMART; SM00249; PHD; 7.
DR   SMART; SM00508; PostSET; 1.
DR   SMART; SM00184; RING; 6.
DR   SMART; SM00317; SET; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   SUPFAM; SSF57903; SSF57903; 5.
DR   PROSITE; PS51805; EPHD; 2.
DR   PROSITE; PS51543; FYRC; 1.
DR   PROSITE; PS51542; FYRN; 1.
DR   PROSITE; PS50868; POST_SET; 1.
DR   PROSITE; PS50280; SET; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 5.
DR   PROSITE; PS50016; ZF_PHD_2; 5.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromatin regulator;
KW   Coiled coil; Disease mutation; Isopeptide bond; Mental retardation;
KW   Metal-binding; Methylation; Methyltransferase; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; S-adenosyl-L-methionine;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation;
KW   Zinc; Zinc-finger.
FT   CHAIN           1..5537
FT                   /note="Histone-lysine N-methyltransferase 2D"
FT                   /id="PRO_0000124878"
FT   REPEAT          442..446
FT                   /note="1"
FT   REPEAT          460..464
FT                   /note="2"
FT   REPEAT          469..473
FT                   /note="3"
FT   REPEAT          496..500
FT                   /note="4"
FT   REPEAT          504..508
FT                   /note="5"
FT   REPEAT          521..525
FT                   /note="6"
FT   REPEAT          555..559
FT                   /note="7"
FT   REPEAT          564..568
FT                   /note="8"
FT   REPEAT          573..577
FT                   /note="9"
FT   REPEAT          582..586
FT                   /note="10"
FT   REPEAT          609..613
FT                   /note="11"
FT   REPEAT          618..622
FT                   /note="12"
FT   REPEAT          627..631
FT                   /note="13"
FT   REPEAT          645..649
FT                   /note="14"
FT   REPEAT          663..667
FT                   /note="15"
FT   DOMAIN          5175..5235
FT                   /note="FYR N-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00875"
FT   DOMAIN          5236..5321
FT                   /note="FYR C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00876"
FT   DOMAIN          5397..5513
FT                   /note="SET"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT   DOMAIN          5521..5537
FT                   /note="Post-SET"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00155"
FT   ZN_FING         104..149
FT                   /note="C2HC pre-PHD-type 1; degenerate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01146"
FT   ZN_FING         170..218
FT                   /note="PHD-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01146"
FT   ZN_FING         226..276
FT                   /note="PHD-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   ZN_FING         229..274
FT                   /note="RING-type 1; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         273..323
FT                   /note="PHD-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   ZN_FING         276..321
FT                   /note="RING-type 2; degenerate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         1377..1430
FT                   /note="PHD-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   ZN_FING         1427..1477
FT                   /note="PHD-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   ZN_FING         1504..1559
FT                   /note="PHD-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   ZN_FING         1507..1557
FT                   /note="RING-type 3; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         5029..5069
FT                   /note="C2HC pre-PHD-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01146"
FT   ZN_FING         5090..5137
FT                   /note="PHD-type 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01146"
FT   REGION          439..668
FT                   /note="15 X 5 AA repeats of S/P-P-P-E/P-E/A"
FT   REGION          5474..5475
FT                   /note="S-adenosyl-L-methionine binding"
FT                   /evidence="ECO:0000250"
FT   COILED          2669..2707
FT                   /evidence="ECO:0000255"
FT   COILED          3249..3282
FT                   /evidence="ECO:0000255"
FT   COILED          3562..3614
FT                   /evidence="ECO:0000255"
FT   COILED          3714..3750
FT                   /evidence="ECO:0000255"
FT   COILED          3897..3975
FT                   /evidence="ECO:0000255"
FT   MOTIF           2686..2690
FT                   /note="LXXLL motif 1"
FT   MOTIF           3038..3042
FT                   /note="LXXLL motif 2"
FT   MOTIF           4222..4236
FT                   /note="LXXLL motif 3"
FT   MOTIF           4253..4257
FT                   /note="LXXLL motif 4"
FT   MOTIF           4463..4467
FT                   /note="LXXLL motif 5"
FT   MOTIF           4990..4994
FT                   /note="LXXLL motif 6"
FT   MOTIF           5337..5342
FT                   /note="WDR5 interaction motif (WIN)"
FT                   /evidence="ECO:0000269|PubMed:22266653,
FT                   ECO:0000269|PubMed:22665483"
FT   COMPBIAS        229..326
FT                   /note="Cys-rich"
FT   COMPBIAS        374..1197
FT                   /note="Pro-rich"
FT   COMPBIAS        1290..1328
FT                   /note="Arg-rich"
FT   COMPBIAS        1351..1355
FT                   /note="Poly-Glu"
FT   COMPBIAS        1397..1510
FT                   /note="Cys-rich"
FT   COMPBIAS        2107..2626
FT                   /note="Pro-rich"
FT   COMPBIAS        2385..2392
FT                   /note="Poly-Pro"
FT   COMPBIAS        2707..2713
FT                   /note="Poly-Ala"
FT   COMPBIAS        2811..2822
FT                   /note="Gln-rich"
FT   COMPBIAS        2862..2978
FT                   /note="Pro-rich"
FT   COMPBIAS        3261..4275
FT                   /note="Gln-rich"
FT   COMPBIAS        4241..4360
FT                   /note="Pro-rich"
FT   COMPBIAS        4909..4977
FT                   /note="Pro-rich"
FT   COMPBIAS        5494..5497
FT                   /note="Poly-Ile"
FT   METAL           5477
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           5525
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           5527
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           5532
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   BINDING         5451
FT                   /note="S-adenosyl-L-methionine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT   MOD_RES         27
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         744
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDK2"
FT   MOD_RES         1151
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         1195
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         1249
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         1267
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDK2"
FT   MOD_RES         1270
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDK2"
FT   MOD_RES         1606
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         1671
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163"
FT   MOD_RES         1820
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1834
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1843
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1865
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDK2"
FT   MOD_RES         2239
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         2240
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         2246
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         2260
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         2274
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         2309
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         2311
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         2342
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDK2"
FT   MOD_RES         2535
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDK2"
FT   MOD_RES         2640
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         2836
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDK2"
FT   MOD_RES         3079
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         3130
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         3197
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231"
FT   MOD_RES         3199
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         3433
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         3727
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         4198
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDK2"
FT   MOD_RES         4215
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         4359
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163"
FT   MOD_RES         4465
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         4738
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   MOD_RES         4776
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         4822
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:23186163"
FT   MOD_RES         4849
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   CROSSLNK        4756
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        4880
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1729
FT                   /note="E -> EGET (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:9247308"
FT                   /id="VSP_008560"
FT   VARIANT         170
FT                   /note="Q -> H (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074216"
FT   VARIANT         170
FT                   /note="Q -> L (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074217"
FT   VARIANT         337
FT                   /note="S -> L (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs200245957)"
FT                   /evidence="ECO:0000269|PubMed:22126750"
FT                   /id="VAR_074218"
FT   VARIANT         476
FT                   /note="A -> T (in dbSNP:rs1064210)"
FT                   /id="VAR_057359"
FT   VARIANT         543
FT                   /note="S -> L (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs776242478)"
FT                   /evidence="ECO:0000269|PubMed:21607748"
FT                   /id="VAR_074219"
FT   VARIANT         647
FT                   /note="P -> Q (in KABUK1; dbSNP:rs200088180)"
FT                   /evidence="ECO:0000269|PubMed:21607748,
FT                   ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074220"
FT   VARIANT         692
FT                   /note="P -> T (in dbSNP:rs202076833)"
FT                   /evidence="ECO:0000269|PubMed:21280141"
FT                   /id="VAR_064370"
FT   VARIANT         813
FT                   /note="P -> L (in dbSNP:rs75226229)"
FT                   /evidence="ECO:0000269|PubMed:21280141"
FT                   /id="VAR_064371"
FT   VARIANT         1192
FT                   /note="V -> M (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21607748"
FT                   /id="VAR_074221"
FT   VARIANT         1258
FT                   /note="R -> Q (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs1341612248)"
FT                   /evidence="ECO:0000269|PubMed:21658225"
FT                   /id="VAR_074222"
FT   VARIANT         1376
FT                   /note="M -> R (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074223"
FT   VARIANT         1380
FT                   /note="C -> R (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074224"
FT   VARIANT         1388
FT                   /note="R -> L (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs202217665)"
FT                   /evidence="ECO:0000269|PubMed:21671394"
FT                   /id="VAR_074225"
FT   VARIANT         1417
FT                   /note="M -> V (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21658225"
FT                   /id="VAR_074226"
FT   VARIANT         1418
FT                   /note="L -> M (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21658225"
FT                   /id="VAR_074227"
FT   VARIANT         1423
FT                   /note="R -> C (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074228"
FT   VARIANT         1424
FT                   /note="C -> F (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:24739679"
FT                   /id="VAR_074229"
FT   VARIANT         1430
FT                   /note="C -> R (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21671394"
FT                   /id="VAR_074230"
FT   VARIANT         1445
FT                   /note="C -> G (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074231"
FT   VARIANT         1453
FT                   /note="H -> R (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21607748"
FT                   /id="VAR_074232"
FT   VARIANT         1471
FT                   /note="C -> R (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074233"
FT   VARIANT         1471
FT                   /note="C -> Y (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21671394"
FT                   /id="VAR_074234"
FT   VARIANT         1522
FT                   /note="Q -> R (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21658225"
FT                   /id="VAR_074235"
FT   VARIANT         1526
FT                   /note="C -> F (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074236"
FT   VARIANT         1718
FT                   /note="A -> V (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs111266743)"
FT                   /evidence="ECO:0000269|PubMed:21607748"
FT                   /id="VAR_074237"
FT   VARIANT         2382
FT                   /note="P -> S (in dbSNP:rs3741626)"
FT                   /evidence="ECO:0000269|PubMed:21280141"
FT                   /id="VAR_064372"
FT   VARIANT         2460
FT                   /note="R -> C (in dbSNP:rs570260017)"
FT                   /evidence="ECO:0000269|PubMed:21280141"
FT                   /id="VAR_064373"
FT   VARIANT         2557
FT                   /note="P -> L (in dbSNP:rs189888707)"
FT                   /evidence="ECO:0000269|PubMed:21280141,
FT                   ECO:0000269|PubMed:23320472"
FT                   /id="VAR_064374"
FT   VARIANT         2652
FT                   /note="M -> L (in dbSNP:rs147706410)"
FT                   /evidence="ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074238"
FT   VARIANT         2841
FT                   /note="P -> T (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs763347763)"
FT                   /evidence="ECO:0000269|PubMed:21658225"
FT                   /id="VAR_074239"
FT   VARIANT         3398
FT                   /note="M -> V (in dbSNP:rs75937132)"
FT                   /evidence="ECO:0000269|PubMed:21280141"
FT                   /id="VAR_064375"
FT   VARIANT         3419
FT                   /note="D -> G (in dbSNP:rs146044282)"
FT                   /evidence="ECO:0000269|PubMed:21280141"
FT                   /id="VAR_064376"
FT   VARIANT         3876
FT                   /note="L -> R (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074240"
FT   VARIANT         3897
FT                   /note="L -> S (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs1342235871)"
FT                   /evidence="ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074241"
FT   VARIANT         4010
FT                   /note="S -> P (in dbSNP:rs80132640)"
FT                   /evidence="ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074242"
FT   VARIANT         4353
FT                   /note="P -> L (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs778418522)"
FT                   /evidence="ECO:0000269|PubMed:22126750"
FT                   /id="VAR_074243"
FT   VARIANT         4357
FT                   /note="R -> S (in dbSNP:rs533214351)"
FT                   /evidence="ECO:0000269|PubMed:21280141"
FT                   /id="VAR_064377"
FT   VARIANT         4420
FT                   /note="R -> Q (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs375999143)"
FT                   /evidence="ECO:0000269|PubMed:24739679"
FT                   /id="VAR_074244"
FT   VARIANT         5028
FT                   /note="D -> E (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21658225"
FT                   /id="VAR_074245"
FT   VARIANT         5030
FT                   /note="R -> C (in KABUK1; dbSNP:rs1555185875)"
FT                   /evidence="ECO:0000269|PubMed:23320472,
FT                   ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074246"
FT   VARIANT         5034
FT                   /note="F -> V (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21658225"
FT                   /id="VAR_074247"
FT   VARIANT         5040
FT                   /note="D -> G (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074248"
FT   VARIANT         5047
FT                   /note="A -> V (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:22126750"
FT                   /id="VAR_074249"
FT   VARIANT         5048
FT                   /note="R -> C (in KABUK1; dbSNP:rs398123724)"
FT                   /evidence="ECO:0000269|PubMed:21671394,
FT                   ECO:0000269|PubMed:22126750, ECO:0000269|PubMed:23320472,
FT                   ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074250"
FT   VARIANT         5048
FT                   /note="R -> H (in KABUK1; dbSNP:rs886041404)"
FT                   /evidence="ECO:0000269|PubMed:23320472,
FT                   ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074251"
FT   VARIANT         5059
FT                   /note="H -> P (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21658225"
FT                   /id="VAR_074252"
FT   VARIANT         5109
FT                   /note="C -> F (in KABUK1)"
FT                   /evidence="ECO:0000269|PubMed:20711175,
FT                   ECO:0000269|PubMed:21671394"
FT                   /id="VAR_063830"
FT   VARIANT         5154
FT                   /note="R -> Q (in KABUK1; dbSNP:rs886043497)"
FT                   /evidence="ECO:0000269|PubMed:21607748,
FT                   ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074253"
FT   VARIANT         5179
FT                   /note="R -> H (in KABUK1; dbSNP:rs267607237)"
FT                   /evidence="ECO:0000269|PubMed:20711175,
FT                   ECO:0000269|PubMed:21671394, ECO:0000269|PubMed:23913813"
FT                   /id="VAR_063831"
FT   VARIANT         5189
FT                   /note="G -> R (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs1555185701)"
FT                   /evidence="ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074254"
FT   VARIANT         5210
FT                   /note="Y -> C (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21280141"
FT                   /id="VAR_064378"
FT   VARIANT         5214
FT                   /note="R -> C (in KABUK1)"
FT                   /evidence="ECO:0000269|PubMed:21671394,
FT                   ECO:0000269|PubMed:22126750, ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074255"
FT   VARIANT         5214
FT                   /note="R -> H (in KABUK1; dbSNP:rs398123729)"
FT                   /evidence="ECO:0000269|PubMed:20711175,
FT                   ECO:0000269|PubMed:21671394"
FT                   /id="VAR_063832"
FT   VARIANT         5224
FT                   /note="R -> H (in dbSNP:rs3782356)"
FT                   /id="VAR_017115"
FT   VARIANT         5340
FT                   /note="R -> L (in KABUK1)"
FT                   /evidence="ECO:0000269|PubMed:20711175,
FT                   ECO:0000269|PubMed:21671394"
FT                   /id="VAR_063833"
FT   VARIANT         5340
FT                   /note="R -> Q (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21658225"
FT                   /id="VAR_074256"
FT   VARIANT         5351
FT                   /note="R -> Q (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs1555185217)"
FT                   /evidence="ECO:0000269|PubMed:23913813"
FT                   /id="VAR_074257"
FT   VARIANT         5428
FT                   /note="G -> D (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:21280141"
FT                   /id="VAR_064379"
FT   VARIANT         5432
FT                   /note="R -> W (in KABUK1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074258"
FT   VARIANT         5464
FT                   /note="T -> M (in KABUK1; dbSNP:rs267607238)"
FT                   /evidence="ECO:0000269|PubMed:20711175,
FT                   ECO:0000269|PubMed:21671394"
FT                   /id="VAR_063834"
FT   VARIANT         5471
FT                   /note="R -> T (in KABUK1)"
FT                   /evidence="ECO:0000269|PubMed:21671394,
FT                   ECO:0000269|PubMed:22126750"
FT                   /id="VAR_074259"
FT   VARIANT         5481
FT                   /note="C -> Y (in KABUK1; unknown pathological
FT                   significance; dbSNP:rs1388523736)"
FT                   /evidence="ECO:0000269|PubMed:22126750"
FT                   /id="VAR_074260"
FT   VARIANT         5498
FT                   /note="S -> F (in KABUK1)"
FT                   /evidence="ECO:0000269|PubMed:21607748,
FT                   ECO:0000269|PubMed:23320472"
FT                   /id="VAR_074261"
FT   CONFLICT        5
FT                   /note="K -> N (in Ref. 1; AAC51734)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        14
FT                   /note="E -> Q (in Ref. 1; AAC51734)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        75
FT                   /note="S -> A (in Ref. 1; AAC51734)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        156
FT                   /note="E -> Q (in Ref. 1; AAC51734)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        674..948
FT                   /note="Missing (in Ref. 1; AAC51734)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1178
FT                   /note="Q -> R (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1544..1547
FT                   /note="EQAA -> DHAP (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1761
FT                   /note="K -> R (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1766
FT                   /note="D -> G (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2171
FT                   /note="V -> A (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2413
FT                   /note="A -> V (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3079
FT                   /note="K -> E (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3287
FT                   /note="S -> P (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3319
FT                   /note="G -> V (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3422
FT                   /note="D -> G (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4478
FT                   /note="R -> Q (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4747
FT                   /note="A -> D (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4793
FT                   /note="A -> D (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4826
FT                   /note="A -> G (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4865
FT                   /note="P -> A (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4871
FT                   /note="S -> R (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4893
FT                   /note="S -> R (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4974
FT                   /note="S -> T (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        5116
FT                   /note="A -> G (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        5522
FT                   /note="K -> E (in Ref. 1; AAC51734/AAC51735)"
FT                   /evidence="ECO:0000305"
FT   TURN            1508..1511
FT                   /evidence="ECO:0000244|PDB:6O7G"
FT   STRAND          1516..1518
FT                   /evidence="ECO:0000244|PDB:6O7G"
FT   STRAND          1520..1522
FT                   /evidence="ECO:0000244|PDB:6O7G"
FT   TURN            1524..1526
FT                   /evidence="ECO:0000244|PDB:6O7G"
FT   STRAND          1529..1532
FT                   /evidence="ECO:0000244|PDB:6O7G"
FT   HELIX           1533..1535
FT                   /evidence="ECO:0000244|PDB:6O7G"
FT   HELIX           1540..1548
FT                   /evidence="ECO:0000244|PDB:6O7G"
FT   HELIX           1556..1560
FT                   /evidence="ECO:0000244|PDB:6O7G"
FT   HELIX           5339..5341
FT                   /evidence="ECO:0000244|PDB:3UVK"
FT   HELIX           5384..5398
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5399..5403
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5405..5415
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5422..5425
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5428..5432
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   HELIX           5433..5444
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   TURN            5445..5447
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5452..5454
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5456..5462
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   TURN            5464..5466
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   HELIX           5469..5472
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5480..5488
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5491..5500
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5516..5520
FT                   /evidence="ECO:0000244|PDB:4Z4P"
FT   STRAND          5534..5536
FT                   /evidence="ECO:0000244|PDB:4Z4P"
SQ   SEQUENCE   5537 AA;  593389 MW;  31C6DAB0A754F72A CRC64;
     MDSQKLAGED KDSEPAADGP AASEDPSATE SDLPNPHVGE VSVLSSGSPR LQETPQDCSG
     GPVRRCALCN CGEPSLHGQR ELRRFELPFD WPRCPVVSPG GSPGPNEAVL PSEDLSQIGF
     PEGLTPAHLG EPGGSCWAHH WCAAWSAGVW GQEGPELCGV DKAIFSGISQ RCSHCTRLGA
     SIPCRSPGCP RLYHFPCATA SGSFLSMKTL QLLCPEHSEG AAYLEEARCA VCEGPGELCD
     LFFCTSCGHH YHGACLDTAL TARKRAGWQC PECKVCQACR KPGNDSKMLV CETCDKGYHT
     FCLKPPMEEL PAHSWKCKAC RVCRACGAGS AELNPNSEWF ENYSLCHRCH KAQGGQTIRS
     VAEQHTPVCS RFSPPEPGDT PTDEPDALYV ACQGQPKGGH VTSMQPKEPG PLQCEAKPLG
     KAGVQLEPQL EAPLNEEMPL LPPPEESPLS PPPEESPTSP PPEASRLSPP PEELPASPLP
     EALHLSRPLE ESPLSPPPEE SPLSPPPESS PFSPLEESPL SPPEESPPSP ALETPLSPPP
     EASPLSPPFE ESPLSPPPEE LPTSPPPEAS RLSPPPEESP MSPPPEESPM SPPPEASRLF
     PPFEESPLSP PPEESPLSPP PEASRLSPPP EDSPMSPPPE ESPMSPPPEV SRLSPLPVVS
     RLSPPPEESP LSPPPEESPT SPPPEASRLS PPPEDSPTSP PPEDSPASPP PEDSLMSLPL
     EESPLLPLPE EPQLCPRSEG PHLSPRPEEP HLSPRPEEPH LSPQAEEPHL SPQPEEPCLC
     AVPEEPHLSP QAEGPHLSPQ PEELHLSPQT EEPHLSPVPE EPCLSPQPEE SHLSPQSEEP
     CLSPRPEESH LSPELEKPPL SPRPEKPPEE PGQCPAPEEL PLFPPPGEPS LSPLLGEPAL
     SEPGEPPLSP LPEELPLSPS GEPSLSPQLM PPDPLPPPLS PIITAAAPPA LSPLGELEYP
     FGAKGDSDPE SPLAAPILET PISPPPEANC TDPEPVPPMI LPPSPGSPVG PASPILMEPL
     PPQCSPLLQH SLVPQNSPPS QCSPPALPLS VPSPLSPIGK VVGVSDEAEL HEMETEKVSE
     PECPALEPSA TSPLPSPMGD LSCPAPSPAP ALDDFSGLGE DTAPLDGIDA PGSQPEPGQT
     PGSLASELKG SPVLLDPEEL APVTPMEVYP ECKQTAGQGS PCEEQEEPRA PVAPTPPTLI
     KSDIVNEISN LSQGDASASF PGSEPLLGSP DPEGGGSLSM ELGVSTDVSP ARDEGSLRLC
     TDSLPETDDS LLCDAGTAIS GGKAEGEKGR RRSSPARSRI KQGRSSSFPG RRRPRGGAHG
     GRGRGRARLK STASSIETLV VADIDSSPSK EEEEEDDDTM QNTVVLFSNT DKFVLMQDMC
     VVCGSFGRGA EGHLLACSQC SQCYHPYCVN SKITKVMLLK GWRCVECIVC EVCGQASDPS
     RLLLCDDCDI SYHTYCLDPP LLTVPKGGWK CKWCVSCMQC GAASPGFHCE WQNSYTHCGP
     CASLVTCPIC HAPYVEEDLL IQCRHCERWM HAGCESLFTE DDVEQAADEG FDCVSCQPYV
     VKPVAPVAPP ELVPMKVKEP EPQYFRFEGV WLTETGMALL RNLTMSPLHK RRQRRGRLGL
     PGEAGLEGSE PSDALGPDDK KDGDLDTDEL LKGEGGVEHM ECEIKLEGPV SPDVEPGKEE
     TEESKKRKRK PYRPGIGGFM VRQRKSHTRT KKGPAAQAEV LSGDGQPDEV IPADLPAEGA
     VEQSLAEGDE KKKQQRRGRK KSKLEDMFPA YLQEAFFGKE LLDLSRKALF AVGVGRPSFG
     LGTPKAKGDG GSERKELPTS QKGDDGPDIA DEESRGLEGK ADTPGPEDGG VKASPVPSDP
     EKPGTPGEGM LSSDLDRIST EELPKMESKD LQQLFKDVLG SEREQHLGCG TPGLEGSRTP
     LQRPFLQGGL PLGNLPSSSP MDSYPGLCQS PFLDSRERGG FFSPEPGEPD SPWTGSGGTT
     PSTPTTPTTE GEGDGLSYNQ RSLQRWEKDE ELGQLSTISP VLYANINFPN LKQDYPDWSS
     RCKQIMKLWR KVPAADKAPY LQKAKDNRAA HRINKVQKQA ESQINKQTKV GDIARKTDRP
     ALHLRIPPQP GALGSPPPAA APTIFIGSPT TPAGLSTSAD GFLKPPAGSV PGPDSPGELF
     LKLPPQVPAQ VPSQDPFGLA PAYPLEPRFP TAPPTYPPYP SPTGAPAQPP MLGASSRPGA
     GQPGEFHTTP PGTPRHQPST PDPFLKPRCP SLDNLAVPES PGVGGGKASE PLLSPPPFGE
     SRKALEVKKE ELGASSPSYG PPNLGFVDSP SSGTHLGGLE LKTPDVFKAP LTPRASQVEP
     QSPGLGLRPQ EPPPAQALAP SPPSHPDIFR PGSYTDPYAQ PPLTPRPQPP PPESCCALPP
     RSLPSDPFSR VPASPQSQSS SQSPLTPRPL SAEAFCPSPV TPRFQSPDPY SRPPSRPQSR
     DPFAPLHKPP RPQPPEVAFK AGSLAHTSLG AGGFPAALPA GPAGELHAKV PSGQPPNFVR
     SPGTGAFVGT PSPMRFTFPQ AVGEPSLKPP VPQPGLPPPH GINSHFGPGP TLGKPQSTNY
     TVATGNFHPS GSPLGPSSGS TGESYGLSPL RPPSVLPPPA PDGSLPYLSH GASQRSGITS
     PVEKREDPGT GMGSSLATAE LPGTQDPGMS GLSQTELEKQ RQRQRLRELL IRQQIQRNTL
     RQEKETAAAA AGAVGPPGSW GAEPSSPAFE QLSRGQTPFA GTQDKSSLVG LPPSKLSGPI
     LGPGSFPSDD RLSRPPPPAT PSSMDVNSRQ LVGGSQAFYQ RAPYPGSLPL QQQQQQLWQQ
     QQATAATSMR FAMSARFPST PGPELGRQAL GSPLAGISTR LPGPGEPVPG PAGPAQFIEL
     RHNVQKGLGP GGTPFPGQGP PQRPRFYPVS EDPHRLAPEG LRGLAVSGLP PQKPSAPPAP
     ELNNSLHPTP HTKGPTLPTG LELVNRPPSS TELGRPNPLA LEAGKLPCED PELDDDFDAH
     KALEDDEELA HLGLGVDVAK GDDELGTLEN LETNDPHLDD LLNGDEFDLL AYTDPELDTG
     DKKDIFNEHL RLVESANEKA EREALLRGVE PGPLGPEERP PPAADASEPR LASVLPEVKP
     KVEEGGRHPS PCQFTIATPK VEPAPAANSL GLGLKPGQSM MGSRDTRMGT GPFSSSGHTA
     EKASFGATGG PPAHLLTPSP LSGPGGSSLL EKFELESGAL TLPGGPAASG DELDKMESSL
     VASELPLLIE DLLEHEKKEL QKKQQLSAQL QPAQQQQQQQ QQHSLLSAPG PAQAMSLPHE
     GSSPSLAGSQ QQLSLGLAGA RQPGLPQPLM PTQPPAHALQ QRLAPSMAMV SNQGHMLSGQ
     HGGQAGLVPQ QSSQPVLSQK PMGTMPPSMC MKPQQLAMQQ QLANSFFPDT DLDKFAAEDI
     IDPIAKAKMV ALKGIKKVMA QGSIGVAPGM NRQQVSLLAQ RLSGGPSSDL QNHVAAGSGQ
     ERSAGDPSQP RPNPPTFAQG VINEADQRQY EEWLFHTQQL LQMQLKVLEE QIGVHRKSRK
     ALCAKQRTAK KAGREFPEAD AEKLKLVTEQ QSKIQKQLDQ VRKQQKEHTN LMAEYRNKQQ
     QQQQQQQQQQ QQHSAVLALS PSQSPRLLTK LPGQLLPGHG LQPPQGPPGG QAGGLRLTPG
     GMALPGQPGG PFLNTALAQQ QQQQHSGGAG SLAGPSGGFF PGNLALRSLG PDSRLLQERQ
     LQLQQQRMQL AQKLQQQQQQ QQQQQHLLGQ VAIQQQQQQG PGVQTNQALG PKPQGLMPPS
     SHQGLLVQQL SPQPPQGPQG MLGPAQVAVL QQQHPGALGP QGPHRQVLMT QSRVLSSPQL
     AQQGQGLMGH RLVTAQQQQQ QQQHQQQGSM AGLSHLQQSL MSHSGQPKLS AQPMGSLQQL
     QQQQQLQQQQ QLQQQQQQQL QQQQQLQQQQ LQQQQQQQQL QQQQQQQLQQ QQQQLQQQQQ
     QQQQQFQQQQ QQQQMGLLNQ SRTLLSPQQQ QQQQVALGPG MPAKPLQHFS SPGALGPTLL
     LTGKEQNTVD PAVSSEATEG PSTHQGGPLA IGTTPESMAT EPGEVKPSLS GDSQLLLVQP
     QPQPQPSSLQ LQPPLRLPGQ QQQQVSLLHT AGGGSHGQLG SGSSSEASSV PHLLAQPSVS
     LGDQPGSMTQ NLLGPQQPML ERPMQNNTGP QPPKPGPVLQ SGQGLPGVGI MPTVGQLRAQ
     LQGVLAKNPQ LRHLSPQQQQ QLQALLMQRQ LQQSQAVRQT PPYQEPGTQT SPLQGLLGCQ
     PQLGGFPGPQ TGPLQELGAG PRPQGPPRLP APPGALSTGP VLGPVHPTPP PSSPQEPKRP
     SQLPSPSSQL PTEAQLPPTH PGTPKPQGPT LEPPPGRVSP AAAQLADTLF SKGLGPWDPP
     DNLAETQKPE QSSLVPGHLD QVNGQVVPEA SQLSIKQEPR EEPCALGAQS VKREANGEPI
     GAPGTSNHLL LAGPRSEAGH LLLQKLLRAK NVQLSTGRGS EGLRAEINGH IDSKLAGLEQ
     KLQGTPSNKE DAAARKPLTP KPKRVQKASD RLVSSRKKLR KEDGVRASEA LLKQLKQELS
     LLPLTEPAIT ANFSLFAPFG SGCPVNGQSQ LRGAFGSGAL PTGPDYYSQL LTKNNLSNPP
     TPPSSLPPTP PPSVQQKMVN GVTPSEELGE HPKDAASARD SERALRDTSE VKSLDLLAAL
     PTPPHNQTED VRMESDEDSD SPDSIVPASS PESILGEEAP RFPHLGSGRW EQEDRALSPV
     IPLIPRASIP VFPDTKPYGA LGLEVPGKLP VTTWEKGKGS EVSVMLTVSA AAAKNLNGVM
     VAVAELLSMK IPNSYEVLFP ESPARAGTEP KKGEAEGPGG KEKGLEGKSP DTGPDWLKQF
     DAVLPGYTLK SQLDILSLLK QESPAPEPPT QHSYTYNVSN LDVRQLSAPP PEEPSPPPSP
     LAPSPASPPT EPLVELPTEP LAEPPVPSPL PLASSPESAR PKPRARPPEE GEDSRPPRLK
     KWKGVRWKRL RLLLTIQKGS GRQEDEREVA EFMEQLGTAL RPDKVPRDMR RCCFCHEEGD
     GATDGPARLL NLDLDLWVHL NCALWSTEVY ETQGGALMNV EVALHRGLLT KCSLCQRTGA
     TSSCNRMRCP NVYHFACAIR AKCMFFKDKT MLCPMHKIKG PCEQELSSFA VFRRVYIERD
     EVKQIASIIQ RGERLHMFRV GGLVFHAIGQ LLPHQMADFH SATALYPVGY EATRIYWSLR
     TNNRRCCYRC SIGENNGRPE FVIKVIEQGL EDLVFTDASP QAVWNRIIEP VAAMRKEADM
     LRLFPEYLKG EELFGLTVHA VLRIAESLPG VESCQNYLFR YGRHPLMELP LMINPTGCAR
     SEPKILTHYK RPHTLNSTSM SKAYQSTFTG ETNTPYSKQF VHSKSSQYRR LRTEWKNNVY
     LARSRIQGLG LYAAKDLEKH TMVIEYIGTI IRNEVANRRE KIYEEQNRGI YMFRINNEHV
     IDATLTGGPA RYINHSCAPN CVAEVVTFDK EDKIIIISSR RIPKGEELTY DYQFDFEDDQ
     HKIPCHCGAW NCRKWMN
//
ID   Q59FG6_HUMAN            Unreviewed;      2704 AA.
AC   Q59FG6;
DT   26-APR-2005, integrated into UniProtKB/TrEMBL.
DT   26-APR-2005, sequence version 1.
DT   26-FEB-2020, entry version 93.
DE   SubName: Full=Myeloid/lymphoid or mixed-lineage leukemia 2 variant {ECO:0000313|EMBL:BAD92731.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD92731.1};
RN   [1] {ECO:0000313|EMBL:BAD92731.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:BAD92731.1};
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB209494; BAD92731.1; -; mRNA.
DR   RefSeq; NP_003473.3; NM_003482.3.
DR   PeptideAtlas; Q59FG6; -.
DR   PRIDE; Q59FG6; -.
DR   GeneID; 8085; -.
DR   KEGG; hsa:8085; -.
DR   CTD; 8085; -.
DR   PharmGKB; PA30846; -.
DR   eggNOG; KOG4443; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   KO; K09187; -.
DR   OrthoDB; 61027at2759; -.
DR   GenomeRNAi; 8085; -.
DR   Genevisible; Q59FG6; HS.
DR   GO; GO:0035097; C:histone methyltransferase complex; IEA:InterPro.
DR   GO; GO:0042800; F:histone methyltransferase activity (H3-K4 specific); IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   CDD; cd15698; ePHD2_KMT2D; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR034732; EPHD.
DR   InterPro; IPR003889; FYrich_C.
DR   InterPro; IPR003888; FYrich_N.
DR   InterPro; IPR037890; KMT2D.
DR   InterPro; IPR041964; KMT2D_ePHD2.
DR   InterPro; IPR003616; Post-SET_dom.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR45888:SF2; PTHR45888:SF2; 1.
DR   Pfam; PF05965; FYRC; 1.
DR   Pfam; PF05964; FYRN; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM00542; FYRC; 1.
DR   SMART; SM00541; FYRN; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00508; PostSET; 1.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51805; EPHD; 1.
DR   PROSITE; PS51543; FYRC; 1.
DR   PROSITE; PS51542; FYRN; 1.
DR   PROSITE; PS50868; POST_SET; 1.
DR   PROSITE; PS50280; SET; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|SAAS:SAAS00981487};
KW   S-adenosyl-L-methionine {ECO:0000256|SAAS:SAAS00591079};
KW   Zinc {ECO:0000256|SAAS:SAAS00981487};
KW   Zinc-finger {ECO:0000256|SAAS:SAAS00981487}.
FT   DOMAIN          2196..2304
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000259|PROSITE:PS51805"
FT   DOMAIN          2342..2402
FT                   /note="FYR N-terminal"
FT                   /evidence="ECO:0000259|PROSITE:PS51542"
FT   DOMAIN          2403..2488
FT                   /note="FYR C-terminal"
FT                   /evidence="ECO:0000259|PROSITE:PS51543"
FT   DOMAIN          2564..2680
FT                   /note="SET"
FT                   /evidence="ECO:0000259|PROSITE:PS50280"
FT   DOMAIN          2688..2704
FT                   /note="Post-SET"
FT                   /evidence="ECO:0000259|PROSITE:PS50868"
FT   REGION          1..163
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          244..277
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          314..376
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          430..508
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          521..546
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          629..666
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          763..840
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          925..969
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1151..1358
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1400..1619
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1670..1711
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1780..1894
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1989..2024
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2072..2147
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          883..910
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COILED          1064..1139
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        330..349
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        431..456
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        465..484
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        629..654
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        763..796
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        948..963
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1188..1217
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1259..1334
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1400..1424
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1470..1488
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1489..1503
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1504..1523
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1552..1579
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1681..1711
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1787..1801
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1814..1837
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1994..2016
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2076..2123
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2129..2147
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:BAD92731.1"
SQ   SEQUENCE   2704 AA;  293186 MW;  41D0C6900D23C5ED CRC64;
     SARFPSTPGP ELGRQALGSP LAGISTRLPG PGEPVPGPAG PAQFIELRHN VQKGLGPGGT
     PFPGQGPPQR PRFYPVSEDP HRLAPEGLRG LAVSGLPPQK PSAPPAPELN NSLHPTPHTK
     GPTLPTGLEL VNRPPSSTEL GRPNPLALEA GKLPCEDPEL DDDFDAHKAL EDDEELAHLG
     LGVDVAKGDD ELGTLENLET NDPHLDDLLN GDEFDLLAYT DPELDTGDKK DIFNEHLRLV
     ESANEKAERE ALLRGVEPGP LGPEERPPPA ADASEPRLAS VLPEVKPKVE EGGRHPSPCQ
     FTIATPKVEP APAANSLGLG LKPGQSMMGS RDTRMGTGPF SSSGHTAEKA SFGATGGPPA
     HLLTPSPLSG PGGSSLLEKF ELESGALTLP GGPAASGDEL DKMESSLVAS ELPLLIEDLL
     EHEKKELQKK QQLSAQLQPA QQQQQQQQQH SLLSAPGPAQ AMSLPHEGSS PSLAGSQQQL
     SLGLAGARQP GLPQPLMPTQ PPAHALQQRL APSMAMVSNQ GHMLSGQHGG QAGLVPQQSS
     QPVLSQKPMG TMPPSMCMKP QQLAMQQQLA NSFFPDTDLD KFAAEDIIDP IAKAKMVALK
     GIKKVMAQGS IGVAPGMNRQ QVSLLAQRLS GGPSSDLQNH VAAGSGQERS AGDPSQPRPN
     PPTFAQGVIN EADQRQYEEW LFHTQQLLQM QLKVLEEQIG VHRKSRKALC AKQRTAKKAG
     REFPEADAEK LKLVTEQQSK IQKQLDQVRK QQKEHTNLMA EYRNKQQQQQ QQQQQQQQQH
     SAVLALSPSQ SPRLLTKLPG QLLPGHGLQP PQGPPGGQAG GLRLTPGGMA LPGQPGGPFL
     NTALAQQQQQ QHSGGAGSLA GPSGGFFPGN LALRSLGPDS RLLQERQLQL QQQRMQLAQK
     LQQQQQQQQQ QQHLLGQVAI QQQQQQGPGV QTNQALGPKP QGLMPPSSHQ GLLVQQLSPQ
     PPQGPQGMLG PAQVAVLQQQ HPGALGPQGP HRQVLMTQSR VLSSPQLAQQ GQGLMGHRLV
     TAQQQQQQQQ HQQQGSMAGL SHLQQSLMSH SGQPKLSAQP MGSLQQLQQQ QQLQQQQQLQ
     QQQQQQLQQQ QQLQQQQLQQ QQQQQQLQQQ QQQQLQQQQQ QLQQQQQQQQ QQFQQQQQQQ
     QMGLLNQSRT LLSPQQQQQQ QVALGPGMPA KPLQHFSSPG ALGPTLLLTG KEQNTVDPAV
     SSEATEGPST HQGGPLAIGT TPESMATEPG EVKPSLSGDS QLLLVQPQPQ PQPSSLQLQP
     PLRLPGQQQQ QVSLLHTAGG GSHGQLGSGS SSEASSVPHL LAQPSVSLGD QPGSMTQNLL
     GPQQPMLERP MQNNTGPQPP KPGPVLQSGQ GLPGVGIMPT VGQLRAQLQG VLAKNPQLRH
     LSPQQQQQLQ ALLMQRQLQQ SQAVRQTPPY QEPGTQTSPL QGLLGCQPQL GGFPGPQTGP
     LQELGAGPRP QGPPRLPAPP GALSTGPVLG PVHPTPPPSS PQEPKRPSQL PSPSSQLPTE
     AQLPPTHPGT PKPQGPTLEP PPGRVSPAAA QLADTLFSKG LGPWDPPDNL AETQKPEQSS
     LVPGHLDQVN GQVVPEASQL SIKQEPREEP CALGAQSVKR EANGEPIGAP GTSNHLLLAG
     PRSEAGHLLL QKLLRAKNVQ LSTGRGSEGL RAEINGHIDS KLAGLEQKLQ GTPSNKEDAA
     ARKPLTPKPK RVQKASDRLV SSRKKLRKED GVRASEALLK QLKQELSLLP LTEPAITANF
     SLFAPFGSGC PVNGQSQLRG AFGSGALPTG PDYYSQLLTK NNLSNPPTPP SSLPPTPPPS
     VQQKMVNGVT PSEELGEHPK DAASARDSER ALRDTSEVKS LDLLAALPTP PHNQTEDVRM
     ESDEDSDSPD SIVPASSPES ILGEEAPRFP HLGSGRWEQE DRALSPVIPL IPRASIPVFP
     DTKPYGALGL EVPGKLPVTT WEKGKGSEVS VMLTVSAAAA KNLNGVMVAV AELLSMKIPN
     SYEVLFPESP ARAGTEPKKG EAEGPGGKEK GLEGKSPDTG PDWLKQFDAV LPGYTLKSQL
     DILSLLKQES PAPEPPTQHS YTYNVSNLDV RQLSAPPPEE PSPPPSPLAP SPASPPTEPL
     VELPTEPLAE PPVPSPLPLA SSPESARPKP RARPPEEGED SRPPRLKKWK GVRWKRLRLL
     LTIQKGSGRQ EDEREVAEFM EQLGTALRPD KVPRDMRRCC FCHEEGDGAT DGPARLLNLD
     LDLWVHLNCA LWSTEVYETQ GGALMNVEVA LHRGLLTKCS LCQRTGATSS CNRMRCPNVY
     HFACAIRAKC MFFKDKTMLC PMHKIKGPCE QELSSFAVFR RVYIERDEVK QIASIIQRGE
     RLHMFRVGGL VFHAIGQLLP HQMADFHSAT ALYPVGYEAT RIYWSLRTNN RRCCYRCSIG
     ENNGRPEFVI KVIEQGLEDL VFTDASPQAV WNRIIEPVAA MRKEADMLRL FPEYLKGEEL
     FGLTVHAVLR IAESLPGVES CQNYLFRYGR HPLMELPLMI NPTGCARSEP KILTHYKRPH
     TLNSTSMSKA YQSTFTGETN TPYSKQFVHS KSSQYRRLRT EWKNNVYLAR SRIQGLGLYA
     AKDLEKHTMV IEYIGTIIRN EVANRREKIY EEQNRGIYMF RINNEHVIDA TLTGGPARYI
     NHSCAPNCVA EVVTFDKEDK IIIISSRRIP KGEELTYDYQ FDFEDDQHKI PCHCGAWNCR
     KWMN
//
ID   Q6PIA1_HUMAN            Unreviewed;       395 AA.
AC   Q6PIA1;
DT   05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   05-JUL-2004, sequence version 1.
DT   26-FEB-2020, entry version 93.
DE   SubName: Full=MLL2 protein {ECO:0000313|EMBL:AAH39197.1};
DE   Flags: Fragment;
GN   Name=MLL2 {ECO:0000313|EMBL:AAH39197.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH39197.1};
RN   [1] {ECO:0000313|EMBL:AAH39197.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAH39197.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC039197; AAH39197.1; -; mRNA.
DR   RefSeq; NP_003473.3; NM_003482.3.
DR   PeptideAtlas; Q6PIA1; -.
DR   PRIDE; Q6PIA1; -.
DR   GeneID; 8085; -.
DR   KEGG; hsa:8085; -.
DR   CTD; 8085; -.
DR   PharmGKB; PA30846; -.
DR   eggNOG; KOG4443; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   KO; K09187; -.
DR   OrthoDB; 61027at2759; -.
DR   GenomeRNAi; 8085; -.
DR   Genevisible; Q6PIA1; HS.
DR   GO; GO:0035097; C:histone methyltransferase complex; IEA:InterPro.
DR   GO; GO:0042800; F:histone methyltransferase activity (H3-K4 specific); IEA:InterPro.
DR   InterPro; IPR003889; FYrich_C.
DR   InterPro; IPR003888; FYrich_N.
DR   InterPro; IPR037890; KMT2D.
DR   InterPro; IPR003616; Post-SET_dom.
DR   InterPro; IPR001214; SET_dom.
DR   PANTHER; PTHR45888:SF2; PTHR45888:SF2; 1.
DR   Pfam; PF05965; FYRC; 1.
DR   Pfam; PF05964; FYRN; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM00542; FYRC; 1.
DR   SMART; SM00541; FYRN; 1.
DR   SMART; SM00508; PostSET; 1.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51543; FYRC; 1.
DR   PROSITE; PS51542; FYRN; 1.
DR   PROSITE; PS50868; POST_SET; 1.
DR   PROSITE; PS50280; SET; 1.
PE   2: Evidence at transcript level;
KW   S-adenosyl-L-methionine {ECO:0000256|SAAS:SAAS00591079}.
FT   DOMAIN          33..93
FT                   /note="FYR N-terminal"
FT                   /evidence="ECO:0000259|PROSITE:PS51542"
FT   DOMAIN          94..179
FT                   /note="FYR C-terminal"
FT                   /evidence="ECO:0000259|PROSITE:PS51543"
FT   DOMAIN          255..371
FT                   /note="SET"
FT                   /evidence="ECO:0000259|PROSITE:PS50280"
FT   DOMAIN          379..395
FT                   /note="Post-SET"
FT                   /evidence="ECO:0000259|PROSITE:PS50868"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:AAH39197.1"
SQ   SEQUENCE   395 AA;  45887 MW;  FFFB100760B8623B CRC64;
     EQELSSFAVF RRVYIERDEV KQIASIIQRG ERLHMFRVGG LVFHAIGQLL PHQMADFHSA
     TALYPVGYEA TRIYWSLRTN NRRCCYRCSI GENNGRPEFV IKVIEQGLED LVFTDASPQA
     VWNRIIEPVA AMRKEADMLR LFPEYLKGEE LFGLTVHAVL RIAESLPGVE SCQNYLFRYG
     RHPLMELPLM INPTGCARSE PKILTHYKRP HTLNSTSMSK AYQSTFTGET NTPYSKQFVH
     SKSSQYRRLR TEWKNNVYLA RSRIQGLGLY AAKDLEKHTM VIEYIGTIIR NEVANRREKI
     YEEQNRGIYM FRINNEHVID ATLTGGPARY INHSCAPNCV AEVVTFDKED KIIIISSRRI
     PKGEELTYDY QFDFEDDQHK IPCHCGAWNC RKWMN
//
ID   Q659G9_HUMAN            Unreviewed;        69 AA.
AC   Q659G9;
DT   25-OCT-2004, integrated into UniProtKB/TrEMBL.
DT   25-OCT-2004, sequence version 1.
DT   11-DEC-2019, entry version 91.
DE   SubName: Full=Uncharacterized protein DKFZp586H0919 {ECO:0000313|EMBL:CAH56421.1};
DE   Flags: Fragment;
GN   Name=DKFZp586H0919 {ECO:0000313|EMBL:CAH56421.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:CAH56421.1};
RN   [1] {ECO:0000313|EMBL:CAH56421.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Uterus {ECO:0000313|EMBL:CAH56421.1};
RG   The German cDNA Consortium;
RA   Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A., Fobo G.,
RA   Han M., Wiemann S.;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL049409; CAH56421.1; -; mRNA.
DR   RefSeq; NP_001124185.1; NM_001130713.2.
DR   RefSeq; NP_001124186.1; NM_001130714.2.
DR   RefSeq; NP_001159591.1; NM_001166119.1.
DR   RefSeq; NP_057353.1; NM_016269.4.
DR   PeptideAtlas; Q659G9; -.
DR   PRIDE; Q659G9; -.
DR   DNASU; 51176; -.
DR   GeneID; 51176; -.
DR   KEGG; hsa:51176; -.
DR   CTD; 51176; -.
DR   PharmGKB; PA30331; -.
DR   eggNOG; KOG3248; Eukaryota.
DR   eggNOG; ENOG41109RU; LUCA.
DR   KO; K04492; -.
DR   OrthoDB; 807716at2759; -.
DR   GenomeRNAi; 51176; -.
DR   Genevisible; Q659G9; HS.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-UniRule.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:InterPro.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IEA:InterPro.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:InterPro.
DR   Gene3D; 1.10.30.10; -; 1.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR028769; LEF1.
DR   InterPro; IPR024940; TCF/LEF.
DR   PANTHER; PTHR10373; PTHR10373; 1.
DR   PANTHER; PTHR10373:SF11; PTHR10373:SF11; 1.
DR   Pfam; PF00505; HMG_box; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00267};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00267}.
FT   DOMAIN          1..37
FT                   /note="HMG box"
FT                   /evidence="ECO:0000259|PROSITE:PS50118"
FT   DNA_BIND        1..37
FT                   /note="HMG box"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00267"
FT   REGION          39..69
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:CAH56421.1"
SQ   SEQUENCE   69 AA;  8251 MW;  CBF29BD0C3287867 CRC64;
     QILGRRWHAL SREEQAKYYE LARKERQLHM QLYPGWSARD NYGKKKKRKR EKLQESASGT
     GPRMTAAYI
//
ID   LEF1_HUMAN              Reviewed;         399 AA.
AC   Q9UJU2; B4DG38; B7Z8E2; E9PDK3; Q3ZCU4; Q9HAZ0;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   22-APR-2020, entry version 192.
DE   RecName: Full=Lymphoid enhancer-binding factor 1;
DE            Short=LEF-1;
DE   AltName: Full=T cell-specific transcription factor 1-alpha;
DE            Short=TCF1-alpha;
GN   Name=LEF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   FUNCTION.
RX   PubMed=2010090; DOI=10.1101/gad.5.4.656;
RA   Waterman M.L., Fischer W.H., Jones K.A.;
RT   "A thymus-specific member of the HMG protein family regulates the human T
RT   cell receptor C alpha enhancer.";
RL   Genes Dev. 5:656-669(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RX   PubMed=10756202; DOI=10.1093/nar/28.9.1994;
RA   Hovanes K., Li T.W., Waterman M.L.;
RT   "The human LEF-1 gene contains a promoter preferentially active in
RT   lymphocytes and encodes multiple isoforms derived from alternative
RT   splicing.";
RL   Nucleic Acids Res. 28:1994-2003(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 5), ALTERNATIVE SPLICING,
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=19653274; DOI=10.1002/ijc.24802;
RA   Jesse S., Koenig A., Ellenrieder V., Menke A.;
RT   "Lef-1 isoforms regulate different target genes and reduce cellular
RT   adhesion.";
RL   Int. J. Cancer 126:1109-1120(2010).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3).
RA   Kobielak A., Kobielak K., Trzeciak W.H.;
RT   "New transcript isoform of the human LEF-1 devoid of HMG domain, derived
RT   from alternative splicing of exon 8.";
RL   Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 5 AND 7).
RC   TISSUE=Amygdala, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 6).
RC   TISSUE=Skin, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH ALYREF/THOC4.
RX   PubMed=9119228; DOI=10.1101/gad.11.5.640;
RA   Bruhn L., Munnerlyn A., Grosschedl R.;
RT   "ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for
RT   TCRalpha enhancer function.";
RL   Genes Dev. 11:640-653(1997).
RN   [10]
RP   INTERACTION WITH CTNNB1.
RX   PubMed=9488439; DOI=10.1128/mcb.18.3.1248;
RA   Korinek V., Barker N., Willert K., Molenaar M., Roose J., Wagenaar G.,
RA   Markman M., Lamers W., Destree O., Clevers H.;
RT   "Two members of the Tcf family implicated in Wnt/b-catenin signaling during
RT   embryogenesis in the mouse.";
RL   Mol. Cell. Biol. 18:1248-1256(1998).
RN   [11]
RP   INTERACTION WITH TLE1, AND INHIBITION OF TRANSCRIPTIONAL ACTIVATION BY
RP   TLE1.
RX   PubMed=9751710; DOI=10.1073/pnas.95.20.11590;
RA   Levanon D., Goldstein R.E., Bernstein Y., Tang H., Goldenberg D.,
RA   Stifani S., Paroush Z., Groner Y.;
RT   "Transcriptional repression by AML1 and LEF-1 is mediated by the
RT   TLE/Groucho corepressors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11590-11595(1998).
RN   [12]
RP   IDENTIFICATION (ISOFORM 3), FUNCTION, AND EXPRESSION IN COLON CANCER.
RX   PubMed=11326276; DOI=10.1038/ng0501-53;
RA   Hovanes K., Li T.W.H., Munguia J.E., Truong T., Milovanovic T.,
RA   Lawrence Marsh J., Holcombe R.F., Waterman M.L.;
RT   "Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are
RT   selectively expressed in colon cancer.";
RL   Nat. Genet. 28:53-57(2001).
RN   [13]
RP   FUNCTIONAL INTERACTION WITH TLE1; TLE2; TLE3 AND TLE4.
RX   PubMed=11266540; DOI=10.1093/nar/29.7.1410;
RA   Brantjes H., Roose J., van De Wetering M., Clevers H.;
RT   "All Tcf HMG box transcription factors interact with Groucho-related co-
RT   repressors.";
RL   Nucleic Acids Res. 29:1410-1419(2001).
RN   [14]
RP   INTERACTION WITH MDFI AND MDFIC.
RX   PubMed=12192039; DOI=10.1128/mcb.22.18.6393-6405.2002;
RA   Kusano S., Raab-Traub N.;
RT   "I-mfa domain proteins interact with Axin and affect its regulation of the
RT   Wnt and c-Jun N-terminal kinase signaling pathways.";
RL   Mol. Cell. Biol. 22:6393-6405(2002).
RN   [15]
RP   INTERACTION WITH NLK, PHOSPHORYLATION AT THR-155 AND/OR SER-166 BY NLK, AND
RP   MUTAGENESIS OF THR-155 AND SER-166.
RX   PubMed=12556497; DOI=10.1128/mcb.23.4.1379-1389.2003;
RA   Ishitani T., Ninomiya-Tsuji J., Matsumoto K.;
RT   "Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-
RT   activated protein kinase-related Nemo-like kinase-dependent phosphorylation
RT   in Wnt/beta-catenin signaling.";
RL   Mol. Cell. Biol. 23:1379-1389(2003).
RN   [16]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-132, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-113.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Transcription factor that binds DNA in a sequence-specific
CC       manner (PubMed:2010090). Participates in the Wnt signaling pathway (By
CC       similarity). Activates transcription of target genes in the presence of
CC       CTNNB1 and EP300 (By similarity). PIAG antagonizes both Wnt-dependent
CC       and Wnt-independent activation by LEF1 (By similarity). TLE1, TLE2,
CC       TLE3 and TLE4 repress transactivation mediated by LEF1 and CTNNB1
CC       (PubMed:11266540). Regulates T-cell receptor alpha enhancer function
CC       (PubMed:19653274). Required for IL17A expressing gamma-delta T-cell
CC       maturation and development, via binding to regulator loci of BLK to
CC       modulate expression (By similarity). May play a role in hair cell
CC       differentiation and follicle morphogenesis (By similarity).
CC       {ECO:0000250|UniProtKB:P27782, ECO:0000269|PubMed:11266540,
CC       ECO:0000269|PubMed:19653274, ECO:0000269|PubMed:2010090}.
CC   -!- FUNCTION: [Isoform 1]: Transcriptionally activates MYC and CCND1
CC       expression and enhances proliferation of pancreatic tumor cells.
CC       {ECO:0000269|PubMed:19653274}.
CC   -!- FUNCTION: [Isoform 3]: Lacks the CTNNB1 interaction domain and may
CC       therefore be an antagonist for Wnt signaling.
CC       {ECO:0000269|PubMed:11326276}.
CC   -!- FUNCTION: [Isoform 5]: Transcriptionally activates the fibronectin
CC       promoter, binds to and represses transcription from the E-cadherin
CC       promoter in a CTNNB1-independent manner, and is involved in reducing
CC       cellular aggregation and increasing cell migration of pancreatic cancer
CC       cells. {ECO:0000269|PubMed:19653274}.
CC   -!- SUBUNIT: Binds the armadillo repeat of CTNNB1 and forms a stable
CC       complex. Interacts with EP300, TLE1 and PIASG (By similarity). Binds
CC       ALYREF/THOC4, MDFI and MDFIC. Interacts with NLK. {ECO:0000250,
CC       ECO:0000269|PubMed:12192039, ECO:0000269|PubMed:12556497,
CC       ECO:0000269|PubMed:9119228, ECO:0000269|PubMed:9488439,
CC       ECO:0000269|PubMed:9751710}.
CC   -!- INTERACTION:
CC       Q9UJU2; P35222: CTNNB1; NbExp=10; IntAct=EBI-926131, EBI-491549;
CC       Q9UJU2; P49789: FHIT; NbExp=2; IntAct=EBI-926131, EBI-741760;
CC       Q9UJU2; P08069: IGF1R; NbExp=5; IntAct=EBI-926131, EBI-475981;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00267}.
CC       Note=Found in nuclear bodies upon PIASG binding. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=7;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=A;
CC         IsoId=Q9UJU2-1; Sequence=Displayed;
CC       Name=2; Synonyms=B, 8A;
CC         IsoId=Q9UJU2-2; Sequence=VSP_002188;
CC       Name=3; Synonyms=LEF-1-DN;
CC         IsoId=Q9UJU2-3; Sequence=VSP_007022;
CC       Name=4;
CC         IsoId=Q9UJU2-4; Sequence=VSP_007022, VSP_002188;
CC       Name=5;
CC         IsoId=Q9UJU2-5; Sequence=VSP_040068;
CC       Name=6;
CC         IsoId=Q9UJU2-6; Sequence=VSP_040068, VSP_040069;
CC       Name=7;
CC         IsoId=Q9UJU2-7; Sequence=VSP_044877, VSP_040068;
CC   -!- TISSUE SPECIFICITY: Detected in thymus. Not detected in normal colon,
CC       but highly expressed in colon cancer biopsies and colon cancer cell
CC       lines. Expressed in several pancreatic tumors and weakly expressed in
CC       normal pancreatic tissue. Isoforms 1 and 5 are detected in several
CC       pancreatic cell lines. {ECO:0000269|PubMed:19653274}.
CC   -!- DOMAIN: Proline-rich and acidic regions are implicated in the
CC       activation functions of RNA polymerase II transcription factors.
CC   -!- PTM: Phosphorylated at Thr-155 and/or Ser-166 by NLK. Phosphorylation
CC       by NLK at these sites represses LEF1-mediated transcriptional
CC       activation of target genes of the canonical Wnt signaling pathway.
CC       {ECO:0000269|PubMed:12556497}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative splicing of isoform
CC       1. May be produced at very low levels due to a premature stop codon in
CC       the mRNA, leading to nonsense-mediated mRNA decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage.
CC       Acts as dominant negative mutant. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform
CC       3. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the TCF/LEF family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF288571; AAG01022.1; -; mRNA.
DR   EMBL; AF198532; AAF13268.1; -; mRNA.
DR   EMBL; AF294627; AAG26886.1; -; mRNA.
DR   EMBL; AK294395; BAG57649.1; -; mRNA.
DR   EMBL; AK303272; BAH13928.1; -; mRNA.
DR   EMBL; AC092539; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC097067; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118062; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC123576; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471057; EAX06223.1; -; Genomic_DNA.
DR   EMBL; CH471057; EAX06225.1; -; Genomic_DNA.
DR   EMBL; BC040559; AAH40559.1; -; mRNA.
DR   EMBL; BC050632; AAH50632.1; -; mRNA.
DR   CCDS; CCDS3679.1; -. [Q9UJU2-1]
DR   CCDS; CCDS47122.1; -. [Q9UJU2-6]
DR   CCDS; CCDS47123.1; -. [Q9UJU2-5]
DR   CCDS; CCDS54791.1; -. [Q9UJU2-7]
DR   PIR; A39625; A39625.
DR   RefSeq; NP_001124185.1; NM_001130713.2. [Q9UJU2-5]
DR   RefSeq; NP_001124186.1; NM_001130714.2. [Q9UJU2-6]
DR   RefSeq; NP_001159591.1; NM_001166119.1. [Q9UJU2-7]
DR   RefSeq; NP_057353.1; NM_016269.4. [Q9UJU2-1]
DR   SMR; Q9UJU2; -.
DR   BioGrid; 119354; 43.
DR   ComplexPortal; CPX-316; beta1-catenin - LEF1 complex.
DR   CORUM; Q9UJU2; -.
DR   DIP; DIP-29946N; -.
DR   IntAct; Q9UJU2; 24.
DR   MINT; Q9UJU2; -.
DR   STRING; 9606.ENSP00000265165; -.
DR   ChEMBL; CHEMBL3217392; -.
DR   DrugBank; DB00903; Etacrynic acid.
DR   GlyConnect; 2055; -.
DR   iPTMnet; Q9UJU2; -.
DR   PhosphoSitePlus; Q9UJU2; -.
DR   BioMuta; LEF1; -.
DR   DMDM; 8928194; -.
DR   jPOST; Q9UJU2; -.
DR   MassIVE; Q9UJU2; -.
DR   PaxDb; Q9UJU2; -.
DR   PeptideAtlas; Q9UJU2; -.
DR   PRIDE; Q9UJU2; -.
DR   ProteomicsDB; 19686; -.
DR   ProteomicsDB; 84650; -. [Q9UJU2-1]
DR   ProteomicsDB; 84651; -. [Q9UJU2-2]
DR   ProteomicsDB; 84652; -. [Q9UJU2-3]
DR   ProteomicsDB; 84653; -. [Q9UJU2-4]
DR   ProteomicsDB; 84654; -. [Q9UJU2-5]
DR   ProteomicsDB; 84655; -. [Q9UJU2-6]
DR   TopDownProteomics; Q9UJU2-2; -. [Q9UJU2-2]
DR   Antibodypedia; 912; 746 antibodies.
DR   DNASU; 51176; -.
DR   Ensembl; ENST00000265165; ENSP00000265165; ENSG00000138795. [Q9UJU2-1]
DR   Ensembl; ENST00000379951; ENSP00000369284; ENSG00000138795. [Q9UJU2-6]
DR   Ensembl; ENST00000438313; ENSP00000406176; ENSG00000138795. [Q9UJU2-5]
DR   Ensembl; ENST00000506680; ENSP00000422334; ENSG00000138795. [Q9UJU2-2]
DR   Ensembl; ENST00000510624; ENSP00000422840; ENSG00000138795. [Q9UJU2-7]
DR   GeneID; 51176; -.
DR   KEGG; hsa:51176; -.
DR   UCSC; uc003hyt.3; human. [Q9UJU2-1]
DR   CTD; 51176; -.
DR   DisGeNET; 51176; -.
DR   GeneCards; LEF1; -.
DR   HGNC; HGNC:6551; LEF1.
DR   HPA; ENSG00000138795; Tissue enriched (lymphoid).
DR   MIM; 153245; gene.
DR   neXtProt; NX_Q9UJU2; -.
DR   OpenTargets; ENSG00000138795; -.
DR   PharmGKB; PA30331; -.
DR   eggNOG; KOG3248; Eukaryota.
DR   eggNOG; ENOG41109RU; LUCA.
DR   GeneTree; ENSGT00940000159660; -.
DR   HOGENOM; CLU_013229_5_0_1; -.
DR   InParanoid; Q9UJU2; -.
DR   KO; K04492; -.
DR   OMA; YIMMSNM; -.
DR   OrthoDB; 807716at2759; -.
DR   PhylomeDB; Q9UJU2; -.
DR   TreeFam; TF318448; -.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-4411364; Binding of TCF/LEF:CTNNB1 to target gene promoters.
DR   Reactome; R-HSA-4641265; Repression of WNT target genes.
DR   Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX.
DR   Reactome; R-HSA-8951430; RUNX3 regulates WNT signaling.
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
DR   SignaLink; Q9UJU2; -.
DR   SIGNOR; Q9UJU2; -.
DR   ChiTaRS; LEF1; human.
DR   GeneWiki; Lymphoid_enhancer-binding_factor_1; -.
DR   GenomeRNAi; 51176; -.
DR   Pharos; Q9UJU2; Tchem.
DR   PRO; PR:Q9UJU2; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9UJU2; protein.
DR   Bgee; ENSG00000138795; Expressed in female gonad and 201 other tissues.
DR   ExpressionAtlas; Q9UJU2; baseline and differential.
DR   Genevisible; Q9UJU2; HS.
DR   GO; GO:1990907; C:beta-catenin-TCF complex; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:BHF-UCL.
DR   GO; GO:0005667; C:transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0070016; F:armadillo repeat domain binding; IPI:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL.
DR   GO; GO:0070742; F:C2H2 zinc finger domain binding; IPI:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0035326; F:cis-regulatory region binding; IDA:UniProtKB.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0008301; F:DNA binding, bending; ISS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IMP:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISM:NTNU_SB.
DR   GO; GO:0030284; F:estrogen receptor activity; IDA:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; IDA:UniProtKB.
DR   GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0042393; F:histone binding; IPI:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0046632; P:alpha-beta T cell differentiation; IBA:GO_Central.
DR   GO; GO:0060033; P:anatomical structure regression; IEA:Ensembl.
DR   GO; GO:1902262; P:apoptotic process involved in blood vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0060561; P:apoptotic process involved in morphogenesis; IBA:GO_Central.
DR   GO; GO:0042100; P:B cell proliferation; IBA:GO_Central.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0030509; P:BMP signaling pathway; IBA:GO_Central.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IBA:GO_Central.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IMP:BHF-UCL.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IDA:UniProtKB.
DR   GO; GO:0060710; P:chorio-allantoic fusion; IBA:GO_Central.
DR   GO; GO:0021542; P:dentate gyrus development; IBA:GO_Central.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IBA:GO_Central.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0048069; P:eye pigmentation; IBA:GO_Central.
DR   GO; GO:0060325; P:face morphogenesis; IBA:GO_Central.
DR   GO; GO:0021873; P:forebrain neuroblast division; IBA:GO_Central.
DR   GO; GO:0021861; P:forebrain radial glial cell differentiation; IBA:GO_Central.
DR   GO; GO:0021943; P:formation of radial glial scaffolds; IBA:GO_Central.
DR   GO; GO:0043966; P:histone H3 acetylation; IMP:UniProtKB.
DR   GO; GO:0043967; P:histone H4 acetylation; IMP:UniProtKB.
DR   GO; GO:0030879; P:mammary gland development; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0071866; P:negative regulation of apoptotic process in bone marrow cell; IMP:UniProtKB.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043392; P:negative regulation of DNA binding; IDA:UniProtKB.
DR   GO; GO:0071899; P:negative regulation of estrogen receptor binding; IDA:UniProtKB.
DR   GO; GO:0032696; P:negative regulation of interleukin-13 production; IDA:UniProtKB.
DR   GO; GO:0032713; P:negative regulation of interleukin-4 production; IDA:UniProtKB.
DR   GO; GO:0032714; P:negative regulation of interleukin-5 production; IDA:UniProtKB.
DR   GO; GO:0045843; P:negative regulation of striated muscle tissue development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030223; P:neutrophil differentiation; IMP:UniProtKB.
DR   GO; GO:0071895; P:odontoblast differentiation; IBA:GO_Central.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; IEP:UniProtKB.
DR   GO; GO:0048341; P:paraxial mesoderm formation; IBA:GO_Central.
DR   GO; GO:0043923; P:positive regulation by host of viral transcription; IDA:UniProtKB.
DR   GO; GO:0090068; P:positive regulation of cell cycle process; IDA:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0071864; P:positive regulation of cell proliferation in bone marrow; IMP:UniProtKB.
DR   GO; GO:0022409; P:positive regulation of cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:UniProtKB.
DR   GO; GO:0045588; P:positive regulation of gamma-delta T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:AgBase.
DR   GO; GO:0030854; P:positive regulation of granulocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; IBA:GO_Central.
DR   GO; GO:0016202; P:regulation of striated muscle tissue development; IBA:GO_Central.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IBA:GO_Central.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0062009; P:secondary palate development; ISS:BHF-UCL.
DR   GO; GO:0050909; P:sensory perception of taste; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IBA:GO_Central.
DR   GO; GO:0002040; P:sprouting angiogenesis; IBA:GO_Central.
DR   GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl.
DR   GO; GO:0045063; P:T-helper 1 cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043586; P:tongue development; IEA:Ensembl.
DR   GO; GO:0061153; P:trachea gland development; IBA:GO_Central.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0016055; P:Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; TAS:Reactome.
DR   Gene3D; 1.10.30.10; -; 1.
DR   Gene3D; 4.10.900.10; -; 1.
DR   InterPro; IPR027397; Catenin_binding_dom_sf.
DR   InterPro; IPR013558; CTNNB1-bd_N.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR028769; LEF1.
DR   InterPro; IPR024940; TCF/LEF.
DR   PANTHER; PTHR10373; PTHR10373; 1.
DR   PANTHER; PTHR10373:SF11; PTHR10373:SF11; 1.
DR   Pfam; PF08347; CTNNB1_binding; 1.
DR   Pfam; PF00505; HMG_box; 1.
DR   SMART; SM00398; HMG; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative promoter usage; Alternative splicing;
KW   Direct protein sequencing; DNA-binding; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Wnt signaling pathway.
FT   CHAIN           1..399
FT                   /note="Lymphoid enhancer-binding factor 1"
FT                   /id="PRO_0000048595"
FT   DNA_BIND        299..367
FT                   /note="HMG box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00267"
FT   REGION          1..62
FT                   /note="CTNNB1-binding"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        6..13
FT                   /note="Poly-Gly"
FT   COMPBIAS        14..52
FT                   /note="Asp/Glu-rich (acidic)"
FT   COMPBIAS        77..273
FT                   /note="Pro-rich"
FT   COMPBIAS        374..379
FT                   /note="Poly-Lys"
FT   MOD_RES         132
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332"
FT   MOD_RES         155
FT                   /note="Phosphothreonine; by NLK"
FT                   /evidence="ECO:0000305|PubMed:12556497"
FT   MOD_RES         166
FT                   /note="Phosphoserine; by NLK"
FT                   /evidence="ECO:0000305|PubMed:12556497"
FT   CROSSLNK        27
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        269
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..115
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_007022"
FT   VAR_SEQ         1..70
FT                   /note="MPQLSGGGGGGGGDPELCATDEMIPFKDEGDPQKEKIFAEISHPEEEGDLAD
FT                   IKSSLVNESEIIPASNGH -> MA (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044877"
FT   VAR_SEQ         214..241
FT                   /note="Missing (in isoform 5, isoform 6 and isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:19653274"
FT                   /id="VSP_040068"
FT   VAR_SEQ         283..399
FT                   /note="KPQHEQRKEQEPKRPHIKKPLNAFMLYMKEMRANVVAECTLKESAAINQILG
FT                   RRWHALSREEQAKYYELARKERQLHMQLYPGWSARDNYGKKKKRKREKLQESASGTGPR
FT                   MTAAYI -> CSAFLLPHPFLIPSTPSPNHHHHHLLGSLSMNRERSRSQKDLTLRSL
FT                   (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_002188"
FT   VAR_SEQ         390..399
FT                   /note="TGPRMTAAYI -> GKRSSFPTCKAKAATPGPLLEMEAC (in isoform
FT                   6)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_040069"
FT   VARIANT         113
FT                   /note="G -> R (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs369649181)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035935"
FT   MUTAGEN         155
FT                   /note="T->A: Reduced phosphorylation by NLK; when
FT                   associated with A-166."
FT                   /evidence="ECO:0000269|PubMed:12556497"
FT   MUTAGEN         166
FT                   /note="S->A: Reduced phosphorylation by NLK; when
FT                   associated with A-155."
FT                   /evidence="ECO:0000269|PubMed:12556497"
FT   CONFLICT        146
FT                   /note="Q -> R (in Ref. 5; BAH13928)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   399 AA;  44201 MW;  D480D440698EEFE3 CRC64;
     MPQLSGGGGG GGGDPELCAT DEMIPFKDEG DPQKEKIFAE ISHPEEEGDL ADIKSSLVNE
     SEIIPASNGH EVARQAQTSQ EPYHDKAREH PDDGKHPDGG LYNKGPSYSS YSGYIMMPNM
     NNDPYMSNGS LSPPIPRTSN KVPVVQPSHA VHPLTPLITY SDEHFSPGSH PSHIPSDVNS
     KQGMSRHPPA PDIPTFYPLS PGGVGQITPP LGWQGQPVYP ITGGFRQPYP SSLSVDTSMS
     RFSHHMIPGP PGPHTTGIPH PAIVTPQVKQ EHPHTDSDLM HVKPQHEQRK EQEPKRPHIK
     KPLNAFMLYM KEMRANVVAE CTLKESAAIN QILGRRWHAL SREEQAKYYE LARKERQLHM
     QLYPGWSARD NYGKKKKRKR EKLQESASGT GPRMTAAYI
//
ID   MP2K4_HUMAN             Reviewed;         399 AA.
AC   P45985; B2R7N7; B3KYB2; D3DTS5; Q5U0B8; Q6FHX4; Q6P9H2; Q6PIE6;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   22-APR-2020, entry version 201.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 4;
DE            Short=MAP kinase kinase 4;
DE            Short=MAPKK 4;
DE            EC=2.7.12.2;
DE   AltName: Full=JNK-activating kinase 1;
DE   AltName: Full=MAPK/ERK kinase 4;
DE            Short=MEK 4;
DE   AltName: Full=SAPK/ERK kinase 1;
DE            Short=SEK1;
DE   AltName: Full=Stress-activated protein kinase kinase 1;
DE            Short=SAPK kinase 1;
DE            Short=SAPKK-1;
DE            Short=SAPKK1;
DE   AltName: Full=c-Jun N-terminal kinase kinase 1;
DE            Short=JNKK;
GN   Name=MAP2K4; Synonyms=JNKK1, MEK4, MKK4, PRKMK4, SEK1, SERK1, SKK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=7839144; DOI=10.1126/science.7839144;
RA   Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J., Ulevitch R.J.,
RA   Davis R.J.;
RT   "Independent human MAP-kinase signal transduction pathways defined by MEK
RT   and MKK isoforms.";
RL   Science 267:682-685(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=7716521; DOI=10.1126/science.7716521;
RA   Lin A., Minden A., Martinetto H., Claret F.-X., Lange-Carter C.,
RA   Mercurio F., Johnson G.L., Karin M.;
RT   "Identification of a dual specificity kinase that activates the Jun kinases
RT   and p38-Mpk2.";
RL   Science 268:286-290(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9622070;
RA   Su G.H., Hilgers W., Shekher M.C., Tang D.J., Yeo C.J., Hruban R.H.,
RA   Kern S.E.;
RT   "Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as
RT   a genetically targeted tumor suppressor gene.";
RL   Cancer Res. 58:2339-2342(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-16.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PHOSPHORYLATION AT THR-261, ACTIVITY REGULATION, AND INTERACTION WITH
RP   MAP3K11/MLK3.
RX   PubMed=9003778; DOI=10.1002/j.1460-2075.1996.tb01094.x;
RA   Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R.,
RA   Lassam N.J.;
RT   "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6.";
RL   EMBO J. 15:7026-7035(1996).
RN   [12]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family members
RT   to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [13]
RP   INTERACTION WITH ARRB2.
RX   PubMed=11090355; DOI=10.1126/science.290.5496.1574;
RA   McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E., Lin F.-T.,
RA   Davis R.J., Lefkowitz R.J.;
RT   "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of
RT   JNK3.";
RL   Science 290:1574-1577(2000).
RN   [14]
RP   INTERACTION WITH MAPK8IP3/JIP3.
RX   PubMed=12189133; DOI=10.1074/jbc.m202004200;
RA   Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M.,
RA   Yoshioka K., Ichijo H.;
RT   "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK
RT   signaling pathway. A new mode of regulation of the MAP kinase cascade.";
RL   J. Biol. Chem. 277:40703-40709(2002).
RN   [15]
RP   DOMAIN, AND INTERACTION WITH MAPK8/JNK1; MAPK9/JNK2; MAPK10/JNK3; MAPK11
RP   AND MAPK14.
RX   PubMed=12788955; DOI=10.1074/jbc.m304229200;
RA   Ho D.T., Bardwell A.J., Abdollahi M., Bardwell L.;
RT   "A docking site in MKK4 mediates high affinity binding to JNK MAPKs and
RT   competes with similar docking sites in JNK substrates.";
RL   J. Biol. Chem. 278:32662-32672(2003).
RN   [16]
RP   DOMAIN.
RX   PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001;
RA   Takekawa M., Tatebayashi K., Saito H.;
RT   "Conserved docking site is essential for activation of mammalian MAP kinase
RT   kinases by specific MAP kinase kinase kinases.";
RL   Mol. Cell 18:295-306(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=19782076; DOI=10.1016/j.febslet.2009.09.035;
RA   Li X., MacLeod R., Dunlop A.J., Edwards H.V., Advant N., Gibson L.C.,
RA   Devine N.M., Brown K.M., Adams D.R., Houslay M.D., Baillie G.S.;
RT   "A scanning peptide array approach uncovers association sites within the
RT   JNK/beta arrestin signalling complex.";
RL   FEBS Lett. 583:3310-3316(2009).
RN   [20]
RP   REVIEW ON ACTIVITY REGULATION.
RX   PubMed=17496909; DOI=10.1038/sj.onc.1210392;
RA   Raman M., Chen W., Cobb M.H.;
RT   "Differential regulation and properties of MAPKs.";
RL   Oncogene 26:3100-3112(2007).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=20801953; DOI=10.1093/jb/mvq098;
RA   Asaoka Y., Nishina H.;
RT   "Diverse physiological functions of MKK4 and MKK7 during early
RT   embryogenesis.";
RL   J. Biochem. 148:393-401(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   REVIEW ON REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008;
RA   Haeusgen W., Herdegen T., Waetzig V.;
RT   "The bottleneck of JNK signaling: molecular and functional characteristics
RT   of MKK4 and MKK7.";
RL   Eur. J. Cell Biol. 90:536-544(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-58, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 80-399.
RX   PubMed=20732303; DOI=10.1016/j.bbrc.2010.08.071;
RA   Matsumoto T., Kinoshita T., Kirii Y., Yokota K., Hamada K., Tada T.;
RT   "Crystal structures of MKK4 kinase domain reveal that substrate peptide
RT   binds to an allosteric site and induces an auto-inhibition state.";
RL   Biochem. Biophys. Res. Commun. 400:369-373(2010).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-142; TRP-154; ILE-234; ASN-251 AND
RP   THR-279.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual specificity protein kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. Essential
CC       component of the stress-activated protein kinase/c-Jun N-terminal
CC       kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the
CC       only known kinase to directly activate the stress-activated protein
CC       kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3.
CC       MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation,
CC       but they differ in their preference for the phosphorylation site in the
CC       Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the
CC       Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of
CC       the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK
CC       activation at least in response to proinflammatory cytokines, while
CC       other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which
CC       synergistically phosphorylate JNKs. MAP2K4 is required for maintaining
CC       peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also
CC       involved in mitochondrial death signaling pathway, including the
CC       release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7
CC       exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38
CC       MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. {ECO:0000269|PubMed:7716521}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- ACTIVITY REGULATION: Activated in response to a variety of cellular
CC       stresses, including UV and gamma-irradiation, heat shock,
CC       hyperosmolarity, T-cell receptor stimulation, peroxide and inflammatory
CC       cytokines. Also activated by developmental cues. MAP2K4/MKK4 is
CC       activated by the majority of MKKKs, such as MAP3K5/ASK1, MAP3K1/MEKK1,
CC       MAP3K7/TAK1, MAP3K10/MLK2, MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.
CC       {ECO:0000269|PubMed:9003778}.
CC   -!- SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via its D
CC       domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3, MAPK11
CC       and MAPK14. Interacts (via its DVD domain) with MAP3Ks activators like
CC       MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts with ARRB1, ARRB2 and
CC       MAPK8IP3/JIP3. {ECO:0000250, ECO:0000269|PubMed:11090355,
CC       ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:12788955,
CC       ECO:0000269|PubMed:19782076, ECO:0000269|PubMed:9003778}.
CC   -!- INTERACTION:
CC       P45985; Q13233: MAP3K1; NbExp=3; IntAct=EBI-447868, EBI-49776;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P45985-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P45985-2; Sequence=VSP_038838;
CC   -!- TISSUE SPECIFICITY: Abundant expression is seen in the skeletal muscle.
CC       It is also widely expressed in other tissues.
CC   -!- DOMAIN: The DVD domain (residues 364-387) contains a conserved docking
CC       site and is found in the mammalian MAP kinase kinases (MAP2Ks). The DVD
CC       sites bind to their specific upstream MAP kinase kinase kinases
CC       (MAP3Ks) and are essential for activation.
CC   -!- DOMAIN: The D domain (residues 34-52) contains a conserved docking site
CC       and is required for the binding to MAPK substrates.
CC   -!- PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAP kinase
CC       kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/map2k4/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L36870; AAC41719.1; -; mRNA.
DR   EMBL; U17743; AAC50127.1; -; mRNA.
DR   EMBL; AF070090; AAC24130.1; -; Genomic_DNA.
DR   EMBL; AF070080; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070081; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070082; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070083; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070084; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070085; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070086; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070087; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070088; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070089; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; CR536564; CAG38801.1; -; mRNA.
DR   EMBL; BT019676; AAV38482.1; -; mRNA.
DR   EMBL; AK131544; BAG54774.1; -; mRNA.
DR   EMBL; AK313053; BAG35884.1; -; mRNA.
DR   EMBL; DQ015703; AAY22176.1; -; Genomic_DNA.
DR   EMBL; AC005244; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005410; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW89975.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW89974.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW89976.1; -; Genomic_DNA.
DR   EMBL; BC036032; AAH36032.1; -; mRNA.
DR   EMBL; BC060764; AAH60764.1; -; mRNA.
DR   CCDS; CCDS11162.1; -. [P45985-1]
DR   CCDS; CCDS62095.1; -. [P45985-2]
DR   PIR; I38901; I38901.
DR   RefSeq; NP_001268364.1; NM_001281435.1. [P45985-2]
DR   RefSeq; NP_003001.1; NM_003010.3. [P45985-1]
DR   PDB; 3ALN; X-ray; 2.30 A; A/B/C=80-399.
DR   PDB; 3ALO; X-ray; 2.60 A; A=80-399.
DR   PDB; 3VUT; X-ray; 3.50 A; A/B=80-399.
DR   PDBsum; 3ALN; -.
DR   PDBsum; 3ALO; -.
DR   PDBsum; 3VUT; -.
DR   SMR; P45985; -.
DR   BioGrid; 112315; 43.
DR   CORUM; P45985; -.
DR   IntAct; P45985; 18.
DR   MINT; P45985; -.
DR   STRING; 9606.ENSP00000410402; -.
DR   BindingDB; P45985; -.
DR   ChEMBL; CHEMBL2897; -.
DR   DrugCentral; P45985; -.
DR   GuidetoPHARMACOLOGY; 2065; -.
DR   iPTMnet; P45985; -.
DR   PhosphoSitePlus; P45985; -.
DR   BioMuta; MAP2K4; -.
DR   DMDM; 1170596; -.
DR   CPTAC; CPTAC-816; -.
DR   CPTAC; CPTAC-817; -.
DR   EPD; P45985; -.
DR   jPOST; P45985; -.
DR   MassIVE; P45985; -.
DR   MaxQB; P45985; -.
DR   PaxDb; P45985; -.
DR   PeptideAtlas; P45985; -.
DR   PRIDE; P45985; -.
DR   ProteomicsDB; 55703; -. [P45985-1]
DR   ProteomicsDB; 55704; -. [P45985-2]
DR   Antibodypedia; 3571; 1320 antibodies.
DR   DNASU; 6416; -.
DR   Ensembl; ENST00000353533; ENSP00000262445; ENSG00000065559. [P45985-1]
DR   Ensembl; ENST00000415385; ENSP00000410402; ENSG00000065559. [P45985-2]
DR   GeneID; 6416; -.
DR   KEGG; hsa:6416; -.
DR   UCSC; uc002gnj.5; human. [P45985-1]
DR   CTD; 6416; -.
DR   DisGeNET; 6416; -.
DR   GeneCards; MAP2K4; -.
DR   HGNC; HGNC:6844; MAP2K4.
DR   HPA; ENSG00000065559; Low tissue specificity.
DR   MIM; 601335; gene.
DR   neXtProt; NX_P45985; -.
DR   OpenTargets; ENSG00000065559; -.
DR   PharmGKB; PA30589; -.
DR   eggNOG; KOG0984; Eukaryota.
DR   eggNOG; ENOG410XT3F; LUCA.
DR   GeneTree; ENSGT00940000154744; -.
DR   HOGENOM; CLU_000288_63_23_1; -.
DR   InParanoid; P45985; -.
DR   KO; K04430; -.
DR   OMA; MKSNDCN; -.
DR   OrthoDB; 688282at2759; -.
DR   PhylomeDB; P45985; -.
DR   TreeFam; TF350701; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   SABIO-RK; P45985; -.
DR   SignaLink; P45985; -.
DR   SIGNOR; P45985; -.
DR   ChiTaRS; MAP2K4; human.
DR   EvolutionaryTrace; P45985; -.
DR   GeneWiki; MAP2K4; -.
DR   GenomeRNAi; 6416; -.
DR   Pharos; P45985; Tchem.
DR   PRO; PR:P45985; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P45985; protein.
DR   Bgee; ENSG00000065559; Expressed in frontal cortex and 226 other tissues.
DR   ExpressionAtlas; P45985; baseline and differential.
DR   Genevisible; P45985; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0032839; C:dendrite cytoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008545; F:JUN kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; IBA:GO_Central.
DR   GO; GO:0032147; P:activation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0061049; P:cell growth involved in cardiac muscle cell development; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0072709; P:cellular response to sorbitol; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007254; P:JNK cascade; TAS:Reactome.
DR   GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IBA:GO_Central.
DR   DisProt; DP01400; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW   Cytoplasm; Kinase; Methylation; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Stress response; Transferase;
KW   Tyrosine-protein kinase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   CHAIN           2..399
FT                   /note="Dual specificity mitogen-activated protein kinase
FT                   kinase 4"
FT                   /id="PRO_0000086381"
FT   DOMAIN          102..367
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         108..116
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          37..52
FT                   /note="D domain"
FT   REGION          364..387
FT                   /note="DVD domain"
FT   COMPBIAS        5..19
FT                   /note="Gly/Ser-rich"
FT   ACT_SITE        229
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         131
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            45..46
FT                   /note="Cleavage; by anthrax lethal factor"
FT   SITE            58..59
FT                   /note="Cleavage; by anthrax lethal factor"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   MOD_RES         58
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         58
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         90
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         257
FT                   /note="Phosphoserine; by MAP3K"
FT                   /evidence="ECO:0000244|PubMed:19369195,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         261
FT                   /note="Phosphothreonine; by MAP3K"
FT                   /evidence="ECO:0000269|PubMed:9003778"
FT   VAR_SEQ         39
FT                   /note="G -> GFQINFCEKAQS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038838"
FT   VARIANT         16
FT                   /note="S -> R (in dbSNP:rs17855590)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_062963"
FT   VARIANT         142
FT                   /note="Q -> L (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040818"
FT   VARIANT         154
FT                   /note="R -> W (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040819"
FT   VARIANT         234
FT                   /note="N -> I (in an ovarian serous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040820"
FT   VARIANT         251
FT                   /note="S -> N (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040821"
FT   VARIANT         279
FT                   /note="A -> T (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs753665559)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040822"
FT   CONFLICT        118
FT                   /note="K -> R (in Ref. 4; CAG38801)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        179
FT                   /note="E -> G (in Ref. 6; BAG35884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        356
FT                   /note="P -> L (in Ref. 10; AAH60764)"
FT                   /evidence="ECO:0000305"
FT   STRAND          81..83
FT                   /evidence="ECO:0000244|PDB:3VUT"
FT   STRAND          85..88
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          93..95
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          101..103
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          107..110
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          112..121
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   TURN            122..124
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          127..134
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           139..153
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          164..169
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          171..178
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          182..184
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           185..194
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           202..223
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           232..234
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          235..237
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          243..245
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          249..251
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          255..259
FT                   /evidence="ECO:0000244|PDB:3VUT"
FT   STRAND          267..270
FT                   /evidence="ECO:0000244|PDB:3ALO"
FT   HELIX           272..274
FT                   /evidence="ECO:0000244|PDB:3ALO"
FT   HELIX           287..302
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          312..314
FT                   /evidence="ECO:0000244|PDB:3ALO"
FT   STRAND          316..321
FT                   /evidence="ECO:0000244|PDB:3ALO"
FT   HELIX           338..347
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           352..354
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           358..361
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           365..372
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           377..387
FT                   /evidence="ECO:0000244|PDB:3ALN"
SQ   SEQUENCE   399 AA;  44288 MW;  A472537F2F26770B CRC64;
     MAAPSPSGGG GSGGGSGSGT PGPVGSPAPG HPAVSSMQGK RKALKLNFAN PPFKSTARFT
     LNPNPTGVQN PHIERLRTHS IESSGKLKIS PEQHWDFTAE DLKDLGEIGR GAYGSVNKMV
     HKPSGQIMAV KRIRSTVDEK EQKQLLMDLD VVMRSSDCPY IVQFYGALFR EGDCWICMEL
     MSTSFDKFYK YVYSVLDDVI PEEILGKITL ATVKALNHLK ENLKIIHRDI KPSNILLDRS
     GNIKLCDFGI SGQLVDSIAK TRDAGCRPYM APERIDPSAS RQGYDVRSDV WSLGITLYEL
     ATGRFPYPKW NSVFDQLTQV VKGDPPQLSN SEEREFSPSF INFVNLCLTK DESKRPKYKE
     LLKHPFILMY EERAVEVACY VCKILDQMPA TPSSPMYVD
//
ID   M3K1_HUMAN              Reviewed;        1512 AA.
AC   Q13233;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 4.
DT   22-APR-2020, entry version 197.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 1;
DE            EC=2.7.11.25;
DE   AltName: Full=MAPK/ERK kinase kinase 1;
DE            Short=MEK kinase 1;
DE            Short=MEKK 1;
GN   Name=MAP3K1; Synonyms=MAPKKK1, MEKK, MEKK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-1512, FUNCTION, AND INTERACTION WITH
RP   MAP2K4.
RX   PubMed=9808624; DOI=10.1101/gad.12.21.3369;
RA   Xia Y., Wu Z., Su B., Murray B., Karin M.;
RT   "JNKK1 organizes a MAP kinase module through specific and sequential
RT   interactions with upstream and downstream components mediated by its amino-
RT   terminal extension.";
RL   Genes Dev. 12:3369-3381(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1238-1274.
RC   TISSUE=Leukocyte;
RX   PubMed=8597633; DOI=10.1007/bf00539003;
RA   Vinik B.S., Kay E.S., Fiedorek F.T. Jr.;
RT   "Mapping of the MEK kinase gene (Mekk) to mouse chromosome 13 and human
RT   chromosome 5.";
RL   Mamm. Genome 6:782-783(1995).
RN   [4]
RP   INTERACTION WITH AXIN1.
RX   PubMed=12223491; DOI=10.1074/jbc.m208099200;
RA   Rui H.L., Fan E., Zhou H.M., Xu Z., Zhang Y., Lin S.C.;
RT   "SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK
RT   activation but has no effect on Wnt signaling.";
RL   J. Biol. Chem. 277:42981-42986(2002).
RN   [5]
RP   INTERACTION WITH AXIN1.
RX   PubMed=15262978; DOI=10.1074/jbc.m404598200;
RA   Wong C.K., Luo W., Deng Y., Zou H., Ye Z., Lin S.-C.;
RT   "The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase
RT   activation by Axin and dishevelled through distinct mechanisms.";
RL   J. Biol. Chem. 279:39366-39373(2004).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH GRIPAP1.
RX   PubMed=17761173; DOI=10.1016/j.febslet.2007.08.008;
RA   Ye B., Yu W.P., Thomas G.M., Huganir R.L.;
RT   "GRASP-1 is a neuronal scaffold protein for the JNK signaling pathway.";
RL   FEBS Lett. 581:4403-4410(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-154 AND SER-1043, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   INTERACTION WITH STK38.
RX   PubMed=17906693; DOI=10.1038/sj.onc.1210828;
RA   Enomoto A., Kido N., Ito M., Morita A., Matsumoto Y., Takamatsu N.,
RA   Hosoi Y., Miyagawa K.;
RT   "Negative regulation of MEKK1/2 signaling by serine-threonine kinase 38
RT   (STK38).";
RL   Oncogene 27:1930-1938(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292; SER-297; SER-300;
RP   SER-507 AND SER-1018, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-275 AND SER-292, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-35; SER-275; THR-285;
RP   SER-292; SER-531; SER-923 AND SER-1018, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-92 AND SER-443.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [15]
RP   VARIANTS SRXY6 PRO-189; ARG-189; ILE-GLN-211 INS AND ARG-616, AND
RP   CHARACTERIZATION OF VARIANTS SRXY6 PRO-189 AND ARG-189.
RX   PubMed=21129722; DOI=10.1016/j.ajhg.2010.11.003;
RA   Pearlman A., Loke J., Le Caignec C., White S., Chin L., Friedman A.,
RA   Warr N., Willan J., Brauer D., Farmer C., Brooks E., Oddoux C., Riley B.,
RA   Shajahan S., Camerino G., Homfray T., Crosby A.H., Couper J., David A.,
RA   Greenfield A., Sinclair A., Ostrer H.;
RT   "Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate
RT   a common signal transduction pathway in human testis determination.";
RL   Am. J. Hum. Genet. 87:898-904(2010).
CC   -!- FUNCTION: Component of a protein kinase signal transduction cascade
CC       (PubMed:9808624). Activates the ERK and JNK kinase pathways by
CC       phosphorylation of MAP2K1 and MAP2K4 (PubMed:9808624). May
CC       phosphorylate the MAPK8/JNK1 kinase (PubMed:17761173). Activates CHUK
CC       and IKBKB, the central protein kinases of the NF-kappa-B pathway
CC       (PubMed:9808624). {ECO:0000269|PubMed:17761173,
CC       ECO:0000269|PubMed:9808624}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.25;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by autophosphorylation on Thr-1400 and
CC       Thr-1412 following oligomerization.
CC   -!- SUBUNIT: Binds both upstream activators and downstream substrates in
CC       multimolecular complexes through its N-terminus (PubMed:9808624).
CC       Oligomerizes after binding MAP2K4 or TRAF2 (PubMed:9808624). Interacts
CC       with AXIN1 (PubMed:12223491, PubMed:15262978). Interacts (via the
CC       kinase catalytic domain) with STK38 (PubMed:17906693). Interacts with
CC       GRIPAP1 (PubMed:17761173). {ECO:0000269|PubMed:12223491,
CC       ECO:0000269|PubMed:15262978, ECO:0000269|PubMed:17761173,
CC       ECO:0000269|PubMed:17906693, ECO:0000269|PubMed:9808624}.
CC   -!- INTERACTION:
CC       Q13233; P32121: ARRB2; NbExp=2; IntAct=EBI-49776, EBI-714559;
CC       Q13233; P15056: BRAF; NbExp=2; IntAct=EBI-49776, EBI-365980;
CC       Q13233; P61962: DCAF7; NbExp=7; IntAct=EBI-49776, EBI-359808;
CC       Q13233; O75369: FLNB; NbExp=2; IntAct=EBI-49776, EBI-352089;
CC       Q13233; P45985: MAP2K4; NbExp=3; IntAct=EBI-49776, EBI-447868;
CC       Q13233; Q12851: MAP4K2; NbExp=2; IntAct=EBI-49776, EBI-49783;
CC       Q13233; Q12933: TRAF2; NbExp=2; IntAct=EBI-49776, EBI-355744;
CC   -!- PTM: Autophosphorylated. {ECO:0000250}.
CC   -!- DISEASE: 46,XY sex reversal 6 (SRXY6) [MIM:613762]: A disorder of sex
CC       development. Affected individuals have a 46,XY karyotype but present as
CC       phenotypically normal females. {ECO:0000269|PubMed:21129722}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC008937; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF042838; AAC97073.1; -; mRNA.
DR   EMBL; U29671; AAB05828.1; -; Genomic_DNA.
DR   CCDS; CCDS43318.1; -.
DR   PIR; G01887; G01887.
DR   RefSeq; NP_005912.1; NM_005921.1.
DR   SMR; Q13233; -.
DR   BioGrid; 110378; 140.
DR   DIP; DIP-27520N; -.
DR   ELM; Q13233; -.
DR   IntAct; Q13233; 41.
DR   MINT; Q13233; -.
DR   STRING; 9606.ENSP00000382423; -.
DR   ChEMBL; CHEMBL3956; -.
DR   DrugBank; DB06061; AZD-8330.
DR   DrugBank; DB11967; Binimetinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q13233; -.
DR   GuidetoPHARMACOLOGY; 2069; -.
DR   iPTMnet; Q13233; -.
DR   PhosphoSitePlus; Q13233; -.
DR   BioMuta; MAP3K1; -.
DR   DMDM; 218512139; -.
DR   SWISS-2DPAGE; Q13233; -.
DR   CPTAC; CPTAC-1046; -.
DR   CPTAC; CPTAC-824; -.
DR   CPTAC; CPTAC-825; -.
DR   CPTAC; CPTAC-826; -.
DR   CPTAC; CPTAC-827; -.
DR   CPTAC; CPTAC-829; -.
DR   CPTAC; CPTAC-830; -.
DR   CPTAC; CPTAC-831; -.
DR   CPTAC; CPTAC-832; -.
DR   EPD; Q13233; -.
DR   jPOST; Q13233; -.
DR   MassIVE; Q13233; -.
DR   MaxQB; Q13233; -.
DR   PaxDb; Q13233; -.
DR   PeptideAtlas; Q13233; -.
DR   PRIDE; Q13233; -.
DR   ProteomicsDB; 59240; -.
DR   Antibodypedia; 3855; 430 antibodies.
DR   DNASU; 4214; -.
DR   Ensembl; ENST00000399503; ENSP00000382423; ENSG00000095015.
DR   GeneID; 4214; -.
DR   KEGG; hsa:4214; -.
DR   UCSC; uc003jqw.5; human.
DR   CTD; 4214; -.
DR   DisGeNET; 4214; -.
DR   GeneCards; MAP3K1; -.
DR   GeneReviews; MAP3K1; -.
DR   HGNC; HGNC:6848; MAP3K1.
DR   HPA; ENSG00000095015; Low tissue specificity.
DR   MalaCards; MAP3K1; -.
DR   MIM; 600982; gene.
DR   MIM; 613762; phenotype.
DR   neXtProt; NX_Q13233; -.
DR   OpenTargets; ENSG00000095015; -.
DR   Orphanet; 242; 46,XY complete gonadal dysgenesis.
DR   Orphanet; 251510; 46,XY partial gonadal dysgenesis.
DR   PharmGKB; PA30592; -.
DR   eggNOG; KOG4279; Eukaryota.
DR   eggNOG; ENOG410XQGS; LUCA.
DR   GeneTree; ENSGT00940000159154; -.
DR   HOGENOM; CLU_005805_0_0_1; -.
DR   InParanoid; Q13233; -.
DR   KO; K04416; -.
DR   OMA; STTMEQP; -.
DR   OrthoDB; 797346at2759; -.
DR   PhylomeDB; Q13233; -.
DR   TreeFam; TF105112; -.
DR   Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation.
DR   Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane.
DR   SignaLink; Q13233; -.
DR   SIGNOR; Q13233; -.
DR   ChiTaRS; MAP3K1; human.
DR   GeneWiki; MAP3K1; -.
DR   GenomeRNAi; 4214; -.
DR   Pharos; Q13233; Tchem.
DR   PRO; PR:Q13233; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q13233; protein.
DR   Bgee; ENSG00000095015; Expressed in blood and 212 other tissues.
DR   Genevisible; Q13233; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; NAS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0032147; P:activation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IBA:GO_Central.
DR   Gene3D; 1.25.10.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR007527; Znf_SWIM.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
DR   PROSITE; PS50966; ZF_SWIM; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   CHAIN           2..1512
FT                   /note="Mitogen-activated protein kinase kinase kinase 1"
FT                   /id="PRO_0000086240"
FT   DOMAIN          1243..1508
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         338..366
FT                   /note="SWIM-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00325"
FT   ZN_FING         443..492
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   NP_BIND         1249..1257
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   COMPBIAS        2..5
FT                   /note="Poly-Ala"
FT   COMPBIAS        25..29
FT                   /note="Poly-Gly"
FT   COMPBIAS        36..41
FT                   /note="Poly-Ala"
FT   COMPBIAS        422..431
FT                   /note="Poly-Ser"
FT   COMPBIAS        842..847
FT                   /note="Poly-Ser"
FT   COMPBIAS        942..949
FT                   /note="Poly-Thr"
FT   COMPBIAS        1182..1187
FT                   /note="Poly-Glu"
FT   COMPBIAS        1216..1219
FT                   /note="Poly-Ile"
FT   ACT_SITE        1369
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         1272
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         35
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         137
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P53349"
FT   MOD_RES         154
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18691976"
FT   MOD_RES         275
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19369195,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         285
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         292
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336,
FT                   ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:19369195,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         297
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         300
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         507
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         531
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         923
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1018
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         1043
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18691976"
FT   MOD_RES         1400
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P53349"
FT   MOD_RES         1412
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P53349"
FT   VARIANT         92
FT                   /note="S -> N"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040680"
FT   VARIANT         189
FT                   /note="L -> P (in SRXY6; increases phosphorylation of the
FT                   downstream target MAPK3/MAPK1 compared to wild-type and
FT                   enhances binding of RHOA to the mutant MAP3K1 complex;
FT                   dbSNP:rs387906788)"
FT                   /evidence="ECO:0000269|PubMed:21129722"
FT                   /id="VAR_065504"
FT   VARIANT         189
FT                   /note="L -> R (in SRXY6; increases phosphorylation of the
FT                   downstream targets MAPK14 and MAPK3/MAPK1 compared to wild-
FT                   type and enhances binding of RHOA to the mutant MAP3K1
FT                   complex; dbSNP:rs387906788)"
FT                   /evidence="ECO:0000269|PubMed:21129722"
FT                   /id="VAR_065505"
FT   VARIANT         211
FT                   /note="V -> VIQ (in SRXY6)"
FT                   /id="VAR_065506"
FT   VARIANT         443
FT                   /note="C -> S"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040681"
FT   VARIANT         616
FT                   /note="G -> R (in SRXY6; dbSNP:rs143853590)"
FT                   /evidence="ECO:0000269|PubMed:21129722"
FT                   /id="VAR_065507"
FT   VARIANT         806
FT                   /note="D -> N (in dbSNP:rs702689)"
FT                   /id="VAR_051636"
FT   VARIANT         906
FT                   /note="V -> I (in dbSNP:rs832582)"
FT                   /id="VAR_051637"
FT   CONFLICT        20
FT                   /note="T -> P (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        37
FT                   /note="P -> R (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        120
FT                   /note="G -> R (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        351
FT                   /note="R -> H (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        845
FT                   /note="S -> SV (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        859
FT                   /note="I -> Y (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        878..902
FT                   /note="DGQQDSFLQASVPNNYLETTENSSP -> QRQQHNSFCRHLFPTTIWKPQRT
FT                   VPL (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        933
FT                   /note="S -> R (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1097
FT                   /note="C -> L (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1104..1107
FT                   /note="AVIP -> CCYT (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1200
FT                   /note="D -> V (in Ref. 2; AAC97073)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1512 AA;  164470 MW;  5CB78242295411D9 CRC64;
     MAAAAGNRAS SSGFPGARAT SPEAGGGGGA LKASSAPAAA AGLLREAGSG GRERADWRRR
     QLRKVRSVEL DQLPEQPLFL AASPPASSTS PSPEPADAAG SGTGFQPVAV PPPHGAASRG
     GAHLTESVAA PDSGASSPAA AEPGEKRAPA AEPSPAAAPA GREMENKETL KGLHKMDDRP
     EERMIREKLK ATCMPAWKHE WLERRNRRGP VVVKPIPVKG DGSEMNHLAA ESPGEVQASA
     ASPASKGRRS PSPGNSPSGR TVKSESPGVR RKRVSPVPFQ SGRITPPRRA PSPDGFSPYS
     PEETNRRVNK VMRARLYLLQ QIGPNSFLIG GDSPDNKYRV FIGPQNCSCA RGTFCIHLLF
     VMLRVFQLEP SDPMLWRKTL KNFEVESLFQ KYHSRRSSRI KAPSRNTIQK FVSRMSNSHT
     LSSSSTSTSS SENSIKDEEE QMCPICLLGM LDEESLTVCE DGCRNKLHHH CMSIWAEECR
     RNREPLICPL CRSKWRSHDF YSHELSSPVD SPSSLRAAQQ QTVQQQPLAG SRRNQESNFN
     LTHYGTQQIP PAYKDLAEPW IQVFGMELVG CLFSRNWNVR EMALRRLSHD VSGALLLANG
     ESTGNSGGSS GSSPSGGATS GSSQTSISGD VVEACCSVLS MVCADPVYKV YVAALKTLRA
     MLVYTPCHSL AERIKLQRLL QPVVDTILVK CADANSRTSQ LSISTLLELC KGQAGELAVG
     REILKAGSIG IGGVDYVLNC ILGNQTESNN WQELLGRLCL IDRLLLEFPA EFYPHIVSTD
     VSQAEPVEIR YKKLLSLLTF ALQSIDNSHS MVGKLSRRIY LSSARMVTTV PHVFSKLLEM
     LSVSSSTHFT RMRRRLMAIA DEVEIAEAIQ LGVEDTLDGQ QDSFLQASVP NNYLETTENS
     SPECTVHLEK TGKGLCATKL SASSEDISER LASISVGPSS STTTTTTTTE QPKPMVQTKG
     RPHSQCLNSS PLSHHSQLMF PALSTPSSST PSVPAGTATD VSKHRLQGFI PCRIPSASPQ
     TQRKFSLQFH RNCPENKDSD KLSPVFTQSR PLPSSNIHRP KPSRPTPGNT SKQGDPSKNS
     MTLDLNSSSK CDDSFGCSSN SSNAVIPSDE TVFTPVEEKC RLDVNTELNS SIEDLLEASM
     PSSDTTVTFK SEVAVLSPEK AENDDTYKDD VNHNQKCKEK MEAEEEEALA IAMAMSASQD
     ALPIVPQLQV ENGEDIIIIQ QDTPETLPGH TKAKQPYRED TEWLKGQQIG LGAFSSCYQA
     QDVGTGTLMA VKQVTYVRNT SSEQEEVVEA LREEIRMMSH LNHPNIIRML GATCEKSNYN
     LFIEWMAGGS VAHLLSKYGA FKESVVINYT EQLLRGLSYL HENQIIHRDV KGANLLIDST
     GQRLRIADFG AAARLASKGT GAGEFQGQLL GTIAFMAPEV LRGQQYGRSC DVWSVGCAII
     EMACAKPPWN AEKHSNHLAL IFKIASATTA PSIPSHLSPG LRDVALRCLE LQPQDRPPSR
     ELLKHPVFRT TW
//
ID   M3K13_HUMAN             Reviewed;         966 AA.
AC   O43283; B2R6U2; B4DLE3; B4DMV2; B4DZJ4; D3DNU1; Q05BY6; Q15450; Q2NKN3;
DT   21-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   22-APR-2020, entry version 167.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 13;
DE            EC=2.7.11.25;
DE   AltName: Full=Leucine zipper-bearing kinase;
DE   AltName: Full=Mixed lineage kinase;
DE            Short=MLK;
GN   Name=MAP3K13 {ECO:0000312|HGNC:HGNC:6852};
GN   Synonyms=LZK {ECO:0000312|EMBL:BAA24817.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:BAA24817.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   ACTIVITY REGULATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   AUTOPHOSPHORYLATION.
RC   TISSUE=Cerebellum {ECO:0000269|PubMed:9353328};
RX   PubMed=9353328; DOI=10.1074/jbc.272.45.28622;
RA   Sakuma H., Ikeda A., Oka S., Kozutsumi Y., Zanetta J., Kawasaki T.;
RT   "Molecular cloning and functional expression of a cDNA encoding a new
RT   member of mixed lineage protein kinase from human brain.";
RL   J. Biol. Chem. 272:28622-28629(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4).
RC   TISSUE=Brain, Testis, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 5).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 230-340 (ISOFORM 1).
RX   PubMed=8274451;
RA   Schultz S.J., Nigg E.A.;
RT   "Identification of 21 novel human protein kinases, including 3 members of a
RT   family related to the cell cycle regulator nimA of Aspergillus nidulans.";
RL   Cell Growth Differ. 4:821-830(1993).
RN   [7] {ECO:0000305}
RP   HOMODIMERIZATION.
RX   PubMed=11163770; DOI=10.1016/s0014-5793(00)02432-7;
RA   Ikeda A., Masaki M., Kozutsumi Y., Oka S., Kawasaki T.;
RT   "Identification and characterization of functional domains in a mixed
RT   lineage kinase LZK.";
RL   FEBS Lett. 488:190-195(2001).
RN   [8] {ECO:0000305}
RP   FUNCTION, AND INTERACTION WITH MAPK8IP1.
RX   PubMed=11726277; DOI=10.1093/oxfordjournals.jbchem.a003048;
RA   Ikeda A., Hasegawa K., Masaki M., Moriguchi T., Nishida E., Kozutsumi Y.,
RA   Oka S., Kawasaki T.;
RT   "Mixed lineage kinase LZK forms a functional signaling complex with JIP-1,
RT   a scaffold protein of the c-Jun NH(2)-terminal kinase pathway.";
RL   J. Biochem. 130:773-781(2001).
RN   [9] {ECO:0000305}
RP   FUNCTION, INTERACTION WITH PRDX3, AND MUTAGENESIS OF LYS-195.
RX   PubMed=12492477; DOI=10.1046/j.1432-1033.2003.03363.x;
RA   Masaki M., Ikeda A., Shiraki E., Oka S., Kawasaki T.;
RT   "Mixed lineage kinase LZK and antioxidant protein-1 activate NF-kappaB
RT   synergistically.";
RL   Eur. J. Biochem. 270:76-83(2003).
RN   [10]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-517; LYS-712 AND LEU-746.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Activates the JUN N-terminal pathway through activation of
CC       the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to
CC       regulate the activation of NF-kappa-B in the cytosol. This activation
CC       is kinase-dependent and involves activating the IKK complex, the IKBKB-
CC       containing complex that phosphorylates inhibitors of NF-kappa-B.
CC       {ECO:0000269|PubMed:11726277, ECO:0000269|PubMed:12492477,
CC       ECO:0000269|PubMed:9353328}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25;
CC         Evidence={ECO:0000269|PubMed:9353328};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.25; Evidence={ECO:0000269|PubMed:9353328};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q60700};
CC   -!- ACTIVITY REGULATION: Activated by autophosphorylation and
CC       homodimerization. {ECO:0000269|PubMed:11163770,
CC       ECO:0000269|PubMed:9353328}.
CC   -!- SUBUNIT: Homodimer; forms dimers through the leucine-zipper motif.
CC       Interacts with the C-terminus of MAPK8IP1 through the kinase catalytic
CC       domain. Binds PRDX3. Associates with the IKK complex through the kinase
CC       domain. {ECO:0000269|PubMed:11163770, ECO:0000269|PubMed:11726277,
CC       ECO:0000269|PubMed:12492477}.
CC   -!- INTERACTION:
CC       O43283; O43283; NbExp=2; IntAct=EBI-1168480, EBI-1168480;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9353328}. Membrane
CC       {ECO:0000269|PubMed:9353328}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:9353328}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O43283-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43283-3; Sequence=VSP_036567, VSP_036568;
CC       Name=3;
CC         IsoId=O43283-4; Sequence=VSP_036563, VSP_036566;
CC       Name=4;
CC         IsoId=O43283-5; Sequence=VSP_036562, VSP_036569;
CC       Name=5;
CC         IsoId=O43283-6; Sequence=VSP_036564, VSP_036565;
CC   -!- TISSUE SPECIFICITY: Expressed in the adult brain, liver, placenta and
CC       pancreas, with expression strongest in the pancreas.
CC       {ECO:0000269|PubMed:9353328}.
CC   -!- PTM: Autophosphorylated on serine and threonine residues.
CC       {ECO:0000269|PubMed:9353328}.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAI11727.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC       Sequence=BAG59505.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB001872; BAA24817.1; -; mRNA.
DR   EMBL; AK296961; BAG59505.1; ALT_SEQ; mRNA.
DR   EMBL; AK297646; BAG60014.1; -; mRNA.
DR   EMBL; AK302951; BAG64106.1; -; mRNA.
DR   EMBL; AK312714; BAG35589.1; -; mRNA.
DR   EMBL; AC099661; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC128680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC132516; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78224.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78225.1; -; Genomic_DNA.
DR   EMBL; BC031677; AAH31677.1; -; mRNA.
DR   EMBL; BC111726; AAI11727.1; ALT_SEQ; mRNA.
DR   EMBL; Z25428; CAA80915.1; -; mRNA.
DR   CCDS; CCDS3270.1; -. [O43283-1]
DR   CCDS; CCDS56298.1; -. [O43283-5]
DR   PIR; I38218; I38218.
DR   RefSeq; NP_001229243.1; NM_001242314.1. [O43283-1]
DR   RefSeq; NP_001229246.1; NM_001242317.1. [O43283-5]
DR   RefSeq; NP_004712.1; NM_004721.4. [O43283-1]
DR   RefSeq; XP_011511612.1; XM_011513310.2. [O43283-1]
DR   RefSeq; XP_016862945.1; XM_017007456.1. [O43283-1]
DR   SMR; O43283; -.
DR   BioGrid; 114614; 12.
DR   IntAct; O43283; 6.
DR   STRING; 9606.ENSP00000265026; -.
DR   BindingDB; O43283; -.
DR   ChEMBL; CHEMBL1163124; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; O43283; -.
DR   GuidetoPHARMACOLOGY; 2073; -.
DR   iPTMnet; O43283; -.
DR   PhosphoSitePlus; O43283; -.
DR   BioMuta; MAP3K13; -.
DR   jPOST; O43283; -.
DR   MassIVE; O43283; -.
DR   PaxDb; O43283; -.
DR   PeptideAtlas; O43283; -.
DR   PRIDE; O43283; -.
DR   ProteomicsDB; 48852; -. [O43283-1]
DR   ProteomicsDB; 48853; -. [O43283-3]
DR   ProteomicsDB; 48854; -. [O43283-4]
DR   ProteomicsDB; 48855; -. [O43283-5]
DR   ProteomicsDB; 48856; -. [O43283-6]
DR   Antibodypedia; 33834; 281 antibodies.
DR   Ensembl; ENST00000265026; ENSP00000265026; ENSG00000073803. [O43283-1]
DR   Ensembl; ENST00000424227; ENSP00000399910; ENSG00000073803. [O43283-1]
DR   Ensembl; ENST00000433092; ENSP00000389798; ENSG00000073803. [O43283-6]
DR   Ensembl; ENST00000438053; ENSP00000403561; ENSG00000073803. [O43283-3]
DR   Ensembl; ENST00000443863; ENSP00000409325; ENSG00000073803. [O43283-4]
DR   Ensembl; ENST00000446828; ENSP00000411483; ENSG00000073803. [O43283-5]
DR   GeneID; 9175; -.
DR   KEGG; hsa:9175; -.
DR   UCSC; uc003fph.5; human. [O43283-1]
DR   CTD; 9175; -.
DR   DisGeNET; 9175; -.
DR   GeneCards; MAP3K13; -.
DR   HGNC; HGNC:6852; MAP3K13.
DR   HPA; ENSG00000073803; Low tissue specificity.
DR   MIM; 604915; gene.
DR   neXtProt; NX_O43283; -.
DR   OpenTargets; ENSG00000073803; -.
DR   PharmGKB; PA30596; -.
DR   eggNOG; KOG4721; Eukaryota.
DR   eggNOG; ENOG410YKX2; LUCA.
DR   GeneTree; ENSGT00940000158216; -.
DR   HOGENOM; CLU_1869795_0_0_1; -.
DR   InParanoid; O43283; -.
DR   KO; K04422; -.
DR   OMA; NHAQRRM; -.
DR   OrthoDB; 938929at2759; -.
DR   PhylomeDB; O43283; -.
DR   TreeFam; TF105119; -.
DR   SignaLink; O43283; -.
DR   SIGNOR; O43283; -.
DR   ChiTaRS; MAP3K13; human.
DR   GeneWiki; MAP3K13; -.
DR   GenomeRNAi; 9175; -.
DR   Pharos; O43283; Tchem.
DR   PRO; PR:O43283; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; O43283; protein.
DR   Bgee; ENSG00000073803; Expressed in corpus epididymis and 224 other tissues.
DR   ExpressionAtlas; O43283; baseline and differential.
DR   Genevisible; O43283; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0106137; F:IkappaB kinase complex binding; IDA:UniProtKB.
DR   GO; GO:0004706; F:JUN kinase kinase kinase activity; ISS:ARUK-UCL.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISS:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007256; P:activation of JNKK activity; ISS:ARUK-UCL.
DR   GO; GO:0007257; P:activation of JUN kinase activity; ISS:ARUK-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:ARUK-UCL.
DR   GO; GO:0045773; P:positive regulation of axon extension; ISS:ARUK-UCL.
DR   GO; GO:1905492; P:positive regulation of branching morphogenesis of a nerve; ISS:ARUK-UCL.
DR   GO; GO:0014042; P:positive regulation of neuron maturation; ISS:ARUK-UCL.
DR   GO; GO:0150012; P:positive regulation of neuron projection arborization; ISS:ARUK-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017419; MAP3K12_MAP3K13.
DR   InterPro; IPR027258; MAPKKK13.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF038165; MAPKKK12_MAPKKK13; 1.
DR   PIRSF; PIRSF500742; MAPKKK13; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cytoplasm; Kinase; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..966
FT                   /note="Mitogen-activated protein kinase kinase kinase 13"
FT                   /id="PRO_0000086264"
FT   DOMAIN          168..409
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         174..182
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:Q12852,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          433..454
FT                   /note="Leucine-zipper 1"
FT   REGION          486..507
FT                   /note="Leucine-zipper 2"
FT   REGION          815..828
FT                   /note="Acidic"
FT                   /evidence="ECO:0000305"
FT   ACT_SITE        279
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:Q12852,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         195
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:Q60700,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   VAR_SEQ         1..207
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_036562"
FT   VAR_SEQ         1..144
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_036563"
FT   VAR_SEQ         122..128
FT                   /note="RSGSGSG -> RYLGSAI (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_036564"
FT   VAR_SEQ         129..966
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_036565"
FT   VAR_SEQ         145..159
FT                   /note="IGKAYSTDYKLQQQD -> MSYVECKCLQLENKN (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_036566"
FT   VAR_SEQ         159..160
FT                   /note="DT -> VF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_036567"
FT   VAR_SEQ         161..966
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_036568"
FT   VAR_SEQ         208..220
FT                   /note="LRKLKHPNIIAFK -> MYCGIQILALWER (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_036569"
FT   VARIANT         44
FT                   /note="E -> K (in dbSNP:rs35266179)"
FT                   /id="VAR_051640"
FT   VARIANT         517
FT                   /note="R -> G (in dbSNP:rs56408536)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040708"
FT   VARIANT         712
FT                   /note="E -> K (in dbSNP:rs56309231)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040709"
FT   VARIANT         746
FT                   /note="P -> L (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040710"
FT   VARIANT         915
FT                   /note="R -> H (in dbSNP:rs3732576)"
FT                   /id="VAR_030577"
FT   MUTAGEN         195
FT                   /note="K->A: Kinase inactive. Fails to activate NF-kappa-
FT                   B."
FT                   /evidence="ECO:0000269|PubMed:12492477"
FT   CONFLICT        106
FT                   /note="D -> G (in Ref. 2; BAG59505)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        230..232
FT                   /note="CII -> YLY (in Ref. 6; CAA80915)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        268
FT                   /note="N -> D (in Ref. 2; BAG59505)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        339..340
FT                   /note="FG -> MV (in Ref. 6; CAA80915)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        508
FT                   /note="E -> G (in Ref. 2; BAG64106)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        821
FT                   /note="G -> R (in Ref. 2; BAG60014)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   966 AA;  108296 MW;  9687F38C8AB20AB1 CRC64;
     MANFQEHLSC SSSPHLPFSE SKTFNGLQDE LTAMGNHPSP KLLEDQQEKG MVRTELIESV
     HSPVTTTVLT SVSEDSRDQF ENSVLQLREH DESETAVSQG NSNTVDGEST SGTEDIKIQF
     SRSGSGSGGF LEGLFGCLRP VWNIIGKAYS TDYKLQQQDT WEVPFEEISE LQWLGSGAQG
     AVFLGKFRAE EVAIKKVREQ NETDIKHLRK LKHPNIIAFK GVCTQAPCYC IIMEYCAHGQ
     LYEVLRAGRK ITPRLLVDWS TGIASGMNYL HLHKIIHRDL KSPNVLVTHT DAVKISDFGT
     SKELSDKSTK MSFAGTVAWM APEVIRNEPV SEKVDIWSFG VVLWELLTGE IPYKDVDSSA
     IIWGVGSNSL HLPVPSTCPD GFKILMKQTW QSKPRNRPSF RQTLMHLDIA SADVLATPQE
     TYFKSQAEWR EEVKKHFEKI KSEGTCIHRL DEELIRRRRE ELRHALDIRE HYERKLERAN
     NLYMELSAIM LQLEMREKEL IKREQAVEKK YPGTYKRHPV RPIIHPNAME KLMKRKGVPH
     KSGMQTKRPD LLRSEGIPTT EVAPTASPLS GSPKMSTSSS KSRYRSKPRH RRGNSRGSHS
     DFAAILKNQP AQENSPHPTY LHQAQSQYPS LHHHNSLQQQ YQQPPPAMSQ SHHPRLNMHG
     QDIATCANNL RYFGPAAALR SPLSNHAQRQ LPGSSPDLIS TAMAADCWRS SEPDKGQAGP
     WGCCQADAYD PCLQCRPEQY GSLDIPSAEP VGRSPDLSKS PAHNPLLENA QSSEKTEENE
     FSGCRSESSL GTSHLGTPPA LPRKTRPLQK SGDDSSEEEE GEVDSEVEFP RRQRPHRCIS
     SCQSYSTFSS ENFSVSDGEE GNTSDHSNSP DELADKLEDR LAEKLDDLLS QTPEIPIDIS
     SHSDGLSDKE CAVRRVKTQM SLGKLCVEER GYENPMQFEE SDCDSSDGEC SDATVRTNKH
     YSSATW
//
ID   NF2L2_HUMAN             Reviewed;         605 AA.
AC   Q16236; B2RBU2; B4E338; E9PGJ7; Q53RW6; Q59HH2; Q96F71;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2002, sequence version 3.
DT   22-APR-2020, entry version 199.
DE   RecName: Full=Nuclear factor erythroid 2-related factor 2 {ECO:0000303|PubMed:11035812};
DE            Short=NF-E2-related factor 2 {ECO:0000303|PubMed:11035812};
DE            Short=NFE2-related factor 2 {ECO:0000303|PubMed:11035812};
DE            Short=Nrf-2 {ECO:0000303|PubMed:11256947};
DE   AltName: Full=HEBP1;
DE   AltName: Full=Nuclear factor, erythroid derived 2, like 2 {ECO:0000303|PubMed:7937919};
GN   Name=NFE2L2 {ECO:0000303|PubMed:29018201, ECO:0000312|HGNC:HGNC:7782};
GN   Synonyms=NRF2 {ECO:0000303|PubMed:7937919};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Tongue, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Myeloid leukemia cell;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-202 (ISOFORM 1).
RC   TISSUE=Melanoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4-605 (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal liver;
RX   PubMed=7937919; DOI=10.1073/pnas.91.21.9926;
RA   Moi P., Chan K., Asunis I., Cao A., Kan Y.W.;
RT   "Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine
RT   zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat
RT   of the beta-globin locus control region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9926-9930(1994).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY PKC.
RX   PubMed=11035812; DOI=10.1073/pnas.220418997;
RA   Huang H.-C., Nguyen T., Pickett C.B.;
RT   "Regulation of the antioxidant response element by protein kinase C-
RT   mediated phosphorylation of NF-E2-related factor 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:12475-12480(2000).
RN   [9]
RP   INTERACTION WITH PMF1.
RX   PubMed=11256947; DOI=10.1042/0264-6021:3550045;
RA   Wang Y., Devereux W., Stewart T.M., Casero R.A. Jr.;
RT   "Characterization of the interaction between the transcription factors
RT   human polyamine modulated factor (PMF-1) and NF-E2-related factor 2 (Nrf-2)
RT   in the transcriptional regulation of the spermidine/spermine N1-
RT   acetyltransferase (SSAT) gene.";
RL   Biochem. J. 355:45-49(2001).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH KEAP1, UBIQUITINATION,
RP   ETGE MOTIF, DOMAIN, AND MUTAGENESIS OF 79-GLU--GLU-82 AND GLU-82.
RX   PubMed=15601839; DOI=10.1128/mcb.25.1.162-171.2005;
RA   Furukawa M., Xiong Y.;
RT   "BTB protein Keap1 targets antioxidant transcription factor Nrf2 for
RT   ubiquitination by the Cullin 3-Roc1 ligase.";
RL   Mol. Cell. Biol. 25:162-171(2005).
RN   [11]
RP   UBIQUITINATION.
RX   PubMed=15983046; DOI=10.1074/jbc.m501279200;
RA   Zhang D.D., Lo S.C., Sun Z., Habib G.M., Lieberman M.W., Hannink M.;
RT   "Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3,
RT   targets Keap1 for degradation by a proteasome-independent pathway.";
RL   J. Biol. Chem. 280:30091-30099(2005).
RN   [12]
RP   FUNCTION, AND UBIQUITINATION.
RX   PubMed=19489739; DOI=10.1042/bj20090471;
RA   Eggler A.L., Small E., Hannink M., Mesecar A.D.;
RT   "Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE)
RT   activation are dependent on the partial molar volume at position 151 of
RT   Keap1.";
RL   Biochem. J. 422:171-180(2009).
RN   [13]
RP   INTERACTION WITH PGAM5 AND KEAP1.
RX   PubMed=18387606; DOI=10.1016/j.yexcr.2008.02.014;
RA   Lo S.-C., Hannink M.;
RT   "PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to
RT   mitochondria.";
RL   Exp. Cell Res. 314:1789-1803(2008).
RN   [14]
RP   INDUCTION.
RX   PubMed=19424503; DOI=10.1371/journal.pone.0005492;
RA   Wang X.J., Zhang D.D.;
RT   "Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational
RT   level.";
RL   PLoS ONE 4:E5492-E5492(2009).
RN   [15]
RP   FUNCTION.
RX   PubMed=20452972; DOI=10.1074/jbc.m110.118976;
RA   Jain A., Lamark T., Sjoettem E., Larsen K.B., Awuh J.A., Oevervatn A.,
RA   McMahon M., Hayes J.D., Johansen T.;
RT   "p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a
RT   positive feedback loop by inducing antioxidant response element-driven gene
RT   transcription.";
RL   J. Biol. Chem. 285:22576-22591(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-215, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   INTERACTION WITH EEF1D.
RX   PubMed=21597468; DOI=10.1038/embor.2011.82;
RA   Kaitsuka T., Tomizawa K., Matsushita M.;
RT   "Transformation of eEF1Bdelta into heat-shock response transcription factor
RT   by alternative splicing.";
RL   EMBO Rep. 12:673-681(2011).
RN   [18]
RP   ACETYLATION AT LYS-596 AND LYS-599, DEACETYLATION BY SIRT1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=21196497; DOI=10.1074/jbc.m110.208173;
RA   Kawai Y., Garduno L., Theodore M., Yang J., Arinze I.J.;
RT   "Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor
RT   erythroid 2-related factor 2) regulates its transcriptional activity and
RT   nucleocytoplasmic localization.";
RL   J. Biol. Chem. 286:7629-7640(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-215, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   INTERACTION WITH HERPES VIRUS 8 PROTEIN LANA1 (MICROBIAL INFECTION), AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=25995248; DOI=10.1128/jvi.00895-15;
RA   Gjyshi O., Roy A., Dutta S., Veettil M.V., Dutta D., Chandran B.;
RT   "Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus
RT   Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene
RT   Repression.";
RL   J. Virol. 89:7874-7892(2015).
RN   [21]
RP   FUNCTION, INVOLVEMENT IN IMDDHH, VARIANTS IMDDHH ARG-31; LYS-79; LYS-80 AND
RP   SER-81, AND CHARACTERIZATION OF VARIANT IMDDHH LYS-80.
RX   PubMed=29018201; DOI=10.1038/s41467-017-00932-7;
RA   Huppke P., Weissbach S., Church J.A., Schnur R., Krusen M.,
RA   Dreha-Kulaczewski S., Kuehn-Velten W.N., Wolf A., Huppke B., Millan F.,
RA   Begtrup A., Almusafri F., Thiele H., Altmueller J., Nuernberg P.,
RA   Mueller M., Gaertner J.;
RT   "Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem
RT   disorder.";
RL   Nat. Commun. 8:818-818(2017).
RN   [22]
RP   FUNCTION.
RX   PubMed=29590092; DOI=10.1038/nature25986;
RA   Mills E.L., Ryan D.G., Prag H.A., Dikovskaya D., Menon D., Zaslona Z.,
RA   Jedrychowski M.P., Costa A.S.H., Higgins M., Hams E., Szpyt J.,
RA   Runtsch M.C., King M.S., McGouran J.F., Fischer R., Kessler B.M.,
RA   McGettrick A.F., Hughes M.M., Carroll R.G., Booty L.M., Knatko E.V.,
RA   Meakin P.J., Ashford M.L.J., Modis L.K., Brunori G., Sevin D.C.,
RA   Fallon P.G., Caldwell S.T., Kunji E.R.S., Chouchani E.T., Frezza C.,
RA   Dinkova-Kostova A.T., Hartley R.C., Murphy M.P., O'Neill L.A.;
RT   "Itaconate is an anti-inflammatory metabolite that activates Nrf2 via
RT   alkylation of KEAP1.";
RL   Nature 556:113-117(2018).
RN   [23]
RP   FUNCTION, GLYCATION AT LYS-462; LYS-472; LYS-487; ARG-499; ARG-569 AND
RP   LYS-574, AND MUTAGENESIS OF LYS-462; LYS-472; LYS-487; ARG-499; ARG-569 AND
RP   ARG-587.
RX   PubMed=31398338; DOI=10.1016/j.cell.2019.07.031;
RA   Sanghvi V.R., Leibold J., Mina M., Mohan P., Berishaj M., Li Z.,
RA   Miele M.M., Lailler N., Zhao C., de Stanchina E., Viale A., Akkari L.,
RA   Lowe S.W., Ciriello G., Hendrickson R.C., Wendel H.G.;
RT   "The oncogenic action of NRF2 depends on de-glycation by fructosamine-3-
RT   kinase.";
RL   Cell 178:807-819(2019).
RN   [24]
RP   REVIEW.
RX   PubMed=28842501; DOI=10.1074/jbc.r117.800169;
RA   Suzuki T., Yamamoto M.;
RT   "Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2
RT   system during cellular stress.";
RL   J. Biol. Chem. 292:16817-16824(2017).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 69-84 IN COMPLEX WITH KEAP1, AND
RP   MUTAGENESIS OF THR-80.
RX   PubMed=16888629; DOI=10.1038/sj.emboj.7601243;
RA   Lo S.-C., Li X., Henzl M.T., Beamer L.J., Hannink M.;
RT   "Structure of the Keap1:Nrf2 interface provides mechanistic insight into
RT   Nrf2 signaling.";
RL   EMBO J. 25:3605-3617(2006).
CC   -!- FUNCTION: Transcription factor that plays a key role in the response to
CC       oxidative stress: binds to antioxidant response (ARE) elements present
CC       in the promoter region of many cytoprotective genes, such as phase 2
CC       detoxifying enzymes, and promotes their expression, thereby
CC       neutralizing reactive electrophiles (PubMed:11035812, PubMed:19489739,
CC       PubMed:29018201, PubMed:31398338). In normal conditions, ubiquitinated
CC       and degraded in the cytoplasm by the BCR(KEAP1) complex
CC       (PubMed:11035812, PubMed:15601839, PubMed:29018201). In response to
CC       oxidative stress, electrophile metabolites inhibit activity of the
CC       BCR(KEAP1) complex, promoting nuclear accumulation of NFE2L2/NRF2,
CC       heterodimerization with one of the small Maf proteins and binding to
CC       ARE elements of cytoprotective target genes (PubMed:19489739,
CC       PubMed:29590092). The NFE2L2/NRF2 pathway is also activated in response
CC       to selective autophagy: autophagy promotes interaction between KEAP1
CC       and SQSTM1/p62 and subsequent inactivation of the BCR(KEAP1) complex,
CC       leading to NFE2L2/NRF2 nuclear accumulation and expression of
CC       cytoprotective genes (PubMed:20452972). May also be involved in the
CC       transcriptional activation of genes of the beta-globin cluster by
CC       mediating enhancer activity of hypersensitive site 2 of the beta-globin
CC       locus control region (PubMed:7937919). {ECO:0000269|PubMed:11035812,
CC       ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:19489739,
CC       ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:29018201,
CC       ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:31398338,
CC       ECO:0000269|PubMed:7937919}.
CC   -!- SUBUNIT: Heterodimer; heterodimerizes with small Maf proteins (By
CC       similarity). Interacts (via the bZIP domain) with MAFG and MAFK;
CC       required for binding to antioxidant response elements (AREs) on DNA (By
CC       similarity). Interacts with KEAP1; the interaction is direct and
CC       promotes ubiquitination by the BCR(KEAP1) E3 ubiquitin ligase complex
CC       (PubMed:16888629, PubMed:15601839). Forms a ternary complex with PGAM5
CC       and KEAP1 (PubMed:18387606). Interacts with EEF1D at heat shock
CC       promoter elements (HSE) (PubMed:21597468). Interacts via its leucine-
CC       zipper domain with the coiled-coil domain of PMF1 (PubMed:11256947).
CC       Interacts with CHD6; involved in activation of the transcription (By
CC       similarity). Interacts with ESRRB; represses NFE2L2 transcriptional
CC       activity (By similarity). {ECO:0000250|UniProtKB:O54968,
CC       ECO:0000250|UniProtKB:Q60795, ECO:0000269|PubMed:11256947,
CC       ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:16888629,
CC       ECO:0000269|PubMed:18387606, ECO:0000269|PubMed:21597468}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein
CC       LANA1. {ECO:0000269|PubMed:25995248}.
CC   -!- INTERACTION:
CC       Q16236; P18848: ATF4; NbExp=4; IntAct=EBI-2007911, EBI-492498;
CC       Q16236; O60341: KDM1A; NbExp=5; IntAct=EBI-2007911, EBI-710124;
CC       Q16236; Q14145: KEAP1; NbExp=22; IntAct=EBI-2007911, EBI-751001;
CC       Q16236; O15525: MAFG; NbExp=7; IntAct=EBI-2007911, EBI-713514;
CC       Q16236; O60675: MAFK; NbExp=4; IntAct=EBI-2007911, EBI-2559512;
CC       Q16236; Q60953: Pml; Xeno; NbExp=2; IntAct=EBI-2007911, EBI-3895605;
CC       Q16236; P10276: RARA; NbExp=2; IntAct=EBI-2007911, EBI-413374;
CC       Q16236; P11416: Rara; Xeno; NbExp=2; IntAct=EBI-2007911, EBI-346736;
CC       Q16236; P13805: TNNT1; NbExp=4; IntAct=EBI-2007911, EBI-726527;
CC       Q16236; P13805-3: TNNT1; NbExp=3; IntAct=EBI-2007911, EBI-12151635;
CC       Q16236; Q9BTA9: WAC; NbExp=3; IntAct=EBI-2007911, EBI-749118;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:11035812,
CC       ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:21196497}. Nucleus
CC       {ECO:0000255|PROSITE-ProRule:PRU00978, ECO:0000269|PubMed:11035812,
CC       ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:21196497}.
CC       Note=Cytosolic under unstressed conditions: ubiquitinated and degraded
CC       by the BCR(KEAP1) E3 ubiquitin ligase complex (PubMed:15601839,
CC       PubMed:21196497). Translocates into the nucleus upon induction by
CC       electrophilic agents that inactivate the BCR(KEAP1) E3 ubiquitin ligase
CC       complex (PubMed:21196497). {ECO:0000269|PubMed:15601839,
CC       ECO:0000269|PubMed:21196497}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q16236-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16236-2; Sequence=VSP_025045;
CC       Name=3;
CC         IsoId=Q16236-3; Sequence=VSP_025045, VSP_046168;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest expression in adult
CC       muscle, kidney, lung, liver and in fetal muscle.
CC       {ECO:0000269|PubMed:7937919}.
CC   -!- INDUCTION: Down-regulated by ENC1 via a proteasomal ubiquitin-
CC       independent protein catabolic process. {ECO:0000269|PubMed:19424503}.
CC   -!- DOMAIN: The ETGE motif, and to a lower extent the DLG motif, mediate
CC       interaction with KEAP1. {ECO:0000269|PubMed:15601839}.
CC   -!- PTM: Ubiquitinated in the cytoplasm by the BCR(KEAP1) E3 ubiquitin
CC       ligase complex leading to its degradation (PubMed:15601839,
CC       PubMed:15983046, PubMed:19489739). In response to oxidative stress,
CC       electrophile metabolites, such as sulforaphane, modify KEAP1, leading
CC       to inhibit activity of the BCR(KEAP1) complex, promoting NFE2L2/NRF2
CC       nuclear accumulation and activity (PubMed:19489739, PubMed:29590092).
CC       In response to autophagy, the BCR(KEAP1) complex is inactivated (By
CC       similarity). {ECO:0000250|UniProtKB:Q60795,
CC       ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:15983046,
CC       ECO:0000269|PubMed:19489739, ECO:0000269|PubMed:29590092}.
CC   -!- PTM: Phosphorylation of Ser-40 by PKC in response to oxidative stress
CC       dissociates NFE2L2 from its cytoplasmic inhibitor KEAP1, promoting its
CC       translocation into the nucleus. {ECO:0000250|UniProtKB:O54968}.
CC   -!- PTM: Acetylation at Lys-596 and Lys-599 increases nuclear localization
CC       whereas deacetylation by SIRT1 enhances cytoplasmic presence.
CC       {ECO:0000269|PubMed:21196497}.
CC   -!- PTM: Glycation impairs transcription factor activity by preventing
CC       heterodimerization with small Maf proteins (PubMed:31398338).
CC       Deglycation by FN3K restores activity (PubMed:31398338).
CC       {ECO:0000269|PubMed:31398338}.
CC   -!- DISEASE: Immunodeficiency, developmental delay, and hypohomocysteinemia
CC       (IMDDHH) [MIM:617744]: An early onset multisystem disorder
CC       characterized by immunodeficiency, recurrent infections, developmental
CC       delay, poor growth, intellectual disability, and hypohomocysteinemia.
CC       Some patients manifest congenital cardiac defects. IMDDHH inheritance
CC       pattern is autosomal dominant. {ECO:0000269|PubMed:29018201}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the bZIP family. CNC subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB32188.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAD92023.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK304555; BAG65350.1; -; mRNA.
DR   EMBL; AK314816; BAG37339.1; -; mRNA.
DR   EMBL; AB208786; BAD92023.1; ALT_INIT; mRNA.
DR   EMBL; AC019080; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079305; AAY14710.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11062.1; -; Genomic_DNA.
DR   EMBL; BC011558; AAH11558.1; -; mRNA.
DR   EMBL; AL135266; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S74017; AAB32188.1; ALT_INIT; mRNA.
DR   CCDS; CCDS42782.1; -. [Q16236-1]
DR   CCDS; CCDS46457.1; -. [Q16236-2]
DR   CCDS; CCDS46458.1; -. [Q16236-3]
DR   RefSeq; NP_001138884.1; NM_001145412.3. [Q16236-2]
DR   RefSeq; NP_001138885.1; NM_001145413.3. [Q16236-3]
DR   RefSeq; NP_001300829.1; NM_001313900.1. [Q16236-2]
DR   RefSeq; NP_001300830.1; NM_001313901.1. [Q16236-2]
DR   RefSeq; NP_006155.2; NM_006164.4. [Q16236-1]
DR   PDB; 2FLU; X-ray; 1.50 A; P=69-84.
DR   PDB; 2LZ1; NMR; -; A=445-523.
DR   PDB; 3ZGC; X-ray; 2.20 A; C=76-82.
DR   PDB; 4IFL; X-ray; 1.80 A; P=69-84.
DR   PDB; 5WFV; X-ray; 1.91 A; P=76-84.
DR   PDBsum; 2FLU; -.
DR   PDBsum; 2LZ1; -.
DR   PDBsum; 3ZGC; -.
DR   PDBsum; 4IFL; -.
DR   PDBsum; 5WFV; -.
DR   SMR; Q16236; -.
DR   BioGrid; 110852; 70.
DR   CORUM; Q16236; -.
DR   DIP; DIP-29971N; -.
DR   ELM; Q16236; -.
DR   IntAct; Q16236; 31.
DR   MINT; Q16236; -.
DR   STRING; 9606.ENSP00000380252; -.
DR   BindingDB; Q16236; -.
DR   ChEMBL; CHEMBL1075094; -.
DR   iPTMnet; Q16236; -.
DR   PhosphoSitePlus; Q16236; -.
DR   BioMuta; NFE2L2; -.
DR   DMDM; 25453452; -.
DR   EPD; Q16236; -.
DR   jPOST; Q16236; -.
DR   MassIVE; Q16236; -.
DR   MaxQB; Q16236; -.
DR   PaxDb; Q16236; -.
DR   PeptideAtlas; Q16236; -.
DR   PRIDE; Q16236; -.
DR   ProteomicsDB; 20333; -.
DR   ProteomicsDB; 60843; -. [Q16236-1]
DR   ProteomicsDB; 60844; -. [Q16236-2]
DR   Antibodypedia; 903; 805 antibodies.
DR   DNASU; 4780; -.
DR   Ensembl; ENST00000397062; ENSP00000380252; ENSG00000116044. [Q16236-1]
DR   Ensembl; ENST00000397063; ENSP00000380253; ENSG00000116044. [Q16236-2]
DR   Ensembl; ENST00000446151; ENSP00000411575; ENSG00000116044. [Q16236-3]
DR   Ensembl; ENST00000464747; ENSP00000467401; ENSG00000116044. [Q16236-2]
DR   GeneID; 4780; -.
DR   KEGG; hsa:4780; -.
DR   UCSC; uc002ulg.6; human. [Q16236-1]
DR   CTD; 4780; -.
DR   DisGeNET; 4780; -.
DR   GeneCards; NFE2L2; -.
DR   HGNC; HGNC:7782; NFE2L2.
DR   HPA; ENSG00000116044; Low tissue specificity.
DR   MalaCards; NFE2L2; -.
DR   MIM; 600492; gene.
DR   MIM; 617744; phenotype.
DR   neXtProt; NX_Q16236; -.
DR   OpenTargets; ENSG00000116044; -.
DR   PharmGKB; PA31588; -.
DR   eggNOG; ENOG410ISV3; Eukaryota.
DR   eggNOG; ENOG41100FB; LUCA.
DR   GeneTree; ENSGT00950000182892; -.
DR   HOGENOM; CLU_498373_0_0_1; -.
DR   InParanoid; Q16236; -.
DR   KO; K05638; -.
DR   OMA; MFSLNFQ; -.
DR   OrthoDB; 1095280at2759; -.
DR   PhylomeDB; Q16236; -.
DR   TreeFam; TF326681; -.
DR   SignaLink; Q16236; -.
DR   SIGNOR; Q16236; -.
DR   ChiTaRS; NFE2L2; human.
DR   EvolutionaryTrace; Q16236; -.
DR   GeneWiki; NFE2L2; -.
DR   GenomeRNAi; 4780; -.
DR   Pharos; Q16236; Tchem.
DR   PRO; PR:Q16236; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q16236; protein.
DR   Bgee; ENSG00000116044; Expressed in epithelium of nasopharynx and 243 other tissues.
DR   ExpressionAtlas; Q16236; baseline and differential.
DR   Genevisible; Q16236; HS.
DR   GO; GO:0005623; C:cell; IEA:GOC.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0032993; C:protein-DNA complex; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001221; F:transcription cofactor binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0046223; P:aflatoxin catabolic process; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0045454; P:cell redox homeostasis; IMP:UniProtKB.
DR   GO; GO:1904385; P:cellular response to angiotensin; IEA:Ensembl.
DR   GO; GO:0071280; P:cellular response to copper ion; IEA:Ensembl.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IDA:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IMP:BHF-UCL.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IMP:BHF-UCL.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:1902037; P:negative regulation of hematopoietic stem cell differentiation; IEA:Ensembl.
DR   GO; GO:1903206; P:negative regulation of hydrogen peroxide-induced cell death; IGI:ParkinsonsUK-UCL.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:1904753; P:negative regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0036499; P:PERK-mediated unfolded protein response; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IEA:Ensembl.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IEA:Ensembl.
DR   GO; GO:1903071; P:positive regulation of ER-associated ubiquitin-dependent protein catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:CACAO.
DR   GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
DR   GO; GO:1903788; P:positive regulation of glutathione biosynthetic process; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0036091; P:positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0036003; P:positive regulation of transcription from RNA polymerase II promoter in response to stress; IMP:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IBA:GO_Central.
DR   GO; GO:0010499; P:proteasomal ubiquitin-independent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0045995; P:regulation of embryonic development; IEA:Ensembl.
DR   GO; GO:2000121; P:regulation of removal of superoxide radicals; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   DisProt; DP01115; -.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR004826; bZIP_Maf.
DR   InterPro; IPR029845; Nrf2.
DR   InterPro; IPR008917; TF_DNA-bd_sf.
DR   PANTHER; PTHR24411:SF3; PTHR24411:SF3; 1.
DR   Pfam; PF03131; bZIP_Maf; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   SUPFAM; SSF47454; SSF47454; 1.
DR   PROSITE; PS50217; BZIP; 1.
DR   PROSITE; PS00036; BZIP_BASIC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Cytoplasm;
KW   Disease mutation; DNA-binding; Glycation; Glycoprotein;
KW   Host-virus interaction; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..605
FT                   /note="Nuclear factor erythroid 2-related factor 2"
FT                   /id="PRO_0000076449"
FT   DOMAIN          497..560
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          499..518
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          522..529
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          591..596
FT                   /note="Mediates interaction with CHD6 and is necessary to
FT                   activate transcription"
FT                   /evidence="ECO:0000250|UniProtKB:O54968"
FT   MOTIF           29..31
FT                   /note="DLG motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q60795"
FT   MOTIF           79..82
FT                   /note="ETGE motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q60795"
FT   MOD_RES         40
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000250|UniProtKB:O54968"
FT   MOD_RES         215
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         596
FT                   /note="N6-acetyllysine; by CREBBP"
FT                   /evidence="ECO:0000269|PubMed:21196497"
FT   MOD_RES         599
FT                   /note="N6-acetyllysine; by CREBBP"
FT                   /evidence="ECO:0000269|PubMed:21196497"
FT   CARBOHYD        462
FT                   /note="N-linked (Glc) (glycation) lysine"
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   CARBOHYD        472
FT                   /note="N-linked (Glc) (glycation) lysine"
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   CARBOHYD        487
FT                   /note="N-linked (Glc) (glycation) lysine"
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   CARBOHYD        499
FT                   /note="N-linked (Glc) (glycation) arginine"
FT                   /evidence="ECO:0000305|PubMed:31398338"
FT   CARBOHYD        569
FT                   /note="N-linked (Glc) (glycation) arginine"
FT                   /evidence="ECO:0000305|PubMed:31398338"
FT   CARBOHYD        574
FT                   /note="N-linked (Glc) (glycation) lysine"
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   VAR_SEQ         1..16
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.2"
FT                   /id="VSP_025045"
FT   VAR_SEQ         135..141
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046168"
FT   VARIANT         31
FT                   /note="G -> R (in IMDDHH; dbSNP:rs1553488015)"
FT                   /evidence="ECO:0000269|PubMed:29018201"
FT                   /id="VAR_080492"
FT   VARIANT         43
FT                   /note="R -> Q (in dbSNP:rs35248500)"
FT                   /id="VAR_032110"
FT   VARIANT         79
FT                   /note="E -> K (in IMDDHH; dbSNP:rs1057519922)"
FT                   /evidence="ECO:0000269|PubMed:29018201"
FT                   /id="VAR_080493"
FT   VARIANT         80
FT                   /note="T -> K (in IMDDHH; increased protein abundance;
FT                   increased positive regulation of transcription of target
FT                   genes; changed cell redox homeostasis; dbSNP:rs1553487947)"
FT                   /evidence="ECO:0000269|PubMed:29018201"
FT                   /id="VAR_080494"
FT   VARIANT         81
FT                   /note="G -> S (in IMDDHH; dbSNP:rs1553487942)"
FT                   /evidence="ECO:0000269|PubMed:29018201"
FT                   /id="VAR_080495"
FT   VARIANT         99
FT                   /note="S -> P (in dbSNP:rs5031039)"
FT                   /id="VAR_020322"
FT   VARIANT         268
FT                   /note="V -> M (in dbSNP:rs34154613)"
FT                   /id="VAR_032111"
FT   MUTAGEN         79..82
FT                   /note="Missing: Abolished interaction with KEAP1."
FT                   /evidence="ECO:0000269|PubMed:15601839"
FT   MUTAGEN         80
FT                   /note="T->A: Loss of interaction with KEAP1."
FT                   /evidence="ECO:0000269|PubMed:16888629"
FT   MUTAGEN         82
FT                   /note="E->G: Abolished interaction with KEAP1."
FT                   /evidence="ECO:0000269|PubMed:15601839"
FT   MUTAGEN         462
FT                   /note="K->A: Loss of function; when associated with A-472;
FT                   A-487; A-499; A-569 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         472
FT                   /note="K->A: Loss of function; when associated with A-462;
FT                   A-487; A-499; A-569 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         487
FT                   /note="K->A: Loss of function; when associated with A-462;
FT                   A-472; A-499; A-569 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         499
FT                   /note="R->A: Loss of function; when associated with A-462;
FT                   A-472; A-487; A-569 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         569
FT                   /note="R->A: Loss of function; when associated with A-462;
FT                   A-472; A-487; A-499 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         587
FT                   /note="R->A: Loss of function; when associated with A-462;
FT                   A-472; A-487; A-499 and A-569."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   CONFLICT        72
FT                   /note="A -> T (in Ref. 7; AAB32188)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        92
FT                   /note="I -> T (in Ref. 7; AAB32188)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        178
FT                   /note="D -> Y (in Ref. 3; AL135266)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        521
FT                   /note="N -> D (in Ref. 1; BAG65350)"
FT                   /evidence="ECO:0000305"
FT   TURN            78..80
FT                   /evidence="ECO:0000244|PDB:2FLU"
FT   HELIX           456..464
FT                   /evidence="ECO:0000244|PDB:2LZ1"
FT   HELIX           470..475
FT                   /evidence="ECO:0000244|PDB:2LZ1"
FT   HELIX           478..487
FT                   /evidence="ECO:0000244|PDB:2LZ1"
FT   HELIX           492..504
FT                   /evidence="ECO:0000244|PDB:2LZ1"
SQ   SEQUENCE   605 AA;  67827 MW;  99FAFD811B6C1416 CRC64;
     MMDLELPPPG LPSQQDMDLI DILWRQDIDL GVSREVFDFS QRRKEYELEK QKKLEKERQE
     QLQKEQEKAF FAQLQLDEET GEFLPIQPAQ HIQSETSGSA NYSQVAHIPK SDALYFDDCM
     QLLAQTFPFV DDNEVSSATF QSLVPDIPGH IESPVFIATN QAQSPETSVA QVAPVDLDGM
     QQDIEQVWEE LLSIPELQCL NIENDKLVET TMVPSPEAKL TEVDNYHFYS SIPSMEKEVG
     NCSPHFLNAF EDSFSSILST EDPNQLTVNS LNSDATVNTD FGDEFYSAFI AEPSISNSMP
     SPATLSHSLS ELLNGPIDVS DLSLCKAFNQ NHPESTAEFN DSDSGISLNT SPSVASPEHS
     VESSSYGDTL LGLSDSEVEE LDSAPGSVKQ NGPKTPVHSS GDMVQPLSPS QGQSTHVHDA
     QCENTPEKEL PVSPGHRKTP FTKDKHSSRL EAHLTRDELR AKALHIPFPV EKIINLPVVD
     FNEMMSKEQF NEAQLALIRD IRRRGKNKVA AQNCRKRKLE NIVELEQDLD HLKDEKEKLL
     KEKGENDKSL HLLKKQLSTL YLEVFSMLRD EDGKPYSPSE YSLQQTRDGN VFLVPKSKKP
     DVKKN
//
ID   NKX21_HUMAN             Reviewed;         371 AA.
AC   P43699; D3DSA3; O14954; O14955; Q7KZF6; Q9BRJ8;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   22-APR-2020, entry version 194.
DE   RecName: Full=Homeobox protein Nkx-2.1;
DE   AltName: Full=Homeobox protein NK-2 homolog A;
DE   AltName: Full=Thyroid nuclear factor 1;
DE   AltName: Full=Thyroid transcription factor 1;
DE            Short=TTF-1;
DE   AltName: Full=Thyroid-specific enhancer-binding protein;
DE            Short=T/EBP;
GN   Name=NKX2-1 {ECO:0000312|HGNC:HGNC:11825}; Synonyms=NKX2A, TITF1, TTF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=7711079; DOI=10.1016/0167-4781(95)00033-d;
RA   Oguchi H., Pan Y.-T., Kimura S.;
RT   "The complete nucleotide sequence of the mouse thyroid-specific enhancer-
RT   binding protein (T/EBP) gene: extensive identity of the deduced amino acid
RT   sequence with the human protein.";
RL   Biochim. Biophys. Acta 1261:304-306(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Thyroid;
RX   PubMed=7711080; DOI=10.1016/0167-4781(95)00034-e;
RA   Saiardi A., Tassi V., de Filippis V., Civitareale D.;
RT   "Cloning and sequence analysis of human thyroid transcription factor 1.";
RL   Biochim. Biophys. Acta 1261:307-310(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=7713914; DOI=10.1074/jbc.270.14.8108;
RA   Ikeda K., Clark J.C., Shaw-White J.R., Stahlman M.T., Boutell C.J.,
RA   Whitsett J.A.;
RT   "Gene structure and expression of human thyroid transcription factor-1 in
RT   respiratory epithelial cells.";
RL   J. Biol. Chem. 270:8108-8114(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lung;
RX   PubMed=9545595; DOI=10.1016/s0167-4781(97)00210-8;
RA   Hamdan H., Liu H., Li C., Jones C., Lee M., deLemos R., Minoo P.;
RT   "Structure of the human Nkx2.1 gene.";
RL   Biochim. Biophys. Acta 1396:336-348(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RC   TISSUE=Thyroid;
RA   Endo T., Ohno M., Nakazato M.;
RT   "Cloning of the human TTF-1 gene.";
RL   Submitted (MAY-1995) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH WWTR1.
RX   PubMed=19010321; DOI=10.1016/j.yexcr.2008.10.016;
RA   Di Palma T., D'Andrea B., Liguori G.L., Liguoro A., de Cristofaro T.,
RA   Del Prete D., Pappalardo A., Mascia A., Zannini M.;
RT   "TAZ is a coactivator for Pax8 and TTF-1, two transcription factors
RT   involved in thyroid differentiation.";
RL   Exp. Cell Res. 315:162-175(2009).
RN   [11]
RP   INVOLVEMENT IN NMTC1, VARIANT NMTC1 VAL-339, AND CHARACTERIZATION OF
RP   VARIANT NMTC1 VAL-339.
RX   PubMed=19176457; DOI=10.1093/jnci/djn471;
RA   Ngan E.S., Lang B.H., Liu T., Shum C.K., So M.T., Lau D.K., Leon T.Y.,
RA   Cherny S.S., Tsai S.Y., Lo C.Y., Khoo U.S., Tam P.K., Garcia-Barcelo M.M.;
RT   "A germline mutation (A339V) in thyroid transcription factor-1 (TITF-
RT   1/NKX2.1) in patients with multinodular goiter and papillary thyroid
RT   carcinoma.";
RL   J. Natl. Cancer Inst. 101:162-175(2009).
RN   [12]
RP   VARIANTS BHC LEU-208 AND SER-213, AND INVOLVEMENT IN BHC.
RX   PubMed=11971878; DOI=10.1093/hmg/11.8.971;
RA   Breedveld G.J., van Dongen J.W.F., Danesino C., Guala A., Percy A.K.,
RA   Dure L.S., Harper P., Lazarou L.P., van der Linde H., Joosse M.,
RA   Grueters A., MacDonald M.E., de Vries B.B.A., Arts W.F.M., Oostra B.A.,
RA   Krude H., Heutink P.;
RT   "Mutations in TITF-1 are associated with benign hereditary chorea.";
RL   Hum. Mol. Genet. 11:971-979(2002).
RN   [13]
RP   INVOLVEMENT IN CAHTP.
RX   PubMed=11854318; DOI=10.1172/jci14192;
RA   Pohlenz J., Dumitrescu A., Zundel D., Martine U., Schoenberger W., Koo E.,
RA   Weiss R.E., Cohen R.N., Kimura S., Refetoff S.;
RT   "Partial deficiency of thyroid transcription factor 1 produces
RT   predominantly neurological defects in humans and mice.";
RL   J. Clin. Invest. 109:469-473(2002).
RN   [14]
RP   VARIANT CAHTP PHE-205.
RX   PubMed=11854319; DOI=10.1172/jci14341;
RA   Krude H., Schuetz B., Biebermann H., von Moers A., Schnabel D., Neitzel H.,
RA   Toennies H., Weise D., Lafferty A., Schwarz S., DeFelice M.,
RA   von Deimling A., van Landeghem F., DiLauro R., Grueters A.;
RT   "Choreoathetosis, hypothyroidism, and pulmonary alterations due to human
RT   NKX2-1 haploinsufficiency.";
RL   J. Clin. Invest. 109:475-480(2002).
RN   [15]
RP   INVOLVEMENT IN CAHTP.
RX   PubMed=15289765; DOI=10.1016/j.jpeds.2004.04.011;
RA   Doyle D.A., Gonzalez I., Thomas B., Scavina M.;
RT   "Autosomal dominant transmission of congenital hypothyroidism, neonatal
RT   respiratory distress, and ataxia caused by a mutation of NKX2-1.";
RL   J. Pediatr. 145:190-193(2004).
RN   [16]
RP   INVOLVEMENT IN CAHTP AND IN BHC.
RX   PubMed=15955952; DOI=10.1212/01.wnl.0000164000.75046.cc;
RA   Asmus F., Horber V., Pohlenz J., Schwabe D., Zimprich A., Munz M.,
RA   Schoening M., Gasser T.;
RT   "A novel TITF-1 mutation causes benign hereditary chorea with response to
RT   levodopa.";
RL   Neurology 64:1952-1954(2005).
RN   [17]
RP   VARIANT BHC PRO-179.
RX   PubMed=24453141; DOI=10.1177/0883073813518243;
RA   Williamson S., Kirkpatrick M., Greene S., Goudie D.;
RT   "A novel mutation of NKX2-1 affecting 2 generations with hypothyroidism and
RT   choreoathetosis: part of the spectrum of brain-thyroid-lung syndrome.";
RL   J. Child Neurol. 29:666-669(2014).
RN   [18]
RP   VARIANTS CAHTP ARG-203 AND PHE-205.
RX   PubMed=24714694; DOI=10.1136/jmedgenet-2013-102248;
RA   Thorwarth A., Schnittert-Huebener S., Schrumpf P., Mueller I., Jyrch S.,
RA   Dame C., Biebermann H., Kleinau G., Katchanov J., Schuelke M., Ebert G.,
RA   Steininger A., Boennemann C., Brockmann K., Christen H.J., Crock P.,
RA   deZegher F., Griese M., Hewitt J., Ivarsson S., Huebner C., Kapelari K.,
RA   Plecko B., Rating D., Stoeva I., Ropers H.H., Grueters A., Ullmann R.,
RA   Krude H.;
RT   "Comprehensive genotyping and clinical characterisation reveal 27 novel
RT   NKX2-1 mutations and expand the phenotypic spectrum.";
RL   J. Med. Genet. 51:375-387(2014).
RN   [19]
RP   VARIANTS BHC HIS-172 AND SER-208, AND CHARACTERIZATION OF VARIANTS BHC
RP   HIS-172 AND SER-208.
RX   PubMed=26723978; DOI=10.1016/j.jns.2015.11.050;
RA   Provenzano C., Zamboni M., Veneziano L., Mantuano E., Garavaglia B.,
RA   Zorzi G., Pagonabarraga J., Giunti P., Civitareale D.;
RT   "Functional characterization of two novel mutations in TTF-1/NKX2.1
RT   homeodomain in patients with benign hereditary chorea.";
RL   J. Neurol. Sci. 360:78-83(2016).
CC   -!- FUNCTION: Transcription factor that binds and activates the promoter of
CC       thyroid specific genes such as thyroglobulin, thyroperoxidase, and
CC       thyrotropin receptor. Crucial in the maintenance of the thyroid
CC       differentiation phenotype. May play a role in lung development and
CC       surfactant homeostasis. Forms a regulatory loop with GRHL2 that
CC       coordinates lung epithelial cell morphogenesis and differentiation.
CC       Activates the transcription of GNRHR and plays a role in enhancing the
CC       circadian oscillation of its gene expression. Represses the
CC       transcription of the circadian transcriptional repressor NR1D1 (By
CC       similarity). {ECO:0000250|UniProtKB:P23441,
CC       ECO:0000250|UniProtKB:P50220}.
CC   -!- SUBUNIT: Interacts with WWTR1. {ECO:0000269|PubMed:19010321}.
CC   -!- INTERACTION:
CC       P43699; Q9P031: CCDC59; NbExp=4; IntAct=EBI-1391923, EBI-1047110;
CC       P43699; P16333: NCK1; NbExp=2; IntAct=EBI-1391923, EBI-389883;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P50220}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P43699-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=P43699-3; Sequence=VSP_037890;
CC   -!- TISSUE SPECIFICITY: Thyroid and lung.
CC   -!- PTM: Phosphorylated on serine residues by STK3/MST2. {ECO:0000250}.
CC   -!- DISEASE: Chorea, hereditary benign (BHC) [MIM:118700]: A rare autosomal
CC       dominant movement disorder, defined by early onset in childhood, a
CC       stable or non-progressive course of chorea, and no mental
CC       deterioration. Chorea is characterized by involuntary, forcible, rapid,
CC       jerky movements that may be subtle or become confluent, markedly
CC       altering normal patterns of movement. {ECO:0000269|PubMed:11971878,
CC       ECO:0000269|PubMed:15955952, ECO:0000269|PubMed:24453141,
CC       ECO:0000269|PubMed:26723978}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Choreoathetosis and congenital hypothyroidism with or without
CC       pulmonary dysfunction (CAHTP) [MIM:610978]: An autosomal dominant
CC       disorder that manifests in infancy with neurological disturbances,
CC       hypothyroidism, and respiratory problems. It is characterized by
CC       movement abnormalities beginning with muscular hypotonia followed by
CC       the development of chorea, athetosis, dystonia, ataxia, and dysarthria.
CC       {ECO:0000269|PubMed:11854318, ECO:0000269|PubMed:11854319,
CC       ECO:0000269|PubMed:15289765, ECO:0000269|PubMed:15955952,
CC       ECO:0000269|PubMed:24714694}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Thyroid cancer, non-medullary, 1 (NMTC1) [MIM:188550]: A form
CC       of non-medullary thyroid cancer (NMTC), a cancer characterized by
CC       tumors originating from the thyroid follicular cells. NMTCs represent
CC       approximately 95% of all cases of thyroid cancer and are classified
CC       into papillary, follicular, Hurthle cell, and anaplastic neoplasms.
CC       {ECO:0000269|PubMed:19176457}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the NK-2 homeobox family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH06221.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA23527.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NKX2-1ID44015ch14q13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U19756; AAA86099.1; -; mRNA.
DR   EMBL; X82850; CAA58053.1; -; mRNA.
DR   EMBL; U19816; AAC50125.1; -; Genomic_DNA.
DR   EMBL; U33749; AAB52381.1; -; mRNA.
DR   EMBL; U43203; AAA89066.1; -; mRNA.
DR   EMBL; D50739; BAA23527.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; D50740; BAA23529.1; -; mRNA.
DR   EMBL; BT009773; AAP88775.1; -; mRNA.
DR   EMBL; AL132857; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471078; EAW65858.1; -; Genomic_DNA.
DR   EMBL; CH471078; EAW65856.1; -; Genomic_DNA.
DR   EMBL; CH471078; EAW65859.1; -; Genomic_DNA.
DR   EMBL; BC006221; AAH06221.2; ALT_INIT; mRNA.
DR   CCDS; CCDS41945.1; -. [P43699-3]
DR   CCDS; CCDS9659.1; -. [P43699-1]
DR   PIR; G02321; G02321.
DR   RefSeq; NP_001073136.1; NM_001079668.2. [P43699-3]
DR   RefSeq; NP_003308.1; NM_003317.3. [P43699-1]
DR   SMR; P43699; -.
DR   BioGrid; 112936; 162.
DR   IntAct; P43699; 10.
DR   MINT; P43699; -.
DR   STRING; 9606.ENSP00000346879; -.
DR   iPTMnet; P43699; -.
DR   PhosphoSitePlus; P43699; -.
DR   BioMuta; NKX2-1; -.
DR   DMDM; 1174819; -.
DR   jPOST; P43699; -.
DR   MassIVE; P43699; -.
DR   MaxQB; P43699; -.
DR   PaxDb; P43699; -.
DR   PeptideAtlas; P43699; -.
DR   PRIDE; P43699; -.
DR   ProteomicsDB; 55653; -. [P43699-1]
DR   ProteomicsDB; 55654; -. [P43699-3]
DR   Antibodypedia; 3519; 1033 antibodies.
DR   DNASU; 7080; -.
DR   Ensembl; ENST00000354822; ENSP00000346879; ENSG00000136352. [P43699-3]
DR   Ensembl; ENST00000498187; ENSP00000429607; ENSG00000136352. [P43699-1]
DR   Ensembl; ENST00000518149; ENSP00000428341; ENSG00000136352. [P43699-1]
DR   Ensembl; ENST00000522719; ENSP00000429519; ENSG00000136352. [P43699-1]
DR   GeneID; 7080; -.
DR   KEGG; hsa:7080; -.
DR   UCSC; uc001wtt.4; human. [P43699-1]
DR   CTD; 7080; -.
DR   DisGeNET; 7080; -.
DR   GeneCards; NKX2-1; -.
DR   GeneReviews; NKX2-1; -.
DR   HGNC; HGNC:11825; NKX2-1.
DR   HPA; ENSG00000136352; Group enriched (lung, thyroid gland).
DR   MalaCards; NKX2-1; -.
DR   MIM; 118700; phenotype.
DR   MIM; 188550; phenotype.
DR   MIM; 600635; gene.
DR   MIM; 610978; phenotype.
DR   neXtProt; NX_P43699; -.
DR   OpenTargets; ENSG00000136352; -.
DR   Orphanet; 95713; Athyreosis.
DR   Orphanet; 1429; Benign hereditary chorea.
DR   Orphanet; 209905; Brain-lung-thyroid syndrome.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   PharmGKB; PA36531; -.
DR   eggNOG; KOG0842; Eukaryota.
DR   eggNOG; ENOG410XR21; LUCA.
DR   GeneTree; ENSGT00940000161107; -.
DR   HOGENOM; CLU_052416_0_0_1; -.
DR   InParanoid; P43699; -.
DR   KO; K09342; -.
DR   OMA; MGHNGTV; -.
DR   OrthoDB; 1209625at2759; -.
DR   PhylomeDB; P43699; -.
DR   TreeFam; TF351204; -.
DR   SIGNOR; P43699; -.
DR   GeneWiki; NK2_homeobox_1; -.
DR   GenomeRNAi; 7080; -.
DR   Pharos; P43699; Tbio.
DR   PRO; PR:P43699; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P43699; protein.
DR   Bgee; ENSG00000136352; Expressed in left lobe of thyroid gland and 78 other tissues.
DR   ExpressionAtlas; P43699; baseline and differential.
DR   Genevisible; P43699; HS.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; IMP:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0044213; F:intronic transcription regulatory region DNA binding; IDA:MGI.
DR   GO; GO:0001161; F:intronic transcription regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0001012; F:RNA polymerase II regulatory region DNA binding; IDA:MGI.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IMP:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl.
DR   GO; GO:0021892; P:cerebral cortex GABAergic interneuron differentiation; IEA:Ensembl.
DR   GO; GO:0060486; P:club cell differentiation; IEA:Ensembl.
DR   GO; GO:0031128; P:developmental induction; IEA:Ensembl.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEP:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEP:UniProtKB.
DR   GO; GO:0021798; P:forebrain dorsal/ventral pattern formation; IEA:Ensembl.
DR   GO; GO:0021877; P:forebrain neuron fate commitment; IEA:Ensembl.
DR   GO; GO:0021759; P:globus pallidus development; IMP:UniProtKB.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0033327; P:Leydig cell differentiation; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEP:UniProtKB.
DR   GO; GO:0060430; P:lung saccule development; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0006644; P:phospholipid metabolic process; IEA:Ensembl.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0042753; P:positive regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0009725; P:response to hormone; IEP:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0030878; P:thyroid gland development; IMP:UniProtKB.
DR   GO; GO:0060510; P:type II pneumocyte differentiation; IEA:Ensembl.
DR   CDD; cd00086; homeodomain; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR020479; Homeobox_metazoa.
DR   Pfam; PF00046; Homeodomain; 1.
DR   PRINTS; PR00024; HOMEOBOX.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; Biological rhythms;
KW   Congenital hypothyroidism; Disease mutation; DNA-binding; Homeobox;
KW   Nucleus; Phosphoprotein; Reference proteome; Repressor; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..371
FT                   /note="Homeobox protein Nkx-2.1"
FT                   /id="PRO_0000049343"
FT   DNA_BIND        161..220
FT                   /note="Homeobox"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT   COMPBIAS        234..243
FT                   /note="Poly-Gly"
FT   COMPBIAS        246..253
FT                   /note="Poly-Gln"
FT   COMPBIAS        294..303
FT                   /note="Poly-Ala"
FT   MOD_RES         254
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P23441"
FT   VAR_SEQ         1
FT                   /note="M -> MWSGGSGKARGWEAAAGGRSSPGRLSRRRIM (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9545595, ECO:0000303|Ref.6"
FT                   /id="VSP_037890"
FT   VARIANT         172
FT                   /note="Q -> H (in BHC; decrease in DNA-binding; no effect
FT                   on transcription activation from thyroglobulin/TG, nor from
FT                   pulmonary surfactant-associated protein C/SFTPC gene
FT                   promoters)"
FT                   /evidence="ECO:0000269|PubMed:26723978"
FT                   /id="VAR_075209"
FT   VARIANT         179
FT                   /note="R -> P (in BHC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:24453141"
FT                   /id="VAR_077542"
FT   VARIANT         203
FT                   /note="T -> R (in CAHTP)"
FT                   /evidence="ECO:0000269|PubMed:24714694"
FT                   /id="VAR_073040"
FT   VARIANT         205
FT                   /note="V -> F (in CAHTP; dbSNP:rs137852692)"
FT                   /evidence="ECO:0000269|PubMed:11854319,
FT                   ECO:0000269|PubMed:24714694"
FT                   /id="VAR_034906"
FT   VARIANT         208
FT                   /note="W -> L (in BHC; dbSNP:rs28936672)"
FT                   /evidence="ECO:0000269|PubMed:11971878"
FT                   /id="VAR_015188"
FT   VARIANT         208
FT                   /note="W -> S (in BHC; loss of transcription activation)"
FT                   /evidence="ECO:0000269|PubMed:26723978"
FT                   /id="VAR_075210"
FT   VARIANT         213
FT                   /note="R -> S (in BHC; dbSNP:rs28936671)"
FT                   /evidence="ECO:0000269|PubMed:11971878"
FT                   /id="VAR_015189"
FT   VARIANT         339
FT                   /note="A -> V (in NMTC1; loss of transcription regulatory
FT                   region DNA binding; decreased transcription factor
FT                   activity, sequence-specific DNA binding; tested for the
FT                   thyroglobulin gene; associated with dominant impairment of
FT                   thyroid-specific genes transcription and increased thyroid
FT                   cells proliferation; dbSNP:rs537209983)"
FT                   /evidence="ECO:0000269|PubMed:19176457"
FT                   /id="VAR_075769"
FT   CONFLICT        49
FT                   /note="P -> H (in Ref. 5; BAA23527/BAA23529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        61
FT                   /note="H -> P (in Ref. 5; BAA23527/BAA23529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        158
FT                   /note="S -> T (in Ref. 5; BAA23527/BAA23529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        161
FT                   /note="R -> G (in Ref. 5; BAA23527/BAA23529)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   371 AA;  38596 MW;  5F1E3B40A1BBD862 CRC64;
     MSMSPKHTTP FSVSDILSPL EESYKKVGME GGGLGAPLAA YRQGQAAPPT AAMQQHAVGH
     HGAVTAAYHM TAAGVPQLSH SAVGGYCNGN LGNMSELPPY QDTMRNSASG PGWYGANPDP
     RFPAISRFMG PASGMNMSGM GGLGSLGDVS KNMAPLPSAP RRKRRVLFSQ AQVYELERRF
     KQQKYLSAPE REHLASMIHL TPTQVKIWFQ NHRYKMKRQA KDKAAQQQLQ QDSGGGGGGG
     GTGCPQQQQA QQQSPRRVAV PVLVKDGKPC QAGAPAPGAA SLQGHAQQQA QHQAQAAQAA
     AAAISVGSGG AGLGAHPGHQ PGSAGQSPDL AHHAASPAAL QGQVSSLSHL NSSGSDYGTM
     SCSTLLYGRT W
//
ID   NOTC2_HUMAN             Reviewed;        2471 AA.
AC   Q04721; Q5T3X7; Q99734; Q9H240;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 3.
DT   22-APR-2020, entry version 230.
DE   RecName: Full=Neurogenic locus notch homolog protein 2 {ECO:0000305};
DE            Short=Notch 2;
DE            Short=hN2;
DE   Contains:
DE     RecName: Full=Notch 2 extracellular truncation;
DE              Short=N2ECD {ECO:0000303|PubMed:25985737};
DE   Contains:
DE     RecName: Full=Notch 2 intracellular domain;
DE              Short=N2ICD {ECO:0000303|PubMed:25985737};
DE   Flags: Precursor;
GN   Name=NOTCH2 {ECO:0000312|HGNC:HGNC:7882};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Blaumueller C.M., Mann R.S.;
RT   "Complete human notch 2 (hN2) cDNA sequence.";
RL   Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary tumor;
RA   Correa R.G., Camargo A.A., Moreira E.S., Simpson A.J.G.;
RT   "Human Notch2, a novel member of cell-fate determining NOTCH family.";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 967-1229.
RC   TISSUE=T-cell;
RA   Lemasson I., Devaux C., Mesnard J.-M.;
RT   "Partial sequence of EGF-like repeat domain of human Notch2 mRNA.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1810-2447.
RC   TISSUE=Brain;
RX   PubMed=1303260; DOI=10.1038/ng1092-119;
RA   Stifani S., Blaumueller C.M., Redhead N.J., Hill R.E.,
RA   Artavanis-Tsakonas S.;
RT   "Human homologs of a Drosophila enhancer of split gene product define a
RT   novel family of nuclear proteins.";
RL   Nat. Genet. 2:119-127(1992).
RN   [6]
RP   PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION.
RX   PubMed=9244302; DOI=10.1016/s0092-8674(00)80336-0;
RA   Blaumueller C.M., Qi H., Zagouras P., Artavanis-Tsakonas S.;
RT   "Intracellular cleavage of Notch leads to a heterodimeric receptor on the
RT   plasma membrane.";
RL   Cell 90:281-291(1997).
RN   [7]
RP   IDENTIFICATION OF LIGANDS.
RX   PubMed=10079256; DOI=10.1016/s0002-9440(10)65325-4;
RA   Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.-L., Banks A.,
RA   Leiman J., Ward D., Ish-Horowitz D., Artavanis-Tsakonas S.;
RT   "Human ligands of the Notch receptor.";
RL   Am. J. Pathol. 154:785-794(1999).
RN   [8]
RP   INTERACTION WITH MAML1.
RX   PubMed=11101851; DOI=10.1038/82644;
RA   Wu L., Aster J.C., Blacklow S.C., Lake R., Artavanis-Tsakonas S.,
RA   Griffin J.D.;
RT   "MAML1, a human homologue of Drosophila mastermind, is a transcriptional
RT   co-activator for NOTCH receptors.";
RL   Nat. Genet. 26:484-489(2000).
RN   [9]
RP   INTERACTION WITH MAML2 AND MAML3.
RX   PubMed=12370315; DOI=10.1128/mcb.22.21.7688-7700.2002;
RA   Wu L., Sun T., Kobayashi K., Gao P., Griffin J.D.;
RT   "Identification of a family of mastermind-like transcriptional coactivators
RT   for mammalian notch receptors.";
RL   Mol. Cell. Biol. 22:7688-7700(2002).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   INTERACTION WITH HIF1AN.
RX   PubMed=17573339; DOI=10.1074/jbc.m704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor
RT   inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
RN   [12]
RP   INTERACTION WITH MDK.
RX   PubMed=18469519; DOI=10.4161/cc.7.11.5952;
RA   Huang Y., Hoque M.O., Wu F., Trink B., Sidransky D., Ratovitski E.A.;
RT   "Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-
RT   Stat3 signaling in human keratinocytes.";
RL   Cell Cycle 7:1613-1622(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1716; THR-1802; SER-1804;
RP   THR-1808; SER-1845; SER-2070; SER-2081 AND THR-2097, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   HYDROXYLATION BY HIF1AN.
RX   PubMed=18299578; DOI=10.1073/pnas.0711591105;
RA   Zheng X., Linke S., Dias J.M., Zheng X., Gradin K., Wallis T.P.,
RA   Hamilton B.R., Gustafsson M., Ruas J.L., Wilkins S., Bilton R.L.,
RA   Brismar K., Whitelaw M.L., Pereira T., Gorman J.J., Ericson J., Peet D.J.,
RA   Lendahl U., Poellinger L.;
RT   "Interaction with factor inhibiting HIF-1 defines an additional mode of
RT   cross-coupling between the Notch and hypoxia signaling pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3368-3373(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1778 AND SER-1845, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1778, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   INVOLVEMENT IN HJCYS, AND VARIANTS HJCYS 2208-GLN--ALA-2471 DEL;
RP   2223-GLN--ALA-2471 DEL AND 2360-GLN--ALA-2471 DEL.
RX   PubMed=21681853; DOI=10.1002/humu.21546;
RG   FORGE Canada Consortium;
RA   Majewski J., Schwartzentruber J.A., Caqueret A., Patry L., Marcadier J.,
RA   Fryns J.P., Boycott K.M., Ste-Marie L.G., McKiernan F.E., Marik I.,
RA   Van Esch H., Michaud J.L., Samuels M.E.;
RT   "Mutations in NOTCH2 in families with Hajdu-Cheney syndrome.";
RL   Hum. Mutat. 32:1114-1117(2011).
RN   [18]
RP   FUNCTION, INVOLVEMENT IN HJCYS, AND VARIANTS HJCYS 2285-GLN--ALA-2471 DEL;
RP   2317-GLN--ALA-2471 DEL AND 2373-TYR--ALA-2471 DEL.
RX   PubMed=21378989; DOI=10.1038/ng.778;
RA   Isidor B., Lindenbaum P., Pichon O., Bezieau S., Dina C., Jacquemont S.,
RA   Martin-Coignard D., Thauvin-Robinet C., Le Merrer M., Mandel J.L.,
RA   David A., Faivre L., Cormier-Daire V., Redon R., Le Caignec C.;
RT   "Truncating mutations in the last exon of NOTCH2 cause a rare skeletal
RT   disorder with osteoporosis.";
RL   Nat. Genet. 43:306-308(2011).
RN   [19]
RP   FUNCTION, INVOLVEMENT IN HJCYS, TISSUE SPECIFICITY, AND VARIANTS HJCYS
RP   2140-GLN--ALA-2471 DEL; 2208-GLN--ALA-2471 DEL; 2325-GLN--ALA-2471 DEL AND
RP   2400-ARG--ALA-2471 DEL.
RX   PubMed=21378985; DOI=10.1038/ng.779;
RA   Simpson M.A., Irving M.D., Asilmaz E., Gray M.J., Dafou D., Elmslie F.V.,
RA   Mansour S., Holder S.E., Brain C.E., Burton B.K., Kim K.H., Pauli R.M.,
RA   Aftimos S., Stewart H., Kim C.A., Holder-Espinasse M., Robertson S.P.,
RA   Drake W.M., Trembath R.C.;
RT   "Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and
RT   progressive bone loss.";
RL   Nat. Genet. 43:303-305(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1778, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   FUNCTION, INTERACTION WITH TCIM, AND SUBCELLULAR LOCATION.
RX   PubMed=25985737; DOI=10.1038/ncomms8122;
RA   Zhu P., Wang Y., Du Y., He L., Huang G., Zhang G., Yan X., Fan Z.;
RT   "C8orf4 negatively regulates self-renewal of liver cancer stem cells via
RT   suppression of NOTCH2 signalling.";
RL   Nat. Commun. 6:7122-7122(2015).
RN   [22]
RP   FUNCTION, PHOSPHORYLATION BY GSK3, UBIQUITINATION, INTERACTION WITH CUL1;
RP   SKP1; RBX1 AND FBW7, MUTAGENESIS OF THR-2416, AND CHARACTERIZATION OF
RP   VARIANT HJCYS 2317-GLN--ALA-2471 DEL.
RX   PubMed=29149593; DOI=10.1016/j.molcel.2017.10.018;
RA   Fukushima H., Shimizu K., Watahiki A., Hoshikawa S., Kosho T., Oba D.,
RA   Sakano S., Arakaki M., Yamada A., Nagashima K., Okabe K., Fukumoto S.,
RA   Jimi E., Bigas A., Nakayama K.I., Nakayama K., Aoki Y., Wei W., Inuzuka H.;
RT   "NOTCH2 Hajdu-Cheney mutations escape SCFFBW7-dependent proteolysis to
RT   promote osteoporosis.";
RL   Mol. Cell 68:645-658(2017).
RN   [23]
RP   INTERACTION WITH NOTCH2NLA; NOTCH2NLB AND NOTCH2NLC.
RX   PubMed=29856954; DOI=10.1016/j.cell.2018.03.051;
RA   Fiddes I.T., Lodewijk G.A., Mooring M., Bosworth C.M., Ewing A.D.,
RA   Mantalas G.L., Novak A.M., van den Bout A., Bishara A., Rosenkrantz J.L.,
RA   Lorig-Roach R., Field A.R., Haeussler M., Russo L., Bhaduri A.,
RA   Nowakowski T.J., Pollen A.A., Dougherty M.L., Nuttle X., Addor M.C.,
RA   Zwolinski S., Katzman S., Kriegstein A., Eichler E.E., Salama S.R.,
RA   Jacobs F.M.J., Haussler D.;
RT   "Human-specific NOTCH2NL genes affect Notch signaling and cortical
RT   neurogenesis.";
RL   Cell 173:1356-1369(2018).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH MINAR1.
RX   PubMed=29329397; DOI=10.1093/jmcb/mjy002;
RA   Ho R.X., Meyer R.D., Chandler K.B., Ersoy E., Park M., Bondzie P.A.,
RA   Rahimi N., Xu H., Costello C.E., Rahimi N.;
RT   "MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast
RT   cancer growth.";
RL   J. Mol. Cell Biol. 10:195-204(2018).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1426-1677, AND DISULFIDE BONDS.
RX   PubMed=17401372; DOI=10.1038/nsmb1227;
RA   Gordon W.R., Vardar-Ulu D., Histen G., Sanchez-Irizarry C., Aster J.C.,
RA   Blacklow S.C.;
RT   "Structural basis for autoinhibition of Notch.";
RL   Nat. Struct. Mol. Biol. 14:295-300(2007).
RN   [26]
RP   VARIANT ALGS2 TYR-444.
RX   PubMed=16773578; DOI=10.1086/505332;
RA   McDaniell R., Warthen D.M., Sanchez-Lara P.A., Pai A., Krantz I.D.,
RA   Piccoli D.A., Spinner N.B.;
RT   "NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the
RT   notch signaling pathway.";
RL   Am. J. Hum. Genet. 79:169-173(2006).
RN   [27]
RP   VARIANT HJCYS 2400-ARG--ALA-2471 DEL.
RX   PubMed=21793104; DOI=10.1002/humu.21563;
RA   Isidor B., Le Merrer M., Exner G.U., Pichon O., Thierry G.,
RA   Guiochon-Mantel A., David A., Cormier-Daire V., Le Caignec C.;
RT   "Serpentine fibula-polycystic kidney syndrome caused by truncating
RT   mutations in NOTCH2.";
RL   Hum. Mutat. 32:1239-1242(2011).
RN   [28]
RP   VARIANTS HJCYS 2299-GLU--ALA-2471 DEL AND 2389-GLN--ALA-2471 DEL.
RX   PubMed=21712856; DOI=10.1038/ejhg.2011.125;
RA   Gray M.J., Kim C.A., Bertola D.R., Arantes P.R., Stewart H., Simpson M.A.,
RA   Irving M.D., Robertson S.P.;
RT   "Serpentine fibula polycystic kidney syndrome is part of the phenotypic
RT   spectrum of Hajdu-Cheney syndrome.";
RL   Eur. J. Hum. Genet. 20:122-124(2012).
RN   [29]
RP   VARIANTS HJCYS 2196-GLN--ALA-2471 DEL AND 2400-ARG--ALA-2471 DEL.
RX   PubMed=23389697; DOI=10.1007/s00198-013-2298-5;
RA   Zhao W., Petit E., Gafni R.I., Collins M.T., Robey P.G., Seton M.,
RA   Miller K.K., Mannstadt M.;
RT   "Mutations in NOTCH2 in patients with Hajdu-Cheney syndrome.";
RL   Osteoporos. Int. 24:2275-2281(2013).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands Jagged-1
CC       (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate
CC       determination. Upon ligand activation through the released notch
CC       intracellular domain (NICD) it forms a transcriptional activator
CC       complex with RBPJ/RBPSUH and activates genes of the enhancer of split
CC       locus (PubMed:21378985, PubMed:21378989). Affects the implementation of
CC       differentiation, proliferation and apoptotic programs (By similarity).
CC       Involved in bone remodeling and homeostasis. In collaboration with
CC       RELA/p65 enhances NFATc1 promoter activity and positively regulates
CC       RANKL-induced osteoclast differentiation (PubMed:29149593). Positively
CC       regulates self-renewal of liver cancer cells (PubMed:25985737).
CC       {ECO:0000250|UniProtKB:O35516, ECO:0000269|PubMed:21378985,
CC       ECO:0000269|PubMed:21378989, ECO:0000269|PubMed:25985737,
CC       ECO:0000269|PubMed:29149593}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and an N-terminal
CC       fragment N(EC) which are probably linked by disulfide bonds (By
CC       similarity). Interacts with MAML1, MAML2 and MAML3 which act as
CC       transcriptional coactivators for NOTCH2. Interacts with RELA/p65 (By
CC       similarity). Interacts with HIF1AN. Interacts (via ANK repeats) with
CC       TCIM, the interaction inhibits the nuclear translocation of NOTCH2
CC       N2ICD (PubMed:25985737). Interacts with CUL1, RBX1, SKP1 and FBXW7 that
CC       are SCF(FBXW7) E3 ubiquitin-protein ligase complex components
CC       (PubMed:29149593). Interacts with MINAR1; this interaction increases
CC       MINAR1 stability and function (PubMed:29329397). Interacts with
CC       NOTCH2NL (NOTCH2NLA, NOTCH2NLB and/or NOTCH2NLC); leading to enhance
CC       Notch signaling pathway in a non-cell-autonomous manner
CC       (PubMed:29856954). Interacts with MDK; this interaction mediates a
CC       nuclear accumulation of NOTCH2 and therefore activation of NOTCH2
CC       signaling leading to interaction between HES1 and STAT3
CC       (PubMed:18469519). {ECO:0000250, ECO:0000269|PubMed:11101851,
CC       ECO:0000269|PubMed:12370315, ECO:0000269|PubMed:17573339,
CC       ECO:0000269|PubMed:18469519, ECO:0000269|PubMed:25985737,
CC       ECO:0000269|PubMed:29149593, ECO:0000269|PubMed:29329397,
CC       ECO:0000269|PubMed:29856954}.
CC   -!- SUBCELLULAR LOCATION: [Notch 2 extracellular truncation]: Cell membrane
CC       {ECO:0000269|PubMed:29329397, ECO:0000269|PubMed:9244302}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:9244302}.
CC   -!- SUBCELLULAR LOCATION: [Notch 2 intracellular domain]: Nucleus
CC       {ECO:0000269|PubMed:25985737}. Cytoplasm {ECO:0000269|PubMed:25985737}.
CC       Note=Following proteolytical processing NICD is translocated to the
CC       nucleus. Retained at the cytoplasm by TCIM (PubMed:25985737).
CC       {ECO:0000269|PubMed:25985737}.
CC   -!- TISSUE SPECIFICITY: Expressed in the brain, heart, kidney, lung,
CC       skeletal muscle and liver. Ubiquitously expressed in the embryo.
CC       {ECO:0000269|PubMed:21378985}.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form which
CC       is proteolytically cleaved by a furin-like convertase in the trans-
CC       Golgi network before it reaches the plasma membrane to yield an active,
CC       ligand-accessible form (By similarity). Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC) (By
CC       similarity). Following ligand binding, it is cleaved by TNF-alpha
CC       converting enzyme (TACE) to yield a membrane-associated intermediate
CC       fragment called notch extracellular truncation (NEXT) (By similarity).
CC       This fragment is then cleaved by presenilin dependent gamma-secretase
CC       to release a notch-derived peptide containing the intracellular domain
CC       (NICD) from the membrane (By similarity).
CC       {ECO:0000250|UniProtKB:O35516, ECO:0000250|UniProtKB:Q01705}.
CC   -!- PTM: Hydroxylated by HIF1AN. {ECO:0000269|PubMed:18299578}.
CC   -!- PTM: Can be either O-glucosylated or O-xylosylated at Ser-613 by
CC       POGLUT1. {ECO:0000250|UniProtKB:O35516}.
CC   -!- PTM: Phosphorylated by GSK3. GSK3-mediated phosphorylation is necessary
CC       for NOTCH2 recognition by FBXW7, ubiquitination and degradation via the
CC       ubiquitin proteasome pathway. {ECO:0000269|PubMed:29149593}.
CC   -!- DISEASE: Alagille syndrome 2 (ALGS2) [MIM:610205]: A form of Alagille
CC       syndrome, an autosomal dominant multisystem disorder. It is clinically
CC       defined by hepatic bile duct paucity and cholestasis in association
CC       with cardiac, skeletal, and ophthalmologic manifestations. There are
CC       characteristic facial features and less frequent clinical involvement
CC       of the renal and vascular systems. {ECO:0000269|PubMed:16773578}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Hajdu-Cheney syndrome (HJCYS) [MIM:102500]: A rare, autosomal
CC       dominant skeletal disorder characterized by the association of facial
CC       anomalies, acro-osteolysis, general osteoporosis, insufficient
CC       ossification of the skull, and periodontal disease (premature loss of
CC       permanent teeth). Other features include cleft palate, congenital heart
CC       defects, polycystic kidneys, orthopedic problems and anomalies of the
CC       genitalia, intestines and eyes. {ECO:0000269|PubMed:21378985,
CC       ECO:0000269|PubMed:21378989, ECO:0000269|PubMed:21681853,
CC       ECO:0000269|PubMed:21712856, ECO:0000269|PubMed:21793104,
CC       ECO:0000269|PubMed:23389697, ECO:0000269|PubMed:29149593}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry. NOTCH2 nonsense and frameshift mutations associated with Hajdu-
CC       Cheney syndrome cluster to the last coding exon of the gene. Mutant
CC       mRNA products escape nonsense-mediated decay and the resulting
CC       truncated NOTCH2 proteins act in a gain-of-function manner
CC       (PubMed:21378989). The pathological mechanism at cellular level
CC       involves disruption of a high affinity degron recognized by FBXW7 at
CC       the C-terminus, loss of interaction with FBXW7, reduced ubiquitination
CC       and degradation, and increased NOTCH2 levels. Bone marrow cells derived
CC       from HJCYS patients have an enhanced capacity of osteoclastogenesis due
CC       to sustained NOTCH2 activity (PubMed:29149593).
CC       {ECO:0000269|PubMed:21378989, ECO:0000269|PubMed:29149593}.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NOTCH2ID41556ch1p12.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF308601; AAA36377.2; -; mRNA.
DR   EMBL; AF315356; AAG37073.1; -; mRNA.
DR   EMBL; AL359752; CAI18974.1; -; Genomic_DNA.
DR   EMBL; AL512503; CAI18974.1; JOINED; Genomic_DNA.
DR   EMBL; AL596222; CAI18974.1; JOINED; Genomic_DNA.
DR   EMBL; AL512503; CAH72483.1; -; Genomic_DNA.
DR   EMBL; AL359752; CAH72483.1; JOINED; Genomic_DNA.
DR   EMBL; AL596222; CAH72483.1; JOINED; Genomic_DNA.
DR   EMBL; AL596222; CAH70182.1; -; Genomic_DNA.
DR   EMBL; AL359752; CAH70182.1; JOINED; Genomic_DNA.
DR   EMBL; AL512503; CAH70182.1; JOINED; Genomic_DNA.
DR   EMBL; U77493; AAB19224.1; -; mRNA.
DR   CCDS; CCDS908.1; -.
DR   RefSeq; NP_001186930.1; NM_001200001.1.
DR   RefSeq; NP_077719.2; NM_024408.3.
DR   PDB; 2OO4; X-ray; 2.00 A; A/B=1423-1677.
DR   PDB; 5MWB; X-ray; 1.86 A; A=414-532.
DR   PDBsum; 2OO4; -.
DR   PDBsum; 5MWB; -.
DR   SMR; Q04721; -.
DR   BioGrid; 110915; 69.
DR   CORUM; Q04721; -.
DR   ELM; Q04721; -.
DR   IntAct; Q04721; 42.
DR   MINT; Q04721; -.
DR   STRING; 9606.ENSP00000256646; -.
DR   BindingDB; Q04721; -.
DR   ChEMBL; CHEMBL3407320; -.
DR   GuidetoPHARMACOLOGY; 2859; -.
DR   GlyConnect; 1553; -.
DR   iPTMnet; Q04721; -.
DR   PhosphoSitePlus; Q04721; -.
DR   BioMuta; NOTCH2; -.
DR   DMDM; 143811429; -.
DR   EPD; Q04721; -.
DR   jPOST; Q04721; -.
DR   MassIVE; Q04721; -.
DR   MaxQB; Q04721; -.
DR   PaxDb; Q04721; -.
DR   PeptideAtlas; Q04721; -.
DR   PRIDE; Q04721; -.
DR   ProteomicsDB; 58265; -.
DR   ABCD; Q04721; -.
DR   Antibodypedia; 20208; 611 antibodies.
DR   Ensembl; ENST00000256646; ENSP00000256646; ENSG00000134250.
DR   GeneID; 4853; -.
DR   KEGG; hsa:4853; -.
DR   UCSC; uc001eik.4; human.
DR   CTD; 4853; -.
DR   DisGeNET; 4853; -.
DR   GeneCards; NOTCH2; -.
DR   GeneReviews; NOTCH2; -.
DR   HGNC; HGNC:7882; NOTCH2.
DR   HPA; ENSG00000134250; Low tissue specificity.
DR   MalaCards; NOTCH2; -.
DR   MIM; 102500; phenotype.
DR   MIM; 600275; gene.
DR   MIM; 610205; phenotype.
DR   neXtProt; NX_Q04721; -.
DR   OpenTargets; ENSG00000134250; -.
DR   Orphanet; 955; Acroosteolysis dominant type.
DR   Orphanet; 261629; Alagille syndrome due to a NOTCH2 point mutation.
DR   PharmGKB; PA31684; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00940000155030; -.
DR   HOGENOM; CLU_000576_0_0_1; -.
DR   InParanoid; Q04721; -.
DR   KO; K20994; -.
DR   OMA; LGDYCQY; -.
DR   OrthoDB; 7525at2759; -.
DR   PhylomeDB; Q04721; -.
DR   TreeFam; TF351641; -.
DR   Reactome; R-HSA-1912399; Pre-NOTCH Processing in the Endoplasmic Reticulum.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-2197563; NOTCH2 intracellular domain regulates transcription.
DR   Reactome; R-HSA-2979096; NOTCH2 Activation and Transmission of Signal to the Nucleus.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-5083630; Defective LFNG causes SCDO3.
DR   Reactome; R-HSA-9013695; NOTCH4 Intracellular Domain Regulates Transcription.
DR   SignaLink; Q04721; -.
DR   SIGNOR; Q04721; -.
DR   ChiTaRS; NOTCH2; human.
DR   EvolutionaryTrace; Q04721; -.
DR   GeneWiki; Notch-2; -.
DR   GenomeRNAi; 4853; -.
DR   Pharos; Q04721; Tchem.
DR   PRO; PR:Q04721; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q04721; protein.
DR   Bgee; ENSG00000134250; Expressed in testis and 237 other tissues.
DR   ExpressionAtlas; Q04721; baseline and differential.
DR   Genevisible; Q04721; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005929; C:cilium; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0051059; F:NF-kappaB binding; IEA:Ensembl.
DR   GO; GO:0038023; F:signaling receptor activity; NAS:UniProtKB.
DR   GO; GO:0009887; P:animal organ morphogenesis; IEP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0060413; P:atrial septum morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0046849; P:bone remodeling; IMP:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0001709; P:cell fate determination; TAS:UniProtKB.
DR   GO; GO:1990705; P:cholangiocyte proliferation; IEA:Ensembl.
DR   GO; GO:0061073; P:ciliary body morphogenesis; IEA:Ensembl.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:Ensembl.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IEA:Ensembl.
DR   GO; GO:0072104; P:glomerular capillary formation; IEA:Ensembl.
DR   GO; GO:0072015; P:glomerular visceral epithelial cell development; IEA:Ensembl.
DR   GO; GO:0001947; P:heart looping; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; TAS:UniProtKB.
DR   GO; GO:0072574; P:hepatocyte proliferation; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0072602; P:interleukin-4 secretion; IEA:Ensembl.
DR   GO; GO:0035622; P:intrahepatic bile duct development; IEA:Ensembl.
DR   GO; GO:0070986; P:left/right axis specification; IEA:Ensembl.
DR   GO; GO:0002315; P:marginal zone B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0002011; P:morphogenesis of an epithelial sheet; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; NAS:UniProtKB.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045967; P:negative regulation of growth rate; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; NAS:UniProtKB.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IC:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060674; P:placenta blood vessel development; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IDA:UniProtKB.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0072014; P:proximal tubule development; IEA:Ensembl.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:2001204; P:regulation of osteoclast development; IMP:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; TAS:UniProtKB.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR035993; Notch-like_dom_sf.
DR   InterPro; IPR022336; Notch_2.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 24.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF12661; hEGF; 3.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01985; NOTCH2.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM01334; DUF3454; 1.
DR   SMART; SM00181; EGF; 36.
DR   SMART; SM00179; EGF_CA; 34.
DR   SMART; SM00004; NL; 3.
DR   SMART; SM01338; NOD; 1.
DR   SMART; SM01339; NODP; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 6.
DR   SUPFAM; SSF90193; SSF90193; 2.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 34.
DR   PROSITE; PS01186; EGF_2; 29.
DR   PROSITE; PS50026; EGF_3; 35.
DR   PROSITE; PS01187; EGF_CA; 22.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; ANK repeat; Cell membrane; Cytoplasm;
KW   Developmental protein; Differentiation; Disease mutation; Disulfide bond;
KW   EGF-like domain; Glycoprotein; Membrane; Notch signaling pathway; Nucleus;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transcription; Transcription regulation; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..2471
FT                   /note="Neurogenic locus notch homolog protein 2"
FT                   /id="PRO_0000007683"
FT   CHAIN           1666..2471
FT                   /note="Notch 2 extracellular truncation"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT                   /id="PRO_0000007684"
FT   CHAIN           1697..2471
FT                   /note="Notch 2 intracellular domain"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT                   /id="PRO_0000007685"
FT   TOPO_DOM        26..1677
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1678..1698
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1699..2471
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          26..63
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          64..102
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          105..143
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          144..180
FT                   /note="EGF-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          182..219
FT                   /note="EGF-like 5; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          221..258
FT                   /note="EGF-like 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          260..296
FT                   /note="EGF-like 7; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          298..336
FT                   /note="EGF-like 8; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          338..374
FT                   /note="EGF-like 9; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          375..413
FT                   /note="EGF-like 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          415..454
FT                   /note="EGF-like 11; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          456..492
FT                   /note="EGF-like 12; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          494..530
FT                   /note="EGF-like 13; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          532..568
FT                   /note="EGF-like 14; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          570..605
FT                   /note="EGF-like 15; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          607..643
FT                   /note="EGF-like 16; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          645..680
FT                   /note="EGF-like 17; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          682..718
FT                   /note="EGF-like 18; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          720..755
FT                   /note="EGF-like 19"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          757..793
FT                   /note="EGF-like 20; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          795..831
FT                   /note="EGF-like 21; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          833..871
FT                   /note="EGF-like 22"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          873..909
FT                   /note="EGF-like 23; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          911..947
FT                   /note="EGF-like 24; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          949..985
FT                   /note="EGF-like 25; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          987..1023
FT                   /note="EGF-like 26; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1025..1061
FT                   /note="EGF-like 27; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1063..1099
FT                   /note="EGF-like 28"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1101..1147
FT                   /note="EGF-like 29"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          1149..1185
FT                   /note="EGF-like 30; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1187..1223
FT                   /note="EGF-like 31; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1225..1262
FT                   /note="EGF-like 32; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1264..1302
FT                   /note="EGF-like 33"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1304..1343
FT                   /note="EGF-like 34"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1374..1412
FT                   /note="EGF-like 35"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   REPEAT          1425..1465
FT                   /note="LNR 1"
FT   REPEAT          1466..1502
FT                   /note="LNR 2"
FT   REPEAT          1503..1544
FT                   /note="LNR 3"
FT   REPEAT          1827..1871
FT                   /note="ANK 1"
FT   REPEAT          1876..1905
FT                   /note="ANK 2"
FT   REPEAT          1909..1939
FT                   /note="ANK 3"
FT   REPEAT          1943..1972
FT                   /note="ANK 4"
FT   REPEAT          1976..2005
FT                   /note="ANK 5"
FT   REPEAT          2009..2038
FT                   /note="ANK 6"
FT   REGION          1425..1677
FT                   /note="Negative regulatory region (NRR)"
FT   COMPBIAS        1645..1648
FT                   /note="Poly-Ala"
FT   COMPBIAS        1994..1997
FT                   /note="Poly-Leu"
FT   COMPBIAS        2426..2429
FT                   /note="Poly-Ser"
FT   SITE            614
FT                   /note="Essential for O-xylosylation"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT   MOD_RES         1716
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         1778
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163"
FT   MOD_RES         1802
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         1804
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         1808
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         1842
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT   MOD_RES         1845
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332"
FT   MOD_RES         2070
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         2078
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QW30"
FT   MOD_RES         2081
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         2097
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   CARBOHYD        46
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        155
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        613
FT                   /note="O-linked (Glc...) serine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT   CARBOHYD        613
FT                   /note="O-linked (Xyl...) serine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT   CARBOHYD        733
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1102
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1465
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        28..41
FT                   /evidence="ECO:0000250"
FT   DISULFID        35..51
FT                   /evidence="ECO:0000250"
FT   DISULFID        53..62
FT                   /evidence="ECO:0000250"
FT   DISULFID        68..79
FT                   /evidence="ECO:0000250"
FT   DISULFID        73..90
FT                   /evidence="ECO:0000250"
FT   DISULFID        92..101
FT                   /evidence="ECO:0000250"
FT   DISULFID        109..121
FT                   /evidence="ECO:0000250"
FT   DISULFID        115..131
FT                   /evidence="ECO:0000250"
FT   DISULFID        133..142
FT                   /evidence="ECO:0000250"
FT   DISULFID        148..159
FT                   /evidence="ECO:0000250"
FT   DISULFID        153..168
FT                   /evidence="ECO:0000250"
FT   DISULFID        170..179
FT                   /evidence="ECO:0000250"
FT   DISULFID        186..198
FT                   /evidence="ECO:0000250"
FT   DISULFID        192..207
FT                   /evidence="ECO:0000250"
FT   DISULFID        209..218
FT                   /evidence="ECO:0000250"
FT   DISULFID        225..236
FT                   /evidence="ECO:0000250"
FT   DISULFID        230..246
FT                   /evidence="ECO:0000250"
FT   DISULFID        248..257
FT                   /evidence="ECO:0000250"
FT   DISULFID        264..275
FT                   /evidence="ECO:0000250"
FT   DISULFID        269..284
FT                   /evidence="ECO:0000250"
FT   DISULFID        286..295
FT                   /evidence="ECO:0000250"
FT   DISULFID        302..315
FT                   /evidence="ECO:0000250"
FT   DISULFID        309..324
FT                   /evidence="ECO:0000250"
FT   DISULFID        326..335
FT                   /evidence="ECO:0000250"
FT   DISULFID        342..353
FT                   /evidence="ECO:0000250"
FT   DISULFID        347..362
FT                   /evidence="ECO:0000250"
FT   DISULFID        364..373
FT                   /evidence="ECO:0000250"
FT   DISULFID        379..390
FT                   /evidence="ECO:0000250"
FT   DISULFID        384..401
FT                   /evidence="ECO:0000250"
FT   DISULFID        403..412
FT                   /evidence="ECO:0000250"
FT   DISULFID        419..433
FT                   /evidence="ECO:0000250"
FT   DISULFID        427..442
FT                   /evidence="ECO:0000250"
FT   DISULFID        444..453
FT                   /evidence="ECO:0000250"
FT   DISULFID        460..471
FT                   /evidence="ECO:0000250"
FT   DISULFID        465..480
FT                   /evidence="ECO:0000250"
FT   DISULFID        482..491
FT                   /evidence="ECO:0000250"
FT   DISULFID        498..509
FT                   /evidence="ECO:0000250"
FT   DISULFID        503..518
FT                   /evidence="ECO:0000250"
FT   DISULFID        520..529
FT                   /evidence="ECO:0000250"
FT   DISULFID        536..547
FT                   /evidence="ECO:0000250"
FT   DISULFID        541..556
FT                   /evidence="ECO:0000250"
FT   DISULFID        558..567
FT                   /evidence="ECO:0000250"
FT   DISULFID        574..584
FT                   /evidence="ECO:0000250"
FT   DISULFID        579..593
FT                   /evidence="ECO:0000250"
FT   DISULFID        595..604
FT                   /evidence="ECO:0000250"
FT   DISULFID        611..622
FT                   /evidence="ECO:0000250"
FT   DISULFID        616..631
FT                   /evidence="ECO:0000250"
FT   DISULFID        633..642
FT                   /evidence="ECO:0000250"
FT   DISULFID        649..659
FT                   /evidence="ECO:0000250"
FT   DISULFID        654..668
FT                   /evidence="ECO:0000250"
FT   DISULFID        670..679
FT                   /evidence="ECO:0000250"
FT   DISULFID        686..697
FT                   /evidence="ECO:0000250"
FT   DISULFID        691..706
FT                   /evidence="ECO:0000250"
FT   DISULFID        708..717
FT                   /evidence="ECO:0000250"
FT   DISULFID        724..734
FT                   /evidence="ECO:0000250"
FT   DISULFID        729..743
FT                   /evidence="ECO:0000250"
FT   DISULFID        745..754
FT                   /evidence="ECO:0000250"
FT   DISULFID        761..772
FT                   /evidence="ECO:0000250"
FT   DISULFID        766..781
FT                   /evidence="ECO:0000250"
FT   DISULFID        783..792
FT                   /evidence="ECO:0000250"
FT   DISULFID        799..810
FT                   /evidence="ECO:0000250"
FT   DISULFID        804..819
FT                   /evidence="ECO:0000250"
FT   DISULFID        821..830
FT                   /evidence="ECO:0000250"
FT   DISULFID        837..848
FT                   /evidence="ECO:0000250"
FT   DISULFID        842..859
FT                   /evidence="ECO:0000250"
FT   DISULFID        861..870
FT                   /evidence="ECO:0000250"
FT   DISULFID        877..888
FT                   /evidence="ECO:0000250"
FT   DISULFID        882..897
FT                   /evidence="ECO:0000250"
FT   DISULFID        899..908
FT                   /evidence="ECO:0000250"
FT   DISULFID        915..926
FT                   /evidence="ECO:0000250"
FT   DISULFID        920..935
FT                   /evidence="ECO:0000250"
FT   DISULFID        937..946
FT                   /evidence="ECO:0000250"
FT   DISULFID        953..964
FT                   /evidence="ECO:0000250"
FT   DISULFID        958..973
FT                   /evidence="ECO:0000250"
FT   DISULFID        975..984
FT                   /evidence="ECO:0000250"
FT   DISULFID        991..1002
FT                   /evidence="ECO:0000250"
FT   DISULFID        996..1011
FT                   /evidence="ECO:0000250"
FT   DISULFID        1013..1022
FT                   /evidence="ECO:0000250"
FT   DISULFID        1029..1040
FT                   /evidence="ECO:0000250"
FT   DISULFID        1034..1049
FT                   /evidence="ECO:0000250"
FT   DISULFID        1051..1060
FT                   /evidence="ECO:0000250"
FT   DISULFID        1067..1078
FT                   /evidence="ECO:0000250"
FT   DISULFID        1072..1087
FT                   /evidence="ECO:0000250"
FT   DISULFID        1089..1098
FT                   /evidence="ECO:0000250"
FT   DISULFID        1105..1126
FT                   /evidence="ECO:0000305"
FT   DISULFID        1120..1135
FT                   /evidence="ECO:0000250"
FT   DISULFID        1137..1146
FT                   /evidence="ECO:0000250"
FT   DISULFID        1153..1164
FT                   /evidence="ECO:0000250"
FT   DISULFID        1158..1173
FT                   /evidence="ECO:0000250"
FT   DISULFID        1175..1184
FT                   /evidence="ECO:0000250"
FT   DISULFID        1191..1202
FT                   /evidence="ECO:0000250"
FT   DISULFID        1196..1211
FT                   /evidence="ECO:0000250"
FT   DISULFID        1213..1222
FT                   /evidence="ECO:0000250"
FT   DISULFID        1229..1241
FT                   /evidence="ECO:0000250"
FT   DISULFID        1235..1250
FT                   /evidence="ECO:0000250"
FT   DISULFID        1252..1261
FT                   /evidence="ECO:0000250"
FT   DISULFID        1268..1281
FT                   /evidence="ECO:0000250"
FT   DISULFID        1273..1290
FT                   /evidence="ECO:0000250"
FT   DISULFID        1292..1301
FT                   /evidence="ECO:0000250"
FT   DISULFID        1308..1319
FT                   /evidence="ECO:0000250"
FT   DISULFID        1313..1331
FT                   /evidence="ECO:0000250"
FT   DISULFID        1333..1342
FT                   /evidence="ECO:0000250"
FT   DISULFID        1378..1389
FT                   /evidence="ECO:0000250"
FT   DISULFID        1383..1400
FT                   /evidence="ECO:0000250"
FT   DISULFID        1402..1411
FT                   /evidence="ECO:0000250"
FT   DISULFID        1425..1448
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1430..1443
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1439..1455
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1466..1489
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1472..1484
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1480..1496
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1503..1527
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1509..1522
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1518..1534
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1632..1639
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   VARIANT         444
FT                   /note="C -> Y (in ALGS2; dbSNP:rs111033632)"
FT                   /evidence="ECO:0000269|PubMed:16773578"
FT                   /id="VAR_029361"
FT   VARIANT         1667
FT                   /note="V -> F (in dbSNP:rs17024517)"
FT                   /id="VAR_031463"
FT   VARIANT         2140..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378985"
FT                   /id="VAR_080195"
FT   VARIANT         2196..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:23389697"
FT                   /id="VAR_080196"
FT   VARIANT         2208..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378985,
FT                   ECO:0000269|PubMed:21681853"
FT                   /id="VAR_080197"
FT   VARIANT         2223..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21681853"
FT                   /id="VAR_080198"
FT   VARIANT         2285..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378989"
FT                   /id="VAR_080199"
FT   VARIANT         2299..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21712856"
FT                   /id="VAR_080200"
FT   VARIANT         2317..2471
FT                   /note="Missing (in HJCYS; loss of interaction with FBW7;
FT                   decreased ubiquitination)"
FT                   /evidence="ECO:0000269|PubMed:21378989,
FT                   ECO:0000269|PubMed:29149593"
FT                   /id="VAR_080201"
FT   VARIANT         2325..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378985"
FT                   /id="VAR_080202"
FT   VARIANT         2360..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21681853"
FT                   /id="VAR_080203"
FT   VARIANT         2373..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378989"
FT                   /id="VAR_080204"
FT   VARIANT         2389..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21712856"
FT                   /id="VAR_080205"
FT   VARIANT         2400..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378985,
FT                   ECO:0000269|PubMed:21793104, ECO:0000269|PubMed:23389697"
FT                   /id="VAR_080206"
FT   MUTAGEN         2416
FT                   /note="T->A: Loss of interaction with FBW7. Results in
FT                   decreased ubiquitination and degradation."
FT                   /evidence="ECO:0000269|PubMed:29149593"
FT   CONFLICT        21
FT                   /note="A -> T (in Ref. 2; AAG37073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        210
FT                   /note="P -> L (in Ref. 2; AAG37073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1037
FT                   /note="E -> D (in Ref. 4; AAB19224)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1084..1085
FT                   /note="ES -> SP (in Ref. 4; AAB19224)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1094
FT                   /note="A -> V (in Ref. 4; AAB19224)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1139
FT                   /note="L -> V (in Ref. 4; AAB19224)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1519
FT                   /note="D -> N (in Ref. 1; AAA36377)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2053
FT                   /note="R -> H (in Ref. 2; AAG37073)"
FT                   /evidence="ECO:0000305"
FT   TURN            418..420
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   STRAND          426..428
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   STRAND          432..436
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   STRAND          439..443
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   STRAND          448..450
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   HELIX           459..462
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   STRAND          470..474
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   STRAND          477..481
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   STRAND          486..488
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   HELIX           497..500
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   STRAND          508..512
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   STRAND          515..519
FT                   /evidence="ECO:0000244|PDB:5MWB"
FT   HELIX           1428..1433
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   STRAND          1436..1438
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1441..1443
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   TURN            1446..1448
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1449..1452
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   TURN            1453..1458
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   TURN            1462..1465
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1472..1474
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   STRAND          1477..1479
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1482..1484
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   TURN            1487..1490
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1491..1494
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1506..1512
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   STRAND          1515..1517
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1520..1522
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1525..1532
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   STRAND          1544..1553
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1555..1560
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1562..1573
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   STRAND          1575..1579
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   STRAND          1589..1595
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   STRAND          1618..1628
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1632..1635
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   HELIX           1643..1656
FT                   /evidence="ECO:0000244|PDB:2OO4"
FT   STRAND          1663..1670
FT                   /evidence="ECO:0000244|PDB:2OO4"
SQ   SEQUENCE   2471 AA;  265405 MW;  605B1B963C812BE1 CRC64;
     MPALRPALLW ALLALWLCCA APAHALQCRD GYEPCVNEGM CVTYHNGTGY CKCPEGFLGE
     YCQHRDPCEK NRCQNGGTCV AQAMLGKATC RCASGFTGED CQYSTSHPCF VSRPCLNGGT
     CHMLSRDTYE CTCQVGFTGK ECQWTDACLS HPCANGSTCT TVANQFSCKC LTGFTGQKCE
     TDVNECDIPG HCQHGGTCLN LPGSYQCQCP QGFTGQYCDS LYVPCAPSPC VNGGTCRQTG
     DFTFECNCLP GFEGSTCERN IDDCPNHRCQ NGGVCVDGVN TYNCRCPPQW TGQFCTEDVD
     ECLLQPNACQ NGGTCANRNG GYGCVCVNGW SGDDCSENID DCAFASCTPG STCIDRVASF
     SCMCPEGKAG LLCHLDDACI SNPCHKGALC DTNPLNGQYI CTCPQGYKGA DCTEDVDECA
     MANSNPCEHA GKCVNTDGAF HCECLKGYAG PRCEMDINEC HSDPCQNDAT CLDKIGGFTC
     LCMPGFKGVH CELEINECQS NPCVNNGQCV DKVNRFQCLC PPGFTGPVCQ IDIDDCSSTP
     CLNGAKCIDH PNGYECQCAT GFTGVLCEEN IDNCDPDPCH HGQCQDGIDS YTCICNPGYM
     GAICSDQIDE CYSSPCLNDG RCIDLVNGYQ CNCQPGTSGV NCEINFDDCA SNPCIHGICM
     DGINRYSCVC SPGFTGQRCN IDIDECASNP CRKGATCING VNGFRCICPE GPHHPSCYSQ
     VNECLSNPCI HGNCTGGLSG YKCLCDAGWV GINCEVDKNE CLSNPCQNGG TCDNLVNGYR
     CTCKKGFKGY NCQVNIDECA SNPCLNQGTC FDDISGYTCH CVLPYTGKNC QTVLAPCSPN
     PCENAAVCKE SPNFESYTCL CAPGWQGQRC TIDIDECISK PCMNHGLCHN TQGSYMCECP
     PGFSGMDCEE DIDDCLANPC QNGGSCMDGV NTFSCLCLPG FTGDKCQTDM NECLSEPCKN
     GGTCSDYVNS YTCKCQAGFD GVHCENNINE CTESSCFNGG TCVDGINSFS CLCPVGFTGS
     FCLHEINECS SHPCLNEGTC VDGLGTYRCS CPLGYTGKNC QTLVNLCSRS PCKNKGTCVQ
     KKAESQCLCP SGWAGAYCDV PNVSCDIAAS RRGVLVEHLC QHSGVCINAG NTHYCQCPLG
     YTGSYCEEQL DECASNPCQH GATCSDFIGG YRCECVPGYQ GVNCEYEVDE CQNQPCQNGG
     TCIDLVNHFK CSCPPGTRGL LCEENIDDCA RGPHCLNGGQ CMDRIGGYSC RCLPGFAGER
     CEGDINECLS NPCSSEGSLD CIQLTNDYLC VCRSAFTGRH CETFVDVCPQ MPCLNGGTCA
     VASNMPDGFI CRCPPGFSGA RCQSSCGQVK CRKGEQCVHT ASGPRCFCPS PRDCESGCAS
     SPCQHGGSCH PQRQPPYYSC QCAPPFSGSR CELYTAPPST PPATCLSQYC ADKARDGVCD
     EACNSHACQW DGGDCSLTME NPWANCSSPL PCWDYINNQC DELCNTVECL FDNFECQGNS
     KTCKYDKYCA DHFKDNHCDQ GCNSEECGWD GLDCAADQPE NLAEGTLVIV VLMPPEQLLQ
     DARSFLRALG TLLHTNLRIK RDSQGELMVY PYYGEKSAAM KKQRMTRRSL PGEQEQEVAG
     SKVFLEIDNR QCVQDSDHCF KNTDAAAALL ASHAIQGTLS YPLVSVVSES LTPERTQLLY
     LLAVAVVIIL FIILLGVIMA KRKRKHGSLW LPEGFTLRRD ASNHKRREPV GQDAVGLKNL
     SVQVSEANLI GTGTSEHWVD DEGPQPKKVK AEDEALLSEE DDPIDRRPWT QQHLEAADIR
     RTPSLALTPP QAEQEVDVLD VNVRGPDGCT PLMLASLRGG SSDLSDEDED AEDSSANIIT
     DLVYQGASLQ AQTDRTGEMA LHLAARYSRA DAAKRLLDAG ADANAQDNMG RCPLHAAVAA
     DAQGVFQILI RNRVTDLDAR MNDGTTPLIL AARLAVEGMV AELINCQADV NAVDDHGKSA
     LHWAAAVNNV EATLLLLKNG ANRDMQDNKE ETPLFLAARE GSYEAAKILL DHFANRDITD
     HMDRLPRDVA RDRMHHDIVR LLDEYNVTPS PPGTVLTSAL SPVICGPNRS FLSLKHTPMG
     KKSRRPSAKS TMPTSLPNLA KEAKDAKGSR RKKSLSEKVQ LSESSVTLSP VDSLESPHTY
     VSDTTSSPMI TSPGILQASP NPMLATAAPP APVHAQHALS FSNLHEMQPL AHGASTVLPS
     VSQLLSHHHI VSPGSGSAGS LSRLHPVPVP ADWMNRMEVN ETQYNEMFGM VLAPAEGTHP
     GIAPQSRPPE GKHITTPREP LPPIVTFQLI PKGSIAQPAG APQPQSTCPP AVAGPLPTMY
     QIPEMARLPS VAFPTAMMPQ QDGQVAQTIL PAYHPFPASV GKYPTPPSQH SYASSNAAER
     TPSHSGHLQG EHPYLTPSPE SPDQWSSSSP HSASDWSDVT TSPTPGGAGG GQRGPGTHMS
     EPPHNNMQVY A
//
ID   Q6IQ50_HUMAN            Unreviewed;      1235 AA.
AC   Q6IQ50;
DT   05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   30-AUG-2005, sequence version 2.
DT   11-DEC-2019, entry version 113.
DE   SubName: Full=NOTCH2 protein {ECO:0000313|EMBL:AAH71562.2};
GN   Name=NOTCH2 {ECO:0000313|EMBL:AAH71562.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH71562.2};
RN   [1] {ECO:0000313|EMBL:AAH71562.2}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis {ECO:0000313|EMBL:AAH71562.2};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- CAUTION: Lacks conserved residue(s) required for the propagation of
CC       feature annotation. {ECO:0000256|PROSITE-ProRule:PRU00076}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC071562; AAH71562.2; -; mRNA.
DR   RefSeq; NP_001186930.1; NM_001200001.1.
DR   RefSeq; NP_077719.2; NM_024408.3.
DR   PeptideAtlas; Q6IQ50; -.
DR   PRIDE; Q6IQ50; -.
DR   GeneID; 4853; -.
DR   KEGG; hsa:4853; -.
DR   CTD; 4853; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   KO; K20994; -.
DR   OrthoDB; 7525at2759; -.
DR   ChiTaRS; NOTCH2; human.
DR   GenomeRNAi; 4853; -.
DR   Genevisible; Q6IQ50; HS.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   Pfam; PF00008; EGF; 21.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF12661; hEGF; 5.
DR   SMART; SM00181; EGF; 31.
DR   SMART; SM00179; EGF_CA; 30.
DR   SUPFAM; SSF57184; SSF57184; 5.
DR   PROSITE; PS00010; ASX_HYDROXYL; 21.
DR   PROSITE; PS00022; EGF_1; 28.
DR   PROSITE; PS01186; EGF_2; 25.
DR   PROSITE; PS50026; EGF_3; 31.
DR   PROSITE; PS01187; EGF_CA; 9.
PE   2: Evidence at transcript level;
KW   Calcium {ECO:0000256|SAAS:SAAS00909960};
KW   Disulfide bond {ECO:0000256|PROSITE-ProRule:PRU00076,
KW   ECO:0000256|SAAS:SAAS00601599};
KW   EGF-like domain {ECO:0000256|PROSITE-ProRule:PRU00076,
KW   ECO:0000256|SAAS:SAAS00438935}; Repeat {ECO:0000256|SAAS:SAAS00594563};
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT   CHAIN           26..1235
FT                   /evidence="ECO:0000256|SAM:SignalP"
FT                   /id="PRO_5004275902"
FT   DOMAIN          24..63
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          64..102
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          105..143
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          144..180
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          182..219
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          221..258
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          260..296
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          298..336
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          338..374
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          375..413
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          415..454
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          456..492
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          494..530
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          532..568
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          570..605
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          607..643
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          645..680
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          682..718
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          720..755
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          757..793
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          795..831
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          833..871
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          873..909
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          911..947
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          949..985
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          987..1023
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          1025..1061
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          1063..1099
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          1112..1147
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          1149..1185
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DOMAIN          1187..1223
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000259|PROSITE:PS50026"
FT   DISULFID        53..62
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        73..90
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        92..101
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        133..142
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        170..179
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        209..218
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        248..257
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        286..295
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        326..335
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        364..373
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        384..401
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        403..412
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        444..453
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        482..491
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        520..529
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        558..567
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        574..584
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        595..604
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        633..642
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        649..659
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        670..679
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        708..717
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        724..734
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        745..754
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        783..792
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        821..830
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        842..859
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        861..870
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        899..908
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        975..984
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        1013..1022
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        1051..1060
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        1089..1098
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        1116..1126
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        1137..1146
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
FT   DISULFID        1175..1184
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00076"
SQ   SEQUENCE   1235 AA;  132112 MW;  2ADBD704B1552B61 CRC64;
     MPALRPALLW ALLALWLCCA APAHALQCRD GYEPCVNEGM CVTYHNGTGY CKCPEGFLGE
     YCQHRDPCEK NRCQNGGTCV AQAMLGKATC RCASGFTGED CQYSTSHPCF VSRPCLNGGT
     CHMLSRDTYE CTCQVGFTGK ECQWTDACLS HPCANGSTCT TVANQFSCKC LTGFTGQKCE
     TDVNECDIPG HCQHGGTCLN LPGSYQCQCP QGFTGQYCDS LYVPCAPSPC VNGGTCRQTG
     DFTFECNCLP GFEGSTCERN IDDCPNHRCQ NGGVCVDGVN TYNCRCPPQW TGQFCTEDVD
     ECLLQPNACQ NGGTCANRNG GYGCVCVNGW SGDDCSENID DCAFASCTPG STCIDRVASF
     SCMCPEGKAG LLCHLDDACI SNPCHKGALC DTNPLNGQYI CTCPQGYKGA DCTEDVDECA
     MANSNPCEHA GKCVNTDGAF HCECLKGYAG PRCEMDINEC HSDPCQNDAT CLDKIGGFTC
     LCMPGFKGVH CELEINECQS NPCVNNGQCV DKVNRFQCLC PPGFTGPVCQ IDIDDCSSTP
     CLNGAKCIDH PNGYECQCAT GFTGVLCEEN IDNCDPDPCH HGQCQDGIDS YTCICNPGYM
     GAICSDQIDE CYSSPCLNDG RCIDLVNGYQ CNCQPGTSGV NCEINFDDCA SNPCIHGICM
     DGINRYSCVC SPGFTGQRCN IDIDECASNP CRKGATCING VNGFRCICPE GPHHPSCYSQ
     VNECLSNPCI HGNCTGGLSG YKCLCDAGWV GINCEVDKNE CLSNPCQNGG TCDNLVNGYR
     CTCKKGFKGY NCQVNIDECA SNPCLNQGTC FDDISGYTCH CVLPYTGKNC QTVLAPCSPN
     PCENAAVCKE SPNFESYTCL CAPGWQGQRC TIDIDECISK PCMNHGLCHN TQGSYMCECP
     PGFSGMDCEE DIDDCLANPC QNGGSCMDGV NTFSCLCLPG FTGDKYQTDM NECLSEPCKN
     GGTCSDYVNS YTCKCQAGFD GVHCENNINE CTESSCFNGG TCVDGINSFS CLCPVGFTGS
     FCLHEINECS SHPCLNEGTC VDGLGTYRCS CPLGYTGKNC QTLVNLCSRS PCKNKGTCVQ
     KKAESQCLCP SGWAGAYCDV PNVSCDIAAS RRGVLVEHLC QHSGVCINAG NTHYCQCPLG
     YTGSYCEEQL DECASNPCQH GATCSDFIGG YRCECVPGYQ GVNCEYEVDE CQNQPCQNGG
     TCIDLVNHFK CSCPPGTRGM KSSLSIFHPG HCLKL
//
ID   Q9UFD5_HUMAN            Unreviewed;       462 AA.
AC   Q9UFD5;
DT   01-MAY-2000, integrated into UniProtKB/TrEMBL.
DT   01-MAY-2000, sequence version 1.
DT   11-DEC-2019, entry version 101.
DE   SubName: Full=Uncharacterized protein DKFZp434N181 {ECO:0000313|EMBL:CAB61366.1};
DE   Flags: Fragment;
GN   Name=DKFZp434N181 {ECO:0000313|EMBL:CAB61366.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:CAB61366.1};
RN   [1] {ECO:0000313|EMBL:CAB61366.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Testis {ECO:0000313|EMBL:CAB61366.1};
RG   The German cDNA Consortium;
RA   Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA   Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL133036; CAB61366.1; -; mRNA.
DR   PIR; A56695; A56695.
DR   PIR; T42679; T42679.
DR   RefSeq; NP_077719.2; NM_024408.3.
DR   PeptideAtlas; Q9UFD5; -.
DR   GeneID; 4853; -.
DR   KEGG; hsa:4853; -.
DR   CTD; 4853; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   KO; K20994; -.
DR   OrthoDB; 7525at2759; -.
DR   GenomeRNAi; 4853; -.
DR   Genevisible; Q9UFD5; HS.
DR   GO; GO:0038023; F:signaling receptor activity; IEA:InterPro.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR022336; Notch_2.
DR   Pfam; PF11936; DUF3454; 1.
DR   PRINTS; PR01985; NOTCH2.
DR   SMART; SM01334; DUF3454; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 1.
PE   2: Evidence at transcript level;
KW   ANK repeat {ECO:0000256|PROSITE-ProRule:PRU00023}.
FT   DOMAIN          1..53
FT                   /note="ANK_REP_REGION"
FT                   /evidence="ECO:0000259|PROSITE:PS50297"
FT   REPEAT          1..32
FT                   /note="ANK"
FT                   /evidence="ECO:0000256|PROSITE-ProRule:PRU00023"
FT   REGION          85..159
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          371..462
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        114..129
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        130..159
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        375..394
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        410..438
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:CAB61366.1"
SQ   SEQUENCE   462 AA;  49309 MW;  CB86B0969BA26678 CRC64;
     EETPLFLAAR EGSYEAAKIL LDHFANRDIT DHMDRLPRDV ARDRMHHDIV RLLDEYNVTP
     SPPGTVLTSA LSPVICGPNR SFLSLKHTPM GKKSRRPSAK STMPTSLPNL AKEAKDAKGS
     RRKKSLSEKV QLSESSVTLS PVDSLESPHT YVSDTTSSPM ITSPGILQAS PNPMLATAAP
     PAPVHAQHAL SFSNLHEMQP LAHGASTVLP SVSQLLSHHH IVSPGSGSAG SLSRLHPVPV
     PADWMNRMEV NETQYNEMFG MVLAPAEGTH PGIAPQSRPP EGKHITTPRE PLPPIVTFQL
     IPKGSIAQPA GAPQPQSTCP PAVAGPLPTM YQIPEMARLP SVAFPTAMMP QQDGQVAQTI
     LPAYHPFPAS VGKYPTPPSQ HSYASSNAAE RTPSHSGHLQ GEHPYLTPSP ESPDQWSSSS
     PHSASDWSDV TTSPTPGGAG GGQRGPGTHM SEPPHNNMQV YA
//
ID   DPOLQ_HUMAN             Reviewed;        2590 AA.
AC   O75417; O95160; Q6VMB5;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   08-MAR-2011, sequence version 2.
DT   22-APR-2020, entry version 149.
DE   RecName: Full=DNA polymerase theta {ECO:0000303|PubMed:10395804, ECO:0000303|PubMed:14576298, ECO:0000312|HGNC:HGNC:9186};
DE            EC=2.7.7.7 {ECO:0000269|PubMed:14576298, ECO:0000269|PubMed:22135286};
DE   AltName: Full=DNA polymerase eta {ECO:0000303|Ref.4};
GN   Name=POLQ {ECO:0000303|PubMed:10395804, ECO:0000303|PubMed:14576298,
GN   ECO:0000312|HGNC:HGNC:9186}; Synonyms=POLH {ECO:0000303|Ref.4};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Spleen;
RX   PubMed=10395804; DOI=10.1006/geno.1999.5843;
RA   Sharief F.S., Vojta P.J., Ropp P.A., Copeland W.C.;
RT   "Cloning and chromosomal mapping of the human DNA polymerase theta (POLQ),
RT   the eighth human DNA polymerase.";
RL   Genomics 59:90-96(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=14576298; DOI=10.1093/nar/gkg814;
RA   Seki M., Marini F., Wood R.D.;
RT   "POLQ (Pol theta), a DNA polymerase and DNA-dependent ATPase in human
RT   cells.";
RL   Nucleic Acids Res. 31:6117-6126(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1435-2590.
RA   Harris P.V., Kaelin C.B., Burtis K.C.;
RT   "Catalytic activity of Pol eta, a new human DNA polymerase related to the
RT   bacterial DNA polymerase I family and Drosophila Mus308.";
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   FUNCTION.
RX   PubMed=18503084; DOI=10.1093/nar/gkn310;
RA   Arana M.E., Seki M., Wood R.D., Rogozin I.B., Kunkel T.A.;
RT   "Low-fidelity DNA synthesis by human DNA polymerase theta.";
RL   Nucleic Acids Res. 36:3847-3856(2008).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF 2540-ASP-GLU-2541.
RX   PubMed=19188258; DOI=10.1093/nar/gkp035;
RA   Prasad R., Longley M.J., Sharief F.S., Hou E.W., Copeland W.C.,
RA   Wilson S.H.;
RT   "Human DNA polymerase theta possesses 5'-dRP lyase activity and functions
RT   in single-nucleotide base excision repair in vitro.";
RL   Nucleic Acids Res. 37:1868-1877(2009).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-990, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [8]
RP   INVOLVEMENT IN BC.
RX   PubMed=20700469; DOI=10.18632/oncotarget.124;
RA   Higgins G.S., Harris A.L., Prevo R., Helleday T., McKenna W.G., Buffa F.M.;
RT   "Overexpression of POLQ confers a poor prognosis in early breast cancer
RT   patients.";
RL   Oncotarget 1:175-184(2010).
RN   [9]
RP   INVOLVEMENT IN BC.
RX   PubMed=20624954; DOI=10.1073/pnas.0910759107;
RA   Lemee F., Bergoglio V., Fernandez-Vidal A., Machado-Silva A.,
RA   Pillaire M.J., Bieth A., Gentil C., Baker L., Martin A.L., Leduc C.,
RA   Lam E., Magdeleine E., Filleron T., Oumouhou N., Kaina B., Seki M.,
RA   Grimal F., Lacroix-Triki M., Thompson A., Roche H., Bourdon J.C.,
RA   Wood R.D., Hoffmann J.S., Cazaux C.;
RT   "DNA polymerase theta up-regulation is associated with poor survival in
RT   breast cancer, perturbs DNA replication, and promotes genetic
RT   instability.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:13390-13395(2010).
RN   [10]
RP   FUNCTION.
RX   PubMed=21050863; DOI=10.1016/j.jmb.2010.10.041;
RA   Hogg M., Seki M., Wood R.D., Doublie S., Wallace S.S.;
RT   "Lesion bypass activity of DNA polymerase theta (POLQ) is an intrinsic
RT   property of the pol domain and depends on unique sequence inserts.";
RL   J. Mol. Biol. 405:642-652(2011).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=22135286; DOI=10.1093/nar/gkr1102;
RA   Hogg M., Sauer-Eriksson A.E., Johansson E.;
RT   "Promiscuous DNA synthesis by human DNA polymerase theta.";
RL   Nucleic Acids Res. 40:2611-2622(2012).
RN   [12]
RP   INVOLVEMENT IN BC.
RX   PubMed=25409685; DOI=10.1186/1471-2407-14-850;
RA   Brandalize A.P., Schueler-Faccini L., Hoffmann J.S., Caleffi M., Cazaux C.,
RA   Ashton-Prolla P.;
RT   "A DNA repair variant in POLQ (c.-1060A > G) is associated to hereditary
RT   breast cancer patients: a case-control study.";
RL   BMC Cancer 14:850-850(2014).
RN   [13]
RP   FUNCTION, AND MUTAGENESIS OF 2540-ASP-GLU-2541.
RX   PubMed=24648516; DOI=10.1074/jbc.m114.556977;
RA   Yoon J.H., Roy Choudhury J., Park J., Prakash S., Prakash L.;
RT   "A role for DNA polymerase theta in promoting replication through oxidative
RT   DNA lesion, thymine glycol, in human cells.";
RL   J. Biol. Chem. 289:13177-13185(2014).
RN   [14]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH ORC2 AND ORC4.
RX   PubMed=24989122; DOI=10.1038/ncomms5285;
RA   Fernandez-Vidal A., Guitton-Sert L., Cadoret J.C., Drac M., Schwob E.,
RA   Baldacci G., Cazaux C., Hoffmann J.S.;
RT   "A role for DNA polymerase theta in the timing of DNA replication.";
RL   Nat. Commun. 5:4285-4285(2014).
RN   [15]
RP   FUNCTION, INTERACTION WITH RAD51, AND SUBCELLULAR LOCATION.
RX   PubMed=25642963; DOI=10.1038/nature14184;
RA   Ceccaldi R., Liu J.C., Amunugama R., Hajdu I., Primack B., Petalcorin M.I.,
RA   O'Connor K.W., Konstantinopoulos P.A., Elledge S.J., Boulton S.J.,
RA   Yusufzai T., D'Andrea A.D.;
RT   "Homologous-recombination-deficient tumours are dependent on Poltheta-
RT   mediated repair.";
RL   Nature 518:258-262(2015).
RN   [16]
RP   FUNCTION, SUBUNIT, AND DOMAIN.
RX   PubMed=25643323; DOI=10.1038/nsmb.2961;
RA   Kent T., Chandramouly G., McDevitt S.M., Ozdemir A.Y., Pomerantz R.T.;
RT   "Mechanism of microhomology-mediated end-joining promoted by human DNA
RT   polymerase theta.";
RL   Nat. Struct. Mol. Biol. 22:230-237(2015).
CC   -!- FUNCTION: DNA polymerase that promotes microhomology-mediated end-
CC       joining (MMEJ), an alternative non-homologous end-joining (NHEJ)
CC       machinery triggered in response to double-strand breaks in DNA
CC       (PubMed:25642963, PubMed:25643323). MMEJ is an error-prone repair
CC       pathway that produces deletions of sequences from the strand being
CC       repaired and promotes genomic rearrangements, such as telomere fusions,
CC       some of them leading to cellular transformation (PubMed:25642963,
CC       PubMed:25643323). POLQ acts as an inhibitor of homology-recombination
CC       repair (HR) pathway by limiting RAD51 accumulation at resected ends
CC       (PubMed:25642963). POLQ-mediated MMEJ may be required to promote the
CC       survival of cells with a compromised HR repair pathway, thereby
CC       preventing genomic havoc by resolving unrepaired lesions (By
CC       similarity). The polymerase acts by binding directly the 2 ends of
CC       resected double-strand breaks, allowing microhomologous sequences in
CC       the overhangs to form base pairs. It then extends each strand from the
CC       base-paired region using the opposing overhang as a template. Requires
CC       partially resected DNA containing 2 to 6 base pairs of microhomology to
CC       perform MMEJ (PubMed:25643323). The polymerase activity is highly
CC       promiscuous: unlike most polymerases, promotes extension of ssDNA and
CC       partial ssDNA (pssDNA) substrates (PubMed:18503084, PubMed:21050863,
CC       PubMed:22135286). Also exhibits low-fidelity DNA synthesis, translesion
CC       synthesis and lyase activity, and it is implicated in interstrand-
CC       cross-link repair, base excision repair and DNA end-joining
CC       (PubMed:14576298, PubMed:18503084, PubMed:19188258, PubMed:24648516).
CC       Involved in somatic hypermutation of immunoglobulin genes, a process
CC       that requires the activity of DNA polymerases to ultimately introduce
CC       mutations at both A/T and C/G base pairs (By similarity).
CC       {ECO:0000250|UniProtKB:Q8CGS6, ECO:0000269|PubMed:14576298,
CC       ECO:0000269|PubMed:18503084, ECO:0000269|PubMed:19188258,
CC       ECO:0000269|PubMed:21050863, ECO:0000269|PubMed:22135286,
CC       ECO:0000269|PubMed:24648516, ECO:0000269|PubMed:25642963,
CC       ECO:0000269|PubMed:25643323}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxyribonucleoside 5'-triphosphate + DNA(n) =
CC         diphosphate + DNA(n+1); Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:11130,
CC         Rhea:RHEA-COMP:11131, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560,
CC         ChEBI:CHEBI:83828; EC=2.7.7.7; Evidence={ECO:0000269|PubMed:14576298,
CC         ECO:0000269|PubMed:22135286};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.095 uM for dATP:T {ECO:0000269|PubMed:22135286};
CC         KM=0.622 uM for dATP: abasic site {ECO:0000269|PubMed:22135286};
CC         KM=3.08 uM for dGTP: no template {ECO:0000269|PubMed:22135286};
CC   -!- SUBUNIT: Homomultimer; forms dimers and multimers (PubMed:25643323).
CC       Interacts with RAD51 (PubMed:25642963). Interacts with ORC2 and ORC4
CC       (PubMed:24989122). {ECO:0000269|PubMed:24989122,
CC       ECO:0000269|PubMed:25642963, ECO:0000269|PubMed:25643323}.
CC   -!- INTERACTION:
CC       O75417-1; O75417-1; NbExp=5; IntAct=EBI-16141065, EBI-16141065;
CC       O75417-1; Q06609: RAD51; NbExp=3; IntAct=EBI-16141065, EBI-297202;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:O18475}.
CC       Chromosome {ECO:0000269|PubMed:25642963}. Note=Enriched in chromatin in
CC       response to ultaviolet (UV) light (PubMed:25642963). Binds to chromatin
CC       during early G1 (PubMed:24989122). {ECO:0000269|PubMed:24989122,
CC       ECO:0000269|PubMed:25642963}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O75417-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75417-2; Sequence=VSP_040747, VSP_040748;
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis.
CC       {ECO:0000269|PubMed:14576298}.
CC   -!- DOMAIN: The loop 2 region is involved in the binding of the 2 ends of
CC       resected double-strand breaks and homomultimerization.
CC       {ECO:0000269|PubMed:25643323}.
CC   -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy
CC       originating from breast epithelial tissue. Breast neoplasms can be
CC       distinguished by their histologic pattern. Invasive ductal carcinoma is
CC       by far the most common type. Breast cancer is etiologically and
CC       genetically heterogeneous. Important genetic factors have been
CC       indicated by familial occurrence and bilateral involvement. Mutations
CC       at more than one locus can be involved in different families or even in
CC       the same case. {ECO:0000269|PubMed:20624954,
CC       ECO:0000269|PubMed:20700469, ECO:0000269|PubMed:25409685}. Note=The
CC       gene represented in this entry may be involved in disease pathogenesis.
CC   -!- SIMILARITY: Belongs to the DNA polymerase type-A family. {ECO:0000305}.
CC   -!- CAUTION: Was wrongly named DNA polymerase eta (POLH) somne authors
CC       (Ref.4). This protein corresponds to DNA polymerase theta (POLQ) and
CC       should not be confused with DNA polymerase eta (POLH) (AC Q9Y253).
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD05272.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF052573; AAC33565.1; -; mRNA.
DR   EMBL; AY338826; AAR08421.2; -; mRNA.
DR   EMBL; AC069239; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079841; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF043628; AAD05272.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS33833.1; -. [O75417-1]
DR   RefSeq; NP_955452.3; NM_199420.3. [O75417-1]
DR   PDB; 4X0P; X-ray; 3.91 A; A/B/C/D=1792-2590.
DR   PDB; 4X0Q; X-ray; 3.90 A; A/B=1819-2590.
DR   PDB; 5A9F; X-ray; 3.20 A; A=67-894.
DR   PDB; 5A9J; X-ray; 3.55 A; A/B/C/D=1-894.
DR   PDB; 5AGA; X-ray; 2.90 A; A=67-894.
DR   PDBsum; 4X0P; -.
DR   PDBsum; 4X0Q; -.
DR   PDBsum; 5A9F; -.
DR   PDBsum; 5A9J; -.
DR   PDBsum; 5AGA; -.
DR   SMR; O75417; -.
DR   BioGrid; 115946; 4.
DR   DIP; DIP-61500N; -.
DR   IntAct; O75417; 3.
DR   STRING; 9606.ENSP00000264233; -.
DR   ChEMBL; CHEMBL6025; -.
DR   iPTMnet; O75417; -.
DR   PhosphoSitePlus; O75417; -.
DR   BioMuta; POLQ; -.
DR   EPD; O75417; -.
DR   jPOST; O75417; -.
DR   MassIVE; O75417; -.
DR   MaxQB; O75417; -.
DR   PaxDb; O75417; -.
DR   PeptideAtlas; O75417; -.
DR   PRIDE; O75417; -.
DR   ProteomicsDB; 49988; -. [O75417-1]
DR   ProteomicsDB; 49989; -. [O75417-2]
DR   Antibodypedia; 32825; 72 antibodies.
DR   DNASU; 10721; -.
DR   Ensembl; ENST00000264233; ENSP00000264233; ENSG00000051341. [O75417-1]
DR   GeneID; 10721; -.
DR   KEGG; hsa:10721; -.
DR   UCSC; uc003eee.5; human. [O75417-1]
DR   CTD; 10721; -.
DR   DisGeNET; 10721; -.
DR   GeneCards; POLQ; -.
DR   HGNC; HGNC:9186; POLQ.
DR   HPA; ENSG00000051341; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MIM; 114480; phenotype.
DR   MIM; 604419; gene.
DR   neXtProt; NX_O75417; -.
DR   OpenTargets; ENSG00000051341; -.
DR   PharmGKB; PA33506; -.
DR   eggNOG; KOG0950; Eukaryota.
DR   eggNOG; COG0749; LUCA.
DR   eggNOG; COG1204; LUCA.
DR   GeneTree; ENSGT00940000158694; -.
DR   HOGENOM; CLU_000818_0_1_1; -.
DR   InParanoid; O75417; -.
DR   KO; K02349; -.
DR   OrthoDB; 179246at2759; -.
DR   PhylomeDB; O75417; -.
DR   TreeFam; TF105018; -.
DR   Reactome; R-HSA-5685939; HDR through MMEJ (alt-NHEJ).
DR   ChiTaRS; POLQ; human.
DR   GeneWiki; POLQ; -.
DR   GenomeRNAi; 10721; -.
DR   Pharos; O75417; Tbio.
DR   PRO; PR:O75417; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; O75417; protein.
DR   Bgee; ENSG00000051341; Expressed in secondary oocyte and 98 other tissues.
DR   ExpressionAtlas; O75417; baseline and differential.
DR   Genevisible; O75417; HS.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0051575; F:5'-deoxyribose-5-phosphate lyase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; TAS:ProtInc.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0017116; F:single-stranded DNA helicase activity; IDA:UniProtKB.
DR   GO; GO:0006284; P:base-excision repair; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0006261; P:DNA-dependent DNA replication; IBA:GO_Central.
DR   GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB.
DR   GO; GO:0097681; P:double-strand break repair via alternative nonhomologous end joining; IDA:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; TAS:Reactome.
DR   GO; GO:2000042; P:negative regulation of double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; ISS:UniProtKB.
DR   Gene3D; 3.30.420.10; -; 1.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR019760; DNA-dir_DNA_pol_A_CS.
DR   InterPro; IPR001098; DNA-dir_DNA_pol_A_palm_dom.
DR   InterPro; IPR002298; DNA_polymerase_A.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR012337; RNaseH-like_sf.
DR   InterPro; IPR036397; RNaseH_sf.
DR   PANTHER; PTHR10133; PTHR10133; 1.
DR   Pfam; PF00270; DEAD; 1.
DR   Pfam; PF00476; DNA_pol_A; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   PRINTS; PR00868; DNAPOLI.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SMART; SM00482; POLAc; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF53098; SSF53098; 1.
DR   PROSITE; PS00447; DNA_POLYMERASE_A; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Chromosome;
KW   Coiled coil; DNA damage; DNA repair; DNA-directed DNA polymerase;
KW   Nucleotide-binding; Nucleotidyltransferase; Nucleus; Polymorphism;
KW   Reference proteome; Transferase.
FT   CHAIN           1..2590
FT                   /note="DNA polymerase theta"
FT                   /id="PRO_0000101279"
FT   DOMAIN          102..286
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          321..554
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   NP_BIND         115..122
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   REGION          847..894
FT                   /note="Interaction with RAD51"
FT                   /evidence="ECO:0000269|PubMed:25642963"
FT   REGION          2142..2177
FT                   /note="Loop 1"
FT                   /evidence="ECO:0000269|PubMed:21050863"
FT   REGION          2257..2322
FT                   /note="Loop 2"
FT                   /evidence="ECO:0000269|PubMed:21050863,
FT                   ECO:0000269|PubMed:25643323"
FT   REGION          2491..2535
FT                   /note="Loop 3"
FT                   /evidence="ECO:0000269|PubMed:21050863"
FT   COILED          1655..1716
FT                   /evidence="ECO:0000255"
FT   MOTIF           216..219
FT                   /note="DEAH box"
FT   MOD_RES         990
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   VAR_SEQ         1..828
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10395804"
FT                   /id="VSP_040747"
FT   VAR_SEQ         829..840
FT                   /note="VEVILKNAVPFK -> MNSFLSFPISLC (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10395804"
FT                   /id="VSP_040748"
FT   VARIANT         1056
FT                   /note="P -> L (in dbSNP:rs34778629)"
FT                   /id="VAR_055707"
FT   MUTAGEN         2540..2541
FT                   /note="DE->AA: Abolishes DNA polymerase activity."
FT                   /evidence="ECO:0000269|PubMed:19188258,
FT                   ECO:0000269|PubMed:24648516"
FT   CONFLICT        66
FT                   /note="R -> I (in Ref. 2; AAR08421)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        982
FT                   /note="T -> R (in Ref. 2; AAR08421)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2013
FT                   /note="L -> F (in Ref. 4; AAD05272)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2513
FT                   /note="Q -> R (in Ref. 1; AAC33565 and 2; AAR08421)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2547
FT                   /note="A -> V (in Ref. 1; AAC33565)"
FT                   /evidence="ECO:0000305"
FT   HELIX           71..73
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           78..85
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           94..101
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          102..104
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   TURN            105..108
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          111..114
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           121..135
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          139..146
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           147..161
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           162..164
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          168..171
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           181..183
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          185..190
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           191..203
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           207..209
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          210..216
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           218..221
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           229..243
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           245..247
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          260..266
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           271..277
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          281..284
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          292..298
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          301..303
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          309..312
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           326..335
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          340..343
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           347..366
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          380..383
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           384..395
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           403..408
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           409..411
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          413..416
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           422..433
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          439..442
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           444..447
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          454..460
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          462..464
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           471..478
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   TURN            484..486
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          490..496
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          498..500
FT                   /evidence="ECO:0000244|PDB:5A9F"
FT   HELIX           501..509
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           529..540
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           547..556
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   TURN            559..562
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           581..591
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          594..598
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          607..611
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           613..620
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           625..638
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          645..647
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           648..653
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           666..674
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           678..687
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           691..698
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   TURN            708..711
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           712..728
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   TURN            729..731
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           734..741
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           745..768
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           772..778
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           781..787
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           791..794
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           796..798
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           804..811
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   TURN            812..814
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           818..822
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   HELIX           826..834
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          840..842
FT                   /evidence="ECO:0000244|PDB:5AGA"
FT   STRAND          856..858
FT                   /evidence="ECO:0000244|PDB:5A9F"
FT   HELIX           872..889
FT                   /evidence="ECO:0000244|PDB:5AGA"
SQ   SEQUENCE   2590 AA;  289619 MW;  F5550BED2DAD8013 CRC64;
     MNLLRRSGKR RRSESGSDSF SGSGGDSSAS PQFLSGSVLS PPPGLGRCLK AAAAGECKPT
     VPDYERDKLL LANWGLPKAV LEKYHSFGVK KMFEWQAECL LLGQVLEGKN LVYSAPTSAG
     KTLVAELLIL KRVLEMRKKA LFILPFVSVA KEKKYYLQSL FQEVGIKVDG YMGSTSPSRH
     FSSLDIAVCT IERANGLINR LIEENKMDLL GMVVVDELHM LGDSHRGYLL ELLLTKICYI
     TRKSASCQAD LASSLSNAVQ IVGMSATLPN LELVASWLNA ELYHTDFRPV PLLESVKVGN
     SIYDSSMKLV REFEPMLQVK GDEDHVVSLC YETICDNHSV LLFCPSKKWC EKLADIIARE
     FYNLHHQAEG LVKPSECPPV ILEQKELLEV MDQLRRLPSG LDSVLQKTVP WGVAFHHAGL
     TFEERDIIEG AFRQGLIRVL AATSTLSSGV NLPARRVIIR TPIFGGRPLD ILTYKQMVGR
     AGRKGVDTVG ESILICKNSE KSKGIALLQG SLKPVRSCLQ RREGEEVTGS MIRAILEIIV
     GGVASTSQDM HTYAACTFLA ASMKEGKQGI QRNQESVQLG AIEACVMWLL ENEFIQSTEA
     SDGTEGKVYH PTHLGSATLS SSLSPADTLD IFADLQRAMK GFVLENDLHI LYLVTPMFED
     WTTIDWYRFF CLWEKLPTSM KRVAELVGVE EGFLARCVKG KVVARTERQH RQMAIHKRFF
     TSLVLLDLIS EVPLREINQK YGCNRGQIQS LQQSAAVYAG MITVFSNRLG WHNMELLLSQ
     FQKRLTFGIQ RELCDLVRVS LLNAQRARVL YASGFHTVAD LARANIVEVE VILKNAVPFK
     SARKAVDEEE EAVEERRNMR TIWVTGRKGL TEREAAALIV EEARMILQQD LVEMGVQWNP
     CALLHSSTCS LTHSESEVKE HTFISQTKSS YKKLTSKNKS NTIFSDSYIK HSPNIVQDLN
     KSREHTSSFN CNFQNGNQEH QTCSIFRARK RASLDINKEK PGASQNEGKT SDKKVVQTFS
     QKTKKAPLNF NSEKMSRSFR SWKRRKHLKR SRDSSPLKDS GACRIHLQGQ TLSNPSLCED
     PFTLDEKKTE FRNSGPFAKN VSLSGKEKDN KTSFPLQIKQ NCSWNITLTN DNFVEHIVTG
     SQSKNVTCQA TSVVSEKGRG VAVEAEKINE VLIQNGSKNQ NVYMKHHDIH PINQYLRKQS
     HEQTSTITKQ KNIIERQMPC EAVSSYINRD SNVTINCERI KLNTEENKPS HFQALGDDIS
     RTVIPSEVLP SAGAFSKSEG QHENFLNISR LQEKTGTYTT NKTKNNHVSD LGLVLCDFED
     SFYLDTQSEK IIQQMATENA KLGAKDTNLA AGIMQKSLVQ QNSMNSFQKE CHIPFPAEQH
     PLGATKIDHL DLKTVGTMKQ SSDSHGVDIL TPESPIFHSP ILLEENGLFL KKNEVSVTDS
     QLNSFLQGYQ TQETVKPVIL LIPQKRTPTG VEGECLPVPE TSLNMSDSLL FDSFSDDYLV
     KEQLPDMQMK EPLPSEVTSN HFSDSLCLQE DLIKKSNVNE NQDTHQQLTC SNDESIIFSE
     MDSVQMVEAL DNVDIFPVQE KNHTVVSPRA LELSDPVLDE HHQGDQDGGD QDERAEKSKL
     TGTRQNHSFI WSGASFDLSP GLQRILDKVS SPLENEKLKS MTINFSSLNR KNTELNEEQE
     VISNLETKQV QGISFSSNNE VKSKIEMLEN NANHDETSSL LPRKESNIVD DNGLIPPTPI
     PTSASKLTFP GILETPVNPW KTNNVLQPGE SYLFGSPSDI KNHDLSPGSR NGFKDNSPIS
     DTSFSLQLSQ DGLQLTPASS SSESLSIIDV ASDQNLFQTF IKEWRCKKRF SISLACEKIR
     SLTSSKTATI GSRFKQASSP QEIPIRDDGF PIKGCDDTLV VGLAVCWGGR DAYYFSLQKE
     QKHSEISASL VPPSLDPSLT LKDRMWYLQS CLRKESDKEC SVVIYDFIQS YKILLLSCGI
     SLEQSYEDPK VACWLLDPDS QEPTLHSIVT SFLPHELPLL EGMETSQGIQ SLGLNAGSEH
     SGRYRASVES ILIFNSMNQL NSLLQKENLQ DVFRKVEMPS QYCLALLELN GIGFSTAECE
     SQKHIMQAKL DAIETQAYQL AGHSFSFTSS DDIAEVLFLE LKLPPNREMK NQGSKKTLGS
     TRRGIDNGRK LRLGRQFSTS KDVLNKLKAL HPLPGLILEW RRITNAITKV VFPLQREKCL
     NPFLGMERIY PVSQSHTATG RITFTEPNIQ NVPRDFEIKM PTLVGESPPS QAVGKGLLPM
     GRGKYKKGFS VNPRCQAQME ERAADRGMPF SISMRHAFVP FPGGSILAAD YSQLELRILA
     HLSHDRRLIQ VLNTGADVFR SIAAEWKMIE PESVGDDLRQ QAKQICYGII YGMGAKSLGE
     QMGIKENDAA CYIDSFKSRY TGINQFMTET VKNCKRDGFV QTILGRRRYL PGIKDNNPYR
     KAHAERQAIN TIVQGSAADI VKIATVNIQK QLETFHSTFK SHGHREGMLQ SDQTGLSRKR
     KLQGMFCPIR GGFFILQLHD ELLYEVAEED VVQVAQIVKN EMESAVKLSV KLKVKVKIGA
     SWGELKDFDV
//
ID   Q59EE4_HUMAN            Unreviewed;      2214 AA.
AC   Q59EE4;
DT   26-APR-2005, integrated into UniProtKB/TrEMBL.
DT   26-APR-2005, sequence version 1.
DT   11-DEC-2019, entry version 80.
DE   SubName: Full=DNA polymerase theta variant {ECO:0000313|EMBL:BAD93104.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD93104.1};
RN   [1] {ECO:0000313|EMBL:BAD93104.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Aorta endothelial cell {ECO:0000313|EMBL:BAD93104.1};
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB209867; BAD93104.1; -; mRNA.
DR   RefSeq; NP_955452.3; NM_199420.3.
DR   PeptideAtlas; Q59EE4; -.
DR   PRIDE; Q59EE4; -.
DR   DNASU; 10721; -.
DR   GeneID; 10721; -.
DR   KEGG; hsa:10721; -.
DR   CTD; 10721; -.
DR   PharmGKB; PA33506; -.
DR   eggNOG; KOG0950; Eukaryota.
DR   eggNOG; COG0749; LUCA.
DR   eggNOG; COG1204; LUCA.
DR   KO; K02349; -.
DR   OrthoDB; 179246at2759; -.
DR   GenomeRNAi; 10721; -.
DR   Genevisible; Q59EE4; HS.
DR   GO; GO:0003677; F:DNA binding; IEA:InterPro.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA:InterPro.
DR   GO; GO:0006261; P:DNA-dependent DNA replication; IEA:InterPro.
DR   Gene3D; 3.30.420.10; -; 1.
DR   InterPro; IPR019760; DNA-dir_DNA_pol_A_CS.
DR   InterPro; IPR001098; DNA-dir_DNA_pol_A_palm_dom.
DR   InterPro; IPR002298; DNA_polymerase_A.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR012337; RNaseH-like_sf.
DR   InterPro; IPR036397; RNaseH_sf.
DR   PANTHER; PTHR10133; PTHR10133; 1.
DR   Pfam; PF00476; DNA_pol_A; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   PRINTS; PR00868; DNAPOLI.
DR   SMART; SM00490; HELICc; 1.
DR   SMART; SM00482; POLAc; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF53098; SSF53098; 1.
DR   PROSITE; PS00447; DNA_POLYMERASE_A; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN          1..178
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000259|PROSITE:PS51194"
FT   REGION          658..684
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1218..1246
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1401..1421
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          1282..1312
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        1218..1245
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1406..1421
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:BAD93104.1"
SQ   SEQUENCE   2214 AA;  247978 MW;  327C2D6AC85F7753 CRC64;
     MPTSNSGQKE LLEVMDQLRR LPSGLDSVLQ KTVPWGVAFH HAGLTFEERD IIEGAFRQGL
     IRVLAATSTL SSGVNLPARR VIIRTPIFGG RPLDILTYKQ MVGRAGRKGV DTVGESILIC
     KNSEKSKGIA LLQGSLKPVR SCLQRREGEE VTGSMIRAIL EIIVGGVAST SQDMHTYAAC
     TFLAASMKEG KQGIQRNQES VQLGAIEACV MWLLENEFIQ STEASDGTEG KVYHPTHLGS
     ATLSSSLSPA DTLDIFADLQ RAMKGFVLEN DLHILYLVTP MFEDWTTIDW YRFFCLWEKL
     PTSMKRVAEL VGVEEGFLAR CVKGKVVART ERQHRQMAIH KRFFTSLVLL DLISEVPLRE
     INQKYGCNRG QIQSLQQSAA VYAGMITVFS NRLGWHNMEL LLSQFQKRLT FGIQRELCDL
     VRVSLLNAQR ARVLYASGFH TVADLARANI VEVEVILKNA VPFKSARKAV DEEEEAVEER
     RNMRTIWVTG RKGLTEREAA ALIVEEARMI LQQDLVEMGV QWNPCALLHS STCSLTHSES
     EVKEHTFISQ TKSSYKKLTS KNKSNTIFSD SYIKHSPNIV QDLNKSREHT SSFNCNFQNG
     NQEHQRCSIF RARKRASLDI NKEKPGASQN EGKTSDKKVV QTFSQKTKKA PLNFNSEKMS
     RSFRSWKRRK HLKRSRDSSP LKDSGACRIH LQGQTLSNPS LCEDPFTLDE KKTEFRNSGP
     FAKNVSLSGK EKDNKTSFPL QIKQNCSWNI TLTNDNFVEH IVTGSQSKNV TCQATSVVSE
     KGRGVAVEAE KINEVLIQNG SKNQNVYMKH HDIHPINQYL RKQSHEQTST ITKQKNIIER
     QMPCEAVSSY INRDSNVTIN CERIKLNTEE NKPSHFQALG DDISRTVIPS EVLPSAGAFS
     KSEGQHENFL NISRLQEKTG TYTTNKTKNN HVSDLGLVLC DFEDSFYLDT QSEKIIQQMA
     TENAKLGAKD TNLAAGIMQK SLVQQNSMNS FQKECHIPFP AEQHPLGATK IDHLDLKTVG
     TMKQSSDSHG VDILTPESPI FHSPILLEEN GLFLKKNEVS VTDSQLNSFL QGYQTQETVK
     PVILLIPQKR TPTGVEGECL PVPETSLNMS DSLLFDSFSD DYLVKEQLPD MQMKEPLPSE
     VTSNHFSDSL CLQEDLIKKS NVNENQDTHQ QLTCSNDESI IFSEMDSVQM VEALDNVDIF
     PVQEKNHTVV SPRALELSDP VLDEHHQGDQ DGGDQDERAE KSKLTGTRQN HSFIWSGASF
     DLSPGLQRIL DKVSSPLENE KLKSMTINFS SLNRKNTELN EEQEVISNLE TKQVQGISFS
     SNNEVKSKIE MLENNANHDE TSSLLPRKES NIVDDNGLIP PTPIPTSASK LTFPGILETP
     VNPWKTNNVL QPGESYLFGS PSDIKNHDLS PGSRNGFKDN SPISDTSFSL QLSQDGLQLT
     PASSSSESLS IIDVASDQNL FQTFIKEWRC KKRFSISLAC EKIRSLTSSK TATIGSRFKQ
     ASSPQEIPIR DDGFPIKGCD DTLVVGLAVC WGGRDAYYFS LQKEQKHSEI SASLVPPSLD
     PSLTLKDRMW YLQSCLRKES DKECSVVIYD FIQSYKILLL SCGISLEQSY EDPKVACWLL
     DPDSQEPTLH SIVTSFLPHE LPLLEGMETS QGIQSLGLNA GSEHSGRYRA SVESILIFNS
     MNQLNSLLQK ENLQDVFRKV EMPSQYCLAL LELNGIGFST AECESQKHIM QAKLDAIETQ
     AYQLAGHSFS FTSSDDIAEV LFLELKLPPN REMKNQGSKK TLGSTRRGID NGRKLRLGRQ
     FSTSKDVLNK LKALHPLPGL ILEWRRITNA ITKVVFPLQR EKCLNPFLGM ERIYPVSQSH
     TATGRITFTE PNIQNVPRDF EIKMPTLVGE SPPSQAVGKG LLPMGRGKYK KGFSVNPRCQ
     AQMEERAADR GMPFSISMRH AFVPFPGGSI LAADYSQLEL RILAHLSHDR RLIQVLNTGA
     DVFRSIAAEW KMIEPESVGD DLRQQAKQIC YGIIYGMGAK SLGEQMGIKE NDAACYIDSF
     KSRYTGINQF MTETVKNCKR DGFVQTILGR RRYLPGIKDN NPYRKAHAER QAINTIVQGS
     AADIVKIATV NIQKQLETFH STFKSHGHRE GMLQSDRTGL SRKRKLQGMF CPIRGGFFIL
     QLHDELLYEV AEEDVVQVAQ IVKNEMESAV KLSVKLKVKV KIGASWGELK DFDV
//
ID   PTK6_HUMAN              Reviewed;         451 AA.
AC   Q13882; B2RCR3; B4DW46; Q58F01;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   22-APR-2020, entry version 206.
DE   RecName: Full=Protein-tyrosine kinase 6;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680};
DE   AltName: Full=Breast tumor kinase;
DE   AltName: Full=Tyrosine-protein kinase BRK;
GN   Name=PTK6; Synonyms=BRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary tumor;
RX   PubMed=8036022;
RA   Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N.,
RA   Page M.J., Gusterson B.A., Crompton M.R.;
RT   "Cloning and characterisation of cDNAs encoding a novel non-receptor
RT   tyrosine kinase, brk, expressed in human breast tumours.";
RL   Oncogene 9:2383-2390(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=9333026; DOI=10.1038/sj.onc.1201292;
RA   Mitchell P.J., Barker K.T., Shipley J., Crompton M.R.;
RT   "Characterisation and chromosome mapping of the human non receptor tyrosine
RT   kinase gene, brk.";
RL   Oncogene 15:1497-1502(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Melanocyte;
RX   PubMed=9749526;
RA   Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T.;
RT   "Exon-intron structure of the human PTK6 gene demonstrates that PTK6
RT   constitutes a distinct family of non-receptor tyrosine kinase.";
RL   Mol. Cells 8:401-407(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Urinary bladder;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION, INTERACTION WITH EGFR, AND MUTAGENESIS OF LYS-219 AND
RP   TYR-447.
RX   PubMed=8940083; DOI=10.1074/jbc.271.48.30956;
RA   Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E.,
RA   Dean C.J., Page M.J., Gusterson B.A., Crompton M.R.;
RT   "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase,
RT   sensitizes mammary epithelial cells to epidermal growth factor.";
RL   J. Biol. Chem. 271:30956-30963(1996).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=9185712;
RX   DOI=10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f;
RA   Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A.,
RA   Bennett D.C.;
RT   "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK
RT   in metastatic melanoma.";
RL   Int. J. Cancer 71:1061-1065(1997).
RN   [9]
RP   FUNCTION, INTERACTION WITH STAP2, AND MUTAGENESIS OF TRP-44; TYR-66;
RP   ARG-105 AND LYS-219.
RX   PubMed=10980601; DOI=10.1038/sj.onc.1203775;
RA   Mitchell P.J., Sara E.A., Crompton M.R.;
RT   "A novel adaptor-like protein which is a substrate for the non-receptor
RT   tyrosine kinase, BRK.";
RL   Oncogene 19:4273-4282(2000).
RN   [10]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-447, AND INTERACTION WITH
RP   KHDRBS1.
RX   PubMed=10913193; DOI=10.1128/mcb.20.16.6114-6126.2000;
RA   Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V.,
RA   Cochrane A.W., Chen T., Tyner A.L.;
RT   "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its
RT   RNA binding ability.";
RL   Mol. Cell. Biol. 20:6114-6126(2000).
RN   [11]
RP   PHOSPHORYLATION AT TYR-13; TYR-61; TYR-66; TYR-114; TYR-342 AND TYR-351,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF TYR-342
RP   AND TYR-447, ACTIVITY REGULATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12121988; DOI=10.1074/jbc.m203877200;
RA   Qiu H., Miller W.T.;
RT   "Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation
RT   and by autoinhibition.";
RL   J. Biol. Chem. 277:34634-34641(2002).
RN   [12]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12833144; DOI=10.1038/sj.onc.1206465;
RA   Derry J.J., Prins G.S., Ray V., Tyner A.L.;
RT   "Altered localization and activity of the intracellular tyrosine kinase
RT   BRK/Sik in prostate tumor cells.";
RL   Oncogene 22:4212-4220(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447, AND
RP   PHOSPHORYLATION.
RX   PubMed=15471878; DOI=10.1074/jbc.m409579200;
RA   Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L.;
RT   "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-
RT   binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2.";
RL   J. Biol. Chem. 279:54398-54404(2004).
RN   [14]
RP   FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH PXN.
RX   PubMed=15572663; DOI=10.1128/mcb.24.24.10558-10572.2004;
RA   Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H.;
RT   "Brk activates rac1 and promotes cell migration and invasion by
RT   phosphorylating paxillin.";
RL   Mol. Cell. Biol. 24:10558-10572(2004).
RN   [15]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=15509496; DOI=10.1016/j.oraloncology.2004.05.010;
RA   Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K.;
RT   "Differential expression of the non-receptor tyrosine kinase BRK in oral
RT   squamous cell carcinoma and normal oral epithelium.";
RL   Oral Oncol. 40:1040-1047(2004).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF BTK, AND INTERACTION WITH BTK.
RX   PubMed=15539407; DOI=10.1074/jbc.m412038200;
RA   Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D.,
RA   Lange C.A.;
RT   "Regulated association of protein kinase B/Akt with breast tumor kinase.";
RL   J. Biol. Chem. 280:1982-1991(2005).
RN   [17]
RP   MUTAGENESIS OF TRP-184, AND ACTIVITY REGULATION.
RX   PubMed=15961400; DOI=10.1074/jbc.m504568200;
RA   Kim H.I.E., Lee S.T.;
RT   "An intramolecular interaction between SH2-kinase linker and kinase domain
RT   is essential for the catalytic activity of protein-tyrosine kinase-6.";
RL   J. Biol. Chem. 280:28973-28980(2005).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF KHDRBS1.
RX   PubMed=16179349; DOI=10.1074/jbc.m505802200;
RA   Lukong K.E., Larocque D., Tyner A.L., Richard S.;
RT   "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates
RT   intranuclear localization and cell cycle progression.";
RL   J. Biol. Chem. 280:38639-38647(2005).
RN   [19]
RP   INTERACTION WITH IRS4, AND ACTIVITY REGULATION.
RX   PubMed=15870689; DOI=10.1038/sj.onc.1208721;
RA   Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.;
RT   "Interaction between Brk kinase and insulin receptor substrate-4.";
RL   Oncogene 24:5656-5664(2005).
RN   [20]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=16651629; DOI=10.2353/ajpath.2006.050521;
RA   Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M., Zhang Q.,
RA   Marzec M., Gimotty P., Crompton M.R., Wasik M.A.;
RT   "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in
RT   lymphocytes.";
RL   Am. J. Pathol. 168:1631-1641(2006).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF STAT3, AND ACTIVITY REGULATION.
RX   PubMed=16568091; DOI=10.1038/sj.onc.1209501;
RA   Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.;
RT   "Identification of STAT3 as a specific substrate of breast tumor kinase.";
RL   Oncogene 25:4904-4912(2006).
RN   [22]
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF TRP-44.
RX   PubMed=17822667; DOI=10.1016/j.bbrc.2007.08.055;
RA   Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T.;
RT   "Molecular dissection of the interaction between the SH3 domain and the
RT   SH2-Kinase Linker region in PTK6.";
RL   Biochem. Biophys. Res. Commun. 362:829-834(2007).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF STAT5B.
RX   PubMed=17997837; DOI=10.1186/bcr1794;
RA   Weaver A.M., Silva C.M.;
RT   "Signal transducer and activator of transcription 5b: a new target of
RT   breast tumor kinase/protein tyrosine kinase 6.";
RL   Breast Cancer Res. 9:R79-R79(2007).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF ARHGAP35.
RX   PubMed=18829532; DOI=10.1158/0008-5472.can-08-0997;
RA   Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L.,
RA   Settleman J., Chen R.H.;
RT   "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and
RT   promote breast carcinoma growth, migration, and invasion.";
RL   Cancer Res. 68:7779-7787(2008).
RN   [25]
RP   INTERACTION WITH ADAM15.
RX   PubMed=18296648; DOI=10.1158/1541-7786.mcr-07-2028;
RA   Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M.,
RA   Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C.,
RA   Edwards D.R.;
RT   "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human
RT   mammary carcinoma.";
RL   Mol. Cancer Res. 6:383-394(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [27]
RP   INTERACTION WITH ERBB2.
RX   PubMed=18719096; DOI=10.1073/pnas.0805009105;
RA   Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M.,
RA   Miller W.T., Muthuswamy S.K.;
RT   "Brk is coamplified with ErbB2 to promote proliferation in breast cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008).
RN   [28]
RP   INTERACTION WITH SFPQ.
RX   PubMed=19439179; DOI=10.1016/j.cellsig.2009.04.008;
RA   Lukong K.E., Huot M.E., Richard S.;
RT   "BRK phosphorylates PSF promoting its cytoplasmic localization and cell
RT   cycle arrest.";
RL   Cell. Signal. 21:1415-1422(2009).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=20193745; DOI=10.1016/j.bbcan.2010.02.003;
RA   Brauer P.M., Tyner A.L.;
RT   "Building a better understanding of the intracellular tyrosine kinase PTK6
RT   - BRK by BRK.";
RL   Biochim. Biophys. Acta 1806:66-73(2010).
RN   [30]
RP   PHOSPHORYLATION OF CTNNB1, AND INTERACTION WITH CTNNB1.
RX   PubMed=20026641; DOI=10.1242/jcs.053264;
RA   Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M.,
RA   Tyner A.L.;
RT   "Identification of beta-catenin as a target of the intracellular tyrosine
RT   kinase PTK6.";
RL   J. Cell Sci. 123:236-245(2010).
RN   [31]
RP   FUNCTION (ISOFORM 2), AND INTERACTION (ISOFORM 2) WITH KHDRBS1 AND CTNNB1.
RX   PubMed=21479203; DOI=10.1371/journal.pone.0014789;
RA   Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M.,
RA   Tyner A.L.;
RT   "The alternative splice variant of protein tyrosine kinase 6 negatively
RT   regulates growth and enhances PTK6-mediated inhibition of beta-catenin.";
RL   PLoS ONE 6:E14789-E14789(2011).
RN   [32]
RP   STRUCTURE BY NMR OF 75-174.
RX   PubMed=15056653; DOI=10.1074/jbc.m313185200;
RA   Hong E., Shin J., Kim H.I., Lee S.T., Lee W.;
RT   "Solution structure and backbone dynamics of the non-receptor protein-
RT   tyrosine kinase-6 Src homology 2 domain.";
RL   J. Biol. Chem. 279:29700-29708(2004).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 185-446, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF LYS-219.
RX   PubMed=27480927; DOI=10.1016/j.bbrc.2016.07.121;
RA   Thakur M.K., Kumar A., Birudukota S., Swaminathan S., Tyagi R., Gosu R.;
RT   "Crystal structure of the kinase domain of human protein tyrosine kinase 6
RT   (PTK6) at 2.33 A resolution.";
RL   Biochem. Biophys. Res. Commun. 478:637-642(2016).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 185-446 IN COMPLEXES WITH
RP   INHIBITORS, AND CATALYTIC ACTIVITY.
RX   PubMed=27993680; DOI=10.1016/j.bbrc.2016.12.030;
RA   Thakur M.K., Birudukota S., Swaminathan S., Battula S.K., Vadivelu S.,
RA   Tyagi R., Gosu R.;
RT   "Co-crystal structures of PTK6: With Dasatinib at 2.24 A, with novel
RT   imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 A resolution.";
RL   Biochem. Biophys. Res. Commun. 482:1289-1295(2017).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase implicated in the
CC       regulation of a variety of signaling pathways that control the
CC       differentiation and maintenance of normal epithelia, as well as tumor
CC       growth. Function seems to be context dependent and differ depending on
CC       cell type, as well as its intracellular localization. A number of
CC       potential nuclear and cytoplasmic substrates have been identified.
CC       These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1,
CC       KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B
CC       and a variety of signaling molecules: ARHGAP35/p190RhoGAP,
CC       PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of
CC       proteins that are likely upstream of PTK6 in various signaling
CC       pathways, or for which PTK6 may play an adapter-like role. These
CC       proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-
CC       tumorigenic tissues, PTK6 promotes cellular differentiation and
CC       apoptosis. In tumors PTK6 contributes to cancer progression by
CC       sensitizing cells to mitogenic signals and enhancing proliferation,
CC       anchorage-independent survival and migration/invasion. Association with
CC       EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and
CC       growth through enhancement of EGF-induced signaling via BTK/AKT and PI3
CC       kinase. Contributes to migration and proliferation by contributing to
CC       EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes
CC       association with RASA1/p120RasGAP, inactivating RhoA while activating
CC       RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by
CC       PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration
CC       and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation.
CC       Nuclear PTK6 may be important for regulating growth in normal
CC       epithelia, while cytoplasmic PTK6 might activate oncogenic signaling
CC       pathways.
CC   -!- FUNCTION: Isoform 2 inhibits PTK6 phosphorylation and PTK6 association
CC       with other tyrosine-phosphorylated proteins.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927,
CC         ECO:0000269|PubMed:27993680};
CC   -!- ACTIVITY REGULATION: Activated by EGF, NRG1 and IGF1. Inhibited by
CC       SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by an
CC       association between the SH3 domain and the SH2-TK linker region.
CC       Interaction between Trp-184 within SH2-TK linker region and the
CC       catalytic domain appears essential for positive regulation of kinase
CC       activity. {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:15870689,
CC       ECO:0000269|PubMed:15961400, ECO:0000269|PubMed:16568091,
CC       ECO:0000269|PubMed:17822667}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=83 uM for ATP {ECO:0000269|PubMed:12121988};
CC         Vmax=37 nmol/min/mg enzyme {ECO:0000269|PubMed:12121988};
CC   -!- SUBUNIT: Interacts with GAP-A.p65 (By similarity). Interacts (via SH3
CC       and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2 domains) with
CC       phosphorylated IRS4. Interacts with ADAM15. Interacts (via SH3 domain)
CC       with SFPQ. Interacts with EGFR and ERBB2. Interacts with STAP2.
CC       Interacts with PNX. Interacts with SFPQ. Interacts with PTK/ATK.
CC       Interacts with CTNNB1. {ECO:0000250, ECO:0000269|PubMed:10913193,
CC       ECO:0000269|PubMed:10980601, ECO:0000269|PubMed:15539407,
CC       ECO:0000269|PubMed:15572663, ECO:0000269|PubMed:15870689,
CC       ECO:0000269|PubMed:18296648, ECO:0000269|PubMed:18719096,
CC       ECO:0000269|PubMed:19439179, ECO:0000269|PubMed:20026641,
CC       ECO:0000269|PubMed:8940083}.
CC   -!- INTERACTION:
CC       Q13882; Q13882; NbExp=3; IntAct=EBI-1383632, EBI-1383632;
CC       Q13882; Q08043: ACTN3; NbExp=3; IntAct=EBI-1383632, EBI-2880652;
CC       Q13882; Q3KP44: ANKRD55; NbExp=3; IntAct=EBI-1383632, EBI-14493093;
CC       Q13882; Q13191: CBLB; NbExp=3; IntAct=EBI-1383632, EBI-744027;
CC       Q13882; Q16543: CDC37; NbExp=4; IntAct=EBI-1383632, EBI-295634;
CC       Q13882; Q92841: DDX17; NbExp=4; IntAct=EBI-1383632, EBI-746012;
CC       Q13882; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-1383632, EBI-2340258;
CC       Q13882; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-1383632, EBI-2349927;
CC       Q13882; P04626: ERBB2; NbExp=4; IntAct=EBI-1383632, EBI-641062;
CC       Q13882; O00471: EXOC5; NbExp=6; IntAct=EBI-1383632, EBI-949824;
CC       Q13882; O14526: FCHO1; NbExp=4; IntAct=EBI-1383632, EBI-719823;
CC       Q13882; Q13480: GAB1; NbExp=6; IntAct=EBI-1383632, EBI-517684;
CC       Q13882; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1383632, EBI-352572;
CC       Q13882; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383632, EBI-747204;
CC       Q13882; Q5VWX1: KHDRBS2; NbExp=4; IntAct=EBI-1383632, EBI-742808;
CC       Q13882; Q5T5P2-6: KIAA1217; NbExp=3; IntAct=EBI-1383632, EBI-10188326;
CC       Q13882; P10721: KIT; NbExp=4; IntAct=EBI-1383632, EBI-1379503;
CC       Q13882; O14770-4: MEIS2; NbExp=3; IntAct=EBI-1383632, EBI-8025850;
CC       Q13882; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383632, EBI-2340269;
CC       Q13882; Q8TDC0: MYOZ3; NbExp=3; IntAct=EBI-1383632, EBI-5662487;
CC       Q13882; P78337: PITX1; NbExp=3; IntAct=EBI-1383632, EBI-748265;
CC       Q13882; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383632, EBI-11320284;
CC       Q13882; Q04864: REL; NbExp=3; IntAct=EBI-1383632, EBI-307352;
CC       Q13882; P23246: SFPQ; NbExp=5; IntAct=EBI-1383632, EBI-355453;
CC       Q13882; Q13239-3: SLA; NbExp=3; IntAct=EBI-1383632, EBI-17630587;
CC       Q13882; O00401: WASL; NbExp=3; IntAct=EBI-1383632, EBI-957615;
CC       Q13882; Q9BYN7: ZNF341; NbExp=3; IntAct=EBI-1383632, EBI-9089622;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle.
CC       Membrane {ECO:0000250}. Note=Colocalizes with KHDRBS1, KHDRBS2 or
CC       KHDRBS3, within the nucleus. Nuclear localization in epithelial cells
CC       of normal prostate but cytoplasmic localization in cancer prostate.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13882-1; Sequence=Displayed;
CC       Name=2; Synonyms=ALT-PTK6, LambdaM5;
CC         IsoId=Q13882-2; Sequence=VSP_042066, VSP_042067;
CC   -!- TISSUE SPECIFICITY: Epithelia-specific. Very high level in colon and
CC       high levels in small intestine and prostate, and low levels in some
CC       fetal tissues. Not expressed in breast or ovarian tissue but expressed
CC       in high percentage of breast and ovarian cancers. Also overexpressed in
CC       some metastatic melanomas, lymphomas, colon cancers, squamous cell
CC       carcinomas and prostate cancers. Also found in melanocytes. Not
CC       expressed in heart, brain, placenta, lung, liver, skeletal muscle,
CC       kidney and pancreas. Isoform 2 is present in prostate epithelial cell
CC       lines derived from normal prostate and prostate adenocarcinomas, as
CC       well as in a variety of cell lines. {ECO:0000269|PubMed:12833144,
CC       ECO:0000269|PubMed:15509496, ECO:0000269|PubMed:16651629,
CC       ECO:0000269|PubMed:9185712}.
CC   -!- DOMAIN: The SH3 domain plays a major role in substrate interactions.
CC       The SH2 domain of PTK6 plays a role in protein-protein interactions,
CC       but is likely more important for the regulation of catalytic activity.
CC   -!- PTM: Autophosphorylated. Autophosphorylation of Tyr-342 leads to an
CC       increase of kinase activity. Tyr-447 binds to the SH2 domain when
CC       phosphorylated and negatively regulates kinase activity.
CC       {ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:12121988,
CC       ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20026641}.
CC   -!- MISCELLANEOUS: The inhibitors bind to the ATP-binding pocket.
CC       {ECO:0000269|PubMed:27993680}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. BRK/PTK6/SIK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG62908.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X78549; CAA55295.1; -; mRNA.
DR   EMBL; U61412; AAC34935.1; -; Genomic_DNA.
DR   EMBL; U61406; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61407; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61408; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61409; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61410; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61411; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; AK315232; BAG37660.1; -; mRNA.
DR   EMBL; AK301364; BAG62908.1; ALT_SEQ; mRNA.
DR   EMBL; AL121829; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035843; AAH35843.1; -; mRNA.
DR   CCDS; CCDS13524.1; -. [Q13882-1]
DR   CCDS; CCDS74750.1; -. [Q13882-2]
DR   PIR; S49016; S49016.
DR   RefSeq; NP_001243287.1; NM_001256358.1. [Q13882-2]
DR   RefSeq; NP_005966.1; NM_005975.3. [Q13882-1]
DR   PDB; 1RJA; NMR; -; A=75-174.
DR   PDB; 2KGT; NMR; -; A=1-72.
DR   PDB; 5D7V; X-ray; 2.33 A; A/B/C/D=185-446.
DR   PDB; 5DA3; X-ray; 1.70 A; A=185-446.
DR   PDB; 5H2U; X-ray; 2.24 A; A/B/C/D=185-446.
DR   PDB; 6CZ2; X-ray; 2.50 A; A=182-443.
DR   PDB; 6CZ3; X-ray; 1.80 A; A=182-443.
DR   PDB; 6CZ4; X-ray; 1.50 A; A=182-443.
DR   PDBsum; 1RJA; -.
DR   PDBsum; 2KGT; -.
DR   PDBsum; 5D7V; -.
DR   PDBsum; 5DA3; -.
DR   PDBsum; 5H2U; -.
DR   PDBsum; 6CZ2; -.
DR   PDBsum; 6CZ3; -.
DR   PDBsum; 6CZ4; -.
DR   SMR; Q13882; -.
DR   BioGrid; 111720; 37.
DR   DIP; DIP-39785N; -.
DR   IntAct; Q13882; 73.
DR   MINT; Q13882; -.
DR   STRING; 9606.ENSP00000442460; -.
DR   BindingDB; Q13882; -.
DR   ChEMBL; CHEMBL4601; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB05294; Vandetanib.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugCentral; Q13882; -.
DR   GuidetoPHARMACOLOGY; 2182; -.
DR   iPTMnet; Q13882; -.
DR   PhosphoSitePlus; Q13882; -.
DR   BioMuta; PTK6; -.
DR   DMDM; 8928302; -.
DR   EPD; Q13882; -.
DR   jPOST; Q13882; -.
DR   MassIVE; Q13882; -.
DR   MaxQB; Q13882; -.
DR   PaxDb; Q13882; -.
DR   PeptideAtlas; Q13882; -.
DR   PRIDE; Q13882; -.
DR   ProteomicsDB; 59709; -. [Q13882-1]
DR   ProteomicsDB; 59710; -. [Q13882-2]
DR   Antibodypedia; 29774; 497 antibodies.
DR   DNASU; 5753; -.
DR   Ensembl; ENST00000217185; ENSP00000217185; ENSG00000101213. [Q13882-2]
DR   Ensembl; ENST00000542869; ENSP00000442460; ENSG00000101213. [Q13882-1]
DR   GeneID; 5753; -.
DR   KEGG; hsa:5753; -.
DR   UCSC; uc002yfg.5; human. [Q13882-1]
DR   CTD; 5753; -.
DR   DisGeNET; 5753; -.
DR   GeneCards; PTK6; -.
DR   HGNC; HGNC:9617; PTK6.
DR   HPA; ENSG00000101213; Tissue enhanced (esophagus, intestine, skin).
DR   MIM; 602004; gene.
DR   neXtProt; NX_Q13882; -.
DR   OpenTargets; ENSG00000101213; -.
DR   PharmGKB; PA33960; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00940000161218; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; Q13882; -.
DR   KO; K08894; -.
DR   OMA; EDIYLSH; -.
DR   OrthoDB; 539311at2759; -.
DR   PhylomeDB; Q13882; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling.
DR   Reactome; R-HSA-8849468; PTK6 Regulates Proteins Involved in RNA Processing.
DR   Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
DR   Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle.
DR   Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases.
DR   Reactome; R-HSA-8849472; PTK6 Down-Regulation.
DR   Reactome; R-HSA-8849473; PTK6 Expression.
DR   Reactome; R-HSA-8849474; PTK6 Activates STAT3.
DR   Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization.
DR   SignaLink; Q13882; -.
DR   SIGNOR; Q13882; -.
DR   EvolutionaryTrace; Q13882; -.
DR   GeneWiki; PTK6; -.
DR   GenomeRNAi; 5753; -.
DR   Pharos; Q13882; Tchem.
DR   PRO; PR:Q13882; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q13882; protein.
DR   Bgee; ENSG00000101213; Expressed in lower esophagus mucosa and 128 other tissues.
DR   Genevisible; Q13882; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0060575; P:intestinal epithelial cell differentiation; IBA:GO_Central.
DR   GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl.
DR   GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0009968; P:negative regulation of signal transduction; TAS:Reactome.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; TAS:Reactome.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:UniProtKB.
DR   CDD; cd10358; SH2_PTK6_Brk; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR035846; PTK6_SH2.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection;
KW   Cytoplasm; Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN           1..451
FT                   /note="Protein-tyrosine kinase 6"
FT                   /id="PRO_0000088133"
FT   DOMAIN          8..72
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          78..170
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          191..445
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         197..205
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          171..190
FT                   /note="Linker"
FT   ACT_SITE        312
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         219
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000305|PubMed:27480927, ECO:0000305|PubMed:27993680"
FT   MOD_RES         13
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         61
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         66
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         114
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000244|PubMed:18691976,
FT                   ECO:0000269|PubMed:12121988"
FT   MOD_RES         342
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         351
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MOD_RES         447
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10913193"
FT   VAR_SEQ         78..134
FT                   /note="WFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKI
FT                   WRRAG -> AGHAGCAALQDLAACRGPAAPERGGVLPQPARACELPQGPEPVPRPAAGR
FT                   ALPEARA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:9333026"
FT                   /id="VSP_042066"
FT   VAR_SEQ         135..451
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:9333026"
FT                   /id="VSP_042067"
FT   VARIANT         16
FT                   /note="L -> F (in a renal papillary sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041760"
FT   VARIANT         436
FT                   /note="A -> T (in dbSNP:rs56145017)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041761"
FT   MUTAGEN         44
FT                   /note="W->A: Strong decrease in STAP2 phosphorylation.
FT                   Markedly decreased interaction between SH3 domain the
FT                   linker region."
FT                   /evidence="ECO:0000269|PubMed:10980601,
FT                   ECO:0000269|PubMed:17822667"
FT   MUTAGEN         66
FT                   /note="Y->A: Decrease in STAP2 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:10980601"
FT   MUTAGEN         105
FT                   /note="R->L: Decrease in STAP2 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:10980601"
FT   MUTAGEN         184
FT                   /note="W->A: Abrogates interaction between PTK6-domain
FT                   kinase and PTK6-linker. Abrogates autophosphorylation and
FT                   phosphorylation of KHDRBS1."
FT                   /evidence="ECO:0000269|PubMed:15961400"
FT   MUTAGEN         219
FT                   /note="K->M: Abolishes kinase activity and cell
FT                   transformation, and phosphorylation of STAP2."
FT                   /evidence="ECO:0000269|PubMed:10980601,
FT                   ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083"
FT   MUTAGEN         219
FT                   /note="K->R: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:27480927"
FT   MUTAGEN         342
FT                   /note="Y->A: 3-fold lower specific kinase activity.
FT                   Decreased, but still significant, autophosphorylation.
FT                   Decreased, but still significant, autophosphorylation; when
FT                   associated with A-447."
FT                   /evidence="ECO:0000269|PubMed:12121988"
FT   MUTAGEN         447
FT                   /note="Y->F: Decrease in transforming potential and
FT                   increase in the kinase activity level. Decreased, but still
FT                   significant, autophosphorylation; when associated with A-
FT                   342."
FT                   /evidence="ECO:0000269|PubMed:12121988,
FT                   ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083"
FT   STRAND          12..14
FT                   /evidence="ECO:0000244|PDB:2KGT"
FT   STRAND          35..40
FT                   /evidence="ECO:0000244|PDB:2KGT"
FT   STRAND          45..50
FT                   /evidence="ECO:0000244|PDB:2KGT"
FT   STRAND          56..62
FT                   /evidence="ECO:0000244|PDB:2KGT"
FT   TURN            64..66
FT                   /evidence="ECO:0000244|PDB:2KGT"
FT   STRAND          67..70
FT                   /evidence="ECO:0000244|PDB:2KGT"
FT   HELIX           85..92
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   STRAND          102..106
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   STRAND          108..112
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   STRAND          114..118
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   STRAND          125..131
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   STRAND          133..135
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   STRAND          137..140
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   STRAND          143..147
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   HELIX           148..157
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   STRAND          162..164
FT                   /evidence="ECO:0000244|PDB:1RJA"
FT   HELIX           188..190
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   STRAND          191..200
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   STRAND          203..210
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   TURN            211..213
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   STRAND          214..221
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           223..225
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           229..240
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   STRAND          250..254
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   STRAND          256..264
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   STRAND          268..271
FT                   /evidence="ECO:0000244|PDB:6CZ2"
FT   HELIX           272..278
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   TURN            281..283
FT                   /evidence="ECO:0000244|PDB:5DA3"
FT   HELIX           286..305
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           315..317
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   STRAND          318..320
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           322..324
FT                   /evidence="ECO:0000244|PDB:5DA3"
FT   STRAND          326..328
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   TURN            334..336
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           339..342
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           345..348
FT                   /evidence="ECO:0000244|PDB:5DA3"
FT   HELIX           351..353
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           356..361
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           366..380
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   TURN            381..384
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           393..402
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           414..423
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           428..430
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           434..441
FT                   /evidence="ECO:0000244|PDB:6CZ4"
FT   HELIX           442..444
FT                   /evidence="ECO:0000244|PDB:5D7V"
SQ   SEQUENCE   451 AA;  51834 MW;  CDCAC0EE242E1BD7 CRC64;
     MVSRDQAHLG PKYVGLWDFK SRTDEELSFR AGDVFHVARK EEQWWWATLL DEAGGAVAQG
     YVPHNYLAER ETVESEPWFF GCISRSEAVR RLQAEGNATG AFLIRVSEKP SADYVLSVRD
     TQAVRHYKIW RRAGGRLHLN EAVSFLSLPE LVNYHRAQSL SHGLRLAAPC RKHEPEPLPH
     WDDWERPREE FTLCRKLGSG YFGEVFEGLW KDRVQVAIKV ISRDNLLHQQ MLQSEIQAMK
     KLRHKHILAL YAVVSVGDPV YIITELMAKG SLLELLRDSD EKVLPVSELL DIAWQVAEGM
     CYLESQNYIH RDLAARNILV GENTLCKVGD FGLARLIKED VYLSHDHNIP YKWTAPEALS
     RGHYSTKSDV WSFGILLHEM FSRGQVPYPG MSNHEAFLRV DAGYRMPCPL ECPPSVHKLM
     LTCWCRDPEQ RPCFKALRER LSSFTSYENP T
//
ID   Q8WY44_HUMAN            Unreviewed;       193 AA.
AC   Q8WY44;
DT   01-MAR-2002, integrated into UniProtKB/TrEMBL.
DT   01-MAR-2002, sequence version 1.
DT   11-DEC-2019, entry version 72.
DE   SubName: Full=Quaking protein 3 {ECO:0000313|EMBL:AAL36980.1};
DE   Flags: Fragment;
GN   Name=QK3 {ECO:0000313|EMBL:AAL36980.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAL36980.1};
RN   [1] {ECO:0000313|EMBL:AAL36980.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=12511597; DOI=10.1073/pnas.0234478100;
RA   Moore F.L., Jaruzelska J., Fox M.S., Urano J., Firpo M.T., Turek P.J.,
RA   Dorfman D.M., Reijo Pera R.A.;
RT   "Human Pumilio-2 is expressed in embryonic stem cells and germ cells and
RT   interacts with DAZ (Deleted in AZoospermia) and DAZ-like proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:538-543(2003).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF272349; AAL36980.1; -; mRNA.
DR   RefSeq; NP_006766.1; NM_006775.2.
DR   RefSeq; NP_996735.1; NM_206853.2.
DR   RefSeq; NP_996736.1; NM_206854.2.
DR   RefSeq; NP_996737.1; NM_206855.2.
DR   SMR; Q8WY44; -.
DR   IntAct; Q8WY44; 1.
DR   PeptideAtlas; Q8WY44; -.
DR   PRIDE; Q8WY44; -.
DR   DNASU; 9444; -.
DR   GeneID; 9444; -.
DR   KEGG; hsa:9444; -.
DR   CTD; 9444; -.
DR   PharmGKB; PA134912180; -.
DR   KO; K14945; -.
DR   OrthoDB; 1565749at2759; -.
DR   ChiTaRS; QKI; human.
DR   GenomeRNAi; 9444; -.
DR   Genevisible; Q8WY44; HS.
PE   2: Evidence at transcript level;
FT   REGION          1..193
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        48..77
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        93..109
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        151..175
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:AAL36980.1"
SQ   SEQUENCE   193 AA;  20673 MW;  631052977044AF13 CRC64;
     TSPERPPEPA AQAAAALSGL DQPSERRPRL LLVRRQQPAP RARTRPAETR LPPARRPREG
     RAEPGGRERR RLGARRARAE SACGGRASAR CRPPRGSARE PEREPARSGT PGPERPAAGA
     RPRPSLLSGG GGGGGGRSEL RSLEYGRGNG NEGEAEAHPR LPDAADERQE AHEQPAQLLR
     DLQPPRAAAG RRN
//
ID   QKI_HUMAN               Reviewed;         341 AA.
AC   Q96PU8; Q2I375; Q5MJQ1; Q969L9; Q96EJ3; Q96KA3; Q96PU6; Q96PU7; Q9P0X6;
AC   Q9P0X7; Q9P0X8; Q9P0X9; Q9P0Y0; Q9P0Y1;
DT   13-JUN-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   22-APR-2020, entry version 163.
DE   RecName: Full=Protein quaking;
DE            Short=Hqk;
DE            Short=HqkI;
GN   Name=QKI; Synonyms=HKQ;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 4 AND 5).
RC   TISSUE=Brain;
RX   PubMed=11856480; DOI=10.1111/j.1349-7006.2002.tb01255.x;
RA   Li Z.Z., Kondo T., Murata T., Ebersole T.A., Nishi T., Tada K., Ushio Y.,
RA   Yamamura K., Abe K.;
RT   "Expression of Hqk encoding a KH RNA binding protein is altered in human
RT   glioma.";
RL   Jpn. J. Cancer Res. 93:167-177(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 4), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 5-341 (ISOFORM 6).
RA   Xia J.-H., Xiao J.-F., He Y.-G., Yu K.-P., Pan Q., Dai H.-P.;
RT   "Molecular cloning of human QUAKING gene.";
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 5-341 (ISOFORM 3).
RA   Li H., Nong W., Zhou G., Ke R., Shen C., Zhong G., Liang M., Tang Z.,
RA   Huang B., Lin L., Yang S.;
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 15-341 (ISOFORM 1).
RC   TISSUE=Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   METHYLATION.
RX   PubMed=12529443; DOI=10.1091/mbc.e02-08-0484;
RA   Cote J., Boisvert F.-M., Boulanger M.-C., Bedford M.T., Richard S.;
RT   "Sam68 RNA binding protein is an in vivo substrate for protein arginine N-
RT   methyltransferase 1.";
RL   Mol. Biol. Cell 14:274-287(2003).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=16342280; DOI=10.1002/ajmg.b.30243;
RA   Aeberg K., Saetre P., Lindholm E., Ekholm B., Pettersson U., Adolfsson R.,
RA   Jazin E.;
RT   "Human QKI, a new candidate gene for schizophrenia involved in
RT   myelination.";
RL   Am. J. Med. Genet. B Neuropsychiatr. Genet. 141:84-90(2006).
RN   [9]
RP   FUNCTION AS REGULATOR OF OLIGODENDROCYTE DIFFERENTIATION.
RX   PubMed=16641098; DOI=10.1073/pnas.0601213103;
RA   Aberg K., Saetre P., Jareborg N., Jazin E.;
RT   "Human QKI, a potential regulator of mRNA expression of human
RT   oligodendrocyte-related genes involved in schizophrenia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7482-7487(2006).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   METHYLATION AT ARG-242 BY CARM1.
RX   PubMed=23455924; DOI=10.1038/nmeth.2397;
RA   Weimann M., Grossmann A., Woodsmith J., Ozkan Z., Birth P., Meierhofer D.,
RA   Benlasfer N., Valovka T., Timmermann B., Wanker E.E., Sauer S., Stelzl U.;
RT   "A Y2H-seq approach defines the human protein methyltransferase
RT   interactome.";
RL   Nat. Methods 10:339-342(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-227 AND ARG-242, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-336.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (3.50 ANGSTROMS) OF 7-204 IN COMPLEX WITH RNA,
RP   RNA-BINDING, FUNCTION, SUBUNIT, DOMAIN, AND MUTAGENESIS OF ASN-97; LYS-120;
RP   ARG-124; ARG-130; LYS-190 AND GLN-193.
RX   PubMed=23630077; DOI=10.1101/gad.216531.113;
RA   Teplova M., Hafner M., Teplov D., Essig K., Tuschl T., Patel D.J.;
RT   "Structure-function studies of STAR family Quaking proteins bound to their
RT   in vivo RNA target sites.";
RL   Genes Dev. 27:928-940(2013).
CC   -!- FUNCTION: RNA-binding protein that plays a central role in
CC       myelinization (PubMed:16641098). Binds to the 5'-NACUAAY-N(1,20)-UAAY-
CC       3' RNA core sequence. Regulates target mRNA stability
CC       (PubMed:23630077). In addition, acts by regulating pre-mRNA splicing,
CC       mRNA export and protein translation. Required to protect and promote
CC       stability of mRNAs such as MBP and CDKN1B. Regulator of oligodendrocyte
CC       differentiation and maturation in the brain that may play a role in
CC       myelin and oligodendrocyte dysfunction in schizophrenia
CC       (PubMed:16641098). Participates in mRNA transport by regulating the
CC       nuclear export of MBP mRNA. Also involved in regulation of mRNA
CC       splicing of MAG pre-mRNA. Acts as a translational repressor (By
CC       similarity). {ECO:0000250|UniProtKB:Q9QYS9,
CC       ECO:0000269|PubMed:16641098, ECO:0000269|PubMed:23630077}.
CC   -!- SUBUNIT: Homodimer (PubMed:23630077). Does not require RNA to
CC       homodimerize. Able to heterodimerize with BICC1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q9QYS9, ECO:0000269|PubMed:23630077}.
CC   -!- INTERACTION:
CC       Q96PU8; Q86X55: CARM1; NbExp=2; IntAct=EBI-945792, EBI-2339854;
CC       Q96PU8; Q96I24: FUBP3; NbExp=4; IntAct=EBI-945792, EBI-954200;
CC       Q96PU8; P61978: HNRNPK; NbExp=7; IntAct=EBI-945792, EBI-304185;
CC       Q96PU8; P61978-2: HNRNPK; NbExp=3; IntAct=EBI-945792, EBI-7060731;
CC       Q96PU8; Q8WVV9: HNRNPLL; NbExp=3; IntAct=EBI-945792, EBI-535849;
CC       Q96PU8; Q96AH0: NABP1; NbExp=3; IntAct=EBI-945792, EBI-2889252;
CC       Q96PU8; Q15365: PCBP1; NbExp=2; IntAct=EBI-945792, EBI-946095;
CC       Q96PU8; O43741: PRKAB2; NbExp=3; IntAct=EBI-945792, EBI-1053424;
CC       Q96PU8; P26599: PTBP1; NbExp=3; IntAct=EBI-945792, EBI-350540;
CC       Q96PU8; Q9NWB1: RBFOX1; NbExp=2; IntAct=EBI-945792, EBI-945906;
CC       Q96PU8; O43251: RBFOX2; NbExp=3; IntAct=EBI-945792, EBI-746056;
CC       Q96PU8; P57052: RBM11; NbExp=3; IntAct=EBI-945792, EBI-741332;
CC       Q96PU8; Q93062: RBPMS; NbExp=5; IntAct=EBI-945792, EBI-740322;
CC       Q96PU8; P09012: SNRPA; NbExp=3; IntAct=EBI-945792, EBI-607085;
CC       Q96PU8; Q01085-2: TIAL1; NbExp=3; IntAct=EBI-945792, EBI-11064654;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=HQK-5, QKI-5;
CC         IsoId=Q96PU8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96PU8-3; Sequence=VSP_019188;
CC       Name=3;
CC         IsoId=Q96PU8-5; Sequence=VSP_019188, VSP_019190;
CC       Name=4; Synonyms=HQK-7;
CC         IsoId=Q96PU8-6; Sequence=VSP_019190;
CC       Name=5; Synonyms=HQK-7B;
CC         IsoId=Q96PU8-8; Sequence=VSP_019191;
CC       Name=6;
CC         IsoId=Q96PU8-9; Sequence=VSP_019189;
CC   -!- TISSUE SPECIFICITY: Expressed in the frontal cortex of brain. Down-
CC       regulated in the brain of schizophrenic patients.
CC       {ECO:0000269|PubMed:16342280}.
CC   -!- DOMAIN: The KH domain and the Qua2 region are involved in RNA binding.
CC       {ECO:0000269|PubMed:23630077}.
CC   -!- PTM: Methylated by PRMT1. {ECO:0000250}.
CC   -!- PTM: Tyrosine phosphorylated at its C-terminus, probably by FYN.
CC       Phosphorylation leads to decreased mRNA-binding affinity, affecting
CC       transport and/or stabilization of MBP mRNA (By similarity).
CC       {ECO:0000250}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF63412.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC       Sequence=AAF63413.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAF63413.1; Type=Miscellaneous discrepancy; Note=Cloning artifact in N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAF63414.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAF63414.1; Type=Miscellaneous discrepancy; Note=Cloning artifact in N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAF63415.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC       Sequence=AAF63416.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC       Sequence=AAF63417.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAF63417.1; Type=Miscellaneous discrepancy; Note=Cloning artifact in N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB55032.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB067798; BAB69496.1; -; mRNA.
DR   EMBL; AB067799; BAB69497.1; -; mRNA.
DR   EMBL; AB067800; BAB69498.1; -; mRNA.
DR   EMBL; AB067801; BAB69499.1; -; mRNA.
DR   EMBL; AB067808; BAB69681.1; -; Genomic_DNA.
DR   EMBL; AF142417; AAF63412.1; ALT_SEQ; mRNA.
DR   EMBL; AF142418; AAF63413.1; ALT_SEQ; mRNA.
DR   EMBL; AF142419; AAF63414.1; ALT_SEQ; mRNA.
DR   EMBL; AF142420; AAF63415.1; ALT_SEQ; mRNA.
DR   EMBL; AF142421; AAF63416.1; ALT_SEQ; mRNA.
DR   EMBL; AF142422; AAF63417.1; ALT_SEQ; mRNA.
DR   EMBL; AY780788; AAV98358.1; -; mRNA.
DR   EMBL; DQ323998; ABC88600.1; -; mRNA.
DR   EMBL; AL356119; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL031781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012222; AAH12222.1; -; mRNA.
DR   EMBL; BC019917; AAH19917.1; -; mRNA.
DR   EMBL; AK027309; BAB55032.1; ALT_INIT; mRNA.
DR   CCDS; CCDS43525.1; -. [Q96PU8-8]
DR   CCDS; CCDS5285.1; -. [Q96PU8-1]
DR   CCDS; CCDS5286.1; -. [Q96PU8-9]
DR   CCDS; CCDS5287.1; -. [Q96PU8-6]
DR   CCDS; CCDS75546.1; -. [Q96PU8-3]
DR   RefSeq; NP_001288014.1; NM_001301085.1. [Q96PU8-3]
DR   RefSeq; NP_006766.1; NM_006775.2. [Q96PU8-1]
DR   RefSeq; NP_996735.1; NM_206853.2. [Q96PU8-9]
DR   RefSeq; NP_996736.1; NM_206854.2. [Q96PU8-6]
DR   RefSeq; NP_996737.1; NM_206855.2. [Q96PU8-8]
DR   RefSeq; XP_011534561.1; XM_011536259.2. [Q96PU8-5]
DR   PDB; 4JVH; X-ray; 3.50 A; A=7-214.
DR   PDBsum; 4JVH; -.
DR   SMR; Q96PU8; -.
DR   BioGrid; 114834; 94.
DR   IntAct; Q96PU8; 51.
DR   MINT; Q96PU8; -.
DR   STRING; 9606.ENSP00000355094; -.
DR   iPTMnet; Q96PU8; -.
DR   PhosphoSitePlus; Q96PU8; -.
DR   SwissPalm; Q96PU8; -.
DR   BioMuta; QKI; -.
DR   DMDM; 74761039; -.
DR   EPD; Q96PU8; -.
DR   jPOST; Q96PU8; -.
DR   MassIVE; Q96PU8; -.
DR   MaxQB; Q96PU8; -.
DR   PaxDb; Q96PU8; -.
DR   PeptideAtlas; Q96PU8; -.
DR   PRIDE; Q96PU8; -.
DR   ProteomicsDB; 77761; -. [Q96PU8-1]
DR   ProteomicsDB; 77762; -. [Q96PU8-3]
DR   ProteomicsDB; 77763; -. [Q96PU8-5]
DR   ProteomicsDB; 77764; -. [Q96PU8-6]
DR   ProteomicsDB; 77765; -. [Q96PU8-8]
DR   ProteomicsDB; 77766; -. [Q96PU8-9]
DR   ABCD; Q96PU8; -.
DR   Antibodypedia; 20048; 389 antibodies.
DR   DNASU; 9444; -.
DR   Ensembl; ENST00000275262; ENSP00000275262; ENSG00000112531. [Q96PU8-6]
DR   Ensembl; ENST00000361195; ENSP00000354867; ENSG00000112531. [Q96PU8-3]
DR   Ensembl; ENST00000361752; ENSP00000355094; ENSG00000112531. [Q96PU8-1]
DR   Ensembl; ENST00000361758; ENSP00000354951; ENSG00000112531. [Q96PU8-9]
DR   Ensembl; ENST00000392127; ENSP00000375973; ENSG00000112531. [Q96PU8-8]
DR   Ensembl; ENST00000424802; ENSP00000408382; ENSG00000112531. [Q96PU8-5]
DR   Ensembl; ENST00000453779; ENSP00000408775; ENSG00000112531. [Q96PU8-9]
DR   GeneID; 9444; -.
DR   KEGG; hsa:9444; -.
DR   UCSC; uc003que.4; human. [Q96PU8-1]
DR   CTD; 9444; -.
DR   DisGeNET; 9444; -.
DR   GeneCards; QKI; -.
DR   HGNC; HGNC:21100; QKI.
DR   HPA; ENSG00000112531; Tissue enhanced (brain).
DR   MalaCards; QKI; -.
DR   MIM; 609590; gene.
DR   neXtProt; NX_Q96PU8; -.
DR   OpenTargets; ENSG00000112531; -.
DR   Orphanet; 251671; Angiocentric glioma.
DR   PharmGKB; PA134912180; -.
DR   eggNOG; KOG1588; Eukaryota.
DR   eggNOG; COG5176; LUCA.
DR   GeneTree; ENSGT00940000155310; -.
DR   HOGENOM; CLU_046595_2_0_1; -.
DR   InParanoid; Q96PU8; -.
DR   KO; K14945; -.
DR   OMA; XAEGEDS; -.
DR   PhylomeDB; Q96PU8; -.
DR   TreeFam; TF314878; -.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   ChiTaRS; QKI; human.
DR   GeneWiki; QKI; -.
DR   GenomeRNAi; 9444; -.
DR   Pharos; Q96PU8; Tbio.
DR   PRO; PR:Q96PU8; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q96PU8; protein.
DR   Bgee; ENSG00000112531; Expressed in substantia nigra and 248 other tissues.
DR   ExpressionAtlas; Q96PU8; baseline and differential.
DR   Genevisible; Q96PU8; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0003729; F:mRNA binding; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0042759; P:long-chain fatty acid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0051028; P:mRNA transport; IEA:UniProtKB-KW.
DR   GO; GO:0042692; P:muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW.
DR   GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR   GO; GO:0007286; P:spermatid development; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   Gene3D; 3.30.1370.10; -; 1.
DR   InterPro; IPR004087; KH_dom.
DR   InterPro; IPR004088; KH_dom_type_1.
DR   InterPro; IPR036612; KH_dom_type_1_sf.
DR   InterPro; IPR032367; Quaking_NLS.
DR   InterPro; IPR032377; STAR_dimer.
DR   Pfam; PF00013; KH_1; 1.
DR   Pfam; PF16551; Quaking_NLS; 1.
DR   Pfam; PF16544; STAR_dimer; 1.
DR   SMART; SM00322; KH; 1.
DR   SUPFAM; SSF54791; SSF54791; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Developmental protein;
KW   Differentiation; Methylation; mRNA processing; mRNA splicing;
KW   mRNA transport; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   RNA-binding; SH3-binding; Translation regulation; Transport.
FT   CHAIN           1..341
FT                   /note="Protein quaking"
FT                   /id="PRO_0000239373"
FT   DOMAIN          87..153
FT                   /note="KH"
FT   REGION          11..82
FT                   /note="Qua1 domain; involved in homodimerization"
FT                   /evidence="ECO:0000250|UniProtKB:Q17339"
FT   REGION          182..213
FT                   /note="Qua2 domain; involved in RNA binding"
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   MOTIF           276..279
FT                   /note="SH3-binding"
FT   MOTIF           324..330
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250"
FT   SITE            97
FT                   /note="Involved in RNA binding"
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   SITE            120
FT                   /note="Involved in RNA binding"
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   SITE            124
FT                   /note="Involved in RNA binding"
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   SITE            130
FT                   /note="Involved in RNA binding"
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   SITE            190
FT                   /note="Involved in RNA binding"
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   SITE            193
FT                   /note="Involved in RNA binding"
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   MOD_RES         188
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         227
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         242
FT                   /note="Asymmetric dimethylarginine; by CARM1; alternate"
FT                   /evidence="ECO:0000269|PubMed:23455924"
FT   MOD_RES         242
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         256
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QYS9"
FT   VAR_SEQ         213..220
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_019188"
FT   VAR_SEQ         312..341
FT                   /note="GAVATKVRRHDMRVHPYQRIVTADRAATGN -> EWIEMPVMPDISAH (in
FT                   isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:11856480, ECO:0000303|Ref.2,
FT                   ECO:0000303|Ref.3"
FT                   /id="VSP_019190"
FT   VAR_SEQ         312..341
FT                   /note="GAVATKVRRHDMRVHPYQRIVTADRAATGN -> GKFFSPWG (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:11856480"
FT                   /id="VSP_019191"
FT   VAR_SEQ         312..341
FT                   /note="GAVATKVRRHDMRVHPYQRIVTADRAATGN -> GMAFPTKG (in
FT                   isoform 6)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_019189"
FT   VARIANT         336
FT                   /note="R -> Q (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1258390251)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036051"
FT   MUTAGEN         97
FT                   /note="N->A: Decrease in target mRNA abundance and 10-fold
FT                   decrease in RNA binding affinity; when associated with A-
FT                   130."
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   MUTAGEN         120
FT                   /note="K->A: Decrease in target mRNA abundance and 20-fold
FT                   decrease in RNA binding affinity; when associated with A-
FT                   124."
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   MUTAGEN         124
FT                   /note="R->A: Decrease in target mRNA abundance and 20-fold
FT                   decrease in RNA binding affinity; when associated with A-
FT                   120."
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   MUTAGEN         130
FT                   /note="R->A: Decrease in target mRNA abundance and 10-fold
FT                   decrease in RNA binding affinity; when associated with A-
FT                   97."
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   MUTAGEN         190
FT                   /note="K->A: Decrease in target mRNA abundance and 124-fold
FT                   decrease in RNA binding affinity; when associated with A-
FT                   193."
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   MUTAGEN         193
FT                   /note="Q->A: Decrease in target mRNA abundance and 124-fold
FT                   decrease in RNA binding affinity; when associated with A-
FT                   190."
FT                   /evidence="ECO:0000269|PubMed:23630077"
FT   CONFLICT        30
FT                   /note="S -> G (in Ref. 3; ABC88600)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        208
FT                   /note="N -> D (in Ref. 5; AAH12222)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   341 AA;  37671 MW;  43E7F3A426A494C4 CRC64;
     MVGEMETKEK PKPTPDYLMQ LMNDKKLMSS LPNFCGIFNH LERLLDEEIS RVRKDMYNDT
     LNGSTEKRSA ELPDAVGPIV QLQEKLYVPV KEYPDFNFVG RILGPRGLTA KQLEAETGCK
     IMVRGKGSMR DKKKEEQNRG KPNWEHLNED LHVLITVEDA QNRAEIKLKR AVEEVKKLLV
     PAAEGEDSLK KMQLMELAIL NGTYRDANIK SPALAFSLAA TAQAAPRIIT GPAPVLPPAA
     LRTPTPAGPT IMPLIRQIQT AVMPNGTPHP TAAIVPPGPE AGLIYTPYEY PYTLAPATSI
     LEYPIEPSGV LGAVATKVRR HDMRVHPYQR IVTADRAATG N
//
ID   A0A024R9J0_HUMAN        Unreviewed;       631 AA.
AC   A0A024R9J0;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   22-APR-2020, entry version 38.
DE   SubName: Full=RAD21 homolog (S. pombe), isoform CRA_a {ECO:0000313|EMBL:EAW91965.1};
GN   Name=RAD21 {ECO:0000313|EMBL:EAW91965.1};
GN   ORFNames=hCG_19969 {ECO:0000313|EMBL:EAW91965.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW91965.1};
RN   [1] {ECO:0000313|EMBL:EAW91965.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW91965.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH471060; EAW91965.1; -; Genomic_DNA.
DR   RefSeq; NP_006256.1; NM_006265.2.
DR   SMR; A0A024R9J0; -.
DR   IntAct; A0A024R9J0; 1.
DR   PRIDE; A0A024R9J0; -.
DR   Antibodypedia; 13592; 293 antibodies.
DR   GeneID; 5885; -.
DR   KEGG; hsa:5885; -.
DR   CTD; 5885; -.
DR   EuPathDB; HostDB:ENSG00000164754.12; -.
DR   eggNOG; KOG1213; Eukaryota.
DR   eggNOG; ENOG410XRB4; LUCA.
DR   HOGENOM; CLU_015775_1_1_1; -.
DR   KO; K06670; -.
DR   OMA; ENMGYDQ; -.
DR   OrthoDB; 1253899at2759; -.
DR   PhylomeDB; A0A024R9J0; -.
DR   ChiTaRS; RAD21; human.
DR   GenomeRNAi; 5885; -.
DR   Bgee; ENSG00000164754; Expressed in cerebral cortex and 248 other tissues.
DR   ExpressionAtlas; A0A024R9J0; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0008278; C:cohesin complex; IEA:Ensembl.
DR   GO; GO:0000794; C:condensed nuclear chromosome; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0010972; P:negative regulation of G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045841; P:negative regulation of mitotic metaphase/anaphase transition; IEA:Ensembl.
DR   GO; GO:0007062; P:sister chromatid cohesion; IEA:InterPro.
DR   InterPro; IPR039781; Rad21/Rec8-like.
DR   InterPro; IPR006909; Rad21/Rec8_C_eu.
DR   InterPro; IPR006910; Rad21_Rec8_N.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR12585; PTHR12585; 1.
DR   Pfam; PF04824; Rad21_Rec8; 1.
DR   Pfam; PF04825; Rad21_Rec8_N; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
PE   4: Predicted;
FT   DOMAIN          1..103
FT                   /note="Rad21_Rec8_N"
FT                   /evidence="ECO:0000259|Pfam:PF04825"
FT   DOMAIN          575..628
FT                   /note="Rad21_Rec8"
FT                   /evidence="ECO:0000259|Pfam:PF04824"
FT   REGION          258..285
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          423..489
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          517..558
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        423..448
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        533..547
FT                   /note="Acidic"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   631 AA;  71690 MW;  7D4A6EA6392BE73D CRC64;
     MFYAHFVLSK RGPLAKIWLA AHWDKKLTKA HVFECNLESS VESIISPKVK MALRTSGHLL
     LGVVRIYHRK AKYLLADCNE AFIKIKMAFR PGVVDLPEEN REAAYNAITL PEEFHDFDQP
     LPDLDDIDVA QQFSLNQSRV EEITMREEVG NISILQENDF GDFGMDDREI MREGSAFEDD
     DMLVSTTTSN LLLESEQSTS NLNEKINHLE YEDQYKDDNF GEGNDGGILD DKLISNNDGG
     IFDDPPALSE AGVMLPEQPA HDDMDEDDNV SMGGPDSPDS VDPVEPMPTM TDQTTLVPNE
     EEAFALEPID ITVKETKAKR KRKLIVDSVK ELDSKTIRAQ LSDYSDIVTT LDLAPPTKKL
     MMWKETGGVE KLFSLPAQPL WNNRLLKLFT RCLTPLVPED LRKRRKGGEA DNLDEFLKEF
     ENPEVPREDQ QQQHQQRDVI DEPIIEEPSR LQESVMEASR TNIDESAMPP PPPQGVKRKA
     GQIDPEPVMP PQQVEQMEIP PVELPPEEPP NICQLIPELE LLPEKEKEKE KEKEDDEEEE
     DEDASGGDQD QEERRWNKRT QQMLHGLQRA LAKTGAESIS LLELCRNTNR KQAAAKFYSF
     LVLKKQQAIE LTQEEPYSDI IATPGPRFHI I
//
ID   RAD21_HUMAN             Reviewed;         631 AA.
AC   O60216; A8K0E0; Q15001; Q99568;
DT   15-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   15-NOV-2002, sequence version 2.
DT   22-APR-2020, entry version 185.
DE   RecName: Full=Double-strand-break repair protein rad21 homolog;
DE            Short=hHR21 {ECO:0000303|PubMed:8812457};
DE   AltName: Full=Nuclear matrix protein 1 {ECO:0000303|PubMed:10623634};
DE            Short=NXP-1 {ECO:0000303|PubMed:10623634};
DE   AltName: Full=SCC1 homolog;
DE   Contains:
DE     RecName: Full=64-kDa C-terminal product {ECO:0000303|PubMed:12417729};
DE     AltName: Full=64-kDa carboxy-terminal product {ECO:0000303|PubMed:12417729};
DE     AltName: Full=65-kDa carboxy-terminal product {ECO:0000303|PubMed:11875078};
GN   Name=RAD21;
GN   Synonyms=HR21 {ECO:0000303|PubMed:11483345}, KIAA0078, NXP1,
GN   SCC1 {ECO:0000303|PubMed:11509732};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND DEVELOPMENTAL STAGE.
RC   TISSUE=Testis;
RX   PubMed=8812457; DOI=10.1006/geno.1996.0466;
RA   McKay M.J., Troelstra C., van der Spek P., Kanaar R., Smit B.,
RA   Hagemeijer A., Bootsma D., Hoeijmakers J.H.J.;
RT   "Sequence conservation of the rad21 Schizosaccharomyces pombe DNA double-
RT   strand break repair gene in human and mouse.";
RL   Genomics 36:305-315(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S., Seki N.,
RA   Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II. The
RT   coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   IDENTIFICATION IN THE COHESIN COMPLEX.
RX   PubMed=10931856; DOI=10.1083/jcb.150.3.405;
RA   Losada A., Yokochi T., Kobayashi R., Hirano T.;
RT   "Identification and characterization of SA/Scc3p subunits in the Xenopus
RT   and human cohesin complexes.";
RL   J. Cell Biol. 150:405-416(2000).
RN   [8]
RP   PROTEIN SEQUENCE OF 406-418, IDENTIFICATION IN THE COHESIN COMPLEX,
RP   INTERACTION WITH NUMA1, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=11590136; DOI=10.1074/jbc.m103364200;
RA   Gregson H.C., Schmiesing J.A., Kim J.-S., Kobayashi T., Zhou S.,
RA   Yokomori K.;
RT   "A potential role for human cohesin in mitotic spindle aster assembly.";
RL   J. Biol. Chem. 276:47575-47582(2001).
RN   [9]
RP   PHOSPHORYLATION BY PLK1.
RX   PubMed=11931760; DOI=10.1016/s1097-2765(02)00473-2;
RA   Sumara I., Vorlaufer E., Stukenberg P.T., Kelm O., Redemann N., Nigg E.A.,
RA   Peters J.-M.;
RT   "The dissociation of cohesin from chromosomes in prophase is regulated by
RT   Polo-like kinase.";
RL   Mol. Cell 9:515-525(2002).
RN   [10]
RP   PROTEIN SEQUENCE OF 280-286 (64-KDA C-TERMINAL PRODUCT), CLEAVAGE BY
RP   CASPASE-3 OR CASPASE-7, FUNCTION, MUTAGENESIS OF 276-ASP--SER-280 AND
RP   ASP-279, AND SUBCELLULAR LOCATION.
RX   PubMed=12417729; DOI=10.1128/mcb.22.23.8267-8277.2002;
RA   Pati D., Zhang N., Plon S.E.;
RT   "Linking sister chromatid cohesion and apoptosis: role of rad21.";
RL   Mol. Cell. Biol. 22:8267-8277(2002).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10623634; DOI=10.1006/bbrc.1999.1969;
RA   Sadano H., Sugimoto H., Sakai F., Nomura N., Osumi T.;
RT   "NXP-1, a human protein related to Rad21/Scc1/Mcd1, is a component of the
RT   nuclear matrix.";
RL   Biochem. Biophys. Res. Commun. 267:418-422(2000).
RN   [12]
RP   SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND PHOSPHORYLATION.
RX   PubMed=11073952; DOI=10.1074/jbc.m007809200;
RA   Hoque M.T., Ishikawa F.;
RT   "Human chromatid cohesin component hRad21 is phosphorylated in M phase and
RT   associated with metaphase centromeres.";
RL   J. Biol. Chem. 276:5059-5067(2001).
RN   [13]
RP   FUNCTION, CLEAVAGE BY ESPL1, MUTAGENESIS OF ARG-172 AND ARG-450, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=11509732; DOI=10.1126/science.1061376;
RA   Hauf S., Waizenegger I.C., Peters J.-M.;
RT   "Cohesin cleavage by separase required for anaphase and cytokinesis in
RT   human cells.";
RL   Science 293:1320-1323(2001).
RN   [14]
RP   FUNCTION, CLEAVAGE BY CASPASE-3 OR CASPASE-7, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF ASP-279 AND ASP-282.
RX   PubMed=11875078; DOI=10.1074/jbc.m201322200;
RA   Chen F., Kamradt M., Mulcahy M., Byun Y., Xu H., McKay M.J., Cryns V.L.;
RT   "Caspase proteolysis of the cohesin component RAD21 promotes apoptosis.";
RL   J. Biol. Chem. 277:16775-16781(2002).
RN   [15]
RP   INTERACTION WITH CDCA5; PDS5A AND PDS5B.
RX   PubMed=15837422; DOI=10.1016/j.molcel.2005.03.017;
RA   Rankin S., Ayad N.G., Kirschner M.W.;
RT   "Sororin, a substrate of the anaphase-promoting complex, is required for
RT   sister chromatid cohesion in vertebrates.";
RL   Mol. Cell 18:185-200(2005).
RN   [16]
RP   ERRATUM OF PUBMED:15837422.
RA   Rankin S., Ayad N.G., Kirschner M.W.;
RL   Mol. Cell 18:609-609(2005).
RN   [17]
RP   INTERACTION WITH DDX11.
RX   PubMed=17105772; DOI=10.1242/jcs.03262;
RA   Parish J.L., Rosa J., Wang X., Lahti J.M., Doxsey S.J., Androphy E.J.;
RT   "The DNA helicase ChlR1 is required for sister chromatid cohesion in
RT   mammalian cells.";
RL   J. Cell Sci. 119:4857-4865(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46 AND SER-175, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   INTERACTION WITH PDS5B; STAG1 AND WAPL.
RX   PubMed=19696148; DOI=10.1101/gad.1844309;
RA   Shintomi K., Hirano T.;
RT   "Releasing cohesin from chromosome arms in early mitosis: opposing actions
RT   of Wapl-Pds5 and Sgo1.";
RL   Genes Dev. 23:2224-2236(2009).
RN   [20]
RP   VARIANT ARG-481.
RX   PubMed=11483345; DOI=10.1016/s0360-3016(01)01608-x;
RA   Severin D.M., Leong T., Cassidy B., Elsaleh H., Peters L., Venter D.,
RA   Southey M., McKay M.;
RT   "Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive
RT   cancer patients.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 50:1323-1331(2001).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-153 AND SER-175, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46 AND SER-153, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   IDENTIFICATION IN THE COHESIN COMPLEX, AND INTERACTION WITH NIPBL AND MAU2.
RX   PubMed=22628566; DOI=10.1073/pnas.1206840109;
RA   Bermudez V.P., Farina A., Higashi T.L., Du F., Tappin I., Takahashi T.S.,
RA   Hurwitz J.;
RT   "In vitro loading of human cohesin on DNA by the human Scc2-Scc4 loader
RT   complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9366-9371(2012).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394; SER-454; SER-545 AND
RP   THR-623, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-153 AND SER-249, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-48; LYS-216 AND LYS-418, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   VARIANTS CDLS4 ARG-376 AND ARG-585.
RX   PubMed=22633399; DOI=10.1016/j.ajhg.2012.04.019;
RA   Deardorff M.A., Wilde J.J., Albrecht M., Dickinson E., Tennstedt S.,
RA   Braunholz D., Monnich M., Yan Y., Xu W., Gil-Rodriguez M.C., Clark D.,
RA   Hakonarson H., Halbach S., Michelis L.D., Rampuria A., Rossier E.,
RA   Spranger S., Van Maldergem L., Lynch S.A., Gillessen-Kaesbach G.,
RA   Ludecke H.J., Ramsay R.G., McKay M.J., Krantz I.D., Xu H., Horsfield J.A.,
RA   Kaiser F.J.;
RT   "RAD21 mutations cause a human cohesinopathy.";
RL   Am. J. Hum. Genet. 90:1014-1027(2012).
RN   [29]
RP   INVOLVEMENT IN MGS, VARIANT MGS THR-622, CHARACTERIZATION OF VARIANT MGS
RP   THR-622, FUNCTION, INTERACTION WITH SMC1, AND TISSUE SPECIFICITY.
RX   PubMed=25575569; DOI=10.1053/j.gastro.2014.12.034;
RA   Bonora E., Bianco F., Cordeddu L., Bamshad M., Francescatto L., Dowless D.,
RA   Stanghellini V., Cogliandro R.F., Lindberg G., Mungan Z., Cefle K.,
RA   Ozcelik T., Palanduz S., Ozturk S., Gedikbasi A., Gori A., Pippucci T.,
RA   Graziano C., Volta U., Caio G., Barbara G., D'Amato M., Seri M.,
RA   Katsanis N., Romeo G., De Giorgio R.;
RT   "Mutations in RAD21 disrupt regulation of APOB in patients with chronic
RT   intestinal pseudo-obstruction.";
RL   Gastroenterology 148:771-782(2015).
CC   -!- FUNCTION: [Double-strand-break repair protein rad21 homolog]: As a
CC       member of the cohesin complex, involved in sister chromatid cohesion
CC       from the time of DNA replication in S phase to their segregation in
CC       mitosis, a function that is essential for proper chromosome
CC       segregation, post-replicative DNA repair, and the prevention of
CC       inappropriate recombination between repetitive regions
CC       (PubMed:11509732). The cohesin complex may also play a role in spindle
CC       pole assembly during mitosis (PubMed:11590136). In interphase, cohesins
CC       may function in the control of gene expression by binding to numerous
CC       sites within the genome (By similarity). May control RUNX1 gene
CC       expression (Probable). Binds to and represses APOB gene promoter
CC       (PubMed:25575569). May play a role in embryonic gut development,
CC       possibly through the regulation of enteric neuron development (By
CC       similarity). {ECO:0000250|UniProtKB:Q61550,
CC       ECO:0000250|UniProtKB:Q6TEL1, ECO:0000269|PubMed:11509732,
CC       ECO:0000269|PubMed:11590136, ECO:0000269|PubMed:25575569,
CC       ECO:0000305|PubMed:25575569}.
CC   -!- FUNCTION: [64-kDa C-terminal product]: May promote apoptosis.
CC       {ECO:0000269|PubMed:11875078, ECO:0000269|PubMed:12417729}.
CC   -!- SUBUNIT: Component of the cohesin complex, which consists of an SMC1A/B
CC       and SMC3 heterodimer core and 2 non-Smc subunits RAD21 and STAG1/SA1,
CC       STAG2/SA2 or STAG3/SA3 (PubMed:10931856, PubMed:11590136,
CC       PubMed:22628566, PubMed:25575569). The cohesin complex interacts with
CC       NUMA1 (PubMed:11590136). The cohesin complex also interacts with CDCA5,
CC       PDS5A and PDS5B; this interaction might regulate the ability of the
CC       cohesin complex to mediate sister chromatid cohesion (PubMed:15837422).
CC       The interaction with PDS5B is direct and is stimulated by STAG1/SA1
CC       (PubMed:19696148). The cohesin complex interacts with the cohesin
CC       loading complex subunits NIPBL/Scc2 (via HEAT repeats) and MAU2/Scc4
CC       (PubMed:22628566). The cohesin complex interacts with DDX11/ChIR1
CC       (PubMed:17105772). Directly interacts with WAPL; this interaction is
CC       stimulated by STAG1/SA1 (PubMed:19696148).
CC       {ECO:0000269|PubMed:10931856, ECO:0000269|PubMed:11590136,
CC       ECO:0000269|PubMed:15837422, ECO:0000269|PubMed:17105772,
CC       ECO:0000269|PubMed:19696148, ECO:0000269|PubMed:22628566,
CC       ECO:0000269|PubMed:25575569}.
CC   -!- INTERACTION:
CC       O60216; Q13643: FHL3; NbExp=4; IntAct=EBI-80739, EBI-741101;
CC       O60216; Q29RF7: PDS5A; NbExp=5; IntAct=EBI-80739, EBI-1175454;
CC       O60216; Q9NTI5: PDS5B; NbExp=4; IntAct=EBI-80739, EBI-1175604;
CC       O60216; Q14683: SMC1A; NbExp=15; IntAct=EBI-80739, EBI-80690;
CC       O60216; Q9UQE7: SMC3; NbExp=16; IntAct=EBI-80739, EBI-80718;
CC       O60216; Q9NP77: SSU72; NbExp=9; IntAct=EBI-80739, EBI-2515416;
CC       O60216; Q8N3U4: STAG2; NbExp=14; IntAct=EBI-80739, EBI-1057252;
CC       O60216; Q7Z5K2: WAPL; NbExp=15; IntAct=EBI-80739, EBI-1022242;
CC   -!- SUBCELLULAR LOCATION: [Double-strand-break repair protein rad21
CC       homolog]: Nucleus {ECO:0000269|PubMed:11073952,
CC       ECO:0000269|PubMed:11509732, ECO:0000269|PubMed:12417729}. Nucleus
CC       matrix {ECO:0000269|PubMed:10623634, ECO:0000269|PubMed:11590136}.
CC       Chromosome {ECO:0000269|PubMed:11073952, ECO:0000269|PubMed:11590136}.
CC       Chromosome, centromere {ECO:0000269|PubMed:11073952}. Cytoplasm,
CC       cytoskeleton, spindle pole {ECO:0000269|PubMed:11073952,
CC       ECO:0000269|PubMed:11590136}. Note=Associates with chromatin
CC       (PubMed:11590136, PubMed:11073952). Before prophase, scattered along
CC       chromosome arms (PubMed:11073952). During prophase and prometaphase,
CC       most cohesins dissociate from the arms of condensing chromosome,
CC       possibly through PLK1-mediated phosphorylation (PubMed:11931760). A
CC       small amount of cohesin remains in centromeric regions and is removed
CC       from chromosomes only at the onset of anaphase. At anaphase, cleavage
CC       by separase/ESPL1 leads to the dissociation of cohesin from chromosomes
CC       and chromosome separation (PubMed:11073952, PubMed:11509732).
CC       {ECO:0000269|PubMed:11073952, ECO:0000269|PubMed:11509732,
CC       ECO:0000269|PubMed:11590136, ECO:0000269|PubMed:11931760}.
CC   -!- SUBCELLULAR LOCATION: [64-kDa C-terminal product]: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:11875078, ECO:0000269|PubMed:12417729}. Nucleus
CC       {ECO:0000269|PubMed:11875078, ECO:0000269|PubMed:12417729}.
CC   -!- TISSUE SPECIFICITY: Expressed in the gut (at protein level).
CC       {ECO:0000269|PubMed:25575569}.
CC   -!- DEVELOPMENTAL STAGE: Regulated in a cell cycle-dependent manner:
CC       expression increases in late S phase and reaches maximum in G2 at the
CC       nucleotide level (PubMed:8812457). Not regulated during the cell cycle
CC       (at protein level) (PubMed:11073952). {ECO:0000269|PubMed:11073952,
CC       ECO:0000269|PubMed:8812457}.
CC   -!- DOMAIN: The C-terminal part associates with the head of SMC1A, while
CC       the N-terminal part binds to the head of SMC3. {ECO:0000250}.
CC   -!- PTM: Cleaved by separase/ESPL1 at the onset of anaphase; this cleavage
CC       is required for sister chromatid separation and cytokinesis
CC       (PubMed:11509732). Cleaved by caspase-3/CASP3 or caspase-7/CASP7 at the
CC       beginning of apoptosis (PubMed:12417729, PubMed:11875078).
CC       {ECO:0000269|PubMed:11509732, ECO:0000269|PubMed:11875078,
CC       ECO:0000269|PubMed:12417729}.
CC   -!- PTM: Phosphorylated; becomes hyperphosphorylated in M phase of cell
CC       cycle. The large dissociation of cohesin from chromosome arms during
CC       prophase may be partly due to its phosphorylation by PLK1.
CC       {ECO:0000269|PubMed:11073952}.
CC   -!- DISEASE: Cornelia de Lange syndrome 4 (CDLS4) [MIM:614701]: A form of
CC       Cornelia de Lange syndrome, a clinically heterogeneous developmental
CC       disorder associated with malformations affecting multiple systems. It
CC       is characterized by facial dysmorphisms, abnormal hands and feet,
CC       growth delay, cognitive retardation, hirsutism, gastroesophageal
CC       dysfunction and cardiac, ophthalmologic and genitourinary anomalies.
CC       {ECO:0000269|PubMed:22633399}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Mungan syndrome (MGS) [MIM:611376]: An autosomal recessive
CC       disease characterized by visceral neuromyopathy, intestinal dysmotility
CC       and chronic intestinal pseudoobstruction, megaduodenum, long-segment
CC       Barrett esophagus, and a variety of cardiac valve or septal defects
CC       such as membranous ventricular septal defect, pulmonary and tricuspid
CC       valve regurgitation. {ECO:0000269|PubMed:25575569}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the rad21 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA07554.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/rad21/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X98294; CAA66940.1; -; mRNA.
DR   EMBL; D38551; BAA07554.2; ALT_INIT; mRNA.
DR   EMBL; AY675320; AAT70725.1; -; Genomic_DNA.
DR   EMBL; AK289505; BAF82194.1; -; mRNA.
DR   EMBL; CH471060; EAW91963.1; -; Genomic_DNA.
DR   EMBL; BC050381; AAH50381.1; -; mRNA.
DR   CCDS; CCDS6321.1; -.
DR   RefSeq; NP_006256.1; NM_006265.2.
DR   PDB; 4PJU; X-ray; 3.05 A; B=281-420.
DR   PDB; 4PJW; X-ray; 2.85 A; B=281-420.
DR   PDB; 4PK7; X-ray; 2.95 A; B=281-420.
DR   PDB; 6QNX; X-ray; 2.70 A; B=1-631.
DR   PDB; 6RRC; X-ray; 2.37 A; B/D=321-345.
DR   PDB; 6RRK; X-ray; 3.17 A; C/D=356-395.
DR   PDBsum; 4PJU; -.
DR   PDBsum; 4PJW; -.
DR   PDBsum; 4PK7; -.
DR   PDBsum; 6QNX; -.
DR   PDBsum; 6RRC; -.
DR   PDBsum; 6RRK; -.
DR   SMR; O60216; -.
DR   BioGrid; 111822; 290.
DR   CORUM; O60216; -.
DR   DIP; DIP-29201N; -.
DR   ELM; O60216; -.
DR   IntAct; O60216; 56.
DR   MINT; O60216; -.
DR   STRING; 9606.ENSP00000297338; -.
DR   iPTMnet; O60216; -.
DR   MetOSite; O60216; -.
DR   PhosphoSitePlus; O60216; -.
DR   SwissPalm; O60216; -.
DR   BioMuta; RAD21; -.
DR   EPD; O60216; -.
DR   jPOST; O60216; -.
DR   MassIVE; O60216; -.
DR   MaxQB; O60216; -.
DR   PaxDb; O60216; -.
DR   PeptideAtlas; O60216; -.
DR   PRIDE; O60216; -.
DR   ProteomicsDB; 49246; -.
DR   Antibodypedia; 13592; 293 antibodies.
DR   Ensembl; ENST00000297338; ENSP00000297338; ENSG00000164754.
DR   GeneID; 5885; -.
DR   KEGG; hsa:5885; -.
DR   UCSC; uc003yod.4; human.
DR   CTD; 5885; -.
DR   DisGeNET; 5885; -.
DR   GeneCards; RAD21; -.
DR   GeneReviews; RAD21; -.
DR   HGNC; HGNC:9811; RAD21.
DR   HPA; ENSG00000164754; Low tissue specificity.
DR   MalaCards; RAD21; -.
DR   MIM; 606462; gene.
DR   MIM; 611376; phenotype.
DR   MIM; 614701; phenotype.
DR   neXtProt; NX_O60216; -.
DR   OpenTargets; ENSG00000164754; -.
DR   Orphanet; 199; Cornelia de Lange syndrome.
DR   PharmGKB; PA34170; -.
DR   eggNOG; KOG1213; Eukaryota.
DR   eggNOG; ENOG410XRB4; LUCA.
DR   GeneTree; ENSGT00940000154655; -.
DR   HOGENOM; CLU_015775_1_1_1; -.
DR   InParanoid; O60216; -.
DR   KO; K06670; -.
DR   OMA; ENMGYDQ; -.
DR   OrthoDB; 1253899at2759; -.
DR   PhylomeDB; O60216; -.
DR   TreeFam; TF101215; -.
DR   BioCyc; MetaCyc:ENSG00000164754-MONOMER; -.
DR   Reactome; R-HSA-1221632; Meiotic synapsis.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2468052; Establishment of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-2470946; Cohesin Loading onto Chromatin.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   SIGNOR; O60216; -.
DR   ChiTaRS; RAD21; human.
DR   GeneWiki; RAD21; -.
DR   GenomeRNAi; 5885; -.
DR   Pharos; O60216; Tbio.
DR   PRO; PR:O60216; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; O60216; protein.
DR   Bgee; ENSG00000164754; Expressed in cerebral cortex and 248 other tissues.
DR   ExpressionAtlas; O60216; baseline and differential.
DR   Genevisible; O60216; HS.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005694; C:chromosome; TAS:Reactome.
DR   GO; GO:0000775; C:chromosome, centromeric region; TAS:Reactome.
DR   GO; GO:0008278; C:cohesin complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030893; C:meiotic cohesin complex; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0000798; C:nuclear cohesin complex; IBA:GO_Central.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000922; C:spindle pole; IEA:UniProtKB-SubCell.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0006310; P:DNA recombination; TAS:ProtInc.
DR   GO; GO:0006302; P:double-strand break repair; IBA:GO_Central.
DR   GO; GO:0051321; P:meiotic cell cycle; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0010972; P:negative regulation of G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045841; P:negative regulation of mitotic metaphase/anaphase transition; IEA:Ensembl.
DR   GO; GO:0045876; P:positive regulation of sister chromatid cohesion; IMP:UniProtKB.
DR   GO; GO:0071168; P:protein localization to chromatin; IMP:UniProtKB.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0007062; P:sister chromatid cohesion; IBA:GO_Central.
DR   InterPro; IPR039781; Rad21/Rec8-like.
DR   InterPro; IPR006909; Rad21/Rec8_C_eu.
DR   InterPro; IPR006910; Rad21_Rec8_N.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR12585; PTHR12585; 1.
DR   Pfam; PF04824; Rad21_Rec8; 1.
DR   Pfam; PF04825; Rad21_Rec8_N; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Apoptosis; Cell cycle; Cell division; Centromere;
KW   Chromosome; Chromosome partition; Cytoplasm; Cytoskeleton;
KW   Developmental protein; Direct protein sequencing; Disease mutation;
KW   DNA damage; DNA repair; Isopeptide bond; Mental retardation; Mitosis;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..631
FT                   /note="Double-strand-break repair protein rad21 homolog"
FT                   /id="PRO_0000097872"
FT   CHAIN           280..631
FT                   /note="64-kDa C-terminal product"
FT                   /evidence="ECO:0000269|PubMed:12417729"
FT                   /id="PRO_0000446317"
FT   REGION          287..403
FT                   /note="Interaction with WAPL and PDS5B"
FT                   /evidence="ECO:0000269|PubMed:19696148"
FT   REGION          362..403
FT                   /note="Interaction with STAG1"
FT                   /evidence="ECO:0000269|PubMed:19696148"
FT   COMPBIAS        469..510
FT                   /note="Pro-rich"
FT   SITE            172..173
FT                   /note="Cleavage; by ESPL1"
FT                   /evidence="ECO:0000269|PubMed:11509732"
FT   SITE            279..280
FT                   /note="Cleavage; by caspase-3 or caspase-7"
FT                   /evidence="ECO:0000269|PubMed:12417729"
FT   SITE            450..451
FT                   /note="Cleavage; by ESPL1"
FT                   /evidence="ECO:0000269|PubMed:11509732"
FT   MOD_RES         46
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231"
FT   MOD_RES         153
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:24275569"
FT   MOD_RES         175
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332"
FT   MOD_RES         249
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         394
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         454
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         545
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         623
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   CROSSLNK        48
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        216
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        418
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VARIANT         376
FT                   /note="P -> R (in CDLS4; dbSNP:rs387907212)"
FT                   /evidence="ECO:0000269|PubMed:22633399"
FT                   /id="VAR_068691"
FT   VARIANT         481
FT                   /note="G -> R (found in a radiation-sensitive cancer
FT                   patient; dbSNP:rs755168088)"
FT                   /evidence="ECO:0000269|PubMed:11483345"
FT                   /id="VAR_014281"
FT   VARIANT         585
FT                   /note="C -> R (in CDLS4; dbSNP:rs387907213)"
FT                   /evidence="ECO:0000269|PubMed:22633399"
FT                   /id="VAR_068692"
FT   VARIANT         622
FT                   /note="A -> T (in MGS; causes delayed food transit along
FT                   the gut, when tested in zebrafish; may affect RUNX1 and
FT                   APOB expression; dbSNP:rs775266057)"
FT                   /evidence="ECO:0000269|PubMed:25575569"
FT                   /id="VAR_081285"
FT   MUTAGEN         172
FT                   /note="R->A: Abolishes first cleavage by ESPL1, no effect
FT                   on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:11509732"
FT   MUTAGEN         276..280
FT                   /note="DSPDS->AAPAA: Loss of cleavage by caspase-3 or
FT                   caspase-7."
FT                   /evidence="ECO:0000269|PubMed:12417729"
FT   MUTAGEN         279
FT                   /note="D->A,E: Loss of cleavage by caspase-3 or caspase-7."
FT                   /evidence="ECO:0000269|PubMed:11875078,
FT                   ECO:0000269|PubMed:12417729"
FT   MUTAGEN         282
FT                   /note="D->E: No effect on cleavage by caspase-3 or caspase-
FT                   7."
FT                   /evidence="ECO:0000269|PubMed:11875078"
FT   MUTAGEN         450
FT                   /note="R->A: Abolishes second cleavage by ESPL1, no effect
FT                   on nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:11509732"
FT   CONFLICT        136
FT                   /note="N -> I (in Ref. 1; CAA66940)"
FT                   /evidence="ECO:0000305"
FT   HELIX           334..336
FT                   /evidence="ECO:0000244|PDB:6RRC"
FT   HELIX           345..347
FT                   /evidence="ECO:0000244|PDB:4PK7"
FT   HELIX           358..366
FT                   /evidence="ECO:0000244|PDB:4PJW"
FT   HELIX           369..372
FT                   /evidence="ECO:0000244|PDB:4PJW"
FT   HELIX           383..390
FT                   /evidence="ECO:0000244|PDB:4PJW"
FT   TURN            391..393
FT                   /evidence="ECO:0000244|PDB:4PK7"
SQ   SEQUENCE   631 AA;  71690 MW;  7D4A6EA6392BE73D CRC64;
     MFYAHFVLSK RGPLAKIWLA AHWDKKLTKA HVFECNLESS VESIISPKVK MALRTSGHLL
     LGVVRIYHRK AKYLLADCNE AFIKIKMAFR PGVVDLPEEN REAAYNAITL PEEFHDFDQP
     LPDLDDIDVA QQFSLNQSRV EEITMREEVG NISILQENDF GDFGMDDREI MREGSAFEDD
     DMLVSTTTSN LLLESEQSTS NLNEKINHLE YEDQYKDDNF GEGNDGGILD DKLISNNDGG
     IFDDPPALSE AGVMLPEQPA HDDMDEDDNV SMGGPDSPDS VDPVEPMPTM TDQTTLVPNE
     EEAFALEPID ITVKETKAKR KRKLIVDSVK ELDSKTIRAQ LSDYSDIVTT LDLAPPTKKL
     MMWKETGGVE KLFSLPAQPL WNNRLLKLFT RCLTPLVPED LRKRRKGGEA DNLDEFLKEF
     ENPEVPREDQ QQQHQQRDVI DEPIIEEPSR LQESVMEASR TNIDESAMPP PPPQGVKRKA
     GQIDPEPVMP PQQVEQMEIP PVELPPEEPP NICQLIPELE LLPEKEKEKE KEKEDDEEEE
     DEDASGGDQD QEERRWNKRT QQMLHGLQRA LAKTGAESIS LLELCRNTNR KQAAAKFYSF
     LVLKKQQAIE LTQEEPYSDI IATPGPRFHI I
//
ID   RECQ4_HUMAN             Reviewed;        1208 AA.
AC   O94761; A0A087WZ30; Q3Y424; Q96DW2; Q96F55;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 2.
DT   22-APR-2020, entry version 189.
DE   RecName: Full=ATP-dependent DNA helicase Q4;
DE            EC=3.6.4.12;
DE   AltName: Full=DNA helicase, RecQ-like type 4;
DE            Short=RecQ4;
DE   AltName: Full=RTS;
DE   AltName: Full=RecQ protein-like 4;
GN   Name=RECQL4; Synonyms=RECQ4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT PRO-92.
RC   TISSUE=Testis;
RX   PubMed=9878247; DOI=10.1006/geno.1998.5595;
RA   Kitao S., Ohsugi I., Ichikawa K., Goto M., Furuichi Y., Shimamoto A.;
RT   "Cloning of two new human helicase genes of the RecQ family: biological
RT   significance of multiple species in higher eukaryotes.";
RL   Genomics 54:443-452(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], SUBCELLULAR LOCATION, INVOLVEMENT IN
RP   ROTHMUND-THOMSON SYNDROME, AND VARIANT PRO-92.
RX   PubMed=10552928; DOI=10.1006/geno.1999.5959;
RA   Kitao S., Lindor N.M., Shiratori M., Furuichi Y., Shimamoto A.;
RT   "Rothmund-Thomson syndrome responsible gene, RECQL4: genomic structure and
RT   products.";
RL   Genomics 61:268-276(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-54; GLY-71; PRO-92;
RP   SER-189; ASP-267; THR-273; LYS-301; CYS-522; HIS-522; LEU-591; SER-793;
RP   MET-799; THR-964; LYS-976; TRP-1004; GLN-1005; GLN-1021; THR-1045;
RP   SER-1105; ASP-1105; HIS-1106; ARG-1113 AND PHE-1148.
RG   NIEHS SNPs program;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 468-1208.
RC   TISSUE=Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INDUCTION.
RX   PubMed=11032027; DOI=10.1038/sj.onc.1203841;
RA   Kawabe T., Tsuyama N., Kitao S., Nishikawa K., Shimamoto A., Shiratori M.,
RA   Matsumoto T., Anno K., Sato T., Mitsui Y., Seki M., Enomoto T., Goto M.,
RA   Ellis N.A., Ide T., Furuichi Y., Sugimoto M.;
RT   "Differential regulation of human RecQ family helicases in cell
RT   transformation and cell cycle.";
RL   Oncogene 19:4764-4772(2000).
RN   [7]
RP   INVOLVEMENT IN RAPADILINOS.
RX   PubMed=12952869; DOI=10.1093/hmg/ddg306;
RA   Siitonen H.A., Kopra O., Kaeaeriaeinen H., Haravuori H., Winter R.M.,
RA   Saeaemaenen A.-M., Peltonen L., Kestilae M.;
RT   "Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of
RT   RECQL diseases.";
RL   Hum. Mol. Genet. 12:2837-2844(2003).
RN   [8]
RP   INTERACTION WITH UBR1 AND UBR2, SUBCELLULAR LOCATION, FUNCTION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15317757; DOI=10.1093/hmg/ddh269;
RA   Yin J., Kwon Y.T., Varshavsky A., Wang W.;
RT   "RECQL4, mutated in the Rothmund-Thomson and RAPADILINO syndromes,
RT   interacts with ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway.";
RL   Hum. Mol. Genet. 13:2421-2430(2004).
RN   [9]
RP   INTERACTION WITH MCM10.
RX   PubMed=19696745; DOI=10.1038/emboj.2009.235;
RA   Xu X., Rochette P.J., Feyissa E.A., Su T.V., Liu Y.;
RT   "MCM10 mediates RECQ4 association with MCM2-7 helicase complex during DNA
RT   replication.";
RL   EMBO J. 28:3005-3014(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-178 AND SER-180, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   VARIANTS ASP-267 AND GLN-1005.
RX   PubMed=12601557; DOI=10.1007/s100380300016;
RA   Roversi G., Beghini A., Zambruno G., Paradisi M., Larizza L.;
RT   "Identification of two novel RECQL4exonic SNPs and genomic characterization
RT   of the IVS12 minisatellite.";
RL   J. Hum. Genet. 48:107-109(2003).
RN   [12]
RP   VARIANTS GLN-355; SER-441 AND 857-CYS--THR-858 DEL.
RX   PubMed=15221963; DOI=10.1002/ijc.20269;
RA   Nishijo K., Nakayama T., Aoyama T., Okamoto T., Ishibe T., Yasura K.,
RA   Shima Y., Shibata K.R., Tsuboyama T., Nakamura T., Toguchida J.;
RT   "Mutation analysis of the RECQL4 gene in sporadic osteosarcomas.";
RL   Int. J. Cancer 111:367-372(2004).
RN   [13]
RP   VARIANT BGS TRP-1021, AND VARIANT THR-523.
RX   PubMed=15964893; DOI=10.1136/jmg.2005.031781;
RA   Van Maldergem L., Siitonen H.A., Jalkh N., Chouery E., De Roy M.,
RA   Delague V., Muenke M., Jabs E.W., Cai J., Wang L.L., Plon S.E.,
RA   Fourneau C., Kestilae M., Gillerot Y., Megarbane A., Verloes A.;
RT   "Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-
RT   Gerold syndrome caused by mutations in the RECQL4 gene.";
RL   J. Med. Genet. 43:148-152(2006).
CC   -!- FUNCTION: DNA-dependent ATPase. May modulate chromosome segregation.
CC       {ECO:0000269|PubMed:15317757}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.12;
CC   -!- SUBUNIT: Interacts with UBR1 and UBR2. Interacts with MCM10; this
CC       interaction regulates RECQL4 unwinding activity.
CC       {ECO:0000269|PubMed:15317757, ECO:0000269|PubMed:19696745}.
CC   -!- INTERACTION:
CC       O94761; P54274: TERF1; NbExp=2; IntAct=EBI-722861, EBI-710997;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15317757}. Nucleus
CC       {ECO:0000269|PubMed:10552928}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       thymus and testis. {ECO:0000269|PubMed:9878247}.
CC   -!- INDUCTION: Up-regulated in actively dividing cells.
CC       {ECO:0000269|PubMed:11032027}.
CC   -!- DISEASE: Rothmund-Thomson syndrome (RTS) [MIM:268400]: Characterized by
CC       dermatological features such as atrophy, pigmentation, and
CC       telangiectasia and frequently accompanied by juvenile cataract, saddle
CC       nose, congenital bone defects, disturbances of hair growth, and
CC       hypogonadism. {ECO:0000269|PubMed:10552928}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: RAPADILINO syndrome (RAPADILINOS) [MIM:266280]: Disease
CC       characterized by radial and patellar aplasia or hypoplasia.
CC       {ECO:0000269|PubMed:12952869}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Baller-Gerold syndrome (BGS) [MIM:218600]: An autosomal
CC       recessive syndrome characterized by short stature, craniosynostosis,
CC       absent or hypoplastic radii, short and curved ulna, fused carpal bones
CC       and absent carpals, metacarpals and phalanges. Some patients manifest
CC       poikiloderma. Cases reported as Baller-Gerold syndrome have phenotypic
CC       overlap with several other disorders, including Saethre-Chotzen
CC       syndrome. {ECO:0000269|PubMed:15964893}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the helicase family. RecQ subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH13277.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RECQL4ID285.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/recql4/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB006532; BAA74453.1; -; mRNA.
DR   EMBL; AB026546; BAA86899.1; -; Genomic_DNA.
DR   EMBL; DQ176868; AAZ85145.1; -; Genomic_DNA.
DR   EMBL; AC084125; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF495717; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC011602; AAH11602.2; -; mRNA.
DR   EMBL; BC013277; AAH13277.2; ALT_INIT; mRNA.
DR   CCDS; CCDS75804.1; -.
DR   RefSeq; NP_004251.3; NM_004260.3.
DR   PDB; 2KMU; NMR; -; A=1-54.
DR   PDB; 5LST; X-ray; 2.75 A; A=427-1116.
DR   PDBsum; 2KMU; -.
DR   PDBsum; 5LST; -.
DR   SMR; O94761; -.
DR   BioGrid; 114798; 1363.
DR   DIP; DIP-48475N; -.
DR   IntAct; O94761; 21.
DR   STRING; 9606.ENSP00000482313; -.
DR   iPTMnet; O94761; -.
DR   PhosphoSitePlus; O94761; -.
DR   BioMuta; RECQL4; -.
DR   EPD; O94761; -.
DR   jPOST; O94761; -.
DR   MassIVE; O94761; -.
DR   PeptideAtlas; O94761; -.
DR   PRIDE; O94761; -.
DR   ProteomicsDB; 50424; -.
DR   Antibodypedia; 4498; 117 antibodies.
DR   Ensembl; ENST00000617875; ENSP00000482313; ENSG00000160957.
DR   GeneID; 9401; -.
DR   KEGG; hsa:9401; -.
DR   CTD; 9401; -.
DR   DisGeNET; 9401; -.
DR   GeneCards; RECQL4; -.
DR   GeneReviews; RECQL4; -.
DR   HGNC; HGNC:9949; RECQL4.
DR   MalaCards; RECQL4; -.
DR   MIM; 218600; phenotype.
DR   MIM; 266280; phenotype.
DR   MIM; 268400; phenotype.
DR   MIM; 603780; gene.
DR   neXtProt; NX_O94761; -.
DR   OpenTargets; ENSG00000160957; -.
DR   Orphanet; 1225; Baller-Gerold syndrome.
DR   Orphanet; 3021; RAPADILINO syndrome.
DR   Orphanet; 221016; Rothmund-Thomson syndrome type 2.
DR   PharmGKB; PA34316; -.
DR   GeneTree; ENSGT00940000160387; -.
DR   InParanoid; O94761; -.
DR   KO; K10730; -.
DR   OMA; ACLHSGM; -.
DR   OrthoDB; 445763at2759; -.
DR   PhylomeDB; O94761; -.
DR   SIGNOR; O94761; -.
DR   ChiTaRS; RECQL4; human.
DR   EvolutionaryTrace; O94761; -.
DR   GeneWiki; RECQL4; -.
DR   GenomeRNAi; 9401; -.
DR   Pharos; O94761; Tbio.
DR   PRO; PR:O94761; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; O94761; protein.
DR   Bgee; ENSG00000160957; Expressed in lower esophagus mucosa and 169 other tissues.
DR   ExpressionAtlas; O94761; baseline and differential.
DR   GO; GO:0005694; C:chromosome; IBA:GO_Central.
DR   GO; GO:0000781; C:chromosome, telomeric region; IMP:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0043138; F:3'-5' DNA helicase activity; IMP:UniProtKB.
DR   GO; GO:0036310; F:annealing helicase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000405; F:bubble DNA binding; IDA:UniProtKB.
DR   GO; GO:0009378; F:four-way junction helicase activity; IBA:GO_Central.
DR   GO; GO:0004386; F:helicase activity; TAS:BHF-UCL.
DR   GO; GO:0032357; F:oxidized purine DNA binding; IDA:BHF-UCL.
DR   GO; GO:0061821; F:telomeric D-loop binding; IDA:BHF-UCL.
DR   GO; GO:0032508; P:DNA duplex unwinding; IDA:UniProtKB.
DR   GO; GO:0006310; P:DNA recombination; IBA:GO_Central.
DR   GO; GO:0006281; P:DNA repair; IBA:GO_Central.
DR   GO; GO:0006260; P:DNA replication; IDA:UniProtKB.
DR   GO; GO:0000733; P:DNA strand renaturation; IDA:UniProtKB.
DR   GO; GO:0006268; P:DNA unwinding involved in DNA replication; IBA:GO_Central.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0000723; P:telomere maintenance; IMP:BHF-UCL.
DR   GO; GO:0061820; P:telomeric D-loop disassembly; IDA:BHF-UCL.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR004589; DNA_helicase_ATP-dep_RecQ.
DR   InterPro; IPR021110; DNA_rep_checkpnt_protein.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00270; DEAD; 1.
DR   Pfam; PF11719; Drc1-Sld2; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00614; recQ_fam; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cataract; Craniosynostosis; Cytoplasm;
KW   Disease mutation; Dwarfism; Helicase; Hydrolase; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN           1..1208
FT                   /note="ATP-dependent DNA helicase Q4"
FT                   /id="PRO_0000205053"
FT   DOMAIN          489..662
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          683..850
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   NP_BIND         502..509
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   MOTIF           605..608
FT                   /note="DEAH box"
FT   MOD_RES         27
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         180
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   VARIANT         54
FT                   /note="Q -> R (in dbSNP:rs35198096)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025117"
FT   VARIANT         71
FT                   /note="E -> G (in dbSNP:rs34642881)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025118"
FT   VARIANT         92
FT                   /note="S -> P (in dbSNP:rs2721190)"
FT                   /evidence="ECO:0000269|PubMed:10552928,
FT                   ECO:0000269|PubMed:9878247, ECO:0000269|Ref.3"
FT                   /id="VAR_025119"
FT   VARIANT         189
FT                   /note="G -> S (in dbSNP:rs34371341)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025120"
FT   VARIANT         267
FT                   /note="E -> D (common polymorphism; dbSNP:rs4244612)"
FT                   /evidence="ECO:0000269|PubMed:12601557, ECO:0000269|Ref.3"
FT                   /id="VAR_023295"
FT   VARIANT         273
FT                   /note="A -> T (in dbSNP:rs34103564)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025121"
FT   VARIANT         301
FT                   /note="E -> K (in dbSNP:rs34633809)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025122"
FT   VARIANT         355
FT                   /note="R -> Q (in dbSNP:rs374743591)"
FT                   /evidence="ECO:0000269|PubMed:15221963"
FT                   /id="VAR_023296"
FT   VARIANT         441
FT                   /note="P -> S (in dbSNP:rs557142414)"
FT                   /evidence="ECO:0000269|PubMed:15221963"
FT                   /id="VAR_023297"
FT   VARIANT         522
FT                   /note="R -> C (in dbSNP:rs35407712)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025123"
FT   VARIANT         522
FT                   /note="R -> H (in dbSNP:rs35842750)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025124"
FT   VARIANT         523
FT                   /note="S -> T (in dbSNP:rs754735053)"
FT                   /evidence="ECO:0000269|PubMed:15964893"
FT                   /id="VAR_026590"
FT   VARIANT         591
FT                   /note="P -> L (in dbSNP:rs2721191)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025125"
FT   VARIANT         793
FT                   /note="P -> L (in dbSNP:rs1034558903)"
FT                   /id="VAR_057125"
FT   VARIANT         793
FT                   /note="P -> S (in dbSNP:rs35098923)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025126"
FT   VARIANT         799
FT                   /note="V -> M (in dbSNP:rs34293591)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025127"
FT   VARIANT         857..858
FT                   /note="Missing"
FT                   /id="VAR_023298"
FT   VARIANT         964
FT                   /note="P -> T (in dbSNP:rs33972310)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025128"
FT   VARIANT         976
FT                   /note="E -> K (in dbSNP:rs35070885)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025129"
FT   VARIANT         1004
FT                   /note="R -> W (in dbSNP:rs36023964)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025130"
FT   VARIANT         1005
FT                   /note="R -> Q (in dbSNP:rs4251691)"
FT                   /evidence="ECO:0000269|PubMed:12601557, ECO:0000269|Ref.3"
FT                   /id="VAR_023299"
FT   VARIANT         1021
FT                   /note="R -> Q (in dbSNP:rs34666647)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025131"
FT   VARIANT         1021
FT                   /note="R -> W (in BGS; dbSNP:rs137853232)"
FT                   /evidence="ECO:0000269|PubMed:15964893"
FT                   /id="VAR_026591"
FT   VARIANT         1043
FT                   /note="L -> P (in dbSNP:rs4925828)"
FT                   /id="VAR_057126"
FT   VARIANT         1045
FT                   /note="A -> T (in dbSNP:rs35348691)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025132"
FT   VARIANT         1105
FT                   /note="G -> D (in dbSNP:rs36078464)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025133"
FT   VARIANT         1105
FT                   /note="G -> S (in dbSNP:rs34915097)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025134"
FT   VARIANT         1106
FT                   /note="R -> H (in dbSNP:rs34236392)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025135"
FT   VARIANT         1113
FT                   /note="G -> R (in dbSNP:rs35101495)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025136"
FT   VARIANT         1148
FT                   /note="S -> F (in dbSNP:rs35346077)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025137"
FT   HELIX           1..21
FT                   /evidence="ECO:0000244|PDB:2KMU"
FT   HELIX           28..31
FT                   /evidence="ECO:0000244|PDB:2KMU"
FT   HELIX           36..52
FT                   /evidence="ECO:0000244|PDB:2KMU"
FT   HELIX           458..460
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           467..476
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           485..492
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   TURN            493..495
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          498..501
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          503..505
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   TURN            506..509
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           510..522
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          526..530
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           533..536
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   TURN            544..546
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          548..551
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   TURN            556..558
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           559..570
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          575..579
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           581..585
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          586..588
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   TURN            593..595
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          599..605
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           607..610
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           620..630
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          637..642
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           646..655
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          674..679
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           684..693
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   TURN            695..699
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          703..709
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           710..723
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          739..744
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           750..761
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          765..771
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   TURN            772..774
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          785..790
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           795..802
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          807..810
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          812..817
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           823..835
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           839..849
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          900..905
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           906..913
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           917..929
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          931..933
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          936..948
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           952..957
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   TURN            958..962
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           964..972
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          985..988
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           989..996
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           1000..1008
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           1009..1011
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          1016..1018
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          1027..1039
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           1045..1078
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          1082..1085
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           1086..1088
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   STRAND          1089..1091
FT                   /evidence="ECO:0000244|PDB:5LST"
FT   HELIX           1094..1108
FT                   /evidence="ECO:0000244|PDB:5LST"
SQ   SEQUENCE   1208 AA;  133067 MW;  7634BC134AD7FB4D CRC64;
     MERLRDVRER LQAWERAFRR QRGRRPSQDD VEAAPEETRA LYREYRTLKR TTGQAGGGLR
     SSESLPAAAE EAPEPRCWGP HLNRAATKSP QSTPGRSRQG SVPDYGQRLK ANLKGTLQAG
     PALGRRPWPL GRASSKASTP KPPGTGPVPS FAEKVSDEPP QLPEPQPRPG RLQHLQASLS
     QRLGSLDPGW LQRCHSEVPD FLGAPKACRP DLGSEESQLL IPGESAVLGP GAGSQGPEAS
     AFQEVSIRVG SPQPSSSGGE KRRWNEEPWE SPAQVQQESS QAGPPSEGAG AVAVEEDPPG
     EPVQAQPPQP CSSPSNPRYH GLSPSSQARA GKAEGTAPLH IFPRLARHDR GNYVRLNMKQ
     KHYVRGRALR SRLLRKQAWK QKWRKKGECF GGGGATVTTK ESCFLNEQFD HWAAQCPRPA
     SEEDTDAVGP EPLVPSPQPV PEVPSLDPTV LPLYSLGPSG QLAETPAEVF QALEQLGHQA
     FRPGQERAVM RILSGISTLL VLPTGAGKSL CYQLPALLYS RRSPCLTLVV SPLLSLMDDQ
     VSGLPPCLKA ACIHSGMTRK QRESVLQKIR AAQVHVLMLT PEALVGAGGL PPAAQLPPVA
     FACIDEAHCL SQWSHNFRPC YLRVCKVLRE RMGVHCFLGL TATATRRTAS DVAQHLAVAE
     EPDLHGPAPV PTNLHLSVSM DRDTDQALLT LLQGKRFQNL DSIIIYCNRR EDTERIAALL
     RTCLHAAWVP GSGGRAPKTT AEAYHAGMCS RERRRVQRAF MQGQLRVVVA TVAFGMGLDR
     PDVRAVLHLG LPPSFESYVQ AVGRAGRDGQ PAHCHLFLQP QGEDLRELRR HVHADSTDFL
     AVKRLVQRVF PACTCTCTRP PSEQEGAVGG ERPVPKYPPQ EAEQLSHQAA PGPRRVCMGH
     ERALPIQLTV QALDMPEEAI ETLLCYLELH PHHWLELLAT TYTHCRLNCP GGPAQLQALA
     HRCPPLAVCL AQQLPEDPGQ GSSSVEFDMV KLVDSMGWEL ASVRRALCQL QWDHEPRTGV
     RRGTGVLVEF SELAFHLRSP GDLTAEEKDQ ICDFLYGRVQ ARERQALARL RRTFQAFHSV
     AFPSCGPCLE QQDEERSTRL KDLLGRYFEE EEGQEPGGME DAQGPEPGQA RLQDWEDQVR
     CDIRQFLSLR PEEKFSSRAV ARIFHGIGSP CYPAQVYGQD RRFWRKYLHL SFHALVGLAT
     EELLQVAR
//
ID   A0A024R324_HUMAN        Unreviewed;       193 AA.
AC   A0A024R324; A0A024R2W1;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   22-APR-2020, entry version 50.
DE   SubName: Full=Epididymis secretory sperm binding protein {ECO:0000313|EMBL:ADO22512.1};
DE   SubName: Full=Ras homolog gene family, member A, isoform CRA_a {ECO:0000313|EMBL:EAW64978.1};
GN   Name=RHOA {ECO:0000313|EMBL:EAW64978.1};
GN   ORFNames=hCG_20136 {ECO:0000313|EMBL:EAW64978.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ADO22512.1};
RN   [1] {ECO:0000313|EMBL:EAW64978.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW64978.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:ADO22512.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Hoernsten L., Su C., Osbourn A.E., Hellman U., Wernstedt C., Oliw E.H.;
RL   Submitted (SEP-2009) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; GQ900995; ADO22512.1; -; mRNA.
DR   EMBL; CH471055; EAW64978.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW64979.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW64980.1; -; Genomic_DNA.
DR   RefSeq; NP_001300870.1; NM_001313941.1.
DR   RefSeq; NP_001655.1; NM_001664.3.
DR   IntAct; A0A024R324; 1.
DR   Antibodypedia; 30508; 626 antibodies.
DR   GeneID; 387; -.
DR   KEGG; hsa:387; -.
DR   CTD; 387; -.
DR   EuPathDB; HostDB:ENSG00000067560.10; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   HOGENOM; CLU_041217_21_2_1; -.
DR   KO; K04513; -.
DR   OMA; EVLHFCH; -.
DR   OrthoDB; 1166960at2759; -.
DR   ChiTaRS; RHOA; human.
DR   GenomeRNAi; 387; -.
DR   Bgee; ENSG00000067560; Expressed in metanephric glomerulus and 242 other tissues.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0030027; C:lamellipodium; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0032587; C:ruffle membrane; IEA:Ensembl.
DR   GO; GO:0019003; F:GDP binding; IEA:Ensembl.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IEA:Ensembl.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0051022; F:Rho GDP-dissociation inhibitor binding; IEA:Ensembl.
DR   GO; GO:0002363; P:alpha-beta T cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0001998; P:angiotensin-mediated vasoconstriction involved in regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0043297; P:apical junction assembly; IEA:Ensembl.
DR   GO; GO:0043366; P:beta selection; IEA:Ensembl.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl.
DR   GO; GO:0021861; P:forebrain radial glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0046039; P:GTP metabolic process; IEA:Ensembl.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0033144; P:negative regulation of intracellular steroid hormone receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0090324; P:negative regulation of oxidative phosphorylation; IEA:Ensembl.
DR   GO; GO:1903427; P:negative regulation of reactive oxygen species biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IEA:Ensembl.
DR   GO; GO:0042476; P:odontogenesis; IEA:Ensembl.
DR   GO; GO:0043931; P:ossification involved in bone maturation; IEA:Ensembl.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:1904695; P:positive regulation of vascular smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0050773; P:regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:1905244; P:regulation of modification of synaptic structure; IEA:Ensembl.
DR   GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:0033688; P:regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:0003100; P:regulation of systemic arterial blood pressure by endothelin; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007266; P:Rho protein signal transduction; IEA:Ensembl.
DR   GO; GO:1902766; P:skeletal muscle satellite cell migration; ISS:AgBase.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IEA:Ensembl.
DR   GO; GO:0061383; P:trabecula morphogenesis; IEA:Ensembl.
DR   GO; GO:0044319; P:wound healing, spreading of cells; ISS:AgBase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR003578; Small_GTPase_Rho.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51420; RHO; 1.
PE   2: Evidence at transcript level;
KW   GTP-binding {ECO:0000256|SAAS:SAAS00466048};
KW   Nucleotide-binding {ECO:0000256|SAAS:SAAS00466048}.
SQ   SEQUENCE   193 AA;  21768 MW;  C4DA2DC31FF858BC CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQVELALWDT
     AGQEDYDRLR PLSYPDTDVI LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD
     LRNDEHTRRE LAKMKQEPVK PEEGRDMANR IGAFGYMECS AKTKDGVREV FEMATRAALQ
     ARRGKKKSGC LVL
//
ID   B4DKN9_HUMAN            Unreviewed;       173 AA.
AC   B4DKN9;
DT   23-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   23-SEP-2008, sequence version 1.
DT   22-APR-2020, entry version 62.
DE   SubName: Full=cDNA FLJ57740, highly similar to Transforming protein RhoA {ECO:0000313|EMBL:BAG59251.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG59251.1};
RN   [1] {ECO:0000313|EMBL:BAG59251.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Colon {ECO:0000313|EMBL:BAG59251.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A.,
RA   Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y.,
RA   Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T.,
RA   Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK296654; BAG59251.1; -; mRNA.
DR   RefSeq; NP_001300873.1; NM_001313944.1.
DR   PeptideAtlas; B4DKN9; -.
DR   PRIDE; B4DKN9; -.
DR   GeneID; 387; -.
DR   CTD; 387; -.
DR   GenomeRNAi; 387; -.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:InterPro.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR003578; Small_GTPase_Rho.
DR   Pfam; PF00071; Ras; 2.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51420; RHO; 1.
PE   2: Evidence at transcript level;
KW   GTP-binding {ECO:0000256|SAAS:SAAS00466048};
KW   Nucleotide-binding {ECO:0000256|SAAS:SAAS00466048}.
SQ   SEQUENCE   173 AA;  19570 MW;  32B8F0A4C2DB820D CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADYDRLR PLSYPDTDVI
     LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD LRNDEHTRRE LAKMKQEPVK
     PEEGRDMANR IGAFGYMECS AKTKDGVREV FEMATRAALQ ARRGKKKSGC LVL
//
ID   C9JRM1_HUMAN            Unreviewed;        90 AA.
AC   C9JRM1;
DT   03-NOV-2009, integrated into UniProtKB/TrEMBL.
DT   03-NOV-2009, sequence version 1.
DT   22-APR-2020, entry version 68.
DE   SubName: Full=Transforming protein RhoA {ECO:0000313|Ensembl:ENSP00000394483};
GN   Name=RHOA {ECO:0000313|Ensembl:ENSP00000394483};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000394483, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000394483, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [2] {ECO:0000313|Ensembl:ENSP00000394483}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
RN   [3] {ECO:0000213|PubMed:25944712}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC104452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC121247; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC137114; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001300876.1; NM_001313947.1.
DR   SwissPalm; C9JRM1; -.
DR   jPOST; C9JRM1; -.
DR   MaxQB; C9JRM1; -.
DR   PeptideAtlas; C9JRM1; -.
DR   PRIDE; C9JRM1; -.
DR   ProteomicsDB; 11380; -.
DR   Antibodypedia; 30508; 626 antibodies.
DR   Ensembl; ENST00000454011; ENSP00000394483; ENSG00000067560.
DR   GeneID; 387; -.
DR   UCSC; uc062jta.1; human.
DR   CTD; 387; -.
DR   EuPathDB; HostDB:ENSG00000067560.10; -.
DR   HGNC; HGNC:667; RHOA.
DR   OpenTargets; ENSG00000067560; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   GeneTree; ENSGT00950000182945; -.
DR   HOGENOM; CLU_2440242_0_0_1; -.
DR   ChiTaRS; RHOA; human.
DR   GenomeRNAi; 387; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000067560; Expressed in metanephric glomerulus and 242 other tissues.
DR   ExpressionAtlas; C9JRM1; baseline and differential.
DR   GO; GO:0005525; F:GTP binding; IEA:InterPro.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
PE   1: Evidence at protein level;
KW   Proteomics identification {ECO:0000213|EPD:C9JRM1,
KW   ECO:0000213|MaxQB:C9JRM1, ECO:0000213|PeptideAtlas:C9JRM1,
KW   ECO:0000213|ProteomicsDB:C9JRM1};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
SQ   SEQUENCE   90 AA;  9715 MW;  D149B6073D36E321 CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQKTSQKSGP
     QKSSISVPTC PSSWLGIRRI FGMMSTQGGS
//
ID   C9JX21_HUMAN            Unreviewed;       187 AA.
AC   C9JX21;
DT   03-NOV-2009, integrated into UniProtKB/TrEMBL.
DT   03-NOV-2009, sequence version 1.
DT   22-APR-2020, entry version 79.
DE   SubName: Full=Transforming protein RhoA {ECO:0000313|Ensembl:ENSP00000413587};
GN   Name=RHOA {ECO:0000313|Ensembl:ENSP00000413587};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000413587, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000413587, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [2] {ECO:0000313|Ensembl:ENSP00000413587}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
RN   [3] {ECO:0000213|PubMed:25944712}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC104452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC121247; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC137114; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001300872.1; NM_001313943.1.
DR   SMR; C9JX21; -.
DR   iPTMnet; C9JX21; -.
DR   SwissPalm; C9JX21; -.
DR   jPOST; C9JX21; -.
DR   MaxQB; C9JX21; -.
DR   PeptideAtlas; C9JX21; -.
DR   PRIDE; C9JX21; -.
DR   ProteomicsDB; 12066; -.
DR   Antibodypedia; 30508; 626 antibodies.
DR   Ensembl; ENST00000422781; ENSP00000413587; ENSG00000067560.
DR   GeneID; 387; -.
DR   UCSC; uc062jtb.1; human.
DR   CTD; 387; -.
DR   EuPathDB; HostDB:ENSG00000067560.10; -.
DR   HGNC; HGNC:667; RHOA.
DR   OpenTargets; ENSG00000067560; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   GeneTree; ENSGT00950000182945; -.
DR   ChiTaRS; RHOA; human.
DR   GenomeRNAi; 387; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000067560; Expressed in metanephric glomerulus and 242 other tissues.
DR   ExpressionAtlas; C9JX21; baseline and differential.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:InterPro.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR003578; Small_GTPase_Rho.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51420; RHO; 1.
PE   1: Evidence at protein level;
KW   GTP-binding {ECO:0000256|SAAS:SAAS00466048};
KW   Nucleotide-binding {ECO:0000256|SAAS:SAAS00466048};
KW   Proteomics identification {ECO:0000213|EPD:C9JX21,
KW   ECO:0000213|MaxQB:C9JX21, ECO:0000213|PeptideAtlas:C9JX21,
KW   ECO:0000213|ProteomicsDB:C9JX21};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
SQ   SEQUENCE   187 AA;  21164 MW;  FC5FBC55C61CFE2A CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQVELALWDT
     AGQEDYDRLR PLSYPDTDVI LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD
     LRNDEHTRRE LAKMKQEPHC VARLECCGTI LAQLQPPPPR FKRFPCLSLL SSWGYRRPLP
     HPGAGET
//
ID   RHOA_HUMAN              Reviewed;         193 AA.
AC   P61586; P06749; Q53HM4; Q5U024; Q9UDJ0; Q9UEJ4;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   22-APR-2020, entry version 194.
DE   RecName: Full=Transforming protein RhoA {ECO:0000305};
DE            EC=3.6.5.2 {ECO:0000269|PubMed:21565175, ECO:0000269|PubMed:23940119};
DE   AltName: Full=Rho cDNA clone 12;
DE            Short=h12;
DE   Flags: Precursor;
GN   Name=RHOA {ECO:0000312|HGNC:HGNC:667}; Synonyms=ARH12, ARHA, RHO12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3822842; DOI=10.1093/nar/15.4.1869;
RA   Yeramian P., Chardin P., Madaule P., Tavitian A.;
RT   "Nucleotide sequence of human rho cDNA clone 12.";
RL   Nucleic Acids Res. 15:1869-1869(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Retina;
RX   PubMed=7835413; DOI=10.1006/exer.1994.1102;
RA   Fagan K.P., Oliveira L., Pittler S.J.;
RT   "Sequence of rho small GTP-binding protein cDNAs from human retina and
RT   identification of novel 5' end cloning artifacts.";
RL   Exp. Eye Res. 59:235-237(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Adipose tissue;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Esophageal carcinoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 5-193.
RC   TISSUE=Mammary cancer;
RX   PubMed=8039707; DOI=10.1016/0378-1119(94)90382-4;
RA   Moscow J.A., He R., Gudas J.M., Cowan K.H.;
RT   "Utilization of multiple polyadenylation signals in the human RHOA
RT   protooncogene.";
RL   Gene 144:229-236(1994).
RN   [10]
RP   PROTEIN SEQUENCE OF 28-39; 45-57; 78-86; 130-144; 146-162 AND 165-184, AND
RP   ADP-RIBOSYLATION AT ASN-41 (MICROBIAL INFECTION).
RC   TISSUE=Platelet;
RX   PubMed=1328215;
RA   Nemoto Y., Namba T., Teru-uchi T., Ushikubi F., Morii N., Narumiya S.;
RT   "A rho gene product in human blood platelets. I. Identification of the
RT   platelet substrate for botulinum C3 ADP-ribosyltransferase as rhoA
RT   protein.";
RL   J. Biol. Chem. 267:20916-20920(1992).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 137-193.
RX   PubMed=1556108;
RA   Moscow J.A., Morrow C.S., He R., Mullenbach G.T., Cowan K.H.;
RT   "Structure and function of the 5'-flanking sequence of the human cytosolic
RT   selenium-dependent glutathione peroxidase gene (hgpx1).";
RL   J. Biol. Chem. 267:5949-5958(1992).
RN   [12]
RP   INTERACTION WITH ROCK1.
RX   PubMed=8617235; DOI=10.1002/j.1460-2075.1996.tb00539.x;
RA   Ishizaki T., Maekawa M., Fujisawa K., Okawa K., Iwamatsu A., Fujita A.,
RA   Watanabe N., Saito Y., Kakizuka A., Morii N., Narumiya S.;
RT   "The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr
RT   protein kinase homologous to myotonic dystrophy kinase.";
RL   EMBO J. 15:1885-1893(1996).
RN   [13]
RP   INTERACTION WITH ROCK2.
RX   PubMed=8641286; DOI=10.1002/j.1460-2075.1996.tb00574.x;
RA   Matsui T., Amano M., Yamamoto T., Chihara K., Nakafuku M., Ito M.,
RA   Nakano T., Okawa K., Iwamatsu A., Kaibuchi K.;
RT   "Rho-associated kinase, a novel serine/threonine kinase, as a putative
RT   target for small GTP binding protein Rho.";
RL   EMBO J. 15:2208-2216(1996).
RN   [14]
RP   FUNCTION.
RX   PubMed=8910519; DOI=10.1074/jbc.271.46.28772;
RA   Quilliam L.A., Lambert Q.T., Mickelson-Young L.A., Westwick J.K.,
RA   Sparks A.B., Kay B.K., Jenkins N.A., Gilbert D.J., Copeland N.G., Der C.J.;
RT   "Isolation of a NCK-associated kinase, PRK2, an SH3-binding protein and
RT   potential effector of Rho protein signaling.";
RL   J. Biol. Chem. 271:28772-28776(1996).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH PKN2.
RX   PubMed=9121475; DOI=10.1128/mcb.17.4.2247;
RA   Vincent S., Settleman J.;
RT   "The PRK2 kinase is a potential effector target of both Rho and Rac GTPases
RT   and regulates actin cytoskeletal organization.";
RL   Mol. Cell. Biol. 17:2247-2256(1997).
RN   [16]
RP   FUNCTION, INTERACTION WITH KCNA2, AND SUBCELLULAR LOCATION.
RX   PubMed=9635436; DOI=10.1016/s0092-8674(00)81212-x;
RA   Cachero T.G., Morielli A.D., Peralta E.G.;
RT   "The small GTP-binding protein RhoA regulates a delayed rectifier potassium
RT   channel.";
RL   Cell 93:1077-1085(1998).
RN   [17]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=9857026; DOI=10.1074/jbc.273.52.34954;
RA   Ren Y., Li R., Zheng Y., Busch H.;
RT   "Cloning and characterization of GEF-H1, a microtubule-associated guanine
RT   nucleotide exchange factor for Rac and Rho GTPases.";
RL   J. Biol. Chem. 273:34954-34960(1998).
RN   [18]
RP   INTERACTION WITH DGKQ, AND MUTAGENESIS OF TYR-34.
RX   PubMed=10066731; DOI=10.1074/jbc.274.11.6820;
RA   Houssa B., de Widt J., Kranenburg O., Moolenaar W.H.,
RA   van Blitterswijk W.J.;
RT   "Diacylglycerol kinase theta binds to and is negatively regulated by active
RT   RhoA.";
RL   J. Biol. Chem. 274:6820-6822(1999).
RN   [19]
RP   INTERACTION WITH HRSV PROTEIN F (MICROBIAL INFECTION).
RX   PubMed=10438814;
RA   Pastey M.K., Crowe J.E. Jr., Graham B.S.;
RT   "RhoA interacts with the fusion glycoprotein of respiratory syncytial virus
RT   and facilitates virus-induced syncytium formation.";
RL   J. Virol. 73:7262-7270(1999).
RN   [20]
RP   INTERACTION WITH RTKN.
RX   PubMed=10940294; DOI=10.1074/jbc.m000465200;
RA   Reynaud C., Fabre S., Jalinot P.;
RT   "The PDZ protein TIP-1 interacts with the Rho effector rhotekin and is
RT   involved in Rho signaling to the serum response element.";
RL   J. Biol. Chem. 275:33962-33968(2000).
RN   [21]
RP   PHOSPHORYLATION AT SER-188 BY PRKG1.
RX   PubMed=11162591; DOI=10.1006/bbrc.2000.4194;
RA   Sawada N., Itoh H., Yamashita J., Doi K., Inoue M., Masatsugu K.,
RA   Fukunaga Y., Sakaguchi S., Sone M., Yamahara K., Yurugi T., Nakao K.;
RT   "cGMP-dependent protein kinase phosphorylates and inactivates RhoA.";
RL   Biochem. Biophys. Res. Commun. 280:798-805(2001).
RN   [22]
RP   INTERACTION WITH AKAP13.
RX   PubMed=11696353; DOI=10.1016/s0014-5793(01)02995-7;
RA   Klussmann E., Edemir B., Pepperle B., Tamma G., Henn V., Klauschenz E.,
RA   Hundsrucker C., Maric K., Rosenthal W.;
RT   "Ht31: the first protein kinase A anchoring protein to integrate protein
RT   kinase A and Rho signaling.";
RL   FEBS Lett. 507:264-268(2001).
RN   [23]
RP   INTERACTION WITH ARHGEF3, AND ACTIVITY REGULATION.
RX   PubMed=12221096; DOI=10.1074/jbc.m207401200;
RA   Arthur W.T., Ellerbroek S.M., Der C.J., Burridge K., Wennerberg K.;
RT   "XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not
RT   RhoC.";
RL   J. Biol. Chem. 277:42964-42972(2002).
RN   [24]
RP   INTERACTION WITH YERSINIA PESTIS YOPT (MICROBIAL INFECTION), CLEAVAGE
RP   (MICROBIAL INFECTION), AND FUNCTION (MICROBIAL INFECTION).
RX   PubMed=12062101; DOI=10.1016/s0092-8674(02)00766-3;
RA   Shao F., Merritt P.M., Bao Z., Innes R.W., Dixon J.E.;
RT   "A Yersinia effector and a Pseudomonas avirulence protein define a family
RT   of cysteine proteases functioning in bacterial pathogenesis.";
RL   Cell 109:575-588(2002).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH PLCE1.
RX   PubMed=12900402; DOI=10.1074/jbc.m306904200;
RA   Wing M.R., Snyder J.T., Sondek J., Harden T.K.;
RT   "Direct activation of phospholipase C-epsilon by Rho.";
RL   J. Biol. Chem. 278:41253-41258(2003).
RN   [26]
RP   INTERACTION WITH YERSINIA PSEUDOTUBERCULOSIS YOPT (MICROBIAL INFECTION),
RP   CLEAVAGE (MICROBIAL INFECTION), MUTAGENESIS OF LEU-193, AND FUNCTION
RP   (MICROBIAL INFECTION).
RX   PubMed=12538863; DOI=10.1073/pnas.252770599;
RA   Shao F., Vacratsis P.O., Bao Z., Bowers K.E., Fierke C.A., Dixon J.E.;
RT   "Biochemical characterization of the Yersinia YopT protease: cleavage site
RT   and recognition elements in Rho GTPases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:904-909(2003).
RN   [27]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16103226; DOI=10.1083/jcb.200501097;
RA   Yuce O., Piekny A., Glotzer M.;
RT   "An ECT2-centralspindlin complex regulates the localization and function of
RT   RhoA.";
RL   J. Cell Biol. 170:571-582(2005).
RN   [28]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16236794; DOI=10.1091/mbc.e05-06-0569;
RA   Kamijo K., Ohara N., Abe M., Uchimura T., Hosoya H., Lee J.S., Miki T.;
RT   "Dissecting the role of Rho-mediated signaling in contractile ring
RT   formation.";
RL   Mol. Biol. Cell 17:43-55(2006).
RN   [29]
RP   INTERACTION WITH PKP4, AND SUBCELLULAR LOCATION.
RX   PubMed=17115030; DOI=10.1038/ncb1504;
RA   Wolf A., Keil R., Gotzl O., Mun A., Schwarze K., Lederer M.,
RA   Huttelmaier S., Hatzfeld M.;
RT   "The armadillo protein p0071 regulates Rho signalling during cytokinesis.";
RL   Nat. Cell Biol. 8:1432-1440(2006).
RN   [30]
RP   FUNCTION.
RX   PubMed=19934221; DOI=10.1242/jcs.053728;
RA   Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L., Webb D.J.;
RT   "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin
RT   dynamics and thereby regulate cell migration.";
RL   J. Cell Sci. 122:4535-4546(2009).
RN   [31]
RP   FUNCTION.
RX   PubMed=19403695; DOI=10.1091/mbc.e08-10-1074;
RA   Stirling L., Williams M.R., Morielli A.D.;
RT   "Dual roles for RHOA/RHO-kinase in the regulated trafficking of a voltage-
RT   sensitive potassium channel.";
RL   Mol. Biol. Cell 20:2991-3002(2009).
RN   [32]
RP   AMPYLATION AT TYR-34 (MICROBIAL INFECTION), AND MUTAGENESIS OF TYR-34.
RX   PubMed=19362538; DOI=10.1016/j.molcel.2009.03.008;
RA   Worby C.A., Mattoo S., Kruger R.P., Corbeil L.B., Koller A., Mendez J.C.,
RA   Zekarias B., Lazar C., Dixon J.E.;
RT   "The fic domain: regulation of cell signaling by adenylylation.";
RL   Mol. Cell 34:93-103(2009).
RN   [33]
RP   UBIQUITINATION.
RX   PubMed=19782033; DOI=10.1016/j.molcel.2009.09.004;
RA   Chen Y., Yang Z., Meng M., Zhao Y., Dong N., Yan H., Liu L., Ding M.,
RA   Peng H.B., Shao F.;
RT   "Cullin mediates degradation of RhoA through evolutionarily conserved BTB
RT   adaptors to control actin cytoskeleton structure and cell movement.";
RL   Mol. Cell 35:841-855(2009).
RN   [34]
RP   AMPYLATION AT THR-37 (MICROBIAL INFECTION).
RX   PubMed=19039103; DOI=10.1126/science.1166382;
RA   Yarbrough M.L., Li Y., Kinch L.N., Grishin N.V., Ball H.L., Orth K.;
RT   "AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and
RT   downstream signaling.";
RL   Science 323:269-272(2009).
RN   [35]
RP   MUTAGENESIS OF GLY-14.
RX   PubMed=19948726; DOI=10.1074/jbc.m109.088427;
RA   Chatterjee A., Wang L., Armstrong D.L., Rossie S.;
RT   "Activated Rac1 GTPase translocates protein phosphatase 5 to the cell
RT   membrane and stimulates phosphatase activity in vitro.";
RL   J. Biol. Chem. 285:3872-3882(2010).
RN   [36]
RP   INTERACTION WITH ARHGDIA, AND ACTIVITY REGULATION.
RX   PubMed=20400958; DOI=10.1038/ncb2049;
RA   Boulter E., Garcia-Mata R., Guilluy C., Dubash A., Rossi G.,
RA   Brennwald P.J., Burridge K.;
RT   "Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1.";
RL   Nat. Cell Biol. 12:477-483(2010).
RN   [37]
RP   FUNCTION.
RX   PubMed=20937854; DOI=10.1073/pnas.1000975107;
RA   Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.;
RT   "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the
RT   plasma membrane of migrating cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=21565175; DOI=10.1016/j.bbrc.2011.04.116;
RA   Naji L., Pacholsky D., Aspenstrom P.;
RT   "ARHGAP30 is a Wrch-1-interacting protein involved in actin dynamics and
RT   cell adhesion.";
RL   Biochem. Biophys. Res. Commun. 409:96-102(2011).
RN   [40]
RP   INTERACTION WITH RACK1.
RX   PubMed=20499158; DOI=10.1007/s10549-010-0955-3;
RA   Cao X.X., Xu J.D., Xu J.W., Liu X.L., Cheng Y.Y., Li Q.Q., Xu Z.D.,
RA   Liu X.P.;
RT   "RACK1 promotes breast carcinoma migration/metastasis via activation of the
RT   RhoA/Rho kinase pathway.";
RL   Breast Cancer Res. Treat. 126:555-563(2011).
RN   [41]
RP   FUNCTION, AND INTERACTION WITH PKN2.
RX   PubMed=20974804; DOI=10.1128/mcb.01001-10;
RA   Wallace S.W., Magalhaes A., Hall A.;
RT   "The Rho target PRK2 regulates apical junction formation in human bronchial
RT   epithelial cells.";
RL   Mol. Cell. Biol. 31:81-91(2011).
RN   [42]
RP   FUNCTION, ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=23940119; DOI=10.1083/jcb.201304133;
RA   Dubash A.D., Koetsier J.L., Amargo E.V., Najor N.A., Harmon R.M.,
RA   Green K.J.;
RT   "The GEF Bcr activates RhoA/MAL signaling to promote keratinocyte
RT   differentiation via desmoglein-1.";
RL   J. Cell Biol. 202:653-666(2013).
RN   [43]
RP   INTERACTION WITH DIAPH1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23325789; DOI=10.1091/mbc.e12-08-0597;
RA   Li D., Dammer E.B., Lucki N.C., Sewer M.B.;
RT   "cAMP-stimulated phosphorylation of diaphanous 1 regulates protein
RT   stability and interaction with binding partners in adrenocortical cells.";
RL   Mol. Biol. Cell 24:848-857(2013).
RN   [44]
RP   GLYCOSYLATION AT TYR-34 (MICROBIAL INFECTION).
RX   PubMed=24141704; DOI=10.1038/nsmb.2688;
RA   Jank T., Bogdanovic X., Wirth C., Haaf E., Spoerner M., Boehmer K.E.,
RA   Steinemann M., Orth J.H., Kalbitzer H.R., Warscheid B., Hunte C.,
RA   Aktories K.;
RT   "A bacterial toxin catalyzing tyrosine glycosylation of Rho and deamidation
RT   of Gq and Gi proteins.";
RL   Nat. Struct. Mol. Biol. 20:1273-1280(2013).
RN   [45]
RP   INTERACTION WITH RIPOR2.
RX   PubMed=25588844; DOI=10.1242/jcs.161497;
RA   Gao K., Tang W., Li Y., Zhang P., Wang D., Yu L., Wang C., Wu D.;
RT   "Front-signal-dependent accumulation of the RHOA inhibitor FAM65B at
RT   leading edges polarizes neutrophils.";
RL   J. Cell Sci. 128:992-1000(2015).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [47]
RP   INTERACTION WITH RIPOR1.
RX   PubMed=27807006; DOI=10.1242/jcs.198614;
RA   Mardakheh F.K., Self A., Marshall C.J.;
RT   "RHO binding to FAM65A regulates Golgi reorientation during cell
RT   migration.";
RL   J. Cell Sci. 129:4466-4479(2016).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   PubMed=9302995; DOI=10.1038/nsb0997-699;
RA   Wei Y., Zhang Y., Derewenda U., Liu X., Minor W., Nakamoto R.K.,
RA   Somlyo A.V., Somlyo A.P., Derewenda Z.S.;
RT   "Crystal structure of RhoA-GDP and its functional implications.";
RL   Nat. Struct. Biol. 4:699-703(1997).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 4-181 OF MUTANT VAL-14.
RX   PubMed=9545299; DOI=10.1074/jbc.273.16.9656;
RA   Ihara K., Muraguchi S., Kato M., Shimizu T., Shirakawa M., Kuroda S.,
RA   Kaibuchi K., Hakoshima T.;
RT   "Crystal structure of human RhoA in a dominantly active form complexed with
RT   a GTP analogue.";
RL   J. Biol. Chem. 273:9656-9666(1998).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-181 IN COMPLEX WITH PRKCL1.
RX   PubMed=10388627; DOI=10.1006/jsbi.1999.4114;
RA   Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K., Hakoshima T.;
RT   "Biochemical and crystallographic characterization of a Rho effector domain
RT   of the protein serine/threonine kinase N in a complex with RhoA.";
RL   J. Struct. Biol. 126:166-170(1999).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 3-180 IN COMPLEX WITH GDP.
RX   PubMed=10748207; DOI=10.1074/jbc.m910274199;
RA   Shimizu T., Ihara K., Maesaki R., Kuroda S., Kaibuchi K., Hakoshima T.;
RT   "An open conformation of switch I revealed by the crystal structure of a
RT   Mg2+-free form of RHOA complexed with GDP. Implications for the GDP/GTP
RT   exchange mechanism.";
RL   J. Biol. Chem. 275:18311-18317(2000).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   PubMed=11927263; DOI=10.1016/s1074-5521(02)00112-6;
RA   Graham D.L., Lowe P.N., Grime G.W., Marsh M., Rittinger K., Smerdon S.J.,
RA   Gamblin S.J., Eccleston J.F.;
RT   "MgF(3)(-) as a transition state analog of phosphoryl transfer.";
RL   Chem. Biol. 9:375-381(2002).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.81 ANGSTROMS) IN COMPLEX WITH MCF2.
RX   PubMed=12006984; DOI=10.1038/nsb796;
RA   Snyder J.T., Worthylake D.K., Rossman K.L., Betts L., Pruitt W.M.,
RA   Siderovski D.P., Der C.J., Sondek J.;
RT   "Structural basis for the selective activation of Rho GTPases by Dbl
RT   exchange factors.";
RL   Nat. Struct. Biol. 9:468-475(2002).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF MUTANT LEU-63 IN COMPLEX WITH A
RP   GTP ANALOG AND MG(2+).
RX   PubMed=12777804; DOI=10.1107/s0907444903005390;
RA   Longenecker K., Read P., Lin S.-K., Somlyo A.P., Nakamoto R.K.,
RA   Derewenda Z.S.;
RT   "Structure of a constitutively activated RhoA mutant (Q63L) at 1.55 A
RT   resolution.";
RL   Acta Crystallogr. D 59:876-880(2003).
CC   -!- FUNCTION: Small GTPase which cycles between an active GTP-bound and an
CC       inactive GDP-bound state. Mainly associated with cytoskeleton
CC       organization, in active state binds to a variety of effector proteins
CC       to regulate cellular responses such cytoskeletal dynamics, cell
CC       migration and cell cycle. Regulates a signal transduction pathway
CC       linking plasma membrane receptors to the assembly of focal adhesions
CC       and actin stress fibers (PubMed:8910519, PubMed:9121475). Involved in a
CC       microtubule-dependent signal that is required for the myosin
CC       contractile ring formation during cell cycle cytokinesis
CC       (PubMed:16236794, PubMed:12900402). Plays an essential role in cleavage
CC       furrow formation. Required for the apical junction formation of
CC       keratinocyte cell-cell adhesion (PubMed:20974804, PubMed:23940119).
CC       Essential for the SPATA13-mediated regulation of cell migration and
CC       adhesion assembly and disassembly (PubMed:19934221). The MEMO1-RHOA-
CC       DIAPH1 signaling pathway plays an important role in ERBB2-dependent
CC       stabilization of microtubules at the cell cortex. It controls the
CC       localization of APC and CLASP2 to the cell membrane, via the regulation
CC       of GSK3B activity. In turn, membrane-bound APC allows the localization
CC       of the MACF1 to the cell membrane, which is required for microtubule
CC       capture and stabilization (PubMed:20937854). Regulates KCNA2 potassium
CC       channel activity by reducing its location at the cell surface in
CC       response to CHRM1 activation; promotes KCNA2 endocytosis
CC       (PubMed:9635436, PubMed:19403695). May be an activator of PLCE1
CC       (PubMed:16103226). In neurons, involved in the inhibiton of the initial
CC       spine growth. Upon activation by CaMKII, modulates dendritic spine
CC       structural plasticity by relaying CaMKII transient activation to
CC       synapse-specific, long-term signaling (By similarity).
CC       {ECO:0000250|UniProtKB:P61589, ECO:0000269|PubMed:12900402,
CC       ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16236794,
CC       ECO:0000269|PubMed:19403695, ECO:0000269|PubMed:19934221,
CC       ECO:0000269|PubMed:20937854, ECO:0000269|PubMed:20974804,
CC       ECO:0000269|PubMed:23940119, ECO:0000269|PubMed:8910519,
CC       ECO:0000269|PubMed:9121475, ECO:0000269|PubMed:9635436}.
CC   -!- FUNCTION: (Microbial infection) Serves as a target for the yopT
CC       cysteine peptidase from Yersinia pestis, vector of the plague.
CC       {ECO:0000269|PubMed:12062101, ECO:0000269|PubMed:12538863}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP + H2O = GDP + H(+) + phosphate; Xref=Rhea:RHEA:19669,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2;
CC         Evidence={ECO:0000269|PubMed:21565175, ECO:0000269|PubMed:23940119};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19670;
CC         Evidence={ECO:0000305|PubMed:21565175, ECO:0000305|PubMed:23940119};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:12777804};
CC   -!- ACTIVITY REGULATION: Regulated by guanine nucleotide exchange factors
CC       (GEFs) which promote the exchange of bound GDP for free GTP, GTPase
CC       activating proteins (GAPs) which increase the GTP hydrolysis activity
CC       and GDP dissociation inhibitors which inhibit the dissociation of the
CC       nucleotide from the GTPase. Activated by GEFs such as ARHGEF2, ARHGEF3,
CC       ARHGEF28 and BCR (PubMed:23940119, PubMed:12221096). Inhibited by GAPs
CC       such as ARHGAP30 (PubMed:21565175). Inhibited by GDP dissociation
CC       inhibitors such as ARHGDIA (PubMed:20400958).
CC       {ECO:0000269|PubMed:12221096, ECO:0000269|PubMed:20400958,
CC       ECO:0000269|PubMed:21565175, ECO:0000269|PubMed:23940119}.
CC   -!- SUBUNIT: Interacts with ARHGEF28 (By similarity). Interacts (via GTP-
CC       bound form) with RIPOR1 (via N-terminus); this interaction links RHOA
CC       to STK24 and STK26 kinases (PubMed:27807006). Interacts with RIPOR2
CC       (via active GTP- or inactive GDP-bound forms) isoform 1 and isoform 2;
CC       these interactions are direct, block the loading of GTP to RHOA and
CC       decrease upon chemokine CCL19 stimulation in primary T lymphocytes
CC       (PubMed:25588844). Binds PRKCL1, ROCK1 and ROCK2 (PubMed:10388627,
CC       PubMed:8617235, PubMed:8641286). Interacts with ARHGEF2, ARHGEF3, NET1
CC       and RTKN (PubMed:10940294, PubMed:12221096, PubMed:9857026). Interacts
CC       with PLCE1 and AKAP13 (PubMed:11696353, PubMed:12900402). Interacts
CC       with DIAPH1 (PubMed:23325789). Interacts (in the constitutively
CC       activated, GTP-bound form) with DGKQ (PubMed:10066731). Interacts with
CC       RACK1; enhances RHOA activation (PubMed:20499158). Interacts with PKP4;
CC       the interaction is detected at the midbody (PubMed:17115030). Interacts
CC       (GTP-bound form preferentially) with PKN2; the interaction stimulates
CC       autophosphorylation and phosphorylation of PKN2 (PubMed:20974804,
CC       PubMed:9121475). Interacts with ARHGDIA; this interaction inactivates
CC       and stabilizes RHOA (PubMed:20400958). Interacts with ARHGDIB.
CC       Interacts (GTP-bound form) with KCNA2 (via cytoplasmic N-terminal
CC       domain) (PubMed:9635436). {ECO:0000250|UniProtKB:Q9QUI0,
CC       ECO:0000269|PubMed:10066731, ECO:0000269|PubMed:10388627,
CC       ECO:0000269|PubMed:10940294, ECO:0000269|PubMed:11696353,
CC       ECO:0000269|PubMed:12221096, ECO:0000269|PubMed:12900402,
CC       ECO:0000269|PubMed:17115030, ECO:0000269|PubMed:20400958,
CC       ECO:0000269|PubMed:20499158, ECO:0000269|PubMed:20974804,
CC       ECO:0000269|PubMed:25588844, ECO:0000269|PubMed:27807006,
CC       ECO:0000269|PubMed:8617235, ECO:0000269|PubMed:8641286,
CC       ECO:0000269|PubMed:9121475, ECO:0000269|PubMed:9857026,
CC       ECO:0000305|PubMed:9635436}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with yopT from Yersinia
CC       pestis. {ECO:0000269|PubMed:12062101, ECO:0000269|PubMed:12538863}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human respiratory
CC       syncytial virus (HRSV) protein F; this interaction facilitates virus-
CC       induced syncytium formation. {ECO:0000269|PubMed:10438814}.
CC   -!- INTERACTION:
CC       P61586; Q15109: AGER; NbExp=2; IntAct=EBI-446668, EBI-1646426;
CC       P61586; Q7Z6G8-3: ANKS1B; NbExp=3; IntAct=EBI-446668, EBI-17714371;
CC       P61586; Q07960: ARHGAP1; NbExp=3; IntAct=EBI-446668, EBI-602762;
CC       P61586; P52565: ARHGDIA; NbExp=5; IntAct=EBI-446668, EBI-712693;
CC       P61586; O15085: ARHGEF11; NbExp=9; IntAct=EBI-446668, EBI-311099;
CC       P61586; Q9NZN5: ARHGEF12; NbExp=2; IntAct=EBI-446668, EBI-821440;
CC       P61586; Q8IW93: ARHGEF19; NbExp=2; IntAct=EBI-446668, EBI-7799822;
CC       P61586; Q92974: ARHGEF2; NbExp=3; IntAct=EBI-446668, EBI-302405;
CC       P61586; P46527: CDKN1B; NbExp=3; IntAct=EBI-446668, EBI-519280;
CC       P61586; Q9Y4D1: DAAM1; NbExp=5; IntAct=EBI-446668, EBI-2817289;
CC       P61586; O60610: DIAPH1; NbExp=3; IntAct=EBI-446668, EBI-3959709;
CC       P61586; O08808: Diaph1; Xeno; NbExp=3; IntAct=EBI-446668, EBI-1026445;
CC       P61586; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-446668, EBI-747204;
CC       P61586; Q6PDM6: Mcf2l; Xeno; NbExp=3; IntAct=EBI-446668, EBI-602149;
CC       P61586; P19338: NCL; NbExp=3; IntAct=EBI-446668, EBI-346967;
CC       P61586; Q9Z0S9: Rabac1; Xeno; NbExp=2; IntAct=EBI-446668, EBI-476965;
CC       P61586; Q9Y4F9: RIPOR2; NbExp=4; IntAct=EBI-446668, EBI-2798942;
CC       P61586; Q9Y4F9-2: RIPOR2; NbExp=3; IntAct=EBI-446668, EBI-14509742;
CC       P61586; Q96MK2: RIPOR3; NbExp=3; IntAct=EBI-446668, EBI-12010512;
CC       P61586; Q13464: ROCK1; NbExp=4; IntAct=EBI-446668, EBI-876651;
CC       P61586; Q9BST9: RTKN; NbExp=6; IntAct=EBI-446668, EBI-446694;
CC       P61586; Q8C6B2: Rtkn; Xeno; NbExp=4; IntAct=EBI-446668, EBI-1162441;
CC       P61586; Q15796: SMAD2; NbExp=2; IntAct=EBI-446668, EBI-1040141;
CC       P61586; Q9HCE7-2: SMURF1; NbExp=2; IntAct=EBI-446668, EBI-9845742;
CC       P61586; A0A0F6B1Q8: sseJ; Xeno; NbExp=7; IntAct=EBI-446668, EBI-10760263;
CC       P61586; Q9FD10: sseJ; Xeno; NbExp=3; IntAct=EBI-446668, EBI-10690199;
CC       P61586; Q15654: TRIP6; NbExp=3; IntAct=EBI-446668, EBI-742327;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor; Cytoplasmic side.
CC       Cytoplasm, cytoskeleton. Cleavage furrow. Cytoplasm, cell cortex
CC       {ECO:0000269|PubMed:9635436}. Midbody. Cell projection, lamellipodium
CC       {ECO:0000250|UniProtKB:Q9QUI0}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:Q9QUI0}. Note=Localized to cell-cell contacts in
CC       calcium-treated keratinocytes (By similarity). Translocates to the
CC       equatorial region before furrow formation in a ECT2-dependent manner.
CC       Localizes to the equatorial cell cortex (at the site of the presumptive
CC       furrow) in early anaphase in an activated form and in a myosin- and
CC       actin-independent manner. {ECO:0000250|UniProtKB:Q9QUI0}.
CC   -!- DOMAIN: The basic-rich region is essential for yopT recognition and
CC       cleavage.
CC   -!- PTM: (Microbial infection) Substrate for botulinum ADP-
CC       ribosyltransferase. {ECO:0000269|PubMed:1328215}.
CC   -!- PTM: (Microbial infection) Cleaved by yopT protease when the cell is
CC       infected by some Yersinia pathogens. This removes the lipid attachment,
CC       and leads to its displacement from plasma membrane and to subsequent
CC       cytoskeleton cleavage. {ECO:0000269|PubMed:12062101,
CC       ECO:0000269|PubMed:12538863}.
CC   -!- PTM: (Microbial infection) AMPylation at Tyr-34 and Thr-37 are mediated
CC       by bacterial enzymes in case of infection by H.somnus and
CC       V.parahaemolyticus, respectively. AMPylation occurs in the effector
CC       region and leads to inactivation of the GTPase activity by preventing
CC       the interaction with downstream effectors, thereby inhibiting actin
CC       assembly in infected cells. It is unclear whether some human enzyme
CC       mediates AMPylation; FICD has such ability in vitro but additional
CC       experiments remain to be done to confirm results in vivo.
CC       {ECO:0000269|PubMed:19039103, ECO:0000269|PubMed:19362538}.
CC   -!- PTM: (Microbial infection) Glycosylated at Tyr-34 by Photorhabdus
CC       asymbiotica toxin PAU_02230. Mono-O-GlcNAcylation by PAU_02230 inhibits
CC       downstream signaling by an impaired interaction with diverse regulator
CC       and effector proteins of Rho and leads to actin disassembly.
CC       {ECO:0000269|PubMed:24141704}.
CC   -!- PTM: Phosphorylation by PRKG1 at Ser-188 inactivates RHOA signaling
CC       (PubMed:11162591). Phosphorylation by SLK at Ser-188 in response to
CC       AGTR2 activation (By similarity). {ECO:0000250|UniProtKB:P61589,
CC       ECO:0000269|PubMed:11162591}.
CC   -!- PTM: Ubiquitinated by the BCR(KCTD13) and BCR(TNFAIP1) E3 ubiquitin
CC       ligase complexes, leading to its degradation by the proteasome, thereby
CC       regulating the actin cytoskeleton and synaptic transmission in neurons.
CC       {ECO:0000269|PubMed:19782033}.
CC   -!- SIMILARITY: Belongs to the small GTPase superfamily. Rho family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RHOAID42107ch3p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X05026; CAA28690.1; -; mRNA.
DR   EMBL; L25080; AAC33178.1; -; mRNA.
DR   EMBL; AF498970; AAM21117.1; -; mRNA.
DR   EMBL; BT019870; AAV38673.1; -; mRNA.
DR   EMBL; AK222556; BAD96276.1; -; mRNA.
DR   EMBL; BX647063; CAE46190.1; -; mRNA.
DR   EMBL; AC104452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC121247; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC137114; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001360; AAH01360.1; -; mRNA.
DR   EMBL; BC005976; AAH05976.1; -; mRNA.
DR   EMBL; L09159; AAA50612.1; -; mRNA.
DR   EMBL; M83094; AAA67539.1; -; Genomic_DNA.
DR   CCDS; CCDS2795.1; -.
DR   PIR; A26675; TVHU12.
DR   RefSeq; NP_001300870.1; NM_001313941.1.
DR   RefSeq; NP_001655.1; NM_001664.3.
DR   PDB; 1A2B; X-ray; 2.40 A; A=1-181.
DR   PDB; 1CC0; X-ray; 5.00 A; A/C=1-190.
DR   PDB; 1CXZ; X-ray; 2.20 A; A=1-181.
DR   PDB; 1DPF; X-ray; 2.00 A; A=1-180.
DR   PDB; 1FTN; X-ray; 2.10 A; A=1-193.
DR   PDB; 1KMQ; X-ray; 1.55 A; A=4-181.
DR   PDB; 1LB1; X-ray; 2.81 A; B/D/F/H=1-190.
DR   PDB; 1OW3; X-ray; 1.80 A; B=1-193.
DR   PDB; 1S1C; X-ray; 2.60 A; A/B=1-181.
DR   PDB; 1TX4; X-ray; 1.65 A; B=3-179.
DR   PDB; 1X86; X-ray; 3.22 A; B/D/F/H=1-193.
DR   PDB; 1XCG; X-ray; 2.50 A; B/F=3-180.
DR   PDB; 2RGN; X-ray; 3.50 A; C/F=1-193.
DR   PDB; 3KZ1; X-ray; 2.70 A; E/F=1-181.
DR   PDB; 3LW8; X-ray; 1.85 A; A/B/C/D=2-181.
DR   PDB; 3LWN; X-ray; 2.28 A; A/B=2-181.
DR   PDB; 3LXR; X-ray; 1.68 A; A=2-181.
DR   PDB; 3MSX; X-ray; 1.65 A; A=1-180.
DR   PDB; 3T06; X-ray; 2.84 A; B/F=3-180.
DR   PDB; 4D0N; X-ray; 2.10 A; A=1-184.
DR   PDB; 4XH9; X-ray; 2.00 A; B/E=2-180.
DR   PDB; 4XOI; X-ray; 2.09 A; A/C=1-180.
DR   PDB; 4XSG; X-ray; 1.80 A; A=1-179.
DR   PDB; 4XSH; X-ray; 2.50 A; A=1-179.
DR   PDB; 5A0F; X-ray; 2.00 A; A=1-181.
DR   PDB; 5BWM; X-ray; 2.50 A; A=1-179.
DR   PDB; 5C2K; X-ray; 1.42 A; A=1-193.
DR   PDB; 5C4M; X-ray; 1.30 A; A=1-193.
DR   PDB; 5EZ6; X-ray; 1.80 A; B=1-181.
DR   PDB; 5FR1; X-ray; 2.75 A; A=1-193.
DR   PDB; 5FR2; X-ray; 3.35 A; A=1-193.
DR   PDB; 5HPY; X-ray; 2.40 A; B/F=3-181.
DR   PDB; 5IRC; X-ray; 1.72 A; D/F=2-181.
DR   PDB; 5JCP; X-ray; 2.10 A; A/B=1-181.
DR   PDB; 5JHG; X-ray; 2.50 A; B/F=1-181.
DR   PDB; 5JHH; X-ray; 2.30 A; B/F=1-181.
DR   PDB; 5M6X; X-ray; 2.40 A; B/I=2-193.
DR   PDB; 5M70; X-ray; 2.20 A; B/G=2-193.
DR   PDB; 5ZHX; X-ray; 3.50 A; e/f/g/h=1-193.
DR   PDB; 6BC0; X-ray; 2.20 A; F=1-181.
DR   PDB; 6BCA; X-ray; 2.00 A; C/F=1-181.
DR   PDB; 6BCB; X-ray; 1.40 A; F=1-181.
DR   PDB; 6R3V; X-ray; 1.75 A; B=1-193.
DR   PDBsum; 1A2B; -.
DR   PDBsum; 1CC0; -.
DR   PDBsum; 1CXZ; -.
DR   PDBsum; 1DPF; -.
DR   PDBsum; 1FTN; -.
DR   PDBsum; 1KMQ; -.
DR   PDBsum; 1LB1; -.
DR   PDBsum; 1OW3; -.
DR   PDBsum; 1S1C; -.
DR   PDBsum; 1TX4; -.
DR   PDBsum; 1X86; -.
DR   PDBsum; 1XCG; -.
DR   PDBsum; 2RGN; -.
DR   PDBsum; 3KZ1; -.
DR   PDBsum; 3LW8; -.
DR   PDBsum; 3LWN; -.
DR   PDBsum; 3LXR; -.
DR   PDBsum; 3MSX; -.
DR   PDBsum; 3T06; -.
DR   PDBsum; 4D0N; -.
DR   PDBsum; 4XH9; -.
DR   PDBsum; 4XOI; -.
DR   PDBsum; 4XSG; -.
DR   PDBsum; 4XSH; -.
DR   PDBsum; 5A0F; -.
DR   PDBsum; 5BWM; -.
DR   PDBsum; 5C2K; -.
DR   PDBsum; 5C4M; -.
DR   PDBsum; 5EZ6; -.
DR   PDBsum; 5FR1; -.
DR   PDBsum; 5FR2; -.
DR   PDBsum; 5HPY; -.
DR   PDBsum; 5IRC; -.
DR   PDBsum; 5JCP; -.
DR   PDBsum; 5JHG; -.
DR   PDBsum; 5JHH; -.
DR   PDBsum; 5M6X; -.
DR   PDBsum; 5M70; -.
DR   PDBsum; 5ZHX; -.
DR   PDBsum; 6BC0; -.
DR   PDBsum; 6BCA; -.
DR   PDBsum; 6BCB; -.
DR   PDBsum; 6R3V; -.
DR   SMR; P61586; -.
DR   BioGrid; 106880; 195.
DR   CORUM; P61586; -.
DR   DIP; DIP-29642N; -.
DR   IntAct; P61586; 163.
DR   MINT; P61586; -.
DR   STRING; 9606.ENSP00000400175; -.
DR   BindingDB; P61586; -.
DR   ChEMBL; CHEMBL6052; -.
DR   DrugBank; DB04315; Guanosine-5'-Diphosphate.
DR   iPTMnet; P61586; -.
DR   MetOSite; P61586; -.
DR   PhosphoSitePlus; P61586; -.
DR   SwissPalm; P61586; -.
DR   BioMuta; RHOA; -.
DR   DMDM; 47606458; -.
DR   EPD; P61586; -.
DR   jPOST; P61586; -.
DR   MassIVE; P61586; -.
DR   MaxQB; P61586; -.
DR   PaxDb; P61586; -.
DR   PeptideAtlas; P61586; -.
DR   PRIDE; P61586; -.
DR   ProteomicsDB; 57321; -.
DR   TopDownProteomics; P61586; -.
DR   Antibodypedia; 30508; 626 antibodies.
DR   DNASU; 387; -.
DR   Ensembl; ENST00000418115; ENSP00000400175; ENSG00000067560.
DR   GeneID; 387; -.
DR   KEGG; hsa:387; -.
DR   UCSC; uc003cwu.4; human.
DR   CTD; 387; -.
DR   DisGeNET; 387; -.
DR   GeneCards; RHOA; -.
DR   HGNC; HGNC:667; RHOA.
DR   HPA; ENSG00000067560; Low tissue specificity.
DR   MIM; 165390; gene.
DR   neXtProt; NX_P61586; -.
DR   OpenTargets; ENSG00000067560; -.
DR   PharmGKB; PA134865095; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   GeneTree; ENSGT00950000182945; -.
DR   HOGENOM; CLU_041217_21_2_1; -.
DR   InParanoid; P61586; -.
DR   KO; K04513; -.
DR   OMA; EVLHFCH; -.
DR   OrthoDB; 1166960at2759; -.
DR   PhylomeDB; P61586; -.
DR   TreeFam; TF300837; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-193634; Axonal growth inhibition (RHOA activation).
DR   Reactome; R-HSA-194840; Rho GTPase cycle.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-209563; Axonal growth stimulation.
DR   Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-4086400; PCP/CE pathway.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-416550; Sema4D mediated inhibition of cell attachment and migration.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5625900; RHO GTPases activate CIT.
DR   Reactome; R-HSA-5625970; RHO GTPases activate KTN1.
DR   Reactome; R-HSA-5627117; RHO GTPases Activate ROCKs.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-5666185; RHO GTPases Activate Rhotekin and Rhophilins.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases.
DR   Reactome; R-HSA-8985586; SLIT2:ROBO1 increases RHOA activity.
DR   SignaLink; P61586; -.
DR   SIGNOR; P61586; -.
DR   ChiTaRS; RHOA; human.
DR   EvolutionaryTrace; P61586; -.
DR   GeneWiki; RHOA; -.
DR   GenomeRNAi; 387; -.
DR   Pharos; P61586; Tbio.
DR   PRO; PR:P61586; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P61586; protein.
DR   Bgee; ENSG00000067560; Expressed in metanephric glomerulus and 242 other tissues.
DR   ExpressionAtlas; P61586; baseline and differential.
DR   Genevisible; P61586; HS.
DR   GO; GO:0043296; C:apical junction complex; IDA:UniProtKB.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0032153; C:cell division site; IBA:GO_Central.
DR   GO; GO:0030054; C:cell junction; TAS:Reactome.
DR   GO; GO:0071944; C:cell periphery; IMP:UniProtKB.
DR   GO; GO:0032154; C:cleavage furrow; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IDA:SynGO.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; IMP:AgBase.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IBA:GO_Central.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0030496; C:midbody; IEA:UniProtKB-SubCell.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098794; C:postsynapse; IDA:SynGO.
DR   GO; GO:0032587; C:ruffle membrane; IEA:Ensembl.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0031982; C:vesicle; IDA:AgBase.
DR   GO; GO:0019003; F:GDP binding; IEA:Ensembl.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; IDA:UniProtKB.
DR   GO; GO:0017022; F:myosin binding; IPI:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IBA:GO_Central.
DR   GO; GO:0051022; F:Rho GDP-dissociation inhibitor binding; IEA:Ensembl.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0051017; P:actin filament bundle assembly; IBA:GO_Central.
DR   GO; GO:0007015; P:actin filament organization; IBA:GO_Central.
DR   GO; GO:0002363; P:alpha-beta T cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0001998; P:angiotensin-mediated vasoconstriction involved in regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0043297; P:apical junction assembly; IMP:UniProtKB.
DR   GO; GO:0038027; P:apolipoprotein A-I-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043366; P:beta selection; IEA:Ensembl.
DR   GO; GO:0034329; P:cell junction assembly; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:1990869; P:cellular response to chemokine; IMP:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IMP:ARUK-UCL.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl.
DR   GO; GO:0036089; P:cleavage furrow formation; IDA:UniProtKB.
DR   GO; GO:0043542; P:endothelial cell migration; IGI:MGI.
DR   GO; GO:0097498; P:endothelial tube lumen extension; IGI:MGI.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045198; P:establishment of epithelial cell apical/basal polarity; IMP:UniProtKB.
DR   GO; GO:0030950; P:establishment or maintenance of actin cytoskeleton polarity; IBA:GO_Central.
DR   GO; GO:0007163; P:establishment or maintenance of cell polarity; IBA:GO_Central.
DR   GO; GO:0021861; P:forebrain radial glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0046039; P:GTP metabolic process; IEA:Ensembl.
DR   GO; GO:1903673; P:mitotic cleavage furrow formation; IMP:UniProtKB.
DR   GO; GO:0090307; P:mitotic spindle assembly; IMP:BHF-UCL.
DR   GO; GO:0050919; P:negative chemotaxis; IMP:UniProtKB.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; TAS:Reactome.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IGI:MGI.
DR   GO; GO:0045792; P:negative regulation of cell size; IMP:CAFA.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; ISS:ARUK-UCL.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0033144; P:negative regulation of intracellular steroid hormone receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0090324; P:negative regulation of oxidative phosphorylation; IEA:Ensembl.
DR   GO; GO:1903427; P:negative regulation of reactive oxygen species biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0042476; P:odontogenesis; IEA:Ensembl.
DR   GO; GO:0043931; P:ossification involved in bone maturation; ISS:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; TAS:Reactome.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:1904996; P:positive regulation of leukocyte adhesion to vascular endothelial cell; IMP:ARUK-UCL.
DR   GO; GO:0060193; P:positive regulation of lipase activity; IDA:AgBase.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:MGI.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IMP:ARUK-UCL.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IDA:MGI.
DR   GO; GO:2000406; P:positive regulation of T cell migration; IMP:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:1904695; P:positive regulation of vascular smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:Reactome.
DR   GO; GO:0008360; P:regulation of cell shape; IBA:GO_Central.
DR   GO; GO:0050773; P:regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; TAS:ARUK-UCL.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:1905274; P:regulation of modification of postsynaptic actin cytoskeleton; IMP:SynGO.
DR   GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:0033688; P:regulation of osteoblast proliferation; ISS:BHF-UCL.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0003100; P:regulation of systemic arterial blood pressure by endothelin; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007266; P:Rho protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0035385; P:Roundabout signaling pathway; IDA:UniProtKB.
DR   GO; GO:1902766; P:skeletal muscle satellite cell migration; ISS:AgBase.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0043149; P:stress fiber assembly; IMP:UniProtKB.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IEA:Ensembl.
DR   GO; GO:0021762; P:substantia nigra development; HEP:UniProtKB.
DR   GO; GO:0061383; P:trabecula morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; TAS:Reactome.
DR   GO; GO:0044319; P:wound healing, spreading of cells; ISS:AgBase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR003578; Small_GTPase_Rho.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51420; RHO; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Cell cycle; Cell division; Cell membrane;
KW   Cell projection; Cytoplasm; Cytoskeleton; Direct protein sequencing;
KW   Glycoprotein; GTP-binding; Host-virus interaction; Hydrolase; Lipoprotein;
KW   Magnesium; Membrane; Methylation; Nucleotide-binding; Phosphoprotein;
KW   Prenylation; Proto-oncogene; Reference proteome; Ubl conjugation.
FT   CHAIN           1..190
FT                   /note="Transforming protein RhoA"
FT                   /id="PRO_0000030411"
FT   PROPEP          191..193
FT                   /note="Removed in mature form"
FT                   /id="PRO_0000030412"
FT   NP_BIND         12..19
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|PubMed:10748207,
FT                   ECO:0000269|PubMed:12777804"
FT   NP_BIND         59..63
FT                   /note="GTP"
FT                   /evidence="ECO:0000250"
FT   NP_BIND         117..120
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|PubMed:10748207,
FT                   ECO:0000269|PubMed:12777804"
FT   MOTIF           34..42
FT                   /note="Effector region"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        182..187
FT                   /note="Arg/Lys-rich (basic)"
FT   SITE            189..190
FT                   /note="Cleavage; by yopT"
FT   MOD_RES         34
FT                   /note="O-AMP-tyrosine; by Haemophilus IbpA; alternate"
FT                   /evidence="ECO:0000269|PubMed:19362538"
FT   MOD_RES         37
FT                   /note="O-AMP-threonine; by Vibrio VopS"
FT                   /evidence="ECO:0000269|PubMed:19039103"
FT   MOD_RES         41
FT                   /note="ADP-ribosylasparagine; by botulinum toxin"
FT                   /evidence="ECO:0000305|PubMed:1328215"
FT   MOD_RES         188
FT                   /note="Phosphoserine; by PKG/PRKG1"
FT                   /evidence="ECO:0000269|PubMed:11162591"
FT   MOD_RES         190
FT                   /note="Cysteine methyl ester"
FT                   /evidence="ECO:0000250|UniProtKB:P62745"
FT   LIPID           190
FT                   /note="S-geranylgeranyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P62745"
FT   CARBOHYD        34
FT                   /note="O-linked (GlcNAc) tyrosine; by Photorhabdus
FT                   PAU_02230; alternate"
FT                   /evidence="ECO:0000269|PubMed:24141704"
FT   MUTAGEN         14
FT                   /note="G->V: Causes constitutive activation."
FT                   /evidence="ECO:0000269|PubMed:19948726"
FT   MUTAGEN         34
FT                   /note="Y->A: Abolishes interaction with DGKQ."
FT                   /evidence="ECO:0000269|PubMed:10066731,
FT                   ECO:0000269|PubMed:19362538"
FT   MUTAGEN         34
FT                   /note="Y->F: Abolishes AMPylation by Haemophilus IbpA."
FT                   /evidence="ECO:0000269|PubMed:10066731,
FT                   ECO:0000269|PubMed:19362538"
FT   MUTAGEN         63
FT                   /note="Q->L: Causes constitutive activation."
FT   MUTAGEN         193
FT                   /note="L->M: Converts geranyl-geranylation to
FT                   farnesylation; does not prevent the cleavage by yopT."
FT                   /evidence="ECO:0000269|PubMed:12538863"
FT   CONFLICT        23
FT                   /note="I -> T (in Ref. 5; BAD96276)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..13
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   HELIX           14..16
FT                   /evidence="ECO:0000244|PDB:4XH9"
FT   HELIX           18..27
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   STRAND          43..47
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   STRAND          52..58
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   HELIX           63..69
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   HELIX           70..73
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   STRAND          78..85
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   HELIX           89..97
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   HELIX           99..106
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   STRAND          107..109
FT                   /evidence="ECO:0000244|PDB:5FR2"
FT   STRAND          112..117
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   HELIX           119..121
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   HELIX           125..132
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   TURN            133..135
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   HELIX           141..151
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   STRAND          154..158
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   TURN            161..163
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   HELIX           167..179
FT                   /evidence="ECO:0000244|PDB:5C4M"
FT   TURN            182..184
FT                   /evidence="ECO:0000244|PDB:5ZHX"
FT   STRAND          185..187
FT                   /evidence="ECO:0000244|PDB:5ZHX"
FT   STRAND          190..193
FT                   /evidence="ECO:0000244|PDB:5FR1"
SQ   SEQUENCE   193 AA;  21768 MW;  C4DA2DC31FF858BC CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQVELALWDT
     AGQEDYDRLR PLSYPDTDVI LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD
     LRNDEHTRRE LAKMKQEPVK PEEGRDMANR IGAFGYMECS AKTKDGVREV FEMATRAALQ
     ARRGKKKSGC LVL
//
ID   Q9BVT0_HUMAN            Unreviewed;       101 AA.
AC   Q9BVT0;
DT   01-JUN-2001, integrated into UniProtKB/TrEMBL.
DT   01-MAR-2004, sequence version 2.
DT   11-DEC-2019, entry version 102.
DE   SubName: Full=ARHA protein {ECO:0000313|EMBL:AAH00946.2};
DE   Flags: Fragment;
GN   Name=ARHA {ECO:0000313|EMBL:AAH00946.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH00946.2};
RN   [1] {ECO:0000313|EMBL:AAH00946.2}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta {ECO:0000313|EMBL:AAH00946.2};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC000946; AAH00946.2; -; mRNA.
DR   RefSeq; NP_001655.1; NM_001664.3.
DR   PeptideAtlas; Q9BVT0; -.
DR   PRIDE; Q9BVT0; -.
DR   DNASU; 387; -.
DR   GeneID; 387; -.
DR   CTD; 387; -.
DR   PharmGKB; PA134865095; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   OrthoDB; 1166960at2759; -.
DR   ChiTaRS; RHOA; human.
DR   GenomeRNAi; 387; -.
DR   Genevisible; Q9BVT0; HS.
DR   GO; GO:0005525; F:GTP binding; IEA:InterPro.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
PE   2: Evidence at transcript level;
FT   NON_TER         1
FT                   /evidence="ECO:0000313|EMBL:AAH00946.2"
SQ   SEQUENCE   101 AA;  11523 MW;  5067AD783510BA63 CRC64;
     ENIPEKWTPE VKHFCPNVPI ILVGNKKDLR NDEHTRRELA KMKQEPVKPE EGRDMANRIG
     AFGYMECSAK TKDGVREVFE MATRAALQAR RGKKKSGCLV L
//
ID   A0A024RBL6_HUMAN        Unreviewed;       743 AA.
AC   A0A024RBL6;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   22-APR-2020, entry version 54.
DE   SubName: Full=T-box 3 (Ulnar mammary syndrome), isoform CRA_c {ECO:0000313|EMBL:EAW98073.1};
GN   Name=TBX3 {ECO:0000313|EMBL:EAW98073.1};
GN   ORFNames=hCG_40340 {ECO:0000313|EMBL:EAW98073.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW98073.1};
RN   [1] {ECO:0000313|EMBL:EAW98073.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW98073.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-ProRule:PRU00201,
CC       ECO:0000256|SAAS:SAAS00114217}.
CC   -!- CAUTION: Lacks conserved residue(s) required for the propagation of
CC       feature annotation. {ECO:0000256|PROSITE-ProRule:PRU00201}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH471054; EAW98071.1; -; Genomic_DNA.
DR   EMBL; CH471054; EAW98073.1; -; Genomic_DNA.
DR   RefSeq; NP_057653.3; NM_016569.3.
DR   Antibodypedia; 1789; 438 antibodies.
DR   GeneID; 6926; -.
DR   KEGG; hsa:6926; -.
DR   CTD; 6926; -.
DR   EuPathDB; HostDB:ENSG00000135111.14; -.
DR   eggNOG; KOG3585; Eukaryota.
DR   eggNOG; ENOG410XSTS; LUCA.
DR   KO; K10177; -.
DR   OMA; QSMRSYE; -.
DR   OrthoDB; 301173at2759; -.
DR   ChiTaRS; TBX3; human.
DR   GenomeRNAi; 6926; -.
DR   Bgee; ENSG00000135111; Expressed in adrenal cortex and 200 other tissues.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; IEA:Ensembl.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IEA:Ensembl.
DR   GO; GO:0003167; P:atrioventricular bundle cell differentiation; IEA:Ensembl.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0060923; P:cardiac muscle cell fate commitment; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0001947; P:heart looping; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0021761; P:limbic system development; IEA:Ensembl.
DR   GO; GO:0060596; P:mammary placode formation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0060021; P:roof of mouth development; IEA:Ensembl.
DR   GO; GO:0060931; P:sinoatrial node cell development; IEA:Ensembl.
DR   GO; GO:0010159; P:specification of animal organ position; IEA:Ensembl.
DR   GO; GO:0019827; P:stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; IEA:Ensembl.
DR   CDD; cd00182; TBOX; 1.
DR   Gene3D; 2.60.40.820; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR036960; T-box_sf.
DR   InterPro; IPR022582; TBX.
DR   InterPro; IPR001699; TF_T-box.
DR   InterPro; IPR018186; TF_T-box_CS.
DR   PANTHER; PTHR11267; PTHR11267; 1.
DR   Pfam; PF00907; T-box; 1.
DR   Pfam; PF12598; TBX; 1.
DR   PRINTS; PR00937; TBOX.
DR   SMART; SM00425; TBOX; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS01283; TBOX_1; 1.
DR   PROSITE; PS01264; TBOX_2; 1.
DR   PROSITE; PS50252; TBOX_3; 1.
PE   4: Predicted;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00201,
KW   ECO:0000256|SAAS:SAAS00114223};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00201,
KW   ECO:0000256|SAAS:SAAS00114236};
KW   Transcription {ECO:0000256|SAAS:SAAS00114203};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00114203}.
FT   DOMAIN          323..404
FT                   /note="TBX"
FT                   /evidence="ECO:0000259|Pfam:PF12598"
FT   REGION          301..342
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          357..465
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          688..707
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          714..734
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        305..337
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        371..390
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        417..434
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        436..450
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   743 AA;  79389 MW;  D5572F9CF871E89F CRC64;
     MSLSMRDPVI PGTSMAYHPF LPHRAPDFAM SAVLGHQPPF FPALTLPPNG AAALSLPGAL
     AKPIMDQLVG AAETGIPFSS LGPQAHLRPL KTMEPEEEVE DDPKVHLEAK ELWDQFHKRG
     TEMVITKSGR RMFPPFKVRC SGLDKKAKYI LLMDIIAADD CRYKFHNSRW MVAGKADPEM
     PKRMYIHPDS PATGEQWMSK VVTFHKLKLT NNISDKHGFT LAFPSDHATW QGNYSFGTQT
     ILNSMHKYQP RFHIVRANDI LKLPYSTFRT YLFPETEFIA VTAYQNDKIT QLKIDNNPFA
     KGFRDTGNGR REKRKQLTLQ SMRVFDERHK KENGTSDESS SEQAAFNCFA QASSPAASTV
     GTSNLKDLCP SEGESDAEAE SKEEHGPEAC DAAKISTTTS EEPCRDKGSP AVKAHLFAAE
     RPRDSGRLDK ASPDSRHSPA TISSSTRGLG AEERRSPVRE GTAPAKVEEA RALPGKEAFA
     PLTVQTDAAA AHLAQGPLPG LGFAPGLAGQ QFFNGHPLFL HPSQFAMGGA FSSMAAAGMG
     PLLATVSGAS TGVSGLDSTA MASAAAAQGL SGASAATLPF HLQQHVLASQ GLAMSPFGSL
     FPYPYTYMAA AAAASSAAAS SSVHRHPFLN LNTMRPRLRY SPYSIPVPVP DGSSLLTTAL
     PSMAAAAGPL DGKVAALAAS PASVAVDSGS ELNSRSSTLS SSSMSLSPKL CAEKEAATSE
     LQSIQRLVSG LEAKPDRSRS ASP
//
ID   A0A024RBQ4_HUMAN        Unreviewed;       723 AA.
AC   A0A024RBQ4;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   22-APR-2020, entry version 55.
DE   SubName: Full=T-box 3 (Ulnar mammary syndrome), isoform CRA_a {ECO:0000313|EMBL:EAW98074.1};
GN   Name=TBX3 {ECO:0000313|EMBL:EAW98074.1};
GN   ORFNames=hCG_40340 {ECO:0000313|EMBL:EAW98074.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW98074.1};
RN   [1] {ECO:0000313|EMBL:EAW98074.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW98074.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-ProRule:PRU00201,
CC       ECO:0000256|SAAS:SAAS00114217}.
CC   -!- CAUTION: Lacks conserved residue(s) required for the propagation of
CC       feature annotation. {ECO:0000256|PROSITE-ProRule:PRU00201}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH471054; EAW98069.1; -; Genomic_DNA.
DR   EMBL; CH471054; EAW98074.1; -; Genomic_DNA.
DR   RefSeq; NP_005987.3; NM_005996.3.
DR   Antibodypedia; 1789; 438 antibodies.
DR   GeneID; 6926; -.
DR   CTD; 6926; -.
DR   EuPathDB; HostDB:ENSG00000135111.14; -.
DR   eggNOG; KOG3585; Eukaryota.
DR   eggNOG; ENOG410XSTS; LUCA.
DR   HOGENOM; CLU_023038_1_0_1; -.
DR   ChiTaRS; TBX3; human.
DR   GenomeRNAi; 6926; -.
DR   Bgee; ENSG00000135111; Expressed in adrenal cortex and 200 other tissues.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   CDD; cd00182; TBOX; 1.
DR   Gene3D; 2.60.40.820; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR036960; T-box_sf.
DR   InterPro; IPR022582; TBX.
DR   InterPro; IPR002070; TF_Brachyury.
DR   InterPro; IPR001699; TF_T-box.
DR   InterPro; IPR018186; TF_T-box_CS.
DR   PANTHER; PTHR11267; PTHR11267; 1.
DR   Pfam; PF00907; T-box; 1.
DR   Pfam; PF12598; TBX; 1.
DR   PRINTS; PR00938; BRACHYURY.
DR   PRINTS; PR00937; TBOX.
DR   SMART; SM00425; TBOX; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS01283; TBOX_1; 1.
DR   PROSITE; PS01264; TBOX_2; 1.
DR   PROSITE; PS50252; TBOX_3; 1.
PE   4: Predicted;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00201,
KW   ECO:0000256|SAAS:SAAS00114223};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00201,
KW   ECO:0000256|SAAS:SAAS00114236};
KW   Transcription {ECO:0000256|SAAS:SAAS00114203};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00114203}.
FT   DOMAIN          303..384
FT                   /note="TBX"
FT                   /evidence="ECO:0000259|Pfam:PF12598"
FT   REGION          281..322
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          337..445
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          668..687
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          694..714
FT                   /evidence="ECO:0000256|SAM:Coils"
FT   COMPBIAS        285..317
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        351..370
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        397..414
FT                   /note="Polyampholyte"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        416..430
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   723 AA;  77178 MW;  08A64D15A005F0CF CRC64;
     MSLSMRDPVI PGTSMAYHPF LPHRAPDFAM SAVLGHQPPF FPALTLPPNG AAALSLPGAL
     AKPIMDQLVG AAETGIPFSS LGPQAHLRPL KTMEPEEEVE DDPKVHLEAK ELWDQFHKRG
     TEMVITKSGR RMFPPFKVRC SGLDKKAKYI LLMDIIAADD CRYKFHNSRW MVAGKADPEM
     PKRMYIHPDS PATGEQWMSK VVTFHKLKLT NNISDKHGFT ILNSMHKYQP RFHIVRANDI
     LKLPYSTFRT YLFPETEFIA VTAYQNDKIT QLKIDNNPFA KGFRDTGNGR REKRKQLTLQ
     SMRVFDERHK KENGTSDESS SEQAAFNCFA QASSPAASTV GTSNLKDLCP SEGESDAEAE
     SKEEHGPEAC DAAKISTTTS EEPCRDKGSP AVKAHLFAAE RPRDSGRLDK ASPDSRHSPA
     TISSSTRGLG AEERRSPVRE GTAPAKVEEA RALPGKEAFA PLTVQTDAAA AHLAQGPLPG
     LGFAPGLAGQ QFFNGHPLFL HPSQFAMGGA FSSMAAAGMG PLLATVSGAS TGVSGLDSTA
     MASAAAAQGL SGASAATLPF HLQQHVLASQ GLAMSPFGSL FPYPYTYMAA AAAASSAAAS
     SSVHRHPFLN LNTMRPRLRY SPYSIPVPVP DGSSLLTTAL PSMAAAAGPL DGKVAALAAS
     PASVAVDSGS ELNSRSSTLS SSSMSLSPKL CAEKEAATSE LQSIQRLVSG LEAKPDRSRS
     ASP
//
ID   TBX3_HUMAN              Reviewed;         743 AA.
AC   O15119; Q8TB20; Q9UKF8;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   12-FEB-2003, sequence version 4.
DT   22-APR-2020, entry version 197.
DE   RecName: Full=T-box transcription factor TBX3;
DE            Short=T-box protein 3;
GN   Name=TBX3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I), AND FUNCTION.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=10468588; DOI=10.1073/pnas.96.18.10212;
RA   He M.-L., Wen L., Campbell C.E., Wu J.Y., Rao Y.;
RT   "Transcription repression by Xenopus ET and its human ortholog TBX3, a gene
RT   involved in ulnar-mammary syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:10212-10217(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-488 (ISOFORM I).
RC   TISSUE=Kidney;
RX   PubMed=9207801; DOI=10.1038/ng0797-311;
RA   Bamshad M., Lin R.C., Law D.J., Watkins W.S., Krakowiak P.A., Moore M.E.,
RA   Franceschini P., Lala R., Holmes L.B., Gebuhr T.C., Schinzel A.,
RA   Bruneau B.G., Seidman J.G., Seidman C.E., Jorde L.B.;
RT   "Mutations in human TBX3 alter limb, apocrine and genital development in
RT   ulnar-mammary syndrome.";
RL   Nat. Genet. 16:311-315(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 592-743, ALTERNATIVE SPLICING, AND VARIANTS
RP   UMS PRO-143 AND SER-149.
RX   PubMed=10330342; DOI=10.1086/302417;
RA   Bamshad M., Le T., Watkins W.S., Dixon M.E., Kramer B.E., Roeder A.D.,
RA   Carey J.C., Root S., Schinzel A., Van Maldergem L., Gardner R.J.M.,
RA   Lin R.C., Seidman C.E., Seidman J.G., Wallerstein R., Moran E., Sutphen R.,
RA   Campbell C.E., Jorde L.B.;
RT   "The spectrum of mutations in TBX3: genotype/phenotype relationship in
RT   ulnar-mammary syndrome.";
RL   Am. J. Hum. Genet. 64:1550-1562(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM III).
RC   TISSUE=Adrenal gland;
RA   Song H., Gao G., Peng Y., Ren S., Chen Z., Han Z.;
RT   "A novel gene expressed in human adrenal gland.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM II).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-432 AND SER-438, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-371; SER-707; SER-738;
RP   SER-740 AND SER-742, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH PML.
RX   PubMed=22002537; DOI=10.1038/emboj.2011.370;
RA   Martin N., Benhamed M., Nacerddine K., Demarque M.D., van Lohuizen M.,
RA   Dejean A., Bischof O.;
RT   "Physical and functional interaction between PML and TBX2 in the
RT   establishment of cellular senescence.";
RL   EMBO J. 31:95-109(2012).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-438; SER-456; SER-707 AND
RP   SER-738, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-438, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 101-311.
RX   PubMed=12005433; DOI=10.1016/s0969-2126(02)00722-0;
RA   Coll M., Seidman J.G., Muller C.W.;
RT   "Structure of the DNA-bound T-box domain of human TBX3, a transcription
RT   factor responsible for ulnar-mammary syndrome.";
RL   Structure 10:343-356(2002).
CC   -!- FUNCTION: Transcriptional repressor involved in developmental
CC       processes. Probably plays a role in limb pattern formation. Acts as a
CC       negative regulator of PML function in cellular senescence.
CC       {ECO:0000269|PubMed:10468588, ECO:0000269|PubMed:22002537}.
CC   -!- SUBUNIT: Interacts with PML (isoform PML-4).
CC       {ECO:0000269|PubMed:22002537}.
CC   -!- INTERACTION:
CC       O15119; P35219: CA8; NbExp=3; IntAct=EBI-3452216, EBI-718700;
CC       O15119; Q8N4W3: CSF3; NbExp=3; IntAct=EBI-3452216, EBI-12843274;
CC       O15119; Q99471: PFDN5; NbExp=3; IntAct=EBI-3452216, EBI-357275;
CC       O15119; P86480: PRR20D; NbExp=3; IntAct=EBI-3452216, EBI-12754095;
CC       O15119; Q08117: TLE5; NbExp=3; IntAct=EBI-3452216, EBI-717810;
CC       O15119; Q6NVU6: UFSP1; NbExp=3; IntAct=EBI-3452216, EBI-12068150;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00201}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=II;
CC         IsoId=O15119-1; Sequence=Displayed;
CC       Name=I;
CC         IsoId=O15119-2; Sequence=VSP_006384;
CC       Name=III;
CC         IsoId=O15119-3; Sequence=VSP_006385, VSP_006386;
CC       Name=IV;
CC         IsoId=O15119-4; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DISEASE: Ulnar-mammary syndrome (UMS) [MIM:181450]: Characterized by
CC       ulnar ray defects, obesity, hypogenitalism, delayed puberty, hypoplasia
CC       of nipples and apocrine glands. {ECO:0000269|PubMed:10330342}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform II]: Contains an interrupted T-box domain.
CC   -!- MISCELLANEOUS: [Isoform III]: Contains an interrupted T-box domain.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform IV]: May be produced by joining exon 1 to exon
CC       7 thereby eliminating the T-box. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TBX3ID42486ch12q24.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF170708; AAD50989.2; -; mRNA.
DR   EMBL; AF002228; AAC12947.1; -; mRNA.
DR   EMBL; AF140240; AAF61816.1; -; mRNA.
DR   EMBL; AF216750; AAF61207.1; -; mRNA.
DR   EMBL; BC025258; AAH25258.1; -; mRNA.
DR   CCDS; CCDS9175.1; -. [O15119-2]
DR   CCDS; CCDS9176.1; -. [O15119-1]
DR   RefSeq; NP_005987.3; NM_005996.3. [O15119-2]
DR   RefSeq; NP_057653.3; NM_016569.3. [O15119-1]
DR   PDB; 1H6F; X-ray; 1.70 A; A/B=101-311.
DR   PDBsum; 1H6F; -.
DR   SMR; O15119; -.
DR   BioGrid; 112788; 47.
DR   IntAct; O15119; 19.
DR   MINT; O15119; -.
DR   STRING; 9606.ENSP00000257566; -.
DR   iPTMnet; O15119; -.
DR   PhosphoSitePlus; O15119; -.
DR   BioMuta; TBX3; -.
DR   jPOST; O15119; -.
DR   MassIVE; O15119; -.
DR   PaxDb; O15119; -.
DR   PeptideAtlas; O15119; -.
DR   PRIDE; O15119; -.
DR   ProteomicsDB; 48454; -. [O15119-1]
DR   ProteomicsDB; 48455; -. [O15119-2]
DR   ProteomicsDB; 48456; -. [O15119-3]
DR   Antibodypedia; 1789; 438 antibodies.
DR   DNASU; 6926; -.
DR   Ensembl; ENST00000257566; ENSP00000257566; ENSG00000135111. [O15119-1]
DR   Ensembl; ENST00000349155; ENSP00000257567; ENSG00000135111. [O15119-2]
DR   GeneID; 6926; -.
DR   KEGG; hsa:6926; -.
DR   UCSC; uc001tvt.2; human. [O15119-1]
DR   CTD; 6926; -.
DR   DisGeNET; 6926; -.
DR   GeneCards; TBX3; -.
DR   HGNC; HGNC:11602; TBX3.
DR   HPA; ENSG00000135111; Tissue enhanced (seminal).
DR   MalaCards; TBX3; -.
DR   MIM; 181450; phenotype.
DR   MIM; 601621; gene.
DR   neXtProt; NX_O15119; -.
DR   OpenTargets; ENSG00000135111; -.
DR   Orphanet; 3138; Ulnar-mammary syndrome.
DR   PharmGKB; PA36365; -.
DR   eggNOG; KOG3585; Eukaryota.
DR   eggNOG; ENOG410XSTS; LUCA.
DR   GeneTree; ENSGT00940000158066; -.
DR   HOGENOM; CLU_023038_1_0_1; -.
DR   InParanoid; O15119; -.
DR   KO; K10177; -.
DR   OMA; QSMRSYE; -.
DR   PhylomeDB; O15119; -.
DR   TreeFam; TF106341; -.
DR   SIGNOR; O15119; -.
DR   ChiTaRS; TBX3; human.
DR   EvolutionaryTrace; O15119; -.
DR   GeneWiki; TBX3; -.
DR   GenomeRNAi; 6926; -.
DR   Pharos; O15119; Tbio.
DR   PRO; PR:O15119; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; O15119; protein.
DR   Bgee; ENSG00000135111; Expressed in adrenal cortex and 200 other tissues.
DR   ExpressionAtlas; O15119; baseline and differential.
DR   Genevisible; O15119; HS.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0009887; P:animal organ morphogenesis; IDA:MGI.
DR   GO; GO:0008595; P:anterior/posterior axis specification, embryo; IMP:UniProtKB.
DR   GO; GO:0003167; P:atrioventricular bundle cell differentiation; IEA:Ensembl.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0003205; P:cardiac chamber development; IBA:GO_Central.
DR   GO; GO:0060923; P:cardiac muscle cell fate commitment; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; IDA:UniProtKB.
DR   GO; GO:0001708; P:cell fate specification; IBA:GO_Central.
DR   GO; GO:0090398; P:cellular senescence; IDA:UniProtKB.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IMP:UniProtKB.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IMP:UniProtKB.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0030540; P:female genitalia development; IMP:UniProtKB.
DR   GO; GO:0046884; P:follicle-stimulating hormone secretion; IMP:UniProtKB.
DR   GO; GO:0035136; P:forelimb morphogenesis; IDA:MGI.
DR   GO; GO:0001947; P:heart looping; IBA:GO_Central.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0021761; P:limbic system development; IEA:Ensembl.
DR   GO; GO:0032275; P:luteinizing hormone secretion; IMP:UniProtKB.
DR   GO; GO:0030539; P:male genitalia development; IMP:UniProtKB.
DR   GO; GO:0030879; P:mammary gland development; IMP:UniProtKB.
DR   GO; GO:0060596; P:mammary placode formation; IEA:Ensembl.
DR   GO; GO:0048332; P:mesoderm morphogenesis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:UniProtKB.
DR   GO; GO:0060021; P:roof of mouth development; IEA:Ensembl.
DR   GO; GO:0060931; P:sinoatrial node cell development; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; IMP:UniProtKB.
DR   GO; GO:0010159; P:specification of animal organ position; IEA:Ensembl.
DR   GO; GO:0019827; P:stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; IEA:Ensembl.
DR   CDD; cd00182; TBOX; 1.
DR   Gene3D; 2.60.40.820; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR036960; T-box_sf.
DR   InterPro; IPR022582; TBX.
DR   InterPro; IPR001699; TF_T-box.
DR   InterPro; IPR018186; TF_T-box_CS.
DR   PANTHER; PTHR11267; PTHR11267; 1.
DR   Pfam; PF00907; T-box; 1.
DR   Pfam; PF12598; TBX; 1.
DR   PRINTS; PR00937; TBOX.
DR   SMART; SM00425; TBOX; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS01283; TBOX_1; 1.
DR   PROSITE; PS01264; TBOX_2; 1.
DR   PROSITE; PS50252; TBOX_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Developmental protein;
KW   Disease mutation; DNA-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Repressor; Transcription; Transcription regulation.
FT   CHAIN           1..743
FT                   /note="T-box transcription factor TBX3"
FT                   /id="PRO_0000184428"
FT   DNA_BIND        107..220
FT                   /note="T-box; first part"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00201"
FT   DNA_BIND        241..305
FT                   /note="T-box; second part"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00201"
FT   REGION          544..695
FT                   /note="Transcription repression"
FT   MOD_RES         371
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         432
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336"
FT   MOD_RES         438
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   MOD_RES         456
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         707
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         738
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         740
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         742
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   VAR_SEQ         221..240
FT                   /note="Missing (in isoform I)"
FT                   /evidence="ECO:0000303|PubMed:10468588,
FT                   ECO:0000303|PubMed:9207801"
FT                   /id="VSP_006384"
FT   VAR_SEQ         490..615
FT                   /note="Missing (in isoform III)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_006385"
FT   VAR_SEQ         661..677
FT                   /note="Missing (in isoform III)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_006386"
FT   VARIANT         143
FT                   /note="L -> P (in UMS)"
FT                   /evidence="ECO:0000269|PubMed:10330342"
FT                   /id="VAR_009601"
FT   VARIANT         149
FT                   /note="Y -> S (in UMS)"
FT                   /evidence="ECO:0000269|PubMed:10330342"
FT                   /id="VAR_009602"
FT   CONFLICT        315
FT                   /note="K -> Q (in Ref. 4; AAF61207)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        616..628
FT                   /note="SAAASSSVHRHPF -> LRQPQLRCTAPL (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        674
FT                   /note="V -> A (in Ref. 1; AAD50989)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        692
FT                   /note="L -> P (in Ref. 1; AAD50989)"
FT                   /evidence="ECO:0000305"
FT   STRAND          104..107
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   HELIX           110..119
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   STRAND          122..124
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   STRAND          137..142
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   STRAND          145..166
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   STRAND          169..175
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   STRAND          191..193
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   HELIX           194..197
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   STRAND          246..255
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   HELIX           260..265
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   STRAND          269..272
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   HELIX           274..276
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   STRAND          278..283
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   HELIX           287..296
FT                   /evidence="ECO:0000244|PDB:1H6F"
FT   HELIX           298..303
FT                   /evidence="ECO:0000244|PDB:1H6F"
SQ   SEQUENCE   743 AA;  79389 MW;  D5572F9CF871E89F CRC64;
     MSLSMRDPVI PGTSMAYHPF LPHRAPDFAM SAVLGHQPPF FPALTLPPNG AAALSLPGAL
     AKPIMDQLVG AAETGIPFSS LGPQAHLRPL KTMEPEEEVE DDPKVHLEAK ELWDQFHKRG
     TEMVITKSGR RMFPPFKVRC SGLDKKAKYI LLMDIIAADD CRYKFHNSRW MVAGKADPEM
     PKRMYIHPDS PATGEQWMSK VVTFHKLKLT NNISDKHGFT LAFPSDHATW QGNYSFGTQT
     ILNSMHKYQP RFHIVRANDI LKLPYSTFRT YLFPETEFIA VTAYQNDKIT QLKIDNNPFA
     KGFRDTGNGR REKRKQLTLQ SMRVFDERHK KENGTSDESS SEQAAFNCFA QASSPAASTV
     GTSNLKDLCP SEGESDAEAE SKEEHGPEAC DAAKISTTTS EEPCRDKGSP AVKAHLFAAE
     RPRDSGRLDK ASPDSRHSPA TISSSTRGLG AEERRSPVRE GTAPAKVEEA RALPGKEAFA
     PLTVQTDAAA AHLAQGPLPG LGFAPGLAGQ QFFNGHPLFL HPSQFAMGGA FSSMAAAGMG
     PLLATVSGAS TGVSGLDSTA MASAAAAQGL SGASAATLPF HLQQHVLASQ GLAMSPFGSL
     FPYPYTYMAA AAAASSAAAS SSVHRHPFLN LNTMRPRLRY SPYSIPVPVP DGSSLLTTAL
     PSMAAAAGPL DGKVAALAAS PASVAVDSGS ELNSRSSTLS SSSMSLSPKL CAEKEAATSE
     LQSIQRLVSG LEAKPDRSRS ASP
//
ID   TERT_HUMAN              Reviewed;        1132 AA.
AC   O14746; O14783; Q2XS35; Q8N6C3; Q8NG38; Q8NG46;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   22-APR-2020, entry version 189.
DE   RecName: Full=Telomerase reverse transcriptase;
DE            EC=2.7.7.49 {ECO:0000269|PubMed:21602826, ECO:0000269|PubMed:29695869};
DE   AltName: Full=HEST2;
DE   AltName: Full=Telomerase catalytic subunit;
DE   AltName: Full=Telomerase-associated protein 2;
DE            Short=TP2;
GN   Name=TERT; Synonyms=EST2, TCS1, TRT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9288757; DOI=10.1016/s0092-8674(00)80538-3;
RA   Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P.,
RA   Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q.,
RA   Bacchetti S., Haber D.A., Weinberg R.A.;
RT   "hEST2, the putative human telomerase catalytic subunit gene, is up-
RT   regulated in tumor cells and during immortalization.";
RL   Cell 90:785-795(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Embryonic kidney;
RX   PubMed=9252327; DOI=10.1126/science.277.5328.955;
RA   Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H.,
RA   Lingner J., Harley C.B., Cech T.R.;
RT   "Telomerase catalytic subunit homologs from fission yeast and human.";
RL   Science 277:955-959(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10333526; DOI=10.1016/s0378-1119(99)00108-0;
RA   Wick M., Zubov D., Hagen G.;
RT   "Genomic organization and promoter characterization of the gene encoding
RT   the human telomerase reverse transcriptase (hTERT).";
RL   Gene 232:97-106(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=12869302; DOI=10.1016/s1476-5586(03)80051-9;
RA   Hisatomi H., Ohyashiki K., Ohyashiki J.H., Nagao K., Kanamaru T.,
RA   Hirata H., Hibi N., Tsukada Y.;
RT   "Expression profile of a gamma-deletion variant of the human telomerase
RT   reverse transcriptase gene.";
RL   Neoplasia 5:193-197(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Stomach cancer;
RX   PubMed=14654914;
RA   Nagao K., Katsumata K., Aizawa Y., Saito N., Hirata H., Sasaki H.,
RA   Yamamoto S., Hikiji K., Koiwa T., Hisatomi H.;
RT   "Differential alternative splicing expressions of telomerase reverse
RT   transcriptase in gastrointestinal cell lines.";
RL   Oncol. Rep. 11:127-131(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Londono-Vallejo J.A.;
RT   "Sequence of a BAC carrying the entire hTERT gene.";
RL   Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TYR-412 AND THR-1062.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=8676067; DOI=10.1084/jem.183.6.2471;
RA   Weng N.P., Levine B.L., June C.H., Hodes R.J.;
RT   "Regulated expression of telomerase activity in human T lymphocyte
RT   development and activation.";
RL   J. Exp. Med. 183:2471-2479(1996).
RN   [11]
RP   FUNCTION IN TELOMERASE ACTIVITY, TISSUE SPECIFICITY, ASSOCIATION WITH TEP1,
RP   AND MUTAGENESIS OF ASP-712; ASP-868 AND ASP-869.
RX   PubMed=9389643; DOI=10.1101/gad.11.23.3109;
RA   Harrington L., Zhou W., McPhail T., Oulton R., Yeung D.S., Mar V.,
RA   Bass M.B., Robinson M.O.;
RT   "Human telomerase contains evolutionarily conserved catalytic and
RT   structural subunits.";
RL   Genes Dev. 11:3109-3115(1997).
RN   [12]
RP   RECONSTITUTION OF THE TELOMERASE COMPLEX, AND MUTAGENESIS OF ASP-712;
RP   ASP-868 AND ASP-869.
RX   PubMed=9443919; DOI=10.1016/s0960-9822(98)70067-3;
RA   Beattie T.L., Zhou W., Robinson M.O., Harrington L.;
RT   "Reconstitution of human telomerase activity in vitro.";
RL   Curr. Biol. 8:177-180(1998).
RN   [13]
RP   ASSOCIATION WITH TEP1.
RX   PubMed=11029039; DOI=10.1091/mbc.11.10.3329;
RA   Beattie T.L., Zhou W., Robinson M.O., Harrington L.;
RT   "Polymerization defects within human telomerase are distinct from
RT   telomerase RNA and TEP1 binding.";
RL   Mol. Biol. Cell 11:3329-3340(2000).
RN   [14]
RP   INTERACTION WITH HSPA1A; HSP90A AND PTGES3.
RX   PubMed=11274138; DOI=10.1074/jbc.c100055200;
RA   Forsythe H.L., Jarvis J.L., Turner J.W., Elmore L.W., Holt S.E.;
RT   "Stable association of hsp90 and p23, but Not hsp70, with active human
RT   telomerase.";
RL   J. Biol. Chem. 276:15571-15574(2001).
RN   [15]
RP   PHOSPHORYLATION AT TYR-707, SUBCELLULAR LOCATION, INTERACTION WITH RAN AND
RP   XP01, AND MUTAGENESIS OF TYR-707.
RX   PubMed=12808100; DOI=10.1128/mcb.23.13.4598-4610.2003;
RA   Haendeler J., Hoffmann J., Brandes R.P., Zeiher A.M., Dimmeler S.;
RT   "Hydrogen peroxide triggers nuclear export of telomerase reverse
RT   transcriptase via Src kinase family-dependent phosphorylation of tyrosine
RT   707.";
RL   Mol. Cell. Biol. 23:4598-4610(2003).
RN   [16]
RP   INTERACTION WITH MCRS1.
RX   PubMed=15044100; DOI=10.1016/j.bbrc.2004.02.166;
RA   Song H., Li Y., Chen G., Xing Z., Zhao J., Yokoyama K.K., Li T., Zhao M.;
RT   "Human MCRS2, a cell-cycle-dependent protein, associates with LPTS/PinX1
RT   and reduces the telomere length.";
RL   Biochem. Biophys. Res. Commun. 316:1116-1123(2004).
RN   [17]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=14963003; DOI=10.1161/01.res.0000121104.05977.f3;
RA   Haendeler J., Hoffmann J., Diehl J.F., Vasa M., Spyridopoulos I.,
RA   Zeiher A.M., Dimmeler S.;
RT   "Antioxidants inhibit nuclear export of telomerase reverse transcriptase
RT   and delay replicative senescence of endothelial cells.";
RL   Circ. Res. 94:768-775(2004).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15138842; DOI=10.1007/s00418-004-0645-5;
RA   Yan P., Benhattar J., Seelentag W., Stehle J.C., Bosman F.T.;
RT   "Immunohistochemical localization of hTERT protein in human tissues.";
RL   Histochem. Cell Biol. 121:391-397(2004).
RN   [19]
RP   INTERACTION WITH NCL, AND SUBCELLULAR LOCATION.
RX   PubMed=15371412; DOI=10.1074/jbc.m407643200;
RA   Khurts S., Masutomi K., Delgermaa L., Arai K., Oishi N., Mizuno H.,
RA   Hayashi N., Hahn W.C., Murakami S.;
RT   "Nucleolin interacts with telomerase.";
RL   J. Biol. Chem. 279:51508-51515(2004).
RN   [20]
RP   FUNCTIONAL DOMAINS, AND MUTAGENESIS OF TRP-547 AND ASP-868.
RX   PubMed=15082768; DOI=10.1128/mcb.24.9.3720-3733.2004;
RA   Moriarty T.J., Marie-Egyptienne D.T., Autexier C.;
RT   "Functional organization of repeat addition processivity and DNA synthesis
RT   determinants in the human telomerase multimer.";
RL   Mol. Cell. Biol. 24:3720-3733(2004).
RN   [21]
RP   INTERACTION WITH MKRN1, AND UBIQUITINATION.
RX   PubMed=15805468; DOI=10.1101/gad.1289405;
RA   Kim J.H., Park S.-M., Kang M.R., Oh S.-Y., Lee T.H., Muller M.T.,
RA   Chung I.K.;
RT   "Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a
RT   proteolysis of hTERT.";
RL   Genes Dev. 19:776-781(2005).
RN   [22]
RP   FUNCTION, AND MUTAGENESIS OF ASP-868.
RX   PubMed=15857955; DOI=10.1091/mbc.e05-02-0148;
RA   Moriarty T.J., Ward R.J., Taboski M.A., Autexier C.;
RT   "An anchor site-type defect in human telomerase that disrupts telomere
RT   length maintenance and cellular immortalization.";
RL   Mol. Biol. Cell 16:3152-3161(2005).
RN   [23]
RP   FUNCTION, AND MUTAGENESIS OF ARG-631; ASP-712 AND ASP-868.
RX   PubMed=17026956; DOI=10.1016/j.bbrc.2006.09.125;
RA   Rahman R., Mo L., Cui W.;
RT   "Telomerase with mutated catalytic motifs has dominant negative effects on
RT   telomerase activity and inhibits cell growth.";
RL   Biochem. Biophys. Res. Commun. 350:796-802(2006).
RN   [24]
RP   PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=17548608; DOI=10.4049/jimmunol.178.12.7710;
RA   Plunkett F.J., Franzese O., Finney H.M., Fletcher J.M., Belaramani L.L.,
RA   Salmon M., Dokal I., Webster D., Lawson A.D., Akbar A.N.;
RT   "The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T
RT   cells is associated with decreased Akt (Ser473) phosphorylation.";
RL   J. Immunol. 178:7710-7719(2007).
RN   [25]
RP   INTERACTION WITH NAT10.
RX   PubMed=18082603; DOI=10.1016/j.molcel.2007.09.023;
RA   Fu D., Collins K.;
RT   "Purification of human telomerase complexes identifies factors involved in
RT   telomerase biogenesis and telomere length regulation.";
RL   Mol. Cell 28:773-785(2007).
RN   [26]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF 137-TRP--LEU-141; ASP-712 AND
RP   930-TRP--LEU-934.
RX   PubMed=17296728; DOI=10.1128/mcb.02368-06;
RA   Wyatt H.D., Lobb D.A., Beattie T.L.;
RT   "Characterization of physical and functional anchor site interactions in
RT   human telomerase.";
RL   Mol. Cell. Biol. 27:3226-3240(2007).
RN   [27]
RP   FUNCTION, AND MUTAGENESIS OF LEU-866 AND VAL-867.
RX   PubMed=17264120; DOI=10.1093/nar/gkm002;
RA   Drosopoulos W.C., Prasad V.R.;
RT   "The active site residue Valine 867 in human telomerase reverse
RT   transcriptase influences nucleotide incorporation and fidelity.";
RL   Nucleic Acids Res. 35:1155-1168(2007).
RN   [28]
RP   INTERACTION WITH PTPN11, PHOSPHORYLATION AT TYR-707, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF TYR-707.
RX   PubMed=18829466; DOI=10.1074/jbc.m805138200;
RA   Jakob S., Schroeder P., Lukosz M., Buchner N., Spyridopoulos I.,
RA   Altschmied J., Haendeler J.;
RT   "Nuclear protein tyrosine phosphatase Shp-2 is one important negative
RT   regulator of nuclear export of telomerase reverse transcriptase.";
RL   J. Biol. Chem. 283:33155-33161(2008).
RN   [29]
RP   PHOSPHORYLATION, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19188162; DOI=10.1158/1078-0432.ccr-08-0792;
RA   Ram R., Uziel O., Eldan O., Fenig E., Beery E., Lichtenberg S.,
RA   Nordenberg Y., Lahav M.;
RT   "Ionizing radiation up-regulates telomerase activity in cancer cell lines
RT   by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt
RT   pathway.";
RL   Clin. Cancer Res. 15:914-923(2009).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=19567472; DOI=10.1242/jcs.048066;
RA   Oh W., Ghim J., Lee E.W., Yang M.R., Kim E.T., Ahn J.H., Song J.;
RT   "PML-IV functions as a negative regulator of telomerase by interacting with
RT   TERT.";
RL   J. Cell Sci. 122:2613-2622(2009).
RN   [31]
RP   INTERACTION WITH SMARCA4, AND FUNCTION.
RX   PubMed=19571879; DOI=10.1038/nature08137;
RA   Park J.I., Venteicher A.S., Hong J.Y., Choi J., Jun S., Shkreli M.,
RA   Chang W., Meng Z., Cheung P., Ji H., McLaughlin M., Veenstra T.D.,
RA   Nusse R., McCrea P.D., Artandi S.E.;
RT   "Telomerase modulates Wnt signalling by association with target gene
RT   chromatin.";
RL   Nature 460:66-72(2009).
RN   [32]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF GLN-169.
RX   PubMed=19777057; DOI=10.1371/journal.pone.0007176;
RA   Wyatt H.D., Tsang A.R., Lobb D.A., Beattie T.L.;
RT   "Human telomerase reverse transcriptase (hTERT) Q169 is essential for
RT   telomerase function in vitro and in vivo.";
RL   PLoS ONE 4:E7176-E7176(2009).
RN   [33]
RP   IDENTIFICATION IN THE TELOMERASE HOLOENZYME COMPLEX.
RX   PubMed=19179534; DOI=10.1126/science.1165357;
RA   Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M.,
RA   Veenstra T.D., Terns M.P., Artandi S.E.;
RT   "A human telomerase holoenzyme protein required for Cajal body localization
RT   and telomere synthesis.";
RL   Science 323:644-648(2009).
RN   [34]
RP   IDENTIFICATION IN THE TELOMERASE HOLOENZYME COMPLEX.
RX   PubMed=20351177; DOI=10.1128/mcb.00151-10;
RA   Egan E.D., Collins K.;
RT   "Specificity and stoichiometry of subunit interactions in the human
RT   telomerase holoenzyme assembled in vivo.";
RL   Mol. Cell. Biol. 30:2775-2786(2010).
RN   [35]
RP   INTERACTION WITH DHX36.
RX   PubMed=21846770; DOI=10.1093/nar/gkr630;
RA   Lattmann S., Stadler M.B., Vaughn J.P., Akman S.A., Nagamine Y.;
RT   "The DEAH-box RNA helicase RHAU binds an intramolecular RNA G-quadruplex in
RT   TERC and associates with telomerase holoenzyme.";
RL   Nucleic Acids Res. 39:9390-9404(2011).
RN   [36]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NVL.
RX   PubMed=22226966; DOI=10.1016/j.bbrc.2011.12.101;
RA   Her J., Chung I.K.;
RT   "The AAA-ATPase NVL2 is a telomerase component essential for holoenzyme
RT   assembly.";
RL   Biochem. Biophys. Res. Commun. 417:1086-1092(2012).
RN   [37]
RP   PHOSPHORYLATION AT SER-227, SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION
RP   SIGNAL.
RX   PubMed=22366458; DOI=10.1242/jcs.099267;
RA   Chung J., Khadka P., Chung I.K.;
RT   "Nuclear import of hTERT requires a bipartite nuclear localization signal
RT   and Akt-mediated phosphorylation.";
RL   J. Cell Sci. 125:2684-2697(2012).
RN   [38]
RP   PHOSPHORYLATION AT SER-457, UBIQUITINATION, AND MUTAGENESIS OF SER-457.
RX   PubMed=23362280; DOI=10.1074/jbc.m112.416792;
RA   Jung H.Y., Wang X., Jun S., Park J.I.;
RT   "Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT
RT   degradation.";
RL   J. Biol. Chem. 288:7252-7262(2013).
RN   [39]
RP   UBIQUITINATION.
RX   PubMed=23612978; DOI=10.1074/jbc.m112.416735;
RA   Wang X., Singh S., Jung H.Y., Yang G., Jun S., Sastry K.J., Park J.I.;
RT   "HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3
RT   ligase complex.";
RL   J. Biol. Chem. 288:15474-15480(2013).
RN   [40]
RP   INVOLVEMENT IN CMM9.
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 461-469 IN COMPLEX WITH CLASS I
RP   MAJOR HISTOCOMPATIBILITY COMPLEX (MHC).
RX   PubMed=16323248; DOI=10.1002/eji.200535424;
RA   Cole D.K., Rizkallah P.J., Gao F., Watson N.I., Boulter J.M., Bell J.I.,
RA   Sami M., Gao G.F., Jakobsen B.K.;
RT   "Crystal structure of HLA-A*2402 complexed with a telomerase peptide.";
RL   Eur. J. Immunol. 36:170-179(2006).
RN   [42]
RP   STRUCTURE BY ELECTRON MICROSCOPY (7.7 ANGSTROMS) OF THE TELOMERASE
RP   HOLOENZYME COMPLEX, AND CATALYTIC ACTIVITY.
RX   PubMed=29695869; DOI=10.1038/s41586-018-0062-x;
RA   Nguyen T.H.D., Tam J., Wu R.A., Greber B.J., Toso D., Nogales E.,
RA   Collins K.;
RT   "Cryo-EM structure of substrate-bound human telomerase holoenzyme.";
RL   Nature 557:190-195(2018).
RN   [43]
RP   VARIANT AA THR-202, VARIANTS DKCA2 TRP-979 AND LEU-1127, CHARACTERIZATION
RP   OF VARIANT AA THR-202, AND CHARACTERIZATION OF VARIANTS DKCA2 TRP-979 AND
RP   LEU-1127.
RX   PubMed=15885610; DOI=10.1016/j.bcmd.2004.12.008;
RA   Vulliamy T.J., Walne A., Baskaradas A., Mason P.J., Marrone A., Dokal I.;
RT   "Mutations in the reverse transcriptase component of telomerase (TERT) in
RT   patients with bone marrow failure.";
RL   Blood Cells Mol. Dis. 34:257-263(2005).
RN   [44]
RP   VARIANTS PFBMFT1 THR-202; TYR-412; MET-694; CYS-772 AND MET-1090, AND
RP   VARIANTS THR-279; GLU-441 DEL AND THR-1062.
RX   PubMed=15814878; DOI=10.1056/nejmoa042980;
RA   Yamaguchi H., Calado R.T., Ly H., Kajigaya S., Baerlocher G.M.,
RA   Chanock S.J., Lansdorp P.M., Young N.S.;
RT   "Mutations in TERT, the gene for telomerase reverse transcriptase, in
RT   aplastic anemia.";
RL   N. Engl. J. Med. 352:1413-1424(2005).
RN   [45]
RP   VARIANT DKCA2 ASN-902, AND CHARACTERIZATION OF VARIANT DKCA2 ASN-902.
RX   PubMed=16247010; DOI=10.1073/pnas.0508124102;
RA   Armanios M., Chen J.-L., Chang Y.-P.C., Brodsky R.A., Hawkins A.,
RA   Griffin C.A., Eshleman J.R., Cohen A.R., Chakravarti A., Hamosh A.,
RA   Greider C.W.;
RT   "Haploinsufficiency of telomerase reverse transcriptase leads to
RT   anticipation in autosomal dominant dyskeratosis congenita.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15960-15964(2005).
RN   [46]
RP   INVOLVEMENT IN CAD SUSCEPTIBILITY.
RX   PubMed=16890917; DOI=10.1016/j.bbrc.2006.07.103;
RA   Matsubara Y., Murata M., Watanabe K., Saito I., Miyaki K., Omae K.,
RA   Ishikawa M., Matsushita K., Iwanaga S., Ogawa S., Ikeda Y.;
RT   "Coronary artery disease and a functional polymorphism of hTERT.";
RL   Biochem. Biophys. Res. Commun. 348:669-672(2006).
RN   [47]
RP   VARIANT DKCB4 ARG-721.
RX   PubMed=16332973; DOI=10.1182/blood-2005-07-2622;
RA   Vulliamy T.J., Marrone A., Knight S.W., Walne A., Mason P.J., Dokal I.;
RT   "Mutations in dyskeratosis congenita: their impact on telomere length and
RT   the diversity of clinical presentation.";
RL   Blood 107:2680-2685(2006).
RN   [48]
RP   VARIANTS AA ASP-682 AND MET-726, AND CHARACTERIZATION OF VARIANT AA
RP   MET-726.
RX   PubMed=16627250;
RA   Liang J., Yagasaki H., Kamachi Y., Hama A., Matsumoto K., Kato K., Kudo K.,
RA   Kojima S.;
RT   "Mutations in telomerase catalytic protein in Japanese children with
RT   aplastic anemia.";
RL   Haematologica 91:656-658(2006).
RN   [49]
RP   VARIANT AA ASN-570, AND CHARACTERIZATION OF VARIANTS ASN-570; ASP-682;
RP   ARG-721; MET-726; ASN-902; TRP-979 AND LEU-1127.
RX   PubMed=16990594; DOI=10.1182/blood-2006-07-035089;
RA   Xin Z.T., Beauchamp A.D., Calado R.T., Bradford J.W., Regal J.A.,
RA   Shenoy A., Liang Y., Lansdorp P.M., Young N.S., Ly H.;
RT   "Functional characterization of natural telomerase mutations found in
RT   patients with hematologic disorders.";
RL   Blood 109:524-532(2007).
RN   [50]
RP   VARIANTS DKCB4 CYS-811 AND TRP-901, AND CHARACTERIZATION OF VARIANTS DKCB4
RP   CYS-811 AND TRP-901.
RX   PubMed=17785587; DOI=10.1182/blood-2006-12-062851;
RA   Marrone A., Walne A., Tamary H., Masunari Y., Kirwan M., Beswick R.,
RA   Vulliamy T., Dokal I.;
RT   "Telomerase reverse-transcriptase homozygous mutations in autosomal
RT   recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome.";
RL   Blood 110:4198-4205(2007).
RN   [51]
RP   VARIANTS IDIOPATHIC PULMONARY FIBROSIS SUSCEPTIBILITY GLN-55 AND MET-1110,
RP   AND CHARACTERIZATION OF VARIANTS GLN-55 AND MET-1110.
RX   PubMed=17392301; DOI=10.1056/nejmoa066157;
RA   Armanios M.Y., Chen J.J., Cogan J.D., Alder J.K., Ingersoll R.G.,
RA   Markin C., Lawson W.E., Xie M., Vulto I., Phillips J.A., Lansdorp P.M.,
RA   Greider C.W., Loyd J.E.;
RT   "Telomerase mutations in families with idiopathic pulmonary fibrosis.";
RL   N. Engl. J. Med. 356:1317-1326(2007).
RN   [52]
RP   VARIANT PFBMFT1 HIS-865.
RX   PubMed=17460043; DOI=10.1073/pnas.0701009104;
RA   Tsakiri K.D., Cronkhite J.T., Kuan P.J., Xing C., Raghu G., Weissler J.C.,
RA   Rosenblatt R.L., Shay J.W., Garcia C.K.;
RT   "Adult-onset pulmonary fibrosis caused by mutations in telomerase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7552-7557(2007).
RN   [53]
RP   VARIANTS DKCB4 TYR-412 AND SER-704, AND CHARACTERIZATION OF VARIANTS DKCB4
RP   TYR-412 AND SER-704.
RX   PubMed=18042801; DOI=10.1182/blood-2007-10-120907;
RA   Du H.Y., Pumbo E., Manley P., Field J.J., Bayliss S.J., Wilson D.B.,
RA   Mason P.J., Bessler M.;
RT   "Complex inheritance pattern of dyskeratosis congenita in two families with
RT   2 different mutations in the telomerase reverse transcriptase gene.";
RL   Blood 111:1128-1130(2008).
RN   [54]
RP   VARIANTS ALA-65; MET-299; LYS-522 AND THR-1062, AND VARIANTS AA THR-202;
RP   TYR-412; GLU-441 DEL; ASN-570; GLN-631; MET-694 AND LEU-785.
RX   PubMed=19760749; DOI=10.1002/humu.21115;
RA   Kirwan M., Vulliamy T., Marrone A., Walne A.J., Beswick R., Hillmen P.,
RA   Kelly R., Stewart A., Bowen D., Schonland S.O., Whittle A.M., McVerry A.,
RA   Gilleece M., Dokal I.;
RT   "Defining the pathogenic role of telomerase mutations in myelodysplastic
RT   syndrome and acute myeloid leukemia.";
RL   Hum. Mutat. 30:1567-1573(2009).
RN   [55]
RP   VARIANTS ALA-65; MET-299; TYR-412; GLU-441 DEL; LYS-522 AND THR-1062.
RX   PubMed=19147845; DOI=10.1073/pnas.0807057106;
RA   Calado R.T., Regal J.A., Hills M., Yewdell W.T., Dalmazzo L.F., Zago M.A.,
RA   Lansdorp P.M., Hogge D., Chanock S.J., Estey E.H., Falcao R.P., Young N.S.;
RT   "Constitutional hypomorphic telomerase mutations in patients with acute
RT   myeloid leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:1187-1192(2009).
RN   [56]
RP   VARIANTS PFBMFT1 MET-170; THR-716; PHE-841; ARG-902 AND PHE-1025, AND
RP   CHARACTERIZATION OF VARIANTS PFBMFT1 MET-170; THR-716; PHE-841 AND
RP   PHE-1025.
RX   PubMed=21436073; DOI=10.1182/blood-2010-11-322149;
RA   Parry E.M., Alder J.K., Qi X., Chen J.J., Armanios M.;
RT   "Syndrome complex of bone marrow failure and pulmonary fibrosis predicts
RT   germline defects in telomerase.";
RL   Blood 117:5607-5611(2011).
RN   [57]
RP   VARIANT DKCB4 SER-704, VARIANT DKCA2 TRP-979, CHARACTERIZATION OF VARIANT
RP   DKCB4 SER-704, CHARACTERIZATION OF VARIANT DKCA2 TRP-979, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=21602826; DOI=10.1038/nature10084;
RA   Batista L.F., Pech M.F., Zhong F.L., Nguyen H.N., Xie K.T., Zaug A.J.,
RA   Crary S.M., Choi J., Sebastiano V., Cherry A., Giri N., Wernig M.,
RA   Alter B.P., Cech T.R., Savage S.A., Reijo Pera R.A., Artandi S.E.;
RT   "Telomere shortening and loss of self-renewal in dyskeratosis congenita
RT   induced pluripotent stem cells.";
RL   Nature 474:399-402(2011).
RN   [58]
RP   VARIANTS PFBMFT1 ILE-791 AND MET-867, AND CHARACTERIZATION OF VARIANTS
RP   PFBMFT1 ILE-791 AND MET-867.
RX   PubMed=21483807; DOI=10.1371/journal.pgen.1001352;
RA   Alder J.K., Cogan J.D., Brown A.F., Anderson C.J., Lawson W.E.,
RA   Lansdorp P.M., Phillips J.A. III, Loyd J.E., Chen J.J., Armanios M.;
RT   "Ancestral mutation in telomerase causes defects in repeat addition
RT   processivity and manifests as familial pulmonary fibrosis.";
RL   PLoS Genet. 7:E1001352-E1001352(2011).
RN   [59]
RP   VARIANT PFBMFT1 LEU-923.
RX   PubMed=22512499; DOI=10.1056/nejmc1200999;
RA   Gansner J.M., Rosas I.O., Ebert B.L.;
RT   "Pulmonary fibrosis, bone marrow failure, and telomerase mutation.";
RL   N. Engl. J. Med. 366:1551-1553(2012).
CC   -!- FUNCTION: Telomerase is a ribonucleoprotein enzyme essential for the
CC       replication of chromosome termini in most eukaryotes. Active in
CC       progenitor and cancer cells. Inactive, or very low activity, in normal
CC       somatic cells. Catalytic component of the teleromerase holoenzyme
CC       complex whose main activity is the elongation of telomeres by acting as
CC       a reverse transcriptase that adds simple sequence repeats to chromosome
CC       ends by copying a template sequence within the RNA component of the
CC       enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini
CC       with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The
CC       catalytic cycle involves primer binding, primer extension and release
CC       of product once the template boundary has been reached or nascent
CC       product translocation followed by further extension. More active on
CC       substrates containing 2 or 3 telomeric repeats. Telomerase activity is
CC       regulated by a number of factors including telomerase complex-
CC       associated proteins, chaperones and polypeptide modifiers. Modulates
CC       Wnt signaling. Plays important roles in aging and antiapoptosis.
CC       {ECO:0000269|PubMed:14963003, ECO:0000269|PubMed:15082768,
CC       ECO:0000269|PubMed:15857955, ECO:0000269|PubMed:17026956,
CC       ECO:0000269|PubMed:17264120, ECO:0000269|PubMed:17296728,
CC       ECO:0000269|PubMed:17548608, ECO:0000269|PubMed:19188162,
CC       ECO:0000269|PubMed:19567472, ECO:0000269|PubMed:19571879,
CC       ECO:0000269|PubMed:19777057, ECO:0000269|PubMed:9389643}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxyribonucleoside 5'-triphosphate + DNA(n) =
CC         diphosphate + DNA(n+1); Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:11130,
CC         Rhea:RHEA-COMP:11131, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560,
CC         ChEBI:CHEBI:83828; EC=2.7.7.49;
CC         Evidence={ECO:0000269|PubMed:21602826, ECO:0000269|PubMed:29695869};
CC   -!- SUBUNIT: Catalytic component of the telomerase holoenzyme complex
CC       composed of one molecule of TERT, one molecule of WRAP53/TCAB1, two
CC       molecules of H/ACA ribonucleoprotein complex subunits DKC1, NOP10, NHP2
CC       and GAR1, and a telomerase RNA template component (TERC)
CC       (PubMed:19179534, PubMed:20351177, PubMed:29695869). The telomerase
CC       holoenzyme complex is associated with TEP1, SMG6/EST1A and POT1
CC       (PubMed:19179534). The molecular chaperone HSP90/P23 complex is
CC       required for correct assembly and stabilization of the active
CC       telomerase (PubMed:11274138). Interacts directly with HSP90A and PTGES3
CC       (PubMed:11274138). Interacts with HSPA1A; the interaction occurs in the
CC       absence of TERC and dissociates once the complex has formed
CC       (PubMed:11274138). Interacts with RAN; the interaction promotes nuclear
CC       export of TERT (PubMed:12808100). Interacts with XPO1
CC       (PubMed:12808100). Interacts with PTPN11; the interaction retains TERT
CC       in the nucleus (PubMed:18829466). Interacts with NCL (via RRM1 and C-
CC       terminal RRM4/Arg/Gly-rich domains); the interaction is important for
CC       nucleolar localization of TERT (PubMed:15371412). Interacts with
CC       SMARCA4 (via the bromodomain); the interaction regulates Wnt-mediated
CC       signaling (By similarity). Interacts with MCRS1 (isoform MCRS2); the
CC       interaction inhibits in vitro telomerase activity (PubMed:15044100).
CC       Interacts with PIF1; the interaction has no effect on the elongation
CC       activity of TERT (By similarity). Interacts with PML; the interaction
CC       recruits TERT to PML bodies and inhibits telomerase activity
CC       (PubMed:19567472). Interacts with GNL3L (By similarity). Interacts with
CC       isoform 1 and isoform 2 of NVL (PubMed:22226966). Interacts with DHX36
CC       (PubMed:21846770). {ECO:0000250|UniProtKB:O70372,
CC       ECO:0000269|PubMed:11274138, ECO:0000269|PubMed:12808100,
CC       ECO:0000269|PubMed:15044100, ECO:0000269|PubMed:15371412,
CC       ECO:0000269|PubMed:18829466, ECO:0000269|PubMed:19179534,
CC       ECO:0000269|PubMed:19567472, ECO:0000269|PubMed:20351177,
CC       ECO:0000269|PubMed:21846770, ECO:0000269|PubMed:22226966,
CC       ECO:0000269|PubMed:29695869}.
CC   -!- INTERACTION:
CC       O14746; O14746; NbExp=3; IntAct=EBI-1772203, EBI-1772203;
CC       O14746; P35222: CTNNB1; NbExp=2; IntAct=EBI-1772203, EBI-491549;
CC       O14746; P03126: E6; Xeno; NbExp=7; IntAct=EBI-1772203, EBI-1177242;
CC       O14746; Q9BVP2: GNL3; NbExp=3; IntAct=EBI-1772203, EBI-641642;
CC       O14746; P29590-5: PML; NbExp=7; IntAct=EBI-1772203, EBI-304008;
CC       O14746; Q9Y265: RUVBL1; NbExp=11; IntAct=EBI-1772203, EBI-353675;
CC       O14746; P51532: SMARCA4; NbExp=8; IntAct=EBI-1772203, EBI-302489;
CC       O14746; O14773-1: TPP1; NbExp=2; IntAct=EBI-1772203, EBI-15619703;
CC       O14746; Q92900: UPF1; NbExp=3; IntAct=EBI-1772203, EBI-373471;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:22226966}.
CC       Nucleus, nucleoplasm. Nucleus. Chromosome, telomere. Cytoplasm.
CC       Nucleus, PML body. Note=Shuttling between nuclear and cytoplasm depends
CC       on cell cycle, phosphorylation states, transformation and DNA damage.
CC       Diffuse localization in the nucleoplasm. Enriched in nucleoli of
CC       certain cell types. Translocated to the cytoplasm via nuclear pores in
CC       a CRM1/RAN-dependent manner involving oxidative stress-mediated
CC       phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2
CC       retains TERT in the nucleus. Translocated to the nucleus by
CC       phosphorylation by AKT.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O14746-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14746-2; Sequence=VSP_019587, VSP_019588;
CC       Name=3;
CC         IsoId=O14746-3; Sequence=VSP_021727;
CC       Name=4;
CC         IsoId=O14746-4; Sequence=VSP_053369, VSP_019587, VSP_019588;
CC   -!- TISSUE SPECIFICITY: Expressed at a high level in thymocyte
CC       subpopulations, at an intermediate level in tonsil T-lymphocytes, and
CC       at a low to undetectable level in peripheral blood T-lymphocytes.
CC       {ECO:0000269|PubMed:8676067, ECO:0000269|PubMed:9389643}.
CC   -!- INDUCTION: Activated by cytotoxic events and down-regulated during
CC       aging. In peripheral T-lymphocytes, induced By CD3 and by
CC       PMA/ionomycin. Inhibited by herbimycin B. {ECO:0000269|PubMed:8676067}.
CC   -!- DOMAIN: The primer grip sequence in the RT domain is required for
CC       telomerase activity and for stable association with short telomeric
CC       primers.
CC   -!- DOMAIN: The RNA-interacting domain 1 (RD1)/N-terminal extension (NTE)
CC       is required for interaction with the pseudoknot-template domain of each
CC       of TERC dimers. It contains anchor sites that bind primer nucleotides
CC       upstream of the RNA-DNA hybrid and is thus an essential determinant of
CC       repeat addition processivity.
CC   -!- DOMAIN: The RNA-interacting domain 2 (RD2) is essential for both
CC       interaction with the CR4-CR5 domain of TERC and for DNA synthesis.
CC   -!- PTM: Phosphorylation at Tyr-707 under oxidative stress leads to
CC       translocation of TERT to the cytoplasm and reduces its antiapoptotic
CC       activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention.
CC       Phosphorylation at Ser-227 by the AKT pathway promotes nuclear
CC       location. Phosphorylation at the G2/M phase at Ser-457 by DYRK2
CC       promotes ubiquitination by the EDVP complex and degradation.
CC       {ECO:0000269|PubMed:12808100, ECO:0000269|PubMed:18829466,
CC       ECO:0000269|PubMed:22366458, ECO:0000269|PubMed:23362280}.
CC   -!- PTM: Ubiquitinated by the EDVP complex, a E3 ligase complex following
CC       phosphorylation at Ser-457 by DYRK2. Ubiquitinated leads to proteasomal
CC       degradation. {ECO:0000269|PubMed:23362280}.
CC   -!- PTM: (Microbial infection) In case of infection by HIV-1, the EDVP
CC       complex is hijacked by HIV-1 via interaction between HIV-1 Vpr and
CC       DCAF1/VPRBP, leading to ubiquitination and degradation.
CC       {ECO:0000269|PubMed:23362280}.
CC   -!- DISEASE: Note=Activation of telomerase has been implicated in cell
CC       immortalization and cancer cell pathogenesis.
CC   -!- DISEASE: Aplastic anemia (AA) [MIM:609135]: A form of anemia in which
CC       the bone marrow fails to produce adequate numbers of peripheral blood
CC       elements. It is characterized by peripheral pancytopenia and marrow
CC       hypoplasia. {ECO:0000269|PubMed:15885610, ECO:0000269|PubMed:16627250,
CC       ECO:0000269|PubMed:16990594, ECO:0000269|PubMed:19760749}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=Genetic variations in TERT are associated with coronary
CC       artery disease (CAD).
CC   -!- DISEASE: Dyskeratosis congenita, autosomal dominant, 2 (DKCA2)
CC       [MIM:613989]: A rare multisystem disorder caused by defective telomere
CC       maintenance. It is characterized by progressive bone marrow failure,
CC       and the clinical triad of reticulated skin hyperpigmentation, nail
CC       dystrophy, and mucosal leukoplakia. Common but variable features
CC       include premature graying, aplastic anemia, low platelets,
CC       osteoporosis, pulmonary fibrosis, and liver fibrosis among others.
CC       Early mortality is often associated with bone marrow failure,
CC       infections, fatal pulmonary complications, or malignancy.
CC       {ECO:0000269|PubMed:15885610, ECO:0000269|PubMed:16247010,
CC       ECO:0000269|PubMed:21602826}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Pulmonary fibrosis, and/or bone marrow failure, telomere-
CC       related, 1 (PFBMFT1) [MIM:614742]: A disease associated with shortened
CC       telomeres. Pulmonary fibrosis is the most common manifestation. Other
CC       manifestations include aplastic anemia due to bone marrow failure,
CC       hepatic fibrosis, and increased cancer risk, particularly
CC       myelodysplastic syndrome and acute myeloid leukemia. Phenotype, age at
CC       onset, and severity are determined by telomere length.
CC       {ECO:0000269|PubMed:15814878, ECO:0000269|PubMed:17460043,
CC       ECO:0000269|PubMed:21436073, ECO:0000269|PubMed:21483807,
CC       ECO:0000269|PubMed:22512499}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Dyskeratosis congenita, autosomal recessive, 4 (DKCB4)
CC       [MIM:613989]: A severe form of dyskeratosis congenita, a rare
CC       multisystem disorder caused by defective telomere maintenance. It is
CC       characterized by progressive bone marrow failure, and the clinical
CC       triad of reticulated skin hyperpigmentation, nail dystrophy, and
CC       mucosal leukoplakia. Common but variable features include premature
CC       graying, aplastic anemia, low platelets, osteoporosis, pulmonary
CC       fibrosis, and liver fibrosis among others. Early mortality is often
CC       associated with bone marrow failure, infections, fatal pulmonary
CC       complications, or malignancy. {ECO:0000269|PubMed:16332973,
CC       ECO:0000269|PubMed:17785587, ECO:0000269|PubMed:18042801,
CC       ECO:0000269|PubMed:21602826}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Pulmonary fibrosis, idiopathic (IPF) [MIM:178500]: A lung
CC       disease characterized by shortness of breath, radiographically evident
CC       diffuse pulmonary infiltrates, and varying degrees of inflammation and
CC       fibrosis on biopsy. In some cases, the disorder can be rapidly
CC       progressive and characterized by sequential acute lung injury with
CC       subsequent scarring and end-stage lung disease. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Melanoma, cutaneous malignant 9 (CMM9) [MIM:615134]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but also may
CC       involve other sites. {ECO:0000269|PubMed:23348503}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the reverse transcriptase family. Telomerase
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tert/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF018167; AAC51724.1; -; mRNA.
DR   EMBL; AF015950; AAC51672.1; -; mRNA.
DR   EMBL; AF128894; AAD30037.1; -; Genomic_DNA.
DR   EMBL; AF128893; AAD30037.1; JOINED; Genomic_DNA.
DR   EMBL; AB085628; BAC11010.1; -; mRNA.
DR   EMBL; AB086379; BAC11014.1; -; mRNA.
DR   EMBL; AB086950; BAC11015.1; -; mRNA.
DR   EMBL; AY007685; AAG23289.1; -; Genomic_DNA.
DR   EMBL; DQ264729; ABB72674.1; -; Genomic_DNA.
DR   EMBL; AC114291; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471102; EAX08167.1; -; Genomic_DNA.
DR   CCDS; CCDS3861.2; -. [O14746-1]
DR   CCDS; CCDS54831.1; -. [O14746-3]
DR   PIR; T03844; T03844.
DR   RefSeq; NP_001180305.1; NM_001193376.1. [O14746-3]
DR   RefSeq; NP_937983.2; NM_198253.2. [O14746-1]
DR   PDB; 2BCK; X-ray; 2.80 A; C/F=461-469.
DR   PDB; 4B18; X-ray; 2.52 A; B=222-240.
DR   PDB; 4MNQ; X-ray; 2.74 A; C=540-548.
DR   PDB; 5MEN; X-ray; 2.81 A; C=540-548.
DR   PDB; 5MEO; X-ray; 1.77 A; C=540-548.
DR   PDB; 5MEP; X-ray; 2.71 A; C/F=540-548.
DR   PDB; 5MEQ; X-ray; 2.27 A; C=540-546.
DR   PDB; 5MER; X-ray; 1.88 A; C/F=540-546.
DR   PDB; 5UGW; X-ray; 2.31 A; A=961-1132.
DR   PDBsum; 2BCK; -.
DR   PDBsum; 4B18; -.
DR   PDBsum; 4MNQ; -.
DR   PDBsum; 5MEN; -.
DR   PDBsum; 5MEO; -.
DR   PDBsum; 5MEP; -.
DR   PDBsum; 5MEQ; -.
DR   PDBsum; 5MER; -.
DR   PDBsum; 5UGW; -.
DR   SMR; O14746; -.
DR   BioGrid; 112874; 97.
DR   ComplexPortal; CPX-17; Telomerase catalytic core complex.
DR   ComplexPortal; CPX-20; TERT-RMRP complex.
DR   ComplexPortal; CPX-265; Telomerase holoenzyme complex.
DR   CORUM; O14746; -.
DR   DIP; DIP-40646N; -.
DR   ELM; O14746; -.
DR   IntAct; O14746; 23.
DR   MINT; O14746; -.
DR   STRING; 9606.ENSP00000309572; -.
DR   BindingDB; O14746; -.
DR   ChEMBL; CHEMBL2916; -.
DR   DrugBank; DB05036; Grn163l.
DR   DrugBank; DB12747; Tertomotide.
DR   DrugBank; DB00495; Zidovudine.
DR   DrugCentral; O14746; -.
DR   iPTMnet; O14746; -.
DR   PhosphoSitePlus; O14746; -.
DR   BioMuta; TERT; -.
DR   EPD; O14746; -.
DR   MassIVE; O14746; -.
DR   PaxDb; O14746; -.
DR   PeptideAtlas; O14746; -.
DR   PRIDE; O14746; -.
DR   ProteomicsDB; 48203; -. [O14746-1]
DR   ProteomicsDB; 48204; -. [O14746-2]
DR   ProteomicsDB; 48205; -. [O14746-3]
DR   ProteomicsDB; 73418; -.
DR   ABCD; O14746; -.
DR   Antibodypedia; 8998; 930 antibodies.
DR   DNASU; 7015; -.
DR   Ensembl; ENST00000310581; ENSP00000309572; ENSG00000164362. [O14746-1]
DR   Ensembl; ENST00000334602; ENSP00000334346; ENSG00000164362. [O14746-3]
DR   Ensembl; ENST00000460137; ENSP00000425003; ENSG00000164362. [O14746-4]
DR   GeneID; 7015; -.
DR   KEGG; hsa:7015; -.
DR   UCSC; uc003jcb.2; human. [O14746-1]
DR   CTD; 7015; -.
DR   DisGeNET; 7015; -.
DR   GeneCards; TERT; -.
DR   GeneReviews; TERT; -.
DR   HGNC; HGNC:11730; TERT.
DR   HPA; ENSG00000164362; Group enriched (bone marrow, lymphoid tissue, testis).
DR   MalaCards; TERT; -.
DR   MIM; 178500; phenotype.
DR   MIM; 187270; gene+phenotype.
DR   MIM; 609135; phenotype.
DR   MIM; 613989; phenotype.
DR   MIM; 614742; phenotype.
DR   MIM; 615134; phenotype.
DR   neXtProt; NX_O14746; -.
DR   OpenTargets; ENSG00000164362; -.
DR   Orphanet; 457246; Clear cell sarcoma of kidney.
DR   Orphanet; 1775; Dyskeratosis congenita.
DR   Orphanet; 618; Familial melanoma.
DR   Orphanet; 3322; Hoyeraal-Hreidarsson syndrome.
DR   Orphanet; 88; Idiopathic aplastic anemia.
DR   Orphanet; 2032; Idiopathic pulmonary fibrosis.
DR   PharmGKB; PA36447; -.
DR   eggNOG; KOG1005; Eukaryota.
DR   eggNOG; ENOG410XQJH; LUCA.
DR   GeneTree; ENSGT00390000018531; -.
DR   HOGENOM; CLU_001996_2_0_1; -.
DR   InParanoid; O14746; -.
DR   KO; K11126; -.
DR   OMA; HCAPHRV; -.
DR   OrthoDB; 1297956at2759; -.
DR   PhylomeDB; O14746; -.
DR   TreeFam; TF329048; -.
DR   Reactome; R-HSA-171319; Telomere Extension By Telomerase.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   SIGNOR; O14746; -.
DR   EvolutionaryTrace; O14746; -.
DR   GeneWiki; Telomerase_reverse_transcriptase; -.
DR   GenomeRNAi; 7015; -.
DR   Pharos; O14746; Tchem.
DR   PRO; PR:O14746; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; O14746; protein.
DR   Bgee; ENSG00000164362; Expressed in uterus and 145 other tissues.
DR   Genevisible; O14746; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IC:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:BHF-UCL.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0000783; C:nuclear telomere cap complex; IC:BHF-UCL.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0031379; C:RNA-directed RNA polymerase complex; IPI:BHF-UCL.
DR   GO; GO:0000333; C:telomerase catalytic core complex; IDA:BHF-UCL.
DR   GO; GO:0005697; C:telomerase holoenzyme complex; IDA:UniProtKB.
DR   GO; GO:1990572; C:TERT-RMRP complex; IDA:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; IPI:BHF-UCL.
DR   GO; GO:0003968; F:RNA-directed 5'-3' RNA polymerase activity; IDA:BHF-UCL.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IDA:BHF-UCL.
DR   GO; GO:0003720; F:telomerase activity; IDA:UniProtKB.
DR   GO; GO:0070034; F:telomerase RNA binding; IDA:BHF-UCL.
DR   GO; GO:0003721; F:telomerase RNA reverse transcriptase activity; IDA:BHF-UCL.
DR   GO; GO:0042162; F:telomeric DNA binding; IBA:GO_Central.
DR   GO; GO:0098680; F:template-free RNA nucleotidyltransferase; IDA:BHF-UCL.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL.
DR   GO; GO:0000049; F:tRNA binding; IDA:BHF-UCL.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0071897; P:DNA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0022616; P:DNA strand elongation; IDA:BHF-UCL.
DR   GO; GO:0062103; P:double-stranded RNA biosynthetic process; IDA:ARUK-UCL.
DR   GO; GO:0070200; P:establishment of protein localization to telomere; IDA:BHF-UCL.
DR   GO; GO:0007005; P:mitochondrion organization; IDA:BHF-UCL.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IDA:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:1903704; P:negative regulation of production of siRNA involved in RNA interference; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
DR   GO; GO:0042635; P:positive regulation of hair cycle; ISS:BHF-UCL.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:BHF-UCL.
DR   GO; GO:1904751; P:positive regulation of protein localization to nucleolus; IDA:BHF-UCL.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; ISS:BHF-UCL.
DR   GO; GO:1903620; P:positive regulation of transdifferentiation; IEA:Ensembl.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IGI:BHF-UCL.
DR   GO; GO:0030422; P:production of siRNA involved in RNA interference; IDA:BHF-UCL.
DR   GO; GO:0031647; P:regulation of protein stability; IDA:BHF-UCL.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0006278; P:RNA-dependent DNA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0000723; P:telomere maintenance; TAS:UniProtKB.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; IDA:UniProtKB.
DR   GO; GO:0001172; P:transcription, RNA-templated; IDA:BHF-UCL.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR021891; Telomerase_RBD.
DR   InterPro; IPR003545; Telomerase_RT.
DR   PANTHER; PTHR12066; PTHR12066; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF12009; Telomerase_RBD; 1.
DR   PRINTS; PR01365; TELOMERASERT.
DR   SMART; SM00975; Telomerase_RBD; 1.
DR   PROSITE; PS50878; RT_POL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosome; Cytoplasm;
KW   Disease mutation; DNA-binding; Dyskeratosis congenita; Magnesium;
KW   Metal-binding; Nucleotidyltransferase; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Ribonucleoprotein;
KW   RNA-directed DNA polymerase; Telomere; Transferase; Ubl conjugation.
FT   CHAIN           1..1132
FT                   /note="Telomerase reverse transcriptase"
FT                   /id="PRO_0000054925"
FT   DOMAIN          605..935
FT                   /note="Reverse transcriptase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   REGION          1..230
FT                   /note="RNA-interacting domain 1"
FT   REGION          58..197
FT                   /note="GQ motif"
FT   REGION          137..141
FT                   /note="Required for regulating specificity for telomeric
FT                   DNA and for processivity for primer elongation"
FT   REGION          231..324
FT                   /note="Linker"
FT   REGION          301..538
FT                   /note="Required for oligomerization"
FT   REGION          325..550
FT                   /note="RNA-interacting domain 2"
FT   REGION          376..521
FT                   /note="QFP motif"
FT   REGION          397..417
FT                   /note="CP motif"
FT   REGION          914..928
FT                   /note="Required for oligomerization"
FT   REGION          930..934
FT                   /note="Primer grip sequence"
FT   REGION          936..1132
FT                   /note="CTE"
FT   MOTIF           222..240
FT                   /note="Bipartite nuclear localization signal"
FT   MOTIF           328..333
FT                   /note="TFLY; involved in RNA binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q4KTA7"
FT   METAL           712
FT                   /note="Magnesium; catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   METAL           868
FT                   /note="Magnesium; catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   METAL           869
FT                   /note="Magnesium; catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   SITE            169
FT                   /note="Required for optimal binding of telomeric ssDNA and
FT                   incorporation of nucleotides at the second position of the
FT                   template"
FT   SITE            867
FT                   /note="Required for nucleotide incorporation and primer
FT                   extension rate"
FT   MOD_RES         227
FT                   /note="Phosphoserine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:22366458"
FT   MOD_RES         457
FT                   /note="Phosphoserine; by DYRK2"
FT                   /evidence="ECO:0000269|PubMed:23362280"
FT   MOD_RES         707
FT                   /note="Phosphotyrosine; by SRC-type Tyr-kinases"
FT                   /evidence="ECO:0000269|PubMed:12808100,
FT                   ECO:0000269|PubMed:18829466"
FT   VAR_SEQ         711..722
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14654914"
FT                   /id="VSP_053369"
FT   VAR_SEQ         764..807
FT                   /note="STLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFD -> LRPV
FT                   PGDPAGLHPLHAALQPVLRRHGEQAVCGDSAGRAAPAFGG (in isoform 2 and
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12869302,
FT                   ECO:0000303|PubMed:14654914"
FT                   /id="VSP_019587"
FT   VAR_SEQ         808..1132
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12869302,
FT                   ECO:0000303|PubMed:14654914"
FT                   /id="VSP_019588"
FT   VAR_SEQ         885..947
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14654914"
FT                   /id="VSP_021727"
FT   VARIANT         55
FT                   /note="L -> Q (in idiopathic pulmonary fibrosis
FT                   susceptibility; impaired telomerase activity;
FT                   dbSNP:rs387907247)"
FT                   /evidence="ECO:0000269|PubMed:17392301"
FT                   /id="VAR_062535"
FT   VARIANT         65
FT                   /note="P -> A (associated with acute myeloid leukemia;
FT                   dbSNP:rs544215765)"
FT                   /evidence="ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062780"
FT   VARIANT         170
FT                   /note="V -> M (in PFBMFT1; the mutant protein is
FT                   demonstrated to cause decreased telomerase activity;
FT                   dbSNP:rs387907248)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068792"
FT   VARIANT         202
FT                   /note="A -> T (in PFBMFT1 and AA; severe and moderate;
FT                   associated with disease susceptibility; shorter telomeres;
FT                   dbSNP:rs121918661)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:15885610, ECO:0000269|PubMed:19760749"
FT                   /id="VAR_036863"
FT   VARIANT         279
FT                   /note="A -> T (in dbSNP:rs61748181)"
FT                   /evidence="ECO:0000269|PubMed:15814878"
FT                   /id="VAR_036864"
FT   VARIANT         299
FT                   /note="V -> M (associated with acute myeloid leukemia;
FT                   dbSNP:rs756624928)"
FT                   /evidence="ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062781"
FT   VARIANT         412
FT                   /note="H -> Y (in PFBMFT1, AA and DKCB4; severe and
FT                   moderate; associated with susceptibility to acute
FT                   myelogenous leukemia; the mutant protein has 36% residual
FT                   activity; dbSNP:rs34094720)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:18042801, ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749, ECO:0000269|Ref.7"
FT                   /id="VAR_025149"
FT   VARIANT         441
FT                   /note="Missing (in AA; associated with susceptibility to
FT                   acute myeloid leukemia)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:19147845, ECO:0000269|PubMed:19760749"
FT                   /id="VAR_036865"
FT   VARIANT         522
FT                   /note="R -> K (associated with acute myeloid leukemia)"
FT                   /evidence="ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062782"
FT   VARIANT         570
FT                   /note="K -> N (in AA; abolishes telomerase catalytic
FT                   activity but no effect on binding to TERC)"
FT                   /evidence="ECO:0000269|PubMed:16990594,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062536"
FT   VARIANT         631
FT                   /note="R -> Q (in AA; dbSNP:rs199422294)"
FT                   /evidence="ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062783"
FT   VARIANT         682
FT                   /note="G -> D (in AA; non-severe; abolishes telomerase
FT                   catalytic activity but little effect on binding to TERC;
FT                   dbSNP:rs199422295)"
FT                   /evidence="ECO:0000269|PubMed:16627250,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062537"
FT   VARIANT         694
FT                   /note="V -> M (in PFBMFT1 and AA; moderate;
FT                   dbSNP:rs121918662)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_036866"
FT   VARIANT         704
FT                   /note="P -> S (in DKCB4; the mutant protein has 13%
FT                   residual activity; dbSNP:rs199422297)"
FT                   /evidence="ECO:0000269|PubMed:18042801,
FT                   ECO:0000269|PubMed:21602826"
FT                   /id="VAR_068793"
FT   VARIANT         716
FT                   /note="A -> T (in PFBMFT1; the mutant protein is
FT                   demonstrated to cause severely compromised telomerase
FT                   activity; dbSNP:rs387907249)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068794"
FT   VARIANT         721
FT                   /note="P -> R (in DKCB4; no effect on telomerase catalytic
FT                   activity and little effect on binding to TERC;
FT                   dbSNP:rs199422299)"
FT                   /evidence="ECO:0000269|PubMed:16332973,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062538"
FT   VARIANT         726
FT                   /note="T -> M (in AA; very severe; no effect on telomerase
FT                   catalytic activity but shortened telomeres;
FT                   dbSNP:rs149566858)"
FT                   /evidence="ECO:0000269|PubMed:16627250,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062539"
FT   VARIANT         772
FT                   /note="Y -> C (in PFBMFT1; moderate; dbSNP:rs121918663)"
FT                   /evidence="ECO:0000269|PubMed:15814878"
FT                   /id="VAR_036867"
FT   VARIANT         785
FT                   /note="P -> L (in AA; dbSNP:rs483352771)"
FT                   /evidence="ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062784"
FT   VARIANT         791
FT                   /note="V -> I (in PFBMFT1; associated with Met-867 in cis
FT                   on the same allele; the double mutant shows severe defects
FT                   in telomere repeat addition processivity;
FT                   dbSNP:rs141425941)"
FT                   /evidence="ECO:0000269|PubMed:21483807"
FT                   /id="VAR_068795"
FT   VARIANT         811
FT                   /note="R -> C (in DKCB4; 50% reduction in telomerase
FT                   activity; dbSNP:rs199422301)"
FT                   /evidence="ECO:0000269|PubMed:17785587"
FT                   /id="VAR_062540"
FT   VARIANT         841
FT                   /note="L -> F (in PFBMFT1)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068796"
FT   VARIANT         865
FT                   /note="R -> H (in PFBMFT1; dbSNP:rs121918666)"
FT                   /evidence="ECO:0000269|PubMed:17460043"
FT                   /id="VAR_036868"
FT   VARIANT         867
FT                   /note="V -> M (in PFBMFT1; associated with Ile-791 in cis
FT                   on the same allele; the double mutant shows severe defects
FT                   in telomere repeat addition processivity; this mutation
FT                   causes most if not all of the functional defects;
FT                   dbSNP:rs201159197)"
FT                   /evidence="ECO:0000269|PubMed:21483807"
FT                   /id="VAR_068797"
FT   VARIANT         901
FT                   /note="R -> W (in DKCB4; severe phenotype overlapping with
FT                   Hoyeraal-Hreidarsson syndrome; very short telomeres and
FT                   greatly reduced telomerase activity; dbSNP:rs199422304)"
FT                   /evidence="ECO:0000269|PubMed:17785587"
FT                   /id="VAR_062541"
FT   VARIANT         902
FT                   /note="K -> N (in DKCA2; abolishes telomerase catalytic
FT                   activity but no effect on binding to TERC;
FT                   dbSNP:rs121918665)"
FT                   /evidence="ECO:0000269|PubMed:16247010,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_036869"
FT   VARIANT         902
FT                   /note="K -> R (in PFBMFT1; dbSNP:rs387907250)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068798"
FT   VARIANT         923
FT                   /note="P -> L (in PFBMFT1; dbSNP:rs387907251)"
FT                   /evidence="ECO:0000269|PubMed:22512499"
FT                   /id="VAR_068799"
FT   VARIANT         948
FT                   /note="S -> R (in dbSNP:rs34062885)"
FT                   /id="VAR_053726"
FT   VARIANT         979
FT                   /note="R -> W (in DKCA2; shortened telomeres but no effect
FT                   on telomerase catalytic activity nor on binding to TERC;
FT                   dbSNP:rs199422305)"
FT                   /evidence="ECO:0000269|PubMed:15885610,
FT                   ECO:0000269|PubMed:16990594, ECO:0000269|PubMed:21602826"
FT                   /id="VAR_062542"
FT   VARIANT         1025
FT                   /note="V -> F (in PFBMFT1)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068800"
FT   VARIANT         1062
FT                   /note="A -> T (increased incidence in sporadic acute
FT                   myeloid leukemia; dbSNP:rs35719940)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:19147845, ECO:0000269|PubMed:19760749,
FT                   ECO:0000269|Ref.7"
FT                   /id="VAR_025150"
FT   VARIANT         1090
FT                   /note="V -> M (in PFBMFT1; severe; dbSNP:rs121918664)"
FT                   /evidence="ECO:0000269|PubMed:15814878"
FT                   /id="VAR_036870"
FT   VARIANT         1110
FT                   /note="T -> M (in idiopathic pulmonary fibrosis
FT                   susceptibility; impaired telomerase activity;
FT                   dbSNP:rs199422306)"
FT                   /evidence="ECO:0000269|PubMed:17392301"
FT                   /id="VAR_062543"
FT   VARIANT         1127
FT                   /note="F -> L (in DKCA2; severe; shortened telomeres but no
FT                   effect on telomerase catalytic activity nor on binding to
FT                   TERC; dbSNP:rs1176273130)"
FT                   /evidence="ECO:0000269|PubMed:15885610,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062544"
FT   MUTAGEN         137..141
FT                   /note="WGLLL->AAAAA: Reduced catalytic activity and repeat
FT                   addition processivity. Complete loss of catalytic activity
FT                   but no loss of binding to telomeric primers; when
FT                   associated with 930-A--A-934."
FT                   /evidence="ECO:0000269|PubMed:17296728"
FT   MUTAGEN         169
FT                   /note="Q->A: About 80% loss of enzymatic activity. Greatly
FT                   reduced incorporation of second nucleotide. Altered
FT                   strength of binding to ssDNA. Little effect on repeat
FT                   addition processivity, nor on TR interaction nor on protein
FT                   levels."
FT                   /evidence="ECO:0000269|PubMed:19777057"
FT   MUTAGEN         169
FT                   /note="Q->N: About 85% loss of enzymatic activity. Greatly
FT                   reduced incorporation of second nucleotide. Altered
FT                   strength of binding to ssDNA. No effect on protein levels
FT                   nor on TR interaction."
FT                   /evidence="ECO:0000269|PubMed:19777057"
FT   MUTAGEN         169
FT                   /note="Q->T: About 90% loss of enzymatic activity. Greatly
FT                   reduced incorporation of second nucleotide. Altered
FT                   strength of binding to ssDNA. No effect on protein levels
FT                   nor on TR interaction."
FT                   /evidence="ECO:0000269|PubMed:19777057"
FT   MUTAGEN         457
FT                   /note="S->A: Abolishes phosphorylation by DYRK2."
FT                   /evidence="ECO:0000269|PubMed:23362280"
FT   MUTAGEN         547
FT                   /note="W->A: Defective in high-affinity TERC interactions."
FT                   /evidence="ECO:0000269|PubMed:15082768"
FT   MUTAGEN         631
FT                   /note="R->A: Abolishes telomerase catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:17026956"
FT   MUTAGEN         707
FT                   /note="Y->F: Abolishes oxidative stress-induced
FT                   phosphorylation and RAN binding. Impaired nuclear export
FT                   and enhanced antiapoptotic activity against ROS-dependent
FT                   apoptosis induction. Impaired interaction with PTPN11. No
FT                   dephosphorylation by PTPN11."
FT                   /evidence="ECO:0000269|PubMed:12808100,
FT                   ECO:0000269|PubMed:18829466"
FT   MUTAGEN         712
FT                   /note="D->A: Loss of telomerase activity. In the absence of
FT                   TR, no loss of binding to telomeric primers."
FT                   /evidence="ECO:0000269|PubMed:17026956,
FT                   ECO:0000269|PubMed:17296728, ECO:0000269|PubMed:9389643,
FT                   ECO:0000269|PubMed:9443919"
FT   MUTAGEN         866
FT                   /note="L->Y: Moderate reduction in telomerase activity, no
FT                   change in repeat extension rate nor on nucleotide
FT                   incorporation fidelity. Little further reduction in
FT                   activity but 13.5-fold increase in nucleotide incorporation
FT                   fidelity; when associated with M-867."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         867
FT                   /note="V->A: About 75% reduction in telomerase activity,
FT                   about 80% reduction in repeat reduction rate and 3.9-fold
FT                   increase in nucleotide incorporation fidelity."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         867
FT                   /note="V->M: About 75% reduction in telomerase activity,
FT                   about 50% reduction in repeat extension rate and 5.2-fold
FT                   increase in nucleotide incorporation fidelity. Little
FT                   further reduction in activity and 13.5-fold increase in
FT                   nucleotide incorporation fidelity; when associated with Y-
FT                   866."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         867
FT                   /note="V->T: Severe reduction in telomerase activity, about
FT                   50% reduction in repeat extension rate and 2.2-fold
FT                   increase in nucleotide incorporation fidelity. No further
FT                   reduction in activity but 2.8-fold increase in nucleotide
FT                   incorporation fidelity; when associated with Y-866."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         868..869
FT                   /note="DD->AA: Loss of telomerase activity."
FT   MUTAGEN         868
FT                   /note="D->A: Loss of telomerase activity."
FT                   /evidence="ECO:0000269|PubMed:15082768,
FT                   ECO:0000269|PubMed:15857955, ECO:0000269|PubMed:17026956,
FT                   ECO:0000269|PubMed:9389643, ECO:0000269|PubMed:9443919"
FT   MUTAGEN         869
FT                   /note="D->A: Loss of telomerase activity."
FT                   /evidence="ECO:0000269|PubMed:9389643,
FT                   ECO:0000269|PubMed:9443919"
FT   MUTAGEN         930..934
FT                   /note="WCGLL->AAAAA: Completely abolishes telomerase-
FT                   mediated primer extension and reduced binding to short
FT                   telomeric primers. Complete loss of catalytic activity but
FT                   no further loss of binding to telomeric primers; when
FT                   associated with 137-A--A-141."
FT                   /evidence="ECO:0000269|PubMed:17296728"
FT   CONFLICT        516
FT                   /note="D -> G (in Ref. 1; AAC51724)"
FT                   /evidence="ECO:0000305"
FT   HELIX           966..983
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           984..986
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   TURN            989..991
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           994..1017
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1025..1027
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1029..1050
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   TURN            1051..1053
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1067..1082
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1083..1085
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1086..1104
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1111..1118
FT                   /evidence="ECO:0000244|PDB:5UGW"
SQ   SEQUENCE   1132 AA;  126997 MW;  94E35469C4CA33A0 CRC64;
     MPRAPRCRAV RSLLRSHYRE VLPLATFVRR LGPQGWRLVQ RGDPAAFRAL VAQCLVCVPW
     DARPPPAAPS FRQVSCLKEL VARVLQRLCE RGAKNVLAFG FALLDGARGG PPEAFTTSVR
     SYLPNTVTDA LRGSGAWGLL LRRVGDDVLV HLLARCALFV LVAPSCAYQV CGPPLYQLGA
     ATQARPPPHA SGPRRRLGCE RAWNHSVREA GVPLGLPAPG ARRRGGSASR SLPLPKRPRR
     GAAPEPERTP VGQGSWAHPG RTRGPSDRGF CVVSPARPAE EATSLEGALS GTRHSHPSVG
     RQHHAGPPST SRPPRPWDTP CPPVYAETKH FLYSSGDKEQ LRPSFLLSSL RPSLTGARRL
     VETIFLGSRP WMPGTPRRLP RLPQRYWQMR PLFLELLGNH AQCPYGVLLK THCPLRAAVT
     PAAGVCAREK PQGSVAAPEE EDTDPRRLVQ LLRQHSSPWQ VYGFVRACLR RLVPPGLWGS
     RHNERRFLRN TKKFISLGKH AKLSLQELTW KMSVRDCAWL RRSPGVGCVP AAEHRLREEI
     LAKFLHWLMS VYVVELLRSF FYVTETTFQK NRLFFYRKSV WSKLQSIGIR QHLKRVQLRE
     LSEAEVRQHR EARPALLTSR LRFIPKPDGL RPIVNMDYVV GARTFRREKR AERLTSRVKA
     LFSVLNYERA RRPGLLGASV LGLDDIHRAW RTFVLRVRAQ DPPPELYFVK VDVTGAYDTI
     PQDRLTEVIA SIIKPQNTYC VRRYAVVQKA AHGHVRKAFK SHVSTLTDLQ PYMRQFVAHL
     QETSPLRDAV VIEQSSSLNE ASSGLFDVFL RFMCHHAVRI RGKSYVQCQG IPQGSILSTL
     LCSLCYGDME NKLFAGIRRD GLLLRLVDDF LLVTPHLTHA KTFLRTLVRG VPEYGCVVNL
     RKTVVNFPVE DEALGGTAFV QMPAHGLFPW CGLLLDTRTL EVQSDYSSYA RTSIRASLTF
     NRGFKAGRNM RRKLFGVLRL KCHSLFLDLQ VNSLQTVCTN IYKILLLQAY RFHACVLQLP
     FHQQVWKNPT FFLRVISDTA SLCYSILKAK NAGMSLGAKG AAGPLPSEAV QWLCHQAFLL
     KLTRHRVTYV PLLGSLRTAQ TQLSRKLPGT TLTALEAAAN PALPSDFKTI LD
//
ID   A0A0S2Z4N5_HUMAN        Unreviewed;       680 AA.
AC   A0A0S2Z4N5;
DT   17-FEB-2016, integrated into UniProtKB/TrEMBL.
DT   17-FEB-2016, sequence version 1.
DT   22-APR-2020, entry version 39.
DE   RecName: Full=Tumor protein 63 (p63) {ECO:0000256|RuleBase:RU003304};
DE   Flags: Fragment;
GN   Name=TP63 {ECO:0000313|EMBL:ALQ33893.1};
GN   Synonyms=TP73L {ECO:0000313|EMBL:EAW78112.1};
GN   ORFNames=hCG_16028 {ECO:0000313|EMBL:EAW78112.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ALQ33893.1};
RN   [1] {ECO:0000313|EMBL:EAW78112.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW78112.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:ALQ33893.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=26871637; DOI=10.1016/j.cell.2016.01.029;
RA   Yang X., Coulombe-Huntington J., Kang S., Sheynkman G.M., Hao T.,
RA   Richardson A., Sun S., Yang F., Shen Y.A., Murray R., Spirohn K.,
RA   Begg B.E., Duran-Frigola M., MacWilliams A., Pevzner S.J., Zhong Q.,
RA   Trigg S.A., Tam S., Ghamsari L., Sahni N., Yi S., Rodriguez M.D.,
RA   Balcha D., Tan G., Costanzo M., Andrews B., Boone C., Zhou X.J.,
RA   Salehi-Ashtiani K., Charloteaux B., Chen A., Calderwood M.A., Aloy P.,
RA   Roth F.P., Hill D.E., Iakoucheva L.M., Xia Y., Vidal M.;
RT   "Widespread Expansion of Protein Interaction Capabilities by Alternative
RT   Splicing.";
RL   Cell 164:805-817(2016).
CC   -!- FUNCTION: Acts as a sequence specific DNA binding transcriptional
CC       activator or repressor. The isoforms contain a varying set of
CC       transactivation and auto-regulating transactivation inhibiting domains
CC       thus showing an isoform specific activity. May be required in
CC       conjunction with TP73/p73 for initiation of p53/TP53 dependent
CC       apoptosis in response to genotoxic insults and the presence of
CC       activated oncogenes. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Isoform composition of the
CC       tetramer may determine transactivation activity.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KU178435; ALQ33893.1; -; mRNA.
DR   EMBL; CH471052; EAW78112.1; -; Genomic_DNA.
DR   RefSeq; NP_003713.3; NM_003722.4.
DR   Antibodypedia; 1750; 969 antibodies.
DR   GeneID; 8626; -.
DR   KEGG; hsa:8626; -.
DR   CTD; 8626; -.
DR   KO; K10149; -.
DR   OMA; VIQHIWD; -.
DR   OrthoDB; 257530at2759; -.
DR   ChiTaRS; TP63; human.
DR   GenomeRNAi; 8626; -.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003690; F:double-stranded DNA binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR   GO; GO:0060197; P:cloacal septation; IEA:Ensembl.
DR   GO; GO:1904888; P:cranial skeletal system development; IEA:Ensembl.
DR   GO; GO:0007499; P:ectoderm and mesoderm interaction; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0010481; P:epidermal cell division; IEA:Ensembl.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0001736; P:establishment of planar polarity; IEA:Ensembl.
DR   GO; GO:0061436; P:establishment of skin barrier; IEA:Ensembl.
DR   GO; GO:0048807; P:female genitalia morphogenesis; IEA:Ensembl.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0010259; P:multicellular organism aging; IEA:Ensembl.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045617; P:negative regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:2000381; P:negative regulation of mesoderm development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0030859; P:polarized epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:1904674; P:positive regulation of somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0060513; P:prostatic bud formation; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0010482; P:regulation of epidermal cell division; IEA:Ensembl.
DR   GO; GO:0001302; P:replicative cell aging; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0043589; P:skin morphogenesis; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   CDD; cd09572; SAM_tumor-p63; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR032645; Tp63.
DR   InterPro; IPR037611; Tumor-p63_SAM.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          541..607
FT                   /note="SAM"
FT                   /evidence="ECO:0000259|SMART:SM00454"
FT   REGION          123..171
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          351..393
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          435..472
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        123..166
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        364..389
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         680
FT                   /evidence="ECO:0000313|EMBL:ALQ33893.1"
SQ   SEQUENCE   680 AA;  76785 MW;  F66ECD45E87D9799 CRC64;
     MNFETSRCAT LQYCPDPYIQ RFVETPAHFS WKESYYRSTM SQSTQTNEFL SPEVFQHIWD
     FLEQPICSVQ PIDLNFVDEP SEDGATNKIE ISMDCIRMQD SDLSDPMWPQ YTNLGLLNSM
     DQQIQNGSSS TSPYNTDHAQ NSVTAPSPYA QPSSTFDALS PSPAIPSNTD YPGPHSFDVS
     FQQSSTAKSA TWTYSTELKK LYCQIAKTCP IQIKVMTPPP QGAVIRAMPV YKKAEHVTEV
     VKRCPNHELS REFNEGQIAP PSHLIRVEGN SHAQYVEDPI TGRQSVLVPY EPPQVGTEFT
     TVLYNFMCNS SCVGGMNRRP ILIIVTLETR DGQVLGRRCF EARICACPGR DRKADEDSIR
     KQQVSDSTKN GDGTKRPFRQ NTHGIQMTSI KKRRSPDDEL LYLPVRGRET YEMLLKIKES
     LELMQYLPQH TIETYRQQQQ QQHQHLLQKQ TSIQSPSSYG NSSPPLNKMN SMNKLPSVSQ
     LINPQQRNAL TPTTIPDGMG ANIPMMGTHM PMAGDMNGLS PTQALPPPLS MPSTSHCTPP
     PPYPTDCSIV SFLARLGCSS CLDYFTTQGL TTIYQIEHYS MDDLASLKIP EQFRHAIWKG
     ILDHRQLHEF SSPSHLLRTP SSASTVSVGS SETRGERVID AVRFTLRQTI SFPPRDEWND
     FNFDMDARRN KQQRIKEEGE
//
ID   A0A0S2Z4N6_HUMAN        Unreviewed;       676 AA.
AC   A0A0S2Z4N6;
DT   17-FEB-2016, integrated into UniProtKB/TrEMBL.
DT   17-FEB-2016, sequence version 1.
DT   22-APR-2020, entry version 29.
DE   RecName: Full=Tumor protein 63 (p63) {ECO:0000256|RuleBase:RU003304};
DE   Flags: Fragment;
GN   Name=TP63 {ECO:0000313|EMBL:ALQ33894.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ALQ33894.1};
RN   [1] {ECO:0000313|EMBL:ALQ33894.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=26871637; DOI=10.1016/j.cell.2016.01.029;
RA   Yang X., Coulombe-Huntington J., Kang S., Sheynkman G.M., Hao T.,
RA   Richardson A., Sun S., Yang F., Shen Y.A., Murray R., Spirohn K.,
RA   Begg B.E., Duran-Frigola M., MacWilliams A., Pevzner S.J., Zhong Q.,
RA   Trigg S.A., Tam S., Ghamsari L., Sahni N., Yi S., Rodriguez M.D.,
RA   Balcha D., Tan G., Costanzo M., Andrews B., Boone C., Zhou X.J.,
RA   Salehi-Ashtiani K., Charloteaux B., Chen A., Calderwood M.A., Aloy P.,
RA   Roth F.P., Hill D.E., Iakoucheva L.M., Xia Y., Vidal M.;
RT   "Widespread Expansion of Protein Interaction Capabilities by Alternative
RT   Splicing.";
RL   Cell 164:805-817(2016).
CC   -!- FUNCTION: Acts as a sequence specific DNA binding transcriptional
CC       activator or repressor. The isoforms contain a varying set of
CC       transactivation and auto-regulating transactivation inhibiting domains
CC       thus showing an isoform specific activity. May be required in
CC       conjunction with TP73/p73 for initiation of p53/TP53 dependent
CC       apoptosis in response to genotoxic insults and the presence of
CC       activated oncogenes. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Isoform composition of the
CC       tetramer may determine transactivation activity.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KU178436; ALQ33894.1; -; mRNA.
DR   RefSeq; NP_001316077.1; NM_001329148.1.
DR   SMR; A0A0S2Z4N6; -.
DR   Antibodypedia; 1750; 969 antibodies.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   ChiTaRS; TP63; human.
DR   GenomeRNAi; 8626; -.
DR   ExpressionAtlas; A0A0S2Z4N6; baseline and differential.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   CDD; cd08367; P53; 1.
DR   CDD; cd09572; SAM_tumor-p63; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR032645; Tp63.
DR   InterPro; IPR037611; Tumor-p63_SAM.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          537..603
FT                   /note="SAM"
FT                   /evidence="ECO:0000259|SMART:SM00454"
FT   REGION          123..171
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          351..388
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          431..468
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        123..166
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        364..385
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   NON_TER         676
FT                   /evidence="ECO:0000313|EMBL:ALQ33894.1"
SQ   SEQUENCE   676 AA;  76317 MW;  EB0E2C9E93C6D34A CRC64;
     MNFETSRCAT LQYCPDPYIQ RFVETPAHFS WKESYYRSTM SQSTQTNEFL SPEVFQHIWD
     FLEQPICSVQ PIDLNFVDEP SEDGATNKIE ISMDCIRMQD SDLSDPMWPQ YTNLGLLNSM
     DQQIQNGSSS TSPYNTDHAQ NSVTAPSPYA QPSSTFDALS PSPAIPSNTD YPGPHSFDVS
     FQQSSTAKSA TWTYSTELKK LYCQIAKTCP IQIKVMTPPP QGAVIRAMPV YKKAEHVTEV
     VKRCPNHELS REFNEGQIAP PSHLIRVEGN SHAQYVEDPI TGRQSVLVPY EPPQVGTEFT
     TVLYNFMCNS SCVGGMNRRP ILIIVTLETR DGQVLGRRCF EARICACPGR DRKADEDSIR
     KQQVSDSTKN GDAFRQNTHG IQMTSIKKRR SPDDELLYLP VRGRETYEML LKIKESLELM
     QYLPQHTIET YRQQQQQQHQ HLLQKQTSIQ SPSSYGNSSP PLNKMNSMNK LPSVSQLINP
     QQRNALTPTT IPDGMGANIP MMGTHMPMAG DMNGLSPTQA LPPPLSMPST SHCTPPPPYP
     TDCSIVSFLA RLGCSSCLDY FTTQGLTTIY QIEHYSMDDL ASLKIPEQFR HAIWKGILDH
     RQLHEFSSPS HLLRTPSSAS TVSVGSSETR GERVIDAVRF TLRQTISFPP RDEWNDFNFD
     MDARRNKQQR IKEEGE
//
ID   A0A141PNN3_HUMAN        Unreviewed;       412 AA.
AC   A0A141PNN3;
DT   08-JUN-2016, integrated into UniProtKB/TrEMBL.
DT   08-JUN-2016, sequence version 1.
DT   22-APR-2020, entry version 25.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP63 {ECO:0000313|EMBL:AMC39812.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AMC39812.1};
RN   [1] {ECO:0000313|EMBL:AMC39812.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Bladder tumor {ECO:0000313|EMBL:AMC39812.1};
RA   Banday A.R., Kiss E., Prokunina-Olsson L.;
RT   "Analysis of TP63 in bladder cancer.";
RL   Submitted (MAR-2015) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KP881230; AMC39812.1; -; mRNA.
DR   RefSeq; NP_001316078.1; NM_001329149.1.
DR   PeptideAtlas; A0A141PNN3; -.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   ChiTaRS; TP63; human.
DR   GenomeRNAi; 8626; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR032645; Tp63.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          74..264
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   DOMAIN          293..332
FT                   /note="P53_tetramer"
FT                   /evidence="ECO:0000259|Pfam:PF07710"
FT   REGION          29..77
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          257..294
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          339..412
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        29..72
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        270..291
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   412 AA;  46121 MW;  6825355B5928466B CRC64;
     MLYLENNAQT QFSEPQYTNL GLLNSMDQQI QNGSSSTSPY NTDHAQNSVT APSPYAQPSS
     TFDALSPSPA IPSNTDYPGP HSFDVSFQQS STAKSATWTY STELKKLYCQ IAKTCPIQIK
     VMTPPPQGAV IRAMPVYKKA EHVTEVVKRC PNHELSREFN EGQIAPPSHL IRVEGNSHAQ
     YVEDPITGRQ SVLVPYEPPQ VGTEFTTVLY NFMCNSSCVG GMNRRPILII VTLETRDGQV
     LGRRCFEARI CACPGRDRKA DEDSIRKQQV SDSTKNGDAF RQNTHGIQMT SIKKRRSPDD
     ELLYLPVRGR ETYEMLLKIK ESLELMQYLP QHTIETYRQQ QQQQHQHLLQ KQTSIQSPSS
     YGNSSPPLNK MNSMNKLPSV SQLINPQQRN ALTPTTIPDG MGANRSGKSE NP
//
ID   A0A141PNN4_HUMAN        Unreviewed;       327 AA.
AC   A0A141PNN4;
DT   08-JUN-2016, integrated into UniProtKB/TrEMBL.
DT   08-JUN-2016, sequence version 1.
DT   22-APR-2020, entry version 25.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP63 {ECO:0000313|EMBL:AMC39813.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AMC39813.1};
RN   [1] {ECO:0000313|EMBL:AMC39813.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Bladder tumor {ECO:0000313|EMBL:AMC39813.1};
RA   Banday A.R., Kiss E., Prokunina-Olsson L.;
RT   "Analysis of TP63 in bladder cancer.";
RL   Submitted (MAR-2015) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KP881231; AMC39813.1; -; mRNA.
DR   RefSeq; NP_001316079.1; NM_001329150.1.
DR   PeptideAtlas; A0A141PNN4; -.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   ChiTaRS; TP63; human.
DR   GenomeRNAi; 8626; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR032645; Tp63.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          7..179
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   DOMAIN          208..247
FT                   /note="P53_tetramer"
FT                   /evidence="ECO:0000259|Pfam:PF07710"
FT   REGION          172..209
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          254..327
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        185..206
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   327 AA;  37114 MW;  EE191C8F74C65DBC CRC64;
     MLYLENNAQT QFSEYSTELK KLYCQIAKTC PIQIKVMTPP PQGAVIRAMP VYKKAEHVTE
     VVKRCPNHEL SREFNEGQIA PPSHLIRVEG NSHAQYVEDP ITGRQSVLVP YEPPQVGTEF
     TTVLYNFMCN SSCVGGMNRR PILIIVTLET RDGQVLGRRC FEARICACPG RDRKADEDSI
     RKQQVSDSTK NGDAFRQNTH GIQMTSIKKR RSPDDELLYL PVRGRETYEM LLKIKESLEL
     MQYLPQHTIE TYRQQQQQQH QHLLQKQTSI QSPSSYGNSS PPLNKMNSMN KLPSVSQLIN
     PQQRNALTPT TIPDGMGANR SGKSENP
//
ID   B7Z8X6_HUMAN            Unreviewed;       369 AA.
AC   B7Z8X6;
DT   03-MAR-2009, integrated into UniProtKB/TrEMBL.
DT   03-MAR-2009, sequence version 1.
DT   22-APR-2020, entry version 75.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAH14112.1};
RN   [1] {ECO:0000313|EMBL:BAH14112.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Trachea {ECO:0000313|EMBL:BAH14112.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A.,
RA   Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y.,
RA   Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T.,
RA   Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK304127; BAH14112.1; -; mRNA.
DR   RefSeq; NP_001316074.1; NM_001329145.1.
DR   RefSeq; NP_001316075.1; NM_001329146.1.
DR   RefSeq; NP_001316078.1; NM_001329149.1.
DR   RefSeq; NP_001316079.1; NM_001329150.1.
DR   PeptideAtlas; B7Z8X6; -.
DR   PRIDE; B7Z8X6; -.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   GenomeRNAi; 8626; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR032645; Tp63.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          74..264
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   DOMAIN          297..336
FT                   /note="P53_tetramer"
FT                   /evidence="ECO:0000259|Pfam:PF07710"
FT   REGION          29..77
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          261..298
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        29..72
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        270..295
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   369 AA;  41549 MW;  C81C1C2A3AE4CE51 CRC64;
     MLYLENNAQT QFSEPQYTNL GLLNSMDQQI QNGSSSTSPY NTDHAQNSVT APSPYAQPSS
     TFDALSPSPA IPSNTDYPGP HSFDVSFQQS STAKSATWTY STELKKLYCQ IAKTCPIQIK
     VMTPPPQGAV IRAMPVYKKA EHVTEVVKRC PNHELSREFN EGQIAPPSHL IRVEGNSHAQ
     YVEDPITGRQ SVLVPYEPPQ VGTEFTTVLY NFMCNSSCVG GMNRRPILII VTLETRDGQV
     LGRRCFEARI CACPGRDRKA DEDSIRKQQV SDSTKNGDGT KRPFRQNTHG IQMTSIKKRR
     SPDDELLYLP VRGRETYEML LKIKESLELM QYLPQHTIET YRQQHEQAAF CEPAYQPSAA
     QRPHSYNHS
//
ID   C9D7D0_HUMAN            Unreviewed;       416 AA.
AC   C9D7D0;
DT   03-NOV-2009, integrated into UniProtKB/TrEMBL.
DT   03-NOV-2009, sequence version 1.
DT   22-APR-2020, entry version 90.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP63 {ECO:0000313|EMBL:ACV53610.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ACV53610.1};
RN   [1] {ECO:0000313|EMBL:ACV53610.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=19700772; DOI=10.1093/nar/gkp674;
RA   Mangiulli M., Valletti A., Caratozzolo M.F., Tullo A., Sbisa E., Pesole G.,
RA   D'Erchia A.M.;
RT   "Identification and functional characterization of two new transcriptional
RT   variants of the human p63 gene.";
RL   Nucleic Acids Res. 0:0-0(2009).
RN   [2] {ECO:0000313|EMBL:AMC39811.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Normal bladder {ECO:0000313|EMBL:AMC39811.1};
RA   Banday A.R., Kiss E., Prokunina-Olsson L.;
RT   "Analysis of TP63 in bladder cancer.";
RL   Submitted (MAR-2015) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000256|RuleBase:RU003304}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; GQ202690; ACV53610.1; -; mRNA.
DR   EMBL; KP881229; AMC39811.1; -; mRNA.
DR   RefSeq; NP_001316073.1; NM_001329144.1.
DR   RefSeq; NP_001316074.1; NM_001329145.1.
DR   RefSeq; NP_001316075.1; NM_001329146.1.
DR   RefSeq; NP_001316077.1; NM_001329148.1.
DR   RefSeq; NP_001316078.1; NM_001329149.1.
DR   RefSeq; NP_001316079.1; NM_001329150.1.
DR   Antibodypedia; 1750; 969 antibodies.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   EuPathDB; HostDB:ENSG00000073282.12; -.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   ChiTaRS; TP63; human.
DR   GenomeRNAi; 8626; -.
DR   Bgee; ENSG00000073282; Expressed in skin of abdomen and 140 other tissues.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR032645; Tp63.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN          74..264
FT                   /note="P53"
FT                   /evidence="ECO:0000259|Pfam:PF00870"
FT   DOMAIN          297..336
FT                   /note="P53_tetramer"
FT                   /evidence="ECO:0000259|Pfam:PF07710"
FT   REGION          29..77
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          257..299
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          343..416
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        29..72
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        270..295
FT                   /note="Polar"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   416 AA;  46589 MW;  A5974A14B25E3118 CRC64;
     MLYLENNAQT QFSEPQYTNL GLLNSMDQQI QNGSSSTSPY NTDHAQNSVT APSPYAQPSS
     TFDALSPSPA IPSNTDYPGP HSFDVSFQQS STAKSATWTY STELKKLYCQ IAKTCPIQIK
     VMTPPPQGAV IRAMPVYKKA EHVTEVVKRC PNHELSREFN EGQIAPPSHL IRVEGNSHAQ
     YVEDPITGRQ SVLVPYEPPQ VGTEFTTVLY NFMCNSSCVG GMNRRPILII VTLETRDGQV
     LGRRCFEARI CACPGRDRKA DEDSIRKQQV SDSTKNGDGT KRPFRQNTHG IQMTSIKKRR
     SPDDELLYLP VRGRETYEML LKIKESLELM QYLPQHTIET YRQQQQQQHQ HLLQKQTSIQ
     SPSSYGNSSP PLNKMNSMNK LPSVSQLINP QQRNALTPTT IPDGMGANRS GKSENP
//
ID   P63_HUMAN               Reviewed;         680 AA.
AC   Q9H3D4; O75080; O75195; O75922; O76078; Q6VEG2; Q6VEG3; Q6VEG4; Q6VFJ1;
AC   Q6VFJ2; Q6VFJ3; Q6VH20; Q7LDI3; Q7LDI4; Q7LDI5; Q96KR0; Q9H3D2; Q9H3D3;
AC   Q9H3P8; Q9NPH7; Q9P1B4; Q9P1B5; Q9P1B6; Q9P1B7; Q9UBV9; Q9UE10; Q9UP26;
AC   Q9UP27; Q9UP28; Q9UP74;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   22-APR-2020, entry version 200.
DE   RecName: Full=Tumor protein 63;
DE            Short=p63;
DE   AltName: Full=Chronic ulcerative stomatitis protein;
DE            Short=CUSP;
DE   AltName: Full=Keratinocyte transcription factor KET;
DE   AltName: Full=Transformation-related protein 63;
DE            Short=TP63;
DE   AltName: Full=Tumor protein p73-like;
DE            Short=p73L;
DE   AltName: Full=p40;
DE   AltName: Full=p51;
GN   Name=TP63; Synonyms=KET, P63, P73H, P73L, TP73L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=9703973; DOI=10.1006/bbrc.1998.9013;
RA   Senoo M., Seki N., Ohira M., Sugano S., Watanabe M., Tachibana M.,
RA   Tanaka T., Shinkai Y., Kato H.;
RT   "A second p53-related protein, p73L, with high homology to p73.";
RL   Biochem. Biophys. Res. Commun. 248:603-607(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Keratinocyte, and Skeletal muscle;
RX   PubMed=9799841; DOI=10.1007/s003359900891;
RA   Augustin M., Bamberger C., Paul D., Schmale H.;
RT   "Cloning and chromosomal mapping of the human p53-related KET gene to
RT   chromosome 3q27 and its murine homolog Ket to mouse chromosome 16.";
RL   Mamm. Genome 9:899-902(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 4 AND 6), NUCLEOTIDE SEQUENCE
RP   [GENOMIC DNA] OF 32-680 (ISOFORMS 1; 3 AND 5), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=9774969; DOI=10.1016/s1097-2765(00)80275-0;
RA   Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Doetsch V.,
RA   Andrews N.C., Caput D., McKeon F.;
RT   "p63, a p53 homolog at 3q27-29, encodes multiple products with
RT   transactivating, death-inducing, and dominant-negative activities.";
RL   Mol. Cell 2:305-316(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 5), VARIANT HEAD AND NECK CANCER
RP   LEU-184, VARIANT LUNG CARCINOMA PRO-187, AND VARIANT CERVICAL CANCER
RP   LEU-204.
RC   TISSUE=Skeletal muscle;
RX   PubMed=9662378; DOI=10.1038/nm0798-839;
RA   Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I.,
RA   Ikawa Y., Nimura Y., Nakagawara A., Obinata M., Ikawa S.;
RT   "Cloning and functional analysis of human p51, which structurally and
RT   functionally resembles p53.";
RL   Nat. Med. 4:839-843(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT COLON CANCER HIS-279, AND
RP   VARIANT OVARIAN CANCER ALA-560.
RX   PubMed=10485447;
RA   Hagiwara K., McMenamin M.G., Miura K., Harris C.C.;
RT   "Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer
RT   cell lines using intronic primers.";
RL   Cancer Res. 59:4165-4169(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=10469295; DOI=10.1046/j.1523-1747.1999.00651.x;
RA   Lee L.A., Walsh P., Prater C.A., Su L.-J., Marchbank A., Egbert T.B.,
RA   Dellavalle R.P., Targoff I.N., Kaufman K.M., Chorzelski T.P., Jablonska S.;
RT   "Characterization of an autoantigen associated with chronic ulcerative
RT   stomatitis: the CUSP autoantigen is a member of the p53 family.";
RL   J. Invest. Dermatol. 113:146-151(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 7), AND ALTERNATIVE
RP   SPLICING (ISOFORM 8).
RX   PubMed=10935472; DOI=10.1038/sj.neo.7900008;
RA   Tani M., Shimizu K., Kawahara C., Kohno T., Ishimoto O., Ikawa S.,
RA   Yokota J.;
RT   "Mutation and expression of the p51 gene in human lung cancer.";
RL   Neoplasia 1:71-79(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10), AND TISSUE SPECIFICITY (ISOFORM
RP   10).
RX   PubMed=11336476; DOI=10.1054/bjoc.2000.1735;
RA   Senoo M., Tsuchiya I., Matsumura Y., Mori T., Saito Y., Kato H.,
RA   Okamoto T., Habu S.;
RT   "Transcriptional dysregulation of the p73L/p63/p51/p40/KET gene in human
RT   squamous cell carcinomas: expression of Delta Np73L, a novel dominant-
RT   negative isoform, and loss of expression of the potential tumour suppressor
RT   p51.";
RL   Br. J. Cancer 84:1235-1241(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-450 (ISOFORMS 2/4/8), SUBUNIT,
RP   ZINC-BINDING, AND DNA-BINDING.
RC   TISSUE=Prostate;
RX   PubMed=9662346; DOI=10.1038/nm0798-747;
RA   Trink B., Okami K., Wu L., Sriuranpong V., Jen J., Sidransky D.;
RT   "A new human p53 homologue.";
RL   Nat. Med. 4:747-748(1998).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-21; 95-255; 295-330; 378-502 AND
RP   583-680.
RA   Vieira A.R., Murray J.C.;
RT   "Sequencing of candidate genes for non-syndromic cleft lip and palate.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 153-388 (ISOFORM 11).
RC   TISSUE=Placenta;
RX   PubMed=11477076; DOI=10.1074/jbc.m103801200;
RA   Klein C., Georges G., Kunkele K.P., Huber R., Engh R.A., Hansen S.;
RT   "High thermostability and lack of cooperative DNA binding distinguish the
RT   p63 core domain from the homologous tumor suppressor p53.";
RL   J. Biol. Chem. 276:37390-37401(2001).
RN   [13]
RP   SUBUNIT.
RX   PubMed=10373484; DOI=10.1074/jbc.274.26.18709;
RA   Davison T.S., Vagner C., Kaghad M., Ayed A., Caput D., Arrowsmith C.H.;
RT   "p73 and p63 are homotetramers capable of weak heterotypic interactions
RT   with each other but not with p53.";
RL   J. Biol. Chem. 274:18709-18714(1999).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=11248048; DOI=10.1073/pnas.061032098;
RA   Pellegrini G., Dellambra E., Golisano O., Martinelli E., Fantozzi I.,
RA   Bondanza S., Ponzin D., McKeon F., De Luca M.;
RT   "p63 identifies keratinocyte stem cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:3156-3161(2001).
RN   [15]
RP   FUNCTION IN NOTCH SIGNALING.
RX   PubMed=11641404; DOI=10.1074/jbc.m108080200;
RA   Sasaki Y., Ishida S., Morimoto I., Yamashita T., Kojima T., Kihara C.,
RA   Tanaka T., Imai K., Nakamura Y., Tokino T.;
RT   "The p53 family member genes are involved in the Notch signal pathway.";
RL   J. Biol. Chem. 277:719-724(2002).
RN   [16]
RP   INTERACTION WITH HIPK2.
RX   PubMed=11925430; DOI=10.1074/jbc.m200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [17]
RP   FUNCTION, DOMAIN, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-55; TRP-59
RP   AND LEU-62.
RX   PubMed=12446779; DOI=10.1128/mcb.22.24.8601-8611.2002;
RA   Serber Z., Lai H.C., Yang A., Ou H.D., Sigal M.S., Kelly A.E.,
RA   Darimont B.D., Duijf P.H.G., Van Bokhoven H., McKeon F., Doetsch V.;
RT   "A C-terminal inhibitory domain controls the activity of p63 by an
RT   intramolecular mechanism.";
RL   Mol. Cell. Biol. 22:8601-8611(2002).
RN   [18]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=12446784; DOI=10.1128/mcb.22.24.8659-8668.2002;
RA   Ghioni P., Bolognese F., Duijf P.H.G., Van Bokhoven H., Mantovani R.,
RA   Guerrini L.;
RT   "Complex transcriptional effects of p63 isoforms: identification of novel
RT   activation and repression domains.";
RL   Mol. Cell. Biol. 22:8659-8668(2002).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH SSRP1.
RX   PubMed=12374749; DOI=10.1093/emboj/cdf540;
RA   Zeng S.X., Dai M.-S., Keller D.M., Lu H.;
RT   "SSRP1 functions as a co-activator of the transcriptional activator p63.";
RL   EMBO J. 21:5487-5497(2002).
RN   [20]
RP   ERRATUM OF PUBMED:12374749.
RA   Zeng S.X., Dai M.-S., Keller D.M., Lu H.;
RL   EMBO J. 23:1679-1679(2004).
RN   [21]
RP   UBIQUITINATION, INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-543.
RX   PubMed=18806757; DOI=10.1038/cdd.2008.134;
RA   Li Y., Zhou Z., Chen C.;
RT   "WW domain-containing E3 ubiquitin protein ligase 1 targets p63
RT   transcription factor for ubiquitin-mediated proteasomal degradation and
RT   regulates apoptosis.";
RL   Cell Death Differ. 15:1941-1951(2008).
RN   [22]
RP   INTERACTION WITH PDS5A.
RX   PubMed=17846787; DOI=10.1007/s00432-007-0306-x;
RA   Zheng M.Z., Zheng L.M., Zeng Y.X.;
RT   "SCC-112 gene is involved in tumor progression and promotes the cell
RT   proliferation in G2/M phase.";
RL   J. Cancer Res. Clin. Oncol. 134:453-462(2008).
RN   [23]
RP   FUNCTION, INTERACTION WITH NOC2L, AND SUBCELLULAR LOCATION.
RX   PubMed=20123734; DOI=10.1093/nar/gkq016;
RA   Heyne K., Willnecker V., Schneider J., Conrad M., Raulf N., Schule R.,
RA   Roemer K.;
RT   "NIR, an inhibitor of histone acetyltransferases, regulates transcription
RT   factor TAp63 and is controlled by the cell cycle.";
RL   Nucleic Acids Res. 38:3159-3171(2010).
RN   [24]
RP   FUNCTION.
RX   PubMed=22197488; DOI=10.1016/j.ajhg.2011.11.013;
RA   Mitchell K., O'Sullivan J., Missero C., Blair E., Richardson R.,
RA   Anderson B., Antonini D., Murray J.C., Shanske A.L., Schutte B.C.,
RA   Romano R.A., Sinha S., Bhaskar S.S., Black G.C., Dixon J., Dixon M.J.;
RT   "Exome sequence identifies RIPK4 as the Bartsocas-Papas syndrome locus.";
RL   Am. J. Hum. Genet. 90:69-75(2012).
RN   [25]
RP   STRUCTURE BY NMR OF 540-610.
RA   Cadot B., Candi E., Cicero D.O., Desideri A., Mele S., Melino G., Paci M.;
RT   "Solution structure of the C-terminal domain of p63.";
RL   Submitted (NOV-2004) to the PDB data bank.
RN   [26]
RP   VARIANTS EEC3 TRP-243; GLN-243 AND ARG-345.
RX   PubMed=10535733; DOI=10.1016/s0092-8674(00)81646-3;
RA   Celli J., Duijf P.H.G., Hamel B.C.J., Bamshad M., Kramer B., Smits A.P.T.,
RA   Newbury-Ecob R., Hennekam R.C.M., Van Buggenhout G., van Haeringen A.,
RA   Woods C.G., van Essen A.J., de Waal R., Vriend G., Haber D.A., Yang A.,
RA   McKeon F., Brunner H.G., van Bokhoven H.;
RT   "Heterozygous germline mutations in the p53 homolog p63 are the cause of
RT   EEC syndrome.";
RL   Cell 99:143-153(1999).
RN   [27]
RP   VARIANTS SHFM4 GLU-233 AND CYS-319, AND VARIANTS EEC3 HIS-318 AND GLN-343.
RX   PubMed=10839977; DOI=10.1086/302972;
RA   Ianakiev P., Kilpatrick M.W., Toudjarska I., Basel D., Beighton P.,
RA   Tsipouras P.;
RT   "Split-hand/split-foot malformation is caused by mutations in the p63 gene
RT   on 3q27.";
RL   Am. J. Hum. Genet. 67:59-66(2000).
RN   [28]
RP   VARIANT ADULT IN NDELTA-TYPE ISOFORMS.
RX   PubMed=11528512; DOI=10.1038/sj.ejhg.5200676;
RA   Amiel J., Bougeard G., Francannet C., Raclin V., Munnich A., Lyonnet S.,
RA   Frebourg T.;
RT   "TP63 gene mutation in ADULT syndrome.";
RL   Eur. J. Hum. Genet. 9:642-645(2001).
RN   [29]
RP   VARIANTS AEC PHE-553 AND GLY-561.
RX   PubMed=11159940; DOI=10.1093/hmg/10.3.221;
RA   McGrath J.A., Duijf P.H.G., Doetsch V., Irvine A.D., de Waal R.,
RA   Vanmolkot K.R., Wessagowit V., Kelly A., Atherton D.J., Griffiths W.A.,
RA   Orlow S.J., van Haeringen A., Ausems M.G., Yang A., McKeon F.,
RA   Bamshad M.A., Brunner H.G., Hamel B.C.J., van Bokhoven H.;
RT   "Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM
RT   domain of p63.";
RL   Hum. Mol. Genet. 10:221-229(2001).
RN   [30]
RP   VARIANTS EEC3 GLN-243; TRP-243; GLN-266; TYR-308; ASN-311; CYS-318;
RP   HIS-318; GLN-318; CYS-319; HIS-319; SER-319; TRP-343; GLN-343; ARG-345;
RP   SER-347; SER-348 AND HIS-351, VARIANTS SHFM4 PRO-193 INS; GLU-232 AND
RP   HIS-319, AND INVOLVEMENT IN LMS.
RX   PubMed=11462173; DOI=10.1086/323123;
RA   van Bokhoven H., Hamel B.C.J., Bamshad M., Sangiorgi E., Gurrieri F.,
RA   Duijf P.H.G., Vanmolkot K.R.J., van Beusekom E., van Beersum S.E.C.,
RA   Celli J., Merkx G.F.M., Tenconi R., Fryns J.-P., Verloes A.,
RA   Newbury-Ecob R.A., Raas-Rotschild A., Majewski F., Beemer F.A., Janecke A.,
RA   Chitayat D., Crisponi G., Kayserili H., Yates J.R.W., Neri G.,
RA   Brunner H.G.;
RT   "p63 gene mutations in EEC syndrome, limb-mammary syndrome, and isolated
RT   split hand-split foot malformation suggest a genotype-phenotype
RT   correlation.";
RL   Am. J. Hum. Genet. 69:481-492(2001).
RN   [31]
RP   VARIANT ADULT SYNDROME GLN-337.
RX   PubMed=11929852; DOI=10.1093/hmg/11.7.799;
RA   Duijf P.H.G., Vanmolkot K.R., Propping P., Friedl W., Krieger E.,
RA   McKeon F., Doetsch V., Brunner H.G., van Bokhoven H.;
RT   "Gain-of-function mutation in ADULT syndrome reveals the presence of a
RT   second transactivation domain in p63.";
RL   Hum. Mol. Genet. 11:799-804(2002).
RN   [32]
RP   VARIANT EEC3 GLY-351.
RX   PubMed=12838557; DOI=10.1002/ajmg.a.20064;
RA   Akahoshi K., Sakazume S., Kosaki K., Ohashi H., Fukushima Y.;
RT   "EEC syndrome type 3 with a heterozygous germline mutation in the P63 gene
RT   and B cell lymphoma.";
RL   Am. J. Med. Genet. A 120:370-373(2003).
RN   [33]
RP   VARIANT RHS HIS-318, AND CHARACTERIZATION OF VARIANT RHS HIS-318.
RX   PubMed=12939657; DOI=10.1038/sj.ejhg.5201004;
RA   Bougeard G., Hadj-Rabia S., Faivre L., Sarafan-Vasseur N., Frebourg T.;
RT   "The Rapp-Hodgkin syndrome results from mutations of the TP63 gene.";
RL   Eur. J. Hum. Genet. 11:700-704(2003).
RN   [34]
RP   VARIANT RHS PRO-580.
RX   PubMed=12766194; DOI=10.1177/154405910308200606;
RA   Kantaputra P.N., Hamada T., Kumchai T., McGrath J.A.;
RT   "Heterozygous mutation in the SAM domain of p63 underlies Rapp-Hodgkin
RT   ectodermal dysplasia.";
RL   J. Dent. Res. 82:433-437(2003).
RN   [35]
RP   VARIANT RHS THR-549.
RX   PubMed=15200513; DOI=10.1111/j.0009-9163.2004.00278.x;
RA   Bertola D.R., Kim C.A., Albano L.M.J., Scheffer H., Meijer R.,
RA   van Bokhoven H.;
RT   "Molecular evidence that AEC syndrome and Rapp-Hodgkin syndrome are
RT   variable expression of a single genetic disorder.";
RL   Clin. Genet. 66:79-80(2004).
RN   [36]
RP   INVOLVEMENT IN OFC8, VARIANT OFC8 GLY-352, AND VARIANTS LEU-129 AND
RP   HIS-603.
RX   PubMed=16740912; DOI=10.1136/jmg.2005.036442;
RA   Leoyklang P., Siriwan P., Shotelersuk V.;
RT   "A mutation of the p63 gene in non-syndromic cleft lip.";
RL   J. Med. Genet. 43:E28-E28(2006).
CC   -!- FUNCTION: Acts as a sequence specific DNA binding transcriptional
CC       activator or repressor. The isoforms contain a varying set of
CC       transactivation and auto-regulating transactivation inhibiting domains
CC       thus showing an isoform specific activity. Isoform 2 activates RIPK4
CC       transcription. May be required in conjunction with TP73/p73 for
CC       initiation of p53/TP53 dependent apoptosis in response to genotoxic
CC       insults and the presence of activated oncogenes. Involved in Notch
CC       signaling by probably inducing JAG1 and JAG2. Plays a role in the
CC       regulation of epithelial morphogenesis. The ratio of DeltaN-type and
CC       TA*-type isoforms may govern the maintenance of epithelial stem cell
CC       compartments and regulate the initiation of epithelial stratification
CC       from the undifferentiated embryonal ectoderm. Required for limb
CC       formation from the apical ectodermal ridge. Activates transcription of
CC       the p21 promoter. {ECO:0000269|PubMed:11641404,
CC       ECO:0000269|PubMed:12374749, ECO:0000269|PubMed:12446779,
CC       ECO:0000269|PubMed:12446784, ECO:0000269|PubMed:20123734,
CC       ECO:0000269|PubMed:22197488, ECO:0000269|PubMed:9774969}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Isoform composition of the
CC       tetramer may determine transactivation activity. Isoforms Alpha and
CC       Gamma interact with HIPK2. Interacts with SSRP1, leading to stimulate
CC       coactivator activity. Isoform 1 and isoform 2 interact with WWP1.
CC       Interacts with PDS5A. Isoform 5 (via activation domain) interacts with
CC       NOC2L. {ECO:0000269|PubMed:10373484, ECO:0000269|PubMed:11925430,
CC       ECO:0000269|PubMed:12374749, ECO:0000269|PubMed:17846787,
CC       ECO:0000269|PubMed:18806757, ECO:0000269|PubMed:20123734,
CC       ECO:0000269|PubMed:9662346}.
CC   -!- INTERACTION:
CC       Q9H3D4; Q9H3D4; NbExp=4; IntAct=EBI-2337775, EBI-2337775;
CC       Q9H3D4-1; Q8TDN4: CABLES1; NbExp=7; IntAct=EBI-2400586, EBI-604615;
CC       Q9H3D4; P35637: FUS; NbExp=2; IntAct=EBI-2337775, EBI-400434;
CC       Q9H3D4; Q9H2X6: HIPK2; NbExp=2; IntAct=EBI-2337775, EBI-348345;
CC       Q9H3D4; P61978: HNRNPK; NbExp=2; IntAct=EBI-2337775, EBI-304185;
CC       Q9H3D4; Q96J02: ITCH; NbExp=2; IntAct=EBI-2337775, EBI-1564678;
CC       Q9H3D4; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-2337775, EBI-348259;
CC       Q9H3D4; Q9UFN0: NIPSNAP3A; NbExp=2; IntAct=EBI-2337775, EBI-716291;
CC       Q9H3D4; Q96FA3: PELI1; NbExp=3; IntAct=EBI-2337775, EBI-448369;
CC       Q9H3D4; Q9HAT8: PELI2; NbExp=3; IntAct=EBI-2337775, EBI-448407;
CC       Q9H3D4; Q13526: PIN1; NbExp=3; IntAct=EBI-2337775, EBI-714158;
CC       Q9H3D4; Q05655: PRKCD; NbExp=2; IntAct=EBI-2337775, EBI-704279;
CC       Q9H3D4-2; Q9UPW6: SATB2; NbExp=5; IntAct=EBI-6481107, EBI-8298169;
CC       Q9H3D4; Q15796: SMAD2; NbExp=3; IntAct=EBI-2337775, EBI-1040141;
CC       Q9H3D4; P04637: TP53; NbExp=5; IntAct=EBI-2337775, EBI-366083;
CC       Q9H3D4; Q13625: TP53BP2; NbExp=2; IntAct=EBI-2337775, EBI-77642;
CC       Q9H3D4; O15350: TP73; NbExp=2; IntAct=EBI-2337775, EBI-389606;
CC       Q9H3D4; P57075-2: UBASH3A; NbExp=3; IntAct=EBI-2337775, EBI-7353612;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12446779,
CC       ECO:0000269|PubMed:20123734}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=12;
CC       Name=1; Synonyms=TA*-alpha, TAp63alpha, P51B;
CC         IsoId=Q9H3D4-1; Sequence=Displayed;
CC       Name=2; Synonyms=DeltaN-alpha, DeltaNp63 alpha, P51delNalpha;
CC         IsoId=Q9H3D4-2; Sequence=VSP_012465;
CC       Name=3; Synonyms=TA*-beta, TAp63beta;
CC         IsoId=Q9H3D4-3; Sequence=VSP_012470;
CC       Name=4; Synonyms=DeltaN-beta, DeltaNp63 beta, P51delNbeta;
CC         IsoId=Q9H3D4-4; Sequence=VSP_012465, VSP_012470;
CC       Name=5; Synonyms=TA*-gamma, TAp63gamma, P51A;
CC         IsoId=Q9H3D4-5; Sequence=VSP_012468;
CC       Name=6; Synonyms=DeltaN-gamma, DeltaNp63gamma, P51delNgamma;
CC         IsoId=Q9H3D4-6; Sequence=VSP_012465, VSP_012468;
CC       Name=7; Synonyms=TA*-delta, TAp63delta, P51delta;
CC         IsoId=Q9H3D4-7; Sequence=VSP_012469;
CC       Name=8; Synonyms=DeltaN-delta;
CC         IsoId=Q9H3D4-8; Sequence=VSP_012465, VSP_012469;
CC       Name=9; Synonyms=TA*-epsilon;
CC         IsoId=Q9H3D4-9; Sequence=VSP_012466;
CC       Name=10; Synonyms=DeltaN-epsilon, DeltaNp73L;
CC         IsoId=Q9H3D4-10; Sequence=VSP_012465, VSP_012466;
CC       Name=11; Synonyms=P63 delta;
CC         IsoId=Q9H3D4-11; Sequence=VSP_012467;
CC       Name=12;
CC         IsoId=Q9H3D4-12; Sequence=VSP_012465, VSP_012467;
CC   -!- TISSUE SPECIFICITY: Widely expressed, notably in heart, kidney,
CC       placenta, prostate, skeletal muscle, testis and thymus, although the
CC       precise isoform varies according to tissue type. Progenitor cell layers
CC       of skin, breast, eye and prostate express high levels of DeltaN-type
CC       isoforms. Isoform 10 is predominantly expressed in skin squamous cell
CC       carcinomas, but not in normal skin tissues.
CC       {ECO:0000269|PubMed:11248048, ECO:0000269|PubMed:9774969}.
CC   -!- DOMAIN: The transactivation inhibitory domain (TID) can interact with,
CC       and inhibit the activity of the N-terminal transcriptional activation
CC       domain of TA*-type isoforms. {ECO:0000269|PubMed:12446779,
CC       ECO:0000269|PubMed:12446784}.
CC   -!- PTM: May be sumoylated. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Polyubiquitination involves WWP1 and leads to
CC       proteasomal degradation of this protein. {ECO:0000269|PubMed:18806757}.
CC   -!- DISEASE: Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome)
CC       [MIM:103285]: A form of ectodermal dysplasia. Ectodermal dysplasia
CC       defines a heterogeneous group of disorders due to abnormal development
CC       of two or more ectodermal structures. ADULT syndrome involves
CC       ectrodactyly, syndactyly, finger- and toenail dysplasia, hypoplastic
CC       breasts and nipples, intensive freckling, lacrimal duct atresia,
CC       frontal alopecia, primary hypodontia and loss of permanent teeth. ADULT
CC       syndrome differs significantly from EEC3 syndrome by the absence of
CC       facial clefting. Inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:11929852}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC)
CC       [MIM:106260]: An autosomal dominant condition characterized by
CC       congenital ectodermal dysplasia with coarse, wiry, sparse hair,
CC       dystrophic nails, slight hypohidrosis, scalp infections,
CC       ankyloblepharon filiform adnatum, maxillary hypoplasia, hypodontia and
CC       cleft lip/palate. {ECO:0000269|PubMed:11159940}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Ectrodactyly, ectodermal dysplasia, and cleft lip/palate
CC       syndrome 3 (EEC3) [MIM:604292]: A form of ectodermal dysplasia, a
CC       heterogeneous group of disorders due to abnormal development of two or
CC       more ectodermal structures. It is an autosomal dominant syndrome
CC       characterized by ectrodactyly of hands and feet, ectodermal dysplasia
CC       and facial clefting. {ECO:0000269|PubMed:10535733,
CC       ECO:0000269|PubMed:10839977, ECO:0000269|PubMed:11462173,
CC       ECO:0000269|PubMed:12838557}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Split-hand/foot malformation 4 (SHFM4) [MIM:605289]: A limb
CC       malformation involving the central rays of the autopod and presenting
CC       with syndactyly, median clefts of the hands and feet, and aplasia
CC       and/or hypoplasia of the phalanges, metacarpals, and metatarsals. Some
CC       patients have been found to have mental retardation, ectodermal and
CC       craniofacial findings, and orofacial clefting.
CC       {ECO:0000269|PubMed:10839977, ECO:0000269|PubMed:11462173}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Limb-mammary syndrome (LMS) [MIM:603543]: Characterized by
CC       ectrodactyly, cleft palate and mammary-gland abnormalities.
CC       {ECO:0000269|PubMed:11462173}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in TP63 are a cause of cervical, colon, head and
CC       neck, lung and ovarian cancers.
CC   -!- DISEASE: Rapp-Hodgkin syndrome (RHS) [MIM:129400]: A form of ectodermal
CC       dysplasia, a heterogeneous group of disorders due to abnormal
CC       development of two or more ectodermal structures. Characterized by the
CC       combination of anhidrotic ectodermal dysplasia, cleft lip, and cleft
CC       palate. The clinical syndrome is comprised of a characteristic facies
CC       (narrow nose and small mouth), wiry, slow-growing, and uncombable hair,
CC       sparse eyelashes and eyebrows, obstructed lacrimal puncta/epiphora,
CC       bilateral stenosis of external auditory canals, microsomia, hypodontia,
CC       cone-shaped incisors, enamel hypoplasia, dystrophic nails, and cleft
CC       lip/cleft palate. RHS inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:12766194, ECO:0000269|PubMed:12939657,
CC       ECO:0000269|PubMed:15200513}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Orofacial cleft 8 (OFC8) [MIM:618149]: A birth defect
CC       consisting of cleft lips with or without cleft palate. Cleft lips are
CC       associated with cleft palate in two-third of cases. A cleft lip can
CC       occur on one or both sides and range in severity from a simple notch in
CC       the upper lip to a complete opening in the lip extending into the floor
CC       of the nostril and involving the upper gum.
CC       {ECO:0000269|PubMed:16740912}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform
CC       2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative splicing of isoform
CC       2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative splicing of isoform
CC       2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 10]: Produced by alternative splicing of
CC       isoform 2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 11]: Produced by alternative splicing of
CC       isoform 1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 12]: Produced by alternative splicing of
CC       isoform 2. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF43486.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF43487.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF43488.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF43489.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF61624.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAA32592.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAA32593.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TP63ID365ch3q27.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB010153; BAA32433.1; -; mRNA.
DR   EMBL; Y16961; CAA76562.1; -; mRNA.
DR   EMBL; AF075428; AAC62633.1; -; mRNA.
DR   EMBL; AF075429; AAC62634.1; -; mRNA.
DR   EMBL; AF075430; AAC62635.1; -; mRNA.
DR   EMBL; AF075431; AAC62636.1; -; mRNA.
DR   EMBL; AF075432; AAC62637.1; -; mRNA.
DR   EMBL; AF075433; AAC62638.1; -; mRNA.
DR   EMBL; AF124539; AAG45607.1; -; Genomic_DNA.
DR   EMBL; AF124528; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124529; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124538; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124539; AAG45608.1; -; Genomic_DNA.
DR   EMBL; AF124528; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124529; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124540; AAG45609.1; -; Genomic_DNA.
DR   EMBL; AF124528; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124529; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124539; AAG45610.1; -; Genomic_DNA.
DR   EMBL; AF124530; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124538; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124539; AAG45611.1; -; Genomic_DNA.
DR   EMBL; AF124530; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124540; AAG45612.1; -; Genomic_DNA.
DR   EMBL; AF124531; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124530; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AB016072; BAA32592.1; ALT_FRAME; mRNA.
DR   EMBL; AB016073; BAA32593.1; ALT_FRAME; mRNA.
DR   EMBL; AF091627; AAC43038.1; -; mRNA.
DR   EMBL; AF116770; AAF43486.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43487.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116768; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43488.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43489.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116770; AAF43490.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43491.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116768; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43492.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43493.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116771; AAF61624.1; ALT_FRAME; mRNA.
DR   EMBL; AB042841; BAB20591.1; -; mRNA.
DR   EMBL; BC039815; AAH39815.1; -; mRNA.
DR   EMBL; AF061512; AAC24830.1; -; mRNA.
DR   EMBL; AY342152; AAQ63448.1; -; Genomic_DNA.
DR   EMBL; AY341145; AAQ63448.1; JOINED; Genomic_DNA.
DR   EMBL; AY339663; AAQ63449.1; -; Genomic_DNA.
DR   EMBL; AY341143; AAQ63450.1; -; Genomic_DNA.
DR   EMBL; AY339664; AAQ63450.1; JOINED; Genomic_DNA.
DR   EMBL; AY341142; AAQ63450.1; JOINED; Genomic_DNA.
DR   EMBL; AY341143; AAQ63451.1; -; Genomic_DNA.
DR   EMBL; AY341142; AAQ63451.1; JOINED; Genomic_DNA.
DR   EMBL; AY341144; AAQ63452.1; -; Genomic_DNA.
DR   EMBL; AY342153; AAQ63453.1; -; Genomic_DNA.
DR   EMBL; AY342154; AAQ63454.1; -; Genomic_DNA.
DR   EMBL; AJ315499; CAC48053.1; -; mRNA.
DR   CCDS; CCDS3293.1; -. [Q9H3D4-1]
DR   CCDS; CCDS46976.1; -. [Q9H3D4-3]
DR   CCDS; CCDS46977.1; -. [Q9H3D4-5]
DR   CCDS; CCDS46978.1; -. [Q9H3D4-2]
DR   CCDS; CCDS46979.1; -. [Q9H3D4-4]
DR   CCDS; CCDS46980.1; -. [Q9H3D4-6]
DR   CCDS; CCDS82887.1; -. [Q9H3D4-11]
DR   CCDS; CCDS87179.1; -. [Q9H3D4-7]
DR   CCDS; CCDS87180.1; -. [Q9H3D4-8]
DR   CCDS; CCDS87181.1; -. [Q9H3D4-10]
DR   RefSeq; NP_001108450.1; NM_001114978.1. [Q9H3D4-3]
DR   RefSeq; NP_001108451.1; NM_001114979.1. [Q9H3D4-5]
DR   RefSeq; NP_001108452.1; NM_001114980.1. [Q9H3D4-2]
DR   RefSeq; NP_001108453.1; NM_001114981.1. [Q9H3D4-4]
DR   RefSeq; NP_001108454.1; NM_001114982.1. [Q9H3D4-6]
DR   RefSeq; NP_001316073.1; NM_001329144.1. [Q9H3D4-7]
DR   RefSeq; NP_001316074.1; NM_001329145.1. [Q9H3D4-8]
DR   RefSeq; NP_001316075.1; NM_001329146.1. [Q9H3D4-10]
DR   RefSeq; NP_001316077.1; NM_001329148.1. [Q9H3D4-11]
DR   RefSeq; NP_003713.3; NM_003722.4. [Q9H3D4-1]
DR   RefSeq; XP_016862876.1; XM_017007387.1.
DR   PDB; 1RG6; NMR; -; A=540-614.
DR   PDB; 2NB1; NMR; -; A/C=397-455.
DR   PDB; 2RMN; NMR; -; A=153-388.
DR   PDB; 2Y9T; NMR; -; A=543-622.
DR   PDB; 2Y9U; X-ray; 1.60 A; A=545-611.
DR   PDB; 3QYM; X-ray; 3.20 A; A/B/C/D/E/F/G/H=166-362.
DR   PDB; 3QYN; X-ray; 2.50 A; A/B/C/D=166-362.
DR   PDB; 3US0; X-ray; 2.50 A; A/B/C/D=166-362.
DR   PDB; 3US1; X-ray; 2.80 A; A/D=166-362.
DR   PDB; 3US2; X-ray; 4.20 A; A/B/C/D/G/H/I/J=166-362.
DR   PDB; 3ZY0; X-ray; 1.90 A; A/B/C/D=398-427.
DR   PDB; 3ZY1; X-ray; 2.15 A; A=398-441.
DR   PDB; 4A9Z; X-ray; 2.29 A; A/B/C/D=397-455.
DR   PDB; 6FGN; NMR; -; A=47-73.
DR   PDBsum; 1RG6; -.
DR   PDBsum; 2NB1; -.
DR   PDBsum; 2RMN; -.
DR   PDBsum; 2Y9T; -.
DR   PDBsum; 2Y9U; -.
DR   PDBsum; 3QYM; -.
DR   PDBsum; 3QYN; -.
DR   PDBsum; 3US0; -.
DR   PDBsum; 3US1; -.
DR   PDBsum; 3US2; -.
DR   PDBsum; 3ZY0; -.
DR   PDBsum; 3ZY1; -.
DR   PDBsum; 4A9Z; -.
DR   PDBsum; 6FGN; -.
DR   SMR; Q9H3D4; -.
DR   BioGrid; 114181; 277.
DR   DIP; DIP-29588N; -.
DR   ELM; Q9H3D4; -.
DR   IntAct; Q9H3D4; 84.
DR   MINT; Q9H3D4; -.
DR   STRING; 9606.ENSP00000264731; -.
DR   iPTMnet; Q9H3D4; -.
DR   PhosphoSitePlus; Q9H3D4; -.
DR   BioMuta; TP63; -.
DR   DMDM; 57013009; -.
DR   MassIVE; Q9H3D4; -.
DR   MaxQB; Q9H3D4; -.
DR   PaxDb; Q9H3D4; -.
DR   PeptideAtlas; Q9H3D4; -.
DR   PRIDE; Q9H3D4; -.
DR   ProteomicsDB; 80692; -. [Q9H3D4-1]
DR   ProteomicsDB; 80693; -. [Q9H3D4-10]
DR   ProteomicsDB; 80694; -. [Q9H3D4-11]
DR   ProteomicsDB; 80695; -. [Q9H3D4-12]
DR   ProteomicsDB; 80696; -. [Q9H3D4-2]
DR   ProteomicsDB; 80697; -. [Q9H3D4-3]
DR   ProteomicsDB; 80698; -. [Q9H3D4-4]
DR   ProteomicsDB; 80699; -. [Q9H3D4-5]
DR   ProteomicsDB; 80700; -. [Q9H3D4-6]
DR   ProteomicsDB; 80701; -. [Q9H3D4-7]
DR   ProteomicsDB; 80702; -. [Q9H3D4-8]
DR   ProteomicsDB; 80703; -. [Q9H3D4-9]
DR   Antibodypedia; 1750; 969 antibodies.
DR   DNASU; 8626; -.
DR   Ensembl; ENST00000264731; ENSP00000264731; ENSG00000073282. [Q9H3D4-1]
DR   Ensembl; ENST00000320472; ENSP00000317510; ENSG00000073282. [Q9H3D4-7]
DR   Ensembl; ENST00000354600; ENSP00000346614; ENSG00000073282. [Q9H3D4-2]
DR   Ensembl; ENST00000392460; ENSP00000376253; ENSG00000073282. [Q9H3D4-3]
DR   Ensembl; ENST00000392461; ENSP00000376254; ENSG00000073282. [Q9H3D4-8]
DR   Ensembl; ENST00000392463; ENSP00000376256; ENSG00000073282. [Q9H3D4-4]
DR   Ensembl; ENST00000418709; ENSP00000407144; ENSG00000073282. [Q9H3D4-5]
DR   Ensembl; ENST00000437221; ENSP00000392488; ENSG00000073282. [Q9H3D4-6]
DR   Ensembl; ENST00000440651; ENSP00000394337; ENSG00000073282. [Q9H3D4-11]
DR   Ensembl; ENST00000449992; ENSP00000387839; ENSG00000073282. [Q9H3D4-10]
DR   Ensembl; ENST00000456148; ENSP00000389485; ENSG00000073282. [Q9H3D4-12]
DR   GeneID; 8626; -.
DR   KEGG; hsa:8626; -.
DR   UCSC; uc003frx.3; human. [Q9H3D4-1]
DR   CTD; 8626; -.
DR   DisGeNET; 8626; -.
DR   GeneCards; TP63; -.
DR   GeneReviews; TP63; -.
DR   HGNC; HGNC:15979; TP63.
DR   HPA; ENSG00000073282; Tissue enhanced (skeletal muscle, skin).
DR   MalaCards; TP63; -.
DR   MIM; 103285; phenotype.
DR   MIM; 106260; phenotype.
DR   MIM; 129400; phenotype.
DR   MIM; 603273; gene.
DR   MIM; 603543; phenotype.
DR   MIM; 604292; phenotype.
DR   MIM; 605289; phenotype.
DR   MIM; 618149; phenotype.
DR   neXtProt; NX_Q9H3D4; -.
DR   OpenTargets; ENSG00000073282; -.
DR   Orphanet; 978; ADULT syndrome.
DR   Orphanet; 1071; Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome.
DR   Orphanet; 93930; Bladder exstrophy.
DR   Orphanet; 141291; Cleft lip and alveolus.
DR   Orphanet; 199306; Cleft lip/palate.
DR   Orphanet; 1896; EEC syndrome.
DR   Orphanet; 199302; Isolated cleft lip.
DR   Orphanet; 2440; Isolated split hand-split foot malformation.
DR   Orphanet; 69085; Limb-mammary syndrome.
DR   PharmGKB; PA162406776; -.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   GeneTree; ENSGT00950000183153; -.
DR   HOGENOM; CLU_019621_1_0_1; -.
DR   InParanoid; Q9H3D4; -.
DR   KO; K10149; -.
DR   OMA; VIQHIWD; -.
DR   PhylomeDB; Q9H3D4; -.
DR   TreeFam; TF106101; -.
DR   Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   SignaLink; Q9H3D4; -.
DR   SIGNOR; Q9H3D4; -.
DR   ChiTaRS; TP63; human.
DR   EvolutionaryTrace; Q9H3D4; -.
DR   GeneWiki; TP63; -.
DR   GenomeRNAi; 8626; -.
DR   Pharos; Q9H3D4; Tbio.
DR   PRO; PR:Q9H3D4; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9H3D4; protein.
DR   Bgee; ENSG00000073282; Expressed in skin of abdomen and 140 other tissues.
DR   ExpressionAtlas; Q9H3D4; baseline and differential.
DR   Genevisible; Q9H3D4; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IMP:CAFA.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IPI:CAFA.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002039; F:p53 binding; IPI:CAFA.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0050699; F:WW domain binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR   GO; GO:0060197; P:cloacal septation; IEA:Ensembl.
DR   GO; GO:1904888; P:cranial skeletal system development; IEA:Ensembl.
DR   GO; GO:0007499; P:ectoderm and mesoderm interaction; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0010481; P:epidermal cell division; IEA:Ensembl.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0001736; P:establishment of planar polarity; IEA:Ensembl.
DR   GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB.
DR   GO; GO:0048807; P:female genitalia morphogenesis; IEA:Ensembl.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0010259; P:multicellular organism aging; IEA:Ensembl.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IMP:UniProtKB.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045617; P:negative regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:2000381; P:negative regulation of mesoderm development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0030859; P:polarized epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:1902808; P:positive regulation of cell cycle G1/S phase transition; IMP:UniProtKB.
DR   GO; GO:2000271; P:positive regulation of fibroblast apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:1904674; P:positive regulation of somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0060513; P:prostatic bud formation; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0010482; P:regulation of epidermal cell division; ISS:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0001302; P:replicative cell aging; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0043589; P:skin morphogenesis; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   CDD; cd09572; SAM_tumor-p63; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR032645; Tp63.
DR   InterPro; IPR037611; Tumor-p63_SAM.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative promoter usage; Alternative splicing;
KW   Apoptosis; Developmental protein; Disease mutation; DNA-binding;
KW   Ectodermal dysplasia; Isopeptide bond; Metal-binding;
KW   Notch signaling pathway; Nucleus; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc.
FT   CHAIN           1..680
FT                   /note="Tumor protein 63"
FT                   /id="PRO_0000185729"
FT   DOMAIN          541..607
FT                   /note="SAM"
FT   DNA_BIND        170..362
FT   REGION          1..107
FT                   /note="Transcription activation"
FT   REGION          352..388
FT                   /note="Interaction with HIPK2"
FT                   /evidence="ECO:0000269|PubMed:11925430"
FT   REGION          394..443
FT                   /note="Oligomerization"
FT   REGION          610..680
FT                   /note="Transactivation inhibition"
FT   COMPBIAS        437..444
FT                   /note="Poly-Gln"
FT   METAL           244
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           247
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           308
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           312
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        676
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..108
FT                   /note="MNFETSRCATLQYCPDPYIQRFVETPAHFSWKESYYRSTMSQSTQTNEFLSP
FT                   EVFQHIWDFLEQPICSVQPIDLNFVDEPSEDGATNKIEISMDCIRMQDSDLSDPMW ->
FT                   MLYLENNAQTQFSE (in isoform 2, isoform 4, isoform 6, isoform
FT                   8, isoform 10 and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:10469295,
FT                   ECO:0000303|PubMed:11336476, ECO:0000303|PubMed:9703973,
FT                   ECO:0000303|PubMed:9774969"
FT                   /id="VSP_012465"
FT   VAR_SEQ         109..193
FT                   /note="Missing (in isoform 9 and isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:11336476"
FT                   /id="VSP_012466"
FT   VAR_SEQ         373..377
FT                   /note="GTKRP -> A (in isoform 11 and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:11477076"
FT                   /id="VSP_012467"
FT   VAR_SEQ         450..680
FT                   /note="QTSIQSPSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNALTPTTIPDGMGA
FT                   NIPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLARLGCSS
FT                   CLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHEFSSPSHLLRT
FT                   PSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQQRIKEE
FT                   GE -> HLLSACFRNELVEPRRETPKQSDVFFRHSKPPNRSVYP (in isoform 5
FT                   and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:9662378,
FT                   ECO:0000303|PubMed:9774969"
FT                   /id="VSP_012468"
FT   VAR_SEQ         503..680
FT                   /note="IPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLA
FT                   RLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHEFSSP
FT                   SHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQ
FT                   QRIKEEGE -> RSGKSENP (in isoform 7 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:10935472"
FT                   /id="VSP_012469"
FT   VAR_SEQ         551..680
FT                   /note="SFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGIL
FT                   DHRQLHEFSSPSHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDF
FT                   NFDMDARRNKQQRIKEEGE -> RIWQV (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:9774969"
FT                   /id="VSP_012470"
FT   VARIANT         129
FT                   /note="S -> L (in dbSNP:rs193287780)"
FT                   /evidence="ECO:0000269|PubMed:16740912"
FT                   /id="VAR_035126"
FT   VARIANT         184
FT                   /note="S -> L (in head and neck cancer)"
FT                   /evidence="ECO:0000269|PubMed:9662378"
FT                   /id="VAR_020866"
FT   VARIANT         187
FT                   /note="A -> P (in lung carcinoma; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9662378"
FT                   /id="VAR_020867"
FT   VARIANT         193
FT                   /note="T -> TP (in SHFM4)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032736"
FT   VARIANT         204
FT                   /note="Q -> L (in cervical cancer)"
FT                   /evidence="ECO:0000269|PubMed:9662378"
FT                   /id="VAR_020868"
FT   VARIANT         232
FT                   /note="K -> E (in SHFM4)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032737"
FT   VARIANT         233
FT                   /note="K -> E (in SHFM4; dbSNP:rs121908838)"
FT                   /evidence="ECO:0000269|PubMed:10839977"
FT                   /id="VAR_020869"
FT   VARIANT         243
FT                   /note="R -> Q (in EEC3; dbSNP:rs121908836)"
FT                   /evidence="ECO:0000269|PubMed:10535733,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020870"
FT   VARIANT         243
FT                   /note="R -> W (in EEC3; dbSNP:rs121908835)"
FT                   /evidence="ECO:0000269|PubMed:10535733,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020871"
FT   VARIANT         266
FT                   /note="R -> Q (in EEC3; dbSNP:rs121908849)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032738"
FT   VARIANT         279
FT                   /note="P -> H (in colon cancer)"
FT                   /evidence="ECO:0000269|PubMed:10485447"
FT                   /id="VAR_020872"
FT   VARIANT         308
FT                   /note="C -> Y (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032739"
FT   VARIANT         311
FT                   /note="S -> N (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032740"
FT   VARIANT         318
FT                   /note="R -> C (in EEC3; dbSNP:rs1205536026)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032741"
FT   VARIANT         318
FT                   /note="R -> H (in EEC3 and RHS; does not decrease the
FT                   transcriptional activity of the isoform 5 on a TP53
FT                   reporter system but disrupts the dominant-negative activity
FT                   of isoform 2 and isoform 5 on the transcriptional activity
FT                   of TP53; dbSNP:rs121908840)"
FT                   /evidence="ECO:0000269|PubMed:10839977,
FT                   ECO:0000269|PubMed:11462173, ECO:0000269|PubMed:12939657"
FT                   /id="VAR_020873"
FT   VARIANT         318
FT                   /note="R -> Q (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032742"
FT   VARIANT         319
FT                   /note="R -> C (in EEC3; dbSNP:rs121908839)"
FT                   /evidence="ECO:0000269|PubMed:10839977,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020874"
FT   VARIANT         319
FT                   /note="R -> H (in EEC3 and SHFM4; dbSNP:rs886039442)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032743"
FT   VARIANT         319
FT                   /note="R -> S (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032744"
FT   VARIANT         337
FT                   /note="R -> Q (in ADULT syndrome; confers novel
FT                   transcription activation capacity on isoform 6;
FT                   dbSNP:rs113993967)"
FT                   /evidence="ECO:0000269|PubMed:11929852"
FT                   /id="VAR_020875"
FT   VARIANT         343
FT                   /note="R -> Q (in EEC3; dbSNP:rs121908841)"
FT                   /evidence="ECO:0000269|PubMed:10839977,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020876"
FT   VARIANT         343
FT                   /note="R -> W (in EEC3; dbSNP:rs886041251)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032745"
FT   VARIANT         345
FT                   /note="C -> R (in EEC3; abolishes transcription activation;
FT                   dbSNP:rs121908837)"
FT                   /evidence="ECO:0000269|PubMed:10535733,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020877"
FT   VARIANT         347
FT                   /note="C -> S (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032746"
FT   VARIANT         348
FT                   /note="P -> S (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032747"
FT   VARIANT         351
FT                   /note="D -> G (in EEC3; dbSNP:rs121908844)"
FT                   /evidence="ECO:0000269|PubMed:12838557"
FT                   /id="VAR_020878"
FT   VARIANT         351
FT                   /note="D -> H (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032748"
FT   VARIANT         352
FT                   /note="R -> G (in OFC8; dbSNP:rs121908847)"
FT                   /evidence="ECO:0000269|PubMed:16740912"
FT                   /id="VAR_035127"
FT   VARIANT         549
FT                   /note="I -> T (in RHS; dbSNP:rs121908845)"
FT                   /evidence="ECO:0000269|PubMed:15200513"
FT                   /id="VAR_035128"
FT   VARIANT         553
FT                   /note="L -> F (in AEC; dbSNP:rs121908842)"
FT                   /evidence="ECO:0000269|PubMed:11159940"
FT                   /id="VAR_020879"
FT   VARIANT         560
FT                   /note="S -> A (in ovarian cancer)"
FT                   /evidence="ECO:0000269|PubMed:10485447"
FT                   /id="VAR_020880"
FT   VARIANT         561
FT                   /note="C -> G (in AEC; dbSNP:rs121908843)"
FT                   /evidence="ECO:0000269|PubMed:11159940"
FT                   /id="VAR_020881"
FT   VARIANT         580
FT                   /note="S -> P (in RHS; dbSNP:rs121908846)"
FT                   /evidence="ECO:0000269|PubMed:12766194"
FT                   /id="VAR_035129"
FT   VARIANT         603
FT                   /note="D -> H (in dbSNP:rs767906723)"
FT                   /evidence="ECO:0000269|PubMed:16740912"
FT                   /id="VAR_035130"
FT   MUTAGEN         55
FT                   /note="F->A: Abrogates transcriptional activity and
FT                   interaction with transactivation inhibition domain; when
FT                   associated with A-59 and A-62."
FT                   /evidence="ECO:0000269|PubMed:12446779"
FT   MUTAGEN         59
FT                   /note="W->A: Abrogates transcriptional activity and
FT                   interaction with transactivation inhibition domain; when
FT                   associated with A-55 and A-62."
FT                   /evidence="ECO:0000269|PubMed:12446779"
FT   MUTAGEN         62
FT                   /note="L->A: Abrogates transcriptional activity and
FT                   interaction with transactivation inhibition domain; when
FT                   associated with A-55 and A-59."
FT                   /evidence="ECO:0000269|PubMed:12446779"
FT   MUTAGEN         543
FT                   /note="Y->F: Abolishes ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:18806757"
FT   CONFLICT        125
FT                   /note="Q -> R (in Ref. 1; BAA32433)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        154
FT                   /note="S -> P (in Ref. 1; BAA32433)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        177
FT                   /note="F -> S (in Ref. 1; BAA32433)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        378
FT                   /note="F -> S (in Ref. 10; AAC24830)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        536
FT                   /note="H -> Q (in Ref. 2; CAA76562)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        551
FT                   /note="S -> G (in Ref. 4; BAA32593 and 7; AAF43487/
FT                   AAF43491)"
FT                   /evidence="ECO:0000305"
FT   HELIX           54..63
FT                   /evidence="ECO:0000244|PDB:6FGN"
FT   STRAND          156..161
FT                   /evidence="ECO:0000244|PDB:2RMN"
FT   HELIX           173..175
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          178..180
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          187..189
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          191..195
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   TURN            196..199
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          200..203
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          209..214
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          224..233
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   TURN            234..238
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   HELIX           245..249
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   TURN            252..256
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          263..269
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          274..277
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   TURN            279..281
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          284..289
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          300..306
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   TURN            313..318
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          321..328
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          330..332
FT                   /evidence="ECO:0000244|PDB:3QYM"
FT   STRAND          334..343
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   HELIX           348..355
FT                   /evidence="ECO:0000244|PDB:3QYN"
FT   STRAND          369..372
FT                   /evidence="ECO:0000244|PDB:2RMN"
FT   STRAND          401..407
FT                   /evidence="ECO:0000244|PDB:3ZY0"
FT   HELIX           408..426
FT                   /evidence="ECO:0000244|PDB:3ZY0"
FT   HELIX           429..436
FT                   /evidence="ECO:0000244|PDB:3ZY1"
FT   HELIX           444..449
FT                   /evidence="ECO:0000244|PDB:4A9Z"
FT   STRAND          546..548
FT                   /evidence="ECO:0000244|PDB:2Y9T"
FT   HELIX           549..554
FT                   /evidence="ECO:0000244|PDB:2Y9U"
FT   TURN            555..557
FT                   /evidence="ECO:0000244|PDB:2Y9U"
FT   HELIX           559..561
FT                   /evidence="ECO:0000244|PDB:2Y9U"
FT   HELIX           562..566
FT                   /evidence="ECO:0000244|PDB:2Y9U"
FT   TURN            567..569
FT                   /evidence="ECO:0000244|PDB:2Y9U"
FT   HELIX           573..576
FT                   /evidence="ECO:0000244|PDB:2Y9U"
FT   HELIX           581..586
FT                   /evidence="ECO:0000244|PDB:2Y9U"
FT   HELIX           591..609
FT                   /evidence="ECO:0000244|PDB:2Y9U"
FT   STRAND          613..615
FT                   /evidence="ECO:0000244|PDB:2Y9T"
FT   VARIANT         Q9H3D4-2:6
FT                   /note="N -> H (in ADULT syndrome)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082924"
FT   VARIANT         Q9H3D4-4:6
FT                   /note="N -> H (in ADULT syndrome)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082925"
FT   VARIANT         Q9H3D4-6:6
FT                   /note="N -> H (in ADULT syndrome)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082926"
FT   VARIANT         Q9H3D4-8:6
FT                   /note="N -> H (in ADULT syndrome)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082927"
FT   VARIANT         Q9H3D4-10:6
FT                   /note="N -> H (in ADULT syndrome)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082928"
FT   VARIANT         Q9H3D4-12:6
FT                   /note="N -> H (in ADULT syndrome)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082929"
SQ   SEQUENCE   680 AA;  76785 MW;  F66ECD45E87D9799 CRC64;
     MNFETSRCAT LQYCPDPYIQ RFVETPAHFS WKESYYRSTM SQSTQTNEFL SPEVFQHIWD
     FLEQPICSVQ PIDLNFVDEP SEDGATNKIE ISMDCIRMQD SDLSDPMWPQ YTNLGLLNSM
     DQQIQNGSSS TSPYNTDHAQ NSVTAPSPYA QPSSTFDALS PSPAIPSNTD YPGPHSFDVS
     FQQSSTAKSA TWTYSTELKK LYCQIAKTCP IQIKVMTPPP QGAVIRAMPV YKKAEHVTEV
     VKRCPNHELS REFNEGQIAP PSHLIRVEGN SHAQYVEDPI TGRQSVLVPY EPPQVGTEFT
     TVLYNFMCNS SCVGGMNRRP ILIIVTLETR DGQVLGRRCF EARICACPGR DRKADEDSIR
     KQQVSDSTKN GDGTKRPFRQ NTHGIQMTSI KKRRSPDDEL LYLPVRGRET YEMLLKIKES
     LELMQYLPQH TIETYRQQQQ QQHQHLLQKQ TSIQSPSSYG NSSPPLNKMN SMNKLPSVSQ
     LINPQQRNAL TPTTIPDGMG ANIPMMGTHM PMAGDMNGLS PTQALPPPLS MPSTSHCTPP
     PPYPTDCSIV SFLARLGCSS CLDYFTTQGL TTIYQIEHYS MDDLASLKIP EQFRHAIWKG
     ILDHRQLHEF SSPSHLLRTP SSASTVSVGS SETRGERVID AVRFTLRQTI SFPPRDEWND
     FNFDMDARRN KQQRIKEEGE
//
